PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GLERUM, DM; KOERNER, TJ; TZAGOLOFF, A				GLERUM, DM; KOERNER, TJ; TZAGOLOFF, A			CLONING AND CHARACTERIZATION OF COX14, WHOSE PRODUCT IS REQUIRED FOR ASSEMBLY OF YEAST CYTOCHROME-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; NUCLEAR GENE; ESCHERICHIA-COLI; SUBUNIT-II; PET GENES; PROTEIN; TRANSFORMATION; MUTANTS	Nuclear respiration-deficient mutants of Saccharomyces cerevisiae previously assigned to complementation group G93 lack cytochromes a and a(3) and detectable cytochrome oxidase activity, Other respiratory chain carriers and the ATPase complex are present at near wild-type levels, indicating that the mutations specifically affect cytochrome oxidase, Since synthesis of the mitochondrially derived subunits 1, 2, and 3 of cytochrome oxidase is normal, the defect cannot be related to transcription of the endogenous genes or processing and translation of the corresponding RNAs, The results of Western analysis of the cytochrome oxidase subunits encoded in nuclear DNA also argues against an effect of the mutations on expression of these constituents. The G93 mutants are complemented by a nuclear gene, designated COX14, The product of this gene is a low molecular mass protein of 7,960 Da, A gene fusion expressing a biotinylated form of Cox14p complements cox14 mutants, indicating partial functional equivalence. The biotinylated derivative has been helpful in localizing Cox14p to the mitochondrial membrane and demonstrating that it is not a hitherto unrecognized subunit of cytochrome oxidase, although it does appear to be associated with a high molecular weight complex, This evidence, combined with the assembly-arrested phenotype of cox14 mutants, indicates that Cox14p, like several other recently described mitochondrial constituents, provides an important function at some late stage of the cytochrome oxidase assembly pathway.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1985, J BIOL CHEM, V260, P5871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; POUTRE CG, 1987, GENETICS, V115, P637; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	37	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15585	15590		10.1074/jbc.270.26.15585	http://dx.doi.org/10.1074/jbc.270.26.15585			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797555	hybrid			2022-12-27	WOS:A1995RG53800025
J	HORREVOETS, AJG; SMILDE, AE; FREDENBURGH, JC; PANNEKOEK, H; NESHEIM, ME				HORREVOETS, AJG; SMILDE, AE; FREDENBURGH, JC; PANNEKOEK, H; NESHEIM, ME			THE ACTIVATION-RESISTANT CONFORMATION OF RECOMBINANT HUMAN PLASMINOGEN IS STABILIZED BY BASIC RESIDUES IN THE AMINO-TERMINAL HINGE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYS-PLASMINOGEN; GLU-PLASMINOGEN; N-GLYCOSYLATION; BINDING SITES; FIBRINOLYSIS; UROKINASE; INTERMEDIATE; EXPRESSION; INVITRO; DNA	Fully activable recombinant human plasminogen (rPlg) was expressed in mammalian cells employing either recombinant vaccinia virus or stable lines coexpressing alpha(2)-plasmin inhibitor. A panel of eight variants of rPlg was constructed, in which progressively up to 6 basic amino acid residues in the hinge region of rPlg between the NH2-terminal acidic domain (''proactivation peptide'') and kringle 1 were substituted by neutral residues. Analysis of the cleavage rates of these variants by plasmin revealed that the peptide bond at Arg(68) is most susceptible, followed by Lys(62) and Lys(77). A variant with all 6 basic residues substituted was cleaved at Lys(20). Three of these variants, PlgB (R68A, R70A), PlgF (R68A, R70A, K77H, K78H), and PlgG (R61A, K62A, R68A, R70A, K77H, K78H), as well as rPlg, were analyzed in more detail. The conformation of these plasminogens was analzed by monitoring the change in intrinsic fluorescence upon binding of lysine analogs. This revealed that rPlg exhibits the native tight Glu(1)-plasminogen, conformation, whereas PlgB, PlgF, and Plg G display an open confirmation similar to Lys(78)-plasminogen, leading to an increased affinity for lysine analogs. This allowed a direct study of the impact of the activation-resistant conformation on the properties of Glu(1)-plasminogen. The open conformation of rPlg variants leads to an increased rate of activation by urokinase-type plasminogen activator and streptokinase and increased binding to a fibrin clot. Fibrin clot lysis mediated by tissue-type plasminogen activator was accelerated for the variants as a result of a lower K-m for tissue-type plasminogen activator-mediated plasminogen activation, resulting from the increased affinity of rPlg (variants) for intact fibrin. We conclude that the basic residues in the extremely plasmin susceptible hinge region of plasminogen are directly involved in maintaining the activation resistant Glu(1)-plasminogen conformation.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada	HORREVOETS, AJG (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1-163,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.							BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MCCANCE SG, 1994, J BIOL CHEM, V269, P32405; MULLERTZ S, 1984, BIOCHEM J, V223, P169; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1990, J BIOL CHEM, V265, P22228; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; URANO T, 1991, THROMB RES, V61, P349, DOI 10.1016/0049-3848(91)90648-G; VALI Z, 1982, J BIOL CHEM, V257, P2104; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1973, EUR J BIOCHEM, V39, P1, DOI 10.1111/j.1432-1033.1973.tb03096.x; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022; WU HL, 1990, J BIOL CHEM, V265, P19658	39	39	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15770	15776		10.1074/jbc.270.26.15770	http://dx.doi.org/10.1074/jbc.270.26.15770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797579	hybrid			2022-12-27	WOS:A1995RG53800052
J	LEE, BH; LEY, BW; KANTROWITZ, ER; OLEARY, MH; WEDLER, FC				LEE, BH; LEY, BW; KANTROWITZ, ER; OLEARY, MH; WEDLER, FC			DOMAIN CLOSURE IN THE CATALYTIC CHAINS OF ESCHERICHIA-COLI ASPARTATE TRANSCARBAMOYLASE INFLUENCES THE KINETIC MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; BINDING; C-13; COOPERATIVITY; MODEL; PROBE	The closure of the two domains of the catalytic chains of Escherichia coli aspartate transcarbamoylase, which is critical for completion of the T --> R transition, is stabilized by salt-bridges between Glu-50 and both Arg-167 and Arg-234. Mutation of Glu-50 to Ala shifts the enzyme toward a low activity, low affinity state (Newton, C. J., and Kantrowitz, E. R. (1990) Biochemistry, 29, 1444-1451), Kinetic isotope effects (KIE) and equilibrium isotope exchange kinetics (EIEK) have been used to probe the dynamic properties of the Glu-50 --> Ala enzyme. Unlike the behavior of the wild-type enzyme, the observed kinetic isotope effect for C-13 versus C-12 at the carbonyl group of carbamoyl phosphate (CP) increased upon the binding of ligands which promote the formation of the R-state (Asp, N-phosphonacetyl-L-aspartate (PALA), or ATP). The maximum rate for the [C-14]Asp reversible arrow Carbamoyl aspartate (CAsp) exchange with the Glu-50 --> Ala enzyme was 500-fold slower than for the wild-type enzyme; however, the rate for the [C-14]Cp reversible arrow CAsp exchange was only 50-fold slower, reversing the relative rates observed with the wild-type enzyme. In addition, upon variation of substrate pairs involving Asp or CAsp, loss of inhibition effects in the CP reversible arrow CAsp exchange indicated that the Glu-50 --> Ala substitution caused the kinetic mechanism for the mutant enzyme to shift from ordered to random. Computer simulations of the EIEK data indicate that the Glu-50 --> Ala mutation specifically causes strong decreases in the rates of catalysis and association-dissociation for Asp and CAsp, with minimal effects on the GP and P-i on-off rates, With substrates bound, the Glu-50 --> Ala enzyme apparently does not attain a full R-state conformation. The PALA-activated Glu-50 --> Ala enzyme, however, exhibits substrate affinities comparable to those for the wild-type enzyme, but fails to restore the preferred order substrate binding. Unlike the wild-type enzyme, both the T and R-states of the Glu-50 --> Ala enzyme contribute to catalysis. A third state, I, is proposed for the Glu-50 --> Ala enzyme, in which random order substrate binding is exhibited, and the catalytic step contributes significantly to overall rate limitation.	UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA; PENN STATE UNIV, PM ALTHOUSE LAB, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; BOSTON COLL, MERKERT CHEM CTR, DEPT CHEM, CHESTNUT HILL, MA 02167 USA	University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Boston College					NIGMS NIH HHS [GM43043, GM26237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043043, R01GM026237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; ALLEWELL NM, 1989, ANNU REV BIOPHYS BIO, V18, P71, DOI 10.1146/annurev.bb.18.060189.000443; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOYER PD, 1978, ACCOUNTS CHEM RES, V11, P218, DOI 10.1021/ar50125a007; COOK PF, 1991, ENZYME MECHANISM ISO; HERVE G, 1989, ALLOSTERIC ENZYMES, P61; HSUANYU Y, 1988, J BIOL CHEM, V263, P4172; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OLEARY MH, 1989, ANNU REV BIOCHEM, V58, P377; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6577, DOI 10.1021/bi00143a030; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6598, DOI 10.1021/bi00143a033; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6570, DOI 10.1021/bi00143a029; PORTER RW, 1969, J BIOL CHEM, V244, P1846; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; STARK GR, 1971, J BIOL CHEM, V246, P3064; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TSURUTA H, 1994, BIOCHEMISTRY-US, V33, P10007, DOI 10.1021/bi00199a026; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6585, DOI 10.1021/bi00143a031; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6592, DOI 10.1021/bi00143a032; WEDLER FC, 1995, J BIOL CHEM, V270, P9725, DOI 10.1074/jbc.270.17.9725; WEDLER FC, 1994, ANAL BIOCHEM, V218, P449, DOI 10.1006/abio.1994.1205; WEDLER FC, 1974, J BIOL CHEM, V249, P5080; WEDLER FC, 1995, IN PRESS METHODS ENZ	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15620	15627		10.1074/jbc.270.26.15620	http://dx.doi.org/10.1074/jbc.270.26.15620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797560	hybrid			2022-12-27	WOS:A1995RG53800030
J	PEREGO, M; GLASER, P; MINUTELLO, A; STRAUCH, MA; LEOPOLD, K; FISCHER, W				PEREGO, M; GLASER, P; MINUTELLO, A; STRAUCH, MA; LEOPOLD, K; FISCHER, W			INCORPORATION OF D-ALANINE INTO LIPOTEICHOIC ACID AND WALL TEICHOIC-ACID IN BACILLUS-SUBTILIS - IDENTIFICATION OF GENES AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; STAPHYLOCOCCUS-AUREUS; LACTOBACILLUS-CASEI; ESTER SUBSTITUTION; DNA-SEQUENCE; BIOSYNTHESIS; CLONING; TRANSCRIPTION; SPORULATION; EXPRESSION	The Bacillus subtilis dlt operon (D-alanyl-lipoteichoic acid) is responsible for D alanine esterification of both lipoteichoic acid (LTA) and wall teichoic acid (WTA). The dlt operon contains five genes, dltA-dltE. Insertional inactivation of dltA-dltD results in complete absence of D-alanine from both LTA and WTA. Based on protein sequence similarity with the Lactobacillus casei dlt gene products (Heaton, M. P., and Neuhaus, F. C. (1992) J. Bacteriol. 174, 4707-4717), we propose that dltA encodes the D-alanine-n-alanyl carrier protein ligase (Dcl) and dltC the D-alanyl carrier protein (Dcp). We further hypothesize that the products of dltB and dltD are concerned with the transport of activated n-alanine through the membrane and the final incorporation of D-alanine into LTA. The hydropathy profiles of the dltB and dltD gene products suggest a transmembrane location for the former and an amino-terminal signal peptide for the latter. The incorporation of D-alanine into LTA and WTA did not separate in any of the mutants studied which indicates that either one and the same enzyme is responsible for D-alanine incorporation into both polymers or a separate enzyme, encoded outside the dlt operon, transfers the D-alanyl residues from LTA to WTA (Haas, R., Koch, H.-U., and Fischer, W. (1984) FEMS Microbiol Lett. 21, 27-31). Inactivation of dltE has no effect on D-alanine ester content of both LTA and WTA and at present we cannot propose any function for its gene product. Transcription analysis shows that the dlt operon is transcribed from a sigma(D)-dependent promoter and follows the pattern of transcription of genes belonging to the sigma(D) regulon. However, the turn off of transcription observed before sporulation starts seems to be dependent on the SpoOA and AbrB sporulation proteins and results in a D-alanine-free purely anionic LTA in the spore membrane. The dlt operon is dispensable for cell growth; its inactivation does not affect cell growth or morphology as described for L. casei.	UNIV PARMA, FAC FARM, DIPARTIMENTO FARMACEUT, I-43100 PARMA, ITALY; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV, I-27100 PAVIA, ITALY; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS, FRANCE; UNIV ERLANGEN NURNBERG, FAK MED, INST BIOCHEM, D-91054 ERLANGEN, GERMANY	University of Parma; University of Pavia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Erlangen Nuremberg	PEREGO, M (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTINI AM, 1991, J BACTERIOL, V173, P3573, DOI 10.1128/jb.173.11.3573-3579.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; [Anonymous], 1994, NEW COMPREHENSIVE BI; BIERBAUM G, 1987, J BACTERIOL, V169, P5452, DOI 10.1128/jb.169.12.5452-5458.1987; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHERET G, 1993, YEAST, V9, P661, DOI 10.1002/yea.320090612; CHIN T, 1968, J BACTERIOL, V95, P2044, DOI 10.1128/JB.95.6.2044-2050.1968; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; FISCHER W, 1981, J BACTERIOL, V146, P467, DOI 10.1128/JB.146.2.467-475.1981; FISCHER W, 1980, J BIOL CHEM, V255, P4557; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; Fischer W., 1990, HDB LIPID RES, P123; GLASER L, 1964, J BIOL CHEM, V239, P3187; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GRASSL M, 1985, METHOD ENZYMAT AN, V8, P336; HAAS R, 1984, FEMS MICROBIOL LETT, V21, P27, DOI 10.1111/j.1574-6968.1984.tb00180.x; HANCOCK IC, 1985, ENZYMES BIOL MEMBR, V2, P279; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HEATON MP, 1992, J BACTERIOL, V174, P4707, DOI 10.1128/JB.174.14.4707-4717.1992; HELMANN JD, 1988, J BACTERIOL, V170, P1568, DOI 10.1128/jb.170.4.1568-1574.1988; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; IWASAKI H, 1986, J BACTERIOL, V167, P508, DOI 10.1128/jb.167.2.508-516.1986; JOHNSTONE K, 1982, BIOCHEM J, V202, P459, DOI 10.1042/bj2020459; KATES M, 1994, TECHNIQUES LIPIDOLOG; KELEMEN MV, 1961, BIOCHEM J, V80, P246, DOI 10.1042/bj0800246; KOCH HU, 1984, EUR J BIOCHEM, V138, P357, DOI 10.1111/j.1432-1033.1984.tb07923.x; KOCH HU, 1985, J BACTERIOL, V164, P1211, DOI 10.1128/JB.164.3.1211-1217.1985; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEOPOLD K, 1991, EUR J BIOCHEM, V196, P475, DOI 10.1111/j.1432-1033.1991.tb15839.x; MANCUSO DJ, 1982, J BACTERIOL, V152, P616; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J. H, 1972, EXPT MOL GENETICS; NAGELE U, 1985, METHOD ENZYMAT AN, V8, P2; NTAMERE AS, 1987, J BACTERIOL, V169, P1702, DOI 10.1128/jb.169.4.1702-1711.1987; Ordal Geroge W., 1993, P765; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perego Marta, 1993, P615; PLATT MW, 1990, J BACTERIOL, V172, P5440, DOI 10.1128/jb.172.9.5440-5444.1990; POSTBEITTENMILLER MA, 1989, NUCLEIC ACIDS RES, V17, P1777, DOI 10.1093/nar/17.4.1777; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHNITGER H, 1959, BIOCHEM Z, V332, P167; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHIBAEV VN, 1973, BIOCHEM J, V135, P383, DOI 10.1042/bj1350383; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; STRAUCH MA, 1992, BIOCHIMIE, V74, P619, DOI 10.1016/0300-9084(92)90133-Y; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WARD JB, 1981, MICROBIOL REV, V45, P211, DOI 10.1128/MMBR.45.2.211-243.1981; YOKOYAMA K, 1988, EUR J BIOCHEM, V173, P453, DOI 10.1111/j.1432-1033.1988.tb14020.x	57	205	213	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15598	15606		10.1074/jbc.270.26.15598	http://dx.doi.org/10.1074/jbc.270.26.15598			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797557	hybrid			2022-12-27	WOS:A1995RG53800027
J	CAI, H; YU, H; MCENTEE, K; KUNKEL, TA; GOODMAN, MF				CAI, H; YU, H; MCENTEE, K; KUNKEL, TA; GOODMAN, MF			PURIFICATION AND PROPERTIES OF WILD-TYPE AND EXONUCLEASE-DEFICIENT DNA-POLYMERASE-II FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISPAIR EXTENSION KINETICS; SPONTANEOUS MUTATION; BIOCHEMICAL BASIS; REVERSE-TRANSCRIPTASE; POLB GENE; VIRAL-DNA; BACTERIOPHAGE-T4; FIDELITY; MUTANT; SUBSTITUTION	Wild-type DNA polymerase II (pol II and an exonuclease-deficient pol II mutant (D155A/E157A) have been overexpressed and purified in high yield from Escherichia coli. Wild-type pol II exhibits a high proofreading 3'-exonuclease to polymerase ratio, similar in magnitude to that observed for bacteriophage T4 DNA polymerase. While copying a 250-nucleotide region of the lacZ alpha gene, the fidelity of wild-type pol II is high, with error rates for single-base substitution and frameshift errors being less than or equal to 10(-6). In contrast, the pol II exonuclease-deficient mutant generated a variety of base substitution and single base frameshift errors, as well as deletions between both perfect and imperfect directly repeated sequences separated by a few to hundreds of nucleotides. Error rates for the pol II exonuclease-deficient mutant were from greater than or equal to 13- to greater than or equal to 240-fold higher than for wild-type pol II, depending on the type of error considered. These data suggest that from 90 to >99% of base substitutions, frameshifts, and large deletions are efficiently proofread by the enzyme. The results of these experiments together with recent in vivo studies suggest an important role for pol II in the fidelity of DNA synthesis in cells.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; NIEHS, GENET MOLEC LAB, RES TRIANGLE PK, NC 27709 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	CAI, H (corresponding author), UNIV SO CALIF, HEDCO MOLEC BIOL LABS, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NIGMS NIH HHS [GM21422, GM29558, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM029558, R01GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON WF, 1994, J MOL BIOL, V238, P120, DOI 10.1006/jmbi.1994.1765; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1995, IN PRESS METHODS ENZ, V262; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BONNER CA, 1988, J BIOL CHEM, V263, P18946; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CAI H, 1995, IN PRESS METHODS ENZ, V262; CAIRNS J, 1991, GENETICS, V128, P695; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CHEN H, 1989, J BIOL CHEM, V264, P20591; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; ESCARCELLAR M, 1994, J BACTERIOL, V10, P6221; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GEFTER ML, 1972, J BIOL CHEM, V247, P3321; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; HIROTA Y, 1972, P NATL ACAD SCI USA, V69, P3238, DOI 10.1073/pnas.69.11.3238; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; ISHINO Y, 1994, J BIOL CHEM, V269, P14655; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KNIPPERS R, 1970, NATURE, V228, P1050, DOI 10.1038/2281050a0; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; REHAKRANTZ LJ, 1977, J MOL BIOL, V116, P99, DOI 10.1016/0022-2836(77)90121-8; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; Sambrook J, 1989, MOL CLONING LABORATO; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TESSMAN I, 1994, GENETICS, V136, P439; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WICKNER RB, 1972, J BIOL CHEM, V247, P489; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120	44	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15327	15335		10.1074/jbc.270.25.15327	http://dx.doi.org/10.1074/jbc.270.25.15327			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797520	hybrid			2022-12-27	WOS:A1995RE66600072
J	GELMAN, MS; CHANG, WS; THOMAS, DY; BERGERON, JJM; PRIVES, JM				GELMAN, MS; CHANG, WS; THOMAS, DY; BERGERON, JJM; PRIVES, JM			ROLE OF THE ENDOPLASMIC-RETICULUM CHAPERONE CALNEXIN IN SUBUNIT FOLDING AND ASSEMBLY OF NICOTINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; TRANSFECTED COS CELLS; MUSCLE-CELLS; BREFELDIN-A; MEMBRANE; OLIGOMERIZATION; ER; PHOSPHORYLATION; TRANSPORT; SURFACE	The nicotinic acetylcholine receptor (AChR) is a pentameric complex assembled from four different gene products by mechanisms that are inadequately understood. In this study we investigated the role of the endoplasmic reticulum (ER)-resident molecular chaperone calnexin in AChR subunit folding and assembly. We have shown that calnexin interacts with nascent AChR alpha-subunits (AChR-alpha) in muscle cell cultures and in COS cells transfected with mouse AChR-alpha. In chick muscle cells maximal association of labeled alpha-subunits with calnexin was observed immediately after a 15-min pulse with [S-35]methionine/cysteine and subsequently declined with a t(1/2) of approximately 20 min. The decrease in association with calnexin was concomitant with the folding of the alpha-subunit to achieve conformational maturation shortly before assembly. Brefeldin A did not inhibit AChR subunit assembly or the dissociation of calnexin from the assembling subunits, confirming that the ER is the site of AChR assembly and that calnexin dissociation is not affected under conditions in which the exit of assembled AChR from the ER is blocked. These results indicate that calnexin participates directly in the molecular events that lead to AChR assembly.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA; MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL, PQ H4P 2R2, CANADA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, EUKARYOT GENET GRP, MONTREAL, PQ H4P 2R2, CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; McGill University; National Research Council Canada			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X	NIGMS NIH HHS [GM07518] Funding Source: Medline; NINDS NIH HHS [NS25945] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1989, J BIOL CHEM, V264, P11952; GU Y, 1989, J CELL BIOL, V10, P729; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LENTER M, 1994, J BIOL CHEM, V269, P12263; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MILES K, 1988, MOL NEUROBIOL, V2, P91, DOI 10.1007/BF02935341; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PRIVES J, 1982, J CELL BIOL, V92, P231, DOI 10.1083/jcb.92.1.231; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSS AF, 1987, J BIOL CHEM, V262, P14640; Sambrook J, 1989, MOL CLONING LABORATO; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599	50	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15085	15092		10.1074/jbc.270.25.15085	http://dx.doi.org/10.1074/jbc.270.25.15085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797492	hybrid			2022-12-27	WOS:A1995RE66600038
J	MAITRA, RK; LI, GY; XIAO, W; DONG, BH; TORRENCE, PF; SILVERMAN, RH				MAITRA, RK; LI, GY; XIAO, W; DONG, BH; TORRENCE, PF; SILVERMAN, RH			CATALYTIC CLEAVAGE OF AN RNA TARGET BY 2-5A ANTISENSE AND RNASE-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; DOUBLE-STRANDED-RNA; PROTEIN-SYNTHESIS; PPP(A2'P)NA-DEPENDENT RNASE; CONSTITUTIVE EXPRESSION; 2-5A-DEPENDENT RNASE; JLS-V9R CELLS; INHIBITION; 2',5'-OLIGOADENYLATE; PPPA2'P5'A2'P5'A	2-5A antisense (2-5A-AS) molecules are chimeric oligonucleotides that cause 2-5A-dependent RNase (RNase L) to catalyze the selective cleavage of RNA in human cells. These composite nucleic acids consist of a 5'-monophosphorylated, 2',5'-linked oligoadenylate known as 2-5A (an activator of RNase L) covalently attached to antisense 3',5'-oligodeoxyribonucleotides. Here, we characterize the targeted cleavage of the double-stranded RNA-dependent protein kinase (PKR) mRNA by purified, recombinant human RNase L. A 2-5A-AS chimera, which contains complementary sequence to PKR mRNA, and unmodified 2-5A, which causes general RNA decay, were about 20- and 40-fold more active, respectively, than 2-5A-AS chimeras in which the DNA domains are not complementary to sequences in PKR mRNA. Directed cleavage was efficient because each 2-5A-AS chimera targeted many RNA molecules. Moreover, RNase L caused the catalytic cleavage of the RNA target (k(cat) of approximately 7 s(-1)). The precise sites of PKR mRNA cleavage caused by 2-5A-AS were mapped, using a primer extension assay, to phosphodiester bonds adjacent to the 3' terminus of the chimera binding site (5' on the RNA target) as well as within the chimera's oligonucleotide binding site itself. The selectivity of this approach is shown to be provided by the antisense arm of the chimera, which places the RNA target in close proximity to the RNase.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDK,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NCI NIH HHS [1 PO1 CA 62220-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUICE TC, 1966, BIOORG MECH, V1, P199; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DONG BH, 1994, J BIOL CHEM, V269, P14153; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; Eadie GS, 1942, J BIOL CHEM, V146, P85; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1979, P NATL ACAD SCI USA, V76, P3261, DOI 10.1073/pnas.76.7.3261; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P1; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NILSEN TW, 1981, J BIOL CHEM, V256, P751; PAGE MI, 1987, ENZYME MECHANISMS, P1; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WILLIAMS BRG, 1978, NATURE, V276, P88, DOI 10.1038/276088a0; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; ZOU A, 1993, CELL, V72, P753	28	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15071	15075		10.1074/jbc.270.25.15071	http://dx.doi.org/10.1074/jbc.270.25.15071			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797490	hybrid			2022-12-27	WOS:A1995RE66600036
J	ODA, H; STOCKERT, RJ; COLLINS, C; WANG, H; NOVIKOFF, PM; SATIR, P; WOLKOFF, AW				ODA, H; STOCKERT, RJ; COLLINS, C; WANG, H; NOVIKOFF, PM; SATIR, P; WOLKOFF, AW			INTERACTION OF THE MICROTUBULE CYTOSKELETON WITH ENDOCYTIC VESICLES AND CYTOPLASMIC DYNEIN IN CULTURED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN EGG KINESIN; ORGANELLE MOVEMENT; AXONAL-TRANSPORT; BINDING-PROTEIN; GTP HYDROLYSIS; RECEPTOR; MOTOR; MOTILITY; INVITRO; LIVER	In a recent study (Goltz, J. S., Wolkoff, A. W., Novikoff, P. M., Stockert, R. J., and Satir, P. (1992) Proc. Natl. Acad. Sci. U.S. R 89, 7026-7030), we found that ligand- and receptor containing endocytic vesicles bind to endogenous microtubules in vitro after 60 min of receptor-mediated endocytosis of asialo-orosomucoid. In the presence of ATP, ligand-containing endocytic vesicles are released from microtubules, while those containing receptor are not. We hypothesized that cytoplasmic dynein may associate with ligand-containing, but not receptor-containing, domains of endocytic vesicles and might be involved in the movement of ligand-containing vesicles along microtubules during sorting of ligand from receptor. Direct evidence in support of this hypothesis has been obtained in the present study. Binding of ligand-containing vesicles to microtubules correlates highly (p < 0.001) with binding of dynein, but not kinesin, under a variety of conditions. Binding of receptor-containing vesicles to microtubules is independent of both cytoplasmic dynein and kinesin binding. Tight association of cytoplasmic dynein with a population of ligand-containing vesicles is seen directly by immunoprecipitation. These results support the view that in receptor-mediated endocytosis, ligand-containing vesicles become bound to microtubules by cytoplasmic dynein. While receptor domains of endosomes remain attached to microtubules in an ATP-independent manner, ligand-containing domains might be moved away toward pericentrosomal lysosomes by this motor molecule.	ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwestern University					NCI NIH HHS [CA-06576] Funding Source: Medline; NIDDK NIH HHS [DK-41296, DK-41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, P30DK041296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CLARKE BL, 1989, BIOCHEM J, V262, P277, DOI 10.1042/bj2620277; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DABORA SL, 1988, CELL MOTIL CYTOSKEL, V10, P482, DOI 10.1002/cm.970100405; EUTENEUER U, 1981, P NATL ACAD SCI-BIOL, V78, P372, DOI 10.1073/pnas.78.1.372; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JELICKS LA, 1992, AM J PHYSIOL, V263, pH903, DOI 10.1152/ajpheart.1992.263.3.H903; KAISER J, 1988, EXP CELL RES, V174, P472, DOI 10.1016/0014-4827(88)90316-3; KAUFMAN SS, 1990, AM J PHYSIOL, V258, pG129, DOI 10.1152/ajpgi.1990.258.1.G129; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LIN SXH, 1992, J CELL SCI, V101, P125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; NOVIKOFF PM, 1992, MOL BIOL CELL, V3, P48; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PORTER ME, 1987, J BIOL CHEM, V262, P2794; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; SAMUELSON AC, 1988, AM J PHYSIOL, V254, pC829, DOI 10.1152/ajpcell.1988.254.6.C829; SATIR P, 1990, CANCER INVEST, V8, P685, DOI 10.3109/07357909009018945; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHLIWA M, 1991, J CELL BIOL, V112, P1199, DOI 10.1083/jcb.112.6.1199; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1984, J CELL BIOL, V98, P357	49	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15242	15249		10.1074/jbc.270.25.15242	http://dx.doi.org/10.1074/jbc.270.25.15242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797509	hybrid			2022-12-27	WOS:A1995RE66600060
J	SCHMIDT, B; KIECKESIEMSEN, C; WAHEED, A; BRAULKE, T; VONFIGURA, K				SCHMIDT, B; KIECKESIEMSEN, C; WAHEED, A; BRAULKE, T; VONFIGURA, K			LOCALIZATION OF THE INSULIN-LIKE GROWTH-FACTOR-II BINDING-SITE TO AMINO-ACIDS 1508-1566 IN REPEAT 11 OF THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH-FACTOR-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE RECEPTOR; IGF-II; LIGAND INTERACTIONS; CYTOPLASMIC DOMAIN; CELLS; EXPRESSION; CLONING; LIVER; MANNOSE-6-PHOSPHATE; SEQUENCE	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) binds insulin-like growth factor II (IGF-II) with high affinity. To localize the IGF-II binding site within the 15 repeating units that form the extracytoplasmic domain of the receptor, purified human M6P/IGF-II receptor was digested with thermolysin, and the fragments were analyzed for their ability to bind I-125-IGF-II in a cross-linking assay. Two IGF-II-binding receptor fragments of 23 and 37 kDa were purified. Sequence analysis revealed that the fragments consist of disulfide connected peptides comprising amino acids 1331-1566 and 1331-1697 of the receptor repeats 9-12. In a second approach we expressed truncated forms of the M6P/IGF-II receptor fused to the C terminus of the extracytoplasmic domain of the 46-kDa mannose 6-phosphate receptor. Fusion proteins containing M6P/IGF-II receptor repeats 10-15, 10-11, or 11-15 bound IGF-II, whereas a fusion protein containing the single repeat 10 failed to bind. This result indicates that repeat 11 (amino acids 1508-1650) is sufficient for binding of IGF-II. Residues 1508-1566, which are shared by the 23 kDa IGF-II-binding fragment and repeat 11, are proposed to form the IGF-II binding site of the M6P/IGF-II receptor.			SCHMIDT, B (corresponding author), UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOLEK ZELLBIOL,BIOCHEM ABT 2,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY.		Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BACH LA, 1993, J BIOL CHEM, V268, P9346; BLUNDELL TL, 1983, FED PROC, V42, P2592; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; HEMER F, 1993, J BIOL CHEM, V268, P17108; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIESS W, 1988, J BIOL CHEM, V263, P9339; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; ROTH RA, 1987, BIOCHEM BIOPH RES CO, V149, P600, DOI 10.1016/0006-291X(87)90410-4; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P4598; WENK J, 1991, BIOCHEM INT, V23, P723; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379	44	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14975	14982		10.1074/jbc.270.25.14975	http://dx.doi.org/10.1074/jbc.270.25.14975			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797478	hybrid			2022-12-27	WOS:A1995RE66600023
J	SCHWALBE, RA; WANG, ZG; WIBLE, BK; BROWN, AM				SCHWALBE, RA; WANG, ZG; WIBLE, BK; BROWN, AM			POTASSIUM CHANNEL STRUCTURE AND FUNCTION AS REPORTED BY A SINGLE GLYCOSYLATION SEQUON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION	Inwardly rectifying K+ channels (IRKs) are highly K+-selective, integral membrane proteins that help maintain resting the membrane potential and cell volume. Integral membrane proteins as a class are frequently N-glycosylated with the attached carbohydrate being extracellular and perhaps modulating function. However, dynamic effects of glycosylation have yet to be demonstrated at the molecular level. ROMK1, a member of the IRK family is particularly suited to the study of glycosylation because it has a single N-glycosylation consensus sequence (Ho, K., Nichols, C. G., Lederer, W. J., Lytton, J., Vassilev, P. M., Kanazirska, M. V., and Herbert, S. C. (1993) Nature 362, 31-38). We show that ROMK1 is expressed in a functional state in the plasma-Iemma of an insect cell line (Spodoptera frugiperda, Sf9) and has two structures, glycosylated and unglycosylated, To test functionality, glycosylation was abolished by an N117Q mutation or by treatment with tunicamycin. Whole cell currents were greatly reduced in both of the unglycosylated forms compared to wild-type. Single channel currents revealed a dramatic decrease in opening probability, p(o), as the causative factor. Thus we have shown biochemically that the N-glycosylation sequon is extracellular, a result consistent with present topological models of IRKs, and we conclude that sequon occupancy by carbohydrate stabilizes the open state of ROMK1.	CASE WESTERN RESERVE UNIV,RAMMELKEMP CTR EDUC & RES,CLEVELAND,OH 44109	Case Western Reserve University			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NINDS NIH HHS [NS23877] Funding Source: Medline; PHS HHS [NL36930] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHANG XB, 1994, J BIOL CHEM, V169, P18572; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICOR.C, 1994, BIOCHEM J, V302, P253; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P216; Possee RD., 1992, BACULOVIRUS EXPRESSI; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RECOPINTO E, NEURON, V5, P675; ROBERDS SL, 1993, J CARDIOVASC ELECTR, V4, P68, DOI 10.1111/j.1540-8167.1993.tb01214.x; SAMBROOK J, 1992, MOL CLONING LABORATO; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; TAGLIALATELA M, 1994, SCIENCE, V264, P884; WIHLE BA, 1994, NATURE, V371, P246; ZONA C, 1990, PROC R SOC SER B-BIO, V239, P119, DOI 10.1098/rspb.1990.0011	27	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15336	15340		10.1074/jbc.270.25.15336	http://dx.doi.org/10.1074/jbc.270.25.15336			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797521	hybrid			2022-12-27	WOS:A1995RE66600073
J	HIMANEN, JP; SCHNEIDER, K; CHAIT, B; MANNING, JM				HIMANEN, JP; SCHNEIDER, K; CHAIT, B; MANNING, JM			PARTICIPATION AND STRENGTH OF INTERACTION OF LYSINE 95(BETA) IN THE POLYMERIZATION OF HEMOGLOBIN-S AS DETERMINED BY ITS SITE-DIRECTED SUBSTITUTION BY ISOLEUCINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; DEOXYHEMOGLOBIN-S; MASS-SPECTROMETRY; SICKLE; RESOLUTION; MECHANISM; KINETICS; GELATION; YEAST	The role of Lys-95(beta), which is on the exterior of the hemoglobin (HbS) tetramer, in the aggregation process has been addressed because there is a lack of agreement on its importance, The early studies on the aggregation of HbS in the presence of other mutant hemoglobins are consistent with the subsequent electron microscopic studies in demonstrating the participation of Lys-95(beta) in gelation; the results of the crystal structure do not agree with these conclusions, Therefore, with the objective of clarifying its role we have carried out site directed substitution of Lys-95(beta) to an isoleucine residue, The mutation was introduced by polymerase chain reaction recombination methodology, and the absence of other mutations in the beta-globin gene was established by sequencing the gene in its entirety, The recombinant mutant hemoglobin was expressed in yeast and characterized by peptide mapping and sequencing, which demonstrated that the only different tryptic peptide had the Ile substitution at position 95(beta). The recombinant hemoglobin had the correct amino acid composition and molecular weight by mass spectrometric analysis. It was also pure as judged by isoelectric focusing, It was fully functional because it had an average Hill coefficient of 3.1 and responded normally to the allosteric regulators, chloride, 2,3-diphosphoglycerate, and inositol hexaphosphate, Of particular interest was the finding that this hemoglobin mutant aggregated at a concentration of about 40 g/dl, nearly twice that at which HbS itself aggregated (24 g/dl). Therefore, Lys-95(beta) has a very important role in the aggregation process and is a good candidate site for the design of a therapeutic agent for sickle cell anemia.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University			Schneider, Klaus/N-6604-2014	Schneider, Klaus/0000-0002-3068-8681	NHLBI NIH HHS [HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, R37HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1994, J BIOL CHEM, V269, P17477; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P245; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; CREPEAU RH, 1978, NATURE, V274, P616, DOI 10.1038/274616a0; DEAN J, 1978, NEW ENGL J MED, V299, P863, DOI 10.1056/NEJM197810192991605; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P135; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOFMANN OM, 1994, PROTEIN ENG, V7, P281; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1973, P NATL ACAD SCI USA, V70, P3604, DOI 10.1073/pnas.70.12.3604; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; LOWRY OH, 1954, J BIOL CHEM, V207, P1; Manning J M, 1981, Methods Enzymol, V76, P159; MANNING JM, 1974, ADV ENZYMOL RAMB, V40, P1; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; OGDEN JE, 1994, METHOD ENZYMOL, V231, P374; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YANASE H, 1995, PROTEIN SCI, V4, P21; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13885	13891		10.1074/jbc.270.23.13885	http://dx.doi.org/10.1074/jbc.270.23.13885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775447	hybrid			2022-12-27	WOS:A1995RC44800046
J	PANG, L; SAWADA, T; DECKER, SJ; SALTIEL, AR				PANG, L; SAWADA, T; DECKER, SJ; SALTIEL, AR			INHIBITION OF MAP KINASE KINASE BLOCKS THE DIFFERENTIATION OF PC-12 CELLS INDUCED BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE; PROTEIN-KINASE; CELLULAR ACTIONS; FACTOR RECEPTOR; PHOSPHORYLATION; RAS; RAF-1; ASSOCIATION; MEK	The mitogen-activated protein kinase (MAP kinase) pathway is thought to play an important role in the actions of neurotrophins. A small molecule inhibitor of the upstream kinase activator of MAP kinase, MAP kinase kinase (MER) was examined for its effect on the cellular action of nerve growth factor (NGF) in PC-12 pheochromocytoma cells. PD98059 selectively blocks the activity of MEK, inhibiting both the phosphorylation and activation of MAP kinases in vitro, Pretreatment of PC-12 cells with the compound completely blocked the 4-fold increase in MAP kinase activity produced by NGF. Half-maximal inhibition was observed at 2 mu m PD98059, with maximal effects at 10-100 mu M The tyrosine phosphorylation of immunoprecipitated MAP kinase was also completely blocked by the compound. In contrast, the compound was without effect on NGF-dependent tyrosine phosphorylation of the pp140(trk) receptor or its substrate She and did not block NGF-dependent activation of phosphatidylinositol 3'-kinase. However, PD98059 completely blocked NGF-induced neurite formation in these cells without altering cell viability. These data indicate that the MAP kinase pathway is absolutely required for NGF-induced neuronal differentiation in PC-12 cells.	WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P552; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OHMICHI M, 1992, NEURON, V9, P767; PANG L, 1995, IN PRESS BIOCH J; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALTIEL AR, 1994, BIOESSAYS, V16, P405, DOI 10.1002/bies.950160608; SALTOFF SP, 1992, J BIOL CHEM, V267, P17472; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V238, P351; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	33	892	900	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13585	13588		10.1074/jbc.270.23.13585	http://dx.doi.org/10.1074/jbc.270.23.13585			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775407	hybrid			2022-12-27	WOS:A1995RC44800002
J	PENG, HB; LIBBY, P; LIAO, JK				PENG, HB; LIBBY, P; LIAO, JK			INDUCTION AND STABILIZATION OF I-KAPPA-B-ALPHA BY NITRIC-OXIDE MEDIATES INHIBITION OF NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; ENDOTHELIUM; ADHESION; PROTEINS; INVITRO; FAMILY; CELLS; PHOSPHORYLATION; PROSTACYCLIN	To determine the mechanism(s) by which the endogenous mediator nitric oxide (NO) inhibits the activation of transcription factor NF-kappa B, we stimulated human vascular endothelial cells with tumor necrosis factor-alpha in the presence of two NO donors, sodium nitroprusside and S-nitrosoglutathione. Electrophoretic mobility shift assays demonstrated that both NO donors inhibited NF-kappa B activation by tumor necrosis factor-alpha. This effect was not mediated by guanylyl cyclase activation since the cGMP analogue 8-bromo-cGMP had no similar effect. Inhibition of endogenous constitutive NO production by L-N-monomethylarginine, however, activated NF-kappa B, suggesting tonic inhibition of NF-kappa B under basal conditions. NO had little or no effects on other nuclear binding proteins such as AP-1 and GATA. Immunoprecipitation studies showed that NO stabilized the NF-kappa B inhibitor, I kappa B alpha, by preventing its degradation from NF-kappa B. NO also increased the mRNA expression of I kappa B alpha, but not NF-kappa B subunits, p65 or p50, and transfection experiments with a chloramphenicol acetyltransferase reporter gene linked to the I kappa B alpha promoter suggested transcriptional induction of I kappa B alpha by NO. me propose that the induction and stabilization of I kappa B alpha by NO are important mechanisms by which NO inhibits NF-kappa B and attenuate atherogenesis.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NHLBI NIH HHS [HL34636, HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034636, R01HL034636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKALAY R, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLINS T, 1993, LAB INVEST, V68, P499; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DECATERINA R, 1995, IN PRESS J CLIN INVE; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1995, J BIOL CHEM, V270, P3219; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; XIE QW, 1994, J BIOL CHEM, V269, P4705	44	589	621	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14214	14219		10.1074/jbc.270.23.14214	http://dx.doi.org/10.1074/jbc.270.23.14214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775482	hybrid			2022-12-27	WOS:A1995RC44800090
J	CHALFANT, CE; MISCHAK, H; WATSON, JE; WINKLER, BC; GOODNIGHT, J; FARESE, RV; COOPER, DR				CHALFANT, CE; MISCHAK, H; WATSON, JE; WINKLER, BC; GOODNIGHT, J; FARESE, RV; COOPER, DR			REGULATION OF ALTERNATIVE SPLICING OF PROTEIN-KINASE C-BETA BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED 2-DEOXYGLUCOSE UPTAKE; PHORBOL ESTER TREATMENT; SMOOTH-MUSCLE CELLS; PRE-MESSENGER-RNA; BC3H-1 MYOCYTES; RAT ADIPOCYTES; GLUCOSE-TRANSPORT; PREMESSENGER RNA; DOWN-REGULATION; GROWTH	Insulin regulates a diverse array of cellular signaling processes involved in the control of growth, differentiation, and cellular metabolism. Insulin increases glucose transport via a protein kinase C (PKC) dependent pathway in BC3H-1 myocytes, but the function of specific PKC isozymes in insulin action has not been elucidated. Two isoforms of PKC beta result via alternative splicing of precursor mRNA. As now shown, both isoforms are present in BC3H-1 myocytes, and insulin induces alternative splicing of the PKC beta mRNA thereby switching expression from PKC beta I to PRC beta II mRNA. This effect occurs rapidly (15 min after insulin treatment) and is dose-dependent. The switch in mRNA is reflected by increases in the protein levels of PKC beta II. High levels of 1a-0-tetradecanoylphorbol-13-acetate, which are commonly used to deplete or down-regulate PKC in cells, also induce the switch to PKC beta II mRNA following overnight treatment, and protein levels of PKC beta II reflected mRNA increases. To investigate the functional importance of the shift in PKC beta isoform expression, stable transfectants of NIH-3T3 fibroblasts overexpressing PKC beta I and PKC beta II were established. The overexpression of PKC beta II but not PKC beta I in NIH-3T3 cells significantly enhanced insulin effects on glucose transport. This suggests that PKC beta II may be more selective than PKC beta I for enhancing the glucose transport effects of insulin in at least certain cells and, furthermore, that insulin can regulate the expression of PKC beta II by alternative mRNA splicing.	JAMES A HALEY VET HOSP,RES SERV 151,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV TAMPA,DEPT CHEM,TAMPA,FL 33606; NCI,BETHESDA,MD 20892	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Tampa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011; Farese, Robert/B-3605-2015	Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACEVEDODUNCAN M, 1989, FEBS LETT, V244, P174, DOI 10.1016/0014-5793(89)81186-X; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; CASCIERI MA, 1986, CIRC RES, V59, P171, DOI 10.1161/01.RES.59.2.171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DR, 1993, ARCH BIOCHEM BIOPHYS, V302, P490, DOI 10.1006/abbi.1993.1244; COOPER DR, 1987, FEBS LETT, V214, P122, DOI 10.1016/0014-5793(87)80025-X; COOPER DR, 1992, BIOCHEM BIOPH RES CO, V188, P142, DOI 10.1016/0006-291X(92)92361-Z; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; COOPER DR, 1987, J BIOL CHEM, V262, P3633; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; HOUSEY GM, 1988, CELL, V52, P853; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MIRANDA PV, 1993, ANAL BIOCHEM, V209, P376, DOI 10.1006/abio.1993.1138; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465; OBEID LM, 1992, J BIOL CHEM, V267, P20804; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SELL SM, 1994, J BIOL CHEM, V269, P30769; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; STANDAERT ML, 1988, J BIOL CHEM, V263, P8696; STANDAERT ML, 1990, METABOLISM, V11, P1170; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	41	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13326	13332		10.1074/jbc.270.22.13326	http://dx.doi.org/10.1074/jbc.270.22.13326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768933	hybrid			2022-12-27	WOS:A1995RB43900058
J	CHEN, CS; ROSENWALD, AG; PAGANO, RE				CHEN, CS; ROSENWALD, AG; PAGANO, RE			CERAMIDE AS A MODULATOR OF ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; CULTURED HUMAN-FIBROBLASTS; ACTIVATED PROTEIN-KINASE; LOW-DENSITY LIPOPROTEIN; GOLGI-APPARATUS; SECRETORY PATHWAY; PLASMA-MEMBRANE; LIVING CELLS; SPHINGOMYELIN	The effects of ceramide analogs on the uptake of markers for fluid-phase (horseradish peroxidase, HRP) and receptor-mediated (low density lipoprotein, LDL) endocytosis were studied in Chinese hamster fibroblasts. N-Hexanoyl-D-erythro-sphingosine (C-6-Cer) decreased the uptake of HRP in a dose-dependent manner. Internalization was inhibited >40% with 25 mu M C-6-Cer, relative to controls, and was apparent within 5 min. Internalization of HRP was also inhibited by other Cer analogs and by treatment with agents that raise levels of endogenous Cer (sphingomyelinase or the glycosphingolipid synthesis inhibitor, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP)), but not by N-hexanoyl-D-erythro-sphinganine (C-6-dihydro-Cer) or sphingosine. Internal of LDL was also inhibited by C-6-Cer in a concentration dependent manner, but was less pronounced than the effect on HRP internalization (10% versus 40% inhibition with 25 mu M C-6-Cer), suggesting that ceramide might affect fluid-phase and receptor-mediated endocytosis to different extents. C-6-Cer also slowed HRP and LDL transport from endosomes to lysosomes as studied by analysis of endocytic vesicles on Percoll density gradients and induced a redistribution of endocytic organelles as determined by fluorescence microscopy of intact cells using appropriate markers. This resulted in decreased degradation of I-125-Iabeled LDL in the presence of C-6-Cer. These results suggest that endogenous ceramide may modulate endocytosis.	CARNEGIE INST WASHINGTON, BALTIMORE, MD 21210 USA	Carnegie Institution for Science					NIGMS NIH HHS [R37 GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BETTS JC, 1994, J BIOL CHEM, V269, P8455; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KREIENBUHL P, 1992, BLOOD, V80, P2911; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MERRILL AH, 1993, ADV LIPID RES, V25, P1; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; SPENCE MW, 1993, ADV LIPID RES, V26, P3; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; WILSON RB, 1993, J BIOL CHEM, V268, P25357	45	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13291	13297		10.1074/jbc.270.22.13291	http://dx.doi.org/10.1074/jbc.270.22.13291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768929	hybrid			2022-12-27	WOS:A1995RB43900053
J	MU, FT; CALLAGHAN, JM; STEELEMORTIMER, O; STENMARK, H; PARTON, RG; CAMPBELL, PL; MCCLUSKEY, J; YEO, JP; TOCK, EPC; TOH, BH				MU, FT; CALLAGHAN, JM; STEELEMORTIMER, O; STENMARK, H; PARTON, RG; CAMPBELL, PL; MCCLUSKEY, J; YEO, JP; TOCK, EPC; TOH, BH			EEA1, AN EARLY ENDOSOME-ASSOCIATED PROTEIN - EEA1 IS A CONSERVED ALPHA-HELICAL PERIPHERAL MEMBRANE-PROTEIN FLANKED BY CYSTEINE FINGERS AND CONTAINS A CALMODULIN-BINDING IQ MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; ZINC FINGERS; CONFORMATION; PREDICTION; RECOGNITION; PATTERNS; DOMAINS	Early endosomes are cellular compartments receiving endocytosed material and sorting them for vesicular transport to late endosomes and lysosomes or for recycling to the plasma membrane. We have cloned a human cDNA encoding an evolutionarily conserved 180-kDa protein on early endosomes named EEA1 (Early Endosome Antigen1). EEA1 is associated with early endosomes since it co-localizes by immunofluorescence with the transferrin receptor and with Rab5 but not with Rab7. Immunoelectron microscopy shows that it is associated with tubulovesicular early endosomes containing internalized bovine serum albumin-gold. EEA1 is a hydrophilic peripheral membrane protein present in cytosol and membrane fractions. It partitions in the aqueous phase after Triton X-114 solubilization and is extracted from membranes by 0.3 M NaCl. It is a predominantly cu-helical protein sharing 17-20% sequence identity with the myosins and contains a calmodulin-binding IQ motif. It is flanked by metal-binding, cysteine ''finger'' motifs. The COOH-terminal fingers, Cys-X(2)-Cys-X(12)-Cys-X(2)-Cys and Cys-X(2)-Cys-X(16)-Cys-X(2)-Cys, are present within a region that is strikingly homologous with Saccharomyces cerevisiae FAB1 protein required for endocytosis and with Caenarhabditis elegans ZK632. These fingers also show limited conservation with S. cerevisiae VAC1, Vps11, and Vps18p proteins implicated in vacuolar transport. We propose that EEA1 is required for vesicular transport of proteins through early endosomes and that its finger motifs are required for this activity.	MONASH UNIV SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA; NATL UNIV SINGAPORE,DEPT PATHOL,SINGAPORE 0511,SINGAPORE; EUROPEAN MOLEC BIOL LAB,D-69021 HEIDELBERG,GERMANY; FLINDERS MED CTR,CTR TRANSFUS MED & IMMUNOL,ADELAIDE,SA 5042,AUSTRALIA	Monash University; National University of Singapore; European Molecular Biology Laboratory (EMBL); Flinders Medical Centre			Stenmark, Harald/B-8868-2008; Parton, Robert G/C-5673-2009; McCluskey, James/A-1291-2007	Parton, Robert G/0000-0002-7494-5248; McCluskey, James/0000-0002-8597-815X				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COURTOY PJ, 1991, INTRACELLULAR TRAFFI, P102; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOULD B, 1992, SEMIN CELL BIOL, V3, P301; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOOY J, 1992, J BIOL CHEM, V267, P20255; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MELLMAN I, 1993, J EXP BIOL, V172, P39; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MU FT, 1988, CLIN EXP IMMUNOL, V71, P100; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAYRE F, 1988, FEBS LETT, V234, P245, DOI 10.1016/0014-5793(88)80091-7; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PITT A, 1991, EXP CELL RES, V194, P128, DOI 10.1016/0014-4827(91)90141-G; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SHEPHERD VL, 1989, TRENDS PHARMACOL SCI, V10, P458, DOI 10.1016/S0165-6147(89)80011-2; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; YEO JP, 1994, NATURE, V386, P488	52	604	614	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13503	13511		10.1074/jbc.270.22.13503	http://dx.doi.org/10.1074/jbc.270.22.13503			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768953	hybrid			2022-12-27	WOS:A1995RB43900081
J	KLUMPP, S; HANKE, C; DONELLADEANA, A; BEYER, A; KELLNER, R; PINNA, LA; SCHULTZ, JE				KLUMPP, S; HANKE, C; DONELLADEANA, A; BEYER, A; KELLNER, R; PINNA, LA; SCHULTZ, JE			A MEMBRANE-BOUND PROTEIN PHOSPHATASE TYPE 2C FROM PARAMECIUM-TETRAURELIA - PURIFICATION, CHARACTERIZATION, AND CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULAR-CLONING; MESSENGER-RNA; DEHYDROGENASE PHOSPHATASE; CELLULAR-REGULATION; CILIARY MEMBRANES; SPECIFICITY; LIVER; IDENTIFICATION; SEQUENCE	We isolated the first membrane-bound type 2C serine/threonine protein phosphatase from the ciliated protozoan Paramecium tetraurelia (PtPP2C). Three isozymes of 33, 32, and 31 kDa with a specific activity of 1 mu mol.min(-1).mg(-1) were purified from the ciliary membrane. Ah enzymatic properties including (a) insensitivity toward inhibitors of other protein phosphatase families such as okadaic acid and microcystin, (b) absolute requirement for divalent cat ions, and (c) substrate specificity tested with synthetic phosphopeptides were identical to mammalian PP2C enzymes and identified the PtPP2C as a canonical PP2C in spite of it being about 25% smaller, The NH2-terminal was blocked. Microsequencing of six tryptic peptides established a relationship to other PP2C enzymes. The PtPP2C gene was obtained using degenerate oligonucleotide primers and the polymerase chain reaction. The gene coded for a 33-kDa protein with 300 amino acids and had an (A+T) content of 62%, typical for this protozoan. Nine of 15 Gln residues are encoded by TAA, a universal stop codon which codes for Gln in Paramecium. A large truncation at the COOH-terminal is responsible for the smaller size of the PtPP2C. Only a single transcript of 1 kilobase was detected with a Northern blot indicating that the 32- and 31-kDa proteins were proteolytic products of the 33-kDa enzyme. Sequence comparisons with PP2C enzymes from rat, rabbit, yeast, Arabidopsis, and Leishmania defined a highly diverged enzyme family which shares three conserved domains, I, II, and III, accounting for about 25% of the primary structure. We demonstrated further that the distances between domains I/II and II/III are very similar in all PP2C enzymes (9-13 and 74-80 amino acids, respectively). However, the amino acid sequences of the spacer regions are unrelated. In addition, the COOH-terminal ends of 100-200 amino acids which comprise 30-50% of the enzyme, display no identity. A dendrogramm shows that PtPP2C surprisingly is most closely related to the mammalian PP2C, and enzymes from Leishmania, Arabidopsis, and yeast are more distant relatives.	UNIV TUBINGEN,FAC CHEM & PHARM,D-72076 TUBINGEN,GERMANY; UNIV PADUA,DIPARTIMENTO CHIM BIOL,I-35121 PADUA,ITALY; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; University of Padua; European Molecular Biology Laboratory (EMBL)								ADOUTTE A, 1980, J CELL BIOL, V84, P717, DOI 10.1083/jcb.84.3.717; AEBERSOLD R, 1990, ADV ELECTROPHORESIS, P81; AGOSTINIS P, 1987, J BIOL CHEM, V262, P1060; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRAUTIGAN DL, 1986, J BIOL CHEM, V261, P4924; BURNS JM, 1994, J BIOL CHEM, V268, P17155; CARON F, 1985, NATURE, V314, P185, DOI 10.1038/314185a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FOULKES JG, 1981, FEBS LETT, V130, P197, DOI 10.1016/0014-5793(81)81118-0; GOUY M, 1989, MOL BIOL EVOL, V6, P109; HINRICHSEN RD, 1992, P NATL ACAD SCI USA, V89, P8601, DOI 10.1073/pnas.89.18.8601; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KLUMPP S, 1990, J CHROMATOGR, V521, P179, DOI 10.1016/0021-9673(90)85042-T; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MIESKES G, 1984, EUR J BIOCHEM, V140, P375, DOI 10.1111/j.1432-1033.1984.tb08112.x; OHISHI S, 1992, TOHOKU J EXP MED, V168, P279, DOI 10.1620/tjem.168.279; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; THIELE J, 1982, EUR J CELL BIOL, V28, P3; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G	36	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32774	32780						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806499				2022-12-27	WOS:A1994QA63800012
J	SHAN, SO; ARMSTRONG, RN				SHAN, SO; ARMSTRONG, RN			RATIONAL RECONSTRUCTION OF THE ACTIVE-SITE OF A CLASS-MU GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ISOENZYME 3-3; AZAARENE OXIDES; COMPLEX; PI; RESOLUTION; ARENE; S-(4-BROMO-2,3-DIOXOBUTYL)GLUTATHIONE; STEREOSELECTIVITY; IDENTIFICATION	Isoenzymes 3-3 and 4-4 of the mu class glutathione S-transferases share 77% sequence identity but have distinctly different catalytic properties. Analysis of the crystal structure of isoenzyme 3-3 in complex with the diastereomeric products of the addition of GSH to phenanthrene 9,10-oxide (Ji, X., Johnson, W. W., Sesay, M. A, Dickert, L., Prasad, S. M., Ammon, H. L., Armstrong, R. N., and Gilliland, G. L. (1994) Biochemistry 33, 1043-1052) reveals that 3 residues that are in van der Waals contact with the xenobiotic portion of the product are different in the type 4 subunit. The three mutations, V9I, I111A, and S209A, have been introduced into isoenzyme 3-3 individually and in combination in an attempt to minimally reconstruct the active site of the enzyme to mimic the type 4 subunit in structure and function. The results suggest that the V9I mutation is an important determinant in the stereoselectivity of the enzyme toward enones and epoxides. The I111A mutation increases the catalytic efficiency of the enzyme toward para-substituted 4-phenyl-3-buten-2-ones (XPBO) as measured by k(cat)/K-m(XPBO) but does not affect k(cat). The S209A mutation has no effect on catalysis. The double and triple mutants V9I/I111A and V9I/I111A/S209A exhibit both a high stereoselectivity and high k(cat)/K-m(XPBO) comparable to that of isoenzyme 4-4. Analysis of substituent effects on the kinetics and stereoselectivity of the enzyme toward the enone substrates suggests that the mechanistic bases for the catalytic behavior of the isoenzyme 4-4 and the reconstructed mutants are not identical. The results provide functional evidence for the catalytic importance of specific residues previously identified by x-ray crystallography.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NIGMS NIH HHS [GM30910] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BOEHLERT CC, 1984, BIOCHEM BIOPH RES CO, V121, P980, DOI 10.1016/0006-291X(84)90773-3; BRUICE PY, 1976, J AM CHEM SOC, V98, P2973, DOI 10.1021/ja00426a049; Cleland W W, 1979, Methods Enzymol, V63, P103; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; FUJITA T, 1964, J AM CHEM SOC, V86, P5175, DOI 10.1021/ja01077a028; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; Hansch C, 1979, SUBSTITUENT CONSTANT; HIGUCHI R, 1991, PCR TECHNOLOGY, P61; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KUBO Y, 1989, CHEM RES TOXICOL, V2, P144, DOI 10.1021/tx00009a003; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WANG RW, 1992, J BIOL CHEM, V267, P19866; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZHANG PH, 1991, J BIOL CHEM, V266, P19475; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121; ZHANG PH, 1992, BIOCHEMISTRY-US, V31, P10185, DOI 10.1021/bi00157a005	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32373	32379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798237				2022-12-27	WOS:A1994PX30400055
J	SJOLING, S; ERIKSSON, A; GLASER, E				SJOLING, S; ERIKSSON, A; GLASER, E			A HELICAL ELEMENT IN THE C-TERMINAL DOMAIN OF THE N-PLUMBAGINIFOLIA F-1-BETA PRESEQUENCE IS IMPORTANT FOR RECOGNITION BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPINACH LEAF MITOCHONDRIA; YEAST MITOCHONDRIA; PROTEIN IMPORT; ALDEHYDE DEHYDROGENASE; PRECURSOR; ENZYME; PURIFICATION; REDUCTASE; POTATO	The mitochondrial processing peptidase (MPP) in lower eucaryots and mammals is a matrix enzyme, whereas MPP in plants constitutes an integral part of the be, complex of the respiratory chain, The isolated spinach leaf be, complex catalyzes cleavage of the precursor of Nicotiana plumbaginifolia F1 beta subunit of the ATP synthase, resulting in a production of mature protein and a presequence that consists of 54 amino acids, A synthetic peptide derived from the C-terminal part of the presequence, containing 17 amino acids with a helical structural element, p-F-1 beta(38-54), was an efficient inhibitor of the processing, whereas a peptide derived from the N-terminal part of the presequence, p-F-1 beta(1-18), was much less effective, ATIII, a helical peptide derived from antithrombin III, was not recognized by MPP. Synthetic peptides corresponding to 4, 6, and 11 amino acids of the C terminus of the presequence, p-F-1 beta(51-54), p-F-1 beta(49-54), and p-F-1 beta(44-54) were almost completely inert, Competition studies show that MPP recognizes the C-terminal domain of the presequence rather than the N-terminal domain, Furthermore, the alpha-helical element of the C-terminal domain is shown to be required for the recognition event.	UNIV STOCKHOLM,DEPT BIOCHEM,ARRHENIUS LABS NAT SCI,S-10691 STOCKHOLM,SWEDEN	Stockholm University								ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P404; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHU TW, 1989, J BIOL CHEM, V264, P9552; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; HAMASUR B, 1990, PHYSIOL PLANTARUM, V78, P367, DOI 10.1111/j.1399-3054.1990.tb09050.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SHULTE U, 1989, NATURE, V339, P147; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	29	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32059	32062						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798199				2022-12-27	WOS:A1994PX30400010
J	TAKEUCHI, Y; KODAMA, Y; MATSUMOTO, T				TAKEUCHI, Y; KODAMA, Y; MATSUMOTO, T			BONE-MATRIX DECORIN BINDS TRANSFORMING GROWTH-FACTOR-BETA AND ENHANCES ITS BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT TGF-BETA; SULFATE PROTEOGLYCANS; OSTEOBLASTIC CELLS; PURIFICATION; COMPLEX; IDENTIFICATION; PROTEINS; FORMS	In an effort to clarify the regulation of distribution and actions of transforming growth factor (TGF)-beta in bone, TGF-beta 1 binding to extracted bone matrix proteins and the influence of such binding on TGF-beta 1 actions were examined. In-gel binding of I-125-TGF-beta 1 using extracts from mineralized bovine bone matrix demonstrated that I-125-TGF-beta 1 was almost exclusively bound to a proteoglycan, decorin. The binding was via the core protein of decorin. Scatchard analysis of the binding of I-125-TGF-beta 1 to immobilized decorin purified from osteoblastic MC3T3-E1 cell conditioned medium revealed that there were two specific binding sites with high and low affinities for TGF-beta 1 (K-d = 0.3 and 5 nM, respectively). The addition of decorin along with TGF-beta 1 enhanced the inhibitory effect of TGF-beta 1 on MC3T3-E1 cell proliferation. Decorin in itself did not affect their proliferation. These cells possessed types I and IZ TGF-P receptors and betaglycan, and the addition of decorin increased the binding of I-125-TGF-beta 1 to all these receptors. These results demonstrate that the core protein of decorin specifically binds TGF-beta 1 with high affinities and that the binding of TGF-beta 1 to decorin increases TGF-beta 1 binding to its receptors and enhances its bioactivity. Because TGF-beta is released by bone resorption along with matrix proteins, including decorin, and because it stimulates the synthesis of these proteins, it is suggested that the binding and enhancement of the activities of TGF-beta by decorin may play a role in maintaining bone formation during bone remodeling process.			TAKEUCHI, Y (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.							BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; GEHRONROBEY P, 1987, J CELL BIOL, V105, P457; HARADA S, 1991, J BONE MINER RES, V6, P903; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; RITTER NM, 1992, J BONE MINER RES, V7, P877; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAKEUCHI Y, 1989, J BIOL CHEM, V264, P18407; TAKEUCHI Y, 1992, ARCH BIOCHEM BIOPHYS, V298, P371, DOI 10.1016/0003-9861(92)90424-U; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P821; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	28	182	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32634	32638						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798269				2022-12-27	WOS:A1994PX30400091
J	LEEYOON, D; EASTON, D; MURAWSKI, M; BURD, R; SUBJECK, JR				LEEYOON, D; EASTON, D; MURAWSKI, M; BURD, R; SUBJECK, JR			IDENTIFICATION OF A MAJOR SUBFAMILY OF LARGE HSP70-LIKE PROTEINS THROUGH THE CLONING OF THE MAMMALIAN 110-KDA HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEINS; NUCLEOLAR LOCALIZATION; BINDING DOMAIN; CELL; SIMILARITY; ACTIN; SITE; GLIA; AXON	A major mammalian heat shock protein of 110 kDa (hsp110) has long been observed, but has not been cloned. We have cloned the hamster cDNA for hsp110 and show that it hybridizes on a Northern blot to a 3.5-kilobase heat-inducible message in hamster and mouse. The hsp110 sequence was found to share an similar to 30-33% amino acid identity with members of the hsp70 family, most of which occurs in the conserved ATP-binding domain of these molecules. In addition, five sequences were found to be highly similar to hsp110. These are the sea urchin egg receptor for sperm (Foltz, K. R., Partin, J. S., and Lennarz, W. J. (1993) Science 259, 1421-1425) and additional sequences from human and Caenorhaditis elegans and two from yeast. The carboxyl-teminal two-thirds of hsp110 and these five related proteins contain a pattern of highly conserved regions of sequence unique to this group. A probe containing these conserved sequences was found to strongly cross-react on a Southern blot with genomic sequences from yeast to man. A Western blot analysis of several murine tissues indicates that hsp110 is constitutively expressed in all mouse tissues and is highly expressed in brain. Therefore, hsp110 belongs to a new category of large and structurally unique stress proteins that are the most distantly related known members of the hsp70 family.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; SUNY COLL BUFFALO, DEPT BIOL, BUFFALO, NY 14222 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; Buffalo State College			Easton, Douglas/A-9359-2009; Easton, Douglas/AAU-4216-2020	Easton, Douglas/0000-0003-4288-0774; Easton, Douglas/0000-0003-4288-0774; Burd, Randy/0000-0001-9195-2733	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LANDRY J, 1982, CANCER RES, V42, P2457; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MEIER UT, 1992, CELL, V70, P127; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Moore DD, 1995, GLOB MOB SURV; MUKAI H, 1993, GENE, V132, P57; OHLENDIECK K, 1994, J CELL BIOL, V125, P817, DOI 10.1083/jcb.125.4.817; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; POSNETT DN, 1989, METHOD ENZYMOL, V178, P739; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; SUBJECK JR, 1983, J CELL BIOL, V97, P1389, DOI 10.1083/jcb.97.5.1389; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOMASOVIC SP, 1983, RADIAT RES, V95, P399, DOI 10.2307/3576265; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; TYTELL M, 1987, AXONAL TRANSPORT, P473; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	43	107	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15725	15733		10.1074/jbc.270.26.15725	http://dx.doi.org/10.1074/jbc.270.26.15725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797574	hybrid			2022-12-27	WOS:A1995RG53800046
J	OHTA, T; KOBAYASHI, M; HIROSE, S				OHTA, T; KOBAYASHI, M; HIROSE, S			CLONING OF A CDNA FOR DNA SUPERCOILING FACTOR REVEALS A DISTINCTIVE CA2+-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II; TORSIONAL TENSION; ESCHERICHIA-COLI; HUMAN-CELLS; BINDING; SEQUENCE; PURIFICATION; POLYMERASE; EXPRESSION; REGIONS	DNA supercoiling factor is a protein capable of generating negative supercoils into a relaxed DNA in conjunction with eukaryotic DNA topoisomerase II. A cDNA clone encoding the Bombyx mori supercoiling factor has been isolated and characterized. The cDNA sequence contains an open reading frame of 322 amino acids rich in acidic residues. A local region of the predicted polypeptide shares a weak homology with the central portion of bacterial DNA gyrase A subunit. The cDNA sequence also predicts two direct repeats within the factor. Each repeat unit consists of a potential EF-hand domain. The factor contains three other potential EF-hand domains and actually binds Ca2+. Moreover, the supercoiling reaction has been shown to be activated by Ca2+. These results implicate Ca2+ in the control of the superhelical state of DNA.	NATL INST GENET,DEPT DEV GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,DEPT GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan			Hirose, Susumu/I-8865-2019					ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BATES AD, 1993, DNA TOPOLOGY, P73; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; JUPE ER, 1993, EMBO J, V12, P1067, DOI 10.1002/j.1460-2075.1993.tb05748.x; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OHTA T, 1990, P NATL ACAD SCI USA, V87, P5307, DOI 10.1073/pnas.87.14.5307; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABUCHI H, 1993, BIOCHEM BIOPH RES CO, V192, P1432, DOI 10.1006/bbrc.1993.1576; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; WANG JC, 1992, TRANSCRIPTIONAL REGU, P1253	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15571	15575		10.1074/jbc.270.26.15571	http://dx.doi.org/10.1074/jbc.270.26.15571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797553	hybrid			2022-12-27	WOS:A1995RG53800023
J	TRAUTWEIN, C; WALKER, DL; PLUMPE, J; MANNS, MP				TRAUTWEIN, C; WALKER, DL; PLUMPE, J; MANNS, MP			TRANSACTIVATION OF LAP/NF-IL6 IS MEDIATED BY AN ACIDIC DOMAIN IN THE N-TERMINAL PART OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; LEUCINE ZIPPER; C/EBP FAMILY; FACTOR-TFIIB; NUCLEAR FACTOR; PHOSPHORYLATION; EXPRESSION; ELEMENTS; BINDING; CELLS	LAP/NF-IL6 is a member of the C/EBP family of transcriptional activators and has been shown to be involved in the regulation of the acute-phase response. We have previously shown that phosphorylation of the liver-enriched transcriptional activator protein (LAP) Ser-105 enhances the activation of LAP-dependent genes. To identify the region which is important for gene activation, a series of LAP mutants were constructed, and domain swapping experiments with the DNA-binding domain of GAL4 were performed. These experiments point to an acidic region located between amino acids 21 and 105 of LAP/NF-IL6 which activates genes independent of the DNA-binding domain and the leucine zipper of LAP/NF-IL6. Computer-assisted predictions reveal two regions, a helical and a hydrophobic region in the transactivation domain, which could be important in mediating the direct interaction with the basal machinery. Site-directed mutagenesis of acidic residues in both regions demonstrates that the hydrophobic region located between amino acids 85 and 95 is the likely motif for the interaction with the basal machinery. Our results demonstrate that a hydrophobic region in the acidic transactivation domain of LAP/NF-IL6 seems to be relevant in mediating gene activation of LAP dependent genes.	HANNOVER MED SCH,ZENTRUM INNERE MED & DERMATOL,GASTROENTEROL & HEPATOL ABT,D-30625 HANNOVER,GERMANY	Hannover Medical School								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DELEAGE G, 1987, ANAL BIOCHEM, V163, P292, DOI 10.1016/0003-2697(87)90226-0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15130	15136		10.1074/jbc.270.25.15130	http://dx.doi.org/10.1074/jbc.270.25.15130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797496	hybrid			2022-12-27	WOS:A1995RE66600044
J	LAMA, J; SANZ, MA; RODRIGUEZ, PL				LAMA, J; SANZ, MA; RODRIGUEZ, PL			A ROLE FOR 3AB PROTEIN IN POLIOVIRUS GENOME REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA AMPLIFICATION; LINKED PROTEIN; NONSTRUCTURAL PROTEINS; ESCHERICHIA-COLI; POLYMERASE; VPG; INITIATION; POLYPEPTIDE; PRECURSOR; SEQUENCE	The poliovirus polypeptide 3AB, the precursor of the genome-bound VPg protein, stimulates in vitro the synthesis of poly(U) directed by the viral polymerase 3D(pol) (Lama, J., Paul, A., Harris, K., and Wimmer, E. (1994) J. Biol. Chem. 269, 66-70), suggesting that 3AB could be modulating the activity of the viral polymerase in poliovirus-infected cells. To address the exact function of 3AB in the viral replication cycle, a biochemical and molecular genetic analysis of 3AB has been carried out, 3AB protein bound RNA probes in two different assays, and amino acid positions implicated in the RNA binding activity of 3AB were determined, Mutant proteins with reduced RNA binding activity were unable to stimulate 3D(pol) polymerase activity. Purified protein 3A showed no RNA binding or 3D(pol) stimulatory activity, but 3A and VPg mutations conferred a synergistic effect on the 3AB functions. Polioviruses encoding for these mutant SABs were constructed. These mutant viruses translated their RNA genomes in vitro and processed their polyproteins as wild type virus did. Cells infected with 3AB mutant viruses showed over 90% inhibition in the accumulation of plus and minus viral RNA strands and more than 100-fold reduction of virus yield at 4 h postinfection. Our results suggest that 3AB protein functions in vivo as a co-factor of the viral polymerase and that the activity of 3AB maybe regulated by proteoIytic processing.			LAMA, J (corresponding author), UNIV AUTONOMA MADRID, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN.		Rodriguez, Pedro L./K-4605-2014; Sanz, Miguel A/H-1914-2015; sanz-gomez, miguel/Y-6244-2019	Rodriguez, Pedro L./0000-0002-5886-9425; Sanz, Miguel A/0000-0001-6573-883X; sanz-gomez, miguel/0000-0002-5761-9010				ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; BURNS CC, 1989, J VIROL, V63, P4866, DOI 10.1128/JVI.63.11.4866-4874.1989; Favaloro J, 1980, Methods Enzymol, V65, P718; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1979, J VIROL, V29, P352, DOI 10.1128/JVI.29.1.352-360.1979; FLANEGAN JB, 1979, J VIROL, V32, P155, DOI 10.1128/JVI.32.1.155-161.1979; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; Kirkegaard K, 1992, CURR OPIN GENET DEV, V2, P64, DOI 10.1016/S0959-437X(05)80324-7; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; KUHN RJ, 1988, J VIROL, V62, P4207, DOI 10.1128/JVI.62.11.4207-4215.1988; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1992, J BIOL CHEM, V267, P15932; LARSEN GR, 1982, J VIROL, V41, P340, DOI 10.1128/JVI.41.1.340-344.1982; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SEMLER BL, 1988, RNA GENETICS, V1, P23; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WIMMER E, 1987, J CELL SCI, P251; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	38	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14430	14438		10.1074/jbc.270.24.14430	http://dx.doi.org/10.1074/jbc.270.24.14430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782305	hybrid			2022-12-27	WOS:A1995RD45500032
J	YOUN, HD; YIM, YI; KIM, K; HAH, YC; KANG, SO				YOUN, HD; YIM, YI; KIM, K; HAH, YC; KANG, SO			SPECTRAL CHARACTERIZATION AND CHEMICAL MODIFICATION OF CATALASE-PEROXIDASE FROM STREPTOMYCES SP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL HISTIDINE RESIDUE; RESONANCE RAMAN-SPECTRA; ELECTRON-PARAMAGNETIC RESONANCE; LIGNIN-DEGRADING BASIDIOMYCETE; PHANEROCHAETE-CHRYSOSPORIUM; DIARYLPROPANE OXYGENASE; BACTERIAL CATALASES; HEME ENZYME; PURIFICATION; PROTEINS	Catalase-peroxidase was purified to near homogeneity from Streptomyces sp. The enzyme was composed of two subunits with a molecular mass of 78 kDa and contained 1.05 mol of protoporphyrin IX/mol of dimeric protein. The absorption and resonance Raman spectra of the native and its cyano-enzyme were closely similar to those of other heme proteins with a histidine as the fifth ligand. However, the peak from tyrosine ring at similar to 1612 cm(-1), which is unique in catalases, was not found in resonance Raman spectra of catalase-peroxidase. The electron paramagnetic resonance spectrum of the native enzyme revealed uniquely two sets of rhombic signals, which were converted to a single high spin, hexacoordinate species after the addition of sodium formate. Cyanide bound to the sixth coordination position of the heme iron, thereby converting the enzyme to a low spin, hexacoordinate species. The time-dependent inactivation of the enzyme with diethyl pyrocarbonate and its kinetic analysis strongly suggested the occurrence of histidine residue. From the above-mentioned spectroscopic results and chemical modification, it was deduced that the native enzyme is predominantly in the high spin, ferric form and has a histidine as the fifth ligand.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, DEPT CHEM, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)			Youn, Hong-Duk/J-2774-2012					ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1987, BIOCHEMISTRY-US, V26, P2258, DOI 10.1021/bi00382a028; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; APPLEBY CA, 1959, BIOCHEM J, V73, P539, DOI 10.1042/bj0730539; BEERS RF, 1952, J BIOL CHEM, V195, P133; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BROWNPETERSON NJ, 1993, J BACTERIOL, V175, P4197, DOI 10.1128/JB.175.13.4197-4202.1993; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLAYTON RK, 1959, BIOCHIM BIOPHYS ACTA, V36, P40, DOI 10.1016/0006-3002(59)90067-8; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EHRENBERG A, 1962, ARK KEMI, V19, P119; ESAKA M, 1982, PLANT CELL PHYSIOL, V23, P315; FELTON RH, 1978, PORPHYRINS, V3, P347; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1984, ARCH BIOCHEM BIOPHYS, V234, P353, DOI 10.1016/0003-9861(84)90280-7; HERBERT D, 1948, BIOCHEM J, V43, P193, DOI 10.1042/bj0430193; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; JACOB GS, 1979, BIOCHEMISTRY-US, V18, P2975, DOI 10.1021/bi00581a010; KANG SO, 1993, BIOCHIM BIOPHYS ACTA, V1163, P158, DOI 10.1016/0167-4838(93)90177-S; Kim H. P., 1992, KOREAN J MICROBIOL, V30, P291; KITAGAWA T, 1975, CHEM LETT, P849, DOI 10.1246/cl.1975.849; Kitagawa T, 1978, Adv Biophys, V11, P153; LAMBIN P, 1978, ANAL BIOCHEM, V85, P114, DOI 10.1016/0003-2697(78)90281-6; LANIR A, 1979, BIOCHEMISTRY-US, V18, P1656, DOI 10.1021/bi00576a004; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; LUNDBALD RL, 1984, CHEM REAGENTS PROTEI, V1; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MINO Y, 1988, J BIOL CHEM, V263, P7029; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULRAD A, 1967, BIOCHIM BIOPHYS ACTA, V2, P19; NADLER V, 1986, BIOCHIM BIOPHYS ACTA, V882, P234, DOI 10.1016/0304-4165(86)90160-1; OZOLS J, 1964, J BIOL CHEM, V239, P1018; RAKSHIT G, 1974, BIOCHEMISTRY-US, V13, P5317, DOI 10.1021/bi00723a010; SATO R, 1978, CYTOCHROME P450; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; SIEVERS G, 1979, BIOCHIM BIOPHYS ACTA, V581, P1, DOI 10.1016/0005-2795(79)90215-0; SPAULDING LD, 1975, J AM CHEM SOC, V97, P2517, DOI 10.1021/ja00842a032; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; TORII K, 1968, J BIOCHEM-TOKYO, V64, P171, DOI 10.1093/oxfordjournals.jbchem.a128877; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9	53	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13740	13747		10.1074/jbc.270.23.13740	http://dx.doi.org/10.1074/jbc.270.23.13740			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775429	hybrid			2022-12-27	WOS:A1995RC44800026
J	HERTZ, R; BISHARASHIEBAN, J; BARTANA, J				HERTZ, R; BISHARASHIEBAN, J; BARTANA, J			MODE OF ACTION OF PEROXISOME PROLIFERATORS AS HYPOLIPIDEMIC DRUGS - SUPPRESSION OF APOLIPOPROTEIN C-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; BETA,BETA'-METHYL-SUBSTITUTED HEXADECANEDIOIC ACID; HORMONE RECEPTOR SUPERFAMILY; TRIGLYCERIDE-RICH LIPOPROTEINS; CIII GENE-EXPRESSION; ACTIVATED RECEPTOR; RAT-LIVER; TRANSCRIPTIONAL REGULATION; CLOFIBRIC ACID; HEPATIC-UPTAKE	The hypolipidemic effect exerted by beta,beta'-tetramethyl-hexadecanedioic acid (Medica 16) is accounted for by enhanced catabolism of plasma triglyceride-rich lipoproteins due to a decrease in plasma apolipoprotein C-III (Frenkel, B., Mayorek, N., Hertz, R., and Bar-Tana, J. (1988) J. Biol. Chem. 263, 8491-8497; Frenkel, B., Bishara-Shieban, J., and Bar-Tana, J. (1994) Biochem. J. 298, 409-414). Decrease in apolipoprotein C-III exerted by peroxisome proliferators/hypolipidemic amphipathic carboxylates (e.g. Medica 16, fibrate drugs) is shown here to result from suppression of apolipoprotein C-III gene expression. Transcriptional suppression of apolipoprotein C-III is due to transcriptional suppression of hepatic nuclear factor (HNF)-4 as well as displacement of HNF-4 from the apolipoprotein C-III promoter. HNF-4 displacement exerted by peroxisome proliferators/hypolipidemic amphipathic carboxylates is mediated by the peroxisome proliferators activated receptor (PPAR). Transcriptional suppression of HNF-4-enhanced genes (e.g. apolipoprotein C-III) along with transcriptional activation of peroxisomal and other genes by hypolipidemic drugs may account for their broad spectrum pharmacological effect.	HEBREW UNIV JERUSALEM,FAC MED,DEPT HUMAN NUTR & METAB,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BARTANA J, 1988, J LIPID RES, V29, P431; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BARTANA J, 1989, J MED CHEM, V32, P2072, DOI 10.1021/jm00129a010; CHEN M, 1994, J LIPID RES, V35, P1918; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRENKEL B, 1994, BIOCHEM J, V298, P409, DOI 10.1042/bj2980409; FRENKEL B, 1988, J BIOL CHEM, V263, P8491; GIBSON G, 1993, PEROXISOMES BIOL IMP; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG AP, 1977, NEW ENGL J MED, V301, P1073; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRETEN H, 1980, LIPOPROTEINS CORONAR; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; HERTZ R, 1987, CANCER LETT, V34, P263, DOI 10.1016/0304-3835(87)90176-5; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KALDERON B, 1992, ENDOCRINOLOGY, V131, P1629, DOI 10.1210/en.131.4.1629; KASHYAP ML, 1981, J LIPID RES, V22, P800; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, DECONTAMINATION DILU; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V188, P799, DOI 10.1016/0006-291X(92)91127-C; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REUE K, 1988, J BIOL CHEM, V263, P6857; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, TRANSCRIPTINAL REGUL; THORP JM, 1962, NATURE, V194, P948, DOI 10.1038/194948a0; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VESSBY B, 1980, ATHEROSCLEROSIS, V37, P257, DOI 10.1016/0021-9150(80)90011-8; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V25, P556; YASHUSHI I, 1990, SCIENCE, V249, P790; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	57	303	325	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13470	13475		10.1074/jbc.270.22.13470	http://dx.doi.org/10.1074/jbc.270.22.13470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768950	hybrid			2022-12-27	WOS:A1995RB43900076
J	LEHRICH, RW; FORREST, JN				LEHRICH, RW; FORREST, JN			PROTEIN-KINASE-C-ZETA IS ASSOCIATED WITH THE MITOTIC APPARATUS IN PRIMARY-CELL CULTURES OF THE SHARK RECTAL GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SACCHAROMYCES-CEREVISIAE; ACTIVATION; IMMUNOCHARACTERIZATION; EXPRESSION; ISOFORMS; TUBULES	Protein kinase C zeta (PKC zeta) is an atypical PKC isoform that has recently been implicated in cell division and cell growth. However, there has been no morphologic evidence for the involvement of PKC zeta in mitogenic signal transduction. Here we use immunocytochemistry to demonstrate that PKC zeta co-localizes with microtubules in both interphase and metaphase cells of the shark rectal gland in primary culture. This co-localization is present after non-ionic detergent treatment and is disrupted by nocodazole. During mitosis, PKC zeta is associated with the mitotic apparatus and co-localizes with beta-tubulin in spindle microtubules, while entirely sparing astral microtubules. These findings provide the first evidence that PKC zeta is associated with the mitotic apparatus. The striking presence of PKC zeta in the central portion of the mitotic apparatus suggests a functional role for this kinase isoform in cell division.	YALE UNIV,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,NEW HAVEN,CT 06510; MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672	Yale University; Mount Desert Island Biological Laboratory					NIDDK NIH HHS [DK 34208-09] Funding Source: Medline; NIEHS NIH HHS [P30-ES 3828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; CHURCH DJ, 1993, BIOCHEM J, V290, P477, DOI 10.1042/bj2900477; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVOR DC, 1994, IN PRESS AM J PHYSL; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FORREST JN, 1983, J CLIN INVEST, V72, P1163, DOI 10.1172/JCI111041; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; GREGER R, 1988, COMP BIOCHEM PHYS A, V90, P733, DOI 10.1016/0300-9629(88)90692-5; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRICH RW, 1994, J AM SOC NEPHROL, V5, P721; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; STASIA MJ, 1990, FEBS LETT, V274, P61, DOI 10.1016/0014-5793(90)81329-M; VALENTICH J, 1990, AM J PHYSIOL, V260, pC813; Valentich JD, 1991, J TISS CULT METHODS, V13, P149; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817	35	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32446	32450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798244				2022-12-27	WOS:A1994PX30400065
J	TEPPER, AD; DAMMANN, H; BOMINAAR, AA; VERON, M				TEPPER, AD; DAMMANN, H; BOMINAAR, AA; VERON, M			INVESTIGATION OF THE ACTIVE-SITE AND THE CONFORMATIONAL STABILITY OF NUCLEOSIDE DIPHOSPHATE KINASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; DICTYOSTELIUM-DISCOIDEUM; DROSOPHILA DEVELOPMENT; MYXOCOCCUS-XANTHUS; HEXAMERIC ENZYME; GENE; NM23; MUTATION; CLONING; PROTEIN	Nucleoside-diphosphate kinase (EC 2.7.4.6) catalyzes phosphate exchange between nucleoside triphosphates and nucleoside diphosphates. Its 17 kDa subunits are highly conserved throughout evolution in both sequence and tertiary structure. Using site-directed mutagenesis we investigated the function of 8 amino acids (LyS(16), Tyr(56), Arg(92), Thr(98), Arg(109), Asn(119), Ser(124) and Glu(193)) that are totally conserved among all nucleoside diphosphate kinases known to date. The mutant proteins all show decreased specific activity and support roles for these residues in catalysis, substrate binding, or both, as was previously proposed on the basis of the x-ray structure (Morera, S., Lascu, I., Dumas, C., LeBras, G., Briozzo, P., Veron, M., and Janin, J. (1994) Biochemistry 33, 459-467), Furthermore, residues Lys(16), Arg(109), and Asn(119) were identified to play important roles in conformational stability or subunit interactions. We show that Lys(16) and Asn(119) form a rigid structure that is important for enzymatic function and that Arg(109), known to interact with the phosphate moiety of the substrate, also plays an important role in subunit association. The dual roles of Lys(16), Arg(109), and Asn(119) in both substrate binding and subunit assembly provide further evidence for a functional coupling between catalytic activity and quaternary structure in nucleoside diphosphate kinase.	INST PASTEUR,CNRS,URA 1129,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WALLET V, 1992, THESIS U PARIS 7; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	29	69	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32175	32180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798215				2022-12-27	WOS:A1994PX30400027
J	ELHAYEK, R; YANO, M; IKEMOTO, N				ELHAYEK, R; YANO, M; IKEMOTO, N			A CONFORMATIONAL CHANGE IN THE JUNCTIONAL FOOT PROTEIN IS INVOLVED IN THE REGULATION OF CA2+ RELEASE FROM SARCOPLASMIC-RETICULUM - STUDIES ON POLYLYSINE-INDUCED CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM RELEASE; RYANODINE RECEPTOR; ADENINE-NUCLEOTIDES; TRANSVERSE TUBULE; CHARGE MOVEMENT; CA-2+ RELEASE; CHANNEL; BINDING	We investigated both conformational changes in the junctional foot protein (JFP) and Ca2+ release from sarcoplasmic reticulum (SR) in parallel after stimulation of triadic vesicles by the JFP-specific ligand, polylysine, To monitor protein conformational change, the JFP was labeled in a site-directed fashion with the fluorescent conformational probe methylcoumarin acetate (MCA) (Kang, J, J,, Tarcsafalvi, A., Carlos, A. D,, Fujimoto, E,, Shahrokh, Z,, Thevenin, B, J,-M,, Shohet; S, B,, and Ikemoto, N, (1992) Biochemistry 31, 3288-3293), The induction of SR Ca2+ release by polylysine produced a rapid increase in the fluorescence intensity of the JFP-bound MCA. The polylysine concentration dependence of the fluorescence change was essentially the same as that of Ca2+ release, suggesting that the two events are tightly coupled, However, the rate constant of MCA fluorescence change was much larger than that of Ca2+ release; i.e. the conformational change preceded Ca2+ release, Prevention of protein conformational change by lysine (0.2 M) inhibited Ca2+ release from SR, Inhibition of Ca2+ release by Mg2+ (5 mM), however, had little effect on the conformational change, These results suggest that binding of polylysine to the JFP produces conformational changes in the protein, which in turn activates the Ca2+ channel, leading to Ca2+ release from the SR.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR 16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CHU A, 1990, MOL PHARMACOL, V37, P735; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1985, J BIOL CHEM, V260, P4096; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOUIS CF, 1992, ANESTHESIOLOGY, V77, P114, DOI 10.1097/00000542-199207000-00017; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OHKUSA T, 1991, J BIOCHEM-TOKYO, V109, P609, DOI 10.1093/oxfordjournals.jbchem.a123428; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THEVENIN BJM, 1992, EUR J BIOCHEM, V206, P471, DOI 10.1111/j.1432-1033.1992.tb16949.x; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15634	15638		10.1074/jbc.270.26.15634	http://dx.doi.org/10.1074/jbc.270.26.15634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797562	hybrid			2022-12-27	WOS:A1995RG53800032
J	FRANCIS, JW; HOSLER, BA; BROWN, RH; FISHMAN, PS				FRANCIS, JW; HOSLER, BA; BROWN, RH; FISHMAN, PS			CUZN SUPEROXIDE-DISMUTASE (SOD-1)-TETANUS TOXIN FRAGMENT-C HYBRID PROTEIN FOR TARGETED DELIVERY OF SOD-1 TO NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS; RETROGRADE AXONAL-TRANSPORT; TETANUS TOXIN; ESCHERICHIA-COLI; TRANSGENIC MICE; HIGH-AFFINITY; OXIDATIVE STRESS; CULTURED NEURONS; BRAIN MEMBRANES	Increased levels of CuZn superoxide dismutase (SOD-1) are cytoprotective in experimental models of neurological disorders associated with free radical toxicity (e.g. stroke, trauma). Targeted delivery of SOD-1 to central nervous system neurons may therefore be therapeutic in such diseases. The nontoxic C-fragment of tetanus toxin (TTC) possesses the nerve cell binding/transport properties of tetanus holotoxin and has been used as a vector to enhance the neuronal uptake of proteins including enzymes. We have now produced a recombinant, hybrid protein in Escherichia coli tandemly joining human SOD-1 to TTC. The expressed hybrid protein (SOD:Tet451) has a subunit molecular mass of 68 kDa and is recognized by both anti-SOD-1 and anti-TTC antibodies. Calculated per mol, SOD:Tet451 has approximately 60% of the expected SOD-1 enzymatic activity. Analysis of the hybrid protein's interaction with the neuron-like cell line, N18-RE-105, and cultured hippocampal neurons by enzyme immunoassay for human SOD-1 revealed that SOD:Tet451 association with cells was neuron-specific and dose-dependent. The hybrid protein was also internalized, but there was substantial loss of internalized hybrid protein over the first 24 h. Hybrid protein associated with cells remained enzymatically active. These results suggest that human SOD-1 and TTC retain their respective functional properties when expressed together as a single peptide. SOD: Tet451 may prove to be a useful agent for the targeted delivery of SOD-1 to neurons.	UNIV MARYLAND, SCH MED, DEPT ANAT, BALTIMORE, MD 21201 USA; MASSACHUSETTS GEN HOSP, CECIL B DAY LAB NEUROMUSCULAR RES, BOSTON, MA 02129 USA; UNIV MARYLAND, SCH MED, VET ADM MED CTR, NEUROL SERV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT NEUROL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore					NINDS NIH HHS [NS31248-01, 1P01NS31248] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248, P50NS031248] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBINOTEIXEIRA A, 1991, N-S ARCH PHARMACOL, V344, P36; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEAUDE P, 1990, BIOCHEM J, V271, P87, DOI 10.1042/bj2710087; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BEYER WF, 1987, ANAL BIOCHEM, V161, P559, DOI 10.1016/0003-2697(87)90489-1; BIZZINI B, 1980, BRAIN RES, V193, P221, DOI 10.1016/0006-8993(80)90959-2; BIZZINI B, 1977, J NEUROCHEM, V28, P529, DOI 10.1111/j.1471-4159.1977.tb10423.x; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOUCHER P, 1994, INFECT IMMUN, V62, P449, DOI 10.1128/IAI.62.2.449-456.1994; CABOT JB, 1991, NEUROSCIENCE, V40, P805, DOI 10.1016/0306-4522(91)90014-F; CADET JL, 1994, J NEUROCHEM, V62, P380; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CRITCHLEY DR, 1985, J CELL BIOL, V100, P1499, DOI 10.1083/jcb.100.5.1499; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DOBRENIS K, 1992, P NATL ACAD SCI USA, V89, P2297, DOI 10.1073/pnas.89.6.2297; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; FAIRWEATHER NF, 1986, J BACTERIOL, V165, P21, DOI 10.1128/jb.165.1.21-27.1986; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; FISHMAN PS, 1990, J NEUROL SCI, V98, P311, DOI 10.1016/0022-510X(90)90272-O; FRANCIS J W, 1991, Society for Neuroscience Abstracts, V17, P754; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HABERMANN E, 1973, N-S ARCH PHARMACOL, V276, P327, DOI 10.1007/BF00499887; HABIG WH, 1986, J NEUROCHEM, V47, P930; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HARTMAN JR, 1986, P NATL ACAD SCI USA, V83, P7142, DOI 10.1073/pnas.83.19.7142; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; INOUE M, 1990, ADV EXP MED BIOL, V264, P5; INOUE M, 1991, J BIOL CHEM, V266, P16409; KINOSHITA A, 1991, PATHOBIOLOGY, V59, P340, DOI 10.1159/000163674; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1979, J BIOL CHEM, V254, P3826; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MAKOFF AJ, 1989, BIO-TECHNOL, V7, P1043; MAKOFF AJ, 1989, NUCLEIC ACIDS RES, V17, P10191, DOI 10.1093/nar/17.24.10191; MALOUF AT, 1984, J BIOL CHEM, V259, P2756; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MICHELSON AM, 1980, ACTA PHYSIOL SCAND, P67; MIRSKY R, 1978, BRAIN RES, V148, P251, DOI 10.1016/0006-8993(78)90399-2; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; PIERCE EJ, 1986, BIOCHEM J, V236, P845, DOI 10.1042/bj2360845; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; ROMANOS MA, 1991, NUCLEIC ACIDS RES, V19, P1461, DOI 10.1093/nar/19.7.1461; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAEZ JC, 1987, P NATL ACAD SCI USA, V84, P3056, DOI 10.1073/pnas.84.9.3056; SANDBERG K, 1989, J BIOL CHEM, V264, P5679; STAUB GC, 1986, J NEUROSCI, V6, P1443; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKEDA Y, 1993, AM J PHYSIOL, V264, pH1708, DOI 10.1152/ajpheart.1993.264.5.H1708; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7	69	68	80	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15434	15442		10.1074/jbc.270.25.15434	http://dx.doi.org/10.1074/jbc.270.25.15434			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797532	hybrid			2022-12-27	WOS:A1995RE66600087
J	SINGER, WD; BROWN, HA; BOKOCH, GM; STERNWEIS, PC				SINGER, WD; BROWN, HA; BOKOCH, GM; STERNWEIS, PC			RESOLVED PHOSPHOLIPASE-D ACTIVITY IS MODULATED BY CYTOSOLIC FACTORS OTHER THAN ARF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; REGULATORY PROTEIN; BOVINE BRAIN; RHO; DISSOCIATION; PURIFICATION; HYDROLYSIS; GDP	Phospholipase D, which has been extracted from porcine brain membranes and chromatographically enriched 100-fold, was activated better by impure preparations of Arf than by purified or recombinant Arf. Examination of brain cytosol with this enriched preparation of PLD activity revealed at least three stimulatory components. One of these is Arf or the first cytoplasmic factor. A second peak of PLD-stimulating activity (cytoplasmic factor II, CFII) was resolved from Arf by anion exchange and gel filtration. This CFII can be further separated into multiple activities by chromatography with heparin-agarose. The activities were differentiated by their stimulatory properties as measured in the absence or presence of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) alone and in the presence of added Arf and GTP gamma S. While all of the CFII pools stimulated PLD activity to some degree and showed synergistic activation when administered in conjunction with Arf, they could be classified into two groups with distinct behavior. When used together, pools from the two respective groups showed synergistic activation of PLD. The first set of pools contained the RhoA monomeric G protein. Recombinant RhoA was used to show that it could indeed activate this enriched PLD activity and act synergistically with Arf proteins. A related monomeric G protein, Cdc42, was also effective. The second set of CFII pools were devoid of RhoA and, in contrast to the first group, demonstrated significant stimulating activity in the absence of guanine nucleotides. These data indicate that the PLD activity from brain can be modulated by several cytosolic factors and that Arf-sensitive PLD may represent a complex activity that can be regulated in an interactive fashion by a variety of cellular signaling events.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM044428, F32GM015359] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM44428, GM15359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD M, 1906, ANAL BIOCHEM, V72, P248; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COCKCROFT S, 1994, SIGNAL ACTIVATED PHO, P65; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DRUBIN DG, 1991, CELL, V65, P1039; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Heller M, 1978, Adv Lipid Res, V16, P267; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SIMMONDS AC, 1985, BIOCHIM BIOPHYS ACTA, V813, P331, DOI 10.1016/0005-2736(85)90249-4; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TERUI T, 1994, J BIOL CHEM, V269, P28130; UEDA T, 1990, J BIOL CHEM, V265, P9373; WANG XM, 1994, J BIOL CHEM, V269, P20312; XU XM, 1994, J BIOL CHEM, V269, P23569; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	129	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14944	14950		10.1074/jbc.270.25.14944	http://dx.doi.org/10.1074/jbc.270.25.14944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797474	hybrid			2022-12-27	WOS:A1995RE66600018
J	SWEE, MH; PARKS, WC; PIERCE, RA				SWEE, MH; PARKS, WC; PIERCE, RA			DEVELOPMENTAL REGULATION OF ELASTIN PRODUCTION - EXPRESSION OF TROPOELASTIN PRE-MESSENGER-RNA PERSISTS AFTER DOWN-REGULATION OF STEADY-STATE MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; 5'-FLANKING REGION; POSTTRANSCRIPTIONAL MECHANISM; EXTRACELLULAR-MATRIX; FUNCTIONAL PROMOTER; FIBROBLAST-CULTURES; SKIN FIBROBLASTS; COLLAGEN GENES; RAT LUNG	To assess the mechanisms controlling the developmental regulation of tropoelastin expression in vivo, we developed a reverse-transcription-polymerase chain reaction (RT-PCR) assay to detect tropoelastin pre-mRNA as an indicator of ongoing transcription in intact tissue. RNA was isolated from mid-fetal (early-elastogenic), neonatal (peak tropoelastin expression), and adult (very low tropoelastin expression) rat lungs and reverse transcribed, and the cDNA was amplified with intron specific primers. A weak hybridization signal for tropoelastin pre-mRNA was seen in mid-fetal samples, and paralleling the increase in steady-state mRNA levels, a strong signal for pre-mRNA was detected in neonatal samples, indicating transcriptional regulation. Stimulation of fetal lung tropoelastin expression by maternal administration of dexamethasone also led to an increase in pre-mRNA levels. However, signal for tropoelastin pre-mRNA in adult samples was equal to that detected in neonatal samples, even though mRNA levels had dropped about 80-fold. Persistence of tropoelastin transcription in adult tissue was also seen in cell culture models and was verified by nuclear runoff assay. In addition, an RT-PCR assay for alpha 1 (I) procollagen pre-mRNA accurately revealed the known transcriptional regulation of this gene. Our results demonstrate that the induction and maintenance of elastogenesis is controlled by a transcriptional mechanism, whereas, the cessation of tropoelastin expression is controlled by a post-transcriptional mechanism.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED DERMATOL,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL048762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594, HL-48762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; Belasco J.G., 2012, CONTROL MESSENGER RN; BERNSTEIN EF, 1994, J INVEST DERMATOL, V103, P182, DOI 10.1111/1523-1747.ep12392693; BOTNEY MD, 1992, AM J PATHOL, V140, P357; BOYD CD, 1991, MATRIX, V11, P235, DOI 10.1016/S0934-8832(11)80230-1; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRUCE MC, 1991, AM J RESP CELL MOL, V5, P344, DOI 10.1165/ajrcmb/5.4.344; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1990, EUR RESPIR J, V3, P1048; DAVIDSON JM, 1986, REGULATION MATRIX AC, P177; DSOUZA RN, 1993, J BONE MINER RES, V8, P1127; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; GOLDSTEIN RH, 1991, AM J PHYSIOL, V261, pL29, DOI 10.1152/ajplung.1991.261.2.L29; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HARPOLD MM, 1981, MOL CELL BIOL, V1, P188, DOI 10.1128/MCB.1.2.188; HEIM RA, 1991, MATRIX, V11, P359, DOI 10.1016/S0934-8832(11)80207-6; HSUWONG S, 1994, J BIOL CHEM, V269, P18072; INDIK Z, 1990, EXTRACELLULAR MATRIX, P221; JAKUBOWSKI M, 1994, J BIOL CHEM, V269, P4078; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; Krug RM, 1993, CURR OPIN CELL BIOL, V5, P944, DOI 10.1016/0955-0674(93)90074-Z; LIU RG, 1993, AM J PHYSIOL, V265, pL430, DOI 10.1152/ajplung.1993.265.5.L430; MAUVIEL A, 1993, J BIOL CHEM, V268, P6520; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1981, J CELL BIOL, V90, P332, DOI 10.1083/jcb.90.2.332; NOGUCHI A, 1992, PEDIATR RES, V31, P280, DOI 10.1203/00006450-199203000-00018; PARKER A, 1993, PUBLIC CULTURE, V6, P133, DOI 10.1215/08992363-6-1-133; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PARKS WC, 1992, MATRIX, V12, P156, DOI 10.1016/S0934-8832(11)80057-0; PARKS WC, 1988, DEV BIOL, V129, P555, DOI 10.1016/0012-1606(88)90400-9; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PIECE RA, 1990, BIOCHEMISTRY-US, V29, P9677; PIECE RA, 1991, GENOMICS, V12, P651; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; PIERCE RA, 1995, AM J PHYSIOL-LUNG C, V268, pL491, DOI 10.1152/ajplung.1995.268.3.L491; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RUCKER RB, 1984, ENV HLTH PERSPECT, V53, P179; SACHS A, 1991, CURR OPIN CELL BIOL, V2, P1092; SAGE H, 1981, COMP BIOCHEM PHYS B, V68, P473, DOI 10.1016/0305-0491(81)90158-9; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; SEHGAL PB, 1976, SCIENCE, V1194, P431; SEPHEL GC, 1986, J INVEST DERMATOL, V86, P279, DOI 10.1111/1523-1747.ep12285424; SEPHEL GC, 1987, J INVEST DERMATOL, V88, P732, DOI 10.1111/1523-1747.ep12470403; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; STENMARK KR, 1994, J CLIN INVEST, V93, P1234, DOI 10.1172/JCI117077; WOLFE BL, 1993, J BIOL CHEM, V268, P12418	53	119	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14899	14906		10.1074/jbc.270.25.14899	http://dx.doi.org/10.1074/jbc.270.25.14899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797468	hybrid			2022-12-27	WOS:A1995RE66600012
J	KASTURI, L; ESHLEMAN, JR; WUNNER, WH; SHAKINESHLEMAN, SH				KASTURI, L; ESHLEMAN, JR; WUNNER, WH; SHAKINESHLEMAN, SH			THE HYDROXY AMINO-ACID IN AN ASN-X-SER/THR SEQUON CAN INFLUENCE N-LINKED CORE GLYCOSYLATION EFFICIENCY AND THE LEVEL OF EXPRESSION OF A CELL-SURFACE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABIES VIRUS GLYCOPROTEIN; PLASMINOGEN-ACTIVATOR; ANIMAL-CELLS; SITES; PROTEIN; SEQUENCE; OLIGOSACCHARIDES; MEMBRANE; BIOSYNTHESIS; SECRETION	N-Linked glycosylation usually occurs at the sequon, Asn-X-Ser/Thr. In this sequon, the side chain of the hydroxy amino acid (Ser or Thr) may play a direct catalytic role in the enzymatic transfer of core oligosaccharides to the Asn residue. Using recombinant variants of rabies virus glycoprotein (RGP), we examined the influence of the hydroxy amino acid on core glycosylation efficiency. A variant of RGP containing a single Asn-X-Ser sequon at Asn(37) was modified by site directed mutagenesis to change the sequon to either Asn-X-Cys or Asn-X-Thr. The impact of these changes on core glycosylation efficiency was assessed by expressing the variants in a cell-free transcription/translation/glycosylation system and in transfected tissue culture cells. Substitution of Cys at position 39 blocks glycosylation, whereas substitution of Thr dramatically increases core glycosylation efficiency of Asn(37) in both membrane-anchored and secreted forms of RGP. The substitution of Thr for Ser also dramatically enhances the level of expression and cell surface delivery of RGP when the sequon at Asn(37) is the only sequon in the protein. Novel forms of membrane-anchored and secreted RGP which are fully glycosylated at all three sequons were also generated by substitution of Thr at position 39.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19106	Case Western Reserve University; The Wistar Institute								ANILIONIS A, 1981, NATURE, V294, P275, DOI 10.1038/294275a0; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1989, 10TH INT S GLYC JER; BENMANSOUR A, 1992, VIROLOGY, V187, P33, DOI 10.1016/0042-6822(92)90292-W; BRUGER SR, 1991, J GEN VIROL, V72, P359; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; DIETZSCHOLD B, 1977, J VIROL, V23, P286, DOI 10.1128/JVI.23.2.286-293.1977; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FODOR I, 1994, ARCH VIROL, V135, P451, DOI 10.1007/BF01310030; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HASEGAWA M, 1992, EUR J BIOCHEM, V210, P9, DOI 10.1111/j.1432-1033.1992.tb17384.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KANE SE, 1993, J BIOL CHEM, V268, P11456; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LIVI GP, 1991, J BIOL CHEM, V266, P15348; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; MORIMOTO K, 1992, J GEN VIROL, V73, P335, DOI 10.1099/0022-1317-73-2-335; NAKAMURA S, 1993, J BIOL CHEM, V268, P12706; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; OTVOS L, 1994, BBA-MOL CELL RES, V1224, P68, DOI 10.1016/0167-4889(94)90114-7; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; RAU S, 1993, J GEN VIROL, V74, P699, DOI 10.1099/0022-1317-74-4-699; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; Sambrook J, 1989, MOL CLONING LABORATO; Shakin-Eshleman W. H., 1993, TRENDS GLYCOSCI GLYC, V5, P355; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH JS, 1984, J CLIN MICROBIOL, V19, P267, DOI 10.1128/JCM.19.2.267-272.1984; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WRIGHT A, 1991, EMBO J, V10, P2717, DOI 10.1002/j.1460-2075.1991.tb07819.x; WUNNER WH, 1983, J GEN VIROL, V64, P1649, DOI 10.1099/0022-1317-64-8-1649; WUNNER WH, 1988, REV INFECT DIS, V10, pS771; WUNNER WH, 1985, VIROLOGY, V140, P1, DOI 10.1016/0042-6822(85)90440-4; YELVERTON E, 1983, SCIENCE, V219, P614, DOI 10.1126/science.6297004	53	123	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14756	14761		10.1074/jbc.270.24.14756	http://dx.doi.org/10.1074/jbc.270.24.14756			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782341	hybrid			2022-12-27	WOS:A1995RD45500078
J	CORCORAN, ML; STETLERSTEVENSON, WG				CORCORAN, ML; STETLERSTEVENSON, WG			TISSUE INHIBITOR OF METALLOPROTEINASE-2 STIMULATES FIBROBLAST PROLIFERATION VIA A CAMP-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; SWISS 3T3 CELLS; PROTEIN-KINASE; PERTUSSIS TOXIN; DNA-SYNTHESIS; CYCLIC-AMP; TIMP-2; ACCUMULATION; ENHANCEMENT; COLLAGENASE	In addition to inhibiting the proteolytic activity of the matrix metalloproteinases, tissue inhibitors of metalloproteinases (TIMPs) promote the growth of cells in the absence of other exogenous growth factors. TIMP-2 stimulates the proliferation of fibrosarcoma (HT-1080) cells and normal dermal fibroblasts (Hs68) in a dose-dependent manner. This response is evident as early as 2 h and persists up to 48 h after treatment with recombinant TIMP-2 (rTIMP-2). The specificity of this response is demonstrated by the ability of affinity-purified polyclonal anti-TIMP-2 antibodies to ablate TIMP-2 mitogenesis and by the lack of response to TIMP-1. This response is also blocked by the presence of an adenylate cyclase inhibitor, 9-(tetrahydro-2-furyl) adenine (SQ22536). Although SQ22536 did not affect untreated fibroblasts or fibrosarcoma cells, this inhibitor completely abrogates the proliferative response induced by rTIMP-2. Treatment of these cells with rTIMP-2 also stimulates the production of cAMP in a time-dependent manner that differs for the two cell lines. Moreover, treatment of purified cell membranes with rTIMP-2 suppresses cholera toxin-mediated ADP-ribosylation of the GTP-binding protein, Gs alpha subunit. These results indicate that the alpha beta gamma heterotrimer is dissociated by treatment with rTIMP-2, which may facilitate the Gs alpha-mediated activation of adenylate cyclase and subsequent production of cAMP. Since cAMP binds to the regulatory subunit of cAMP-dependent protein kinase and activates kinase activity, we evaluated how treatment with rTIMP-2 affected both these parameters. We demonstrate in this report that the cAMP produced in response to treatment with rTIMP-2 binds to the type I regulatory subunit of cAMP-dependent protein kinase and stimulates kinase activity. These results are the first demonstration that TIMP-2 directly activates adenylate cyclase to produce cAMP, which increases cAMP-dependent protein kinase activity, resulting in stimulation of fibroblast mitogenesis.	NCI,PATHOL LAB,EXTRACELLULAR MATRIX PATHOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EMMERTBUCK M, 1995, IN PRESS FEBS LETT; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GRAZIANO MP, 1987, J BIOL CHEM, V264, P409; HALENDA SP, 1986, FEBS LETT, V204, P341, DOI 10.1016/0014-5793(86)80840-7; HARRIS DN, 1979, J CYCLIC NUCL PROT, V5, P125; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HUANG N, 1989, P NATL ACAD SCI USA, V86, P7909; LALLI E, 1994, J BIOL CHEM, V269, P17359; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MANNING DR, 1990, ADP RIBOSYLATING TOX, P349; MATSUMOTO H, 1993, BIOCHEM BIOPH RES CO, V194, P909, DOI 10.1006/bbrc.1993.1907; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; OKUYAMA K, 1994, CANCER J - FRANCE, V7, P150; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSENBERG N, 1982, FEBS LETT, V137, P105, DOI 10.1016/0014-5793(82)80324-4; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1989, CELL, V34, P265; SHI WX, 1992, J NEUROSCI, V12, P2433; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSO.WG, 1992, FEBS LETT, V296, P231; STRICKLIN G, 1991, J INVEST DERMATOL, V103, P488; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; ZURIER RB, 1981, P NATL ACAD SCI USA, V86, P251	47	163	167	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13453	13459		10.1074/jbc.270.22.13453	http://dx.doi.org/10.1074/jbc.270.22.13453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768948	hybrid			2022-12-27	WOS:A1995RB43900074
J	REVERT, F; PENADES, JR; PLANA, M; BERNAL, D; JOHANSSON, C; ITARTE, E; CERVERA, J; WIESLANDER, J; QUINONES, S; SAUS, J				REVERT, F; PENADES, JR; PLANA, M; BERNAL, D; JOHANSSON, C; ITARTE, E; CERVERA, J; WIESLANDER, J; QUINONES, S; SAUS, J			PHOSPHORYLATION OF THE GOODPASTURE ANTIGEN BY TYPE-A PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; GLOMERULAR-BASEMENT-MEMBRANE; COLLAGEN TYPE-VI; IV COLLAGEN; ALPHA-3 CHAIN; IDENTIFICATION; SEQUENCE; BINDING; ACTIVATION; POLYMERASE	Collagen IV is the major component of basement membranes. The human alpha 3 chain of collagen IV contains an antigenic domain called the Goodpasture antigen that is the target for the circulating immunopathogenic antibodies present in patients with Goodpasture syndrome. Characteristically, the gene region encoding the Goodpasture antigen generates multiple alternative products that retain the antigen amino-terminal region with a five-residue motif (KRGDS). The serine therein appears to be the major in vitro cAMP-dependent protein kinase phosphorylation site in the isolated antigen and can be phosphorylated in vitro by two protein kinases of approximately 50 and 41 kDa associated with human kidney plasma membrane, suggesting that it can also be phosphorylated in vivo. Consistent with this, the Goodpasture antigen is isolated from human kidney in phosphorylated and non-phosphorylated forms and only the non-phosphorylated form is susceptible to phosphorylation in vitro. Since this motif is exclusive to the human alpha 3(TV) chain and includes the RGD cell adhesion motif, its phosphorylation might play a role in pathogenesis and influence cell attachment to basement membrane.	FDN VALENCIA INVEST BIOMED, INST INVEST CITOL, E-46010 VALENCIA, SPAIN; UNIV AUTONOMA BARCELONA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN; UNIV VALENCIA, FAC FARM, DEPT BIOQUIM & BIOL MOLEC, E-46100 BURJASSOT, SPAIN; UNIV LUND HOSP, DEPT NEPHROL, S-22185 LUND, SWEDEN; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT ENVIRONM & COMMUNITY MED, PISCATAWAY, NJ 08854 USA	Autonomous University of Barcelona; University of Barcelona; University of Valencia; Lund University; Skane University Hospital			Itarte, Emilio/K-5275-2014; REVERT, FERNANDO/ABF-8171-2021; Bernal, Dolores/K-7769-2014; Penadés, José R/W-9685-2019; Plana Coll, Maria/L-3414-2014; Itarte, Emilio/Q-6246-2019	Itarte, Emilio/0000-0002-9366-5807; REVERT, FERNANDO/0000-0002-7304-5846; Bernal, Dolores/0000-0003-4627-8393; Penadés, José R/0000-0002-6439-5262; Plana Coll, Maria/0000-0001-5808-9229; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK-42514] Funding Source: Medline; NIEHS NIH HHS [ESO 5022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERNAL D, 1993, J BIOL CHEM, V268, P12090; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; FENG LL, 1994, J BIOL CHEM, V269, P2342; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P10213, DOI 10.1073/pnas.88.22.10213; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GUASCH MD, 1986, ARCH BIOCHEM BIOPHYS, V250, P294, DOI 10.1016/0003-9861(86)90730-7; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUTCHCROFT JE, 1991, METHOD ENZYMOL, V200, P417; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, J BIOL CHEM, V257, P322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; MORRISON KE, 1991, AM J HUM GENET, V49, P545; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; STETLER DA, 1992, AUTOIMMUNITY, V12, P29, DOI 10.3109/08916939209146127; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VONDERMARK K, 1987, METHOD ENZYMOL, V144, P490; WALKER JM, 1988, J BIOL CHEM, V263, P4537; ZETTERQVIST O, 1982, FEBS LETT, V139, P287, DOI 10.1016/0014-5793(82)80872-7	38	15	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13254	13261		10.1074/jbc.270.22.13254	http://dx.doi.org/10.1074/jbc.270.22.13254			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768924	hybrid			2022-12-27	WOS:A1995RB43900048
J	MIHIC, SJ; WHITING, PJ; KLEIN, RL; WAFFORD, KA; HARRIS, RA				MIHIC, SJ; WHITING, PJ; KLEIN, RL; WAFFORD, KA; HARRIS, RA			A SINGLE AMINO-ACID OF THE HUMAN GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR GAMMA(2) SUBUNIT DETERMINES BENZODIAZEPINE EFFICACY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTOR; MOLECULAR-BIOLOGY; INVERSE AGONISTS; 2 FORMS; PHARMACOLOGY; CDNA; SITE; POTENTIATION; EXPRESSION; ETHANOL	Incorporation of the gamma(2) subunit into gamma-aminobutyric acid type A (GABA,) receptors is required for the expression of benzodiazepine pharmacology, but the regions of the subunit responsible for benzodiazepine actions have not been defined. Using mutagenesis, we identified a single amino acid of the gamma(2) subunit of the human GABA, receptor that profoundly alters the nature of this pharmacology, When threonine 142 was mutated to serine, the benzodiazepine receptor antagonist, flumazenil, and the weak inverse agonist, Ro 15-4513, both acted as po tent partial agonists. Further, potentiation of GABA responses by diazepam, alprazolam, clonazepam, or flunitrazepam doubled in receptors containing the Ser-142 gamma(2) subunit. In contrast, responses to the Type I benzodiazepine receptor selective ligands, zolpidem, alpidem, and CL218,872, were roughly halved. This change in pharmacology appears to occur at a stage following ligand binding, i.e. the mutation affects benzodiazepine efficacy. There was no effect on GABA affinity or efficacy or pentobarbital, Ro 5-4864, or alphaxalone modulation of GABA responses. These findings demonstrate that very minor changes in receptor structure can profoundly affect the efficacy of receptor ligands. Thus, agonism is determined not only by the structure of the drug, but also by the structure of the receptor, or protein complex, with which it interacts.	VET ADM MED CTR,DENVER,CO 80262; MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	US Department of Veterans Affairs; Veterans Health Administration (VHA); Merck & Company	MIHIC, SJ (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,4200 E 9TH AVE,DENVER,CO 80262, USA.			Whiting, Paul/0000-0002-4121-1379	NIAAA NIH HHS [AA06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; GLENCORSE TA, 1990, NUCLEIC ACIDS RES, V18, P7157, DOI 10.1093/nar/18.23.7157; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; HARRIS RA, 1988, J PHARMACOL EXP THER, V247, P1012; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; IM HK, 1993, MOL PHARMACOL, V44, P866; KLEIN RL, 1994, EUR J PHARM-MOLEC PH, V268, P237, DOI 10.1016/0922-4106(94)90194-5; KLEINGOOR C, 1993, NEUROREPORT, V4, P187, DOI 10.1097/00001756-199302000-00018; KNOFLACH F, 1991, FEBS LETT, V293, P1; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MIHIC SJ, 1994, J NEUROCHEM, V62, P1790; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRATHER PL, 1991, PROG NEURO-PSYCHOPH, V15, P921, DOI 10.1016/0278-5846(91)90019-W; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1989, P NATL ACAD SCI USA, V86, P7275, DOI 10.1073/pnas.86.18.7275; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WAFFORD KA, 1993, MOL PHARMACOL, V44, P437; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; WOOD PL, 1984, J PHARMACOL EXP THER, V231, P572; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; ZAMAN SH, 1992, EUR J PHARM-MOLEC PH, V225, P321, DOI 10.1016/0922-4106(92)90106-6	39	103	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32768	32773						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806498				2022-12-27	WOS:A1994QA63800011
J	SHIRATAKI, H; YAMAMOTO, T; HAGI, S; MIURA, H; OISHI, H; JINNO, Y; SENBONMATSU, T; TAKAI, Y				SHIRATAKI, H; YAMAMOTO, T; HAGI, S; MIURA, H; OISHI, H; JINNO, Y; SENBONMATSU, T; TAKAI, Y			RABPHILIN-3A IS ASSOCIATED WITH SYNAPTIC VESICLES THROUGH A VESICLE PROTEIN IN A MANNER INDEPENDENT OF RAB3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; SMG P25A; TARGET PROTEIN; PHOSPHOLIPID-BINDING; ACTIVATING PROTEIN; BOVINE BRAIN; MEMBRANE; NUCLEOTIDE; FUSION; LOCALIZATION	Rabphilin-3A is a putative target protein for Rab3A small GTP-binding protein, which is implicated in regulated secretion, particularly in neurotransmitter release. Rabphilin-3A is associated with synaptic vesicles, although it has no transmembrane segment. Here we have studied how rabphilin-3A is associated with synaptic vesicles. Treatment of the synaptic vesicles isolated from rat brain with 1 M NaCl completely solubilized rabphilin-3A from the vesicles. These vesicles deprived of rabphilin-3A still contained Rab3A and synaptophysin. Exogenous rabphilin-3A bound to the vesicles deprived of endogenous rabphilin-3A in dose-dependent and saturable manners. The concentration of exogenous rabphilin-3A giving a half maximal binding was about 50 nM and maximally 5 +/- 1 molecules of exogenous rabphilin-3A bound to one vesicle. Addition of exogenous Rab3A or removal of endogenous Rab3A by the action of Rab GDI did not affect the binding of exogenous rabphilin-3A BA to the vesicles. However, treatment of the vesicles with trypsin completely abolished the binding of exogenous rabphilin-3A. These results suggest that rabphilin-3A is associated with synaptic vesicles at least through a vesicle protein in a manner independent of Rab3A.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				Miura, Hisayuki/0000-0002-4780-9857				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1994, IN PRESS METHODS ENZ; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SASAKI T, 1995, IN PRESS METHODS ENZ; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHIRATAKI H, 1995, IN PRESS METHODS ENZ; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	34	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32717	32720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806490				2022-12-27	WOS:A1994QA63800003
J	REID, MS; BLOBEL, CP				REID, MS; BLOBEL, CP			APEXIN, AN ACROSOMAL PENTAXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; C-REACTIVE PROTEIN; HUMAN C4B-BINDING PROTEIN; ACUTE-PHASE PROTEINS; AMINO-ACID-SEQUENCE; SPERM-EGG FUSION; GUINEA-PIG SPERM; MEMBRANE-PROTEIN; PENTRAXIN FAMILY; HUMAN-TISSUE	We report the initial biochemical characterization and the primary structure of a guinea pig sperm acrosomal pentaxin (apexin). Pentaxins are a family of penta- or decameric serum proteins that includes serum amyloid protein and C-reactive protein. Apexin consists of disulfide-linked 50-kDa subunits that give rise to an oligomeric protein, Apexin and a sperm protein related to complement receptors coelute with affinity-purified ferritin (PH-30), a potential sperm-egg membrane fusion protein. However, no evidence for a functional association of apexin with fertilin was found. Apexin is localized to the acrosome of mature guinea pig sperm and is thus the first pentaxin for which a defined intracellular localization has been reported. Whereas the C-terminal portion of apexin is clearly related to serum pentaxins, the N-terminal domain shows no strong homology to other known proteins. Northern blot analysis of different tissues revealed expression in the testis. Apexin is distinct from the pentaxins serum amyloid protein and C-reactive protein and may have evolved to perform functions other than those performed by serum pentaxins, such as intracellular protein sorting to the acrosome.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BLOBEL CP, 1991, THESIS U CALIFORNIA; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GREEN DPL, 1978, J CELL SCI, V32, P137; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HICKS PS, 1992, J IMMUNOL, V149, P3689; HILLARP A, 1993, J BIOL CHEM, V268, P15017; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1984, LANCET, V2, P376; KALARIA RN, 1993, BRAIN RES, V631, P151, DOI 10.1016/0006-8993(93)91202-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GW, 1993, J IMMUNOL, V150, P1804; MCINTYRE SS, 1983, BIOCHEM J, V210, P707; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PHELPS BM, 1987, DEV BIOL, V123, P63, DOI 10.1016/0012-1606(87)90428-3; PRELLI F, 1985, J BIOL CHEM, V260, P2895; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROBEY FA, 1981, J BIOL CHEM, V256, P969; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWALBE RA, 1992, BIOCHEMISTRY-US, V31, P4907, DOI 10.1021/bi00135a023; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SHEPHARD EG, 1991, BIOCHEM J, V279, P257, DOI 10.1042/bj2790257; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748	57	70	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32615	32620						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798266				2022-12-27	WOS:A1994PX30400088
J	WEMMIE, JA; SZCZYPKA, MS; THIELE, DJ; MOYEROWLEY, WS				WEMMIE, JA; SZCZYPKA, MS; THIELE, DJ; MOYEROWLEY, WS			CADMIUM TOLERANCE MEDIATED BY THE YEAST AP-1 PROTEIN REQUIRES THE PRESENCE OF AN ATP-BINDING CASSETTE TRANSPORTER-ENCODING GENE, YCF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RESISTANCE; TRANSCRIPTION; CLONING; DNA; IDENTIFICATION; OVEREXPRESSION; TRANSFORMATION; EXPRESSION; DISRUPTION	Elevations in gene dosage of the transcriptional regulatory protein yAP-1 in Saccharomyces cerevisiae can elicit pronounced phenotypic increases in tolerance of a variety of drugs including the toxic heavy metal cadmium, While a large elevation in cadmium tolerance occurs in response to overproduction of yAP-1, the target genes under yAP-1 control have not yet been identified that are responsible for this increase, We show here that the YCF1 gene, encoding a likely integral membrane protein, is required for yAP-1 to exert its normal effects on cadmium tolerance. Mutant strains of yeast that lack the YCF1 gene are hypersensitive to cadmium and this hypersensitivity is epistatic to yAP-1 overexpression. YCF1 mRNA levels and the expression of a YCF1-lacZ reporter construct positively correlates with changes in YAP1 gene dosage, A set of 5' truncation derivatives of the YCF1-lacZ fusion gene identified the region from -201 to +47 as being sufficient for the yAP-1-dependent increase in expression, DNase I footprinting using a probe from this segment of the YCF1 promoter showed that bacterially-produced yAP-1 protein was capable of binding a novel DNA element we have designated the yAP-1 response element, Insertion of the yAP-1 response element upstream of a CYC1-lacZ gene fusion led to the production of beta-galactosidase in a yAP-1-dependent fashion, These data establish that an important physiological target of yAP-1 transcriptional regulation is the YCF1 structural gene.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Iowa; University of Michigan System; University of Michigan			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NIGMS NIH HHS [GM49825, GM25295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; EDGINGTON NP, 1992, PROMEGA NOTES, V41, P14; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GADD GM, 1989, SPEC PUBL SOC GEN MI, V26, P19; GAN ZR, 1991, J BIOL CHEM, V266, P1692; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEPPERT G, 1990, GENETICS, V125, P13; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZHOU PB, 1993, BIOFACTORS, V4, P105	35	193	197	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32592	32597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798263				2022-12-27	WOS:A1994PX30400085
J	YOUNG, JC; URSINI, J; LEGATE, KR; MILLER, JD; WALTER, P; ANDREWS, DW				YOUNG, JC; URSINI, J; LEGATE, KR; MILLER, JD; WALTER, P; ANDREWS, DW			AN AMINO-TERMINAL DOMAIN-CONTAINING HYDROPHOBIC AND HYDROPHILIC SEQUENCES BINDS THE SIGNAL RECOGNITION PARTICLE RECEPTOR-ALPHA SUBUNIT TO THE BETA-SUBUNIT ON THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION; NASCENT PROTEINS; ESCHERICHIA-COLI; DOCKING PROTEIN; MESSENGER-RNA; GTP-BINDING; COMPLEX; TRANSLATION; SEPARATION; INITIATION	The signal recognition particle receptor consists of two subunits of 72 kDa (SR alpha) and 30 kDa (SRP), Assembly of SR alpha on the endoplasmic reticulum membrane can occur independent of the signal recognition particle-mediated translocation pathway, To identify the sequences within SR alpha necessary for membrane binding, a series of amino-terminal and internal deletion mutants was constructed and translated in a cell-free system. In addition, nascent SR alpha polypeptides of varying lengths were generated by cycloheximide treatment of translation reactions, Microsome binding assays performed on these polypeptides revealed a membrane binding domain consisting of the amino-terminal 140 residues of SR alpha. This domain includes the two hydrophobic sequences originally proposed to bind to membranes and a highly charged region not previously implicated in membrane assembly. Furthermore, the domain forms a protease-resistant folding unit that after proteolysis can target and anchor onto microsomes, Extraction of microsomal SR alpha at high pH supplemented with 1 M NaSCN suggests that SR alpha and the membrane binding domain are not integrated in the endoplasmic reticulum membrane. The membrane binding domain is also the major site of tight binding with SR beta, suggesting that SR beta plays a role in the membrane assembly of SR alpha.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	McMaster University; University of California System; University of California San Francisco				Andrews, David/0000-0002-9266-7157; Legate, Kyle/0000-0003-3243-579X				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BLOHEL G, 1970, J CELL BIOL, V45, P130; BORDIER C, 1981, J BIOL CHEM, V256, P1604; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOBDEN AN, 1978, BIOCHEM J, V170, P57, DOI 10.1042/bj1700057; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; THEISEN N, 1986, ANAL BIOCHEM, V152, P211, DOI 10.1016/0003-2697(86)90399-4; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	39	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15650	15657		10.1074/jbc.270.26.15650	http://dx.doi.org/10.1074/jbc.270.26.15650			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797564	hybrid			2022-12-27	WOS:A1995RG53800035
J	CONNOR, H; NORNES, H; NEUMAN, T				CONNOR, H; NORNES, H; NEUMAN, T			EXPRESSION SCREENING REVEALS AN ORPHAN RECEPTOR CHICK OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR-I AS A REGULATOR OF NEURITE SUBSTRATE-CELL CONTACTS AND CELL-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GROWTH CONES; ADHESION MOLECULE; GENE-REGULATION; SUPERFAMILY; MEMBER; COLLAPSE; PROTEIN; FAMILY	A rat homologue of chick ovalbumin upstream promoter transcription factor I (COUP-TF I) was isolated using an expression cloning method developed to isolate neurite outgrowth inhibitors. Overexpression of COUP-TF I in 3T3 fibroblasts resulted in reduction of stable contact formation between neurites and transfected cells. Additionally, COUP-TF I enhanced retinoic acid response element-dependent reporter gene expression in 3T3 fibroblasts, indicating that COUP-TF I can modulate transcriptional activation in these cells. Our data suggest that COUP-TF transcription factors are involved in the regulation of cell surface molecules during neurogenesis.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523	Colorado State University								BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHAN SM, 1992, P NATL ACAD SCI USA, V89, P10568, DOI 10.1073/pnas.89.22.10568; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATHARU PJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P331, DOI 10.1016/0167-4781(92)90512-X; MCEWEN BS, 1991, J STEROID BIOCHEM, V40, P1, DOI 10.1016/0960-0760(91)90160-7; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NEUMAN K, 1995, J NEUROSCI RES, V41, P39, DOI 10.1002/jnr.490410106; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RICHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	43	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15066	15070		10.1074/jbc.270.25.15066	http://dx.doi.org/10.1074/jbc.270.25.15066			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797489	hybrid			2022-12-27	WOS:A1995RE66600035
J	PERILLO, B; TEDESCO, I; LAEZZA, C; SANTILLO, M; ROMANO, A; ALOJ, SM; BIFULCO, M				PERILLO, B; TEDESCO, I; LAEZZA, C; SANTILLO, M; ROMANO, A; ALOJ, SM; BIFULCO, M			REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE GENE-EXPRESSION IN FRTL-5 CELLS .2. DOWN-REGULATION BY V-K-RAS ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID EPITHELIAL-CELLS; MURINE SARCOMA-VIRUS; MAMMALIAN-CELLS; A REDUCTASE; THYROTROPIN; PROTEIN; TRANSFORMATION; INHIBITION; PATHWAY; ADENOSINE-3',5'-MONOPHOSPHATE	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity and mRNA levels were significantly reduced in FRTL-5 cells transformed with the Kirsten-Moloney sarcoma virus (KiMol); these cells have lost thyrotropin dependence and express high levels of p21(ras). FRTL-5 cells, transformed with a temperature-sensitive mutant of the v-K-ras oncogene (Ats cells: 33 degrees C, permissive; 39 degrees C, nonpermissive), showed significant reduction of HMG-CoA reductase expression when exposed to 33 degrees C. In KiMol cells, as well. as in Ats cells at 33 degrees C, the transcription driven by cAMP-responsive element was probed by measuring chloramphenicol acetyl transferase (CAT) levels after transfection with a chimeric plasmid containing the reporter gene linked to the rat reductase promoter, Basal CAT activity in KiMol cells transfected with wild-type promoter was lower than in FRTL-5 cells but was increased by forskolin to the levels attained in thyrotropin-stimulated FRTL-5 cells, Forskolin failed to increase CAT activity in KiMol cells transfected with the plasmid harboring a reductase promoter in which the cAMP-responsive element octamer was mutated to a nonpalindromic sequence. The effect of v-K-ras could be mimicked in FRTL-B cells by tetradecanoyl phorbol acetate and reverted in RiMol and Ats cells, expressing active Ras protein, by increasing intracellular cAMP and/or by protein kinase C inhibition. The data are consistent with the contention that v-K-ras, through protein kinase C and depletion of intracellular cAMP, is inhibitory for the protein kinase A pathway. This is the first demonstration that active v-K-ras down-regulates HMG-CoA reductase expression.	UNIV NAPLES FEDERICO II,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria			laez, chi/AAW-4437-2020	Bifulco, Maurizio/0000-0002-1771-4531; Aloj, Salvatore, M./0000-0003-1703-7523; Perillo, Bruno/0000-0001-8935-0370				ALOJ SM, 1990, MOL ENDOCRINOL, V4, P611, DOI 10.1210/mend-4-4-611; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; BIFULCO M, 1995, J BIOL CHEM, V270, P15231, DOI 10.1074/jbc.270.25.15231; BUNCE CM, 1988, ANAL BIOCHEM, V75, P67; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4853; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KOHN LD, 1975, J BIOL CHEM, V250, P6503; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PERILLO B, 1993, J ENDOCRINOL INVEST, V16, P72; Sambrook J, 1989, MOL CLONING LABORATO; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SPINA A, 1988, BIOCHEM BIOPH RES CO, V157, P1093, DOI 10.1016/S0006-291X(88)80986-0; SUAREZ HG, 1988, ONCOGENE, V2, P403; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	43	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15237	15241		10.1074/jbc.270.25.15237	http://dx.doi.org/10.1074/jbc.270.25.15237			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797508	hybrid			2022-12-27	WOS:A1995RE66600059
J	VENISSE, A; RIVIERE, M; VERCAUTEREN, J; PUZO, G				VENISSE, A; RIVIERE, M; VERCAUTEREN, J; PUZO, G			STRUCTURAL-ANALYSIS OF THE MANNAN REGION OF LIPOARABINOMANNAN FROM MYCOBACTERIUM-BOVIS BCG - HETEROGENEITY IN PHOSPHORYLATION STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE QUANTUM NMR; MYOINOSITOL PHOSPHATES; MASS-SPECTROMETRY; TUBERCULOSIS; SPECTROSCOPY; STRAINS; OLIGOSACCHARIDES; GLYCOPROTEIN; MACROPHAGES	Lipoarabinomannan (LAM) is a major antigen of mycobacterial cell walls, involved in host-Mycobacterium interactions. In a previous work, LAM from the vaccine strain, Mycobacterium bovis BCG, was found to exhibit mannooligosaccharides at its arabinan nonreducing ends (ManLAM). The present report concerns the mannan core structure of this ManLAM. After partial hydrolysis of ManLAM, two populations of mannans (Ma1 and Ma2) were obtained by gel filtration chromatography. Their structural features were defined by means of two dimensional homo- and heteronuclear (H-1-C-13) NMR se sequences and methylation analysis. They were both found to be composed of an alpha-(1 --> 6) linked mannan backbone with alpha-(1 --> 2)-Manp-linked side chains. They are highly branched, and Ma2 presents a higher fre frequency of branching than Ma1. Moreover, chemical analysis indicates that only Ma1 is phosphorylated. By a two-dimensional heteronuclear H-1-P-31 total correlation experiment, the phosphate was found to be involved in a phosphodiester bond between inositol C-1 and glycerol C-3. Then, the molecular mass of mannan was established by mass spectrometry, which revealed a molecular mass of 3517 Da for the major molecular species of Ma1. Likewise, analysis of unfractionated mannans showed the occurrence of other, quantitatively minor molecular species, endowed with two phosphates. This study clearly indicates that the mannan region of M. bovis BCG ManLAM exists as a heterogeneous population of molecules whose structures differ in their degree of glycosylation, level of branching, and phosphorylation state. The hypothesis that the relative abundance of these different molecules modulates the biological functions of LAM is discussed.	CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,DEPT 3,F-31062 TOULOUSE,FRANCE; LAB PHARMACOGNOSIE,F-33076 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Vercauteren, Joseph/AAF-7151-2019	Vercauteren, Joseph/0000-0002-0201-1235				ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; ALLERHAND A, 1984, J AM CHEM SOC, V106, P2400, DOI 10.1021/ja00320a030; BARNES PF, 1992, J IMMUNOL, V149, P541; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRADBURY MG, 1993, CLIN EXP IMMUNOL, V94, P57; CERDAN S, 1986, J BIOL CHEM, V261, P4676; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DANIEL TM, 1984, MYCOBACTERIA SOURCE, P417; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GLUSHKA J, 1992, BIOCHEMISTRY-US, V31, P10741, DOI 10.1021/bi00159a014; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JOHANSSON C, 1990, CARBOHYD RES, V207, P177, DOI 10.1016/0008-6215(90)84047-X; JOSELEAU JP, 1977, CARBOHYD RES, V58, P165, DOI 10.1016/S0008-6215(00)83412-6; KOGAN G, 1988, CARBOHYD RES, V172, P242; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SWEET DP, 1975, CARBOHYD RES, V40, P967; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3	40	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15012	15021		10.1074/jbc.270.25.15012	http://dx.doi.org/10.1074/jbc.270.25.15012			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797482	hybrid			2022-12-27	WOS:A1995RE66600028
J	LEVIN, G; KEREN, T; PERETZ, T; CHIKVASHVILI, D; THORNHILL, WB; LOTAN, I				LEVIN, G; KEREN, T; PERETZ, T; CHIKVASHVILI, D; THORNHILL, WB; LOTAN, I			REGULATION OF RCK1 CURRENTS WITH A CAMP ANALOG VIA ENHANCED PROTEIN-SYNTHESIS AND DIRECT CHANNEL PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; K+-CHANNEL; POTASSIUM CHANNEL; XENOPUS OOCYTES; MESSENGER-RNA; MODULATION; ACTIVATION; APLYSIA; SUBUNIT; BRAIN	We have recently shown that the rat brain Kv1.1 (RCK1) voltage-gated K+ channel is partially phosphorylated in its basal state in Xenopus oocytes and can be further phosphorylated upon treatment for a short time with a cAMP analog (Ivanina, T., Perts, T., Thornhill, W, B., Levin, G., Dascal, N., and Lotan, I. (1994) Biochemistry 33, 8786-8792), In this study, we show, by two-electrode voltage clamp analysis, that whereas treatments for a short time with various cAMP analogs do not affect the channel function, prolonged treatment with 8-bromoadenosine 3',5'-cyclic monophosphorothioate ((S-p)-8-Br-cAMPS), a membrane-permeant cAMP analog, enhances the current amplitude, It also enhances the current amplitude through a mutant channel that cannot be phosphorylated by protein kinase A activation. The enhancement is inhibited in the presence of (R(p))-8-Br-cAMPS, a membrane-permeant protein kinase A inhibitor. Concomitant SDS-polyacrylamide gel electrophoresis analysis reveals that this treatment not only brings about phosphorylation of the wild-type channel, but also increases the amounts of both wild-type and mutant channel proteins; the latter effect can be inhibited by cycloheximide, a protein synthesis inhibitor. In the presence of cycloheximide, the (Sp)-8-Br-cAMPS treatment enhances only the wild-type current amplitudes and induces accumulation of wild-type channels in the plasma membrane of the oocyte, In summary, prolonged treatment with (S-p)-8-Br-cAMPS regulates RCK1 function via two pathways, a pathway leading to enhanced channel synthesis and a pathway involving channel phosphorylation that directs channels to the plasma membrane.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL; MT SINAI HOSP, MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai					NINDS NIH HHS [NS-29633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER GK, 1992, MOL ENDOCRINOL, V6, P476, DOI 10.1210/me.6.3.476; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENSON JA, 1983, P NATL ACAD SCI-BIOL, V80, P3522, DOI 10.1073/pnas.80.11.3522; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; BOSMA MM, 1993, J NEUROSCI, V13, P5242, DOI 10.1523/JNEUROSCI.13-12-05242.1993; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; GILES W, 1989, J PHYSIOL-LONDON, V415, P233, DOI 10.1113/jphysiol.1989.sp017720; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; GREEN WN, 1991, NEURON, V7, P659, DOI 10.1016/0896-6273(91)90378-D; HOSODA K, 1994, J NEUROCHEM, V63, P1635; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHREIBMAYER W, 1993, PFLUEGERS ARCH, V426, P453; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STRONG JA, 1986, J NEUROSCI, V6, P814; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; THORNHILL WB, 1987, BIOCHEMISTRY-US, V26, P4381, DOI 10.1021/bi00388a029; WALSH KB, 1991, AM J PHYSIOL, V261, pC1081, DOI 10.1152/ajpcell.1991.261.6.C1081; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YAZAWA K, 1990, J PHYSIOL-LONDON, V421, P135, DOI 10.1113/jphysiol.1990.sp017937	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14611	14618		10.1074/jbc.270.24.14611	http://dx.doi.org/10.1074/jbc.270.24.14611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782324	hybrid			2022-12-27	WOS:A1995RD45500058
J	RANDAZZO, PA; TERUI, T; STURCH, S; FALES, HM; FERRIGE, AG; KAHN, RA				RANDAZZO, PA; TERUI, T; STURCH, S; FALES, HM; FERRIGE, AG; KAHN, RA			THE MYRISTOYLATED AMINO-TERMINUS OF ADP-RIBOSYLATION FACTOR-1 IS A PHOSPHOLIPID-SENSITIVE AND GTP-SENSITIVE SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; ADENYLATE-CYCLASE; BINDING PROTEINS; GOLGI MEMBRANES; SACCHAROMYCES-CEREVISIAE; REGULATORY COMPONENT; NUCLEOTIDE-BINDING; RNA-POLYMERASE; CHOLERA-TOXIN; CLONED GENES	ADP-ribosylation factor 1 (Arf1) is an essential N-myristoylated 21-kDa GTP-binding protein with activities that include the regulation of membrane traffic and phospholipase D activity. Both the N terminus of the protein and the N-myristate bound to glycine 2 have previously been shown to be essential to the function of Arf in cells. We show that the bound nucleotide affects the conformation of either the N terminus or residues of Arf1 that are in direct contact with the N terminus. This was demonstrated by examining the effects of mutations in this N-terminal domain on guanosine 5'-O-(3-thio)triphosphate (GTP gamma S) and GDP binding and dissociation kinetics. Arf1 mutants, lacking 13 or 17 residues from the N terminus or mutated at residues 3-7, had a greater affinity for GTP gamma S and a lower affinity for GDP than did the wild-type protein. As the N terminus is required for interactions with target proteins, we conclude that the N terminus of Arf1 is a GTP-sensitive effector domain. When Arf1 was acylated, the GTP-dependent conformational changes were codependent on added phospholipids. In the absence of phospholipids, myristoylated Arf1 has a lower affinity for GTP gamma S than for GDP, and in the presence of phospholipids, the myristoylated protein has a greater affinity for GTP gamma S than for GDP. Thus, N-myristoylation is a critical component in the construction of this phospholipid- and GTP-dependent switch.	MAXENT SOLUT LTD, CAMBRIDGE CB75 QS1, ENGLAND		RANDAZZO, PA (corresponding author), NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,BLDG 37, RM 5D-02, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1973, CELL, V75, P113; CHA S, 1970, J BIOL CHEM, V245, P4814; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FERRIGE AG, 1991, MAXIMUM ENTROPY BAYE, P327; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HAYAKAWA T, 1992, GENE, V119, P273, DOI 10.1016/0378-1119(92)90282-T; HONG JX, 1994, J BIOL CHEM, V269, P9743; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KHAN R, 1992, J BIOL CHEM, V267, P13039; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1995, IN PRESS METHODS ENZ; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROSENWALD AG, 1994, CHALL MOD MED, V6, P143; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14809	14815		10.1074/jbc.270.24.14809	http://dx.doi.org/10.1074/jbc.270.24.14809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782347	hybrid			2022-12-27	WOS:A1995RD45500085
J	SAITO, T; KAWABATA, SI; HIRATA, M; IWANAGA, S				SAITO, T; KAWABATA, SI; HIRATA, M; IWANAGA, S			A NOVEL TYPE OF LIMULUS LECTIN-L6 - PURIFICATION, PRIMARY STRUCTURE, AND ANTIBACTERIAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CRAB TACHYPLEUS-TRIDENTATUS; ENDOTOXIN-BINDING PROTEIN; C-REACTIVE PROTEIN; HORSESHOE-CRAB; FLUOROGENIC REAGENT; AMEBOCYTE LYSATE; POLYPHEMUS; HEMOCYTES; PEPTIDES	Lipopolysaccharide (LPS)-binding protein(s) was first screened in the detergent extract of horseshoe crab (limulus) hemocytes, using LPS-immobilized agarose. A protein, designated L6 (M(r) = 27,000), was found to bind to LPS-agarose and was eluted with EDTA or o-phenanthroline. The L6 protein, however, did not inhibit the LPS-mediated activation of a limulus serine protease zymogen factor C. L6 had an affinity to the matrix: of Sepharose CL-6B itself, and it could be eluted with high concentrations of monosaccharides (0.5-1.0 M), such as glucose, mannose, and galactose, suggesting a lectin-like nature. The entire amino acid sequence of L6 was determined by sequencing peptides derived from CNBr sind enzymatic cleavages. L6 contained 7 half-cystines, and 1 cysteine residue at position 201 had a free SH-group. In addition, positions of the remaining three intrachain disulfide bonds were assigned by amino acid and sequence analyses of three cystinyl peptides produced by lysyl endopeptidase digestion. These results indicated that the entire sequence of L6 consisted of 221 residues with no N-linked sugar and was composed of six tandem repeats, each consisting of 33-38 amino acid residues. Inductively coupled plasma spectrometry of L6 indicated the presence of 0.75 mol zinc/mol of protein. No significant sequence homology was observed between L6 and other proteins, including various animal lectins and LPS-binding proteins. However, L6 showed agglutinating activity on LPS-coated sheep erythrocytes;md Gram-negative and Gram-positive bacteria, it inhibited the growth of Gram-negative bacteria, and thus it presumably recognizes carbohydrate components in the cell wall of bacteria.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; IWATE MED UNIV,SCH MED,DEPT BACTERIOL,MORIOKA,IWATE 020,JAPAN	Kyushu University; Kyushu University; Iwate Medical University				Saito, Tetsu/0000-0002-9045-6743				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1991, IMMUNOLOGY INSECTS O, P4; BRANDIN ER, 1983, BIOCHEM BIOPH RES CO, V113, P611, DOI 10.1016/0006-291X(83)91770-9; Brehelin M., 1986, IMMUNITY INVERTEBRAT; FUJII N, 1992, J BIOL CHEM, V267, P22452; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HIRATA M, 1990, ADV EXP MED BIOL, V256, P287; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1993, ANTIMICROB AGENTS CH, V37, P2534, DOI 10.1128/AAC.37.12.2534; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIANG SM, 1980, J BIOL CHEM, V255, P5586; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P467; MEGA T, 1991, J BIOCHEM-TOKYO, V109, P600, DOI 10.1093/oxfordjournals.jbchem.a123426; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; OPPENHEIM JD, 1974, BIOCHEM BIOPH RES CO, V58, P1127, DOI 10.1016/S0006-291X(74)80260-3; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; ROBEY FA, 1981, J BIOL CHEM, V256, P969; ROCHE AC, 1974, BIOCHIM BIOPHYS ACTA, V371, P242, DOI 10.1016/0005-2795(74)90174-3; ROTH RI, 1993, INFECT IMMUN, V61, P1033, DOI 10.1128/IAI.61.3.1033-1039.1993; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SHIMIZU S, 1977, BIOCHIM BIOPHYS ACTA, V500, P71, DOI 10.1016/0304-4165(77)90047-2; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SRIMAL S, 1985, BIOCHEM J, V230, P321, DOI 10.1042/bj2300321; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUEYOSHI T, 1985, J BIOCHEM-TOKYO, V97, P1811, DOI 10.1093/oxfordjournals.jbchem.a135241; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; TOYOOKA T, 1984, ANAL CHEM, V56, P2461, DOI 10.1021/ac00277a044; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	39	77	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14493	14499		10.1074/jbc.270.24.14493	http://dx.doi.org/10.1074/jbc.270.24.14493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782311	hybrid			2022-12-27	WOS:A1995RD45500041
J	ZONDAG, GCM; KONINGSTEIN, GM; JIANG, YP; SAP, J; MOOLENAAR, WH; GEBBINK, MFBG				ZONDAG, GCM; KONINGSTEIN, GM; JIANG, YP; SAP, J; MOOLENAAR, WH; GEBBINK, MFBG			HOMOPHILIC INTERACTIONS MEDIATED BY RECEPTOR TYROSINE PHOSPHATASE-MU AND PHOSPHATASE-KAPPA - A CRITICAL ROLE FOR THE NOVEL EXTRACELLULAR MAM DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL RECOGNITION MOLECULE; FAMILY; PROTEINS; CLONING; REGION	The receptor-like protein tyrosine phosphatases (RPTP) mu and RPTP kappa have a modular ectodomain consisting of four fibronectin type III-like repeats, a single Ig-like domain, and a newly identified N-terminal MAM domain, The function of the latter module, which comprises about 160 amino acids and is found in diverse transmembrane proteins, is not known, We previously reported that both RPTP mu, and RPTP kappa can mediate homophilic cell interactions when expressed in insect cells, Here we show that despite their striking structural similarity, RPTP mu and RPTP kappa fail to interact in a heterophilic manner, To examine the role of the MAM domain in homophilic binding, we expressed a mutant RPTP mu lacking the MAM domain in insect Sf9 cells, Truncated RPTP mu is properly expressed at the cell surface but fails to promote cell-cell adhesion, Homophilic cell adhesion is fully restored in a chimeric RPTP mu molecule containing the MAM domain of RPTP kappa. However, this chimeric RPTP mu does not interact with either RPTP mu or RPTP kappa, These results indicate that the MAM domain of RPTP mu and RPTP kappa is essential for homophilic cell cell interaction and helps determine the specificity of these interactions.	NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS; NYU, CTR MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA	Netherlands Cancer Institute; New York University								BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CRAIG SS, 1987, AM J PHYSIOL, V253, pC535, DOI 10.1152/ajpcell.1987.253.4.C535; DEVEREUX J, 1989, NUCLEIC ACIDS RES, V12, P387; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SAP J, 1994, MOL CELL BIOL, V14, P1; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	19	144	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14247	14250		10.1074/jbc.270.24.14247	http://dx.doi.org/10.1074/jbc.270.24.14247			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782276	hybrid			2022-12-27	WOS:A1995RD45500002
J	CRERAR, MM; KARLSSON, O; FLETTERICK, RJ; HWANG, PK				CRERAR, MM; KARLSSON, O; FLETTERICK, RJ; HWANG, PK			CHIMERIC MUSCLE AND BRAIN GLYCOGEN PHOSPHORYLASES DEFINE PROTEIN DOMAINS GOVERNING ISOZYME-SPECIFIC RESPONSES TO ALLOSTERIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-TISSUES; RABBIT MUSCLE; HUMAN-LIVER; BINDING; EXPRESSION; AMP; QUANTITATION; EVOLUTION; MECHANISM; FAMILY	Muscle and brain glycogen phosphorylases differ in their responses to activation by phosphorylation and AMP. The muscle isozyme is potently activated by either phosphorylation or AMP. In contrast, the brain isozyme is poorly activated by phosphorylation and its phosphorylated a form is more sensitive to AMP activation when enzyme activity is measured in substrate concentrations and temperatures encountered in the brain. The nonphosphorylated b form of the brain isozyme also differs from the muscle isozyme b form in its stronger affinity and lack: of cooperativity for AMP. To identify the structural determinants involved, six enzyme forms, including four chimeric enzymes containing exchanges in amino acid residues 1-88, 89-499, and 500-842 (C terminus), were constructed from rabbit muscle and human brain phosphorylase cDNAs, expressed in Escherichia coli, and purified. Kinetic analysis of the b forms indicated that the brain isozyme amino acid 1-88 and 89-499 regions each contribute in an additive fashion to the formation of an AMP site with higher intrinsic affinity but weakened cooperativity, while the same regions of the muscle isozyme each contribute to greater allosteric coupling but weaker AMP affinity. Kinetic analysis of the a forms indicated that the amino acid 89-499 region correlated with the reduced response of the brain isozyme to activation by phosphorylation and the resultant increased sensitivity of the a form to activation by saturating levels of AMP. This isozyme specific response also correlated with the glycogen affinity of the a forms. Enzymes containing the brain isozyme amino acid 89-499 region exhibited markedly reduced glycogen affinities in the absence of AMP compared to enzymes containing the corresponding muscle isozyme region. Additionally, AMP led to greater increases in glycogen affinity of the former set of enzymes. In contrast, phosphate affinities of all a forms were similar in the absence of AMP and increased approximately the same extent in AMP. The potential importance of a number of isozyme-specific substitutions in these sequence regions is discussed.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CRERAR, MM (corresponding author), YORK UNIV, DEPT BIOL, 4700 KEELE ST, N YORK, ON M3J 1P3, CANADA.				NIDDK NIH HHS [DK32822] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya K.R., 1991, GLYCOGEN PHOSPHORYLA, V2nd; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11291, DOI 10.1021/bi00161a005; BUCHBINDER JL, 1995, IN PRESS BIOCHEMISTR; CARNEY IT, 1978, ANAL BIOCHEM, V85, P321, DOI 10.1016/0003-2697(78)90309-3; COATS WS, 1991, J BIOL CHEM, V266, P16113; CRERAR MM, 1988, GENOME, V30, P582, DOI 10.1139/g88-098; DAVID ES, 1986, BIOCHIM BIOPHYS ACTA, V880, P78, DOI 10.1016/0304-4165(86)90122-4; GELINAS RP, 1989, MOL BRAIN RES, V6, P177, DOI 10.1016/0169-328X(89)90052-1; GEVERS G, 1981, BIOCHEM J, V193, P793, DOI 10.1042/bj1930793; GLASER T, 1989, GENOMICS, V5, P510, DOI 10.1016/0888-7543(89)90017-7; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLDSMITH EJ, 1989, T AM CHEM ASS, V25, P87; GUENARD D, 1977, EUR J BIOCHEM, V76, P447, DOI 10.1111/j.1432-1033.1977.tb11614.x; HUDSON JW, 1993, BIOCHIM BIOPHYS ACTA, V1164, P197, DOI 10.1016/0167-4838(93)90248-P; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; JOHNSON LN, 1993, J MOL BIOL, V232, P253, DOI 10.1006/jmbi.1993.1380; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1967, J BIOL CHEM, V242, P271; LUONG CBH, 1992, J CHROMATOGR-BIOMED, V584, P77, DOI 10.1016/0378-4347(92)80011-E; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; RATH VL, 1987, PROTEINS, V2, P225, DOI 10.1002/prot.340020307; RICHTER F, 1983, BIOMED BIOCHIM ACTA, V42, P1229; RISMAN CA, 1991, BIOCHEM CELL BIOL, V69, P251, DOI 10.1139/o91-038; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1976, CANCER RES, V36, P487; Segel I.H., 1975, ENZYME KINETICS; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0	43	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13748	13756		10.1074/jbc.270.23.13748	http://dx.doi.org/10.1074/jbc.270.23.13748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775430	hybrid			2022-12-27	WOS:A1995RC44800027
J	LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR				LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR			MUTATIONS AFFECTING THE GLYCINE RECEPTOR AGONIST TRANSDUCTION MECHANISM CONVERT THE COMPETITIVE ANTAGONIST, PICROTOXIN, INTO AN ALLOSTERIC POTENTIATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; AMINOBUTYRIC-ACID; MULTIPLE MECHANISMS; CHLORIDE CURRENT; GABA RESPONSES; BETA-SUBUNIT; NEURONS; CHANNELS; RAT	Contrary to its effects on the gamma-aminobutyric acid type A receptor, picrotoxin antagonism of the alpha 1 subunit of the human glycine receptor is shown to be competitive, not use-dependent, and nonselective between the picrotoxin components, picrotin, and picrotoxinin. Competitive antagonism and non-use dependence are consistent with picrotoxin binding to a site in the extracellular domain. The mutations Arg --> Leu or Arg --> Gln at residue 271 of the glycine receptor alpha 1 subunit, which are both associated with human startle disease, have previously been demonstrated to disrupt the transduction process between agonist binding and channel activation, We show here that these mutations also transform picrotoxin from an allosterically acting competitive antagonist to an allosteric potentiator at low (0.01-3 mu M) concentrations and to a noncompetitive antagonist at higher (greater than or equal to 3 mu M) concentrations. This demonstrates that arginine 271 is involved in the transduction process between picrotoxin binding and its mechanism of action, Thus, the allosteric transduction pathways of both agonists and antagonists converge at a common residue prior to the activation gate of the channel, suggesting that this residue may act as an integration point for information from various extracellular ligand binding sites.	UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA	University of New South Wales Sydney	LYNCH, JW (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Lynch, Joseph/C-8636-2009; Schofield, Peter/C-9669-2011	Schofield, Peter/0000-0003-2967-9662				AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; AKAIKE N, 1987, CELL MOL NEUROBIOL, V7, P97, DOI 10.1007/BF00734993; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1400, DOI 10.1152/jn.1989.62.6.1400; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETZ H, 1988, NEUROCHEM INT, V13, P137, DOI 10.1016/0197-0186(88)90048-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONSTANTI A, 1976, BRIT J PHARMACOL, V57, P347, DOI 10.1111/j.1476-5381.1976.tb07673.x; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Curtis D.R., 1974, NEUROPOISONS THEIR P, P207; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HILLE B, 1992, IONIC CHANNELS EXCIT, P390; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLAND KD, 1990, J NEUROSCI, V10, P1719; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; PORTER NM, 1992, MOL PHARMACOL, V42, P872; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1994, J BIOL CHEM, V269, P18739; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SIMMONDS MA, 1982, EUR J PHARMACOL, V80, P347; SMART TG, 1986, PROC R SOC SER B-BIO, V227, P191, DOI 10.1098/rspb.1986.0019; TAKEUCHI A, 1969, J PHYSIOL-LONDON, V205, P377, DOI 10.1113/jphysiol.1969.sp008972; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278	45	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13799	13806		10.1074/jbc.270.23.13799	http://dx.doi.org/10.1074/jbc.270.23.13799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775436	hybrid			2022-12-27	WOS:A1995RC44800035
J	SUPEKOVA, L; SUPEK, F; NELSON, N				SUPEKOVA, L; SUPEK, F; NELSON, N			THE SACCHAROMYCES-CEREVISIAE VMA10 IS AN INTRON-CONTAINING GENE ENCODING A NOVEL 13-KDA SUBUNIT OF VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; MUTATIONAL ANALYSIS; YEAST; MEMBRANE; TRIPHOSPHATASE; ACIDIFICATION; POLYPEPTIDE; EVOLUTION; PROTEINS; COMPLEX	The vacuolar H+-ATPase (V-ATPase) functions as a primary proton pump that generates an electrochemical gradient of protons across the membranes of several internal organelles. It is composed of distinct catalytic and membrane sectors, each containing several subunits. We identified a protein (M16) that copurifies with the V-ATPase complex from Saccharomyces cerevisiae and appears to be present at multiple copies/enzyme. Amino acid sequencing of its proteolytic products yielded three nonoverlapping peptide sequences matching an unidentified reading frame located on chromosome VIII. Sequence analysis of cDNA encoding M16 revealed that the gene encoding this protein (VMA10) is interrupted by a 162-nucleotide intron that begins after the ATG codon of the initiator methionine. The cDNA encodes an hydrophilic protein of 12,713 Da with a basic isoelectric point of pH 9. A Delta vma10::URA3 null mutant exhibited growth characteristics typical of other vma disruptant mutants in genes encoding subunits of V-ATPase. The null mutant does not grow on medium buffered at pH 7.5. It fails to accumulate quinacrine into its vacuole, and subunits of the catalytic sector are not assembled onto the vacuolar membrane in the absence of M16. A cold inactivation experiment demonstrated that M16 is a subunit of the membrane sector of V-ATPase. M16 exhibits a significant sequence homology with subunit b of F-ATPase membrane sector.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HO MN, 1993, J BIOL CHEM, V268, P18286; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1995, ORGANELLAR PROTON AT; NELSON N, 1988, METHOD ENZYMOL, V157, P619; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1983, METHODS YEAST GENETI; SUPEK F, 1994, J BIOL CHEM, V269, P26479; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAKASE K, 1994, J BIOL CHEM, V269, P11037; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG SY, 1988, J BIOL CHEM, V263, P17638; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	44	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13726	13732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775427				2022-12-27	WOS:A1995RC44800024
J	RIIKONEN, T; WESTERMARCK, J; KOIVISTO, L; BROBERG, A; KAHARI, VM; HEINO, J				RIIKONEN, T; WESTERMARCK, J; KOIVISTO, L; BROBERG, A; KAHARI, VM; HEINO, J			INTEGRIN ALPHA-2-BETA-1 IS A POSITIVE REGULATOR OF COLLAGENASE (MMP-1) AND COLLAGEN ALPHA-1(I) GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; FIBRONECTIN RECEPTOR; CELL-ADHESION; MESSENGER-RNA; VLA-2; ANTIGEN; IDENTIFICATION; REORGANIZATION; HOMOLOGY; LAMININ	A classical model for studying the effects of extracellular matrix is to culture cells inside a three-dimensional collagen gel. When surrounded by fibrillar collagen, many cell types decrease the production of type I collagen, and the expression of interstitial collagenase (matrix metalloproteinase-l; MMP-1) is simultaneously induced. To study the role of the collagen-binding integrins (alpha 1 beta 1 and alpha 2 beta 1 in this process, we used three different osteogenic cell lines with distinct patterns of putative collagen receptors: HOS cells, which express only alpha 1 beta 1 integrin, MG-63 cells, which express only alpha 2 beta 1 integrin, and KHOS-240 cells, which express both. Inside collagen gels, alpha 1(I) collagen mRNA levels were decreased in HOS and KHOS-240 cells but not in MG-63 cells. In contrast, MMP-1 expression was induced in KHOS-240 and MG-63 cells but not in HOS cells. Transfection of MG-63 cells with alpha 2 integrin cDNA produced cell clones overexpressing alpha 2 beta 1 integrin. Transfection of MG-63 cells with alpha 2 integrin cDNA in an antisense orientation reduced the expression level of alpha 2 integrin. These cell clones showed induction and reduction of mRNA levels for MMP-1, respectively. HOS cells normally lacking alpha 2 beta 1 integrin mere forced to express it, and this prevented the down-regulation in the levels of (alpha 1(I) collagen mRNA when cells were grown inside collagen gels. The data indicate that the level of MMP-1 expression is regulated by the collagen receptor alpha 2 beta 1 integrin. The down-regulation of collagen alpha 1(I) is mediated by another receptor. Integrin alpha 2 beta 1 may compete with it and thus be a positive regulator of collagen synthesis.	UNIV TURKU,MEDICITY RES LAB,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT DERMATOL,SF-20520 TURKU,FINLAND	University of Turku; University of Turku; University of Turku			Kähäri, Veli-Matti/E-5144-2011; Westermarck, Jukka/AAL-6464-2020; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Kahari, Veli-Matti/0000-0003-2421-9368				AKIYAMA SK, 1990, CANCER RES, V50, P1601; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHIRGMAN JM, 1979, BIOCHEMISTRY-US, V10, P5294; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ECKES B, 1993, FEBS LETT, V318, P128; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HEINO J, 1989, J BIOL CHEM, V264, P21806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVARSSON M, 1993, J INVEST DERMATOL, V101, P216, DOI 10.1111/1523-1747.ep12364810; KATAMA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	37	265	269	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13548	13552		10.1074/jbc.270.22.13548	http://dx.doi.org/10.1074/jbc.270.22.13548			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768957	hybrid			2022-12-27	WOS:A1995RB43900087
J	SHEEHAN, JP; TOLLEFSEN, DM; SADLER, JE				SHEEHAN, JP; TOLLEFSEN, DM; SADLER, JE			HEPARIN-COFACTOR-II IS REGULATED ALLOSTERICALLY AND NOT PRIMARILY BY TEMPLATE EFFECTS - STUDIES WITH MUTANT THROMBINS AND GLYCOSAMINOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; FUNCTIONAL-PROPERTIES; DERMATAN SULFATE; BINDING; INHIBITION; PURIFICATION; SPECIFICITY; COAGULATION; ACTIVATION	Besides its critical role in hemostasis, the serine protease thrombin also participates in wound healing, inflammation, and atherosclerosis. Thrombin is inhibited by the serpins antithrombin and heparin cofactor II (HCII) in reactions that are accelerated markedly by specific glycosaminoglycans. Following vascular injury, thrombin must be inhibited at both intravascular and extravascular sites that impose different constraints on the recognition of thrombin by these inhibitors, The present study examines the role of anion-binding exosite II of thrombin in the interaction with glycosaminoglycans and HCII. Acceleration of thrombin inhibition by serpins in the presence of glycosaminoglycans is proposed to occur by a template mechanism, in which inhibitor and protease bind simultaneously to the same glycosaminoglycan chain, facilitating their interaction, According to the template model, disruption of protease binding to glycosaminoglycan should significantly reduce acceleration of the inhibition, Specific mutations in exosite II (R89E, R245E, K248E, and K252E) disrupted thrombin binding to both dermatan sulfate and heparin, indicating that both glycosaminoglycans bind to a common site in exosite II, The same mutations markedly decreased the rate constant for thrombin inhibition by antithrombin-heparin (up to 100-fold) but had little effect on the rate constant for thrombin inhibition by HCII-heparin (7-fold maximal reduction) and no effect on the rate constant for thrombin inhibition by HCII-dermatan sulfate, These results are incompatible with a template model for thrombin inhibition by HCII and dermatan sulfate, In the presence of glycosaminoglycan, HCII and antithrombin interact with opposing thrombin exosites and use distinct mechanisms of glycosaminoglycan catalysis, Antithrombin employs a template mechanism that requires heparin to interact with thrombin exosite II, whereas HCII employs an allosteric mechanism that requires thrombin exosite I but is largely independent of exosite II, These findings have potential implications for glycosaminoglycan therapy and for the respective physiologic roles of HCII and antithrombin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SHEEHAN, JP (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED, 660 S EUCLID AVE, BOX 8022, ST LOUIS, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sheehan, John/0000-0002-4328-2613	NHLBI NIH HHS [1K08 HL 02923-01, HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, K08HL002923] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BROZE GJ, 1994, MOL BASIS BLOOD DISE, P629; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HATTON MWC, 1989, AM J PATHOL, V135, P499; HATTON MWC, 1993, BLOOD COAGUL FIBRIN, V4, P927, DOI 10.1097/00001721-199304060-00010; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1994, J BIOL CHEM, V269, P3725; YE J, 1994, J BIOL CHEM, V269, P17965	37	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32747	32751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806495				2022-12-27	WOS:A1994QA63800008
J	RESNICK, RJ; TOMASKA, L				RESNICK, RJ; TOMASKA, L			STIMULATION OF YEAST ADENYLYL-CYCLASE ACTIVITY BY LYSOPHOSPHOLIPIDS AND FATTY-ACIDS - IMPLICATIONS FOR THE REGULATION OF RAS/EFFECTOR FUNCTION BY LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE-ACTIVITY; MAMMALIAN RAS PROTEINS; SACCHAROMYCES-CEREVISIAE; GROWTH-FACTOR; NEUROFIBROMATOSIS TYPE-1; ARACHIDONIC-ACID; GENE-PRODUCT; P21; DOMAIN	A reconstituted system containing membranes prepared from various Saccharomyces cerevisiae strains (CYR1 ras1 ras2) and a recombinant RAS2 protein was used to evaluate the effect of lipids on adenylyl cyclase activity. Incubation of wild-type membranes with lysophosphatidylinositol, lysophosphatidylserine, or lysophosphatidylcholine stimulated adenylyl cyclase activity in the absence and presence of RAS between 2-10-fold depending upon the individual lipid. Unsaturated fatty acids preferentially increased activity 2-3-fold in the presence of RAS. Other phospholipids as well as several detergents had only marginal effects on adenylyl cyclase activity. Lipids had no effect on either the binding or hydrolysis of GTP by RAS. LysoPI decreased both the K-m for ATP and the amount of RES required for enzyme activation. Four catalytically active deletion mutants of the CYR1 protein including one containing only the C-terminal 417 amino acids were similarly responsive to lysoPI when compared to the wild-type enzyme. These data suggest that lysophospholipids and fatty acids, metabolites of the mitogenically responsive enzyme phospholipase A(2), may represent a novel mechanism for modulating the activity of downstream effector molecules and their interaction with Ras proteins.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University			Tomaska, Lubomir/I-3071-2014	Tomaska, Lubomir/0000-0003-4886-1910	NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BARSAGI D, 1986, SCIENCE, V233, P10061; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, NATURE, V348, P135; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAVARRETE R, 1983, BIOCHIM BIOPHYS ACTA, V728, P403, DOI 10.1016/0005-2736(83)90512-6; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAMANOI F, 1984, P NATL ACAD SCI-BIOL, V81, P6924, DOI 10.1073/pnas.81.22.6924; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK A, 1992, MOL CELL BIOL, V66, P497; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILSON BA, 1993, ONCOGENE, V8, P3441; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	70	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32336	32341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798234				2022-12-27	WOS:A1994PX30400050
J	WORLEY, JF; MCINTYRE, MS; SPENCER, B; DUKES, ID				WORLEY, JF; MCINTYRE, MS; SPENCER, B; DUKES, ID			DEPLETION OF INTRACELLULAR CA2+ STORES ACTIVATES A MAITOTOXIN-SENSITIVE NONSELECTIVE CATIONIC CURRENT IN BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM RELEASE; DEPOLARIZATION; CHANNELS; ISLETS	Glucose stimulation of beta-cell insulin secretion is initiated by membrane depolarization coupled with an elevation in intracellular Ca2+ concentration ([Ca2+](i)). Both depolarization-dependent Ca2+ entry and intracellular Ca2+ store release contribute to the sugar-induced rise in [Ca2+](i). Here we show that maneuvers depleting intracellular Ca2+ stores induce membrane depolarization and a sustained nitrendipine-sensitive Ca2+ influx, whereas interventions promoting Ca2+ store refilling produce a hyperpolarization and inhibit Ca2+ influx. Both intracellular Ca2+ store depletion and maitotoxin activated a depolarizing nonselective cation current carried principally by Na+ in the physiological range of membrane potentials, The activation of such a current may form the paradigm by which excitable cells refill depleted intracellular Ca2+ stores by depolarization-driven opening of voltage-activated Ca2+ channels.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DIETL P, 1994, MOL PHARMACOL, V45, P300; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GILON P, 1993, J BIOL CHEM, V268, P22265; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; SILVA AM, 1994, J BIOL CHEM, V269, P17095; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; XI D, 1992, J BIOL CHEM, V267, P25025	17	102	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32055	32058						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798198				2022-12-27	WOS:A1994PX30400009
J	LEAH, R; KIGEL, J; SVENDSEN, I; MUNDY, J				LEAH, R; KIGEL, J; SVENDSEN, I; MUNDY, J			BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF A BARLEY SEED BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ZEA-MAYS L; NUCLEOTIDE-SEQUENCE; GERMINATING BARLEY; ALPHA-AMYLASE; ABSCISIC-ACID; PROTEINS; PURIFICATION; EXPRESSION; PLANTS	A 60-kDa beta-glucosidase (BGQ60) was purified and characterized from seeds of barley (Hordeum vulgare L.) BGQ60 catalytic activity was restricted to the cleavage of short-chain oligosaccharides composed of (1-2)-, (1-3)-, and/or (1-4)-beta-linked glucose or mannose units. These oligosaccharides are the primary products of endosperm cell wall polysaccharide hydrolysis by other enzymes. In keeping with this, complete hydrolysis of the major polysaccharide of barley starchy endosperm cell wall, (1.3, 1-4)-beta-glucan, to free glucose was shown to require the concerted action of endo-(1-3, 1-4)-beta-glucanase and BGQ60. The complete amino acid sequence of BGQ60 was determined by protein sequencing combined with the deduced sequence of the corresponding cDNA and genomic clones. The BGQ60 primary structure exhibits extensive homology to members of glycosyl hydrolase family 1 (EC 3.2.1.21). Southern and Northern blot analysis with the cDNA as probe indicated that BGQ60 is encoded by a single gene, and that BGQ60 mRNA only accumulates in the starchy endosperm tissue of late developing seeds. The bgq60 structural gene of approximately kilobases contains an open reading frame encoding 485 amino acids interrupted by 9 introns. The complete nucleotide sequence of the bgq60 structural gene represents the first characterized plant gene encoding a beta-glucosidase. The barley BGQ60 is a novel plant beta-glucosidase with a hitherto undescribed specific enzymatic activity. The possible biological functions of BGQ60 during barley seed development and germination are discussed.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK		LEAH, R (corresponding author), CARLSBERG RES LAB, DEPT CHEM, GAMLE CARLSBERG VEJ 10, DK-2500 COPENHAGEN, DENMARK.		mundy, john/A-2361-2013	mundy, john/0000-0001-7490-4588				AMAN P, 1989, J CEREAL SCI, V10, P45, DOI 10.1016/S0733-5210(89)80033-5; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; CAMPOS N, 1992, PLANT J, V2, P675, DOI 10.1111/j.1365-313X.1992.tb00136.x; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; ERB N, 1979, PHYTOCHEMISTRY, V18, P1515, DOI 10.1016/S0031-9422(00)98486-3; ESEN A, 1992, PLANT PHYSIOL, V98, P174, DOI 10.1104/pp.98.1.174; ESEN A, 1993, ACS S SERIES, V533; Fincher G. B., 1993, P247; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; GIESE H, 1984, PLANTA, V161, P172, DOI 10.1007/BF00395478; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; HAFF LA, 1983, J CHROMATOGR, V266, P409, DOI 10.1016/S0021-9673(01)90913-6; HENNIG J, 1993, PLANT J, V4, P593, DOI 10.1046/j.1365-313X.1993.04040593.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HUGHES MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P273, DOI 10.1016/0003-9861(92)90518-2; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LEAH R, 1989, PLANT MOL BIOL, V12, P673, DOI 10.1007/BF00044158; LEAH R, 1994, PLANT J, V6, P579, DOI 10.1046/j.1365-313X.1994.6040579.x; LEAH R, 1991, J BIOL CHEM, V266, P1564; Macgregor A. W., 1993, P73; MACGREGOR AW, 1987, CRIT REV BIOTECHNOL, V5, P117, DOI 10.3109/07388558709086972; MUNDY J, 1986, FEBS LETT, V198, P349, DOI 10.1016/0014-5793(86)80434-3; MUNDY J, 1986, PLANT PHYSIOL, V81, P630, DOI 10.1104/pp.81.2.630; NISIZAWA K, 1970, CARBOHYDRATES CHEM B, P241; OLSEN O, 1991, MOL GEN GENET, V225, P177, DOI 10.1007/BF00269845; OXTOBY E, 1991, PLANT MOL BIOL, V17, P209, DOI 10.1007/BF00039495; POLITZ O, 1993, EUR J BIOCHEM, V216, P829, DOI 10.1111/j.1432-1033.1993.tb18204.x; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; RODRIGUEZPALENZUELA P, 1988, GENE, V70, P271, DOI 10.1016/0378-1119(88)90199-0; SANTOS MAS, 1993, TRENDS BIOTECHNOL, V11, P500, DOI 10.1016/0167-7799(93)90028-8; SCHLIEMANN W, 1991, NATURWISSENSCHAFTEN, V78, P392, DOI 10.1007/BF01133410; SCHNEIDER G, 1992, P NATL ACAD SCI USA, V89, P8045, DOI 10.1073/pnas.89.17.8045; SHEWRY PR, 1993, BARLEY CHEM TECHNOLO, P73; SIMOS G, 1994, BBA-GEN SUBJECTS, V1199, P52, DOI 10.1016/0304-4165(94)90095-7; SKRIVER K, 1991, P NATL ACAD SCI USA, V88, P7266, DOI 10.1073/pnas.88.16.7266; SOPANEN T, 1989, PLANT PHYSIOL, V89, P244, DOI 10.1104/pp.89.1.244; STAHL E, 1967, DUNNSCHICHT CHROMATO; Stone BA, 1992, CHEM BIOL 1 3 GLUCAN, P431; SUN Z, 1990, PLANT PHYSIOL, V94, P320, DOI 10.1104/pp.94.1.320; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WOOD TM, 1988, METHOD ENZYMOL, V160, P87; Woodward J. R., 1983, Brewers' Digest, V58, P28; WOODWARD JR, 1982, EUR J BIOCHEM, V121, P663, DOI 10.1111/j.1432-1033.1982.tb05837.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	47	168	177	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15789	15797		10.1074/jbc.270.26.15789	http://dx.doi.org/10.1074/jbc.270.26.15789			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797581	hybrid			2022-12-27	WOS:A1995RG53800054
J	MUNDAY, NA; VAILLANCOURT, JP; ALI, A; CASANO, FJ; MILLER, DK; MOLINEAUX, SM; YAMIN, TT; YU, VL; NICHOLSON, DW				MUNDAY, NA; VAILLANCOURT, JP; ALI, A; CASANO, FJ; MILLER, DK; MOLINEAUX, SM; YAMIN, TT; YU, VL; NICHOLSON, DW			MOLECULAR-CLONING AND PRO-APOPTOTIC ACTIVITY OF ICE(REL)II AND ICE(REL)III, MEMBERS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; ENZYME	Cysteine proteases related to mammalian interleukin-1 beta-converting enzyme (ICE) and the nematode cell death abnormal ced-3 gene product have been implicated in the effector mechanism of apoptotic cell death. Two novel members of this new family of ICE/CED-3-related proteases, designated ICE(rel)-II and ICE(rel)-III, were cloned from human monocytic cells. Both were highly homologous to human ICE (52% identical) and CED-3(25% identical) and both contained the absolutely conserved pentapeptide sequence Gln-Ala-Cys-Arg-Asp containing the catalytic cysteine residue. Other structural motifs that were comparable with ICE suggest that ICE(rel)-II and ICE(rel)-III are also synthesized as larger proenzymes which are proteolytically processed to form heterodimeric active enzymes. Pro-interleukin-1 beta processing activity could not be detected in cells transfected with ICE(rel)-II or ICE(rel)-III, but pro-domain-less truncated forms of ICE(rel)-II and ICE(rel)-III were capable of effectively inducing fibroblast apoptosis. ICE(rel)-II and ICE(rel)-III may, therefore, participate in proteolytic events culminating in the apoptotic death of human cells.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company								Ausubel FM, 1988, MOL REPROD DEV; BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; CARSON DA, 1994, LANCET, V341, P1251; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MIURA M, 1993, CELL, V78, P653; NICHOLSON DW, 1995, IN PRESS NATURE; SAMBROOK J, 1989, MOL CLONING LABORTOR; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WYLLIE AH, 1994, NATURE, V369, P272, DOI 10.1038/369272a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	272	301	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15870	15876		10.1074/jbc.270.26.15870	http://dx.doi.org/10.1074/jbc.270.26.15870			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797592	hybrid			2022-12-27	WOS:A1995RG53800066
J	BIFULCO, M; PERILLO, B; SAJI, M; LAEZZA, C; TEDESCO, I; KOHN, LD; ALOJ, SM				BIFULCO, M; PERILLO, B; SAJI, M; LAEZZA, C; TEDESCO, I; KOHN, LD; ALOJ, SM			REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE GENE-EXPRESSION IN FRTL-5 CELLS .1. IDENTIFICATION AND CHARACTERIZATION OF A CYCLIC AMP-RESPONSIVE ELEMENT IN THE RAT REDUCTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG COA REDUCTASE; A REDUCTASE; RECEPTOR PROMOTER; MAMMALIAN-CELLS; THYROID-CELLS; TRANSCRIPTION; THYROTROPIN; BINDING; PROTEIN; INVITRO	Thyrotropin (TSH) increases 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase gene transcription in FRTL-5 rat thyroid cells, and the effect of TSH can be mimicked by cAMP. Sequence analysis of the rat reductase promoter has revealed a hitherto unnoticed cAMP-responsive element (CRE)-like octamer. This octamer is located between 53 and 60 nucleotides downstream of the sterol regulatory element 1; its first 6 nucleotides are identical to the consensus somatostatin CRE, and the entire octamer is identical to the fos CRE. A synthetic oligonucleotide containing the HMG-CoA reductase CRE-like octamer (RED CRE) formed protein-DNA complexes with nuclear extracts from FRTL-5 cells, which could be prevented by unlabeled CRE-containing oligonucleotides whose flanking sequences were otherwise nonidentical. The complexes were specifically supershifted by anti-CREE antibodies. FRTL-5 cells transfected with a fusion plasmid carrying the bacterial chloramphenicol acetyl transferase (CAT) under the control of the HMG-CoA reductase promoter displayed CAT activity, which was specifically stimulated by TSH. In contrast, CAT activity in FRTL-5 cells transfected with similar constructs carrying mutations in the reductase CRE was significantly lower and did not increase after TSH challenge. We suggest that the HMG-CoA reductase gene contains a functional CRE, important for TSH regulation of transcription. The data presented provide the molecular basis for a novel regulatory mechanism for HMG-CoA reductase gene expression in rat thyroid cells, which involves the direct effect of cAMP.	UNIV NAPLES FEDERICO II,CTR ENDOCRINO & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			laez, chi/AAW-4437-2020; Saji, Motoyasu/E-4007-2011	Perillo, Bruno/0000-0001-8935-0370; Bifulco, Maurizio/0000-0002-1771-4531; Aloj, Salvatore, M./0000-0003-1703-7523				ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; BUNCE CM, 1988, ANAL BIOCHEM, V75, P67; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KOHN LD, 1975, J BIOL CHEM, V250, P6503; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMURA H, 1993, J BIOL CHEM, V268, P24125; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; VALENTE WA, 1983, NEW ENGL J MED, V309, P1028, DOI 10.1056/NEJM198310273091705	31	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15231	15236		10.1074/jbc.270.25.15231	http://dx.doi.org/10.1074/jbc.270.25.15231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797507	hybrid			2022-12-27	WOS:A1995RE66600058
J	HOLLENBERG, AN; MONDEN, T; WONDISFORD, FE				HOLLENBERG, AN; MONDEN, T; WONDISFORD, FE			LIGAND-INDEPENDENT AND LIGAND-DEPENDENT FUNCTIONS OF THYROID-HORMONE RECEPTOR ISOFORMS DEPEND UPON THEIR DISTINCT AMINO TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; AUXILIARY PROTEIN; X-RECEPTORS; RXR-BETA; GENE; BINDING; DNA; ACTIVATION; EXPRESSION	Isoform specificity likely plays a large role in the ability of the thyroid hormone receptor (TR) to specifically regulate gene expression in both the presence and absence of its cognate ligand, triiodothyronine. To investigate further the mechanism of isoform specificity of human TRs (TR alpha 1 and TR beta 1), we have examined their functional effects on positive thyroid hormone response elements (TREs) both in the presence and absence of ligand. TR alpha 1 was greater than 2-fold more potent than TR beta 1 on both TREs studied, in terms of both ligand-independent repression and ligand-dependent stimulation. By creating a number of chimeric and mutant receptors, we have established that the increased functional potency of TR alpha 1 is due to its unique amino terminus. Deletion or substitution of the TR alpha 1 amino terminus leads to a loss of both its ligand-independent and -dependent functions on positive TREs. Furthermore, the TR alpha 1 amino terminus antagonizes homodimer formation on the positive TREs studied, TR constructs, which contain the TR alpha 1 amino terminus, are unable to form homodimers and form exclusively heterodimers with RXR alpha on direct repeat and palindromic TREs. Deletion of the amino terminus from either TR isoform leads to preferential homodimer formation, which suggests that the TR amino terminus is important for relative heterodimerization capability. From these data, we conclude that TR alpha 1 isoform specificity on positive TREs resides predominantly in its amino terminus through its ability to favor heterodimerization with the retinoid X receptor or other nuclear proteins.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	HOLLENBERG, AN (corresponding author), BETH ISRAEL HOSP, THYROID UNIT, RES N 330B, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653] Funding Source: Medline; PHS HHS [K08D4-02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLYNN TR, 1994, J BIOL CHEM, V269, P32713; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P702; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; YEN PM, 1993, ENDOCR J, V1, P461; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14274	14280		10.1074/jbc.270.24.14274	http://dx.doi.org/10.1074/jbc.270.24.14274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782283	hybrid			2022-12-27	WOS:A1995RD45500009
J	JOSHI, B; CAI, AL; KEIPER, BD; MINICH, WB; MENDEZ, R; BEACH, CM; STEPINSKI, J; STOLARSKI, R; DARZYNKIEWICZ, E; RHOADS, RE				JOSHI, B; CAI, AL; KEIPER, BD; MINICH, WB; MENDEZ, R; BEACH, CM; STEPINSKI, J; STOLARSKI, R; DARZYNKIEWICZ, E; RHOADS, RE			PHOSPHORYLATION OF EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4E AT SER-209	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; KINASE-C; TRANSLATIONAL INITIATION; NUCLEOTIDE-SEQUENCE; PHORBOL ESTERS; FACTOR EIF-4E; GROWTH-FACTOR; COMPLEX; CELLS; OVEREXPRESSION	Initiation factor 4E (eIF-4E) binds to the m(7)GTP-containing cap of eukaryotic mRNA and facilitates the entry of mRNA into the initiation cycle of protein synthesis. eIF-4E is a phosphoprotein, and the phosphorylated form binds to mRNA caps 3-4-fold more tightly than the nonphosphorylated form. A previous study indicated that the major phosphorylation site was Ser-53 (Rychlik, W., Russ, M. A., and Rhoads, R. E. (1987) J. Biol. Chem. 262, 10434-10437). In the present study, we synthesized the phosphopeptide expected to result from tryptic digestion of eIF-4E, O-phosphoseryllysine. Surprisingly, the tryptic and synthetic phosphopeptides did not comigrate electrophoretically. Accordingly, we redetermined the phosphorylation site by isolating a chymotryptic phosphopeptide on reverse phase high performance liquid chromatography. The peptide was sequenced by Edman degradation and corresponded to (198)QSHADTATKSGSTTKNRF(215). The site of phosphorylation was determined to be Ser-209 by four methods: the increase in the ratio of dehydroalanine to serine derivatives during Edman degradation, the release of P-32, the further digestion of the chymotryptic phosphopeptide with trypsin, Glu-C, and Asp-N, and site-directed mutagenesis of eIF-4E cDNA The S209A variant was not phosphorylated in a rabbit reticulocyte lysate system, whereas the wild-type, S53A, and S207A variants were. This site falls within the consensus sequence for phosphorylation by protein kinase C.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,SHREVEPORT,LA 71130; UNIV KENTUCKY,MED CTR,MACROMOLEC STRUCT ANAL FACIL,LEXINGTON,KY 40536; UNIV WARSAW,DEPT BIOPHYS,PL-02089 WARSAW,POLAND; UNIV WARSAW,DEPT CHEM,PL-02089 WARSAW,POLAND	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky; University of Warsaw; University of Warsaw				Keiper, Brett/0000-0002-8621-9825; Stolarski, Ryszard/0000-0002-3272-5140; Mendez, Raul/0000-0002-1952-6905	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, P145; BU X, 1993, J BIOL CHEM, V268, P4975; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEDNER N, 1988, FEBS LETT, V236, P77, DOI 10.1016/0014-5793(88)80288-6; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HAAS DW, 1992, SEC MESS PHOSPHOPROT, V14, P55; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUG H, 1993, BIOCHEM J, V291, P115; IKEBE M, 1990, J BIOL CHEM, V265, P8975; JAGUS R, 1993, DEV GENET, V14, P412, DOI 10.1002/dvg.1020140603; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KEIPER BD, 1990, J BIOL CHEM, V265, P19397; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1991, NEW BIOL, V3, P601; TRACHSEL H, 1991, TRANSLATION EUKARYOT, P415; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1990, J BIOL CHEM, V265, P10617	49	184	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14597	14603		10.1074/jbc.270.24.14597	http://dx.doi.org/10.1074/jbc.270.24.14597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782323	hybrid			2022-12-27	WOS:A1995RD45500056
J	SCHNITZER, JE; LIU, J; OH, P				SCHNITZER, JE; LIU, J; OH, P			ENDOTHELIAL CAVEOLAE HAVE THE MOLECULAR-TRANSPORT MACHINERY FOR VESICLE BUDDING, DOCKING, AND FUSION INCLUDING VAMP, NSF, SNAP, ANNEXINS, AND GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; SECRETORY PATHWAY; FAMILY; CELLS; YEAST; SYNAPTOBREVIN; COMPONENTS; RECEPTORS	Transport by discrete vesicular carriers is well established at least in part because of recent discoveries identifying key protein mediators of vesicle formation, docking, and fusion. A general mechanism sensitive to N-ethylmaleimide (NEM) is required for the transport of a divergent group of vesicular carriers in all eukaryotes. Many endothelia have an abundant population of noncoated plasmalemmal vesicles or caveolae, which have been reported with considerable controversy to function in transport. We recently have shown that like other vesicular transport systems, caveolae-mediated endocytosis and transcytosis are inhibited by MEM (Schnitzer, J. E., Allard, J., and Oh, P. (1995) Am. J. Physiol. 268, H48-H55). Here, we continue this work by utilizing our recently developed method for purifying endothelial caveolae from rat lung tissue (Schnitzer, J. E., Oh, P., Jacobson, B. S., and Dvorak, A. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1759-1763) to show that these caveolae contain key proteins known to mediate different aspects of vesicle formation, docking, and/or fusion including the vSNARE VAMP-2, monomeric and trimeric GTPases, annexins II and VI, and the NEM-sensitive fusion factor NSF along with its attachment protein SNAP. Like neuronal VAMPs, this endothelial VAMP is sensitive to cleavage by botulinum B and tetanus neurotoxins. Caveolae in endothelium are indeed like other carrier vesicles and contain similar NEM-sensitive molecular machinery for transport.			SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N BATH ISRAEL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL43278, HL52766] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278, R01HL052766] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUNDGAARD M, 1983, FED PROC, V42, P2425; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P231, DOI 10.1016/0968-0004(94)90143-0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FROKJAERJENSEN J, 1980, J ULTRA MOL STRUCT R, V73, P9, DOI 10.1016/0022-5320(80)90111-2; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALADE GE, 1958, ANAT REC, V130, P467; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; RALSTON E, 1994, J BIOL CHEM, V269, P15403; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Simionescu M, 1984, HDB PHYSL 2, P41; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WITEHEART SW, 1994, J CELL BIOL, V126, P945	50	306	314	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14399	14404		10.1074/jbc.270.24.14399	http://dx.doi.org/10.1074/jbc.270.24.14399			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782301	hybrid			2022-12-27	WOS:A1995RD45500028
J	SHEPS, JA; CHEUNG, I; LING, V				SHEPS, JA; CHEUNG, I; LING, V			HEMOLYSIN TRANSPORT IN ESCHERICHIA-COLI - POINT MUTANTS IN HLYB COMPENSATE FOR A DELETION IN THE PREDICTED AMPHIPHILIC HELIX REGION OF THE HLYA SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; TRANSMEMBRANE DOMAIN; ALPHA-HEMOLYSIN; FUNCTIONAL CONSEQUENCES; SECRETION; MUTATIONS; PROTEIN; IDENTIFICATION; SUBSTITUTION; RESISTANCE	The alpha-hemolysin transporter of Escherichia coli, a member of the ATP-binding cassette transporter superfamily, is responsible for secretion of the 107-kDa protein toxin HlyA across both membranes of the Gram-negative envelope in a single step. Secretion of HlyA is dependent on a signal sequence, which occupies the C-terminal 50-60 amino acids of HlyA. Previously, it was shown that point mutants in the transmembrane domain of the transporter HlyB could partially correct the transport defect caused by a deletion of the C-terminal 29 amino acids of HlyA. These suppressor mutations demonstrated a direct interaction between HlyA and HlyB. They also displayed suppressor effects on a broad spectrum of HlyA signal mutants. In the present study, we selected HlyB alleles that complemented an internal deletion of 29 amino acids in HlyA containing a predicted amphiphilic helix region immediately upstream from the previous deletion. This set of HlyB mutants identifies further sites in HlyB that modulate substrate specificity but display allele-specific effects on a range of HlyA signal mutants. The inability to isolate mutations with effects restricted to either half of the signal sequence suggests that the signal is not recognized in a modular fashion by the transporter but rather functions as an integrated whole. We also report the isolation of the first substrate specificity mutation, which lies within the ATP-binding domain of HlyB. This could support a model in which the region of the ATP-binding cassette between the two Walker consensus motifs involved in ATP binding interacts with either the substrate or the transmembrane domains.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; GENTSCHEV I, 1992, MOL GEN GENET, V232, P40, DOI 10.1007/BF00299135; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HACKER J, 1985, CURR TOP MICROBIOL I, V118, P139; HESS J, 1990, MOL GEN GENET, V224, P201, DOI 10.1007/BF00271553; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGHLANDER SK, 1989, DNA-J MOLEC CELL BIO, V8, P15, DOI 10.1089/dna.1.1989.8.15; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JURANKA P, 1992, J BIOL CHEM, V267, P3764; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; KORONAKIS V, 1987, J BACTERIOL, V169, P1509, DOI 10.1128/jb.169.4.1509-1515.1987; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; LETOFFE S, 1993, J BACTERIOL, V175, P7321; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; ZHANG F, 1995, BIOCHEMISTRY-US, V34, P4193, DOI 10.1021/bi00013a007; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211; ZHANG F, 1993, J BIOL CHEM, V268, P19889	33	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14829	14834		10.1074/jbc.270.24.14829	http://dx.doi.org/10.1074/jbc.270.24.14829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782350	hybrid			2022-12-27	WOS:A1995RD45500088
J	COHEN, O; FLYNN, TR; WONDISFORD, FE				COHEN, O; FLYNN, TR; WONDISFORD, FE			LIGAND-DEPENDENT ANTAGONISM BY RETINOID-X RECEPTORS OF INHIBITORY THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; AUXILIARY PROTEIN; DNA-BINDING; RXR-BETA; ENHANCES BINDING; T3 RECEPTOR; ACID; EXPRESSION; H-2RIIBP; HETERODIMERIZATION	The role of retinoid X receptors (RXRs) on negative thyroid hormone response elements (nTREs) is not well understood, In this report, we demonstrate that an orientation-specific monomeric thyroid hormone receptor (T(3)R) DNA-binding site mediates thyroid hormone inhibition in the thyrotropin beta subunit gene (TSH-beta) from human and murine species. Unlike positive TREs, addition of the ligand 9-cis retinoic acid (9-cis RA) to cells transfected with a T(3)R beta 1 expression vector significantly reduces thyroid hormone inhibition of the TSH-beta gene, indicating that endogenous retinoid receptors antagonize T(3)R function. Cotransfection of an RXR-alpha but not a retinoic acid receptor-alpha expression vector further antagonizes thyroid hormone inhibition, but only in the presence of 9-cis RA. Antagonism by RXR requires both an intact DNA- and ligand-binding domain, Removal of monomeric T(3)R binding to the TSH-beta nTRE also requires both RXR domains. A model is proposed whereby monomeric T(3)R is removed from a nTRE by RXR occupied by its ligand 9-cis RA. This is the first report of 9-cis RA-dependent antagonism of thyroid hormone inhibition via negative TREs.	BETH ISRAEL HOSP,THYROID UNIT,BOSTON,MA 02215; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13899	13905		10.1074/jbc.270.23.13899	http://dx.doi.org/10.1074/jbc.270.23.13899			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775449	hybrid			2022-12-27	WOS:A1995RC44800048
J	HONG, J; SALO, WL; ANDERSON, PM				HONG, J; SALO, WL; ANDERSON, PM			NUCLEOTIDE-SEQUENCE AND TISSUE-SPECIFIC EXPRESSION OF THE MULTIFUNCTIONAL PROTEIN CARBAMOYL-PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) MESSENGER-RNA IN SQUALUS-ACANTHIAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE BIOSYNTHESIS; UREA SYNTHESIS; HAMSTER-CELLS; GENE; PHOSPHORYLATION; DOMAIN; ENZYME; ELASMOBRANCHS; POLYPEPTIDE; EVOLUTION	Carbamoyl-phosphate synthetase II (CPSase II), aspartate transcarbamoylase (ATCase), and dihydroorotase (DHOase) catalyze the first three steps of de novo pyrimidine nucleotide biosynthesis, respectively. In mammalian species, these three enzyme activities exist in the cytosol in liver and other tissues as a multifunctional complex on a single polypeptide called carbamoyl-phosphate synthetase-aspartate transcarbamoylase-dihydroorotase (CAD) in the order of NH2-CPSase II-DHOase-ATCase-COOH. Previous studies provided evidence that in Squalus acanthias (spiny dogfish) these enzymes are not expressed in liver and that they exist as separate entities in the cytosol of extra-hepatic tissues such as testes and spleen (Anderson, P. M. (1989) Biochem. J. 261, 528-529). Here we report that the genes for these three enzymes are expressed in testes as a single transcript analogous to CAD in mammalian species and that these genes are not expressed in liver at levels that can be detected by Northern blots or by the polymerase chain reaction. The absence of the pyrimidine pathway in the liver may be related to the exclusive localization of glutamine synthetase in the mitochondrial matrix which provides for efficient assimilation of ammonia as glutamine for urea synthesis in these ureoosmotic species; thus glutamine may not be available for CPSase II or other amidotransferase activities in the cytosol. The amino acid sequence deduced from the nucleotide sequence of the shark CAD cDNA reported here is very similar to CAD from other species; alignment with the hamster CAD sequence shows 77% identical residues.	UNIV MINNESOTA, DEPT BIOCHEM & MOLEC BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth								ANDERSON PM, 1980, SCIENCE, V208, P291, DOI 10.1126/science.6245445; ANDERSON PM, 1991, BIOCHEM CELL BIOL, V69, P317, DOI 10.1139/o91-049; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1989, BIOCHEM J, V261, P523, DOI 10.1042/bj2610523; ANDERSON PM, 1995, J EXP BIOL, V198, P755; ANDERSON PM, 1995, ANIMAL PHYSL EVOLUTI; ANDERSON PM, 1995, FISH PHYSL, V14; AOKI T, 1987, COMP BIOCHEM PHYS B, V87, P143, DOI 10.1016/0305-0491(87)90481-0; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BEIN K, 1991, J BIOL CHEM, V266, P3791; BERGER SL, 1987, ANAL BIOCHEM, V161, P272, DOI 10.1016/0003-2697(87)90451-9; Borson N D, 1992, PCR Methods Appl, V2, P144; Campbell J.W., 1991, Biochemistry and Molecular Biology of Fishes, V1, P43; CAO XY, 1991, J EXP ZOOL, V258, P24, DOI 10.1002/jez.1402580104; CARREY EA, 1992, BIOCHEM J, V287, P791, DOI 10.1042/bj2870791; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CARREY EA, 1993, BIOCHEM SOC T, V21, P191, DOI 10.1042/bst0210191; CARREY EA, 1988, EUR J BIOCHEM, V171, P583, DOI 10.1111/j.1432-1033.1988.tb13828.x; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DENISDUPHIL M, 1981, J BACTERIOL, V148, P659, DOI 10.1128/JB.148.2.659-669.1981; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; EVANS DR, 1993, BIOCHEM SOC T, V21, P186, DOI 10.1042/bst0210186; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KENT RJ, 1975, P NATL ACAD SCI USA, V72, P1712, DOI 10.1073/pnas.72.5.1712; KIM HS, 1992, J BIOL CHEM, V267, P7177; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MOMMSEN TP, 1989, SCIENCE, V243, P72, DOI 10.1126/science.2563172; MUKHERJEE T, 1988, J BIOL CHEM, V263, P708; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; OTSUKI T, 1982, J BIOCHEM-TOKYO, V92, P1431, DOI 10.1093/oxfordjournals.jbchem.a134067; QUINN CL, 1991, J BIOL CHEM, V266, P9113; Sambrook J, 1989, MOL CLONING LABORATO; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; TAMPITAG S, 1986, MOL BIOCHEM PARASIT, V19, P125, DOI 10.1016/0166-6851(86)90117-9; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	43	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14130	14139		10.1074/jbc.270.23.14130	http://dx.doi.org/10.1074/jbc.270.23.14130			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775474	hybrid			2022-12-27	WOS:A1995RC44800079
J	OLSON, DC; OETIKER, JH; YANG, SF				OLSON, DC; OETIKER, JH; YANG, SF			ANALYSIS OF LE-ACS3, A 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID SYNTHASE GENE EXPRESSED DURING FLOODING IN THE ROOTS OF TOMATO PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; ETHYLENE BIOSYNTHESIS; DIFFERENTIAL ACCUMULATION; LYCOPERSICON-ESCULENTUM; MAIZE ADH1; SEQUENCES; FRUIT; TRANSCRIPTS; EPINASTY; ELEMENTS	The plant hormone ethylene is produced in response to a variety of environmental stresses. Previous work has shown that flooding or anaerobic stress in the roots of tomato plants caused an increase in the production of the ethylene precursor 1-aminocyclopropane-1-carboxylate (ACC) in the roots, due to flooding-induced activity of ACC synthase (EC 4.4.1.14). RNA was extracted from roots and leaves of tomato plants flooded over a period of 48 h. Blot analysis of these RNAs hybridized with probes for four different ACC synthases revealed that the ACC synthase gene LE-ACS3 is rapidly induced in roots. LE-ACS2 is also induced, but at later times. The genomic clone for LE-ACS3 was isolated and sequenced. At all time points, the probe from the LE-ACS3 coding region hybridized to two bands in the RNA blots. Hybridization using the first and third introns of LE-ACS3 separately as probes indicate that flooding may inhibit processing of the LE-ACS3 transcript. Sequence homology analysis identified three putative cis-acting response elements in the promoter region, corresponding to the anaerobic response element from the maize adh1 promoter, the root-specific expression element from the cauliflower mosaic virus 35S promoter and a recognition element for chloroplast DNA binding factor I from the maize chloroplast ATP synthase promoter.			OLSON, DC (corresponding author), UNIV CALIF DAVIS,DEPT VEGETABLE CROPS,MANN LAB,DAVIS,CA 95616, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD K J, 1980, Plant Physiology (Rockville), V65, P40; BRADFORD KJ, 1980, PLANT PHYSIOL, V65, P322, DOI 10.1104/pp.65.2.322; BRADFORD KJ, 1978, PLANT PHYSIOL, V61, P506, DOI 10.1104/pp.61.4.506; BROWN WS, 1986, NUCLEIC ACIDS RES, V14, P954; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DEIKMAN J, 1988, EMBO J, V7, P3315, DOI 10.1002/j.1460-2075.1988.tb03202.x; GOSWH D, 1990, NUCLEIC ACIDS RES, V18, P1749; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hoagland D.R., 1950, WATER CULTURE METHOD, V347, P1, DOI DOI 10.1007/S12374-010-9112-0; JACKSON MB, 1976, PLANTA, V129, P273, DOI 10.1007/BF00398271; JACKSON MB, 1976, NEW PHYTOL, V76, P21, DOI 10.1111/j.1469-8137.1976.tb01434.x; JACKSON WT, 1956, AM J BOT, V43, P557; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KAWASE M, 1972, J AM SOC HORTIC SCI, V97, P584; KAWASE M, 1974, PHYSIOL PLANTARUM, V31, P29, DOI 10.1111/j.1399-3054.1974.tb03673.x; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KRAMER PJ, 1951, PLANT PHYSIOL, V26, P722, DOI 10.1104/pp.26.4.722; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1988, J BIOL CHEM, V263, P8288; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; NASH J, 1992, PLANT PHYSIOL, V100, P464, DOI 10.1104/pp.100.1.464; OLIVE MR, 1990, PLANT MOL BIOL, V15, P593, DOI 10.1007/BF00017834; OLSON DC, 1991, P NATL ACAD SCI USA, V88, P5430; ORTIZ DF, 1990, MOL CELL BIOL, V10, P2090, DOI 10.1128/MCB.10.5.2090; PAUL AL, 1991, PLANT CELL, V3, P159, DOI 10.1105/tpc.3.2.159; POULSEN C, 1988, MOL GEN GENET, V214, P16, DOI 10.1007/BF00340173; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Sambrook J, 1989, MOL CLONING LABORATO; SPANU P, 1993, J PLANT PHYSIOL, V141, P557, DOI 10.1016/S0176-1617(11)80456-6; TURKOVA NS, 1944, AKAD NAUK USSR LEN C, V42, P87; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; WALKER JC, 1987, P NATL ACAD SCI USA, V84, P6624, DOI 10.1073/pnas.84.19.6624; WANG TW, 1992, PLANT PHYSIOL, V98, P97, DOI 10.1104/pp.98.1.97; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WINTER J, 1988, MOL GEN GENET, V211, P615; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1992, P NATL ACAD SCI USA, V89, P2475, DOI 10.1073/pnas.89.6.2475	39	99	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14056	14061		10.1074/jbc.270.23.14056	http://dx.doi.org/10.1074/jbc.270.23.14056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775465	hybrid			2022-12-27	WOS:A1995RC44800068
J	SAENKO, EL; SCANDELLA, D				SAENKO, EL; SCANDELLA, D			A MECHANISM FOR INHIBITION OF FACTOR-VIII BINDING TO PHOSPHOLIPID BY VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; COAGULATION FACTOR-VIII; AMINO-ACID-SEQUENCES; ACTIVATED PROTEIN-C; LIGHT CHAIN; MONOCLONAL-ANTIBODY; MEMBRANE-BINDING; FACTOR-V; DOMAIN; PHOSPHATIDYLSERINE	von Willebrand factor (vWf) acts as a carrier for blood coagulation factor VIII (fVIII) in the circulation, The amino-terminal 272 residues of mature vWf contain a high affinity fVIII binding site, Upon thrombin activation, fVIII is released from vWf, thereby allowing its binding to phospholipid which is required for its procoagulant activity. Although phospholipid and vWf compete for fVIII binding, it was previously suggested that their binding sites are not closely juxtaposed within the fVIII protein because only amino-terminal vWf proteolytic fragments larger than SPIII-T4 (1-272) were able to block the binding of fVIII to phospholipid. We have demonstrated, however, that SPIII-T4 is able to inhibit fVIII binding to phosphatidylserine (PS) in a dose-dependent fashion, but only at concentrations higher than those used in previous experiments. Our demonstration that the K-d values for vWf and SPIII-T4 for fVIII are 0.52 nM and 48 nn, respectively, explain this discrepancy. Inhibition (>95%) of SPIII-T4 binding to fVIII by a purified recombinant fVIII C2 domain polypeptide demonstrated that SPIII-T4 binds directly to C2, as we had previously shown for vWf, The similarity of the C2 binding sites for vWf and SPIII-T4 was further confirmed by the identical inhibitory effects of synthetic peptides and monoclonal antibodies (mAbs) on vWf-fVIII or SPIII-T4-fVIII binding, In both cases, binding was inhibited by synthetic peptide 2303-2332, containing a PS binding site, and by mAb NMC-VIII/5 Fab' (epitope within C2 residues 2170-2327), We propose that vWf, via residues 1-272, and PS compete for fVIII binding because they recognize overlapping sites within fVIII C2 domain residues 2303-2332.	AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [R01-HL36094, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GINSBURG D, 1993, THROMB HAEMOSTASIS, V669, P177; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; JORIEUX S, 1994, BRIT J HAEMATOL, V87, P113, DOI 10.1111/j.1365-2141.1994.tb04879.x; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LANGONE JJ, 1980, METHOD ENZYMOL, V7, P221; LAYET S, 1992, BIOCHEM J, V282, P129, DOI 10.1042/bj2820129; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1988, BLOOD, V71, P137; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MERRIL CR, 1986, ANAL BIOCHEM, V156, P96, DOI 10.1016/0003-2697(86)90160-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484	46	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13826	13833		10.1074/jbc.270.23.13826	http://dx.doi.org/10.1074/jbc.270.23.13826			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775440	hybrid			2022-12-27	WOS:A1995RC44800039
J	RUSINOL, AE; VANCE, JE				RUSINOL, AE; VANCE, JE			INHIBITION OF SECRETION OF TRUNCATED APOLIPOPROTEINS-B BY MONOMETHYLETHANOLAMINE IS INDEPENDENT OF THE LENGTH OF THE APOLIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; PAUSE TRANSFER; OLEIC-ACID; TRANSLOCATION; CHOLESTEROL; HEPATOCYTES; RECEPTOR	Translocation of apolipoprotein (ape) B across the endoplasmic reticulum membrane is a likely site for regulation of secretion of very low density lipoproteins from the liver. When primary rat hepatocytes are enriched with the phospholipid phosphatidylmonomethylethanolamine, the secretion of apoB, but not other proteins such as apoprotein Al and albumin, is disrupted (Vance, J. E. (1991) J. Lipid Res. 32, 1971-1982). Moreover, less apoB enters the microsomal lumen and the intracellular degradation of apoB is increased (Rusinol, A E., Chan, E. Y. W., and Vance, J. E. (1993a) J. Biol. Chem. 268, 25168-25175). In the present study we have used McArdle 7777 rat hepatoma cells stably transfected with carboxyl-terminal-truncated variants of human apoB100 and have demonstrated that the reduction in apoB secretion induced by phosphatidylmonomethylethanolamine is not a function of assembly of the apoB into a buoyant Lipoprotein particle. In addition, inhibition of the intracellular degradation of the apoproteins B does not restore apoB secretion, suggesting that the effect of phosphatidylmonomethylethanolamine enrichment on apoB degradation is secondary to the effect on translocation of the protein into the endoplasmic reticulum lumen. Furthermore, supplementation of the culture medium with oleic acid does not increase apoB secretion, reduce the intracellular degradation of apoB or reverse the effects of phosphatidylmonomethylethanolamine enrichment on these processes. Our data support the hypothesis that translocation of apoB protein across the endoplasmic reticulum membrane, regardless of the association of the apoB with neutral lipids, may be a key regulatory step in very low density lipoprotein secretion.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DASHTI N, 1990, J LIPID RES, V31, P113; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; LOWRY OH, 1951, J BIOL CHEM, V192, P265; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VANCE JE, 1991, J LIPID RES, V32, P1971; WHITE AL, 1992, J BIOL CHEM, V267, P15657; YAO ZM, 1991, J BIOL CHEM, V266, P3300	28	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13318	13325		10.1074/jbc.270.22.13318	http://dx.doi.org/10.1074/jbc.270.22.13318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768932	hybrid			2022-12-27	WOS:A1995RB43900057
J	FAZIO, S; MAROTTI, KR; LEE, YL; CASTLE, CK; MELCHIOR, GW; RALL, SC				FAZIO, S; MAROTTI, KR; LEE, YL; CASTLE, CK; MELCHIOR, GW; RALL, SC			COEXPRESSION OF CHOLESTERYL ESTER TRANSFER PROTEIN AND DEFECTIVE APOLIPOPROTEIN-E IN TRANSGENIC MICE ALTERS PLASMA-CHOLESTEROL DISTRIBUTION - IMPLICATIONS FOR THE PATHOGENESIS OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN LEVELS; FAMILIAL DYSBETALIPOPROTEINEMIA; PHENOTYPE-E3/3; METABOLISM; CYSTEINE; VARIANT	Despite the definite etiologic link between apolipoprotein (ape) E mutations and type III hyperlipoproteinemia (HLP), it is not clear what additional factors are involved in the development of florid hyperlipidemia and how to explain the wide variability in the expression of the hyperlipidemic phenotype in carriers of receptor binding-defective apoE variants, The present study was designed to determine whether the overexpression of cholesteryl ester transfer protein (CETP), a plasma protein that transfers cholesteryl esters hom the high density lipoproteins (HDL) to the very low density lipoproteins (VLDL) and whose activity is increased in hyperlipidemic states, plays a role in the development of hyperlipidemia and beta-VLDL accumulation in type III HLP. We produced double-transgenic mice that co-expressed high levels of simian CETP and either high or low levels of a human receptor binding-defective apoE variant, apoE(Cys-142). We previously reported that apoE(Cys-142) high-expresser mice showed spontaneous hyperlipidemia and accumulation of beta-VLDL, whereas the low-expresser mice showed only a modest increase in VLDL cholesterol. Go-expression of CETP induced a massive transfer of cholesteryl esters from the HDL to the VLDL in both lines of double-transgenic mice. As a result, HDL cholesterol and apoA-I levels were reduced to about 50% of normal, VLDL cholesterol increased 2.5-fold, and the cholesteryl ester content of VLDL reached values similar to those observed in human beta-VLDL. The ratio of defective to normal apoE in VLDL was unaffected by CETP co-expression and was higher in animals expressing high apoE levels, Finally, in spite of an increased accumulation of beta-VLDL in the high-expresser mice, the VLDL of the low-expresser mice maintained pre-beta mobility upon co expression of CETP. The results of this study demonstrate that the ratio of defective to normal apoE on the VLDL, rather than the cholesteryl ester content of VLDL, is the major factor determining the development of severe hyperlipidemia and the formation and accumulation of beta-VLDL in type III HLP.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UPJOHN CO, UPJOHN LABS, KALAMAZOO, MI 49001 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; Pfizer					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; ANDERSON LJ, 1989, J LIPID RES, V30, P1819; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; FAINARU M, 1982, J LIPID RES, V23, P702; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1980, P NATL ACAD SCI-BIOL, V77, P4349, DOI 10.1073/pnas.77.7.4349; HAYEK T, 1993, J CLIN INVEST, V92, P1143, DOI 10.1172/JCI116683; HORIE Y, 1992, J BIOL CHEM, V267, P1962; INNERARITY TL, 1986, LIPOPROTEIN DEFICIEN, P273; KIEFT KA, 1991, J LIPID RES, V32, P859; KINOSHITA M, 1993, J LIPID RES, V34, P261; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P476, DOI 10.1161/01.ATV.11.3.476; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MELCHIOR GW, 1994, J BIOL CHEM, V269, P8044; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; SEIP RL, 1993, ARTERIOSCLER THROMB, V13, P1359, DOI 10.1161/01.ATV.13.9.1359; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1986, J LIPID RES, V27, P361; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518	28	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32368	32372						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798236				2022-12-27	WOS:A1994PX30400054
J	YANG, GY; MERRILL, DC; THOMPSON, MW; ROBILLARD, JE; SIGMUND, CD				YANG, GY; MERRILL, DC; THOMPSON, MW; ROBILLARD, JE; SIGMUND, CD			FUNCTIONAL EXPRESSION OF THE HUMAN ANGIOTENSINOGEN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; CELL-SPECIFIC EXPRESSION; HUMAN RENIN GENE; MESSENGER-RNA; BLOOD-PRESSURE; SMOOTH-MUSCLE; INSITU HYBRIDIZATION; CONVERTING ENZYME; POLYMORPHISM; ELEMENTS	The renin-angiotensin system is a major determinant of arterial pressure and volume homeostasis in mammals through the actions of angiotensin II, the proteolytic digestion product of angiotensinogen. Molecular genetic studies in several human populations have revealed genetic linkage between the angiotensinogen gene and both hypertension and increased plasma angiotensinogen. Transgenic mice were generated with a human angiotensinogen genomic clone to develop an animal model to examine tissue- and cell-specific expression of the gene and to determine if overexpression of angiotensinogen results in hypertension. Human angiotensinogen mRNA was expressed in transgenic mouse liver, kidney, heart, adrenal gland, ovary, brain, and white and brown adipose tissue and, in kidney, was exclusively localized to epithelial cells of the proximal convoluted tubules, Plasma levels of human angiotensinogen were approximately 150-fold higher in transgenic mice than that found normally in human plasma. The blood pressure of mice bearing the human angiotensinogen gene was normal but infusion of a single bolus dose of purified human renin resulted in a transient increase in blood pressure of approximately 30 mm Hg within 2 min. These results suggest that abnormalities in the angiotensinogen gene resulting in increased circulating levels of angiotensinogen could potentially contribute in part to the pathogenesis of essential hypertension.	UNIV IOWA,COLL MED,DEPT MED & PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ANAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OBSTET & GYNECOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048058, R37HL048058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAZIL MK, 1993, J CARDIOVASC PHARM, V22, P897, DOI 10.1097/00005344-199312000-00019; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; BURTON J, 1988, BIOCHIM BIOPHYS ACTA, V952, P8, DOI 10.1016/0167-4838(88)90095-7; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLISON KE, 1989, J CLIN INVEST, V83, P1941, DOI 10.1172/JCI114102; GAILLARDSANCHEZ I, 1990, HUM GENET, V84, P341; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GYURKO R, 1993, REGUL PEPTIDES, V49, P167, DOI 10.1016/0167-0115(93)90438-E; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HOGAN E, 1986, MANIPULATING MOUSE E; HUBNER N, 1994, HYPERTENSION, V23, P797, DOI 10.1161/01.HYP.23.6.797; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LEVENS NR, 1981, CIRC RES, V48, P157, DOI 10.1161/01.RES.48.2.157; LIFTON RP, 1989, HYPERTENSION, V13, P884, DOI 10.1161/01.HYP.13.6.884; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; NAFTILAN AJ, 1989, HYPERTENSION, V14, P614, DOI 10.1161/01.HYP.14.6.614; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; NISHIMURA M, 1992, HYPERTENSION, V20, P158, DOI 10.1161/01.HYP.20.2.158; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; WARD R, 1990, HYPERTENSION PATHOPH, P81; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	43	110	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32497	32502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798251				2022-12-27	WOS:A1994PX30400072
J	GANJEIZADEH, M; ZOLOTARJOVA, N; HUANG, WH; ASKARI, A				GANJEIZADEH, M; ZOLOTARJOVA, N; HUANG, WH; ASKARI, A			INTERACTIONS OF PHOSPHORYLATION AND DIMERIZING DOMAINS OF THE ALPHA-SUBUNITS OF NA+/K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; (NA++K+)-ATPASE; NA,K-ATPASE; ANTIBODIES; ENZYME; SITES; UNIT; ION	Chemical cross-linking studies are among a number of experimental approaches that have suggested the functional significance of higher association states of alpha,beta-protomers of Na+/K+-ATPase. Formation of the phosphointermediate of the enzyme on Asp(369) Of the alpha-subunit is known to induce oxidative cross-linking of the alpha-subunits catalyzed by Cu2+-phenanthroline. To localize the phosphorylation-induced alpha,alpha-interface, we cleaved alpha at Arg(438)-Ala(439) by controlled proteolysis and exposed the partially cleaved enzyme to the cross-linking reagent. In addition to the alpha,alpha-dimer, two other phosphorylation-induced cross-linked products were obtained, Using gel electrophoretic resolution of the cross-linked P-32-labeled enzyme, N-terminal analyses of the products, and their reactivities with sequence-specific antibodies, the two products were identified as a homodimer of the C-terminal 64-kDa fragment of alpha and a heterodimer of alpha and the 64-kDa peptide. The latter dimer was also obtained when the cross-linked alpha,alpha-dimer was formed first and then subjected to proteolysis, The findings localize the dimerizing domain to the C-terminal side of Ala(439) and indicate that intersubunit proximities of dimerizing domains are regulated by phosphorylation-dephosphorylation of Asp(369) during the reaction cycle of the enzyme.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA						NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMER E, 1992, BIOPHYS J, V61, P553; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BIGELOW DJ, 1992, J BIOL CHEM, V267, P6952; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BOLDYREV AA, 1994, INT J BIOCHEM, V26, P1323, DOI 10.1016/0020-711X(94)90174-0; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; ESMANN M, 1989, BIOCHIM BIOPHYS ACTA, V978, P209, DOI 10.1016/0005-2736(89)90117-X; Froehlich Jeffrey P., 1995, Biophysical Journal, V68, pA316; GANJEIZADEH M, 1992, BIOPHYS J, V61, P122; GANJEIZADEH M, 1991, BIOPHYS J, V59, P343; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HUANG WH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P65, DOI 10.1016/0005-2736(90)90239-K; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAUNSBACH AB, 1991, SOC GEN PHY, V46, P159; MERSOL JV, 1995, BIOPHYS J, V68, P208, DOI 10.1016/S0006-3495(95)80176-1; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; MOHRAZ M, 1987, J CELL BIOL, V105, P1, DOI 10.1083/jcb.105.1.1; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; NORBY JG, 1989, J BIOL CHEM, V264, P19548; NORBY JG, 1991, SOC GEN PHY, V46, P173; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; SCHONER W, 1994, SODIUM PUMP, P332; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; XIE ZJ, 1994, SODIUM PUMP, P49; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	35	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15707	15710		10.1074/jbc.270.26.15707	http://dx.doi.org/10.1074/jbc.270.26.15707			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797572	hybrid			2022-12-27	WOS:A1995RG53800043
J	HEATH, RJ; ROCK, CO				HEATH, RJ; ROCK, CO			REGULATION OF MALONYL-COA METABOLISM BY ACYL-ACYL CARRIER PROTEIN AND BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHASES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; THERMAL REGULATION; COENZYME-A; ANTIBIOTIC CERULENIN; MUTANTS; SYNTHETASE; INHIBITION; BACTERIA; FLUIDITY; INVIVO	The cessation of phospholipid biosynthesis by the in hibition of the sn-glycerol-3-phosphate acyltransferase using a plsB mutant led to an accumulation of long chain acyl-acyl carrier proteins (acyl-ACP) and the concomitant inhibition of de novo fatty acid biosynthesis in Escherichia coli. Malonyl-CoA did not accumulate when phospholipid and fatty acid synthesis was blocked. However, the inactivation of beta-ketoacyl-ACP synthases I and II: with the antibiotic cerulenin triggered a large increase in the accumulation of malonyl-CoA following the cessation of phospholipid synthesis, illustrating that the beta-ketoacyl-ACP synthases were responsible for the degradation of malonyl-CoA in the presence of long chain acyl-ACP. The acyl-ACP requirement for malonyl-CoA degradation activity was confirmed by shifting enoyl-ACP reductase mutants (fabI(Ts)) to the non-permissive temperature, leading to the abrupt cessation of fatty acid synthesis and the accumulation of malonyl-CoA in the absence of cerulenin. Analysis of the ACP pool composition before and after the temperature shift showed that the fabI block did not result in the accumulation of long chain acyl-ACP. These data indicate a feedback regulatory loop that functions to recycle malonyl-CoA to acetyl-CoA following the down-regulation of fatty acid and phospholipid formation and provides a physiological rationale for the acyl-ACP-dependent, malonyl-ACP decarboxylase reaction catalyzed by beta-ketoacyl-ACP synthases I and II.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; CLEWELL DB, 1969, P NATL ACAD SCI USA, V69, P2110; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MAJERUS PW, 1969, METHOD ENZYMOL, V14, P43; Miller J.H., 1972, EXPT MOL GENETICS; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; TSAY JT, 1992, J BIOL CHEM, V267, P6807; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; VAGELOS PR, 1960, J BIOL CHEM, V235, P2786; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994	37	68	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15531	15538		10.1074/jbc.270.26.15531	http://dx.doi.org/10.1074/jbc.270.26.15531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797547	hybrid			2022-12-27	WOS:A1995RG53800017
J	SABHARWAL, AK; BIRKTOFT, JJ; GORKA, J; WILDGOOSE, P; PETERSEN, LC; BAJAJ, SP				SABHARWAL, AK; BIRKTOFT, JJ; GORKA, J; WILDGOOSE, P; PETERSEN, LC; BAJAJ, SP			HIGH-AFFINITY CA2+-BINDING SITE IN THE SERINE-PROTEASE DOMAIN OF HUMAN FACTOR VIIA AND ITS ROLE IN TISSUE FACTOR-BINDING AND DEVELOPMENT OF CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; CLOTTING FACTOR-VII; CALCIUM-BINDING; BLOOD-COAGULATION; FACTOR-X; ANTITHROMBIN-III; FACTOR-IX; ACTIVATION; COMPLEX; PURIFICATION	Factor VIIa, in the presence of Ca2+ and tissue factor (TF), initiates the extrinsic pathway of blood coagulation. The light chain (amino acids 1-152) of factor VIIa consists of an N terminal gamma-carboxyglutamic acid (Gla) domain followed by two epidermal growth factor-like domains, whereas the heavy chain (amino acids 153-406) contains the serine protease domain. In this study, both recombinant factor VIIa (rVIIa) and factor VIIa lacking the Gla domain were found to contain two high-affinity (K-d similar to 150 mu M) Ca2+ binding sites. The rVIIa also contained similar to 6-7 low-affinity (K-d similar to 1 mM) Ca2+-binding sites. By analogy to other serine proteases, one of the two high affinity Ca2+-binding sites in factor VIIa may be formed involving Glu-210 and Glu-220 of the protease domain. In support of this, a synthetic peptide composed of residues 206-242 of factor VIIa bound one Ca2+ with K-d similar to 230 mu M; however, Ca2+ binding was observed only in Tris buffer (pH 7.5) containing 1 M NaCl and not in buffer containing 0.1 M NaCl. In both low or high salt +/- Ca2+, the peptide existed as a monomer as determined by sedimentation equilibrium measurements and had no detectable secondary structure as determined by CD measurements. This indicates that subtle changes undetectable by CD may occur in the conformation of the peptide that favor calcium binding in high salt. In the presence of recombinant TF and 5 mM Ca2+, the peptide inhibited the amidolytic activity of rVIIa toward the synthetic substrate, 5-2288. The concentration of the peptide required for half-maximal inhibition was similar to 5-fold higher in the low salt buffer than that in the high salt buffer. From direct binding and competitive inhibition assays of active site-blocked I-125-rVIIa binding to TF, the K-d for peptide-TF interaction was calculated to be similar to 15 mu M in the high salt and similar to 55 pM in the low salt buffer containing 5 mM Ca2+. Moreover, as inferred from S-2288 hydrolysis, the K-d for VIIa TF interaction was similar to 1.5 mu M in the absence of Ca2+, and, as inferred from factor X activation studies, it was similar to 10 pM in thepresence of Ca2+. Thus, Ca2+ decreases the functional K-d of VIIa-. TF interaction similar to 150,000-fold. Furthermore, the amidoIytic activity of VIIa . Ca2+, VIIa . TF, and VIIa . Ca2+-TF was increased similar to 7-fold, similar to 100-fold, and similar to 350-fold, respectively, over that of factor VIIa alone; the half-maximal effect was observed at similar to 200 mu M Ca2+ when added. We conclude that TF can interact with the protease domain (and possibly other domains) of factor VIIa in the absence of Ca2+ and that the protease domain Ca2+-binding site, in part, enhances this interaction similar to 10(5)-fold.	ST LOUIS UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK	Saint Louis University; Saint Louis University; Saint Louis University; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Novo Nordisk					NHLBI NIH HHS [HL36365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036365, R56HL036365, R55HL036365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1988, J BIOL CHEM, V263, P9725; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GORKA J, 1989, Peptide Research, V2, P376; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUMAR A, 1993, EUR J BIOCHEM, V217, P509, DOI 10.1111/j.1432-1033.1993.tb18271.x; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MORITA T, 1991, THROMB HAEMOSTASIS, V65, P939; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO LVM, 1993, BLOOD, V81, P2600; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1986, BLOOD, V68, P685; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; RUF W, 1991, J BIOL CHEM, V266, P15719; SABHARWAL AK, 1993, BLOOD S1, V82, P64; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; STENFLO J, 1991, BLOOD, V78, P1637; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V190, P687; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WARNCRAMER BJ, 1986, BIOCHEM J, V239, P757, DOI 10.1042/bj2390757; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	51	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15523	15530		10.1074/jbc.270.26.15523	http://dx.doi.org/10.1074/jbc.270.26.15523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797546	hybrid			2022-12-27	WOS:A1995RG53800016
J	STOVER, DR; BECKER, M; LIEBETANZ, J; LYDON, NB				STOVER, DR; BECKER, M; LIEBETANZ, J; LYDON, NB			SRC PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT NOVEL SITES MEDIATES RECEPTOR INTERACTION WITH SRC AND P85-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BINDING-SITE; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH2 DOMAINS; IDENTIFICATION; ACTIVATION; PURIFICATION; PP60C-SRC	Following ligand binding, the epidermal growth factor receptor (EGF-R) autophosphorylates itself on tyrosine residues located in its carboxyl terminus; in vitro, three sites are highly phosphorylated, while two other sites are phosphorylated to lesser extents. In the presence of the Src protein-tyrosine kinase, in vitro phosphorylation of the minor autophosphorylation sites was increased, and four additional residues were phosphorylated. Following EGF stimulation, two (Tyr-891 and Tyr-920) were found to be phosphorylated in a colorectal cell line (DLD-1) and in a breast tumor cell line (MCF7). The remaining in vitro sites were not found to be highly phosphorylated in vivo. The sequences surrounding Tyr-891 and Tyr-920 match the reported consensus binding sequences for the SH2 domains of Src and the regulatory domain of phosphatidylinositol 3-kinase (p85 alpha), respectively. In vitro, both of these proteins were found to bind to Src-phosphorylated EGF-R with similar to 100-fold greater affinity than to autophosphorylated EGF-R, demonstrating that Src creates new sites for SH2 binding. Furthermore, Csk-inactivated Src was activated by interaction with Src-phosphorylated EGF-R but not by autophosphorylated EGF-R. Upon EGF treatment of MCF7 or three colorectal carcinoma cell lines (WiDr, DLD-1, and LS174T), the EGF-R coimmunoprecipitated with both p85 alpha and Src. Evidence is also presented that suggests that an EGF-R-related protein, ErbB2, may be involved in similar Src-mediated interactions. These data demonstrate that EGF-R is phosphorylated in vivo at non-autophosphorylation sites and that these novel sites can act as docking sites for Src, P85 alpha, and potentially other SH2 containing proteins. In addition, the data suggest a tyrosine phosphatase-independent mechanism for the elevation of Src activity in cells exposed to growth factors. Overexpression of Src, EGF-R, and/or ErbB2 in breast and colorectal tumor cells suggests the potential that such interactions may contribute to the transformed phenotype of these carcinomas.			STOVER, DR (corresponding author), CIBA GEIGY LTD, RES DEPT, DIV PHARMACEUT, K125420, CH-4002 BASEL, SWITZERLAND.							BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG JH, 1993, ONCOGENE, V8, P959; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FENG GS, 1994, ONCOGENE, V9, P1545; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUY PM, 1992, J BIOL CHEM, V267, P13851; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MASANORI I, 1990, VIRCHOWS ARCH B, V59, P173; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOVER DR, 1994, J BIOL CHEM, V269, P26885; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003; TRAXLER PM, 1995, IN PRESS J MED CHEM; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	192	194	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15591	15597		10.1074/jbc.270.26.15591	http://dx.doi.org/10.1074/jbc.270.26.15591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797556	hybrid			2022-12-27	WOS:A1995RG53800026
J	MONGE, JC; STEWART, DJ; CERNACEK, P				MONGE, JC; STEWART, DJ; CERNACEK, P			DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS TO A NEURAL OR CARDIOMYOCYTE LINEAGE IS ASSOCIATED WITH SELECTIVE EXPRESSION OF ENDOTHELIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOREACTIVE ENDOTHELIN; SPINAL-CORD; RAT-HEART; PEPTIDE; GENES; CLONING; MUSCLE; HYPERTROPHY; HYDROLYSIS; MECHANISM	Endothelins (ETs) were initially characterized as potent vasoactive peptides acting through at least two distinct receptors, ET(A) and ET(B). Subsequently, their significant growth- and hypertrophy-promoting properties in cardiac and other cells were recognized. We investigated the expression of endothelin receptors during differentiation of a pluripotential embryonal carcinoma cell line (P19) to a cardiomyocyte or a neural lineage. These cells resemble those of the inner cell mass of the blastocyst, and their differentiation is believed to closely mimic critical events in early embryogenesis. Differentiation of P19 to a cardiomyocyte lineage, by aggregation and exposure to dimethyl sulfoxide resulted in induction of ET(A) receptors as demonstrated by radioligand binding studies, Northern blotting, and reporter gene analysis. Moreover, the P19 differentiated to a cardiac lineage responded to ET-1 with a 3-fold increase in the secretion of atrial natriuretic peptide. In contrast, differentiation to a neural lineage, by aggregation and exposure to retinoic acid, was associated with the induction of predominantly ET(B). Therefore, selective differentiation of the P19 led to the differential expression of endothelin receptors in a pattern consistent with that observed in normal myocardial and neural tissue. The induction of endothelin receptors in a model system of early embryogenesis provides strong support for the critical role of this peptide/receptor family in differentiation and development. As well, this model system is well suited for the study of the mechanisms controlling endothelin receptor expression during differentiation.	ROYAL VICTORIA HOSP,DIV CARDIOL,MCGILL VASC BIOL GRP,MONTREAL,PQ H3A 1A1,CANADA; ROYAL VICTORIA HOSP,DEPT MED,DEPT BIOCHEM MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	MONGE, JC (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DIV CARDIOL,30 BOND ST,TORONTO,ON M5B 1W8,CANADA.							ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; CERNACEK P, 1988, AM J PHYSIOL, V255, pR929, DOI 10.1152/ajpregu.1988.255.6.R929; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CHOMCZYNSKI P, 1983, ANAL BIOCHEM, V162, P156; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GIAID A, 1993, LANCET, V341, P1550; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOSODA K, 1994, CIRCULATION, V90, P634; HOSODA K, 1992, J BIOL CHEM, V267, P18787; IHARA M, 1991, BIOCHEM BIOPH RES CO, V178, P132, DOI 10.1016/0006-291X(91)91789-F; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LI K, 1991, CIRC RES, V69, P301, DOI 10.1161/01.RES.69.2.301; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LUSCHER TF, 1991, KIDNEY INT, V39, P575, DOI 10.1038/ki.1991.68; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MANTYMAA P, 1990, ENDOCRINOLOGY, V126, P587; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEWART DJ, 1994, AM J PHYSIOL, V266, pH944, DOI 10.1152/ajpheart.1994.266.3.H944; STEWART DJ, 1993, EUR HEART J, V14, P48; THIBAULT G, 1994, CIRC RES, V74, P460, DOI 10.1161/01.RES.74.3.460; YANAGISAWA M, 1982, NATURE, V332, P411; YOSHIMI H, 1989, PEPTIDES, V10, P805, DOI 10.1016/0196-9781(89)90117-4; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; [No title captured]	50	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15385	15390		10.1074/jbc.270.25.15385	http://dx.doi.org/10.1074/jbc.270.25.15385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797528	hybrid			2022-12-27	WOS:A1995RE66600080
J	HO, WH; ARMANINI, MP; NUIJENS, A; PHILLIPS, HS; OSHEROFF, PL				HO, WH; ARMANINI, MP; NUIJENS, A; PHILLIPS, HS; OSHEROFF, PL			SENSORY AND MOTOR NEURON-DERIVED FACTOR - A NOVEL HEREGULIN VARIANT HIGHLY EXPRESSED IN SENSORY AND MOTOR-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION FACTOR; RNA; PROTEIN; MEMBRANES; HER4/P180(ERBB4); HYBRIDIZATION; INHIBITORS; MECHANISMS; SEQUENCES; PLASMIDS	The heregulin family of polypeptides arise as splice variants from a single gene and share a conserved epidermal growth factor (EGF)-like domain thought to be the major determinant of their biological activities, We report here the cloning of a novel member of this family, termed sensory and motor neuron-derived factor or SMDF, which is highly expressed in sensory and motor neurons in human and rodent species, It contains a C-terminal beta-type EGF-like domain and an unique N-terminal sequence which lacks an Ig-like domain and is distinct from all known heregulin variants. Mammalian cell-expressed SMDF activates tyrosine phosphorylation of a 185-kDa protein in cell lines expressing p185(erbB2), indicating that it is biologically active. Analyses of expression patterns suggest that, unlike other heregulin variants, SMDF is expressed mainly in the nervous system. In situ hybridization signals with the unique SMDF sequence probe and with a probe to the conserved EGF-like domain are comparable, suggesting that SMDF is the predominant isoform expressed in sensory and motor neurons, Expression of SMDF is maintained in both adult motor neurons and dorsal root ganglion neurons. These findings suggest that SMDF may mediate biological responses such as Schwann cell proliferation and acetylcholine receptor induction in the peripheral nervous system.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech								BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORFAS G, 1993, J NEUROSCI, V13, P2118; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL ZW, 1993, NEURON S, V10, P99; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KING IC, 1993, LIFE SCI, V53, P1465, DOI 10.1016/0024-3205(93)90619-E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PERIN MS, 1991, J BIOL CHEM, V266, P623; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	41	151	156	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14523	14532		10.1074/jbc.270.24.14523	http://dx.doi.org/10.1074/jbc.270.24.14523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782315	hybrid			2022-12-27	WOS:A1995RD45500046
J	SHYNG, SL; MOULDER, KL; LESKO, A; HARRIS, DA				SHYNG, SL; MOULDER, KL; LESKO, A; HARRIS, DA			THE N-TERMINAL DOMAIN OF A GLYCOLIPID-ANCHORED PRION PROTEIN IS ESSENTIAL FOR ITS ENDOCYTOSIS VIA CLATHRIN-COATED PITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; MEMBRANE-PROTEIN; PATHWAY; CONVERSION; SIGNAL; SITES; CELLS; FORM	The cellular prion protein (PrPC) is a glycolipid-anchored protein that is involved in the pathogenesis of fatal spongiform encephalopathies. We have shown previously that, in contrast to several other glycolipid-anchored proteins, chPrP, the chicken homologue of mammalian PrPC, is endocytosed via clathrin-coated pits in cultured neuroblastoma cells, as well as in embryonic neurons and glia (Shyng, S.-L., Heuser, J. E., and Harris, D. A. (1994) J. Cell Biol. 125, 1239-1250). In this study, we have determined that the N-terminal half of the chPrP polypeptide chain is essential for its endocytosis. Deletions within this region reduce the amount of chPrP internalized, as measured by surface iodination or biotinylation, and decrease its concentration in clathrin-coated pits, as determined by quantitative electron microscopic immunogold labeling. Mouse PrP, as well as two mouse PrP/chPrP chimeras, are internalized as efficiently as chPrP, suggesting that conserved feature!s of secondary and tertiary structure are involved in interaction with the endocytic machinery. Our results indicate that the ectodomain of a protein can contain endocytic targeting information, and they strongly support a model in which the polypeptide chain of PrPC binds to the extracellular domain of a transmembrane protein that contains a coated pit localization signal in its cytoplasmic tail.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007071, R29NS030137] Funding Source: NIH RePORTER; NINDS NIH HHS [T32 NS07071, NS30137] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; COYNE KE, 1992, J IMMUNOL, V149, P2906; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; EBERLE W, 1961, CELL, V67, P1203; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Harris D. A., 1993, Molecular Biology of the Cell, V4, p436A; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; LEHMANN S, 1994, NEUROBIOL AGING, V15, pS87; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; Low M.G., 1992, LIPID MODIFICATION P, P117; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULRICH MJ, 1990, BLOOD, V75, P990; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6	37	144	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14793	14800		10.1074/jbc.270.24.14793	http://dx.doi.org/10.1074/jbc.270.24.14793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782345	hybrid			2022-12-27	WOS:A1995RD45500083
J	JACQUIERSARLIN, MR; JORNOT, L; POLLA, BS				JACQUIERSARLIN, MR; JORNOT, L; POLLA, BS			DIFFERENTIAL EXPRESSION AND REGULATION OF HSP70 AND HSP90 BY PHORBOL ESTERS AND HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; PROTEIN-SYNTHESIS; 3'-UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; GENE-TRANSCRIPTION; NADPH-OXIDASE; HUMAN-CELLS; ACTIVATION; DISTINCT	Human peripheral blood monocytes (PBM) produce superoxide anions (O-2-radical-anion) by a process involving electron transfer from NADPH to O-2-radical-anion, catalyzed by the respiratory burst enzyme NADPH oxidase. We have previously shown that phagocytosis, while activating NADPH oxidase, induced in PBM the synthesis of heat shock (HS) proteins (HSP). The present study was undertaken to establish whether this increase in HSP expression was related to O-2-radical-anion and/or to classical second messengers such as protein kinase C (PKC). Thus, the effects of the PKC activator phorbol 12-myristate 13-acetate (PMA) were compared with those of heat shock on the expression, in PBM, of the major HSP, hsp70 and hsp90, using biometabolic labeling, Western and Northern blotting, and gel mobility shift assays. PMA induced the accumulation of mRNA and an increased expression of hsp90 and, to a lesser extent, hsp/hsc70 (hsc is the cognate, constitutive form). This induction was also observed in PBM from patients with chronic granulomatous disease, a genetic defect in NADPH oxidase, and was abolished by the PKC inhibitors staurosporine and H-7. PMA did not cause activation of the HS factor, and the PMA-induced overexpression of HSP was not blocked by the transcriptional inhibitor actinomycin D. HSP-specific mRNA stability was increased after PMA exposure as compared with heat shock. These results suggest that O-2-radical-anion is not involved in the PMA-mediated induction of hsp70 and hsp90 and that, in contrast to HS, PMA increases the expression of HSP as a result of PKC-induced mRNA stabilization rather than of transcriptional activation of HS genes.	CHU COCHIN PORT ROYAL,PHYSIOL RESP LAB,F-75014 PARIS,FRANCE; UNIV HOSP GENEVA,DIV NUCL MED,HLTH & ENVIRONM PROGRAM,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,DIV PULM,CH-1211 GENEVA 14,SWITZERLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Geneva; University of Geneva			Jacquier-Sarlin, Muriel/ABF-4923-2021	Jacquier-Sarlin, Muriel/0000-0001-8501-7511				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLERGET M, 1990, P NATL ACAD SCI USA, V87, P1081, DOI 10.1073/pnas.87.3.1081; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; KANTENGWA S, 1995, IMMUNOL CELL BIOL, V73, P73, DOI 10.1038/icb.1995.12; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KANTENGWA S, 1991, INFECT IMMUN, V61, P1281; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGAGNEUX V, 1989, DIFFERENTIATION, V41, P42, DOI 10.1111/j.1432-0436.1989.tb00730.x; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDSTEN T, 1989, SCIENCE, V246, P339; MALTER JS, 1991, J BIOL CHEM, V266, P31657; MANIATIS T, 1990, MOL CLONING; MARIDONNEAUPARI.I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARI.I, 1993, J CELL PHYSIOL, V156, P204; MOSELEY PL, 1993, AM J PHYSIOL, V264, pL533, DOI 10.1152/ajplung.1993.264.6.L533; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; PETERSEN RB, 1990, STRESS PROTEINS BIOL, P379; POLLA BS, 1991, CURR TOP MICROBIOL, V167, P93; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; REBBE NF, 1989, J BIOL CHEM, V264, P15006; RICHARDS FM, 1988, CANCER RES, V48, P6715; RITZ MF, 1993, RECEPTOR, V3, P311; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WU B, 1986, MOL CELL BIOL, V7, P4357; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	40	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14094	14099		10.1074/jbc.270.23.14094	http://dx.doi.org/10.1074/jbc.270.23.14094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775471	hybrid			2022-12-27	WOS:A1995RC44800074
J	PANG, JHS; HUNG, RY; WU, CJ; FANG, YY; CHAU, LY				PANG, JHS; HUNG, RY; WU, CJ; FANG, YY; CHAU, LY			FUNCTIONAL-CHARACTERIZATION OF THE PROMOTER REGION OF THE PLATELET-ACTIVATING-FACTOR RECEPTOR GENE - IDENTIFICATION OF AN INITIATOR ELEMENT ESSENTIAL FOR GENE-EXPRESSION IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; HIP1 BINDING; PROTEIN; SITE; DIFFERENTIATION; INVITRO; CDNA; TATA	To understand the molecular mechanisms that direct the expression of the gene encoding the platelet-activating factor (PAF) receptor, the 5'-flanking region of the human PAF receptor gene was cloned, and its promoter activity in myeloid cell lines was characterized By the 5'-rapid amplification of cDNA ends method and primer extension, the transcription initiation site was mapped to an adenosine residue 137 bases upstream of the ATG translation initiation codon, The promoter region lacks a typical TATA or CCAAT box. However, the sequence encompassing the transcription initiation site shows high homology to the initiator (Inr) sequence. Transfection of promonocytic U937 cells with recombinant plasmids containing a series of truncated segments of the 5'-flanking region linked to the luciferase reporter gene revealed that the sequence from nucleotides -44 to +27 relative to the transcription initiation site was sufficient to promote a high level of gene expression, The promoter activity was much lower in nonexpressing HeLa cells and promyeIocytic HL-60 cells, which express relatively low levels of the PAF receptor, Gel mobility shift analysis demonstrated the binding of nuclear factors extracted from myelocytic cells to the -16/+18 sequence containing the Inr element, No binding activity was detected using the nuclear extracts from the non-myelocytic HeLa cells, The DNA-protein complexes were sequence-specific since the binding was not significantly affected by the mutated Inr sequences or the Inr sequence of the terminal deoxynucleotidyltransferase gene, Furthermore, point mutations in the Inr element significantly reduced promoter activity in both U937 and THP-1 cell lines. When Me(2)SO or retinoic acid was used to induce granulocytic differentiation of HL-60 cells, a distinct Inr-protein complex was induced concurrently, but the complex was not observed in 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiated HL-60 cells or Me(2)SO-induced differentiated U937 cells, indicating that the inducible Inr binding activity is granulocyte-specific. These results suggest that distinct nuclear factors interact with the unique Inr element and play a role in the transcriptional regulation of the PAF receptor in various myeloid cells.	ACAD SINICA, INST BIOMED SCI, DIV CARDIOVASC RES, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328				BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DIMARTINO JF, 1994, INT IMMUNOL, V6, P1279, DOI 10.1093/intimm/6.8.1279; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; GOMOLIN HI, 1993, BLOOD, V82, P1868; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MULLER E, 1991, BIOCHEM BIOPH RES CO, V181, P1580, DOI 10.1016/0006-291X(91)92119-5; MURPHY PM, 1990, J IMMUNOL, V145, P2227; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PAHL HL, 1991, EXP HEMATOL, V19, P1038; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; VALLARI DS, 1990, J BIOL CHEM, V265, P4261; VENABLE ME, 1993, J LIPID RES, V34, P691; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14123	14129		10.1074/jbc.270.23.14123	http://dx.doi.org/10.1074/jbc.270.23.14123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775473	hybrid			2022-12-27	WOS:A1995RC44800078
J	STRUM, JC; SWENSON, KI; TURNER, JE; BELL, RM				STRUM, JC; SWENSON, KI; TURNER, JE; BELL, RM			CERAMIDE TRIGGERS MEIOTIC CELL-CYCLE PROGRESSION IN XENOPUS OOCYTES - A POTENTIAL MEDIATOR OF PROGESTERONE-INDUCED MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMYELIN TURNOVER; PLASMA-MEMBRANE; LAEVIS OOCYTES; INDUCTION; PROTEIN; DIFFERENTIATION; SPHINGOSINE; RELEASE; KINASE	The role of sphingomyelin-derived second messengers in progesterone-induced reinitiation of the meiotic cell cycle of Xenopus laevis oocytes was investigated. A brief treatment of defolliculated oocytes with sphingomyelinase (Staphylococcus aureus) was sufficient to induce maturation as measured by H1 kinase activity and germinal vesicle breakdown (GVBD). Pretreatment with cycloheximide inhibited sphingomyelinase-induced GVBD demonstrating a requirement for protein synthesis. Microinjection of ceramide or sphingosine, potential products of sphingomyelin hydrolysis, were capable of inducing GVBD in the absence of hormone. Metabolic labeling studies suggested the conversion of sphingosine to ceramide was necessary for sphingosine-induced GVBD. Additionally, fumonisin b(1), an inhibitor of sphingosine N-acyltransferase, blocked sphingosine-induced GVBD demonstrating that ceramide is the more proximal biologically active metabolite. Treatment of oocytes with progesterone, the physiological inducer of oocyte maturation, resulted in a time- and concentration-dependent increase in the mass of ceramide and decrease in the mass of sphingomyelin through activation of a Mg2+-dependent neutral sphingomyelinase. These observations suggest that the generation of ceramide from sphingomyelin is part of the signal transduction pathway activated in response to progesterone and that the increase in ceramide is likely to be functionally important in resumption of the meiotic cell cycle.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020205, R37DK020205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CHIEN EJ, 1991, MOL CELL ENDOCRINOL, V81, P53, DOI 10.1016/0303-7207(91)90204-6; CHRISTIANSEN K, 1975, ANAL BIOCHEM, V66, P93, DOI 10.1016/0003-2697(75)90728-9; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOSTELLOW AB, 1993, MOL CELL ENDOCRINOL, V92, P33, DOI 10.1016/0303-7207(93)90072-R; LIU ZM, 1993, BIOL REPROD, V49, P980, DOI 10.1095/biolreprod49.5.980; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P1009; MATTEN WT, 1994, DEV BIOL, V5, P173; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SMITH LD, 1989, DEVELOPMENT, V107, P685; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STRUM JC, 1994, J BIOL CHEM, V269, P15493; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; VARNOLD RL, 1990, DEVELOPMENT, V109, P597; VARNOLD RL, 1990, UCLA S MOL CELL BIOL, V125, P1; WANG E, 1991, J BIOL CHEM, V266, P14486; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	39	50	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13541	13547		10.1074/jbc.270.22.13541	http://dx.doi.org/10.1074/jbc.270.22.13541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768956	hybrid			2022-12-27	WOS:A1995RB43900086
J	CHAZENBALK, GD; RAPOPORT, B				CHAZENBALK, GD; RAPOPORT, B			CLEAVAGE OF THE THYROTROPIN RECEPTOR DOES NOT OCCUR AT A CLASSICAL SUBTILISIN-RELATED PROPROTEIN CONVERTASE ENDOPROTEOLYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; FUNCTIONAL EXPRESSION; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; GRAVES-DISEASE; BINDING; CELLS; CHAIN; DNA; AUTOANTIBODIES	The human thyrotropin receptor (TSHR) undergoes proteolytic cleavage closely upstream to amino acid 317. Between residues 261 and 313 are three clusters of positively charged amino acids, arginines (Arg) and lysines (Lys), which are potential subtilisin-related proprotein convertase sites, We used oligonucleotide-directed mutagenesis to perform conservative amino acid substitutions within these regions (Arg or Lys to glutamine, Gin), Chinese hamster ovary cells stably transfected with mutant receptor cDNA TSHR-CS1 (Gln(261)) and TSHR-CS3 (Gln(290), Gln(313)) bound radiolabeled TSH with an affinity similar to the wild-type TSHR. Mutant cDNA TSHR-CS2 (Gln(312), Gln(291)) and TSHR-CS4 (Gln(261), Gln(290), Gln(291), Gln(312), Gln(313)) did not express a protein on the cell surface capable of specific TSH binding, After covalent cross-linkage of radiolabeled TSH to TSHR-CS1 and TSHR-CS3, the mutant receptors dissociated into two subunits under reducing conditions, The most prominent cluster of basic amino acids in the TSHR extracellular region (residues 287-293) was studied in a second series of mutations designed to eliminate the classical proprotein convertase sites in this region and yet be compatible with TSHR function, All three mutant receptors, TSHR-CS5 (Gln(290)), TSHR-CS6 (Gln(291)), and TSHR-CS7 (Gln(291), Gln(293)) bound TSH with an affinity similar to that of wild type, and none of these amino acid substitutions prevented proteolytic cleavage of the extracellular domains of the TSHR. Thus, cleavage of the TSHR extracellular domain does not involve a classical subtilisin-related proprotein convertase cleavage site, raising the possibility that TSHR cleavage occurs after processing and trafficking of the protein to the plasma membrane.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco	CHAZENBALK, GD (corresponding author), VET ADM MED CTR,THYROID MOLEC BIOL UNIT 111T,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLAND PR, 1982, FEBS LETT, V145, P245, DOI 10.1016/0014-5793(82)80176-2; CHAZENBALK GD, 1990, ENDOCRINOLOGY, V127, P1240, DOI 10.1210/endo-127-3-1240; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DICKINSON CJ, 1992, J BIOL CHEM, V267, P21795; ENDO K, 1978, J CLIN ENDOCR METAB, V46, P734, DOI 10.1210/jcem-46-5-734; ENDO T, 1992, BIOCHEM BIOPH RES CO, V187, P887, DOI 10.1016/0006-291X(92)91280-4; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; GOLDFINE ID, 1974, ENDOCRINOLOGY, V95, P1228, DOI 10.1210/endo-95-5-1228; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOSSFELT H, 1992, P NATL ACAD SCI USA, V895, P3765; LU WY, 1993, J BIOL CHEM, V268, P14583; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; ORGIAZZI J, 1976, J CLIN ENDOCR METAB, V42, P341, DOI 10.1210/jcem-42-2-341; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SMITH BR, 1974, LANCET, V2, P427; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596	32	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32209	32213						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798220				2022-12-27	WOS:A1994PX30400032
J	PARTISETI, M; LEDEIST, F; HIVROZ, C; FISCHER, A; KORN, H; CHOQUET, D				PARTISETI, M; LEDEIST, F; HIVROZ, C; FISCHER, A; KORN, H; CHOQUET, D			THE CALCIUM CURRENT ACTIVATED BY T-CELL RECEPTOR AND STORE DEPLETION IN HUMAN-LYMPHOCYTES IS ABSENT IN A PRIMARY IMMUNODEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; CYTOPLASMIC FREE CALCIUM; RAT THYMIC LYMPHOCYTES; ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; TUMOR PROMOTER; CROSS-LINKING; MAST-CELLS; INFLUX	Stimulation of antigen receptors of lymphocytes triggers a transitory release of Ca2+ from internal stores and the opening of a transmembrane Ca2+ conductive pathway, The latter underlies the sustained increase of intracellular free calcium concentration, and it seems to be a key event in the Ca2+-dependent biochemical cascade leading to T cell proliferation, Alternatively, pharmacological depletion of internal stores by itself activates Ca2+ influx, This has led to the hypothesis that antigen-triggered Ca2+ influx is secondary to Ca2+ release from internal stores, However, the precise relationship between antigen and Ca2+ release-activated Ca2+ currents remains unclear, particularly since neither of them has been electrophysiologically recorded in normal lymphocytes. Using the whole-cell and the perforated configurations of the patch clamp technique on peripheral blood lymphocytes, we found that a law amplitude Ca2+-selective current was triggered when intracellular stores were depleted by stimuli such as the intracellular perfusion of inositol triphosphate or thapsigargin and the extracellular perfusion of ionomycin, A similar current was elicited by the cross-linking of the T cell receptor-CD3 complex, This current displayed an inward rectification below 0 mV and was completely blocked by the divalent cation Cd2+, It was very selective for Ca2+ over Na+ and insensitive to changes in chloride concentration, The physiological relevance of this conductance was investigated with the analysis of abnormal Ca2+ signaling in lymphocytes from a patient suffering from a primary immunodeficiency associated with a defective T cell proliferation Using fura-2 video imaging, an absence of Ca2+ influx was established in the patient's lymphocytes, whereas the Ca2+ release from internal stores was normal, This was the case whether cells were stimulated physiologically through their antigen receptors or with store depleting pharmacological agents, Most importantly, no Ca2+-selective current was elicited in these cells, Our data strongly suggest that the Ca2+ release-activated current underlies the sustained Ca2+ influx during antigenic stimulation and that it plays a key role in the immune function.	HOP NECKER ENFANTS MALAD,INSERM,U132,F-75743 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	PARTISETI, M (corresponding author), INST PASTEUR,INSERM,U261,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Hivroz, Claire/H-2711-2014; Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/K-7893-2018	Hivroz, Claire/0000-0002-6794-2890; Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOSMA MM, 1989, J PHYSIOL-LONDON, V410, P67, DOI 10.1113/jphysiol.1989.sp017521; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DONNADIEU E, 1993, PFLUG ARCH EUR J PHY, V424, P448, DOI 10.1007/BF00374907; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FISCHER A, 1985, J IMMUNOL, V134, P815; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; GELFAND EW, 1986, EUR J IMMUNOL, V16, P907, DOI 10.1002/eji.1830160806; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIVROZBURGAUD C, 1991, EUR J IMMUNOL, V21, P2811, DOI 10.1002/eji.1830211124; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KIEFER H, 1980, P NATL ACAD SCI-BIOL, V77, P2200, DOI 10.1073/pnas.77.4.2200; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; MACDONALD TV, 1993, J BIOL CHEM, V268, P3889; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MASON MJ, 1991, J BIOL CHEM, V266, P20856; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, CR ACAD SCI III-VIE, V317, P167; PRENTKI M, 1984, J BIOL CHEM, V259, P118; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; SCHLICHTER LC, 1992, CAN J PHYSIOL PHARM, V70, P247, DOI 10.1139/y92-031; SHAPIRO DN, 1985, J IMMUNOL, V135, P2256; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	48	218	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32327	32335						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798233				2022-12-27	WOS:A1994PX30400049
J	SRIKANTH, S; RADO, TA				SRIKANTH, S; RADO, TA			A 30-BASE PAIR ELEMENT IS RESPONSIBLE FOR THE MYELOID-SPECIFIC ACTIVITY OF THE HUMAN NEUTROPHIL ELASTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYELOPEROXIDASE GENE; CD11B PROMOTER; NF-M; EXPRESSION; PROTEIN; DIFFERENTIATION; CELLS; IDENTIFICATION; PROTOONCOGENE; REGION	Human neutrophil elastase (HNE), a serine protease, is expressed only in the promyelocytic stages of granulocyte maturation. We examined several regions of the promoter for transcriptional activity and report that a 30-base pair (bp) element located between -76 and -106 in the 5'-flanking region of HNE is sufficient for myeloid-specific expression of HNE. Gel shift assays using nuclear extracts from myeloid and non-myeloid cells reveal several myeloid-specific complexes binding to the 30-bp element. Examination of DNA-protein interactions shows that at least two myeloid-specific proteins of 38 and 55 kDa bind to this element. DNase I protection analysis reveals two distinct footprints between -80 to -91 and -94 to -104 within this element. Transient expression studies using deletion constructs of the HNE 5'-flanking region show that the 30-bp element is active in myeloid cells It 562 and U 937 but not in HeLa cells. Internal deletion of this element results in a 60-85% loss of promoter activity in myeloid cells. Additional functional studies also show that a 19-bp region between -112 and -131 contributes to transcriptional activity of the elastase promoter as well.	UNIV ALABAMA,DEPT MED,DIV HEMATOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,DIV HEMATOL,BIRMINGHAM,AL 35294; BIRMINGHAM VET AFFAIRS MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007237] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA07237] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BAGIUS S, 1994, ANN HEMATOL, V68, P125; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHUMAKOV AM, 1993, BLOOD, V82, P30; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAN J, 1991, BIOCHEM BIOPH RES CO, V181, P1462, DOI 10.1016/0006-291X(91)92104-R; HASHINAKA K, 1992, ARCH BIOCHEM BIOPHYS, V293, P40, DOI 10.1016/0003-9861(92)90362-Z; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LEE TC, 1992, BIOTECHNIQUES, V12, P486; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LUBBERT M, 1991, BLOOD, V78, P345; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAI S, 1993, P NATL ACAD SCI USA, V90, P1753; TUCKER KA, 1987, BLOOD, V70, P372; YOSHIMURA K, 1992, BLOOD, V79, P2733; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG WW, 1991, BIOTECHNIQUES, V11, P728; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	43	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32626	32633						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798268				2022-12-27	WOS:A1994PX30400090
J	WEN, W; HAROOTUNIAN, AT; ADAMS, SR; FERAMISCO, J; TSIEN, RY; MEINKOTH, JL; TAYLOR, SS				WEN, W; HAROOTUNIAN, AT; ADAMS, SR; FERAMISCO, J; TSIEN, RY; MEINKOTH, JL; TAYLOR, SS			HEAT-STABLE INHIBITORS OF CAMP-DEPENDENT PROTEIN-KINASE CARRY A NUCLEAR EXPORT SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CYCLIC-AMP; ESCHERICHIA-COLI; GOLGI-COMPLEX; PORE COMPLEX; LOCALIZATION; RNA; OOCYTES; TRANSLOCATION; EXPRESSION	The heat-stable inhibitor of cAMP-dependent protein kinase (PKI) was shown previously to export the kinase catalytic subunit (C) from the nucleus (Fantozzi, D. A., Harootunian, A. T., Wen, W., Taylor, S. S., Feramisco, J. R., Tsien, R. Y., and Meinkoth, J. L. (1994) J. Biol. Chem. 269, 2676-2686), in addition to its ability to inhibit kinase activity. In this study, the mechanism of PKI export is investigated. The injection of a C PHI complex containing both labeled PHI and C-subunit revealed that both proteins exit the nucleus in unison. A fusion protein of C-subunit with glutathione S-transferase (GST) (140 kDa) cannot traverse the nuclear membrane in either direction, but can be exported from the nucleus when complexed with PHI, supporting the presence of a nuclear export signal (NES) in the C.PKI complex. Fusions of PKI alpha with GST (70 kDa) or PKI beta 1 with maltose-binding protein (MBP) (50 kDa) remain effective at exporting complexes with C-subunit. The export of C.PKI is also sensitive to temperature and energy depletion. Taken together, these results demonstrate that export is both energy- and temperature-dependent, but size-independent, consistent with an active signal-mediated export process. GST-PKI exits from the nucleus even in the absence of C-subunit, indicating that the NES resides entirely on PKI, but suggesting that fusion of PKI to GST leads 60 a conformational change that mimics the exposure of the NES caused by the binding of C. Since both PKI alpha and PKI beta 1 can export C-subunit, the predicted export signal is likely to reside on the residues conserved between PKI alpha and PKI beta 1.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; CARR DW, 1992, J BIOL CHEM, V267, P13376; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, PEPT PROT PHOSPH, P1; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; WEN W, 1994, J BIOL CHEM, V269, P8423	41	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32214	32220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798221				2022-12-27	WOS:A1994PX30400033
J	LIU, TC; KOROTCHKINA, LG; HYATT, SL; VETTAKKORUMAKANKAV, NN; PATEL, MS				LIU, TC; KOROTCHKINA, LG; HYATT, SL; VETTAKKORUMAKANKAV, NN; PATEL, MS			SPECTROSCOPIC STUDIES OF THE CHARACTERIZATION OF RECOMBINANT HUMAN DIHYDROLIPOAMIDE DEHYDROGENASE AND ITS SITE-DIRECTED MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; DISULFIDE OXIDOREDUCTASES; HIS450-GLU455 DIAD; MUTATED ENZYMES; WILD-TYPE; MUTAGENESIS	In this paper, we report the overexpression and single-step purification of recombinant wild-type and site-directed mutants of human dihydrolipoamide dehydro genase in Escherichia coli and detailed spectroscopic studies aimed at understanding the catalytic mechanism of this enzyme, One mutation (K37E) has been identified in a patient lacking dihydrolipoamide dehydrogenase activity and has been reported previously (Liu, T,-C,, Kim, H,, Arizmendi, C., Kitano, A, and Patel, M. S. (1993) Proc, Natl, Acad, Sci, USA, 90, 5186-5190), while the other two mutations were previously generated specifically to address the role of the active-site base (His-452) and its ion pair (Glu-457). Circular dichroic and fluorescence spectroscopic data illustrate the role of these amino acids in maintaining the structure and function of human dihydrolipoamide dehydrogenase, While mutant H452Q is severely crippled in catalysis of the physiological reaction, the reverse reaction is affected in the E457Q mutant, The K37E mutant shows very little deviation from the wild-type enzyme.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042885] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42885] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON N, 1988, BIOCHEM J, V256, P741, DOI 10.1042/bj2560741; BENEN J, 1991, EUR J BIOCHEM, V202, P863, DOI 10.1111/j.1432-1033.1991.tb16444.x; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; JENTOFT JE, 1992, PROTEINS, V14, P88, DOI 10.1002/prot.340140110; KIKUCHI G, 1982, MOL CELL BIOCHEM, V45, P137; KIM H, 1992, J BIOL CHEM, V267, P5128; KIM HJ, 1991, J BIOL CHEM, V266, P9367; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIU TC, 1993, P NATL ACAD SCI USA, V90, P5186, DOI 10.1073/pnas.90.11.5186; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REED LJ, 1958, J BIOL CHEM, V232, P143; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	24	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15545	15550		10.1074/jbc.270.26.15545	http://dx.doi.org/10.1074/jbc.270.26.15545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797549	hybrid			2022-12-27	WOS:A1995RG53800019
J	MEINNEL, T; BLANQUET, S				MEINNEL, T; BLANQUET, S			MATURATION OF PRE-TRNA(FMET) BY ESCHERICHIA-COLI RNASE-P IS SPECIFIED BY A GUANOSINE OF THE 5'-FLANKING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; PRE-TRANSFER RNAS; CLEAVAGE SITE; ACCEPTOR STEM; M1 RNA; GENE; PRECURSOR; ENZYME; FORMYLTRANSFERASE; RECOGNITION	The C+1/A(+72) base pair at the top of the acceptor stem of Escherichia coli tRNA(fMet) accounts for several of the specialized roles of this tRNA in translation initiation. According to the rules of RNA substrate recognition by RNase P, the C+1/A(+72) pair is likely to disfavor the 5'-maturation of pre-tRNA(fMet). Indeed, in contrast to other E. coli tRNA species, tRNA(fMet) was not properly matured when overproduced from a multicopy expression vector. Half of the recovered tRNA(fMet) retained an extension at the 5' side. Such a defect of tRNA(fMet) processing could be cured by changing bases C+1 and A(+72) by a Watson-Crick base pair or by non-paired bases, provided one of them was a G. It could also be compensated by either (i) overexpression of RNase P or (ii) introduction within the plasmid of one out of the three 5'-flanking sequences naturally occurring in the four E. coli tRNA(fMet) genes. The effect of these flanking sequences on the maturation of tRNA(fMet) could be accounted for by the presence of a G located 2 bases upstream from C+1. Notably, this G is the only residue that is conserved in the 5'-flanking sequences of all four E. coli tRNA(fmet) genes.			MEINNEL, T (corresponding author), ECOLE POLYTECH, BIOCHIM LAB, CNRS, URA 1970, F-91128 PALAISEAU, FRANCE.		Meinnel, Thierry/B-9813-2016	Meinnel, Thierry/0000-0001-5642-8637				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1993, BIOCHEMISTRY-US, V32, P7152, DOI 10.1021/bi00079a012; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HAHN CS, 1989, METHOD ENZYMOL, V180, P121; HOLM PS, 1992, NUCLEIC ACIDS RES, V20, P421, DOI 10.1093/nar/20.3.421; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KENRI T, 1994, GENE, V138, P261, DOI 10.1016/0378-1119(94)90821-4; KIRSEBOM LA, 1993, J MOL BIOL, V231, P594, DOI 10.1006/jmbi.1993.1312; KIRSEBOM LA, 1992, NUCLEIC ACIDS RES, V20, P425, DOI 10.1093/nar/20.3.425; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; KOMINE Y, 1991, J BACTERIOL, V173, P1813, DOI 10.1128/jb.173.5.1813-1816.1991; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; KUCHINO Y, 1989, METHOD ENZYMOL, V180, P154; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEVEQUE F, 1991, J BACTERIOL, V173, P7903, DOI 10.1128/jb.173.24.7903-7910.1991; MASSON JM, 1986, GENE, V47, P179, DOI 10.1016/0378-1119(86)90061-2; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MEINNEL T, 1993, J MOL BIOL, V229, P26, DOI 10.1006/jmbi.1993.1005; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1992, NUCLEIC ACIDS RES, V20, P4741, DOI 10.1093/nar/20.18.4741; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; MOTAMEDI H, 1984, P NATL ACAD SCI-BIOL, V81, P3959, DOI 10.1073/pnas.81.13.3959; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NAKAMURA K, 1979, CELL, V18, P1109, DOI 10.1016/0092-8674(79)90224-1; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; PACE NR, 1990, J BIOL CHEM, V265, P3587; REILLY RM, 1986, J BIOL CHEM, V263, P2344; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHULMAN LH, 1975, J BIOL CHEM, V250, P542; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SVARD SG, 1992, J MOL BIOL, V227, P1019, DOI 10.1016/0022-2836(92)90518-O; SVARD SG, 1993, NUCLEIC ACIDS RES, V21, P427, DOI 10.1093/nar/21.3.427; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15908	15914		10.1074/jbc.270.26.15908	http://dx.doi.org/10.1074/jbc.270.26.15908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797595	hybrid			2022-12-27	WOS:A1995RG53800071
J	PARK, MS				PARK, MS			EXPRESSION OF HUMAN RAD52 CONFERS RESISTANCE TO IONIZING-RADIATION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENETIC-CONTROL; RECOMBINATION; REPAIR; DNA; YEAST; PROTEIN	Processing of mutagenic DNA damages by the double strand breaks (DSB) in eukaryotes is most likely achieved by multiple pathways, including homologous recombination. Although RAD52 has been shown to be important for DSB repair in yeasts, its role in DSB repair in mammalian cells has not been demonstrated. This study reports for the first time that the overexpression of human RAD52 confers enhanced resistance to gamma-rays and induces homologous intrachromosomal recombination in cultured monkey cells. Recombination frequency synergistically increased by the combination of overexpression of RAD52 and ionizing radiation. These observations suggest that homologous recombination mediated by RAD52 is involved in double-stranded break repair in mammalian cells.			PARK, MS (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,M888,LOS ALAMOS,NM 87545, USA.		Park, Min Sung/HCH-2207-2022					ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; AJIMURA M, 1992, GENETICS, V133, P51; BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BERNSTEIN H, 1985, SCIENCE, V229, P1277, DOI 10.1126/science.3898363; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GAME J, 1983, YEAST GENETICS FUNDA, P105; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY R, 1992, AM TYPE CULTURE COLL, V7, P1; IVANOV EL, 1992, GENETICS, V132, P651; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUNZ BA, 1981, ANNU REV GENET, V15, P57, DOI 10.1146/annurev.ge.15.120181.000421; LATT SA, 1981, ANNU REV GENET, V15, P11, DOI 10.1146/annurev.ge.15.120181.000303; LUDWIG DL, 1994, SOMAT CELL MOLEC GEN, V20, P11, DOI 10.1007/BF02257482; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; RESNICK MA, 1975, J THEOR BIOL, V59, P97; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959	34	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15467	15470		10.1074/jbc.270.26.15467	http://dx.doi.org/10.1074/jbc.270.26.15467			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797537	hybrid			2022-12-27	WOS:A1995RG53800007
J	PORTER, DJT; SHORT, SA				PORTER, DJT; SHORT, SA			NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE - PRE-STEADY-STATE KINETIC-ANALYSIS OF NATIVE ENZYME AND MUTANT ENZYME WITH AN ALANYL RESIDUE REPLACING GLU-98	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; TRANS-N-DEOXYRIBOSYLASE; ACTIVE-SITE; ESSENTIAL CARBOXYLATE; DEOXYRIBOSYLTRANSFERASE; CRYSTALLIZATION; NUCLEOPHILE; MECHANISM	Nucleoside 2-deoxyribosyltransferase catalyzes cleavage of a 2'-deoxyribosylnucleoside (A) to a nucleobase (P) with deoxyribosylation of the enzyme, Substrates quenched the intrinsic fluorescence of native enzyme (E) and a catalytically inactive mutant enzyme (E98A enzyme), The time courses of these reactions were analyzed in terms of the following scheme where EX is the 2-deoxyribosyl ester of Glu-98. [GRAPHICS] The initial complexes between E and dAdo, dGuo, dIno, and dCyd or those between EX and the corresponding nucleobases were formed in a rapid equilibrium step, Native enzyme and E98A enzyme bound 2'-deoxyribosylnucleosides with similar affinities (k(-1)/k(1)). From a comparison of the time-dependent fluorescence changes associated with the reaction of native enzyme or E98A enzyme with these substrate, the kinetic step for 2-deoxyribosylation of Glu-98 was identified (k(2) and k(-2)). dThd and dUrd quenched the fluorescence of native enzyme in a biphasic process, The late phase of this reaction was associated with 2-deoxyribosylation of Glu-98. The pre-steady-state kinetic constants calculated from fluorescence quenching data for dAdo and Cyt were consistent with the experimental values for the steady-state kinetic coefficients and the equilibrium constant of the reaction.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9306, DOI 10.1021/bi00450a010; CARDINAUD R, 1979, BIOCHIM BIOPHYS ACTA, V568, P339, DOI 10.1016/0005-2744(79)90301-2; COOK WJ, 1990, J BIOL CHEM, V265, P2682; DANZIN C, 1976, EUR J BIOCHEM, V62, P365, DOI 10.1111/j.1432-1033.1976.tb10168.x; DANZIN C, 1974, EUR J BIOCHEM, V48, P255, DOI 10.1111/j.1432-1033.1974.tb03763.x; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOLGUIN J, 1975, EUR J BIOCHEM, V54, P515, DOI 10.1111/j.1432-1033.1975.tb04164.x; HOLGUINH.J, 1972, FEBS LETT, V20, P171, DOI 10.1016/0014-5793(72)80785-3; HUANG MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P133, DOI 10.1016/0003-9861(83)90510-6; HUANG MC, 1981, BIOCHEM PHARMACOL, V30, P2663, DOI 10.1016/0006-2952(81)90535-9; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V534, P102; MACNUTT WS, 1952, BIOCHEM J, V50, P384, DOI 10.1042/bj0500384; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Mooser G., 1992, ENZYMES, P187; PORTER DJT, 1995, J BIOL CHEM, V270, P15551, DOI 10.1074/jbc.270.26.15551; QUARONI A, 1976, J BIOL CHEM, V251, P3250; Segel IH, 1975, ENZYME KINETICS, P54; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9780; UERKVITZ W, 1971, EUR J BIOCHEM, V23, P387, DOI 10.1111/j.1432-1033.1971.tb01632.x; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929	25	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15557	15562		10.1074/jbc.270.26.15557	http://dx.doi.org/10.1074/jbc.270.26.15557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797551	hybrid			2022-12-27	WOS:A1995RG53800021
J	WALLER, GS; OUYANG, G; SWAFFORD, J; VIBERT, P; LOWEY, S				WALLER, GS; OUYANG, G; SWAFFORD, J; VIBERT, P; LOWEY, S			A MINIMAL MOTOR DOMAIN FROM CHICKEN SKELETAL-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; F-ACTIN; SUBFRAGMENT-1; PROTEIN; BINDING; IMAGES; MICROSCOPY; ANTIBODIES; FILAMENT	The myosin head (S1) consists of a wide, globular region that contains the actin- and nucleotide-binding sites and an alpha-helical, extended region that is stabilized by the presence of two classes of Light chains. The essential light chain abuts the globular domain, whereas the regulatory light chain lies near the head-rod junction of myosin. Removal of the essential Light chain by a mild denaturant exposes the underlying heavy chain to proteolysis by chymotrypsin. The cleaved fragment, or ''motor domain'' (MD), migrates as a single band on SDS-polyacrylamide gel electrophoresis, with a slightly greater mobility than S1 prepared by papain or chymotrypsin. Three-dimensional image analysis of actin filaments decorated with MD reveals a structure similar to S1, but shorter by an amount consistent with the absence of a Light chain-binding domain. The actin-activated MgATPase activity of MD is similar to that of S1 in V-max and K-m. But the ability of MD to move actin filaments in a motility assay is considerably reduced relative to S1. We conclude that the globular, active site region of the myosin head is a stable, independently folded domain with intrinsic motor activity, but the coupling efficiency between ATP hydrolysis and movement declines markedly as the light chain binding region is truncated.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University					NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017350, R37AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; FISHER AJ, 1995, BIOPHYS J, V68, pS19; HUANG TG, 1994, J BIOL CHEM, V269, P16493; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LOWEY S, 1993, J BIOL CHEM, V268, P20414; LOWEY S, 1994, MYOLOGY, P485; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORGAN DG, 1992, ULTRAMICROSCOPY, V46, P263, DOI 10.1016/0304-3991(92)90019-G; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; OKAMOTO Y, 1987, J BIOL CHEM, V262, P7951; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIVARAMAKRISHNA.M, 1982, J BIOL CHEM, V257, P1102; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TRYBUS KM, 1994, J CELL BIOL, P963; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1983, J BIOL CHEM, V258, P8876; WAGNER PD, 1979, EUR J BIOCHEM, V99, P385, DOI 10.1111/j.1432-1033.1979.tb13267.x; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P968; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2	35	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15348	15352		10.1074/jbc.270.25.15348	http://dx.doi.org/10.1074/jbc.270.25.15348			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797523	hybrid			2022-12-27	WOS:A1995RE66600075
J	IYER, M; NORTON, JC; COREY, DR				IYER, M; NORTON, JC; COREY, DR			ACCELERATED HYBRIDIZATION OF OLIGONUCLEOTIDES TO DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST REPLICATION ORIGIN; TRIPLE-HELIX FORMATION; SUPERCOILED DNA; CRUCIFORM STRUCTURES; NUCLEASE; TRANSCRIPTION; POLYMERASE; GENERATION; SEQUENCES; CLEAVAGE	We report two strategies for accelerating the hybridization of oligonucleotides to DNA. We demonstrate that oligodeoxyribonucleotides and peptide nucleic acid oligomers hybridize to inverted repeats within duplex DNA by D-loop formation. Oligonucleotides and duplex template form an active complex, which can be recognized by T7 DNA polymerase to prime polymerization. Quantitation of polymerization products allowed the rate of hybridization to be estimated, and peptide nucleic acid oligomers and oligonucleotide-protein adducts anneal with association constants 500- and 12,000-fold greater, respectively, than the analogous unmodified oligonucleotides. Together, these results indicate that sequences within duplex DNA can be targeted by Watson-Crick base pairing and that chemical modifications can dramatically enhance the rate of strand association. These findings should facilitate targeting of oligomers for priming DNA polymerization, the detection of diagnostic sequences, and the disruption of gene expression. The observed acceleration of hybridization may offer a new perspective on the ability of RecA or other proteins to accelerate strand invasion.			IYER, M (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; COREY DR, 1995, BIOCONJUGATE CHEM, V6, P93, DOI 10.1021/bc00031a011; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; COREY DR, 1987, SCIENCE, V238, P1401, DOI 10.1126/science.3685986; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DILLER JD, 1994, TRENDS BIOCHEM SCI, V19, P320, DOI 10.1016/0968-0004(94)90070-1; DUEHOLM KL, 1994, J ORG CHEM, V59, P5767, DOI 10.1021/jo00098a042; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; LANDGRAF R, 1994, BIOCHEMISTRY-US, V33, P10607, DOI 10.1021/bi00201a006; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; NIELSEN PE, 1994, BIOCONJUGATE CHEM, V5, P3, DOI 10.1021/bc00025a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; PERRIN DM, 1994, BIOCHEMISTRY-US, V33, P3848, DOI 10.1021/bi00179a008; PONTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237, DOI 10.1073/pnas.88.18.8237; REEVES R, 1990, J BIOL CHEM, V265, P8573; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UMEK RM, 1990, NUCLEIC ACIDS RES, V18, P6601, DOI 10.1093/nar/18.22.6601; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	34	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14712	14717		10.1074/jbc.270.24.14712	http://dx.doi.org/10.1074/jbc.270.24.14712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782335	hybrid			2022-12-27	WOS:A1995RD45500072
J	LITHGOW, T; SCHATZ, G				LITHGOW, T; SCHATZ, G			IMPORT OF THE CYTOCHROME-OXIDASE SUBUNIT VA PRECURSOR INTO YEAST MITOCHONDRIA IS MEDIATED BY THE OUTER-MEMBRANE RECEPTOR MAS20P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN IMPORT; INTERMEMBRANE SPACE; MACHINERY; BINDING; PATHWAY	Post-translational import of precursor proteins into yeast mitochondria is mediated by at least four protease-sensitive outer membrane proteins: Mas20p, Mas22p, Mas37p, and Mas70p, These ''import receptors'' recognize either the N-terminal targeting signal or some other feature of mitochondrial precursor proteins. The only exception to this general rule appeared to be the precursor to subunit Va of cytochrome c oxidase (COXVa). Although this precursor carries a typical N-terminal mitochondrial targeting sequence, its import into mitochondria has been suggested to be independent of the known import receptors. Here we show that if import into isolated yeast mitochondria is assayed under conditions in which binding of the COXVa precursor to mitochondria is rate-limiting, import is strongly inhibited by protease pretreatment of the mitochondria or by antibodies against Mas20p. Post-translational import of the COXVa precursor can thus proceed by the general, receptor-mediated pathway.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel			Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1995, IN PRESS METHODS ENZ; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1994, J MEMBRANE BIOL, V135, P191; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353	22	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14267	14269		10.1074/jbc.270.24.14267	http://dx.doi.org/10.1074/jbc.270.24.14267			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782281	hybrid			2022-12-27	WOS:A1995RD45500007
J	GREENFEDER, SA; NUNES, P; KWEE, L; LABOW, M; CHIZZONITE, PA; JU, G				GREENFEDER, SA; NUNES, P; KWEE, L; LABOW, M; CHIZZONITE, PA; JU, G			MOLECULAR-CLONING AND CHARACTERIZATION OF A 2ND SUBUNIT OF THE INTERLEUKIN-1 RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; T-CELLS; MAMMALIAN EXPRESSION; IL-1 RECEPTOR; II RECEPTOR; CDNA; BINDING; GENE; PROTEIN; TARGET	A monoclonal antibody (mAb) was isolated that blocked the binding and bioactivity of both human and murine interleukin 1 beta (LI-1 beta) on murine IL-1 receptor-bearing cells. This mAb recognized a protein that was distinct from the Type I and Type II IL-1 receptors, suggesting that an additional protein exists that is involved in IL-1 biological responses. By expression cloning in COS-7 cells, we have isolated a cDNA from mouse 3T3-LI cells encoding this putative auxiliary molecule, which we term the IL-1 receptor accessory protein (IL-1R AcP), Sequence analysis of the cDNA predicts an open reading frame that encodes a 570-amino acid protein with a molecular mass of similar to 66 kDa. The IL-1R AcP is a member of the Ig superfamily by analysis of its putative extracellular domain and also bears limited homology throughout the protein to both Type I and Type II IL-1 receptors, Northern analysis reveals that murine IL-1R AcP mRNA is expressed in many tissues and appears to be regulated by IL-1, In mammalian cells expressing natural or recombinant Type I IL-1R and IL-1R AcP, the accessory protein forms a complex with the Type I IL-1R and either IL-1 alpha or IL-1 beta but not IL-1ra, The recombinant accessory protein also increases the binding affinity of the recombinant Type I HL-1R for IL-1 beta when the two receptor proteins are coexpressed. Therefore, the functional IL-1 receptor appears to be a complex composed of at least two subunits.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT BIOTECHNOL,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHIZZONITE R, 1991, J IMMUNOL, V147, P1548; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1989, IMMUNOL TODAY, V10, P49, DOI 10.1016/0167-5699(89)90304-6; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER S K, 1990, P137; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORUK R, 1987, J BIOL CHEM, V262, P16275; HORUK R, 1989, BIOCHEM J, V260, P657, DOI 10.1042/bj2600657; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOHIRA T, 1993, J BIOCHEM-TOKYO, V114, P658, DOI 10.1093/oxfordjournals.jbchem.a124233; KUNO K, 1993, J BIOL CHEM, V268, P13510; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANCILLA J, 1992, LYMPHOKINE CYTOK RES, V11, P197; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIZEL SB, 1987, J IMMUNOL, V138, P2906; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; SOLARI R, 1990, Cytokine, V2, P21, DOI 10.1016/1043-4666(90)90039-V; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854	43	534	574	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13757	13765		10.1074/jbc.270.23.13757	http://dx.doi.org/10.1074/jbc.270.23.13757			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775431	hybrid			2022-12-27	WOS:A1995RC44800028
J	JUST, I; WILM, M; SELZER, J; REX, G; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K				JUST, I; WILM, M; SELZER, J; REX, G; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K			THE ENTEROTOXIN FROM CLOSTRIDIUM-DIFFICILE (TOXA) MONOGLUCOSYLATES THE RHO-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; TRIPHOSPHATE CONFORMATION; GENE-PRODUCT; PURIFICATION; TOXINS; CELLS; C-3; MECHANISM; P21	The enterotoxin from Clostridium difficile (ToxA) is one of the causative agents of the antibiotic-associated pseudomembranous colitis. In cultured monolayer cells ToxA exhibits cytotoxic activity to induce disassembly of the actin cytoskeleton, which is accompanied by morphological changes. ToxA-induced depolymerization of actin filaments is correlated with a decrease in the ADP-ribosylation of the low molecular mass GTP-binding Rho proteins (Just, I., Selzer, J., von Eichel-Streiber, C., and Aktories, R. (1995) J. Clin. Invest. 95, 1026-1031). Here we report on the identification of the ToxA-induced modification of Rho. Applying electrospray mass spectrometry, the mass of the modification was determined as 162 Da, which is consistent with the incorporation of a hexose into Rho. From several hexoses tested UDP-glucose selectively served as cosubstrate for ToxA-catalyzed modification. The acceptor amino acid of glucosylation was identified from a Lys-C-generated peptide by tandem mass spectrometry as Thr-37. Mutation of Thr-37 to Ala completely abolished glucosylation. The members of the Rho family (RhoA, Rac1, and Cdc42Hs) were substrates for ToxA, whereas H-Ras, Rab5, and Arf1 were not glucosylated. ToxA-catalyzed glucosylation of lysates from ToxA-pretreated rat basophilic leukemia (RBL) cells resulted in a decreased incorporation of [C-14]glucose, indicating previous glucosylation in the intact cell. Glucosylation of the Rho subtype proteins appears to be the molecular mechanism by which C. difficile ToxA mediates its cytotoxic effects on cells.	INST PHARMAKOL & TOXIKOL,D-79104 FREIBURG,GERMANY; EUROPEAN MOLEC BIOL LABS,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST MED MIKROBIOL,D-55101 MAINZ,GERMANY	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1994, J CELL SCI, V107, P1653; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KNOOP FC, 1993, CLIN MICROBIOL REV, V6, P251, DOI 10.1128/CMR.6.3.251-265.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; MADSHUS IH, 1992, CURR TOP MICROBIOL I, V175, P2; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; VONEICHELSTREIB.C, 1987, MICROB PATHOGENESIS, V2, P307; VONEICHELSTREIB.C, 1991, BIOCHEM SOC T, V19, P1154; VONEICHELSTREIB.C, 1992, MOL GEN GENET, V233, P260; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	25	393	400	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13932	13936		10.1074/jbc.270.23.13932	http://dx.doi.org/10.1074/jbc.270.23.13932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775453	hybrid			2022-12-27	WOS:A1995RC44800052
J	KIM, J; CHUBATSU, LS; ADMON, A; STAHL, J; FELLOUS, R; LINN, S				KIM, J; CHUBATSU, LS; ADMON, A; STAHL, J; FELLOUS, R; LINN, S			IMPLICATION OF MAMMALIAN RIBOSOMAL-PROTEIN S3 IN THE PROCESSING OF DNA-DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA PIGMENTOSUM FIBROBLASTS; NUCLEOTIDE EXCISION REPAIR; COLONY-FORMING ABILITY; ESCHERICHIA-COLI; ENDONUCLEASE-V; RAT-LIVER; CELLS; GENE; PURIFICATION; INITIATION	A human apurinic/apyrimidinic endonuclease activity, called AP endonuclease I, is missing from or altered specifically in cells cultured from Xeroderma pigmentosum group-D individuals (XP-D cells) (Kuhnlein, U., Lee, B., Penhoet, E. E., and Linn, S. (1978) Nucleic Acids Res. 5, 951-960). We have now observed that another nuclease activity, UV endonuclease III, is similarly not detected in XP-D cells and is inseparable from the AP endonuclease I activity. This activity preferentially cleaves the phosphodiester backbone of heavily ultraviolet-irradiated DNA at unknown lesions as well as at one of the phosphodiester bonds within a cyclobutane pyrimidine dimer. The nuclease activities have been purified from mouse cells to yield a peptide of M(r) = 32,000, whose sequence indicates identity with ribosomal protein S3. The nuclease activities all cross-react with immunopurified antibody directed against authentic rat ribosomal protein S3, and, upon expression in Escherichia coli of a cloned rat cDNA for ribosomal protein S3, each of the activities was recovered and was indistinguishable from those of the mammalian UV endonuclease III. Moreover, the protein expressed in E. coli and its activities crossreact with the rat protein antibody. Ribosomal protein S3 contains a potential nuclear localization signal, and the protein isolated as a nuclease also has a glycosylation pattern consistent with a nuclear localization as determined by lectin binding. The unexpected role of a ribosomal protein in DNA damage processing and the unexplained inability to detect the nuclease activities in extracts from XP-D cells are discussed.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; MAX DELBRUCK CENTRUM MOLEK MED,D-13125 BERLIN,GERMANY	University of California System; University of California Berkeley; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Chubatsu, Leda S./H-2603-2012	Chubatsu, Leda S./0000-0002-8687-2816; Admon, Arie/0000-0003-0504-3950	NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMACHER DE, 1977, P NATL ACAD SCI USA, V74, P1553, DOI 10.1073/pnas.74.4.1553; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; ANDERSSON S, 1994, GENETICS, V137, P513; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; BRUCKNER RC, 1989, NUCLEIC ACIDS RES, V17, P3145, DOI 10.1093/nar/17.8.3145; CHAN YL, 1990, ARCH BIOCHEM BIOPHYS, V283, P546, DOI 10.1016/0003-9861(90)90682-O; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DEMPLE B, 1982, NUCLEIC ACIDS RES, V10, P3781, DOI 10.1093/nar/10.12.3781; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEWEERDKASTELEI, 1972, NATURE NEW BIOL, V238, P80; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; GATES FT, 1977, J BIOL CHEM, V252, P1647; HADJINOLOV AA, 1985, CELL BIOL MONOGR, V12; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; KANE CM, 1981, J BIOL CHEM, V256, P3405; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM J, 1989, J BIOL CHEM, V264, P2739; KRAEMER KH, 1976, BIOCHIM BIOPHYS ACTA, V442, P147, DOI 10.1016/0005-2787(76)90485-8; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; KUDRNA RD, 1979, MUTAT RES, V62, P173, DOI 10.1016/0027-5107(79)90230-6; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUHNLEIN U, 1978, NUCLEIC ACIDS RES, V5, P951, DOI 10.1093/nar/5.3.951; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LINN SM, 1993, NUCLEASES, P455; LOEBER G, 1977, Photochemistry and Photobiology, V25, P215; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUSBAUGH D, 1980, J BIOL CHEM, V255, P11743; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; ROBSON CN, 1992, NUCLEIC ACIDS RES, V20, P4417, DOI 10.1093/nar/20.17.4417; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNAPKA RM, 1981, BIOCHEMISTRY-US, V20, P68, DOI 10.1021/bi00504a012; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WILSON DM, 1994, J BIOL CHEM, V269, P25359; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	48	167	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13620	13629		10.1074/jbc.270.23.13620	http://dx.doi.org/10.1074/jbc.270.23.13620			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775413	hybrid			2022-12-27	WOS:A1995RC44800009
J	NAISMITH, JH; DEVINE, TQ; BRANDHUBER, BJ; SPRANG, SR				NAISMITH, JH; DEVINE, TQ; BRANDHUBER, BJ; SPRANG, SR			CRYSTALLOGRAPHIC EVIDENCE FOR DIMERIZATION OF UNLIGANDED TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STRUCTURES; MOLECULAR-CLONING; TNF RECEPTOR; ANTIBODIES; ACTIVATION; EXPRESSION; INTERFACES; BINDING; SURFACE	Activation of the cell surface receptors for tumor necrosis factor (TNF) is effected by the aggregation of cytoplasmic domains that occurs when the extracellular domains of two or three receptors bind to trimeric TNF alpha or TNF beta. The structure of the type I TNF receptor extracellular domain (sTNF-R1), crystallized in the absence of TNF, has now been determined at 2.25-Angstrom resolution. The receptor itself is an elongated molecule comprising four disulfide-rich domains in a nearly linear array. Contrary to expectations, the unliganded domains are found to associate into dimers of two distinct types, in which monomers are related by local two-fold axes of symmetry. In one case, the receptors are antiparallel to each other and associate through an interface that overlaps the TNF binding site. If intact receptors were capable of such an association, their cytoplasmic domains would be separated by over 100 Angstrom. This interaction could inhibit signaling in the absence of TNF. Parallel dimers are also observed in which the dimer interface is well separated from the TNF binding site. Associations among TNF-bound parallel dimers could cause receptor clustering. Both dimers bury substantial areas of protein surface and are formed by polar and non-polar interactions.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; SYNERGEN INC,BOULDER,CO 80301	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Naismith, James Henderson/H-3408-2012; Naismith, James Henderson/AAB-8614-2020	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAJZER Z, 1989, J BIOL CHEM, V264, P13623; BALKWILL F, 1993, IMMUNOL TODAY, V14, P149, DOI 10.1016/0167-5699(93)90228-D; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BAZZONI F, 1995, IN PRESS P NATL ACAD; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Brunger A.T., 1992, X PLOR VERSION 3 1 M; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1990, O VERSION 5 6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OTWINOWSKI Z, 1993 P CCP4 STUD WEE, P56; RODSETH LE, 1994, J MOL BIOL, V238, P332; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	29	149	158	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13303	13307		10.1074/jbc.270.22.13303	http://dx.doi.org/10.1074/jbc.270.22.13303			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768931	hybrid			2022-12-27	WOS:A1995RB43900055
J	REINHOLD, BB; HAUER, CR; PLUMMER, TH; REINHOLD, VN				REINHOLD, BB; HAUER, CR; PLUMMER, TH; REINHOLD, VN			DETAILED STRUCTURAL-ANALYSIS OF A NOVEL, SPECIFIC O-LINKED GLYCAN FROM THE PROKARYOTE FLAVOBACTERIUM-MENINGOSEPTICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; GLYCOPROTEIN OLIGOSACCHARIDES; METHYLATION ANALYSIS	In the preceding paper, preliminary analysis revealed a new type of O-linked oligosaccharide of 1244 Da at each of two proposed glycosylation sites on several proteins secreted by the Gram-negative bacterium Flavobacterium meningosepticum (Plummer, T. H., Jr., Tarentino, A. L., and Hauer, C. R. (1995) J. Biol. Chem. 270, 13192-13196). In this report we detail the linkage, sequence, and branching this unusual heptasaccharide by electrospray (ES) ionization mass spectrometry (MS), and collision induced dissociation (CID). The proposed structure was supported by a combination of isotopic labeling, composition and methylation analysis, and the preparation of several chemical analogs and derivatives with each product evaluated by MS and CID. The singly branched structure contained seven residues, including three different uronyl analogs: a methylated rhamnose and mannose, a glucose, and a reducing terminal mannose. Only pyranose ring forms were detected ((2-OMe)Man1-4GlcNAcU1-4GlcU1-4GIc1-4(2-OMe)GlcU-4[(2-OMe)Rham1-2]Man).	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOLEC MED,ALBANY,NY 12201	Harvard University; Harvard T.H. Chan School of Public Health; State University of New York (SUNY) System; Wadsworth Center				Hauer, Christoph/0000-0001-8704-2198	NIGMS NIH HHS [GM45781, GM30471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045781, R01GM030471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1990, METHOD ENZYMOL, V193, P587, DOI 10.1016/0076-6879(90)93440-V; ASPINALL G. O., 1965, METHOD CARBOHYD CHEM, V5, P397; BJORNDAL H, 1967, ACTA CHEM SCAND, V21, P1801, DOI 10.3891/acta.chem.scand.21-1801; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DANISHEFSKY I, 1958, INTRO POLYSACCHARI A, V2, P375; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GEYER R, 1982, ANAL BIOCHEM, V121, P263, DOI 10.1016/0003-2697(82)90478-X; GEYER R, 1983, ANAL BIOCHEM, V133, P197, DOI 10.1016/0003-2697(83)90243-9; HERSCOVICS A, 1993, FASEB J, V1, P540; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; PLUMMER TH, 1995, J BIOL CHEM, V270, P13192, DOI 10.1074/jbc.270.22.13192; REINHOLD BB, 1994, J BACTERIOL, V176, P1997, DOI 10.1128/jb.176.7.1997-2002.1994; Reinhold V N, 1972, Methods Enzymol, V25, P244, DOI 10.1016/S0076-6879(72)25021-2; REINHOLD VN, 1994, BIOLOGICAL MASS SPECTROMETRY: PRESENT AND FUTURE, P403; REINHOLD VN, 1995, IN PRESS METHODS ENZ; SPIRO RG, 1980, J BIOL CHEM, V255, P5347; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; WHISTLER RL, 1958, ADV CARBOHYD CHEM, V13, P289	23	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13197	13203		10.1074/jbc.270.22.13197	http://dx.doi.org/10.1074/jbc.270.22.13197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768917	hybrid			2022-12-27	WOS:A1995RB43900040
J	TAYLOR, GA; THOMPSON, MJ; LAI, WS; BLACKSHEAR, PJ				TAYLOR, GA; THOMPSON, MJ; LAI, WS; BLACKSHEAR, PJ			PHOSPHORYLATION OF TRISTETRAPROLIN, A POTENTIAL ZINC-FINGER TRANSCRIPTION FACTOR, BY MITOGEN STIMULATION IN INTACT-CELLS AND BY MITOGEN-ACTIVATED PROTEIN-KINASE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; GENE-EXPRESSION; KAPPA-B; SEQUENCE; IDENTIFICATION; ACCUMULATION; PROMOTER; ENCODES; FAMILY; DOMAIN	Tristetraprolin (TTP) is a potential transcription factor that contains three PPPPG repeats and two putative CCCH zinc fingers. TTP is encoded by the early response gene Zfp-36, which is highly expressed in response to growth factors and in several hematopoietic cell lines. In the present studies, we investigated the possibility that TTP is phosphorylated in intact cells. In NIH/3T3 cells that were made to overexpress TTP constitutively, we found that the protein was phosphorylated on serine residues, and that this phosphorylation was rapidly (within 10 min) stimulated by several mitogens. In cell-free assays, recombinant mouse TTP was a substrate for the mitogen-activated protein (MAP) kinase. By a combination of protease digestion experiments and site-directed mutagenesis strategies, we found that serine 220 was phosphorylated by p42 MAP kinase in vitro. Expression of mutant TTP in fibroblasts confirmed that serine 220 was one of the major, mitogen-stimulated phosphorylation sites on the protein in intact cells. These results suggest that TTP may be phosphorylated by MAP kinases in vivo and that this phosphorylation may regulate its function.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710	Duke University; Duke University	TAYLOR, GA (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV METAB ENDOCRINOL & NUTR,DIABET & METAB SECT,POB 3897,DURHAM,NC 27710, USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [K11-DK02227-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AGUILERA G, 1981, NATURE, V292, P262, DOI 10.1038/292262a0; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CONTOR L, 1987, ANAL BIOCHEM, V160, P414, DOI 10.1016/0003-2697(87)90069-8; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KURTZ S, 1984, P NATL ACAD SCI-BIOL, V81, P7323, DOI 10.1073/pnas.81.23.7323; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAI WS, 1990, J BIOL CHEM, V265, P16556; MA QF, 1994, ONCOGENE, V9, P3329; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOHLER J, 1992, GENETICS, V131, P377; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Robertson E, 1987, TERATOCARCINOMAS EMB; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SMITH DB, 1991, CURRENT PROTOCOLS MO; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754	35	113	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13341	13347		10.1074/jbc.270.22.13341	http://dx.doi.org/10.1074/jbc.270.22.13341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768935	hybrid			2022-12-27	WOS:A1995RB43900060
J	COX, JA; DURUSSEL, I; COMTE, M; NEF, S; NEF, P; LENZ, SE; GUNDELFINGER, ED				COX, JA; DURUSSEL, I; COMTE, M; NEF, S; NEF, P; LENZ, SE; GUNDELFINGER, ED			CATION-BINDING AND CONFORMATIONAL-CHANGES IN VILIP AND NCS-1, 2 NEURON-SPECIFIC CALCIUM-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; BOVINE BRAIN; S-MODULIN; CA-2+-BINDING PROTEIN; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; NERVOUS-SYSTEM; RAT-BRAIN; RECOVERIN; CALMODULIN	VILIP and NCS-1, neural-specific, 22-kDa Ca2+-binding proteins possessing four EF-hands, were expressed in Escherichia coli to study their divalent cation properties. Flow dialysis (Ca2+ binding) and equilibrium gel filtration (Mg2+ binding) revealed that both recombinant proteins possess only two active metal-binding sites, which can accommodate either Ca2+ or Mg2+. VILIP binds cations without cooperativity with intrinsic affinity constants K'(Ca) of 1.0 x 10(6) M(-1) and K'(Mg) of 4.8 x 10(3) M(-1). Mg2+ antagonizes Ca2+ binding by shifting the isotherms to higher free Ca2+ concentrations without changing their shape. The competition equation yields a K'(Mg, comp) value of 180 M(-1) for both sites. NCS-1 binds two Mg2+ without cooperativity with K'(Mg) of 8.3 x 10(4) M(-1) and two Ca2+ with very strong positive cooperativity (n(H) = 1.96). In the absence of Mg2+ the K'(Cal) and K'(Ca2) values are 8.9 x 10(4) and 1.4 x 10(8) M(-1), respectively, which represent an allosteric increase of 1600-fold. Mg2+ shifts the Ca2+-binding isotherms to higher Ca2+ concentrations, yielding a K'(Mg, comp) value of 800 M(-1) for both sites. Thus VILIP and NCS-1 show three remarkable differences in the Ca2+/Mg2+ binding parameters: 1) VILIP binds Ca2+ with much lower affinity than NCS-1; 2) VILIP binds Ca2+ in a noncooperative way, whereas NCS-1 shows maximal positive cooperativity; 3) in VILIP the Mg2+/Ca2+ antagonism is much weaker than in NCS-1. Conformational changes monitored by Trp fluorescence indicate that the metal-free forms already are highly structured. Ca2+ binding promotes a 20-30% increase of fluorescence in both proteins, but whereas the Mg2+ form of VILIP has the same fluorescence properties as the metal-free form, Mg2+-saturated NCS-1 has those of the Ca2+ form. Near UV difference spectra confirmed that in VILIP the Mg2+ form is very similar to the metal-free form; in NCS-1 it is different, especially in the Tyr region. NCS-1 possesses one unique Cys-38 in EF-hand site I. Its reactivity (k(SH)) toward 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) is the same for the Ca2+- and Mg2+-loaded protein, but k(SH) is 4-fold higher in metal-free NCS-1. VILIP possesses two additional thiols, one of which is inaccessible to DTNB in the native protein. The reactivity of the two accessible thiols is identical in the metal-free and Mg2+ forms and 5-fold higher than in the Ca2+ form. In NCS-1 the accessibility of the hydrophobic matrix to 2-p-toluidinylnaphthalene-6-sulfonate is increased by Ca2+ binding but decreased by Mg2+ binding. In VILIP this accessibility is highest for the metal-free and Mg2+ forms; Ca2+ binding leads to a 2-fold decrease in fluorescence enhancement. Thus, although these two proteins display 57% sequence identity, not only their Ca2+/Mg2+ binding properties but also their Ca2+/Mg2+-induced conformational changes are very different, suggesting that the two proteins play different roles in the cell.	INST NEUROBIOL,DEPT NEUROCHEM & MOLEC BIOL,D-39118 MAGDEBURG,GERMANY	Leibniz Institut fur Neurobiologie (LIN)	COX, JA (corresponding author), UNIV GENEVA,DEPT BIOCHEM,START UNIT,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.		Nef, Serge/AAV-6445-2020	Nef, Serge/0000-0001-5462-0676				Adair GS, 1925, J BIOL CHEM, V63, P529; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; COX JA, 1992, CHIMIA, V46, P159; COX JA, 1990, J BIOL CHEM, V265, P6633; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; Cox JA, 1990, STIMULUS RESPONSE CO, P83; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P6089, DOI 10.1021/bi00074a021; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FONTANA G, 1993, J NEUROCHEM, V60, P843, DOI 10.1111/j.1471-4159.1993.tb03228.x; HANER M, 1984, ANAL BIOCHEM, V138, P229, DOI 10.1016/0003-2697(84)90793-0; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KUDO Y, 1992, NEUROSCIENCE, V50, P619, DOI 10.1016/0306-4522(92)90451-7; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MANALAN AS, 1984, J BIOL CHEM, V259, P2047; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; MCDONALD JR, 1985, BIOCHEM J, V232, P569, DOI 10.1042/bj2320569; MELAMED N, 1993, J NEUROCHEM, V60, P632; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NEF S, 1995, IN PRESS J RECEPT RE, V15; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PAULS TL, 1993, J BIOL CHEM, V268, P20897; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKAMATSU K, 1992, BIOCHEM BIOPH RES CO, V183, P245, DOI 10.1016/0006-291X(92)91635-4; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; WAISMAN DM, 1983, FEBS LETT, V164, P80; YAMAGATA K, 1990, NEURON, V2, P469	46	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32807	32813						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806504				2022-12-27	WOS:A1994QA63800017
J	ZHU, L; HOPE, TJ; HALL, J; DAVIES, A; STERN, M; MULLEREBERHARD, U; STERN, R; PARSLOW, TG				ZHU, L; HOPE, TJ; HALL, J; DAVIES, A; STERN, M; MULLEREBERHARD, U; STERN, R; PARSLOW, TG			MOLECULAR-CLONING OF A MAMMALIAN HYALURONIDASE REVEALS IDENTITY WITH HEMOPEXIN, A SERUM HEME-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RABBIT HEMOPEXIN; ACID; PURIFICATION; RECEPTOR; IDENTIFICATION; SEQUENCE; CELLS; LIVER	Hyaluronan is the most abundant glycosaminoglycan of the extracellular matrix and is a critical substrate for cellular attachment and locomotion. Little is known about the class of enzymes, termed hyaluronidases, that are responsible for hyaluronan catabolism in mammals. We have determined a partial amino acid sequence from a purified preparation of porcine liver hyaluronidase and have used this information as the basis for cloning complementary DNA that encodes the corresponding protein. When expressed in a recombinant baculovirus system, the protein exhibited hyaluronidase activity in a substrate-gel assay. The deduced sequence of this mammalian hyaluronidase is that of a 459-amino-acid polypeptide bearing four potential N-glycosylation sites as well as a copy of a proposed hyaluronan binding motif. Remarkably, amino acid sequence comparisons and immunologic cross-reactivities strongly suggest that the cloned protein is identical to hemopexin, an abundant, heme-binding serum protein. Although hemopexin has not previously been reported to possess any enzymatic activity, it includes a conserved domain found in collagenases, stromelysins, and other enzymes that metabolize the extracellular matrix. We conclude that hemopexin is the predominant hyaluronidase expressed in mammalian liver.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ORAL & MAXILLOFACIAL SURG, SAN FRANCISCO, CA 94143 USA; CORNELL UNIV, SCH MED, DEPT PEDIAT, NEW YORK, NY 10021 USA; CORNELL UNIV, SCH MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University; Cornell University; Cornell University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30203] Funding Source: Medline; NIGMS NIH HHS [GM43574, GM46765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALTRUDA F, 1988, J MOL EVOL, V27, P102, DOI 10.1007/BF02138368; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON NN, 1967, J BIOL CHEM, V242, P437; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BERTOLAMI CN, 1982, J INVEST DERMATOL, V79, P417, DOI 10.1111/1523-1747.ep12530400; DAVIES AH, 1994, BIO-TECHNOL, V12, P47, DOI 10.1038/nbt0194-47; DESALEGU.M, 1967, ARCH BIOCHEM BIOPHYS, V120, P60, DOI 10.1016/0003-9861(67)90598-X; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GOLD EW, 1982, BIOCHEM J, V205, P69, DOI 10.1042/bj2050069; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; JOY MB, 1985, BIOCHIM BIOPHYS ACTA, V838, P257, DOI 10.1016/0304-4165(85)90087-X; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KULYK WM, 1987, DEV BIOL, V120, P535, DOI 10.1016/0012-1606(87)90256-9; LAMBERG SI, 1986, J INVEST DERMATOL, V86, P659, DOI 10.1111/1523-1747.ep12275707; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MORGAN WT, 1993, J BIOL CHEM, V268, P6256; MORGAN WT, 1984, J BIOL CHEM, V259, P2001; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112; MUSTER P, 1991, J PROTEIN CHEM, V10, P123, DOI 10.1007/BF01024662; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; ORKIN RW, 1980, J BIOL CHEM, V255, P1036; POLANSKY JR, 1974, SCIENCE, V183, P862, DOI 10.1126/science.183.4127.862; Possee RD., 1992, BACULOVIRUS EXPRESSI; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATOH T, 1994, P NATL ACAD SCI USA, V91, P8423, DOI 10.1073/pnas.91.18.8423; SPENCER HT, 1990, INT J BIOCHEM, V22, P367, DOI 10.1016/0020-711X(90)90139-T; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STANLEY KK, 1986, FEBS LETT, V199, P249, DOI 10.1016/0014-5793(86)80489-6; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKETANI S, 1990, J BIOL CHEM, V265, P13981; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	45	32	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32092	32097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798203				2022-12-27	WOS:A1994PX30400015
J	BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P				BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P			PURIFICATION AND CHARACTERIZATION OF A RAT-LIVER ENZYME THAT HYDROLYZES VALACICLOVIR, THE L-VALYL ESTER PRODRUG OF ACYCLOVIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; PROTEINS; MITOCHONDRIA; CELLS	Valaciclovir is an oral prodrug of the antiherpetic agent acyclovir, An enzyme that hydrolyzes valaciclovir to acyclovir, valaciclovir hydrolase (VACVase), was purified from rat liver and characterized, VACVase was a basic (pI 9.4) protein associated with mitochondria, It was monomeric and had a molecular mass of 29 kDa, Amino acid sequences of six VACVase peptides, including its NH2 terminus (13 amino acids) and accounting for approximately 20% of its complete sequence, were not found in the SwissProt protein data base, VACVase hydrolyzed other amino acid esters of acyclovir in addition to valaciclovir (k(cat)/K-m = 58 mM(-1) s(-1)), with a preference for the L-alanyl (k(cat)/K-m = 226 mM(-1) S-1) and L-methionyl (k(cat)/K-m = 200 mM(-1) S-1) esters. It did not hydrolyze other types of esters or numerous di- and tripeptides and aminoacyl-beta-naphthylamides. Hydrolysis of valaciclovir by VACVase was not inhibited by amastatin, antipain, aprotinin, bestatin, chymostatin, E-64, EDTA, ebelactone A, ebelactone B, elastatinal, leupeptin, pepstatin, or phosphoramidon. It was neither inhibited nor activated by Ca2+, Co2+, Mg2+, Mn2+, or Zn2+. Therefore, this enzyme is not a typical esterase or peptidase and, to our knowledge, it has not been described previously. Its physiological function is not known; however, it may play a significant role in the biotransformation of valaciclovir to acyclovir.	BURROUGHS WELLCOME CO, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	BURNETTE, TC (corresponding author), BURROUGHS WELLCOME CO, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							Adibi S. A., 1981, PHYSL GASTROINTESTIN, V2, P1073; Beauchamp Lilia M., 1993, Drugs of the Future, V18, P619; BEAUCHAMP LM, 1992, ANTIVIR CHEM CHEMOTH, V3, P157, DOI 10.1177/095632029200300305; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnette T. C., 1993, Antiviral Research, V20, P115; BURNETTE TC, 1994, DRUG METAB DISPOS, V22, P60; CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31; DEMIRANDA P, 1994, DRUG METAB DISPOS, V22, P55; DEMIRANDA P, 1994, 34TH INT C ANT AG CH; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Fleischer S, 1974, Methods Enzymol, V31, P6; FREITAS JO, 1981, INT J BIOCHEM, V13, P991, DOI 10.1016/0020-711X(81)90004-5; FRICK L, 1984, COMP BIOCHEM PHYS B, V77, P533, DOI 10.1016/0305-0491(84)90271-2; GROSS M, 1992, J BIOL CHEM, V267, P2080; JACOBSON MA, 1994, ANTIMICROB AGENTS CH, V38, P1534, DOI 10.1128/AAC.38.7.1534; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MEADOWS KC, 1990, PHARMACEUT RES, V7, P299, DOI 10.1023/A:1015890516119; MIRCHEFF AK, 1976, J MEMBRANE BIOL, V28, P309, DOI 10.1007/BF01869703; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; SMITH C, 1993, 33RD INT C ANT AG CH; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TERMIGNONI C, 1991, MOL CELL BIOCHEM, V102, P101; VISSER L, 1972, BIOCHIM BIOPHYS ACTA, V268, P257, DOI 10.1016/0005-2744(72)90223-9; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196; WIEDHAUP K, 1981, TOP PHARM SCI, P307	28	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15827	15831		10.1074/jbc.270.26.15827	http://dx.doi.org/10.1074/jbc.270.26.15827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797586	hybrid			2022-12-27	WOS:A1995RG53800059
J	USDIN, TB; GRUBER, C; BONNER, TI				USDIN, TB; GRUBER, C; BONNER, TI			IDENTIFICATION AND FUNCTIONAL EXPRESSION OF A RECEPTOR SELECTIVELY RECOGNIZING PARATHYROID-HORMONE, THE PTH2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDE RECEPTOR; PANCREATIC-ISLETS; CYTOSOLIC CALCIUM; KIDNEY-CELLS; PROTEIN; HYPOTHALAMUS; RESPONSES; SECRETION; CLONING; TISSUES	We have identified a G-protein-coupled receptor specifically activated by parathyroid hormone, which we refer to as the PTH2 receptor. Parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP, hypercalcemia of malignancy factor) activate a previously identified PTH/PTHrP receptor, which has a widespread tissue distribution. The PTH2 receptor is much more selective in ligand recognition and appears to have a more specific tissue distribution. It is activated by PTH and not by PTHrP and is particularly abundant in the brain and pancreas.			USDIN, TB (corresponding author), NIMH,CELL BIOL LAB,BLDG 36 RM 3A17,36 CONVENT DR MSC 4090,BETHESDA,MD 20892, USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BLIND E, 1993, EXP CLIN ENDOCRINOL, V101, P150, DOI 10.1055/s-0029-1211222; BOWDEN SJ, 1994, J ENDOCRINOL, V142, P217, DOI 10.1677/joe.0.1420217; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; FADDA GZ, 1988, KIDNEY INT, V33, P1066, DOI 10.1038/ki.1988.112; FADDA GZ, 1993, KIDNEY INT, V43, P554, DOI 10.1038/ki.1993.82; FERGUSON JE, 1992, P NATL ACAD SCI USA, V89, P8384, DOI 10.1073/pnas.89.17.8384; FRASER RA, 1990, ENDOCRINOLOGY, V127, P2517, DOI 10.1210/endo-127-5-2517; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; HARVEY S, 1993, PEPTIDES, V14, P269, DOI 10.1016/0196-9781(93)90041-E; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KONIG M, 1991, Molecular and Cellular Neuroscience, V2, P331, DOI 10.1016/1044-7431(91)90063-T; KURODA T, 1993, PANCREAS, V8, P732, DOI 10.1097/00006676-199311000-00010; Law F, 1994, Adv Nephrol Necker Hosp, V23, P281; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LIN SC, 1993, NATURE, V15, P208; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTIN TJ, 1993, J INTERN MED, V233, P1, DOI 10.1111/j.1365-2796.1993.tb00638.x; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MATSUI H, 1995, AM J PHYSIOL-REG I, V268, pR21, DOI 10.1152/ajpregu.1995.268.1.R21; Moore DD, 1995, GLOB MOB SURV; MUFF R, 1994, MOL CELL ENDOCRINOL, V100, P35, DOI 10.1016/0303-7207(94)90275-5; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; PANG PKT, 1988, AM J PHYSIOL, V255, pR643, DOI 10.1152/ajpregu.1988.255.4.R643; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHNEIDER H, 1993, EUR J PHARM-MOLEC PH, V246, P149, DOI 10.1016/0922-4106(93)90092-N; SHURTZSWIRSKI R, 1993, HUM REPROD, V8, P107, DOI 10.1093/oxfordjournals.humrep.a137855; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WEAVER DR, 1994, MOL BRAIN RES, V28, P296; 1991, PROGRAM MANUAL WISCO	40	312	333	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15455	15458		10.1074/jbc.270.26.15455	http://dx.doi.org/10.1074/jbc.270.26.15455			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797535	hybrid			2022-12-27	WOS:A1995RG53800004
J	ZHANG, JM; VASILYEVA, E; FENG, Y; FORGAC, M				ZHANG, JM; VASILYEVA, E; FENG, Y; FORGAC, M			INHIBITION AND LABELING OF THE COATED VESICLE V-ATPASE BY 2-AZIDO-[P-32]ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; PROTON PUMP; ESCHERICHIA-COLI; CDNA SEQUENCE; SUBUNIT; (H+)-ATPASE; F1-ATPASE; CLATHRIN; BINDING	Previous studies have indicated that the 73-kDa A subunit of the coated vesicle V-ATPase possesses a nucleotide-binding site essential for activity (Arai, H., Berne, M., Terres, G., Terres, Ii., Puopolo, K., and Forgac, M. (1987) Biochemistry 26, 6632-6638) and have identified a cysteine residue (Cys(254)) whose modification leads to complete loss of activity (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 5817-5822). To further characterize the structure of the nucleotide-binding sites of the V-ATPase, labeling studies using the photoactivated analog 2-azido-[P-32]ATP have been carried out. We have observed that 2-azido-[P-32]ATP is hydrolyzed by the V-ATPase at a rate (at 1 mM) approximately 4-fold lower than observed for ATP, indicating that 2-azido-[P-32]ATP is a good substrate for the V-ATPase. Irradiation of the V-ATPase in the presence of 0.5 mM 2-azido-[P-32]ATP leads to inactivation of V-ATPase activity with a t(1/2) of 56 min, The 73-kDa A subunit, the 58-kDa B subunit, and the 50 kDa subunit of the AP-2 adaptin complex (Myers, M., and Forgac, M. (1993) J. Biol. Chem. 268, 9184-9186) are all labeled in an ATP-protectable manner on irradiation of the purified V-ATPase with 2-azido[P-32]ATP. The time course for inactivation most closely correlates with labeling of the A subunit. Measurement of the stoichiometry of 2-azido-[P-32]ATP incorporation into the A subunit as a function of inactivation indicates that complete loss of activity is obtained on incorporation of 1.2 mol of 2-azido-[P-32]ATP/mol V-ATPase complex. 2-Azido-[32P]ATP labeling indicates that the V-ATPase possesses both rapidly (t(1/2) < 2 min) and slowly (t(1/2) > 2 min) exchangeable nucleotide-binding sites. The A subunit is labeled upon modification of both rapidly and slowly exchangeable sites whereas the B subunit is labeled upon modification of only rapidly exchangeable sites. Inhibition of V-ATPase activity correlates with labeling of the rapidly exchangeable sites. Amino acid sequence analysis of peptides derived from the 2-azido-[P-32]ATP-labeled A subunit indicates labeling of two peptides: a 12-kDa fragment which begins at residue 511 and contains Cys(532) and 3-kDa fragment which begins at residue 233 and contains the glycine-rich loop and Cys(254). Only the 12-kDa fragment is labeled upon modification of the rapidly exchangeable sites. A 12-kDa V-8 peptide, which begins at residue 375 of the B subunit is also labeled by 2-azido-[P-32]ATP under conditions which modify the rapidly exchangeable sites, These results provide further information concerning the nucleotide-binding sites on the V-ATPase A and B subunits. The differences in nucleotide-binding sites between F-and V-ATPases are also discussed.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1987, P NATLA CAD SCI US, V84, P7515; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; LIU Q, 1994, J BIOL CHEM, V269, P31592; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15494	15500		10.1074/jbc.270.26.15494	http://dx.doi.org/10.1074/jbc.270.26.15494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797542	hybrid			2022-12-27	WOS:A1995RG53800012
J	DARNAY, BG; SINGH, S; CHATURVEDI, MM; AGGARWAL, BB				DARNAY, BG; SINGH, S; CHATURVEDI, MM; AGGARWAL, BB			THE P60 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR-ASSOCIATED KINASE (TRAK) BINDS RESIDUES 344-397 WITHIN THE CYTOPLASMIC DOMAIN INVOLVED IN TNF SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; ACTIVATION	The p60 form of the tumor necrosis factor (TNF) receptor lacks motifs characteristic of tyrosine or serine/threonine protein kinases, Our recent observations have indicated that a p60 TNF receptor-associated kinase (p60-TRAK) from U-937 cells physically interacts with and causes the phosphorylation of the cytoplasmic domain of the TNF receptor. To define which region of the cytoplasmic domain is necessary for physical interaction with p60-TRAK, we constructed a series of deletions (grouped into three sets Delta 1-Delta 5, Delta 6-Delta 12, and Delta 13-Delta 16) of the p60 cytoplasmic domain, expressed them as glutathione S-transferase (GST) fusion proteins, and used them in affinity precipitations, followed by in vitro kinase assays. Our detailed analysis indicated that a serine-, threonine-, and proline-rich region (residues 243-274, Delta 2) and the N-terminal half of the cytoplasmic domain (residues 243-323, Delta 3) neither associated with p60-TRAK nor underwent phosphorylation. We found that out of 222 residues (205-426) in the cytoplasmic domain, only 54 (344-397, Delta 12) were sufficient for binding p60-TRAK and for phosphorylation of the cytoplasmic domain. A region of approximately 30 residues (397-426) at the C-terminal end was found to interfere with optimal binding of the p60-TRAK activity. Thus, our results indicate that the minimal region of the cytoplasmic domain necessary for interacting with p60-TRAK and for phosphorylation resides within the domain previously reported to be needed for signaling the cytotoxic effect of TNF.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC ONCOL,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; ENGLEMANN H, 1990, J BIOL CHEM, V265, P14497; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1993, J BIOL CHEM, V268, P10932; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, P1019; SONG RY, 1994, J BIOL CHEM, V269, P22492; SONG RY, 1995, J BIOL CHEM, V270, P3574; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043	20	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14867	14870		10.1074/jbc.270.25.14867	http://dx.doi.org/10.1074/jbc.270.25.14867			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797464	hybrid			2022-12-27	WOS:A1995RE66600007
J	KADRIHASSANI, N; LEGER, CL; DESCOMPS, B				KADRIHASSANI, N; LEGER, CL; DESCOMPS, B			THE FATTY-ACID BIMODAL ACTION ON SUPEROXIDE ANION PRODUCTION BY HUMAN ADHERENT MONOCYTES UNDER PHORBOL 12-MYRISTATE 13-ACETATE OR DIACYLGLYCEROL ACTIVATION CAN BE EXPLAINED BY THE MODULATION OF PROTEIN-KINASE-C AND P47(PHOX) TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; NADPH OXIDASE; CHEMI-LUMINESCENCE; ESTER BINDING; OLEIC-ACID; PHOSPHORYLATION; PHOSPHOLIPIDS; INHIBITION; MEMBRANES	We studied the translocation of protein kinase C (PKC), the endogenous phosphorylation and presence in the membrane fraction of p47(phox) (the 47-kDa cytosolic component of the phagocyte NADPH oxidase), and the O-2-radical-anion production in human adherent monocytes (HAMs). This was performed under phorbol myristate acetate (PMA) or diacylglycerol stimulation after cell preincubation in the presence of either 13-methyltetradecanoate or arachidonate. At 3 nM and 30 mu M, both fatty acids had enhancing and depressing effects, respectively, on PKC translocation and O-2-radical-anion production strictly depending on the PMA- or diacylglycerol-stimulated state of the cell. Endogenous phosphorylation and membrane presence of p47(phox) were markedly reinforced in PMA-stimulated HAMs in the presence as compared to the absence of 13-methyltetradecanoate. These results emphasize the fact that in intact cells the capacity of both FAs to potentiate or depress the HAM O-2-radical-anion production is mediated by a direct action on the PKC membrane translocation leading to a simultaneous endogenous phosphorylation and membrane translocation of p47(phox). They confirm the recent findings (Kadri-Hassani, N., Leger, C. L., and Descomps, B. (1995) J. Lipid Med. Cell Signal. 11, 159-173) on the PKC-mediated, adherent monocyte-specific capacity of these fatty acids and others (with the exception of linear saturated fatty acids) to enhance the PMA-stimulated O-2-radical-anion production at nanomolar concentrations and to depress it at micromolar concentrations.	INSERM, CTR RECH, F-34090 MONTPELLIER, FRANCE; UNIV MONTPELLIER 1, INST BIOL, UNITE FORMAT RECH MED, BIOL & BIOCHIM LIPIDES LAB, F-34000 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier								ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FOLCH J, 1957, J BIOL CHEM, V226, P497; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HUANG XP, 1993, BIOCHIM BIOPHYS ACTA, V1175, P351, DOI 10.1016/0167-4889(93)90228-H; KADRIHASSANI N, 1995, J LIPID MEDIAT CELL, V11, P159, DOI 10.1016/0929-7855(94)00035-B; KHAN W, 1991, FEBS LETT, V292, P98, DOI 10.1016/0014-5793(91)80843-R; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER CL, 1993, PROSTAG LEUKOTR ESS, V48, P17, DOI 10.1016/0952-3278(93)90004-G; LESTER DS, 1991, BIOCHEM BIOPH RES CO, V179, P1522, DOI 10.1016/0006-291X(91)91745-X; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARK JW, 1992, J BIOL CHEM, V267, P19901; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V136, P228, DOI 10.1016/0006-291X(86)90898-3; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; WILSON E, 1986, J BIOL CHEM, V261, P2616; WOLFSON M, 1985, J IMMUNOL, V135, P2057; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	39	36	36	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15111	15118		10.1074/jbc.270.25.15111	http://dx.doi.org/10.1074/jbc.270.25.15111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797495	hybrid, Green Submitted			2022-12-27	WOS:A1995RE66600041
J	ALEXANDER, C; BILGIN, N; LINDSCHAU, C; MESTERS, JR; KRAAL, B; HILGENFELD, R; ERDMANN, VA; LIPPMANN, C				ALEXANDER, C; BILGIN, N; LINDSCHAU, C; MESTERS, JR; KRAAL, B; HILGENFELD, R; ERDMANN, VA; LIPPMANN, C			PHOSPHORYLATION OF ELONGATION-FACTOR TU PREVENTS TERNARY COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR-EF-TU; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; FACTOR-TS; FACTOR-I; KIRROMYCIN; DOMAIN; ACID; MUTAGENESIS	The elongation factor Tu (EF-Tu) is a member of the GTP/GDP-binding proteins and interacts with various partners during the elongation cycle of protein biosynthesis thereby mediating the correct binding of amino-acylated transfer RNA (aa-tRNA) to the acceptor site (A-site) of the ribosome. After GTP hydrolysis EF-Tu is released in its GDP-bound state. lit vivo, EF-Tu is posttranslationally modified by phosphorylation. Here we report that the phosphorylation of EF-Tu by a ribosome associated kinase activity is drastically enhanced by EF-Ts. The antibiotic kirromycin, known to block EF-Tu function, inhibits the modification. This effect is specific, since kirromycin-resistant mutants do become phosphorylated in the presence of the antibiotic. On the other hand, phosphorylated wild-type EF-Tu does not bind kirromycin. Most interestingly, the phosphorylation of EF-Tu abolishes its ability to bind aa-tRNA. In the GTP conformation the site of modification is located at the interface between domains 1 and 3 and is involved in a strong interdomain hydrogen bond. Introduction of a charged phosphate group at this position will change the interaction between the domains, leading to an opening of the molecule reminiscent of the GDP conformation. A model for the function of EF-Tu phosphorylation in protein biosynthesis is presented.	FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; UPPSALA UNIV,INST MOLEK BIOL,BMC,S-75124 UPPSALA,SWEDEN; HUMBOLDT UNIV BERLIN,MAX DELBRUCK CENTRUM MOLEK MED,FRANZ VOLHARD KLIN,D-13122 BERLIN,GERMANY; GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; INST MOLEC BIOTECHNOL,DEPT STRUCT BIOL & CRYSTALLOG,D-07708 JENA,GERMANY	Free University of Berlin; Uppsala University; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Lindschau, Carsten/AAE-6721-2020; Hilgenfeld, Rolf/C-9675-2011; Lindschau, Carsten/G-1798-2011	Lindschau, Carsten/0000-0003-1960-099X; Mesters, Jeroen/0000-0001-8532-6699				ABRAHAMS JP, 1991, BIOCHEMISTRY-US, V30, P6705, DOI 10.1021/bi00241a010; ABRAHAMS JP, 1988, NUCLEIC ACIDS RES, V16, P10099, DOI 10.1093/nar/16.21.10099; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERTRAM S, 1983, NUCLEIC ACIDS RES, V11, P575, DOI 10.1093/nar/11.3.575; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUBUNENKO MG, 1992, BIOCHIMIE, V74, P419, DOI 10.1016/0300-9084(92)90081-O; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; FORSTER C, 1993, BIOCHIMIE, V75, P1159, DOI 10.1016/0300-9084(93)90015-K; HWANG YW, 1989, J BIOL CHEM, V264, P8304; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LIPPMANN C, 1988, FEBS LETT, V240, P139, DOI 10.1016/0014-5793(88)80355-7; LIPPMANN C, 1993, J BIOL CHEM, V268, P601; LIPPMANN C, 1991, NATO ASI H, V56, P441; LITALIEN JJ, 1979, FEBS LETT, V107, P359, DOI 10.1016/0014-5793(79)80407-X; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; NIERHAUS KH, 1982, CURR TOP MICROBIOL I, V97, P82; PETER ME, 1990, NUCLEIC ACIDS RES, V18, P6889, DOI 10.1093/nar/18.23.6889; RODNINA MV, 1993, TRANSLATIONAL APPARATUS, P317; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCOBLE J, 1994, BIOCHIMIE, V76, P59, DOI 10.1016/0300-9084(94)90063-9; VANDERMEIDE PH, 1982, FEBS LETT, V139, P325, DOI 10.1016/0014-5793(82)80881-8; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOLF H, 1977, EUR J BIOCHEM, V75, P67, DOI 10.1111/j.1432-1033.1977.tb11504.x; WOLF H, 1974, P NATL ACAD SCI USA, V71, P4910, DOI 10.1073/pnas.71.12.4910; ZEEF LAH, 1993, MOL GEN GENET, V238, P252, DOI 10.1007/BF00279554	33	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14541	14547		10.1074/jbc.270.24.14541	http://dx.doi.org/10.1074/jbc.270.24.14541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782317	hybrid			2022-12-27	WOS:A1995RD45500048
J	ITOH, K; ADELSTEIN, RS				ITOH, K; ADELSTEIN, RS			NEURONAL CELL EXPRESSION OF INSERTED ISOFORMS OF VERTEBRATE NONMUSCLE MYOSIN HEAVY-CHAIN II-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINOBLASTOMA CELLS; SMOOTH-MUSCLE MYOSIN; DIFFERENTIAL EXPRESSION; SODIUM-BUTYRATE; MESSENGER-RNAS; NERVOUS-SYSTEM; CYCLIC-AMP; CDNA; CLONING; ACID	Previous work has demonstrated that unique isoforms of nonmuscle myosin heavy chain II-B (MHC-B) are expressed in chicken and human neuronal cells (Takahashi, M., Kawamoto, S., and Adelstein, R. S. (1992) J. Biol. Chem. 267, 17864-17871). These isoforms, which appear to be generated by alternative splicing of pre-mRNA, differ from the MHC-B isoform present in a large number of nonmuscle cells in that they contain inserted cassettes of amino acids near the ATP binding region and/or near the actin binding region. The insert near the ATP binding region begins after amino acid 211 and consists of either 10 or 16 amino acids. The insert nc ar the actin binding region begins after amino acid 621 and consists of 21 amino acids. Using a variety of techniques, we have studied the distribution and expression of the inserted MHC-B isoforms. In the developing chick;en brain, mRNA encoding the 10-amino acid insert gradually increases after embryonic day 4, peaks in the 10-14-day embryo, and then declines. In contrast, the mRNA encoding the 21-amino acid insert appears just before birth and is abundantly expressed in the adult chicken cerebellum. There is a marked species difference between the distribution of the inserted isoforms in adult tissues. The mRNA encoding MHC-B containing the 10-amino acid insert near the ATP binding region is expressed at low levels in the adult chicken brain, but makes up most of the MHC-B mRNA expressed in the human cerebrum and approximately 90% of MHC-B in the human retina. It is also expressed in neuronal cell lines. The mRNA encoding MHC-B containing the 21-amino acid insert is abundantly expressed in the chicken cerebellum and human cerebrum, but is absent from the retina and cell lines, Employing human retinoblastoma (Y-79) and neuroblastoma (SK-N-SH) cell lines, an increase in expression of mRNA encoding the 10-amino acid inserted isoform was seen following treatment by a number of agonists or by serum deprivation. In each case, expression of the inserted MHC-B isoform correlated with cell differentiation (neuronal phenotype) and inhibition of cell division. Using a rat pheochromocytoma cell line (PC12), we found that prior to treatment with nerve growth factor (NGF), there was no evidence for either inserted isoform, although noninserted MHC-B was present. NGF treatment resulted in the appearance of mRNA encoding MHC-B containing the 10-amino acid insert, concomitant with neurite outgrowth. Both the inserted isoform and neurites disappeared following withdrawal of NGF, showing that the appearance and disappearance of the neurites is coupled to the inclusion and exclusion of this MHC-B insert.	NHLBI, MOLEC CARDIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Itoh, Kazuyuki/0000-0002-0761-0499; Adelstein, Robert/0000-0002-8683-2144				BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; CAMPBELL M, 1988, OPHTHALMIC PAED GEN, V9, P171, DOI 10.3109/13816818809031495; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHOI OH, 1994, J BIOL CHEM, V269, P536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG MH, 1991, BRAIN RES, V561, P274, DOI 10.1016/0006-8993(91)91604-Y; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Itoh K., 1994, Molecular Biology of the Cell, V5, p403A; Itoh K., 1993, Molecular Biology of the Cell, V4, p41A; ITOH K, 1994, FASEB J, V8, pA1303; KAPOOR CL, 1985, NEUROCHEM INT, V7, P285, DOI 10.1016/0197-0186(85)90117-2; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KELLEY CA, 1995, J BIOL CHEM, V270, P1395, DOI 10.1074/jbc.270.3.1395; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; KYRITSIS AP, 1986, ANTICANCER RES, V6, P465; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MURAKAMI N, 1992, CELL MOTIL CYTOSKEL, V22, P281, DOI 10.1002/cm.970220408; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NAKAGAWA Y, 1987, OPHTHALMIC RES, V19, P205, DOI 10.1159/000265495; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PEARSON R, 1972, AVIAN BRAIN, P74; PHILLIPS CL, 1995, IN PRESS J MUSCLE RE; PIERCE ME, 1989, J NEUROCHEM, V53, P307, DOI 10.1111/j.1471-4159.1989.tb07330.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHROEDER TE, 1976, CELL MOTILITY, P265; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1; WIECHMANN AF, 1990, J NEUROCHEM, V55, P208, DOI 10.1111/j.1471-4159.1990.tb08840.x	47	70	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14533	14540		10.1074/jbc.270.24.14533	http://dx.doi.org/10.1074/jbc.270.24.14533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782316	hybrid			2022-12-27	WOS:A1995RD45500047
J	JEOHN, GH; SERIZAWA, S; IWAMATSU, A; TAKAHASHI, K				JEOHN, GH; SERIZAWA, S; IWAMATSU, A; TAKAHASHI, K			ISOLATION AND CHARACTERIZATION OF GASTRIC TRYPSIN FROM THE MICROSOMAL FRACTION OF PORCINE GASTRIC ANTRAL MUCOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; SERINE PROTEASE; PLASMA PREKALLIKREIN; NUCLEOTIDE-SEQUENCE; CDNA; SPECIFICITY; EXPRESSION; INHIBITOR; PANCREAS	A gastric serine protease(s) was found in porcine gastric antral mucosa and was shown to be distributed in the endoplasmic reticulum (ER)-microsome fraction and also in the vesicle fraction. Two forms of the protease were purified over 6,000-fold from the ER-microsome fraction. Analyses of various molecular and enzymatic characteristics including the N-terminal and partial internal amino acid sequences of both forms revealed that they share the same properties and are indistinguishable from porcine pancreatic trypsin. This is the first time that trypsin or a protease almost identical with trypsin has been found to be present intracellularly in normal tissues. The gastric trypsin activities from the ER-microsome and the vesicle fractions were located in distinct density regions upon density gradient centrifugation, which indicates association of the protease with different organelle membranes. Taken together, these results suggest that there may be a novel function of trypsin in the gastric mucosa; it might function as a specific degrading or processing enzyme as an intracellular protease.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Kirin Brewery Company Limited								ATHAUDA SBP, 1991, FEBS LETT, V292, P53, DOI 10.1016/0014-5793(91)80832-N; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS BP, 1992, J BIOL CHEM, V267, P26070; FREEMAN TC, 1990, GUT, V31, P1318, DOI 10.1136/gut.31.11.1318; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Fujita T, 1988, PARANEURON, P165, DOI [10.1007/978-4-431-68066-6_16, DOI 10.1007/978-4-431-68066-6_16]; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HARTLEY BS, 1966, BIOCHEM J, V101, P229, DOI 10.1042/bj1010229; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JENSEN S, 1989, GASTROENTEROLOGY, V96, P1063, DOI 10.1016/0016-5085(89)91624-7; JOHN GH, 1995, J BIOL CHEM, V270, P7809; KAWASHIMA I, 1987, DNA-J MOLEC CELL BIO, V6, P163, DOI 10.1089/dna.1987.6.163; Keil B., 1971, ENZYMES, V3, P249, DOI [10.1016/S1874-6047(08)60399-6., 10.1021/bi00843a047, DOI 10.1021/BI00843A047]; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LEHUEROU I, 1990, EUR J BIOCHEM, V193, P767; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LOH YP, 1984, J BIOL CHEM, V259, P8238; LOWRY OH, 1957, METHOD ENZYMOL, V4, P371; MACDONALD RJ, 1982, J BIOL CHEM, V257, P9724; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MELOUN B, 1966, BIOCHIM BIOPHYS ACTA, V130, P543, DOI 10.1016/0304-4165(66)90258-3; PLAYFORD RJ, 1994, GASTROENTEROLOGY, V106, P735, DOI 10.1016/0016-5085(94)90709-9; SHIBATA T, 1986, CLIN CHIM ACTA, V159, P27, DOI 10.1016/0009-8981(86)90163-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STORRIE B, 1990, METHOD ENZYMOL, V182, P215; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631; TAYLOR IL, 1991, TXB GASTROENTEROLOGY, V1, P24; UCHINO T, 1993, J BIOL CHEM, V268, P527; USUI Y, 1982, BIOCHIM BIOPHYS ACTA, V719, P539, DOI 10.1016/0304-4165(82)90244-6; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; Walsh K. A., 1970, METHODS ENZYMOL, V19, P41; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K	37	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14748	14755		10.1074/jbc.270.24.14748	http://dx.doi.org/10.1074/jbc.270.24.14748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782340	hybrid			2022-12-27	WOS:A1995RD45500077
J	CHUN, PW				CHUN, PW			NEW THERMODYNAMIC STUDIES ON RIBONUCLEASE-A AT LOW PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILIZATION; ALPHA-CHYMOTRYPSIN; DIMERIZATION; DEPENDENCE; MECHANISM; GLYCEROL	The Planck-Benzinger thermal work function, Delta W-0(T), represents the heat-flux term which is responsible for breaking or forming the noncovalent bonds in macromolecular interactions, while the temperature-invariant chemical bond energy, Delta H-0(T-0), gives molecules the cohesiveness to form macromolecular structures. A method is described for evaluating Delta H-0(T-0) at different temperatures for ribonuclease A at low pH in the standard state, in order to determine the effect of pH on the thermodynamic stability of this protein. Ribonuclease A at pH 1.13 has a Delta H-0(T-0) value of 58 kcal mol(-1); at pH 2.50, Delta H-0(T-0) is 58, at pH 2.77, 59, and at pH 3.15, 60 kcal mol(-1). In the conformational thermal transition of ribonuclease A at pH 2.8, the compensatory temperature ranges from 50 to 320 K, and Delta H-0(T-0) is approximately 5 similar to 6 kcal mol(-1). This widening temperature range is typical of the unfolding process. Such differences in the magnitude of the temperature-invariant chemical bond energy can be attributed to specific changes in the solvent ordering in the immediate domain of ribonuclease A.			CHUN, PW (corresponding author), UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610, USA.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1609; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1617; BARR AJ, 1979, SAS GLM 27 GLM 131 S; BENZINGER TH, 1971, NATURE, V29, P100; BRANDTS JF, 1965, J AM CHEM SOC, V87, P2759, DOI 10.1021/ja01090a043; CHUN PW, 1982, BIOPHYS J, V37, pA398; CHUN PW, 1994, J PHYS CHEM-US, V98, P6851, DOI 10.1021/j100078a030; CHUN PW, 1988, INT J QUANTUM CHEM Q, V15, P247; CHUN PW, 1993, MANUAL COMPUTER AIDE; CHUN PW, 1995, BIOPHYS J, V68; CHUN PW, 1995, ANN M FLORIDA SECTIO, V28, P61; CHUN PW, 1994, BIOPHYS J, V66; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V27, P439; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Gibbs J.W., 1878, AM J SCI, Vs3-16, P441, DOI [DOI 10.2475/AJS.S3-16.96.441, 10.2475/ajs.s3-16.96.441]; GIBBS JW, 1878, T CONN ACAD SCI, V3, P228; HAGERMAN PJ, 1979, BIOCHEMISTRY-US, V18, P293, DOI 10.1021/bi00569a009; HAGERMAN PJ, 1976, BIOCHEMISTRY-US, V15, P1462, DOI 10.1021/bi00652a017; HEARN RP, 1971, BIOCHEMISTRY-US, V10, P806; INOUE H, 1973, BIOPOLYMERS, V11, P737; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KIM PS, 1980, BIOCHEMISTRY-US, V19, P6124, DOI 10.1021/bi00567a027; Kupke D. W., 1973, PHYS PRINCIPLES TECH, P1; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; LEWIS GN, 1961, THERMODYNAMICS, P164; MOELWYNHUGHES EA, 1957, PHYSICAL CHEM, P90; NEUMANN NP, 1962, BIOCHEMISTRY-US, V1, P68, DOI 10.1021/bi00907a011; PLANCK M, 1927, TREATISE THERMODYNAM, P179; REISLER E, 1977, BIOCHEMISTRY-US, V16, P197, DOI 10.1021/bi00621a006; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; STEIN WH, 1960, CHEM MODIFICATIONS R, P104; Utiyama H, 1986, Methods Enzymol, V131, P51	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13925	13931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775452				2022-12-27	WOS:A1995RC44800051
J	LEVINE, SA; NATH, SK; YUN, CHC; YIP, JW; MONTROSE, M; DONOWITZ, M; TSE, CM				LEVINE, SA; NATH, SK; YUN, CHC; YIP, JW; MONTROSE, M; DONOWITZ, M; TSE, CM			SEPARATE C-TERMINAL DOMAINS OF THE EPITHELIAL SPECIFIC BRUSH-BORDER NA+/H+ EXCHANGER ISOFORM NHE3 ARE INVOLVED IN STIMULATION AND INHIBITION BY PROTEIN KINASES GROWTH FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; FUNCTIONAL-PROPERTIES; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; CELL-LINE; EXPRESSION; CALMODULIN; KINETICS; ANTIPORTER	NHE3, a cloned intestinal and renal brush border Na+/H+ exchanger, has previously been shown to be both stimulated and inhibited by different protein kinases/growth factors. For instance, NHE3 is stimulated by serum and fibroblast growth factor (FGF) and inhibited by protein kinase C. In the present study, we used a series of NHE3 C terminus truncation mutants to identify separate regions of the C-terminal cytoplasmic tail responsible for stimulation and inhibition by protein kinases/growth factors. Five NHE3 C terminus truncation mutant stable cell Lines were generated by stably transfecting NHE3 deletion cDNAs into PS120 fibroblasts, which lack any endogenous Na+/H+ exchanger. Using fluorometric techniques, the effects of the calcium/calmodulin (CaM) inhibitor W13, calcium/CaM kinase inhibitor KN-62, phorbol myristate acetate, okadaic acid, FGF, and fetal bovine serum on Na+/H+ exchange were studied in these transfected cells. Inhibition of basal activity of full-length NHE3 is mediated by CaM at a site C-terminal to amino acid 756; this CaM effect occurs through both kinase dependent and independent mechanisms. There is another independent inhibitory domain for protein kinase C between amino acids 585 and 689. In addition, there are at least three stimulatory regions in the C-terminal domain of NHE3, corresponding to amino acids 509-543 for okadaic acid, 475-509 for FGF, and a region N-terminal to amino acid 475 for fetal bovine serum. We conclude that separate regions of the C terminus of NHE3 are involved with stimulation or inhibition of Na+/H+ exchange activity, with both stimulatory and inhibitory domains having several discrete subdomains. A conservative model to explain the way these multiple domains in the C terminus of NHE3 regulate Na+/H+ exchange is via an effect on associated regulatory proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROINTESTINAL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,GASTROINTESTINAL UNIT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NIDDK NIH HHS [F32DK08820, P01DK44484, R01DK26523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484, F32DK008820] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; DEGRADO WF, 1987, METHOD ENZYMOL, V139, P455; DONOWITZ M, 1989, J CLIN INVEST, V83, P1953, DOI 10.1172/JCI114104; EMMER E, 1987, J MEMBRANE BIOL, V108, P207; FALCHETTO R, 1991, PROTEIN SCI, V1, P1613; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; JAMES P, 1988, J BIOL CHEM, V263, P2905; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LEATHERBARROW RJ, 1987, ENZFITTER MANUAL; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LI PM, 1993, ANTICANCER RES, V132, P1957; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SEGEL IH, 1957, ENZYME KINETICS BEHA, P957; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; TSE CM, 1993, P NATL ACAD SCI US; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; YU FH, 1993, J BIOL CHEM, V268, P25536; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; 1991, PC GENE USER REFEREN	33	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13716	13725		10.1074/jbc.270.23.13716	http://dx.doi.org/10.1074/jbc.270.23.13716			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775426	hybrid			2022-12-27	WOS:A1995RC44800023
J	MERRILL, AH; LINGRELL, S; WANG, E; NIKOLOVAKARAKASHIAN, M; VALES, TR; VANCE, DE				MERRILL, AH; LINGRELL, S; WANG, E; NIKOLOVAKARAKASHIAN, M; VALES, TR; VANCE, DE			SPHINGOLIPID BIOSYNTHESIS DE-NOVO BY RAT HEPATOCYTES IN CULTURE - CERAMIDE AND SPHINGOMYELIN ARE ASSOCIATED WITH, BUT NOT REQUIRED FOR, VERY-LOW-DENSITY LIPOPROTEIN SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTESTINAL-CELLS; NECROSIS-FACTOR-ALPHA; LONG-CHAIN BASES; FATTY-ACIDS; LM CELLS; CHOLESTEROL; LIVER; METABOLISM; FIBROBLASTS; MEMBRANES	Sphingolipids are constituents of liver and lipoproteins, but relatively little is known about their synthesis and secretion. Incubation of rat hepatocytes with [C-14]- or [H-3]serine labeled the long-chain base backbones of mainly ceramide and sphingomyelin. Most of the labeled sphingolipids were associated with the cells; however, 1-5% (the majority of which was ceramide) was released into the medium as part of very low density Lipoproteins (VLDL). Since this is the first report that Lipoproteins contain ceramide, lipoproteins were isolated from rat plasma, and the ceramide contents were (per mg of protein): 6.5 nmol for VLDL (d < 1.018), 0.6 nmol for low density lipoproteins (1.018 < d < 1.063), 0.2 nmol for high density lipoproteins (1.063 < d < 1.18), and 0.1 nmol for the albumin fraction; the lipoproteins also contained 0.1-0.4 nmol of free sphingosine/mg of protein. A number of factors affected the secretion of radiolabeled sphingolipids: 1) addition of palmitic acid, but not stearic or oleic acid, enhanced secretion due to an increase in long-chain base synthesis de novo. 2) Choline deficiency caused a 42% reduction in the secretion of radiolabeled sphingomyelin, but this was due to an effect on VLDL secretion rather than a decrease in sphingolipid synthesis. Removal of choline was examined because previous studies (Yao, Z, M., and Vance, D. E. (1988) J. Biol. Chem. 263, 2998-3004) have shown that choline deficiencies depress phosphatidylcholine synthesis and lipoprotein secretion. 3) Incubation of the cells with fumonisin B-1, a mycotoxin inhibitor of sphinganine (sphingosine) N-acyltransferase, reduced overall sphingolipid synthesis and secretion by 90%, but had no effect on the secretion of apoB, phosphatidylcholine, or cholesterol. Ah together, these findings demonstrate that rat hepatocytes synthesize ceramide and sphingomyelin de novo and incorporate them into both cellular membranes and secreted VLDL, but normal sphingolipid synthesis is not required for lipoprotein secretion.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta	MERRILL, AH (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322, USA.			Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BELL RM, 1993, ADV LIPID RES, V26; BELL RM, 1993, ADV LIPID RES, V25, P339; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHATTERJEE S, 1986, J BIOL CHEM, V261, P3474; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHEN H, 1993, J LIPID RES, V34, P2159; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FEX G, 1971, BIOCHIM BIOPHYS ACTA, V231, P161, DOI 10.1016/0005-2760(71)90264-5; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GATT S, 1980, J BIOL CHEM, V255, P3371; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KIM MY, 1991, J BIOL CHEM, V266, P484; KIVATINITZ SC, 1992, BIOCHEM INT, V26, P821; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; MALGAT M, 1986, J LIPID RES, V27, P251; MAZIERE JC, 1984, FEBS LETT, V173, P159, DOI 10.1016/0014-5793(84)81038-8; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MUEHLENBERG BA, 1972, CAN J BIOCHEM CELL B, V50, P166, DOI 10.1139/o72-022; PATTON S, 1970, J THEOR BIOL, V29, P489, DOI 10.1016/0022-5193(70)90111-6; PHILLIPS J, 1985, BIOL CHEM H-S, V366, P1131, DOI 10.1515/bchm3.1985.366.2.1131; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P1463; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; STEIN O, 1988, BIOCHIM BIOPHYS ACTA, V960, P322, DOI 10.1016/0005-2760(88)90040-9; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; SWEELEY CC, 1991, BIOCH LIPIDS LIPOPRO, P327; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VALENTINO LA, 1992, CANCER RES, V52, P810; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1975, J BIOL CHEM, V250, P8119; VANDENHEUVEL FA, 1965, ANN NY ACAD SCI, V122, P57; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VERDERY RB, 1982, J BIOL CHEM, V257, P1412; WANG E, 1991, J BIOL CHEM, V266, P14486; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175	57	110	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13834	13841		10.1074/jbc.270.23.13834	http://dx.doi.org/10.1074/jbc.270.23.13834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775441	hybrid			2022-12-27	WOS:A1995RC44800040
J	JI, L; ARCINAS, M; BOXER, LM				JI, L; ARCINAS, M; BOXER, LM			THE TRANSCRIPTION FACTOR, NM23H2, BINDS TO AND ACTIVATES THE TRANSLOCATED C-MYC ALLELE IN BURKITTS-LYMPHOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LIGATION-MEDIATED PCR; NM23-H2 MESSENGER-RNA; CHROMATIN STRUCTURE; TUMOR-METASTASIS; DIFFERENTIAL EXPRESSION; PROTEIN-BINDING; TRANSGENIC MICE; LEUKEMIA-CELLS; GENE	We have identified an in vivo footprint over the PuF site on the translocated c-myc allele in Burkitt's lymphoma cells. The PuF site on the silent normal c-myc allele was unoccupied. We demonstrated by electrophoretic mobility shift assay, electrophoretic mobility shift assay with antibody, UV cross-linking followed by SDS-gel electrophoresis, and Western analysis that Nm23H2 in B cell nuclear extracts bound to the c-myc PuF site. Transfection experiments with c-myc promoter constructs in both DHL-9 and Raji cells revealed that the PuF site functioned as a positive regulatory element in B cells with a drop in activity with mutation of this site. Access to this site is blocked in the normal silent c-myc allele; these data suggest that the Nm23H2 protein is involved in deregulation of the translocated c-myc allele in Burkitt's lymphoma cells.	STANFORD UNIV, SCH MED, DEPT MED, DIV HEMATOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL MED, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764, P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233, CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARCINAS M, 1994, ONCOGENE, V9, P2699; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1988, ONCOGENE, V3, P397; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1993, ONCOGENE, V8, P2325; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OKABEKADO J, 1988, J BIOL CHEM, V263, P10994; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	56	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13392	13398		10.1074/jbc.270.22.13392	http://dx.doi.org/10.1074/jbc.270.22.13392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768941	hybrid			2022-12-27	WOS:A1995RB43900066
J	SKIBA, NP; ARTEMYEV, NO; HAMM, HE				SKIBA, NP; ARTEMYEV, NO; HAMM, HE			THE CARBOXYL-TERMINUS OF THE GAMMA-SUBUNIT OF ROD CGMP PHOSPHODIESTERASE CONTAINS DISTINCT SITES OF INTERACTION WITH THE ENZYME CATALYTIC SUBUNITS AND THE ALPHA-SUBUNIT OF TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; OUTER SEGMENTS; RETINAL RODS; ACTIVATION MECHANISM; VISUAL EXCITATION; PROTEIN; BOVINE; BINDING; IDENTIFICATION	The interaction between the GTP-bound form of the transducin alpha-subunit (G alpha(t)) and the gamma-subunit (P gamma) of cGMP phosphodiesterase (PDE) is a key event in effector activation during photon signal transduction. The carboxyl-terminal half of P gamma is involved in interaction with G alpha(t), as well as in inhibition of PDE activity. Here we have utilized a combination of synthetic peptide and mutagenesis approaches to localize specific regions of the carboxyl-terminal region of P gamma interacting with G alpha(t) and P alpha beta and have determined residues involved in inhibition of PDE activity. We found that synthetic peptide corresponding to residues 68-87 of P gamma completely inhibit trypsin-activated PDE. The peptide P gamma-63-87 bound to G alpha(t)GTP gamma S with a K-d Of 2.5 mu m, whereas the binding of P gamma-68-87 60 G alpha(t)GTP gamma S was approximately 15-fold less (K-d = 40 mu M) suggesting that carboxyl-terminal P gamma region 68-87 contains a site for interaction with P alpha beta and also a part of the alpha(t) binding site. To map G alpha(t) and P alpha beta sites more precisely within the carboxyl-terminal region, a set of carboxyl-terminal mutants was generated by site-directed mutagenesis. Deletion of residues 63-69 and 70-76 diminished the binding of mutants to alpha(t) while binding to carboxyl-terminally truncated mutants lacking up to 11 amino acid residues was unchanged. In contrast, carboxyl-terminal truncations of P gamma from Delta 1 to Delta 11 resulted in a gradual decrease of its inhibitory activity. Thus, the extreme carboxyl-terminal hydrophobic sequence -Ile(86)-Ile(87) together with 9 adjacent residues provides inhibitory interaction of P gamma with P alpha beta. The carboxyl-terminal G alpha(t)GTP gamma S binding site of P gamma is different from but adjacent to its PDE inhibitory site. During the visual transduction process, G alpha(t)GTP Likely binds to this region of P gamma inducing a displacement of the extreme carboxyl terminus from the inhibitory site on P alpha beta, leading to PDE activation.	UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	PHS HHS [06062] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Artemyev Nikolai O., 1993, Methods (Orlando), V5, P220, DOI 10.1006/meth.1993.1027; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1992, J BIOL CHEM, V267, P19489; CLERC A, 1992, J BIOL CHEM, V267, P6620; COLEMAN DE, 1994, NATURE, V265, P1405; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Maniatis T, 1989, DECONTAMINATION DILU; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPPERT B, 1991, J BIOL CHEM, V266, P16607; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V175, P474; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V204, P288; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1991, J BIOL CHEM, V266, P10711; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539	47	60	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13210	13215		10.1074/jbc.270.22.13210	http://dx.doi.org/10.1074/jbc.270.22.13210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768919	hybrid			2022-12-27	WOS:A1995RB43900042
J	WANG, SP; MILLER, WA				WANG, SP; MILLER, WA			A SEQUENCE LOCATED 4.5 TO 5 KILOBASES FROM THE 5' END OF THE BARLEY YELLOW DWARF VIRUS (PAV) GENOME STRONGLY STIMULATES TRANSLATION OF UNCAPPED MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; EUKARYOTIC MESSENGER-RNAS; POLY(A) TAIL; NUCLEOTIDE-SEQUENCE; PLANT; INITIATION; CAP; INVITRO; PROTEIN; EFFICIENCY	An infectious, in vitro transcript from a full-length cDNA clone of the barley yellow dwarf virus (PAV serotype) genome translated efficiently in a wheat germ translation extract. Deletions in a region that Re call the 3' translational enhancer, located between bases 4,513 and 5,009 in the 5,677-base genome, reduced translation of the 5'-proximal open reading frames from uncapped RNA by at least 30-fold. Deletions elsewhere in all but the 5' end of the genome had no effect on translation. Presence of a m(7)G(5')ppp(5')G cap on the 5' end fully restored translational efficiency of transcripts lacking the 3' translational enhancer. The translation enhancer reduced inhibition of translation by free cap analog, did not affect RNA stability, and did not function in reticulocyte lysates. When placed in the 3'-untranslated region of uncapped mRNA encoding the beta-glucuronidase gene, the translation enhancer stimulated translation more than 80-fold, in the presence of the viral, but not a plasmid-derived, 5' leader. A polyadenylate tail could not substitute for the 3' translation enhancer. These observations provide an extreme example, in terms of distance from the 5' end and level of stimulation, of an mRNA in which a sequence near the 3' end stimulates translation.	IOWA STATE UNIV SCI & TECHNOL,DEPT PLANT PATHOL,AMES,IA 50011; IOWA STATE UNIV SCI & TECHNOL,MOLEC CELLULAR & DEV BIOL PROGRAM,AMES,IA 50011	Iowa State University; Iowa State University								BRAULT V, 1992, P NATL ACAD SCI USA, V89, P2262, DOI 10.1073/pnas.89.6.2262; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHALHOUB BA, 1994, ARCH VIROL, V139, P403, DOI 10.1007/BF01310801; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; DARCY CJ, 1986, MICROBIOL SCI, V3, P309; DAUBERT SD, 1983, METHOD VIROL, P347; DI R, 1993, MOL PLANT MICROBE IN, V6, P444, DOI 10.1094/MPMI-6-444; DINESHKUMAR SP, 1993, PLANT CELL, V5, P679, DOI 10.1105/tpc.5.6.679; DINESHKUMAR SP, 1992, VIROLOGY, V187, P711, DOI 10.1016/0042-6822(92)90474-4; DINESHKUMAR SP, 1993, THESIS IOWA STATE U; DOEL MT, 1976, CELL, V8, P51, DOI 10.1016/0092-8674(76)90184-7; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GALLIE DR, 1991, MOL GEN GENET, V228, P258, DOI 10.1007/BF00282474; GALLIE DR, 1994, GENE, V142, P159, DOI 10.1016/0378-1119(94)90256-9; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KELLY L, 1994, VIROLOGY, V202, P565, DOI 10.1006/viro.1994.1378; KEMPER B, 1977, BIOCHEMISTRY-US, V16, P5676, DOI 10.1021/bi00645a004; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMMEL SA, 1989, NUCLEIC ACIDS RES, V17, P8587; MAYO MA, 1982, J GEN VIROL, V59, P163, DOI 10.1099/0022-1317-59-1-163; MAYO MA, 1991, CLASSIFICATION NOMEN, P400; McBratney S, 1993, CURR OPIN CELL BIOL, V5, P961, DOI 10.1016/0955-0674(93)90077-4; MILLER JS, 1991, J GEN VIROL, V72, P2633, DOI 10.1099/0022-1317-72-11-2633; Miller W. A., 1994, ENCY VIROLOGY, P792; MILLER WA, 1988, NUCLEIC ACIDS RES, V16, P6097, DOI 10.1093/nar/16.13.6097; MILLER WA, 1995, IN PRESS CRIT REV PL; MOSS B, 1977, BIOCHEM BIOPH RES CO, V74, P374, DOI 10.1016/0006-291X(77)90314-X; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; MURPHY JF, 1989, J GEN VIROL, V70, P2253, DOI 10.1099/0022-1317-70-8-2253; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RATHJEN JP, 1994, VIROLOGY, V198, P571; Sambrook J, 1989, MOL CLONING LABORATO; SCHNARE MN, 1982, NUCLEIC ACIDS RES, V10, P3921, DOI 10.1093/nar/10.13.3921; SEELEY KA, 1992, PLANT CELL, V4, P29, DOI 10.1105/tpc.4.1.29; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SILVER SL, 1994, VIROLOGY, V198, P331, DOI 10.1006/viro.1994.1036; SKUZESKI JM, 1990, PLANT MOL BIOL, V15, P65, DOI 10.1007/BF00017725; SLEAT DE, 1992, GENETIC ENG PLANT VI, P55; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TOMASHEVSKAYA OL, 1993, J GEN VIROL, V74, P2717, DOI 10.1099/0022-1317-74-12-2717; TURNER R, 1994, ARCH VIROL, V134, P321, DOI 10.1007/BF01310570; UENG PP, 1992, J GEN VIROL, V73, P487, DOI 10.1099/0022-1317-73-2-487; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5; YOUNG MJ, 1991, VIROLOGY, V180, P372, DOI 10.1016/0042-6822(91)90042-A; YSEBAERT M, 1980, J MOL BIOL, V143, P273, DOI 10.1016/0022-2836(80)90190-4	55	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13446	13452		10.1074/jbc.270.22.13446	http://dx.doi.org/10.1074/jbc.270.22.13446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768947	hybrid			2022-12-27	WOS:A1995RB43900073
J	CHEN, H; SOTTILE, J; OROURKE, KM; DIXIT, VM; MOSHER, DF				CHEN, H; SOTTILE, J; OROURKE, KM; DIXIT, VM; MOSHER, DF			PROPERTIES OF RECOMBINANT MOUSE THROMBOSPONDIN-2 EXPRESSED IN SPODOPTERA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HEPARIN-BINDING PEPTIDES; INDUCED SECRETED PROTEIN; ARG-GLY-ASP; ADHESION RECEPTOR; I REPEATS; ALPHA(V)BETA(5) INTEGRIN; EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; VITRONECTIN	A baculovirus system was used to express full-length recombinant mouse thrombospondin 2 (rTSP2) as a disulfide-bonded homotrimer with an NH2 terminus beginning with Asp(20). rTSP2, like TSP1, was more sensitive to trypsin digestion if depleted of calcium ion. The trypsin digestion pattern of rTSP2 and TSP1 differed in that trypsin cut between the first and second type 1 modules of rTSP2. For bovine aortic endothelial cells adhering to TSP-coated polystyrene plates, reduction after coating caused both TSPs to be much more adhesive; these adhesions were blocked completely by RGDS peptide or antibody to alpha(v) beta(s) integrin. rTSP2 and TSP1 also mediated the adhesion of HT-29 human colon adenocarcinoma cells that carry alpha(v) beta(5) but not alpha(v) beta(3) integrin. Antibody to alpha(v) beta(5) did not inhibit adhesion of HT-29 cells to TSP1 or rTSP2. Rather, adhesion of HT-29 cells was decreased by treatment of TSPs with EDTA, abolished by reduction of the TSPs, and, in the case of rTSP2, blocked by heparin. Adhesion of MG63 cells to both TSPs was complex. Treatment with EDTA enhanced the adhesive activity of rTSP2 but decreased the adhesive activity of TSP1. These results show that TSP2 can be processed and secreted when overexpressed using baculovirus, TSP1 and rTSP2 differ in protease susceptibility in the type 1 module region, and TSP1 and rTSP2 mediate cell adhesion by complex and similar but not identical mechanisms.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA58182] Funding Source: Medline; NHLBI NIH HHS [HL29586, HL49111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049111, P01HL029586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, J CELL SCI, V104, P1061; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LERCH RA, 1993, NUCLEIC ACIDS RES, V21, P1753, DOI 10.1093/nar/21.8.1753; MARGOSSIAN SS, 1981, J BIOL CHEM, V256, P7495; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSHER DF, 1990, ANNU REV MED, V41, P85; MOSHER DF, 1993, ADV MOL CELL BIOL, V6, P115; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P98; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PELLERIN S, 1993, J BIOL CHEM, V268, P4304; PELLERIN S, 1993, J BIOL CHEM, V268, P18810; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1988, CANCER RES, V48, P6785; SCHREINER C, 1991, CLIN EXP METASTAS, V9, P163, DOI 10.1007/BF01756387; SHINGU T, 1993, GENOMICS, V16, P78, DOI 10.1006/geno.1993.1143; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SONCIN F, 1994, J BIOL CHEM, V269, P8999; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	59	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32226	32232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798222				2022-12-27	WOS:A1994PX30400035
J	FAWCETT, TW; SYLVESTER, SL; SARGE, KD; MORIMOTO, RI; HOLBROOK, NJ				FAWCETT, TW; SYLVESTER, SL; SARGE, KD; MORIMOTO, RI; HOLBROOK, NJ			EFFECTS OF NEUROHORMONAL STRESS AND AGING ON THE ACTIVATION OF MAMMALIAN HEAT-SHOCK FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-DEPENDENT RESPONSE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROTEIN INDUCTION; BINDING-ACTIVITY; GENE-EXPRESSION; ADRENAL-CORTEX; FACTOR-II; CELLS; FIBROBLASTS	The mammalian heat shock response has been investigated extensively using tissue culture cells with only a limited amount of information available on animals and intact tissues. The neurohormonal stress response mediated by the hypothalamic-pituitary-adrenal axis leads to the activation of heat shock factor (HSF) in rat adrenal tissue. Here we show through the use of antibodies specific to each member of the HSF family that restraint-induced stress in intact Wistar rats and adrenocorticotropic hormone treatment of hypophysectomized animals leads to the activation of HSF1 monomers to trimers with DNA-binding activity Because HSF1 is also the target factor for metabolic and environmental stress, these data reveal an intersection of pathways leading to HSF1 activation. Comparison of the biochemical properties and levels of HSF1 in the Wistar and Fischer 344 rat strains reveals that HSF1 is constitutively present in an activated DNA-binding state in the adrenals of Fischer 344 rats. During aging, the levels of HSF1 remain constant, yet the transcription factor from aged animals exhibits a decreased ability to bind DNA.	NIA, GENE EXPRESS & AGING SECT, BALTIMORE, MD USA; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Kentucky; Northwestern University								ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANG D, 1991, J BIOL CHEM, V266, P24233; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Baxter JD, 1987, ENDOCRINOL METAB, P511; BLAKE MJ, 1991, P NATL ACAD SCI USA, V88, P9873, DOI 10.1073/pnas.88.21.9873; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIUFFRE KA, 1988, ENDOCRINOLOGY, V122, P306, DOI 10.1210/endo-122-1-306; GOWER DJ, 1989, J NEUROSURG, V70, P605, DOI 10.3171/jns.1989.70.4.0605; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUCE MC, 1992, EXP CELL RES, V202, P9, DOI 10.1016/0014-4827(92)90398-R; MASORO EJ, 1990, HDB BIOL AGING, P72; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PARE WP, 1986, NEUROSCI BIOBEHAV R, V10, P339, DOI 10.1016/0149-7634(86)90017-5; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; UDELSMAN R, 1991, SURGERY, V110, P1125; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WELCH WJ, 1993, PHILOS T ROY SOC B, V339, P327, DOI 10.1098/rstb.1993.0031	35	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32272	32278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798227				2022-12-27	WOS:A1994PX30400041
J	NARANDA, T; MACMILLAN, SE; HERSHEY, JWB				NARANDA, T; MACMILLAN, SE; HERSHEY, JWB			PURIFIED YEAST TRANSLATIONAL INITIATION-FACTOR EIF-3 IS AN RNA-BINDING PROTEIN COMPLEX THAT CONTAINS THE PRT1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; WHEAT-GERM; HELA-CELLS; PURIFICATION; MECHANISM; SYSTEM	Eukaryotic initiation factor-3 (eIF-3) plays a pivotal role in the initiation phase of protein synthesis where it promotes dissociation of 80 S ribosomes into subunits, stabilizes methionyl-tRNA(i) binding to 40 S ribosomal subunits, and is required for mRNA binding. Mammalian eIF-3 is comprised of eight subunits, but no mammalian cDNA encoding these proteins has been cloned and sequenced, nor has the corresponding factor been characterized in yeast. Since many initiation factors are strongly conserved between mammalian and yeast systems, we employed a mammalian assay for initiation, the synthesis of methionyl-puromycin, to detect eIF-3 activity in yeast subcellular fractions. Yeast eIF-3 was purified from the high salt wash of ribosomes by Superose 6 molecular sieve and MonoS ion exchange chromatography. Yeast eIF-3 contains eight subunits with masses of 16, 21, 29, 33, 39, 62, 90, and 135 kilodaltons all of which coelute with an apparent mass of 550 kilodaltons from the Superose 6 column. Immunoblotting shows that the 90-kDa subunit corresponds to the product of the PRT1 gene whose mutant form, prt1-1, exhibits destabilization of methionyl-tRNA(i) binding to 40 S ribosomal subunits. eIF-3, and specifically the 62-kDa subunit, bind to RNA. These biochemical approaches to defining yeast eIF-3 complement genetic methods so far used in characterizing the initiation factors and provide another route to defining the yeast translational machinery.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Benne R, 1979, Methods Enzymol, V60, P15; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; GASIOR E, 1983, METHOD ENZYMOL, V101, P644; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1968, P NATL ACAD SCI USA, V62, P468; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; MOLDAVE K, 1988, GENETICS TRANSLATION, P271; NARANDA T, 1994, J BIOL CHEM, V269, P14465; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; PRAT A, 1990, BIOCHIM BIOPHYS ACTA, V1050, P140, DOI 10.1016/0167-4781(90)90155-U; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SEAL SN, 1983, J BIOL CHEM, V258, P866; SUNDKVIST IC, 1975, J MOL BIOL, V99, P401, DOI 10.1016/S0022-2836(75)80135-5; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	27	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32286	32292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798228				2022-12-27	WOS:A1994PX30400043
J	SHINGU, T; BORNSTEIN, P				SHINGU, T; BORNSTEIN, P			OVERLAPPING EGR-1 AND SP1 SITES FUNCTION IN THE REGULATION OF TRANSCRIPTION OF THE MOUSE THROMBOSPONDIN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; SERUM RESPONSE ELEMENT; GROWTH-FACTOR; C-FOS; REPRESSES TRANSCRIPTION; BINDING-SITE; 1ST INTRON; CHAIN GENE; EXPRESSION	We have evaluated the basis for the constitutive and serum-regulated expression of the mouse thrombospondin (TSP) gene in both transiently and stably transfected NIH-3T3 cells. Experiments with deleted and mutated mouse promoter/CAT constructs and gel mobility assays demonstrated that an Egr-1 binding site in the proximal promoter, flanked by overlapping GC boxes and an adjacent CC-rich region, functioned to positively regulate the constitutive activity of the gene. These motifs, and their cognate transcription factors, appear to act in concert, with partial redundancy, so that discrete mutations were only partially effective in reducing transcriptional activity. The Egr-1 site corresponds in position to an NF-Y binding site which functions synergistically with a distal serum-response element to mediate the serum response of the human TSP1 gene. However, neither the Egr-1 motif nor the surrounding proximal promoter region upstream from the TATA box participates in the serum response of mouse TSP1. These experiments add support to the growing realization that similar physiologic responses of homologous genes in mouse and man need not utilize similarly placed cis-acting elements.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLEZARDIN P, 1993, THROMBOSPONDIN, P41; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JABOKOWITZ R, 1993, J CELL PHYSL, V157, P24; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KITADAI Y, 1993, CELL GROWTH DIFFER, V4, P291; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LAWLER J, 1986, BLOOD, V67, P1197; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LI XY, 1992, J BIOL CHEM, V267, P8984; Liska Deann J., 1992, Gene Expression, V2, P379; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG ZY, 1992, J BIOL CHEM, V267, P21999	45	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32551	32557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798257				2022-12-27	WOS:A1994PX30400079
J	PORTER, DJT; MERRILL, BM; SHORT, SA				PORTER, DJT; MERRILL, BM; SHORT, SA			IDENTIFICATION OF THE ACTIVE-SITE NUCLEOPHILE IN NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE AS GLUTAMIC-ACID-98	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; ESSENTIAL CARBOXYLATE; ESCHERICHIA-COLI; RNA-POLYMERASE; MECHANISM; DEOXYRIBOSYLTRANSFERASE; ALPHA-2-MACROGLOBULIN; GALACTOSIDASE; FRAGMENTATION; GLYCOSIDASE	2'-FIuoro-2'-deoxyarabinonucleosides are time-dependent inhibitors of nucleoside 2-deoxyribosyltransferase. 2,6-Diamino-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-9H-purine (dFDAP) inhibited the enzyme by formation of a primary complex (K-d = 140 mu M) that isomerized to a secondary complex with a first-order rate constant of 0.2 min(-1). Inhibited enzyme contained stoichiometric amounts of covalently bound 2'-fluoro-2'-deoxyarabinosyl moiety, recovered less than 5% of its activity after storage for a week at 5 degrees C, but regained over 70% of the lost activity by treatment with 600 mu m Ade. 6-Amino-9-(2'-deoxy-2'-fluoro-beta-D-arabinosyl)-9H-purine (dFAdo) was a product of the reactivation reaction. Proteolysis of inhibited enzyme identified a modified fragment that spanned residues 82-107 which could not be sequenced past Gly-96. dFDAP inhibited enzyme and enzyme reacted with normal substrates (i.e. dThd and dAdo) were hydrolyzed between Met-97 and Glu-98 by 0.1 M NaOH, These findings and model studies on the base lability of peptides containing glutamyl esters suggested that the gamma-carboxylate of Glu-98 was esterfied during catalysis. The role of Glu-98 was confirmed by changing this residue to alanine. The spe cific activity of wild-type enzyme was 3 orders of magnitude greater than that of the mutant enzyme. Collectively, chemical modification and mutagenesis studies have identified Glu-98 as the active site nucleophile of nucleoside 2-deoxyribosyltransferase.	WELLCOME RES LABS,DIV BIOANALYT SCI,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BATTERSBY A, 1961, J CHEM SOC, P524, DOI 10.1039/jr9610000524; BATTERSBY AR, 1955, J CHEM SOC, P259, DOI 10.1039/jr9550000259; BATTERSBY AR, 1956, J CHEM SOC, P2076, DOI 10.1039/jr9560002076; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDINAUD R, 1979, BIOCHIM BIOPHYS ACTA, V568, P339, DOI 10.1016/0005-2744(79)90301-2; COOK WJ, 1990, J BIOL CHEM, V265, P2682; DANZIN C, 1976, EUR J BIOCHEM, V62, P365, DOI 10.1111/j.1432-1033.1976.tb10168.x; DANZIN C, 1974, EUR J BIOCHEM, V48, P255, DOI 10.1111/j.1432-1033.1974.tb03763.x; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GORSKI JP, 1980, J BIOL CHEM, V255, P25; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOLGUIN J, 1975, EUR J BIOCHEM, V54, P515, DOI 10.1111/j.1432-1033.1975.tb04164.x; HOLGUINH.J, 1972, FEBS LETT, V20, P171, DOI 10.1016/0014-5793(72)80785-3; HOWARD JB, 1986, J BIOL CHEM, V261, P60; HOWARD JB, 1980, J BIOL CHEM, V255, P7082; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HOWARD JB, 1980, J BIOL CHEM, V265, P3820; HUANG MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P133, DOI 10.1016/0003-9861(83)90510-6; HUANG MC, 1981, BIOCHEM PHARMACOL, V30, P2663, DOI 10.1016/0006-2952(81)90535-9; Jencks W. P., 1973, ENZYMES, V9, P483; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V534, P102; MIAO SC, BIOCHEMISTRY-US, V33, P7027; Miller J. H., 1972, EXPT MOL GENETICS, P433; PORTER DJT, 1995, J BIOL CHEM, V270, P15557, DOI 10.1074/jbc.270.26.15557; QUARONI A, 1976, J BIOL CHEM, V251, P3250; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSH AH, 1958, J BIOL CHEM, V233, P261; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9978; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TULL D, 1991, J BIOL CHEM, V266, P15621; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2622	40	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15551	15556		10.1074/jbc.270.26.15551	http://dx.doi.org/10.1074/jbc.270.26.15551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797550	hybrid			2022-12-27	WOS:A1995RG53800020
J	VALVERDE, V; DELMAS, P; KAGHAD, M; LOISON, G; JARA, P				VALVERDE, V; DELMAS, P; KAGHAD, M; LOISON, G; JARA, P			SECRETION AND MATURATION STUDY OF ENDOTHIAPEPSIN IN SACCHAROMYCES-CEREVISIAE - A FIRST STEP TOWARD IMPROVING ITS SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ENCODING ENDOTHIAPEPSIN; SITE-DIRECTED MUTAGENESIS; CRYPHONECTRIA-PARASITICA; ASPARTIC PROTEINASE; YEAST; CHYMOSIN; TRANSFORMATION; PROPEPTIDE; MUTATION; PROTEASE	The gene encoding endothiapepsin (EAP), an extracellular aspartic proteinase from the filamentous ascomycete Cryphonectria parasitica, was expressed into Saccharomyces cerevisiae, Efficient secretion of an active and correctly processed enzyme was achieved when expressing the entire cDNA encoding prepro-EAP under the control of the galactose inducible GRAP1 yeast promoter, Since three independent, site-directed mutations of EAP, including the substitution of an aspartyl catalytic residue, resulted in the intracellular accumulation of zymogen forms, we assumed that the EAP propeptide was autocatalytically processed. As a prerequisite to further improve the specificity of EAP, we therefore attempted to bypass this self-processing step in three different ways: 1) introduction of a Kex2-like recognition site between the pro and the mature part, 2) deletion of the prosequence (pre-EAP), and 3) co-expression in trans of the pre-EAP with its preprosequence. No improvement in the secretion of mutant enzymes was obtained in any of these experiments. As an alternative, we finally replaced the EAP processing site by the chymosin cleavage sequence of kappa-casein, Such a modification remained efficient in directing the secretion of active EAP only when a putative alpha-helix structural motif was conserved at the C terminus of the pro region.	SANOFI RECH, CTR LABEGE, LABEGE INNOPOLE, F-31676 LABEGE, FRANCE	Sanofi-Aventis								AIKAWA J, 1991, ADV EXP MED BIOL, V306, P233; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CHOI GH, 1993, GENE, V125, P135, DOI 10.1016/0378-1119(93)90320-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIRAMATSU R, 1989, J BIOL CHEM, V264, P16862; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMSA M, 1990, J IND MICROBIOL, V5, P229, DOI 10.1007/BF01569680; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; ORPRAYOON P, 1991, BIOCHEM SOC T, V19, pS265, DOI 10.1042/bst019265s; PITTS JE, 1992, SCAND J CLIN LAB INV, V52, P39, DOI 10.3109/00365519209104653; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RAZANAMPARANY V, 1992, CURR GENET, V21, P455, DOI 10.1007/BF00351655; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINTANI T, 1994, BBA-PROTEIN STRUCT M, V1204, P257, DOI 10.1016/0167-4838(94)90016-7; SUZUKI J, 1990, PROTEIN ENG, V4, P69, DOI 10.1093/protein/4.1.69; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	28	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15821	15826		10.1074/jbc.270.26.15821	http://dx.doi.org/10.1074/jbc.270.26.15821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797585	hybrid			2022-12-27	WOS:A1995RG53800058
J	ROSSIER, MF; APTEL, HBC; PYTHON, CP; BURNAY, MM; VALLOTTON, MB; CAPPONI, AM				ROSSIER, MF; APTEL, HBC; PYTHON, CP; BURNAY, MM; VALLOTTON, MB; CAPPONI, AM			INHIBITION OF LOW-THRESHOLD CALCIUM CHANNELS BY ANGIOTENSIN-II IN ADRENAL GLOMERULOSA CELLS THROUGH ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE; RAT; K+; CURRENTS; STEROIDOGENESIS; MODULATION; GENERATION; RESPONSES	In adrenal glomerulosa cells, low threshold voltage-activated (T-type) calcium channels play a crucial role in coupling physiological variations of extracellular potassium to aldosterone biosynthesis. Angiotensin II markedly reduced the activity of these channels by shifting their activation curve toward positive voltage values. This inhibition of the channels resulted in a marked decrease of the cytosolic free calcium concentration maintained by potassium. This effect was abolished by losartan, a specific antagonist of the angiotensin II AT(1) receptor. Hormone action on T-type channels appeared to be mediated by protein kinase C because 1) it was mimicked by phorbol ester and diacylglycerol, and 2) it was significantly reduced by decreasing protein kinase C activity with specific inhibitors such as chelerythrine chloride or a pseudosubstrate of the enzyme, as well as by protein kinase C down-regulation. Similarly, protein kinase C activation reduced the cytosolic calcium response to potassium and the steroidogenic action of this agonist. Low threshold T-type calcium channels therefore appear as potential sites for the modulation of steroidogenesis by protein kinase C in adrenal glomerulosa cells.			ROSSIER, MF (corresponding author), UNIV HOSP GENEVA, DIV ENDOCRINOL, CH-1211 GENEVA 14, SWITZERLAND.		Rossier, Michel/AAW-2895-2021					BALLA T, 1991, MOL PHARMACOL, V40, P401; BALLA T, 1991, BIOCHEM J, V273, P399, DOI 10.1042/bj2730399; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNEIS U, 1991, AM J PHYSIOL, V260, pE772, DOI 10.1152/ajpendo.1991.260.5.E772; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1987, BIOCHEM J, V247, P335, DOI 10.1042/bj2470335; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HESCHELER J, 1988, EMBO J, V7, P619, DOI 10.1002/j.1460-2075.1988.tb02855.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KANAZIRSKA MV, 1992, AM J PHYSIOL, V263, pE760, DOI 10.1152/ajpendo.1992.263.4.E760; LANG U, 1991, METH SURV I, V21, P115; LOBO MV, 1991, J STEROID BIOCHEM, V39, P323, DOI 10.1016/0960-0760(91)90042-4; LU HK, 1994, AM J PHYSIOL, V267, pF183, DOI 10.1152/ajprenal.1994.267.1.F183; MATSUNAGA H, 1987, BIOCHEM BIOPH RES CO, V149, P1049, DOI 10.1016/0006-291X(87)90514-6; MCCARTHY RT, 1993, P NATL ACAD SCI USA, V90, P3260, DOI 10.1073/pnas.90.8.3260; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; QUINN SJ, 1987, ENDOCRINOLOGY, V120, P903, DOI 10.1210/endo-120-3-903; QUINN SJ, 1987, ENDOCRINOLOGY, V120, P1581, DOI 10.1210/endo-120-4-1581; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; ROSSIER MF, 1993, BIOCHEM J, V296, P309, DOI 10.1042/bj2960309; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353	25	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15137	15142		10.1074/jbc.270.25.15137	http://dx.doi.org/10.1074/jbc.270.25.15137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797497	hybrid			2022-12-27	WOS:A1995RE66600045
J	SCHUMACHER, C; KNUDSEN, BS; OHUCHI, T; DIFIORE, PP; GLASSMAN, RH; HANAFUSA, H				SCHUMACHER, C; KNUDSEN, BS; OHUCHI, T; DIFIORE, PP; GLASSMAN, RH; HANAFUSA, H			THE SH3 DOMAIN OF CRK BINDS SPECIFICALLY TO A CONSERVED PROLINE-RICH MOTIF IN EPS15 AND EPS15R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; CDNA; RECEPTOR; SEQUENCE; PRODUCT; SEARCH; REGION; GENE	The Crk protein belongs to the family of proteins consisting of mainly Src homology 2 and 3 (SH2 and SH3) domains. These proteins are thought to transduce signals from tyrosine kinases to downstream effecters. In order to understand the specificity and effector function of the SH3 domain of Crk, we screened an expression library for binding proteins. We isolated Eps15, a substrate of the epidermal growth factor receptor (EGFR) tyrosine kinase, and Eps15R, a novel protein with high sequence homology to the carboxyl-terminal domain of Eps15. Antibodies raised against a fragment of the Eps15R gene product immunoprecipitated a protein of 145 kDa, Eps15 and Eps15R bound specifically to the amino-terminal SH3 domain of Crk and coprecipitated equivalently with both c-Crk and v-Crk from cell lysates. The amino acid sequences of Eps15 and Eps15R featured several proline-rich regions as putative binding motifs for SH3 domains. In both Eps15 and Eps15R, we identified one proline-rich motif which accounts for their interaction with the Crk SH3 domain. Each binding motif contains the sequence P-X-L-P-X-K, an amino acid stretch that is highly conserved in all proteins known to interact specifically with the first SH3 domain of Crk. Furthermore, we found that immunoprecipitates of activated EGFR-kinase stably bound in vitro-translated Eps15 only in the presence of in vitro-translated v-Crk. Crk might therefore be involved in Eps15-mediated signal transduction through the EGFR.	ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA; NCI, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA09673, CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BRUNS GA, 1993, GENOME PRIORITY REPO, V1, P143; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COWBURN D, 1994, NAT STRUCT BIOL, V1, P489, DOI 10.1038/nsb0894-489; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METHODS ENZ; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KNUDSEN BS, 1995, IN PRESS EMBO J; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEADER DP, 1986, DNA-J MOLEC CELL BIO, V5, P235, DOI 10.1089/dna.1986.5.235; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MITELMAN F, 1993, GENOME PRIORITY REPO, V1, P700; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WONG WT, 1994, ONCOGENE, V9, P1591; WU X, 1995, NAT STRUCT BIOL, V3, P215; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15341	15347		10.1074/jbc.270.25.15341	http://dx.doi.org/10.1074/jbc.270.25.15341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797522	hybrid			2022-12-27	WOS:A1995RE66600074
J	KRAMER, RM; ROBERTS, EF; HYSLOP, PA; UTTERBACK, BG; HUI, KY; JAKUBOWSKI, JA				KRAMER, RM; ROBERTS, EF; HYSLOP, PA; UTTERBACK, BG; HUI, KY; JAKUBOWSKI, JA			DIFFERENTIAL ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE A(2) (CPLA(2)) BY THROMBIN AND THROMBIN RECEPTOR AGONIST PEPTIDE IN HUMAN PLATELETS - EVIDENCE FOR ACTIVATION OF CPLA(2) INDEPENDENT OF THE MITOGEN-ACTIVATED PROTEIN-KINASES ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PROTEOLYTIC MECHANISM; ARACHIDONIC-ACID; PHOSPHORYLATION; HYDROLYSIS; DESENSITIZATION; IDENTIFICATION; TRANSLOCATION; MOBILIZATION; EXPRESSION	The thrombin receptor agonist peptide SFLLRN was less effective than thrombin in eliciting the liberation of arachidonic acid and the generation of thromboxane A(2) by human platelets, We found that while SFLLRN evokes an initial transient increase in cytosolic free calcium concentration ([Ca2+](i)) of similar magnitude as that caused by thrombin, the SFLLRN-induced elevation of [Ca2+](i) declines more rapidly to near resting levels than that evoked by thrombin, suggesting that disparate levels of [Ca2+](i) may contribute to the attenuated arachidonic acid release. Furthermore, we observed that SFLLRN is less effective than thrombin in mediating the ''activating'' phosphorylation of cytosolic phospholipase A(2) (cPLA(2)). Both thrombin and SFLLRN rapidly and transiently activated kinases that phosphorylate the 21-residue synthetic peptide Thr(669) derived from the epidermal growth factor receptor, but the maximal activation of proline-directed kinases by SFLLRN was less pronounced than that by thrombin. MonoQ chromatography and immunoblot analysis of extracts from stimulated platelets revealed that while thrombin induced a prominent activation of the mitogen-activated protein kinases ERK1 and ERK2, SFLLRN completely failed to do so. On the other hand, SFLLRN, like thrombin, stimulated the activity of a proline-directed kinase distinct from ERK1/2, but the activation of this kinase was less pronounced following stimulation of platelets with SFLLRN compared with thrombin. We conclude 1) that the partial activation of cPLA(2) and the subsequent attenuated mobilization of arachidonic acid in response to SFLLRN may be the consequence of a less prolonged elevation of [Ca2+](i) and insufficient activation of proline-directed kinase(s) by SFLLRN and 2) that the ability of SFLLRN to mediate the activating phosphorylation of cPLA(2) in the absence of ERK1/2 stimulation suggests that, at least in human platelets, proline-directed kinases other than ERK1/2 may phosphorylate and activate cPLA(2).			KRAMER, RM (corresponding author), LILLY RES LABS, CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA.							AHN NG, 1990, J BIOL CHEM, V265, P11487; BARTHA K, 1993, J BIOL CHEM, V268, P421; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JAKUBOWSKI JA, 1994, PROSTAGLANDINS, V47, P189, DOI 10.1016/0090-6980(94)90060-4; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KINLOUGHRATHBONE RL, 1993, THROMB HAEMOSTASIS, V70, P1019; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KROLL MH, 1989, BLOOD, V74, P1181; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; POLLOCK WK, 1986, BIOCHEM BIOPH RES CO, V139, P308, DOI 10.1016/S0006-291X(86)80114-0; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RITTENHOUSESIMMONS S, 1977, BIOCHIM BIOPHYS ACTA, V488, P370, DOI 10.1016/0005-2760(77)90196-5; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHRAMEK H, 1994, KIDNEY INT, V46, P1644, DOI 10.1038/ki.1994.464; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; THOMPSON CB, 1983, J LAB CLIN MED, V101, P205; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XU XX, 1994, J BIOL CHEM, V269, P31693	44	115	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14816	14823		10.1074/jbc.270.24.14816	http://dx.doi.org/10.1074/jbc.270.24.14816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782348	hybrid			2022-12-27	WOS:A1995RD45500086
J	MAKKINJE, A; XIONG, HS; LI, M; DAMUNI, Z				MAKKINJE, A; XIONG, HS; LI, M; DAMUNI, Z			PHOSPHORYLATION OF EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4E BY INSULIN-STIMULATED PROTAMINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; TUMOR-NECROSIS-FACTOR; BOVINE KIDNEY CORTEX; MESSENGER-RNA; TRANSLATIONAL CONTROL; PHORBOL ESTERS; EIF-4F; SERINE; CELLS; PHOSPHATASE-2A	Insulin-stimulated protamine kinase (cPK) and protein kinase C (PKC) phosphorylated eukaryotic protein synthesis initiation factor 4E (eIF-4E) on serine and threonine residues located on an identical tryptic fragment as judged by two-dimensional phosphopeptide mapping. With cPK and PKC, the apparent K-m for eIF-4E was about 1.2 and 50 mu M, respectively. Relative to recombinant human eIF-4E, cPK exhibited about 100% and less than or equal to 5% activity with eIF-4E(S209A), and eIF-4E(T210A) respectively, and eIF-4E(S209A) was phosphorylated exclusively on threonines. Bovine kidney eIF 4E enhanced up to 1.8-fold globin synthesis in m(7)GTP-Sepharose-treated reticulocyte lysates. In contrast, following incubation with cPK, these eIF-4E preparations stimulated globin synthesis up to 6-fold. Compared to the dephosphorylation of the cPK-modified serine on elF-4E, reticulocyte lysates and highly purified protein phosphatase 2A exhibited marked preference for the cPK-modified threonine. The results indicate that cPK phosphorylates eIF-4E on Ser(209) and Thr(210), that the hydroxyl group or phosphorylation of Thr(210) is necessary for cPK to act on Ser(209), and that Ser(209) phosphorylation activates reticulocyte globin synthesis. The results suggest that cPK could contribute to the insulin-stimulated phosphorylation of eIF-4E, but that protein phosphatase 2A may confer the site specificity of this response.	PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; AMICK GD, 1992, BIOCHEM J, V297, P1019; AMICK GD, 1993, THESIS U S CAROLINA; BRADFORD M, 1976, ANAL BIOCHEM, V72, P579; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BU X, 1993, J BIOL CHEM, V268, P4975; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDRICKSON RM, 1991, MOL CELL BIOL, V12, P1239; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HAAS DW, 1992, SEC MESS PHOSPHOPROT, V14, P55; HAAS DW, 1993, FEBS LETT, V283, P219; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OCHMAN H, 1988, GENETICS, V120, P621; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RUAZON PT, 1988, J BIOL CHEM, V264, P2773; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; Sambrook J, 1989, MOL CLONING LABORATO; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; WEBB NR, 1984, BIOCHEMISTRY-US, V17, P177; XU B, 1991, FEBS LETT, V283, P219	45	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14824	14828		10.1074/jbc.270.24.14824	http://dx.doi.org/10.1074/jbc.270.24.14824			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782349	hybrid			2022-12-27	WOS:A1995RD45500087
J	RICHARDS, SA; LOUNSBURY, KM; MACARA, IG				RICHARDS, SA; LOUNSBURY, KM; MACARA, IG			THE C-TERMINUS OF THE NUCLEAR RAN/TC4 GTPASE STABILIZES THE GDP-BOUND STATE AND MEDIATES INTERACTIONS WITH RCC1, RAN-GAP, AND HTF9A/RANBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; BINDING PROTEIN; MUTANT; MAINTENANCE; MITOSIS; GENES; PRP20	Ran/TC4 is a member of the Ras superfamily of GTPases. It is unusual in being predominantly nuclear and because it possesses an acidic -DEDDDL sequence instead of a consensus prenylation domain at the C terminus. Ran is required for nuclear protein import rind cell cycle progression, and has been implicated in mRNA processing and export and DNA replication. The inhibition of cell cycle progression by a dominant gain-of-function mutant of Ran has been shown to be abrogated by removal of the -DEDDDL sequence, suggesting that this domain is essential for Ran function. We demonstrate here that the -DEDDDL sequence stabilizes GDP ; binding to Ran, and that the domain is required for high affinity interaction with a Ran-binding protein, HTF9A/RanBP1. RTFSA functions as a co-stimulator of Ran-GAP (GTPase activating protein) activity on wild-type Ran, but in the absence of the acidic C terminus of Ran, HTF9A behaves as a Ran-GAP inhibitor. An antibody directed against the C-terminal region preferentially recognizes the GTP;bound form of Ran, suggesting that this domain undergoes a nucleotide-dependent conformational change. The results suggest that the acidic C-terminal domain is important in modulating the interaction of Ran with regulatory factors, and implicate Iran-binding proteins in mediating the effects of Ran on cell cycle progression.			RICHARDS, SA (corresponding author), UNIV VERMONT, COLL MED, DEPT PATHOL, MED ALUMNI BLDG, BURLINGTON, VT 05405 USA.				NIEHS NIH HHS [EST3207122] Funding Source: Medline; NIGMS NIH HHS [GM50526] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACH RA, 1994, P NATL ACAD SCI USA, V91, P5863, DOI 10.1073/pnas.91.13.5863; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Harlow E., 1988, ANTIBODIES LABORATOR, P79; JOHN J, 1989, J BIOL CHEM, V264, P13086; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	30	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14405	14411		10.1074/jbc.270.24.14405	http://dx.doi.org/10.1074/jbc.270.24.14405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782302	hybrid			2022-12-27	WOS:A1995RD45500029
J	SEKIYA, F; YAMASHITA, T; ATODA, H; KOMIYAMA, Y; MORITA, T				SEKIYA, F; YAMASHITA, T; ATODA, H; KOMIYAMA, Y; MORITA, T			REGULATION OF THE TERTIARY STRUCTURE AND FUNCTION OF COAGULATION-FACTOR-IX BY MAGNESIUM(II) IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; GAMMA-CARBOXYGLUTAMIC ACID; PHOSPHOLIPID-BINDING SITE; BOVINE FACTOR-IX; BLOOD-COAGULATION; FACTOR-XIA; FACTOR-X; CONFORMATIONAL TRANSITIONS; PROTHROMBIN FRAGMENT-1; CHRISTMAS FACTOR	The indispensable role of Ca2+ ions in the maintenance of the functional tertiary structures of vitamin K-dependent coagulation factors has been definitively established but the participation of Mg2+ ions, another alkaline earth metal that is present abundantly in blood plasma, in such a process is not yet understood. We show here that the Ca2+-stabilized conformation of coagulation factor IX undergoes a further conformational change upon binding of Mg2+ ions using three independent structural probes, The probes we used were (i) IX/X-bp, a snake venom anticoagulant that recognizes the Gla domains in coagulation factors IX and X, (ii) conformation-specific polyclonal antibodies against bovine factor IX, and (iii) monoclonal antibodies against the Gla domain of human factor IX The binding of all these probes had an absolute requirement for Ca2+ ions, and Mg2+ ions alone were ineffective. However, when added together with Ca2+ ions, Mg2+ ions at physiological concentrations greatly augmented the binding of these probes to factor IX; the required concentration of Ca2+ ions was much reduced, and the affinity of each probe for factor IX was increased even in the presence of an excess of Ca2+ ions, These results suggest the presence of a Mg2+-specific binding site that does not interact with with Ca2+ ions in factor IX, Furthermore, Mg2+ ions potentiated the susceptibility of factor IX to activation by factor XIa, concomitant with their effect on the conformation. Similarly, the required Ca2+ concentration was reduced by Mg2+ ions, and the rate of conversion to factor IXa was increased by Mg2+ ions in the presence of an excess of Ca2+ ions. At a saturating concentration of Ca2+ ions (5 mM), addition of 1 mM Mg2+ reduced the apparent K-m value for factor IX from 0.31 to 0.18 mu M, and in the presence of a physiological concentration of Ca2+ ions (1 mM), the reduction in K-m by Mg2+ ions was far more striking (from 0.91 to 0.24 mu M). The apparent V-max values were hardly affected by Mg2+ ions, Our present data reveal a hitherto novel physiological role of the Mg2+ ions in plasma. Not only Ca2+ ions but also Mg2+ ions are important regulators of the stabilization of the native conformation of factor IX as well as of its efficient activation.	MEIJI COLL PHARM,DEPT BIOCHEM,TANASHI,TOKYO 188,JAPAN; KANSAI MED UNIV,DEPT CLIN SCI,MORIGUCHI,OSAKA 570,JAPAN; KANSAI MED UNIV,MED LAB,MORIGUCHI,OSAKA 570,JAPAN	Meiji Pharmaceutical University; Kansai Medical University; Kansai Medical University								AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; ASAKAI R, 1989, P NATL ACAD SCI USA, V86, P7667, DOI 10.1073/pnas.86.20.7667; ATODA H, 1994, EUR J BIOCHEM, V224, P703, DOI 10.1111/j.1432-1033.1994.t01-1-00703.x; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; BYRNE R, 1980, J BIOL CHEM, V255, P1430; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HOAK JC, 1966, LANCET, V2, P884; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KOMIYAMA Y, 1989, THROMB RES, V55, P527, DOI 10.1016/0049-3848(89)90385-X; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; LIEBMAN HA, 1993, EUR J BIOCHEM, V212, P339, DOI 10.1111/j.1432-1033.1993.tb17667.x; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1980, ANAL BIOCHEM, V105, P340; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PATERSON CR, 1983, ESSENTIALS HUMAN BIO, P237; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; ROSENTHAL RL, 1953, P SOC EXP BIOL MED, V82, P171; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SPERLING R, 1978, J BIOL CHEM, V253, P3898; THOMPSON AR, 1986, BLOOD, V67, P565; VALCARCE C, 1993, METHOD ENZYMOL, V222, P416; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343; WUEPPER KD, 1975, J CLIN INVEST, V56, P1663, DOI 10.1172/JCI108248; ZUR M, 1987, HAEMOSTASIS THROMBOS, P148	39	43	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14325	14331		10.1074/jbc.270.24.14325	http://dx.doi.org/10.1074/jbc.270.24.14325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782291	hybrid			2022-12-27	WOS:A1995RD45500017
J	SLEPAK, VZ; ARTEMYEV, NO; ZHU, Y; DUMKE, CL; SABACAN, L; SONDEK, J; HAMM, HE; BOWNDS, MD; ARSHAVSKY, VY				SLEPAK, VZ; ARTEMYEV, NO; ZHU, Y; DUMKE, CL; SABACAN, L; SONDEK, J; HAMM, HE; BOWNDS, MD; ARSHAVSKY, VY			AN EFFECTOR SITE THAT STIMULATES G-PROTEIN GTPASE IN PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PHOSPHODIESTERASE GAMMA-SUBUNIT; CYCLIC-GMP PHOSPHODIESTERASE; SURFACE-PLASMON RESONANCE; BOVINE RETINAL RODS; CGMP-PHOSPHODIESTERASE; INHIBITORY SUBUNIT; SYNTHETIC PEPTIDES; TRANSDUCIN GTPASE; ALPHA-SUBUNIT	Heterotrimeric G-proteins mediate between receptors and effecters, acting as molecular clocks. G-protein interactions with activated receptors catalyze the replacement of GDP bound to the alpha-subunit with GTP. alpha-Subunits then modulate the activity of downstream effecters until the bound GTP is hydrolyzed. In several signal transduction pathways, including the cGMP cascade of photorecepter cells, the relatively slow GTPase activity of heterotrimeric G-proteins can be significantly accelerated when they are complexed with correspending effecters. In the phototransduction cascade the GTPase activity of photoreceptor G-protein, transducin, is substantially accelerated in a complex with its effector, cGMP phosphodiesterase. Here we characterize the stimulation of transducin GTPase by a set of 23 mutant phosphodiesterase gamma-subunits (PDE(gamma)) containing single alanine substitutions within a stretch of the 25 C-terminal amino acid residues known to be primarily responsible for the GTPase regulation. The substitution of tryptophan at position 70 completely abolished the acceleration of GTP hydrolysis by transducin in a complex with this mutant. This mutation also resulted in a reduction of PDE(gamma) affinity for transducin, but did not affect PDE(gamma) interactions with the phosphodiesterase catalytic subunits. Single substitutions of 7 other hydrophobic amino acids resulted in a 50-70% reduction in the ability of PDE(gamma) to stimulate transducin GTPase, while substitutions of charged and polar amino acids had little or no effect. These observations suggest that the role of PDE(gamma) in activation of the transducin GTPase rate may be based on multiple hydrophobic interactions between these molecules.	CALTECH,DEPT BIOL,PASADENA,CA 91125; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	California Institute of Technology; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yale University			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854; Sondek, John/0000-0002-1127-8310	NATIONAL EYE INSTITUTE [R01EY010336, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY-00463, EY-10336, EY-06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1994, NAT STRUCT BIOL, V1, P752, DOI 10.1038/nsb1194-752; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Gibbs C.S., 1991, METHODS COMPANION ME, V3, P165; GODCHAUX W, 1979, J BIOL CHEM, V54, P7874; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7	39	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14319	14324		10.1074/jbc.270.24.14319	http://dx.doi.org/10.1074/jbc.270.24.14319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782290	hybrid			2022-12-27	WOS:A1995RD45500016
J	COLEMAN, RA; PUGH, BF				COLEMAN, RA; PUGH, BF			EVIDENCE FOR FUNCTIONAL BINDING AND STABLE SLIDING OF THE TATA-BINDING PROTEIN ON NONSPECIFIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; MINOR-GROOVE; ESCHERICHIA-COLI; TFIID BINDS; BOX COMPLEX; ACTIVATION; YEAST; MECHANISM	The TATA binding protein (TBP) is required at RNA polymerase I, II, and III promoters that either contain or lack a TATA box, In an effort to understand how TBP might function at such a wide variety of promoters, we have investigated the specific and nonspecific DNA binding properties of human TBP, We show that TBP has less than a 10(3)-fold preference for binding a TATA box (TATAAAAG) than for an average nonspecific site, In contrast to TBP, which binds to the minor groove of DNA, major groove binding proteins typically display binding specificities in the range of 10(6). Once TBP is bound to DNA, whether it be a TATA box or nonspecific DNA, binding is quite stable with a t(1/2) of dissociation in the range of 20-60 min for a 300-base pair DNA fragment, In this binding state, TBP appears to be capable of stable one-dimensional sliding along the DNA. Sequence-specific binding can be accounted for, in part, by different rates of sliding, Additional findings demonstrate that specific and nonspecific DNA impart upon TBP an enormous and equivalent degree of thermal stability, suggesting that the TBP . DNA interface on nonspecific DNA is not radically different from that on TATA. Consistent with this notion, we find that nonspecifically bound TBP is competent in establishing pol II transcription complexes on DNA. Together, these finding provide a plausible mechanistic explanation for the ability of TBP to function at TATA-containing and TATA-less promoters.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; ARMALEO D, 1985, J BIOL CHEM, V260, P6169; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BURLEY SK, 1994, 1994 FASEB SUMM RES; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUGH BF, 1959, IN VITRO TRANSCRIPTI, V37, P359; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHINDO H, 1993, BIOL PHARM BULL, V16, P437; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	45	113	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13850	13859		10.1074/jbc.270.23.13850	http://dx.doi.org/10.1074/jbc.270.23.13850			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775443	hybrid			2022-12-27	WOS:A1995RC44800042
J	JUNG, HI; KIM, SI; HA, KS; JOE, CO; KANG, KW				JUNG, HI; KIM, SI; HA, KS; JOE, CO; KANG, KW			ISOLATION AND CHARACTERIZATION OF GUAMERIN, A NEW HUMAN-LEUKOCYTE ELASTASE INHIBITOR FROM HIRUDO-NIPPONIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE SITE; FACTOR-XA; NEUTRAL PROTEINASES; CATHEPSIN-G; ANTISTASIN; DEGRADATION; EMPHYSEMA	A new human leukocyte elastase inhibitor was extracted and purified from a Korean native leech Hirudo nipponia. The inhibitor, called guamerin, has a molecular weight of 6,110 and shows inhibition constant (K-i) of 8.1 x 10(-14) M. It is stable at a wide range of pH from 1 to 11 and heat-stable up to 90 degrees C. The complete amino acid sequence of guamerin reveals a cysteine-rich polypeptide of 57 amino acid residues that shows no similarity to any known elastase inhibitors but has 51% sequence homology with hirustasin, Guamerin has identical spacing of 10 cysteine residues as antistasin-type serine proteinase inhibitors, but the P1 reactive site residue is Met(36) instead of Arg, The neighboring sequence of the reactive site consists primarily of hydrophobic amino acid residues, Based on examinations of the target proteinases and the reactive site specificity, guamerin is a new low molecular weight protein that inhibits elastases.	KOREA ADV INST SCI & TECHNOL,DEPT SCI BIOL,TAEJON 305701,SOUTH KOREA; KOREA BASIC SCI CTR,BIOMOLEC ANAL GRP,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Korea Basic Science Institute (KBSI)				Ha, Kwon-Soo/0000-0002-4219-1787				BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P28; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; DUNWIDDIE CT, 1992, ARCH BIOCHEM BIOPHYS, V294, P647, DOI 10.1016/0003-9861(92)90737-H; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FRITZ H, 1978, AGENTS ACTIONS, V8, P57, DOI 10.1007/BF01972403; GLINSKI W, 1980, J INVEST DERMATOL, V75, P481, DOI 10.1111/1523-1747.ep12524244; HERMANN S, 1987, ANAL BIOCHEM, V166, P368; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1369, DOI 10.1515/bchm2.1981.362.2.1369; HOFMANN KJ, 1992, BIOCHEM J, V287, P943, DOI 10.1042/bj2870943; HONG SJ, 1993, KOREAN J ZOOL, V36, P588; JANOFF A, 1980, AM REV RESPIR DIS, V121, P1025; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASZLO L, 1981, METHOD ENZYMOL, V80, P756; LUI TY, 1971, J BIOL CHEM, V246, P2842; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MICHAEL K, 1991, MASS SPECTROM REV, V10, P335; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NEURATH H, 1983, SCIENCE, V224, P350; ODANI S, 1978, J BIOCHEM-TOKYO, V83, P737, DOI 10.1093/oxfordjournals.jbchem.a131967; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; RHODES MB, 1960, J BIOL CHEM, V235, P1686; ROBERT CT, 1986, P NATL ACAD SCI USA, V83, P6692; SCHALWIJK J, 1986, BRIT J DERMATOL, V1512, P181; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SNIDER GL, 1981, MED CLIN N AM, V65, P647, DOI 10.1016/S0025-7125(16)31517-6; SOLLER C, 1944, EUR J BIOCHEM, V219, P937; TARR GE, 1986, MICROCHARACTERIZATIO, P155; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	33	64	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13879	13884		10.1074/jbc.270.23.13879	http://dx.doi.org/10.1074/jbc.270.23.13879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775446	hybrid, Green Accepted			2022-12-27	WOS:A1995RC44800045
J	MAO, F; RECHTIN, TM; JONES, R; CANTU, AA; ANDERSON, LS; RADOMINSKA, A; MOYER, MP; DRAKE, RR				MAO, F; RECHTIN, TM; JONES, R; CANTU, AA; ANDERSON, LS; RADOMINSKA, A; MOYER, MP; DRAKE, RR			SYNTHESIS OF A PHOTOAFFINITY ANALOG OF 3'-AZIDOTHYMIDINE, 5-AZIDO-3'-AZIDO-2',3'-DIDEOXYURIDINE - INTERACTIONS WITH HERPESVIRUS THYMIDLNE KINASE AND CELLULAR ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPY; HIV; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE; 5'-TRIPHOSPHATE; REPLICATION; 3'-AZIDO; SITE	Long term administration of 3'-azidothymidine (AZT) for the treatment of AIDS has led to detrimental clinical side effects in some patients, the biochemical causes of which are still being delineated. Base-substituted, azido-nucleotide photoaffinity analogs have routinely proven to be effective tools for identifying and characterizing nucleotide-utilizing enzymes. Therefore, we have synthesized 5-azido-3'-azido-2',3'-dideoxyuridine, which is a potential photoaffinity analog of two human immunodeficiency virus drugs, AZT and 3'azido-2',3'-dideoxyuridine. A partially purified herpes simplex virus type 1 thymidine kinase and [gamma-P-32]ATP were used to make an AZT monophosphate analog, [P-32]5-azido-3'-azido-2',3'-dideoxyuridine monophosphate. The photoaffinity properties of this analog were initially tested with herpes simplex virus type 1 thymidine kinase. Photoaffinity labeling of this enzyme was saturable (half-maximal, 30 mu M) and could be specifically inhibited by AZT, AZT monophosphate, thymidine, and thymidine monophosphate. Photolabeling of rat Liver microsomal membranes was also done, and several membrane proteins that interact with AZT monophosphate were identified. The antiviral and cytotoxic activities of 5-azido-3'-azido-2',3'-dideoxyuridine were determined using human immunodeficiency virus, type 1 strain IIIB and an AZT drug-resistant strain in human T lymphocyte H9 cells.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, DEPT MED, LITTLE ROCK, AR 72205 USA; UNIV TEXAS, HLTH SCI CTR, DEPT SURG, SAN ANTONIO, TX 78284 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Health San Antonio			Mao, Feng/B-8280-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048497] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48497] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; BOSSUYT X, 1995, BIOCHEM J, V305, P321, DOI 10.1042/bj3050321; CARUSO M, 1992, P NATL ACAD SCI USA, V89, P182, DOI 10.1073/pnas.89.1.182; CHEN MS, 1979, J BIOL CHEM, V254, P747; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DOSHI KJ, 1989, DRUG METAB DISPOS, V17, P590; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GINGERAS TR, 1991, J INFECT DIS, V164, P1066, DOI 10.1093/infdis/164.6.1066; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HALL ET, 1994, J BIOL CHEM, V269, P14355; HERDEWIJN PAMM, 1992, ANTIVIR RES, V19, P1, DOI 10.1016/0166-3542(92)90052-7; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; LIN TS, 1988, J MED CHEM, V31, P336, DOI 10.1021/jm00397a011; LIN TS, 1983, J MED CHEM, V26, P544, DOI 10.1021/jm00358a016; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MOYER MP, 1991, J LEUKOCYTE BIOL, V49, P499, DOI 10.1002/jlb.49.5.499; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RAM Z, 1993, CANCER RES, V53, P83; RECHTIN TM, 1995, J BIOL CHEM, V270, P7055, DOI 10.1074/jbc.270.13.7055; ZHU Z, 1990, MOL PHARMACOL, V38, P929	26	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13660	13664		10.1074/jbc.270.23.13660	http://dx.doi.org/10.1074/jbc.270.23.13660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775417	hybrid			2022-12-27	WOS:A1995RC44800014
J	NAKAMOTO, RK; ALSHAWI, MK; FUTAI, M				NAKAMOTO, RK; ALSHAWI, MK; FUTAI, M			THE ATP SYNTHASE GAMMA-SUBUNIT - SUPPRESSOR MUTAGENESIS REVEALS 3 HELICAL REGIONS INVOLVED IN ENERGY COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGION; ESCHERICHIA-COLI; H+-ATPASE; ADENOSINE-TRIPHOSPHATASE; DIRECTED MUTAGENESIS; CROSS-LINKING; PHOTOPHOSPHORYLATION; F0F1-ATPASE; CATALYSIS; MUTATIONS	A role in coupling proton transport to catalysis of ATP synthesis has been demonstrated for the Escherichia coli F0F1 ATP synthase gamma subunit. Previously, functional interactions between the terminal regions that were important for coupling were shown by finding several mutations in the carboxyl-terminal region of the gamma subunit (involving residues at positions 242 and 269-280) that restored efficient coupling to the mutation, gamma Met-23 --> Lys (Nakamoto, R. K., Maeda, M., and Futai, M. (1993) J. Biol. Chem. 268, 867-872). In this study, we used suppressor mutagenesis to establish that the terminal regions can be separated into three interacting segments. Second-site mutations that cause pseudo reversion of the primary mutations, gamma GLn-269 --> Glu or gamma Thr-273 --> Val, map to an amino-terminal segment with changes at residues 18, 34, and 35, and to a segment near the carboxyl terminus with changes at residues 236, 238, 242, and 246. Each second-site mutation suppressed the effects of both gamma Gln-269 --> Glu and gamma Thr-273 --> Val, and restored efficient coupling to enzyme complexes containing either of the primary mutations. Mapping of these residues in the recently reported x-ray crystallographic structure of the F-1 complex (Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), reveals that the second-site mutations do not directly interact with gamma Gln-269 and gamma Thr-273 and that the effect of suppression occurs at a distance. We propose that the three gamma subunit segments defined by suppressor mutagenesis, residues gamma 18-35, gamma 236-246, and gamma 269-280, constitute a domain that is critical for both catalytic function and energy coupling.	OSAKA UNIV, INST SCI & IND RES, IBARAKI, OSAKA 567, JAPAN	Osaka University	NAKAMOTO, RK (corresponding author), UNIV VIRGINIA, DEPT MOLEC PHYSIOL & BIOL PHYS, JORDAN HALL, BOX 449, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050957] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50957] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1993, J BIOLC EHM, V268, P14563; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI J, 1986, ARCH BIOCHEM BIOPHYS, V251, P458, DOI 10.1016/0003-9861(86)90352-8; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1992, ANN NY ACAD SCI, V671, P335, DOI 10.1111/j.1749-6632.1992.tb43807.x; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIN K, 1992, J BIOL CHEM, V267, P20835; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURINA P, 1994, J BIOL CHEM, V269, P13465; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WEISS MA, 1977, J BIOL CHEM, V252, P8007; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; [No title captured]	32	54	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14042	14046		10.1074/jbc.270.23.14042	http://dx.doi.org/10.1074/jbc.270.23.14042			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775464	hybrid			2022-12-27	WOS:A1995RC44800066
J	MICHAEL, MD; KILGORE, MW; MOROHASHI, K; SIMPSON, ER				MICHAEL, MD; KILGORE, MW; MOROHASHI, K; SIMPSON, ER			AD4BP/SF-1 REGULATES CYCLIC AMP-INDUCED TRANSCRIPTION FROM THE PROXIMAL PROMOTER (PII) OF THE HUMAN AROMATASE P450 (CYP19) GENE IN THE OVARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL MICROSOMES; STEROIDOGENIC FACTOR-I; GRANULOSA-CELLS; ESTROGEN BIOSYNTHESIS; PRIMARY CULTURE; BOVINE LUTEAL; GROWTH-FACTOR; EXPRESSION; CYTOCHROME-P-450; PURIFICATION	Aromatase P450, which is responsible for the metabolism of C-19 steroids to estrogens, is expressed in the pre-ovulatory follicles and corpora lutea of ovulatory women by means of a promoter proximal to the start of translation (PII). To understand how this transcription is controlled by cAMP, we constructed chimeric constructs containing deletion mutations of the proximal promoter 5'-flanking DNA fused to the rabbit beta-globin reporter gene. Assay of reporter gene transcription in transfected bovine granulosa and luteal cells revealed that cAMP-stimulated transcription was lost upon deletion from -278 to -100 base pairs, indicating the presence of a functional cAMP-responsive element in this region; however, no classical cAMP-responsive element was found. Mutation of an AGGTCA motif located at -130 base pairs revealed that this element is crucial for cAMP-stimulated reporter gene transcription. When a single copy of this element was placed upstream of a heterologous promoter, it could act as a weak cAMP-response element. Supershift electrophoretic mobility shift assay and UV cross-linking established that Ad4BP/SF-1 binds to this hexameric element. Ad4BP/SF-1 mRNA and protein levels and DNA binding activity are increased in forskolin-treated luteal cells. We conclude that cAMP-stimulated transcription of human aromatase P450 in the ovary is due, at least in part, to increased levels and DNA binding activity of Ad4BP/SF-1.	UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 812,JAPAN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyushu University				Michael, Mervyn/0000-0002-0224-1065	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234, T32HD007190] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13234, 5-T32-HD07190] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; CASPI E, 1984, J AM CHEM SOC, V106, P7282, DOI 10.1021/ja00335a090; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE PA, 1988, J AM CHEM SOC, V110, P1284, DOI 10.1021/ja00212a043; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GOTO J, 1977, SCIENCE, V195, P80, DOI 10.1126/science.831259; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; JENKINS C, 1993, MOL CELL ENDOCRINOL, V97, pR1, DOI 10.1016/0303-7207(93)90227-B; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V93, P227, DOI 10.1016/0303-7207(93)90128-7; LYNCH JP, 1994, MOL ENDOCRINOL, V7, P776; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1985, ARCH BIOCHEM BIOPHYS, V243, P480, DOI 10.1016/0003-9861(85)90525-9; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OSAWA Y, 1987, Steroids, V50, P11, DOI 10.1016/0039-128X(83)90058-2; Sambrook J, 1989, MOL CLONING LABORATO; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Simpson E.R., 1994, ENDOCR REV, V15, P342, DOI DOI 10.1210/ER.15.3.342.PUBMED:8076586; STEINKAMPF MP, 1988, MOL CELL ENDOCRINOL, V59, P93, DOI 10.1016/0303-7207(88)90199-2; STEINKAMPF MP, 1987, MOL ENDOCRINOL, V1, P465, DOI 10.1210/mend-1-7-465; STIRLING D, 1990, J BIOL CHEM, V265, P5; TAKAYAMA K, 1994, 9TH INT C HORM STER, P120; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	41	203	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13561	13566		10.1074/jbc.270.22.13561	http://dx.doi.org/10.1074/jbc.270.22.13561			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768959	hybrid			2022-12-27	WOS:A1995RB43900089
J	CALABRESI, L; VECCHIO, G; LONGHI, R; GIANAZZA, E; PALM, G; WADENSTEN, H; HAMMARSTROM, A; OLSSON, A; KARLSTROM, A; SEJLITZ, T; AGELAND, H; SIRTORI, CR; FRANCESCHINI, G				CALABRESI, L; VECCHIO, G; LONGHI, R; GIANAZZA, E; PALM, G; WADENSTEN, H; HAMMARSTROM, A; OLSSON, A; KARLSTROM, A; SEJLITZ, T; AGELAND, H; SIRTORI, CR; FRANCESCHINI, G			MOLECULAR CHARACTERIZATION OF NATIVE AND RECOMBINANT APOLIPOPROTEIN A-I-MILANO DIMER - THE INTRODUCTION OF AN INTERCHAIN DISULFIDE BRIDGE REMARKABLY ALTERS THE PHYSICOCHEMICAL PROPERTIES OF APOLIPOPROTEIN-A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; ESCHERICHIA-COLI; SELF-ASSOCIATION; APOA-I; DOMAINS; PLASMA; CONFORMATION; PROTEINS; EFFLUX	The disulfide-linked dimer of apolipoprotein A-I-Milano (A-I-M/A-I-M), a natural Arg(173) --> CYS variant of apoA-I, was purified from carriers' plasma and produced in Escherichia coli. The recombinant A-I-M/A-I-M is identical to native A-I-M/A-I-M, by mass spectrometry, SDS-polyacrylamide gel electrophoresis, and isoelectric focusing. Lipid-free A-I-M/A-I-M undergoes concentration-dependent self-association similar to apoA-I, but at all concentrations apoA-I is more self-associated than A-I-M/A-I-M. Farultraviolet CD spectra of A-I-M/A-I-M reveal a highly alpha-helical structure predicted to be similar to 65% in the lipid-free and similar to 78% in the lipid-associated states, versus 43 and 73% for apoA-I. A significant loss of alpha-helix occurs below pH 3.5 and above pH 10 in both apoA-I and A-I-M/A-I-M; A-I-M/A-I-M constantly shows a higher alpha-helical content than apoA-I over the entire pH range (1.7-12.8), suggesting that hydrophobic forces stabilize the interaction between the two A-I-M chains. Indeed, and differently from apoA-I, the alpha-helical content of A-I-M/A-I-M is minimally affected by solvent ionic strength. The aromatic side chains in both Lipid-free and lipid-bound A-I-M/A-I-M are immobilized in a more asymmetric and hydrophobic environment than in Lipid-free apoA-I, the conformation ofA-I(M)A-I-M, being instead similar to that achieved by apoA-I following interaction with lipids. The present findings prove that rA-I-M/A-I-M is structurally identical to the native protein; the conformation of A-I-M/IA-I-M is remarkably different fi om that of apoA-I, thus possibly explaining some of the peculiar functional properties of the apoA-I-Milano dimer.	UNIV MILAN,INST PHARMACOL SCI,CTR E GROSSI PUOLETTI,I-20133 MILAN,ITALY; CNR,IST CHIM ORMONI,I-20133 MILAN,ITALY; PHARMACIA BIOSCI CTR,S-11287 STOCKHOLM,SWEDEN; PHARMACIA THERAPEUT,S-11287 STOCKHOLM,SWEDEN	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Pfizer			Sirtori, Cesare/F-4658-2012	FRANCESCHINI, GUIDO/0000-0003-2687-1771; Calabresi, Laura/0000-0001-5042-9532				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BANKA CL, 1994, J BIOL CHEM, V269, P10288; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN SH, 1986, HUMAN APOLIPROTEIN M, P99; CHMIELEWSKA J, 1993, P INT S LIPID TRIAD, P41; DALTON MB, 1993, J BIOL CHEM, V268, P19274; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORSBERG G, 1989, Biofactors, V2, P105; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; FRANCESCHINI G, 1982, J BIOL CHEM, V257, P9926; FRANCESCHINI G, 1981, METABOLISM, V30, P502, DOI 10.1016/0026-0495(81)90188-8; FRANCESCHINI G, 1990, J BIOL CHEM, V265, P12224; FRANCESCHINI G, 1985, J BIOL CHEM, V260, P6321; GIANAZZA E, 1986, ELECTROPHORESIS, V7, P76, DOI 10.1002/elps.1150070205; GLOMSET JA, 1968, J LIPID RES, V9, P155; GUALANDRI V, 1985, AM J HUM GENET, V37, P1083; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; ISACCHI A, 1989, GENE, V81, P129, DOI 10.1016/0378-1119(89)90343-0; JACKSON RL, 1972, BIOCHEM BIOPH RES CO, V49, P1444, DOI 10.1016/0006-291X(72)90501-3; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; KISS RS, 1993, BIOCHEMISTRY-US, V32, P7872, DOI 10.1021/bi00082a006; LEROY A, 1994, BBA-LIPID LIPID MET, V1212, P285, DOI 10.1016/0005-2760(94)90202-X; LUX SE, 1972, J BIOL CHEM, V247, P2598; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MENG QH, 1993, J BIOL CHEM, V268, P16966; ORAM JF, 1993, ATHER REV, V24, P87; PIETERS MN, 1993, BIOCHEM J, V292, P819, DOI 10.1042/bj2920819; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROMA P, 1993, J CLIN INVEST, V91, P1445, DOI 10.1172/JCI116349; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYAN RO, 1993, J BIOL CHEM, V268, P1505; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SIRTORI CR, 1993, HUMAN APOLIPOPROTEIN, V3, P121; STONE WL, 1975, J BIOL CHEM, V250, P8045; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; SWANEY JB, 1976, BIOCHEM BIOPH RES CO, V71, P636, DOI 10.1016/0006-291X(76)90835-4; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2508; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZANNIS VI, 1980, J BIOL CHEM, V255, P8612	53	81	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32168	32174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798214				2022-12-27	WOS:A1994PX30400026
J	WU, CB; SEIBERT, FS; KO, K				WU, CB; SEIBERT, FS; KO, K			IDENTIFICATION OF CHLOROPLAST ENVELOPE PROTEINS IN CLOSE PHYSICAL PROXIMITY TO A PARTIALLY TRANSLOCATED CHIMERIC PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TRANSIT PEPTIDE; IMPORT APPARATUS; MEMBRANE-PROTEIN; OUTER-MEMBRANE; BINDING; LOCALIZATION; HSP70; MITOCHONDRIA; POLYPEPTIDES	Translocation intermediates of the chimeric protein precursor Oee1-Dhfr mere generated and used to identify envelope components in close proximity to the arrested precursor. The translocation of Oee1-Dhfr across the chloroplast envelope can be arrested at low ATP levels or by prebinding the fusion precursor with anti-Dhfr IgGs. The arrested Oeel-Dhfr precursors appear to span both the outer and inner envelope membranes. Translocational arrest of Oee1-Dhfr by low ATP levels was reversible, and import was restored upon resupplementation with higher ATP levels. Chemical cross-linking and co-immunoprecipitation with monospecific antibodies indicate that two outer envelope membrane proteins (Com44 and Com70) and at least one inner envelope protein (Cim44 and Cim97) were found to be in close proximity to Oee1-Dhfr during translocation. The Com70 protein was further studied and additional evidence for its role in chloroplast protein import is presented.	QUEENS UNIV, DEPT BIOL, KINGSTON K7L 3N6, ON, CANADA	Queens University - Canada								AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P374; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUA NH, 1982, METHODS CHLOROPLAST, P1063; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HINZ G, 1988, EUR J BIOCHEM, V175, P649, DOI 10.1111/j.1432-1033.1988.tb14241.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; JOYARD J, 1983, J BIOL CHEM, V258, P1; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KO K, 1992, J BIOL CHEM, V267, P13910; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1993, FEBS LETT, V332, P277, DOI 10.1016/0014-5793(93)80649-F; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; MARSHALL JS, 1992, PLANT PHYSIOL, V100, P1048, DOI 10.1104/pp.100.2.1048; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFISTERER J, 1982, EUR J BIOCHEM, V126, P143, DOI 10.1111/j.1432-1033.1982.tb06758.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SUTTON A, 1987, EUR J BIOCHEM, V164, P571, DOI 10.1111/j.1432-1033.1987.tb11165.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WU CB, 1993, J BIOL CHEM, V268, P19384; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616	48	102	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32264	32271						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798226				2022-12-27	WOS:A1994PX30400040
J	MIELE, C; FORMISANO, P; SOHN, KJ; CARUSO, M; PIANESE, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F				MIELE, C; FORMISANO, P; SOHN, KJ; CARUSO, M; PIANESE, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F			DECREASED PHOSPHORYLATION OF MUTANT INSULIN-RECEPTOR BY PROTEIN-KINASE-C AND PROTEIN-KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; THREONINE 1336; BETA-SUBUNIT; AUTOPHOSPHORYLATION; MUTATION; SITES; CELLS; DNA; ACTIVATION; INVITRO	We have recently reported that the Arg(1152) --> Gln insulin receptor mutation (QR single mutant) alters a conserved motif (RK motif) immediately next to the hey tyrosine phosphorylation sites (Tyr(1146), Tyr(1150) Tyr(1151)) of the receptor and constitutively activates its kinase and metabolic signaling. To investigate further the function of the RK motif, we have expressed two additional mutant insulin receptors: a single mutant, in which the second basic residue in the RR motif (Lys(1153)) was substituted (RA mutant); and a double mutant, in which both the Arg and the Lye residues were replaced with noncharged amino acids (QA mutant). As compared with the transfected wild-type receptors (WT), both the single and the double mutant receptors were normally synthetized and transported to the plasma membrane and bound insulin normally, Whereas the double mutant receptor exhibited preserved insulin-dependent autophosphorylation, kinase activity, and a-deoxyglucose uptake, all of these functions were grossly impaired in the two single mutant receptors, Two-dimensional analysis of tryptic phosphopeptides from receptor beta-subunits revealed that decreased autophosphorylation of the single mutant receptors mainly involved regulatory Tyr(1150,1151) and carboxyl-terminal Tyr(1316,1322). At variance with the insulin-stimulated, insulin-independent tyrosine kinase activity toward poly(Glu-Tyr) 4:1 was increased 3-fold in both the double and the single mutants. Ah mutant receptors induced a 2-fold increase in basal 2-deoxyglucose uptake in NIH-3T3 cells, Treatment of WT transfected cells with 12-O-tetradecanoyl-phorbol-13-acetate or 8-bromo-cAMP increased insulin receptor phosphorylation by 3-fold. No phosphorylation was observed in cells expressing the two single or the double mutant receptor, Consistently, purified preparations of PKC and PKA phosphorylated the WT but not the mutant receptors in vitro. A 17-amino acid synthetic peptide encoding the receptor sequence surrounding the RR. motif inhibited phosphorylation of WT insulin receptors by both protein kinases A and C. A mutant peptide in which the RR sequence was replaced by QK (to mimic the mutation in the QK receptor) exhibited no inhibitory effect, Thus, the RK insulin receptor moth is required for insulin receptor phosphorylation by protein kinases C and A and may modulate insulin-independent receptor activity, The RK motif may also have an important structural role in allowing normal insulin regulation of the kinase.	UNIV NAPLES,FAC MED,SCH MED,CONSIGLIO NAZL RIC,CTR ENDOCRINOL & ONCOL SPERIME,I-80131 NAPLES,ITALY; HOSP SAN RAFFAELE,CONSIGLIO NAZL RIC,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CONSIGLIO NAZL RIC,DIPARTIMENTO RICERCA BIOL & TECNOL,MOLEC ONCOL LAB,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Formisano, Pietro/J-4237-2018; Palumbo, Giuseppe/N-3136-2016	Palumbo, Giuseppe/0000-0001-9380-8436; Formisano, Pietro/0000-0001-7020-6870				AHN J, 1993, J BIOL CHEM, V268, P16839; Battey, 1986, BASIC METHODS MOL BI; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CZECH M P, 1985, Diabetes Metabolism Reviews, V1, P33; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELIN K, 1991, ONCOGENE, V6, P825; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUBBARD SR, 1995, NATURE, V372, P22; KARASIK A, 1990, J BIOL CHEM, V265, P10226; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCDONALD NQ, 1995, STRUCTURE, V3, P1, DOI 10.1016/S0969-2126(01)00129-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETRUZZIELLO A, 1993, J CLIN ENDOCR METAB, V77, P409, DOI 10.1210/jc.77.2.409; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WHITE MF, 1994, J BIOL CHEM, V269, P1	36	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15844	15852		10.1074/jbc.270.26.15844	http://dx.doi.org/10.1074/jbc.270.26.15844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797589	hybrid			2022-12-27	WOS:A1995RG53800062
J	OLIVES, B; MATTEI, MG; HUET, M; NEAU, P; MARTIAL, S; CARTRON, JP; BAILLY, P				OLIVES, B; MATTEI, MG; HUET, M; NEAU, P; MARTIAL, S; CARTRON, JP; BAILLY, P			KIDD BLOOD-GROUP AND UREA TRANSPORT FUNCTION OF HUMAN ERYTHROCYTES ARE CARRIED BY THE SAME PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELLS; MONOCLONAL-ANTIBODY; SOLUTE PERMEABILITY; WATER; EXPRESSION; ANTIGEN; LINKAGE	The gene encoding the urea transporter of human erythrocytes (HUT11 clone) has been cloned recently (Olives, B,, Neau, P,, Bailly, P,, Hediger, M. A., Rousselet, G,, Cartron, J, P,, and Ripoche, P, (1994) J, Biol, Chem, 269, 31649-31652), Now, this gene has been assigned to chromosome 18q12-q21 by in situ hybridization, as also found for the Kidd (Jk) blood group locus, In coupled transcription-translation assays, the HUT11 cDNA directed the synthesis of a 36-kDa protein which was immunoprecipitated by a human anti-Jk(3) antibody produced by immunized Jk(a-b-) donors whose red cells lack Kidd antigens, The anti-Jk(3) antibody also immunoprecipitated a protein material of 46-60 kDa from all red cell membranes, except those from Jk(a-b-) cells, After N-glycanase digestion the 46-60-kDa component was reduced to 36 kDa, A rabbit antibody raised against the predicted NH,-terminal amino-acids of the HUT11 protein reacted on immunoblots with a 46-60-kDa component present in all human erythrocytes except those from Jk(a-b-) individuals, Jk(a-b-) red cells lack the Kidd/urea transport protein and have a selective defect of the urea transport capacity, but a normal water permeability and aquaporin-associated Colton blood group antigens, These findings indicate that the erythrocyte urea transporter is encoded by the Kidd locus and may have implications for the biology of urea transporters and their tissue specific regulation.	INST NATL TRANSFUS SANGUINE,INSERM,U76,F-75015 PARIS,FRANCE; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE 05,FRANCE; CEA SACLAY,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CEA; UDICE-French Research Universities; Universite Paris Saclay			Martial, Sonia/L-8270-2019	Martial, Sonia/0000-0002-6732-0936				BLOY C, 1987, BLOOD, V69, P1491; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CHAUDHURI A, 1995, BLOOD, V85, P615, DOI 10.1182/blood.V85.3.615.bloodjournal853615; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; GEITVIK GA, 1987, HUM GENET, V77, P205, DOI 10.1007/BF00284470; GILLIN AG, 1993, SEMIN NEPHROL, V13, P146; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HASEGAWA H, 1993, AM J PHYSIOL, V265, pC514, DOI 10.1152/ajpcell.1993.265.2.C514; HEATON DC, 1982, TRANSFUSION, V22, P70, DOI 10.1046/j.1537-2995.1982.22182154224.x; HODGE SE, 1981, LANCET, V2, P893; HUNTER FR, 1970, BIOCHIM BIOPHYS ACTA, V211, P216, DOI 10.1016/0005-2736(70)90094-5; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATRON F, 1987, BIOCHEM J, V247, P757, DOI 10.1042/bj2470757; LECLAIR K, 1981, J IMMUNOL METHODS, V41, P137, DOI 10.1016/0022-1759(81)90237-4; MACEY RI, 1988, AM J PHYSIOL, V254, pC669, DOI 10.1152/ajpcell.1988.254.5.C669; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MARTIAL S, 1991, ANAL BIOCHEM, V197, P296, DOI 10.1016/0003-2697(91)90395-A; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; OLIVES B, 1994, J BIOL CHEM, V269, P31649; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; ROUSSELET G, 1995, FASEB J, V9, P563; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; SINOR LT, 1987, MED LAB SCI, V44, P294; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	31	128	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15607	15610		10.1074/jbc.270.26.15607	http://dx.doi.org/10.1074/jbc.270.26.15607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797558	hybrid, Green Submitted			2022-12-27	WOS:A1995RG53800028
J	SCHMITZ, ML; SILVA, MAD; BAEUERLE, PA				SCHMITZ, ML; SILVA, MAD; BAEUERLE, PA			TRANSACTIVATION DOMAIN-2 (TA(2)) OF P65 NF-KAPPA-B - SIMILARITY TO TA(1) AND PHORBOL ESTER-STIMULATED ACTIVITY AND PHOSPHORYLATION IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-BINDING; ENHANCER ELEMENT; MAMMALIAN-CELLS; FACTOR-TFIIB; C-REL; ALPHA; PROTEIN; EXPRESSION; MECHANISM	The p65 subunit of the inducible transcription factor NF-kappa B contains at least two strong transactivation domains (TADs) within its C terminus. The first domain, TA(1), is contained within the last 30 amino acids of p65, whereas TA(2) comprises the adjacent 90 amino acids. In this study, squelching experiments revealed that both TADs of p65, as well as the related subunit c-Rel, compete for the same cofactor(s) mediating transactivation. Both TADs of p65 share a common sequence motif, which is evolutionarily conserved and displays a remarkable degree of spatial organization when aligned on an cu-helical surface. The functional importance of the common sequence motif was confirmed by deletion analysis of TA(2). Within the conserved sequence motif, a 7-amino-acid repeat was noted. Idealized heptad repeats fused to the DNA binding domain of Gal4 were transcriptionally active, but only as multimers. Phosphorylation and transcriptional activity of a defined region within the TA(2) domain was found to be stimulated by phorbol ester treatment of cells. In contrast, TA(1) was constitutively phosphorylated, and its activity did not significantly respond to phorbol ester stimulation. The stimulatory effect of phorbol ester on transcription of the TA(2) domain was completely blocked by the protein kinase C inhibitor. These data suggest that protein kinase C has a dual effect on NF-kappa B activity, It not only causes removal of I kappa B-alpha from cytoplasmic NF-KB but also augments the transactivation potential of activated nuclear NF-kappa B.			SCHMITZ, ML (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,D-79104 FREIBURG,GERMANY.		Silva, Marcos/C-7260-2015; Schmitz, M. Lienhard/D-9328-2017; Silva Ferraz, Marcos/X-9172-2018; Ferraz, Marcos A.S. Silva/ABG-4813-2020	Schmitz, M. Lienhard/0000-0002-6984-7192; Silva Ferraz, Marcos/0000-0001-6898-9132; Ferraz, Marcos A.S. Silva/0000-0001-6898-9132				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHMITZ ML, 1995, IN PRESS IMMUNOBIOLO; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SIGLER PB, 1988, NATURE, V331, P210; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TIJIAN R, 1994, CELL, V77, P5; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	56	148	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15576	15584		10.1074/jbc.270.26.15576	http://dx.doi.org/10.1074/jbc.270.26.15576			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797554	hybrid			2022-12-27	WOS:A1995RG53800024
J	SOHAL, RS; AGARWAL, A; AGARWAL, S; ORR, WC				SOHAL, RS; AGARWAL, A; AGARWAL, S; ORR, WC			SIMULTANEOUS OVEREXPRESSION OF COPPER-CONTAINING AND ZINC-CONTAINING SUPEROXIDE-DISMUTASE AND CATALASE RETARDS AGE-RELATED OXIDATIVE DAMAGE AND INCREASES METABOLIC POTENTIAL IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATIVE DISEASES; OXYGEN RADICALS; DNA-DAMAGE; 8-HYDROXY-2'-DEOXYGUANOSINE; URINE	The objective of this study was to elucidate the nature of the mechanisms by which overexpression of copper- and zinc-containing superoxide dismutase (Cu,Zn-SOD) and catalase extends life span of Drosophila melanogaster. Experimental flies containing single extra doses of Drosophila Cu,Zn-SOD and catalase genes were compared with appropriate controls at different ages, Overexpression of Cu,Zn SOD and catalase caused a retardation in the accumulation of 8-hydroxydeoxyguanosine during aging and in response to the exposure of live flies to x-rays, The age related loss of glucose-6-phosphate dehydrogenase activity (Glu-6-P dehydrogenase) and the increase in the rate of mitochondrial H2O2 generation were less steep in the experimental than control flies, The rate of in vivo oxygen consumption in the latter two-thirds of life span was higher in the experimental than in the control flies, Furthermore, the metabolic potential, or the total amount of oxygen consumed during an average life span, was about 30% greater in the experimental than the control flies, Altogether, results of this study indicate that overexpression of Cu,Zn-SOD and catalase ameliorates the age-related accumulation of molecular oxidative damage and susceptibility to such damage in response to acute oxidative stress while prolonging the metabolic life of flies, The concept that oxidative stress is a causal factor in the aging process is supported.			SOHAL, RS (corresponding author), SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275, USA.				NATIONAL INSTITUTE ON AGING [R01AG008459] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG8459] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL S, 1993, BIOCHEM BIOPH RES CO, V194, P1203, DOI 10.1006/bbrc.1993.1950; AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Beutler E., 1971, RED CELL METABOLISM; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; MCARTHUR MC, 1982, J GERONTOL, V37, P268, DOI 10.1093/geronj/37.3.268; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1993, AGING-CLIN EXP RES, V5, P3, DOI 10.1007/BF03324120; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1992, FREE RADICALS AGING, P64; WOOD FE, 1980, INSECT BIOCHEM, V10, P95, DOI 10.1016/0020-1790(80)90044-X	25	193	203	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15671	15674		10.1074/jbc.270.26.15671	http://dx.doi.org/10.1074/jbc.270.26.15671			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797567	hybrid			2022-12-27	WOS:A1995RG53800038
J	PAUL, S; LI, L; KALAGA, R; WILKINSSTEVENS, P; STEVENS, FJ; SOLOMON, A				PAUL, S; LI, L; KALAGA, R; WILKINSSTEVENS, P; STEVENS, FJ; SOLOMON, A			NATURAL CATALYTIC ANTIBODIES - PEPTIDE-HYDROLYZING ACTIVITIES OF BENCE-JONES PROTEINS AND V-L FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; LIGHT-CHAINS; LAMBDA-CHAIN; AUTOANTIBODIES; SITES; IMMUNOGLOBULINS; BINDING; MYELOMA; SERUM; CELLS	Monoclonal human light chains, i.e. Pence Jones proteins, and their recombinant variable fragments (V-L) were screened for proteolytic activity using peptide-methylcoumarinamide (peptide-MCA) conjugates and vasoactive intestinal polypeptide (VIP) as substrates. Sixteen of 21 Pence Jones proteins and one of three V-L fragments were capable of detectable cleavage of one or more substrates. The magnitude and kinetic characteristics of the activity varied with different substrates. Among the peptide-MCA substrates, the presence of tripeptide or tetrapeptide moieties with a basic residue at the scissile bond generally favored expression of the activity. The influence of N-terminal flanking residue recognition was evident from differing values of K-m and k(cat) (turnover number) observed using different Arg-containing peptide-MCA substrates. Different light chains displayed different kinetic parameters for the same substrate, suggesting unique catalytic sites. Hydrolysis of VIP was characterized by nanomolar Michaelis-Menten constants (K-m), suggesting comparatively high affinity recognition of this peptide, The 25-kDa monomer and the 50-kDa dimer forms of one light chain preparation were resolved by gel filtration in 6 M guanidine hydrochloride, Following renaturation, the monomer displayed 51-fold greater peptide-MCA-hydrolyzing activity than the dimer. A renatured V-L domain prepared by gel filtration in 6 M guanidine hydrochloride displayed VIP-hydrolyzing activity in the 12.5-kDa peak fractions. These results provide evidence for the proteolytic activity of certain human light chains and imply that this phenomenon may have a pathophysiological significance.	ARGONNE NATL LAB,ARGONNE,IL 60439; UNIV TENNESSEE,MED CTR,KNOXVILLE,TN 37920; HUMAN IMMUNOL & CANC PROGRAM,KNOXVILLE,TN 37920	United States Department of Energy (DOE); Argonne National Laboratory; University of Tennessee System; University of Tennessee Health Science Center	PAUL, S (corresponding author), UNIV NEBRASKA,MED CTR,DEPT ANESTHESIOL,600 S 42ND ST,OMAHA,NE 68198, USA.				NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043757] Funding Source: NIH RePORTER; NCI NIH HHS [CA10056] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline; NIDDK NIH HHS [DK43757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG CH, 1985, BIOCHEMISTRY-US, V24, P4890, DOI 10.1021/bi00339a025; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1962, J EXP MED, V116, P207; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FINCH RJ, 1989, J IMMUNOL, V142, P1977; GAO QS, 1994, J BIOL CHEM, V269, P32389; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jones H. B., 1848, PHILOS T R SOC LOND, V138, P55; JONSSON V, 1992, J INTERN MED, V232, P185, DOI 10.1111/j.1365-2796.1992.tb00570.x; JONSSON V, 1988, ACTA MED SCAND, V223, P255; KIMATA H, 1993, J IMMUNOL, V150, P4630; LI L, 1994, J IMMUNOL, V154, P3328; MAHANA W, 1994, SCAND J IMMUNOL, V39, P107, DOI 10.1111/j.1365-3083.1994.tb03347.x; MATHEW RC, 1992, J IMMUNOL, V148, P3572; MODY R, 1994, INT J PEPT PROT RES, V44, P441; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; NELSON M, 1992, BRIT J HAEMATOL, V81, P223, DOI 10.1111/j.1365-2141.1992.tb08211.x; NODA Y, 1994, BIOPOLYMERS, V34, P217, DOI 10.1002/bip.360340208; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1985, BIOCHEM BIOPH RES CO, V130, P479, DOI 10.1016/0006-291X(85)90442-5; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SMITH GD, 1977, ANAL BIOCHEM, V79, P643, DOI 10.1016/0003-2697(77)90451-1; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, 1994, J IMMUNOL, V153, P5121; THOMAS NR, 1994, APPL BIOCHEM BIOTECH, V47, P345, DOI 10.1007/BF02787945; TILLYER CR, 1991, J CLIN PATHOL, V44, P466, DOI 10.1136/jcp.44.6.466; WILKINSSTEVENS P, 1995, PROTEIN SCI, V4, P421	34	116	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15257	15261		10.1074/jbc.270.25.15257	http://dx.doi.org/10.1074/jbc.270.25.15257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797511	hybrid			2022-12-27	WOS:A1995RE66600062
J	BELAAOUAJ, A; SHIPLEY, JM; KOBAYASHI, DK; ZIMONJIC, DB; POPESCU, N; SILVERMAN, GA; SHAPIRO, SD				BELAAOUAJ, A; SHIPLEY, JM; KOBAYASHI, DK; ZIMONJIC, DB; POPESCU, N; SILVERMAN, GA; SHAPIRO, SD			HUMAN MACROPHAGE METALLOELASTASE - GENOMIC ORGANIZATION, CHROMOSOMAL LOCATION, GENE LINKAGE, AND TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; INSITU HYBRIDIZATION; COLLAGENASE GENE; DNA-MOLECULES; LOCALIZATION; RNA; ELASTASE; CLONING	Human macrophage metalloelastase (HME) is a recent addition to the matrix metalloproteinase (MMP) family that was initially found to be expressed in alveolar macrophages of cigarette smokers. To understand more about HME expression, analysis of the structure and location of the gene was performed. The gene for HME is composed of 10 exons and 9 introns, similar to the stromelysins and collagenases, and HME shares the highly conserved exon size and intron-exon borders with other MMPs. The 13-kilobase (kb) HME gene has been localized by fluorescence in situ hybridization to chromosome 11q22.2-22.3, the same location of the interstitial collagenase and stromelysin genes. We determined that HME and stromelysin 1 genes are physically linked within 62 kb utilizing pulse field gel electrophoresis. The promoter region of the HME gene contains several features common to other MMP genes including a TATA box 29 bp upstream to the transcription initiation site, an AP-1 motif, and a PEA3 element. HME mRNA is not detectable in normal adult tissues but is induced in rapidly remodeling tissues such as the term placenta. In situ hybridization and immunohistochemistry of placental tissue demonstrated HME mRNA and protein expression in macrophages and stromal cells. Cell-specific expression and response to inflammatory stimuli such as endotoxin is conferred within 2.8 kb of the HME 5'-flanking sequence as demonstrated by HME promoter-CAT expression constructs. Knowledge of the genomic organization and chromosomal location of HME may allow us to further define mechanisms responsible for cell- and tissue-specific expression of HME.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School			A, Bentaher/F-6531-2018; Silverman, Gary/AAJ-1269-2020; Zimonjic, Drazen/AAX-7513-2020; Bentaher, Abderrazzaq/M-4424-2017	A, Bentaher/0000-0001-6001-5456; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0-1 HL29594, HL2401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brophy C M, 1991, Ann Vasc Surg, V5, P229, DOI 10.1007/BF02329378; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; FORMSTONE CJ, 1992, GENOMICS, V16, P289; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; PROSSER IW, 1989, AM J PATHOL, V135, P1073; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, P5160; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Southern E, 1979, Methods Enzymol, V68, P152; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	36	130	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14568	14575		10.1074/jbc.270.24.14568	http://dx.doi.org/10.1074/jbc.270.24.14568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782320	hybrid			2022-12-27	WOS:A1995RD45500052
J	JANOUEIXLEROSEY, I; JOLLIVET, F; CAMONIS, J; MARCHE, PN; GOUD, B				JANOUEIXLEROSEY, I; JOLLIVET, F; CAMONIS, J; MARCHE, PN; GOUD, B			2-HYBRID SYSTEM SCREEN WITH THE SMALL GTP-BINDING PROTEIN RAB6 - IDENTIFICATION OF A NOVEL MOUSE GDP DISSOCIATION INHIBITOR ISOFORM AND 2 OTHER POTENTIAL PARTNERS OF RAB6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMG P25A; ACTIVATING PROTEIN; VESICULAR TRANSPORT; REGULATORY PROTEIN; EXCHANGE PROTEIN; RAS PROTEIN; MUTANTS; FAMILY; MEMBRANES; CYTOSOL	Rab6 is a small GTP-binding protein that belongs to the Ras superfamily and is involved in intra-Golgi transport. Using a two-hybrid system screen of a mouse brain cDNA library, we have isolated several clones encoding proteins that interact with Rab6. Approximately 60% of the clones identified encoded anew mouse Rab GDP dissociation inhibitor (GDI) isoform. This GDI isoform is distinct from mouse mGDI-1 and mGDI-2, which have been characterized previously, and most likely represents the mouse counterpart of the rat Rab GDI beta isoform. In the two-hybrid system, GDI beta interacts with wild-type Rab6 and Rab5, but not with a GTP-bound Rab6 mutant, or a Rab6 mutant that cannot be post-translationally processed. We further examined whether mouse GDI beta is functional; we show that recombinant mouse GDI beta is able to remove several Rab proteins, including Rab1, Rab2, Rab4, and Rab6, from membranes. The identification of a third GDI isoform in mouse raised the question whether GDI genes belong to a larger multigenic family. We have shown, by Southern blot analysis of genomic DNA, that at least five GDI gene copies exist in both the mouse and rat genomes. In our two-hybrid screen, we have also characterized another clone that specifically interacts with Rab6. This clone was partially sequenced but shows no homology to known sequences. Finally, a third clone, interacting with both Rab5 and Rab6. also appears to encode a novel protein.	INST PASTEUR,DEPT IMMUNOL,CNRS,URA 361,UNITE GENET SOMAT,F-75724 PARIS 15,FRANCE; INST PASTEUR,DEPT IMMUNOL,CNRS,URA 359,UNITE IMMUNOCHIM ANALYT,F-75724 PARIS 15,FRANCE; FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Marche, Patrice N/K-5060-2013; Janoueix-Lerosey, Isabelle/G-1758-2018; Goud, Bruno/GWC-4807-2022	Marche, Patrice N/0000-0002-8930-9340; Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; 				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JOUVINMARCHE E, 1990, EMBO J, V9, P2141, DOI 10.1002/j.1460-2075.1990.tb07383.x; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; ROSE MD, 1990, LABORATORY COURSE MA; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; YANG CZ, 1994, J BIOL CHEM, V269, P31891; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217; 1991, PROGRAM MANUAL GCG P	43	96	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14801	14808		10.1074/jbc.270.24.14801	http://dx.doi.org/10.1074/jbc.270.24.14801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782346	hybrid			2022-12-27	WOS:A1995RD45500084
J	KOUMENIS, C; NUNEZREGUEIRO, M; RAJU, U; COOK, R; ESKIN, A				KOUMENIS, C; NUNEZREGUEIRO, M; RAJU, U; COOK, R; ESKIN, A			IDENTIFICATION OF 3 PROTEINS IN THE EYE OF APLYSIA, WHOSE SYNTHESIS IS ALTERED BY SEROTONIN (5-HT) - POSSIBLE INVOLVEMENT OF THESE PROTEINS IN THE OCULAR CIRCADIAN SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DEPENDENT ANION CHANNEL; OUTER MITOCHONDRIAL-MEMBRANE; GLUCOSE-REGULATED PROTEIN; CHAIN BINDING-PROTEIN; BIOCHEMICAL-CHARACTERIZATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; STRESS PROTEINS; MAMMALIAN-CELLS	Previous results using translation inhibitors in the ocular circadian system of Aplysia suggest that protein synthesis may be involved in the light and serotonin (5-HT) entrainment pathways or perhaps in the circadian oscillator. Proteins have been previously identified whose synthesis was altered by treatments of light capable of perturbing the phase of the circadian rhythm in the eye of Aplysia. We extended these studies by investigating the effects of other treatments that perturb the ocular circadian rhythm on protein synthesis. 5-HT altered the synthesis of nine proteins. Interestingly, five of the proteins affected by treatments with 5-HT were previously shown to be affected by treatments with light. Four of the proteins affected by treatments with 5-HT were also affected by treatments with analogs of cAMP, a treatment which mimics the effects of 5-HT on the ocular circadian rhythm. To identify the cellular function of some of these proteins, we obtained their partial amino acid sequences, Based on these sequences and additional characterizations, a 78-kDa, pI 5.6 Aplysia protein appears to be glucose-regulated protein 78/binding protein, and a 36-kDa, pI 5.7 Aplysia protein appears to be porin/voltage-dependent anion channel. Heat shock experiments on Aplysia eyes revealed that yet another one of the Aplysia proteins (70 kDa) affected by 5-HT appears to be a heat-inducible member (heat shock protein 70) of the family of heat shock proteins. These findings suggest that these three identified proteins, together or individually, maybe involved in some way in the regulation of the timing of the circadian oscillator in the eye of Aplysia.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	University of Houston System; University of Houston; Baylor College of Medicine; Baylor College of Medicine			Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NIMH NIH HHS [MH41979] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041979, R37MH041979] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BENZ R, 1990, EXPERIENTIA, V46, P131, DOI 10.1007/BF02027308; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CERVERA J, 1985, CELL BIOL INT REP, V9, P131, DOI 10.1016/0309-1651(85)90087-6; CHAO CCK, 1992, NUCLEIC ACIDS RES, V20, P6481, DOI 10.1093/nar/20.24.6481; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; CORRENT G, 1982, AM J PHYSIOL, V242, pR326, DOI 10.1152/ajpregu.1982.242.3.R326; COURGEON AM, 1984, EXP CELL RES, V153, P515, DOI 10.1016/0014-4827(84)90618-9; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; ESKIN A, 1982, J NEUROBIOL, V13, P241, DOI 10.1002/neu.480130305; FELDMAN JF, 1989, SCI PHOTOBIOLOGY, P193; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENBERG SG, 1985, J NEUROSCI, V5, P1239; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDINPE, 1993, MOL GENETICS BIOL RH, P155; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKLET JW, 1980, J EXP BIOL, V84, P1; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; KHALSA S B S, 1990, Society for Neuroscience Abstracts, V16, P640; KHALSA SBS, 1990, BRAIN RES, V520, P166, DOI 10.1016/0006-8993(90)91702-I; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOUMENIS C, 1992, CHRONOBIOL INT, V3, P201; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEEE AS, 1992, CURR OPIN CELL BIOL, V4, P267; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; LOOMIS WF, 1982, MOL CELL BIOL, V3, P1540; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; NOVER L, 1984, EUR J BIOCHEM, V139, P302; NOVER L, 1991, HEAT SHOCK RESPONSE, P5; OHI K, 1991, Society for Neuroscience Abstracts, V17, P675; PAGE TL, 1994, SCIENCE, V263, P1570, DOI 10.1126/science.8128243; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RAJU U, 1990, AM J PHYSIOL, V258, pR256, DOI 10.1152/ajpregu.1990.258.1.R256; RAJU U, 1994, J NEUROCHEM, V61, P1236; RENSING L, 1987, CHRONOBIOL INT, V4, P543, DOI 10.3109/07420528709078546; RENSING L, 1990, CHRONOBIOL INT, V7, P353, DOI 10.3109/07420529009059146; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROTHMAN BS, 1976, J GEN PHYSIOL, V68, P359, DOI 10.1085/jgp.68.4.359; TAKAGI N, 1989, B SOC SEA WATER SCI, V42, P279; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; UEUNG SJ, 1987, P NATL ACAD SCI USA, V84, P279; VONGROMOFF ED, 1989, MOL CELL BIOL, V9, P3911, DOI 10.1128/MCB.9.9.3911; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZIZI M, 1994, J BIOL CHEM, V269, P1614; [No title captured]	70	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14619	14627		10.1074/jbc.270.24.14619	http://dx.doi.org/10.1074/jbc.270.24.14619			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782325	hybrid			2022-12-27	WOS:A1995RD45500059
J	PERNIS, A; GUPTA, S; YOPP, J; GARFEIN, E; KASHLEVA, H; SCHINDLER, C; ROTHMAN, P				PERNIS, A; GUPTA, S; YOPP, J; GARFEIN, E; KASHLEVA, H; SCHINDLER, C; ROTHMAN, P			GAMMA-CHAIN-ASSOCIATED CYTOKINE RECEPTORS SIGNAL THROUGH DISTINCT TRANSDUCING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; INTERLEUKIN-7 RECEPTOR; FUNCTIONAL COMPONENT; TRANSCRIPTION FACTOR; PHOSPHORYLATION; CELLS; BINDING; ACTIVATION; PATHWAY; JAK2	The IL-2, IL-4, and IL-7 signaling pathways have been shown to utilize shared components. The receptors for these cytokines are composed of ligand-specific binding chains that associate with a shared signaling subunit, the common gamma (gamma(c)) chain. In addition, IL-2, IL-4, and IL-7 induce activation of a common set of nonreceptor tyrosine kinases, Jak-1 and Jak-3. We have further investigated the signaling events induced by these cytokines and find that the gamma(c)-associated receptors activate distinct signal transducing factors (STFs). In addition, we show that a 94-kDa STAT-related protein (p94) is activated in response to IL-2 and IL-7, but not IL-4. These data indicate that IL-2, IL-4, and IL-7 activate distinct signaling molecules which might be differentially recruited to the receptor complex by the ligand-specific units of the IL-2, IL-4, and IL-7 receptors.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033450, R01AI033450] Funding Source: NIH RePORTER; NCI NIH HHS [T 32CA09503] Funding Source: Medline; NHLBI NIH HHS [HL 21006-17] Funding Source: Medline; NIAID NIH HHS [AI 33450-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P68; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	53	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14517	14522		10.1074/jbc.270.24.14517	http://dx.doi.org/10.1074/jbc.270.24.14517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782314	hybrid			2022-12-27	WOS:A1995RD45500045
J	EAKLE, KA; LYU, RM; FARLEY, RA				EAKLE, KA; LYU, RM; FARLEY, RA			THE INFLUENCE OF BETA-SUBUNIT STRUCTURE ON THE INTERACTION OF NA+/K+-ATPASE COMPLEXES WITH NA+ - A CHIMERIC BETA-SUBUNIT REDUCES THE NA+ DEPENDENCE OF PHOSPHOENZYME FORMATION FROM ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; CONFERS OUABAIN RESISTANCE; TISSUE-SPECIFIC EXPRESSION; (NA++K+)-ACTIVATED ATPASE; CATION OCCLUSION; NA,K PUMP; NA+,K+-ATPASE; (NA++K+)-ATPASE; H,K-ATPASE; SODIUM	High-affinity ouabain binding to Na+/K+-ATPase (sodium- and potassium-transport adenosine triphosphatase (EC 3.6.1.37)) requires phosphorylation of the alpha subunit of the enzyme either by ATP or by inorganic phosphate, For the native enzyme (alpha/beta 1), the ATP-dependent reaction proceeds about 4-fold more slowly in the absence of Na+ than when saturating concentrations of Na+ are present, Hybrid pumps were formed from either the alpha 1 or the alpha 3 subunit isoforms of Na+/K+-ATPase and a chimeric beta subunit containing the transmembrane segment of the Na+/K+-ATPase beta 1 isoform and the external domain of the gastric H+/R(+)-ATPase beta subunit (alpha/NH beta 1 complexes), In the absence of Na+, these complexes show a rate of ATP-dependent ouabain binding from similar to 75-100% of the rate seen in the presence of Na+ depending on buffer conditions, Nonhydrolyzable nucleotides or treatment of ATP with apyrase abolishes ouabain binding, demonstrating that ouabain binding to alpha/NH beta 1 complexes requires phosphorylation of the protein, Buffer ions inhibit ouabain binding by alpha/NH beta 1 in the absence of Na+ rather than promote ouabain binding, indicating that they are not substituting for sodium ions in the phosphorylation reaction, The pH dependence of ATP-dependent ouabain binding in the presence or absence of Na+ is similar, suggesting that protons are probably not substituting for Na+, Hybrid alpha/NH beta 1 pumps also show slightly higher apparent affinities (2-3-fold) for ATP, Na+, and ouabain; however, these are not sufficient to account for the increase in ouabain binding in the absence of Na+. In contrast to phosphoenzyme formation and ouabain binding by alpha/NH beta 1 complexes in the absence of Na+. ATPase activity, measured as release of phosphate from ATP, requires Na+. These data suggest that the transition from E(1)P to E(2)P during the catalytic cycle does not occur when the sodium binding sites are not occupied, Thus, the chimeric beta subunit reduces or eliminates the role of Na+ in phosphoenzyme formation from ATP, but Na+ binding or release by the enzyme is still required for ATP hydrolysis and release of phosphate.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA	University of Southern California	EAKLE, KA (corresponding author), UNIV SO CALIF, SCH MED, DEPT PHYSIOL & BIOPHYS, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1968, MOL PHARMACOL, V4, P325; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHARNOCK JS, 1963, NATURE, V199, P910, DOI 10.1038/199910a0; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P834; EAKLEKA, 1991, SODIUM PUMP RECENT D, P125; FALLOWS D, 1987, MOL CELL BIOL, V7, P2985, DOI 10.1128/MCB.7.8.2985; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HARA Y, 1986, J BIOL CHEM, V261, P2655; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; HOOTMAN SR, 1988, METHOD ENZYMOL, V156, P213; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; NOGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1237, DOI 10.1016/S0006-291X(88)81272-5; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POST RL, 1965, J BIOL CHEM, V240, P1437; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Sherman F, 1979, METHODS YEAST GENETI; SHULL GE, 1990, J BIOL CHEM, V265, P12123; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V854, P21; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA S, 1987, J BIOL CHEM, V262, P103	49	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13937	13947		10.1074/jbc.270.23.13937	http://dx.doi.org/10.1074/jbc.270.23.13937			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775454	hybrid			2022-12-27	WOS:A1995RC44800053
J	LARSSON, N; MELANDER, H; MARKLUND, U; OSTERMAN, O; GULLBERG, M				LARSSON, N; MELANDER, H; MARKLUND, U; OSTERMAN, O; GULLBERG, M			G2/M TRANSITION REQUIRES MULTISITE PHOSPHORYLATION OF ONCOPROTEIN-18 BY 2 DISTINCT PROTEIN-KINASE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PHOSPHOPROTEIN P19; LEUKEMIA-ASSOCIATED GENE; MASS-SPECTROMETRY; EXPRESSION; CELLS; IDENTIFICATION; ACTIVATION; LYMPHOCYTES; STATHMIN; SITES	Oncoprotein 18 (Op18) is a conserved cytosolic protein that is a target for both cell cycle and cell surface receptor-regulated phosphorylation events, The four residues Ser(16), Ser(25), Ser(38), and Ser(63) are all subject to cell cycle-regulated phosphorylation, Ser(25) and Ser(38) are targets for cyclin dependent kinases (CDKs), while Ser(16) and Ser(63) are phosphorylated by an unidentified protein kinase, We have recently shown that induced expression of a CDK target site deficient mutant, Op18-S25A,S38A, blocks human cell lines during G2/M transition, In the present report we show that mitosis is associated with complete phosphorylation of the two Op18 CDK target sites Ser(25) and Ser(38) and that Ser(16) and Ser(63) are also phosphorylated to a high stoichiometry, To evaluate the function of multisite phosphorylation of Op18, we expressed and analyzed the cell cycle phenotype of different kinase target site-deficient mutants. The data showed that induced expression of the S16A,S63A, S25A,S38A, and S16A,S25A,S38A,S63A mutants all resulted in an indistinguishable phenotype, i.e. immediate G2/M block and subsequent endoreduplication, a given fraction of G2 versus M-phase blocked cells, and a characteristic nuclear morphology of M-blocked cells, This result was unexpected; however, a likely explanation was provided by analysis of Op18 phosphoisomers, which revealed that mutations of the CDK sites interfere with phosphorylation of Ser(16) and Ser(63). The simplest interpretation of our results is that phosphorylation of Ser(16) and Ser(63) is essential during G2/M transition and that the phenotype of the S25A,S38A mutant is mediated by the observed block of Ser(16)/Ser(63) phosphorylation.	UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN	Umea University				Gullberg, Martin/0000-0002-3984-4572				BERETTA L, 1993, J BIOL CHEM, V268, P20076; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COOPER HL, 1991, J IMMUNOL, V146, P3689; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; DRAETTA DF, 1994, CURR OPIN CELL BIOL, V6, P842; FRIEDRICH B, 1995, IN PRESS PROSTATE; GHOSH PK, 1993, ONCOGENE, V8, P2869; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Hunt T, 1991, Semin Cell Biol, V2, P213; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; ROOS G, 1993, LEUKEMIA, V7, P1538; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; WANG YK, 1993, J BIOL CHEM, V268, P14269; ZHU XX, 1989, J BIOL CHEM, V264, P14556	38	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14175	14183		10.1074/jbc.270.23.14175	http://dx.doi.org/10.1074/jbc.270.23.14175			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775478	hybrid			2022-12-27	WOS:A1995RC44800085
J	DIECI, G; DUIMIO, L; PERACCHIA, G; OTTONELLO, S				DIECI, G; DUIMIO, L; PERACCHIA, G; OTTONELLO, S			SELECTIVE INACTIVATION OF 2 COMPONENTS OF THE MULTIPROTEIN TRANSCRIPTION FACTOR TFIIIB IN CYCLOHEXIMIDE GROWTH-ARRESTED YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TATA-BINDING PROTEIN; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; GENES; SEQUENCES; LOOP; 5S	Following protein synthesis inhibition in cycloheximide growth-arrested yeast cells, the rates of tRNA and 5 S RNA synthesis decrease with apparent half-times of about 20 and 10 min, respectively. This effect is mimicked by extracts of treated cells, and the impairment of tRNA gene transcription activity that is observed in vitro parallels the in vivo inactivation of RNA polymerase III transcription. As revealed by experiments in which partially purified class III transcription factors were singly added to extracts of treated cells, only the activity of the multiprotein transcription factor TFIIIB is severely impaired after 3 h of cycloheximide treatment. Similar assays carried out in an in vitro transcription system in which TFIIIB activity was reconstituted by a combination of the TATA box-binding protein (TBP), the 70-kDa component TFIIIB70, plus a partially purified fraction known as B '' have shown that the latter two components are both necessary and sufficient to restore control levels of transcription. Their activity, but not TBP activity, is considerably reduced in extracts of treated cells. TFIIIB70 and a component of fraction B '' thus appear to be the selective targets of the down-regulation of polymerase ill transcription that is brought about by cycloheximide. A substantial depletion of the TFIIIB70 polypeptide was detected by Western immunoblot analysis of extracts derived from cycloheximide growth-arrested cells, indicating that the inactivation of this TFIIIB component results primarily from its enhanced destabilization under conditions of protein synthesis inhibition.	UNIV PARMA, INST BIOCHEM SCI, I-43100 PARMA, ITALY	University of Parma			Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961				ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROW DA, 1987, J BIOL CHEM, V262, P13953; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEKLOET SR, 1966, BIOCHEM J, V99, P566, DOI 10.1042/bj0990566; DELEON AL, 1992, CELL, V71, P211; DIECI G, 1993, J BIOL CHEM, V268, P11199; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GROSS KJ, 1974, J BIOL CHEM, V249, P568; HARLOW E, 1988, ANTIBODIES LABORATOR; HUET J, 1994, NUCLEIC ACIDS RES, V22, P2282, DOI 10.1093/nar/22.12.2282; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEIGEBORN L, 1990, NUCLEIC ACIDS RES, V18, P4179, DOI 10.1093/nar/18.14.4179; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; PHILIPPSEN P, 1978, J MOL BIOL, V123, P387, DOI 10.1016/0022-2836(78)90086-4; POON D, 1993, J BIOL CHEM, V268, P15325; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHULMAN RW, 1977, J BIOL CHEM, V252, P1344; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SULLIVAN HS, 1994, MOL CELL BIOL, V14, P1806, DOI 10.1128/MCB.14.3.1806; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1994, RNA POLYMERASE 3 TRA, P1; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WISE JA, 1991, METHOD ENZYMOL, V194, P405	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13476	13482		10.1074/jbc.270.22.13476	http://dx.doi.org/10.1074/jbc.270.22.13476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768951	hybrid			2022-12-27	WOS:A1995RB43900077
J	CAMADRO, JM; THOME, F; BROUILLET, N; LABBE, P				CAMADRO, JM; THOME, F; BROUILLET, N; LABBE, P			PURIFICATION AND PROPERTIES OF PROTOPROPHYRINOGEN OXIDASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE - MITOCHONDRIAL LOCATION AND EVIDENCE FOR A PRECURSOR FORM OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHENYL ETHER HERBICIDES; MURINE PROTOPORPHYRINOGEN OXIDASE; MICROBIAL HEME SYNTHESIS; COPROPORPHYRINOGEN OXIDASE; ACIFLUORFEN-METHYL; LATE STEP; CELLULAR-LOCALIZATION; DESULFOVIBRIO-GIGAS; ENZYMIC CONVERSION; BARLEY ORGANELLES	Protoporphyrinogen oxidase, the molecular target of diphenylether-type herbicides, was purified to homogeneity from yeast mitochondrial membranes and found to be a 55-kDa polypeptide with a pI of 8.5 and a specific activity of 40,000 nmol of protoporphyrin/h/mg of protein at 30 degrees C. The Michaelis constant (K-m) for protoporphyrinogen IX was 0.1 mu M. Due to the high affinity of the enzyme toward oxygen, the K-m for oxygen could only be approximated to 0.5-1.5 mu M. The purified enzyme contained a flavin as cofactor. Studies with rabbit antibodies to yeast protoporphyrinogen oxidase showed that the enzyme is synthesized as a high molecular weight precursor (58 kDa) that is rapidly converted in vivo to the mature (55 kDa) membrane bound form. Protoporphyrinogen oxidase activity was found only in purified yeast mitochondrial inner membrane (not in the outer membrane). Acifluorfen-methyl, a potent diphenylethertype herbicide, competitively inhibited the purified enzyme (K-i = 10 nM), The mixed inhibition by acifluorfenmethyl previously reported for the membrane-bound protoporphyrinogen oxidase (Camadro, J. M., Matringe, M., Scalla, R., and Labbe, P. (1991) Biochem. J. 277, 17-21) was shown to be related to partial proteolysis of the enzyme.			CAMADRO, JM (corresponding author), INST JACQUES MONOD, DEPT MICROBIOL, BIOCHIM PORPHYRINES LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.			Camadro, Jean-Michel/0000-0002-8549-2707				AKAGI T, 1993, Z NATURFORSCH C, V48, P345; CAMADRO JM, 1985, ARCH BIOCHEM BIOPHYS, V242, P206, DOI 10.1016/0003-9861(85)90494-1; CAMADRO JM, 1991, BIOCHEM J, V277, P17, DOI 10.1042/bj2770017; CAMADRO JM, 1982, BIOCHEM BIOPH RES CO, V106, P724, DOI 10.1016/0006-291X(82)91771-5; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; CERLETTI P., 1971, Methods in Enzymology, V18B, P285, DOI 10.1016/S0076-6879(71)18090-1; DAILEY HA, 1987, BIOCHEMISTRY-US, V26, P2697, DOI 10.1021/bi00384a007; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; ELDER GH, 1978, BIOCHEM J, V172, P345, DOI 10.1042/bj1720345; FALK JE, 1964, PORPHYRINS METALLOPO, V2, P162; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; HAID A, 1983, METHOD ENZYMOL, V96, P192; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1990, ARCH BIOCHEM BIOPHYS, V280, P369, DOI 10.1016/0003-9861(90)90344-X; JACOBS JM, 1991, PLANT PHYSIOL, V97, P197, DOI 10.1104/pp.97.1.197; JACOBS JM, 1977, BIOCHEM BIOPH RES CO, V78, P429, DOI 10.1016/0006-291X(77)91272-4; JACOBS NJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P540, DOI 10.1016/0304-4165(78)90328-8; JACOBS NJ, 1989, BIOCHEM BIOPH RES CO, V161, P790, DOI 10.1016/0006-291X(89)92669-7; JACOBS NJ, 1976, BIOCHIM BIOPHYS ACTA, V449, P1, DOI 10.1016/0005-2728(76)90002-5; JACOBS NJ, 1977, BIOCHIM BIOPHYS ACTA, V459, P141, DOI 10.1016/0005-2728(77)90017-2; JACOBS NJ, 1975, BIOCHEM BIOPH RES CO, V65, P435, DOI 10.1016/S0006-291X(75)80112-4; JONES C, 1984, J CHEM SOC PERK T 1, P2625, DOI 10.1039/p19840002625; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KLEMM DJ, 1985, J BACTERIOL, V164, P316, DOI 10.1128/JB.164.1.316-320.1985; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; KRIJT J, 1993, ARCH TOXICOL, V67, P255, DOI 10.1007/BF01974344; KRIJT J, 1992, PESTIC BIOCHEM PHYS, V42, P180, DOI 10.1016/0048-3575(92)90064-7; LABBE P, 1971, BIOCHIMIE, V53, P1001, DOI 10.1016/S0300-9084(71)80068-8; LABBE P, 1985, ANAL BIOCHEM, V149, P248, DOI 10.1016/0003-2697(85)90502-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HJ, 1993, PLANT PHYSIOL, V102, P881, DOI 10.1104/pp.102.3.881; LEHNEN LP, 1990, PESTIC BIOCHEM PHYS, V37, P239, DOI 10.1016/0048-3575(90)90130-T; LYDON J, 1988, PESTIC BIOCHEM PHYS, V31, P74, DOI 10.1016/0048-3575(88)90031-4; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MATRINGE M, 1987, P BR CROP PROT C B, V9, P981; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; NANDIHALLI UB, 1992, PESTIC BIOCHEM PHYS, V43, P193, DOI 10.1016/0048-3575(92)90033-V; OHANIANCE L, 1966, BIOCHIM BIOPHYS ACTA, V128, P228, DOI 10.1016/0926-6593(66)90170-6; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; POULSON R, 1976, J BIOL CHEM, V251, P3730; POULSON R, 1975, J BIOL CHEM, V250, P1269; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; SANDMANN G, 1988, Z NATURFORSCH C, V43, P699; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; URBANGRIMAL D, 1981, MOL GEN GENET, V183, P85, DOI 10.1007/BF00270144; URBANGRIMAL D, 1986, EUR J BIOCHEM, V156, P511, DOI 10.1111/j.1432-1033.1986.tb09610.x; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WITKOWSKI DA, 1988, PLANT PHYSIOL, V87, P632, DOI 10.1104/pp.87.3.632; WITKOWSKI DA, 1989, PLANT PHYSIOL, V90, P1239, DOI 10.1104/pp.90.4.1239; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	60	53	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32085	32091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798202				2022-12-27	WOS:A1994PX30400014
J	CHARLESWORTH, A; ROZENGURT, E				CHARLESWORTH, A; ROZENGURT, E			THAPSIGARGIN AND DI-TERT-BUTYLHYDROQUINONE INDUCE SYNERGISTIC STIMULATION OF DNA-SYNTHESIS WITH PHORBOL ESTER AND BOMBESIN IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PASTEURELLA-MULTOCIDA TOXIN; INTRACELLULAR CA-2+ STORES; GROWTH-FACTOR; PLASMA-MEMBRANE; TUMOR PROMOTER; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; INOSITOL PHOSPHATE; MITOGENIC SIGNAL	The specific inhibitors of the endoplasmic reticulum Ca2+ pump, thapsigargin and 2,5-di-tert-butylhydroquinone (DBHQ), stimulated reinitiation of DNA synthesis in synergy with either phorbol 12,13-dibutyrate or bombesin in Swiss 3T3 cells. Maximum stimulation was achieved at 0.5 nM thapsigargin and 7.5 mu M DBHQ. Kinetics of [H-3]thymidine incorporation were consistent with exit from G(0) and entry into S phase. Autoradiography of labeled nuclei showed that the increase in [H-3]thymidine incorporation was due to an increase in the proportion of cells entering into DNA synthesis. Down-regulation or selective inhibition of protein kinase C abolished this synergistic stimulation of DNA synthesis. Thapsigargin and DBHQ and did not potentiate protein kinase C-mediated signals such as direct phosphorylation of myristoylated alanine-rich C-kinase substrate, activation of mitogen-activated protein kinase, and tyrosine phosphorylation of bands 110,000-130,000 and 70,000-80,000. Thapsigargin and DBHQ caused a marked reduction in the ability of bombesin to induce a rapid and transient increase in intracellular Ca2+ via depletion of total cellular Ca2+, measured by Ca-45(2+) content. The synergistic stimulation of DNA synthesis by DBHQ and phorbol 12,13-dibutyrate was dependent on a high concentration of extracellular Ca2+ (ED(50) = 410 mu M) and was preferentially inhibited by the inhibitor of Ca2+ influx econozole. This suggests a role for Ca2+ entry in growth control. This is the first time that either thapsigargin or DBHQ has been shown to stimulate the reinitiation of DNA synthesis in any target cell.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BREITTMAYER JP, 1993, CELL IMMUNOL, V152, P143, DOI 10.1006/cimm.1993.1274; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARA F, 1985, BIOCHEM BIOPH RES CO, V130, P646, DOI 10.1016/0006-291X(85)90466-8; VOSTAL JG, 1993, BIOCHEM J, V295, P525, DOI 10.1042/bj2950525; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	59	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32528	32535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798254				2022-12-27	WOS:A1994PX30400076
J	FIOL, CJ; WILLIAMS, JS; CHOU, CH; WANG, QM; ROACH, PJ; ANDRISANI, OM				FIOL, CJ; WILLIAMS, JS; CHOU, CH; WANG, QM; ROACH, PJ; ANDRISANI, OM			A SECONDARY PHOSPHORYLATION OF CREB(341) AT SER(129) IS REQUIRED FOR THE CAMP-MEDIATED CONTROL OF GENE-EXPRESSION - A ROLE OF GLYCOGEN-SYNTHASE KINASE-3 IN THE CONTROL OF GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; RAT SOMATOSTATIN GENE; AMP RESPONSE ELEMENT; NUCLEAR-PROTEIN; FACTOR CREB; TRANSCRIPTION; PROMOTER; PEPTIDE; CELLS	The cAMP-dependent protein kinase (PKA) phosphorylates CREB(327/341) at a single serine residue, Ser(119/133), respectively, Phosphorylation at this site creates the sequence motif SXXXS(P), a consensus site of the glycogen synthase kinase-3 (GSK-3) enzyme (Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W., and Roach, P. J. (1987) J. Biol, Chem, 262, 14042-14048), We examined the phosphorylation of CREB at the SXXXS(P) consensus site and its role in CREB transactivation to cAMP induction, Neither isoform of the GSK-3 enzyme (GSK-3 alpha or beta) utilizes CREE as its substrate unless CREB is already phosphorylated at Ser(119/133). A 13-amino acid peptide containing the sequence surrounding Ser(119/133) was phosphorylated by GSK-3, at Ser(115/129), only after the primary phosphorylation of the peptide by PKA (at Ser(119/133)), suggesting that Ser(115/129) is a GSK-3 phosphoacceptor site, Mutant CREB(327/341) proteins containing Ser-->Ala substitutions confirmed Ser(115/129) as the only GSK-3 phosphorylation site, Transfection assays of wild type and mutant Gal4-CREB fusion proteins in PC12 cells demonstrated that Ser-->Ala substitution of residue 129 of CREB(341) impairs the transcriptional response to cAMP induction, Analogous mutation in CREB(327) results in 70% decrease in its transactivation response to cAMP. In undifferentiated F9 cells, which are refractory to cAMP induction, transfected GSK-3 beta kinase induces a 60-fold increase in cyclic AMP response element-dependent transcription, mediated via the endogenous CREB protein, We propose that the hierarchical phosphorylation at the PRA and GSK-3 sites of CREB are essential for cAMP control of CREB.	PURDUE UNIV,SCH VET MED,DEPT PHYSIOL & PHARMACOL,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis				Andrisani, Ourania/0000-0002-6230-0303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK044533, R01DK027221, R29DK044533] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221, DK44533] Funding Source: Medline; PHS HHS [NTP1246] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MEEK DW, 1992, BIOCHEM J, V287, P1; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PARK IK, 1991, FASEB J, V5, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WANG QM, 1994, J BIOL CHEM, V269, P14566; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	35	248	252	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32187	32193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798217				2022-12-27	WOS:A1994PX30400029
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			TOPOISOMERASE-III, BUT NOT TOPOISOMERASE-I, CAN SUPPORT NASCENT CHAIN ELONGATION DURING THETA-TYPE DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PBR322 DNA; GYRASE; STRAND; DECATENATION; CHROMOSOME; ORIGIN	Topoisomerase III, but not topoisomerase I, could, in the absence of DNA gyrase, support bidirectional DNA replication in an oriC plasmid DNA replication system reconstituted with purified proteins. The initial rate of DNA synthesis and the efficiency of nascent chain elongation showed that topoisomerase III-stimulated DNA replication was as efficient as gyrase-stimulated DNA replication. In addition, topoisomerase III was also able, in the absence of DNA gyrase, to decatenate the replicating daughter DNA molecules to form monomer product. Thus, of the four topoisomerases in Escherichia coli, three, topoisomerases III and IV and DNA gyrase, can support nascent chain elongation, whereas only two, topoisomerases III and IV can topologically resolve the daughter molecules.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BOHK JJ, 1983, GENE, V24, P265; FILUTOWICZ M, 1982, MOL GEN GENET, V191, P282; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1994, J BIOL CHEM, V269, P2093; KATO J, 1992, J BIOL CHEM, V267, P25676; KEUZER KN, 1979, J BACTERIOL, V140, P424; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030	23	64	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32655	32659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798272				2022-12-27	WOS:A1994PX30400094
J	WIKNER, C; MESHALKINA, L; NILSSON, U; NIKKOLA, M; LINDQVIST, Y; SUNDSTROM, M; SCHNEIDER, G				WIKNER, C; MESHALKINA, L; NILSSON, U; NIKKOLA, M; LINDQVIST, Y; SUNDSTROM, M; SCHNEIDER, G			ANALYSIS OF AN INVARIANT COFACTOR-PROTEIN INTERACTION IN THIAMIN DIPHOSPHATE-DEPENDENT ENZYMES BY SITE-DIRECTED MUTAGENESIS - GLUTAMIC-ACID-418 IN TRANSKETOLASE IS ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; BAKERS-YEAST; GENE; DNA; PYROPHOSPHATE; COLLECTION; DETECTOR; PLASMID	A homologous expression system and a purification protocol for pure, highly active recombinant yeast transketolase have been developed. The invariant transketolase residue Glu(418), which forms a hydrogen bond to the N-1' nitrogen atom of the pyrimidine ring of the cofactor thiamin diphosphate has been replaced by glutamine and alanine. Crystallographic analyses of the mutants show that these amino acid substitutions do not induce structural changes beyond the site of mutation. In both cases, the cofactor binds in a manner identical to the wild-type enzyme. Significant differences in the CD spectra of the mutant transketolases compared with the spectrum of wild-type enzyme indicate differences in the electron distribution of the aminopyrimidine ring of the cofactor. The E418Q mutant shows 2% and the E418A mutant shows about 0.1% of the catalytic activity of wild-type enzyme. The affinities of the mutant enzymes for thiamin diphosphate are comparable with wild-type transketolase, The hydrogen bond between the coenzyme and the side chain of Glu(418) is thus not required for coenzyme binding but essential for catalytic activity. The results demonstrate the functional importance of this interaction and support the molecular model for cofactor deprotonation, the first step in enzymatic thiamin catalysis.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT BIOL MOLEC,S-75124 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Meshalkina, Ludmilla/D-8448-2012; Lindqvist, Ylva/F-9009-2010	Schneider, Gunter/0000-0003-0622-5713; Lindqvist, Ylva/0000-0003-3162-8661				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CALDWELL GA, 1993, PROMEGA NOTES, V44, P6; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; ELODI P, 1956, Acta Physiol Acad Sci Hung, V9, P339; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HEINRICH CP, 1972, BIOCHEM BIOPH RES CO, V49, P1427, DOI 10.1016/0006-291X(72)90498-6; HEINRICH PC, 1972, EUR J BIOCHEM, V30, P533, DOI 10.1111/j.1432-1033.1972.tb02124.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KONIG S, 1994, J BIOL CHEM, V269, P10879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; LINDQVIST Y, 1993, CURR OPIN STRUC BIOL, V3, P896, DOI 10.1016/0959-440X(93)90153-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; OSAWA T, 1972, CHEM PHARM BULL, V20, P2715; Racker E, 1961, ENZYMES, V5, P397; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAITOU S, 1974, FEBS LETT, V40, P114, DOI 10.1016/0014-5793(74)80906-3; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCHAAFFGERSTENSCHLAGER I, 1993, EUR J BIOCHEM, V217, P487, DOI 10.1111/j.1432-1033.1993.tb18268.x; SCHELLENBERGER A, 1965, H-S Z PHYSIOL CHEM, V343, P189; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; SHERMAN F, 1986, METHODS YEAST GENETI, P164; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TIKHOMIROVA NK, 1990, BIOCHEM INT, V22, P31; VILLAFRANCA BL, 1971, J BIOL CHEM, V246, P3126; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1979, SERC4 DAR LAB COLL C	46	108	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32144	32150						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798210				2022-12-27	WOS:A1994PX30400022
J	VOGEL, WK; MOSSER, VA; BULSECO, DA; SCHIMERLIK, MI				VOGEL, WK; MOSSER, VA; BULSECO, DA; SCHIMERLIK, MI			PORCINE M2 MUSCARINIC ACETYLCHOLINE RECEPTOR-EFFECTOR COUPLING IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE INHIBITION; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; PHOSPHOINOSITIDE TURNOVER; PHOSPHOLIPID TURNOVER; CHICK HEART; BINDING; PROTEIN; BRAIN; ACTIVATION	The relationship between porcine ma muscarinic receptor coupling to inhibition of cAMP formation and stimulation of phosphatidylinositol metabolism in Chinese hamster ovary cells was examined. Reduction of the number of receptors per cell with the slowly dissociating antagonist (-)-quinuclidinyl benzilate caused a decrease in maximal response with no effect on EC(50) for coupling to phosphatidylinositol metabolism. Inhibition of cAMP formation showed the opposite dependence with no effect on maximal response but an increase in EC(50) value as receptor density decreased, Pilocarpine appeared to be a partial agonist at low cell receptor density but displayed full agonism at higher receptor density. These results are compatible with a two-state model describing m2 muscarinic receptor acting via two different G proteins, This model is compatible with ob servations of negative antagonism where antagonists stimulated cAMP formation in adenylyl cyclase inhibition assays, and can also be used to estimate receptor affinities for G proteins in systems which display negative antagonism.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, ENVIRONM HLTH SCI CTR, CORVALLIS, OR 97331 USA	Oregon State University; Oregon State University				Vogel, Walter/0000-0002-5663-6660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1987, SCIENCE, V237, P1628; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; COSTA T, 1992, MOL PHARMACOL, V41, P549; DAI YS, 1993, AM J PHYSIOL, V265, pG1122, DOI 10.1152/ajpgi.1993.265.6.G1122; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELHAYE M, 1984, N-S ARCH PHARMACOL, V325, P170, DOI 10.1007/BF00506197; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; EHLERT FJ, 1985, MOL PHARMACOL, V28, P410; FISHER SK, 1984, J NEUROCHEM, V43, P1171, DOI 10.1111/j.1471-4159.1984.tb12858.x; FISHER SK, 1983, J BIOL CHEM, V258, P7358; FURCHGOTT RF, 1964, ANNU REV PHARMACOL, V4, P21, DOI 10.1146/annurev.pa.04.040164.000321; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEE W, 1990, J PHARMACOL EXP THER, V252, P482; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MUKAI H, 1992, J BIOL CHEM, V267, P16237; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHIMERLIK MI, 1980, BIOCHEMISTRY-US, V19, P3407, DOI 10.1021/bi00556a001; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TOTA MR, 1990, MOL PHARMACOL, V37, P996; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037; YOCCA FD, 1992, MOL PHARMACOL, V41, P1066	42	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15485	15493		10.1074/jbc.270.26.15485	http://dx.doi.org/10.1074/jbc.270.26.15485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797541	hybrid			2022-12-27	WOS:A1995RG53800011
J	YU, H; SUCHARD, SJ; NAIRN, R; JOVE, R				YU, H; SUCHARD, SJ; NAIRN, R; JOVE, R			DISSOCIATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION FROM THE OXIDATIVE BURST IN DIFFERENTIATED HL-60 CELLS AND HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST; TYROSINE PHOSPHORYLATION; THREONINE KINASE; MAP KINASES; INHIBITION; RAF; STIMULATION; SPECIFICITY; LEUKOCYTES; OXIDASE	In human polymorphonuclear leukocytes (PMNs), mitogen-activated protein kinases (MAPKs), also known as extracellular signal-regulated kinases (Erks), are activated within minutes upon stimulation with either chemoattractant formyl-Met-Leu-Phe (fMLP) or phorbol 12-myristate 13-acetate (PMA), This activation of MAPKs coincides with the formation of superoxide anion, which occurs through the activation of a multiple-component NADPH oxidase pathway, MAPKs have thus been suggested to be involved in signal transduction leading to the oxidative burst, To investigate whether MAPK activation plays a central role in the oxidative burst, we evaluated the effect of cAMP on MAPK activation induced by fMLP and PMA. cAMP inhibits many PMN functional responses, including the oxidative burst, and has recently been shown to reduce growth factor- and PMA induced MAPK activities in a variety of cells, We found that in differentiated, neutrophil-like HL-60 cells, while cAMP reduced PMA-induced MAPK activation, it had no effect on fMLP-induced MAPK activation, Despite the presence of unchanged levels of activated MAPKs, the fMLP-induced oxidative burst was substantially diminished by cAMP. By contrast, O-2(-) production induced by PMA remained the same even though MAPK activation was inhibited, In PMNs, although the levels of O-2(-) induced by either 10 ng/ml or 100 ng/ml PMA were similar, only 100 ng/ml could stimulate MAPK activation, suggesting that the oxidative burst could occur in the absence of detectable activation of MAPKs. As in HL-60 cells, cAMP inhibited the O-2(-) production in fMLP-stimulated PMNs but had no effect on MAPK activity, These results demonstrate that, while MAPK activation coincides with PMN activation, it can be dissociated from the oxidative burst.	UNIV MICHIGAN,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	YU, H (corresponding author), UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,5812 MED SCI 2,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline; NHLBI NIH HHS [HL53074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDREWS PC, 1983, BLOOD, V61, P333; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V884, P54; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V882, P57, DOI 10.1016/0304-4165(86)90055-3; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURNUTTE JT, 1979, J CLIN INVEST, V63, P637, DOI 10.1172/JCI109346; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FANTONE JC, 1984, BIOCHIM BIOPHYS ACTA, V804, P265, DOI 10.1016/0167-4889(84)90129-0; FANTONE JC, 1984, AM J PATHOL, V115, P9; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LEVY R, 1990, J IMMUNOL, V145, P2595; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; PARSONS WJ, 1988, MOL PHARMACOL, V33, P441; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; THOMPSON HL, 1993, BIOCHEM J, P483; TORRES M, 1993, J IMMUNOL, V150, P1563; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WELLS JN, 1975, MOL PHARMACOL, V11, P775; WORTHON GS, 1994, J CLIN INVEST, V84, P815; WU J, 1992, BIOCHEM SOC T, V20, P675, DOI 10.1042/bst0200675; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	42	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15719	15724		10.1074/jbc.270.26.15719	http://dx.doi.org/10.1074/jbc.270.26.15719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797573	hybrid			2022-12-27	WOS:A1995RG53800045
J	ALONSO, MD; LOMAKO, J; LOMAKO, WM; WHELAN, WJ				ALONSO, MD; LOMAKO, J; LOMAKO, WM; WHELAN, WJ			CATALYTIC ACTIVITIES OF GLYCOGENIN ADDITIONAL TO AUTOCATALYTIC SELF-GLUCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PROTEIN; BIOSYNTHESIS; INITIATION; BIOGENESIS; SYNTHASE	Glycogenin is the autocatalytic, self-glucosylating protein that initiates glycogen synthesis in muscle and other tissues. We have sequenced the cDNA for rabbit muscle glycogenin and expressed and purified the protein in high yield as well as two mutant proteins in which Phe or Thr replaces Tyr-194, the site of glucosylation. While the wildtype protein can self-glucosylate, the mutants cannot, but all three utilize alternative accepters by intermolecular glucose transfer for which the mutants have altered specificity. Tyr-194 is therefore not essential for the catalytic activity of glycogenin. Ah three proteins also hydrolyze UDP-glucose to glucose at rates comparable with the rate of self-glucosylation, The hydrolysis is competitive with glucose transfer to p-nitrophenyl alpha-maltoside, Self-glucosylation, glucosylation of other accepters, and hydrolysis all appear to be catalyzed by the same active center. In the absence of peptidase inhibitors, the homogenous recombinant proteins of M(r) 37,000 break down to equally active species having M(r) 32,000. The kinetics of self-glucosylation catalyzed by the wild-type enzyme suggest that the reaction could be intermolecular rather than, as previously reported, intramolecular, The wild-type recombinant enzyme and native muscle glycogenin, which is phosphorylated, are inhibited quite differently by ATP at physiological concentration.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL M823,POB 016129,MIAMI,FL 33101	University of Miami					NIDDK NIH HHS [DK 37500] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037500] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1994, FEBS LETT, V352, P222, DOI 10.1016/0014-5793(94)00962-7; BAILEY JM, 1993, BIOCHEM SOC T, V21, P124; CAO YJ, 1993, J BIOL CHEM, V268, P14687; LANZILLO JJ, 1990, BIOTECHNIQUES, V8, P661; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, Biofactors, V1, P261; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, Biofactors, V2, P251; MANZELLA SM, 1994, ANAL BIOCHEM, V216, P383, DOI 10.1006/abio.1994.1056; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; RODEN L, 1994, J BIOL CHEM, V269, P11509; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312; [No title captured]	24	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15315	15319		10.1074/jbc.270.25.15315	http://dx.doi.org/10.1074/jbc.270.25.15315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797519	hybrid			2022-12-27	WOS:A1995RE66600070
J	CHAMBERS, RS; WANG, BQ; BURTON, ZF; DAHMUS, ME				CHAMBERS, RS; WANG, BQ; BURTON, ZF; DAHMUS, ME			THE ACTIVITY OF COOH-TERMINAL DOMAIN PHOSPHATASE IS REGULATED BY A DOCKING SITE ON RNA-POLYMERASE-II AND BY THE GENERAL TRANSCRIPTION FACTORS IIF AND IIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; SUBUNIT-IIA; CALF THYMUS; PHOSPHORYLATION; PURIFICATION; PROTEIN; IDENTIFICATION; PROMOTER; KINASES; CLONING	Each cycle of transcription appears to be associated with the reversible phosphorylation of the repetitive COOH-terminal domain (CTD) of the largest RNA polymerase (RNAP) II subunit. The dephosphorylation of RNAP II by CTD phosphatase, therefore, plays an important role in the transcription cycle. The following studies characterize the activity of HeLa cell CTD phosphatase with a special emphasis on the regulation of CTD phosphatase activity. Results presented here suggest that RNAP II contains a docking site for CTD phosphatase that is essential in the dephosphorylation reaction and is distinct from the CTD. This is supported by the observations that (a) phosphorylated recombinant CTD is not a substrate for CTD phosphatase, (b) RNAP IIB, which lacks the CTD, and RNAP IIA are competitive inhibitors of CTD phosphatase and (c) CTD phosphatase can form a stable complex with RNAP II. To test the possibility that the general transcription factors may be involved in the regulation of CTD phosphatase, CTD phosphatase activity was examined in the presence of recombinant or highly purified general transcription factors. TFIIF stimulates CTD phosphatase activity 5-fold. The RAP74 subunit of TFIIF alone contained the stimulatory activity and the minimal region sufficient for stimulation corresponds to COOH-terminal residues 358-517. TFIIB inhibits the stimulatory activity of TFIIF but has no effect on CTD phosphatase activity in the absence of TFIIF. The potential importance of the docking site on RNAP II and the effect of TFIIF and TFIIB in regulating the dephosphorylation of RNAP II at specific times in the transcription cycle are discussed.	UNIV CALIF DAVIS,DIV BIOL SCI,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	University of California System; University of California Davis; Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300, R01GM040708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33300, GM40708] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FINKELSTEIN A, 1972, NATURE, V355, P464; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KANG ME, 1993, J BIOL CHEM, V68, P25033; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1991, P NATL ACAD SCI USA, V8, P10004; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SERIZAWA H, 1992, P NATL ACAD SCI USA, V9, P7476; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN SY, 1994, J BIOL CHEM, V269, P25684; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	39	107	108	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14962	14969		10.1074/jbc.270.25.14962	http://dx.doi.org/10.1074/jbc.270.25.14962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797476	hybrid			2022-12-27	WOS:A1995RE66600021
J	DWORKIN, J; TUMMURU, MKR; BLASER, MJ				DWORKIN, J; TUMMURU, MKR; BLASER, MJ			SEGMENTAL CONSERVATION OF SAPA SEQUENCES IN TYPE-B CAMPYLOBACTER-FETUS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-ARRAY PROTEINS; CHI-LIKE SEQUENCES; S-LAYER; INFECTIONS; PATHOGENESIS; RESISTANCE; SERUM; DNA	Campylobacter fetus cells may exist as either of two defined serogroups (type A or B) based on their lipopolysaccharide (LPS)composition. Wild-type strains contain surface array proteins (S-layer proteins) that have partial antigenic cross-reactivity but bind exclusively to LPS from homologous (type A or B) cells. Type A cells possess 8 homologs of sapA, which encodes a 97-kDa S-layer protein; the gene products of these homologs have a conserved N terminus of 184 amino acids. To further explore the structural relationships between the C. fetus S-layer proteins and their encoding genes, we sought to clone and express an S-layer protein from type B strain 84-91, The cloned type B gene (sapB) was similar in structure to the previously cloned type A gene (sapA) and encoded a full-length 936-amino acid (97-kDa) S-layer protein. Sequence analysis of sapB indicated that the conserved N-terminal encoding region in sapA was absent but that the remainder of the ORF (encoding 751 amino acids) was identical to that of sapA in spite of the nonconserved nature of this region among sapA homologs. Noncoding sequences both 300 base pairs 5' and 1000 base pairs 3' to the sapB and sapA ORFs, including the sapA promoter and transcriptional terminator sequences, were essentially identical. Southern analyses revealed that the sapB N-terminal encoding region was conserved in multiple copies in type B strains but was absent in type A strains. Recombinant sapA and sapB products bound to a substantially greater degree to cells of the homologous LPS type compared with the heterologous LPS type, indicating that the conserved sapA- and sapB-encoded N termini are critical for LPS binding specificity. The parallel genetic organization and identity at the nucleotide level in both coding and noncoding regions for sap homologs in types A and B cells indicates the necessity of both homolog conservation and high fidelity DNA replication in the biology of sap diversity.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,MED SERV,NASHVILLE,TN 37212	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024145] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI24145] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEVERIDGE TJ, 1993, LIFE SCI, V252, P1; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASER MJ, 1990, J BIOL CHEM, V265, P14529; BLASER MJ, 1988, J CLIN INVEST, V81, P1434, DOI 10.1172/JCI113474; BLASER MJ, 1994, MOL MICROBIOL, V14, P453, DOI 10.1111/j.1365-2958.1994.tb02180.x; BLASER MJ, 1987, J INFECT DIS, V155, P696, DOI 10.1093/infdis/155.4.696; BLASER MJ, 1993, J INFECT DIS, V167, P696; CHENG KC, 1984, J MOL BIOL, V180, P371, DOI 10.1016/S0022-2836(84)80009-1; CHENG KC, 1987, J MOL BIOL, V194, P747, DOI 10.1016/0022-2836(87)90252-X; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COVER TL, 1989, ANNU REV MED, V40, P269; DUBREUIL JD, 1990, J BACTERIOL, V172, P5035, DOI 10.1128/jb.172.9.5035-5043.1990; DUBREUIL JD, 1988, J BACTERIOL, V170, P4165, DOI 10.1128/jb.170.9.4165-4173.1988; DWORKIN J, 1995, J BACTERIOL, V177, P1734, DOI 10.1128/jb.177.7.1734-1741.1995; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIMOTO S, 1991, INFECT IMMUN, V59, P2017, DOI 10.1128/IAI.59.6.2017-2022.1991; GARCIA M. M., 1983, Veterinary Bulletin, Weybridge, V53, P793; GARCIA MM, 1995, IN PRESS J BACTERIOL; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MORAN AP, 1994, INFECT IMMUN, V62, P3922, DOI 10.1128/IAI.62.9.3922-3929.1994; PEI ZH, 1990, J CLIN INVEST, V85, P1036, DOI 10.1172/JCI114533; PEI ZH, 1988, J BIOL CHEM, V263, P6416; PENNER J L, 1988, Clinical Microbiology Reviews, V1, P157; PEREZPEREZ GI, 1986, INFECT IMMUN, V51, P209, DOI 10.1128/IAI.51.1.209-212.1986; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V71, P1342; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SKIRROW MB, 1990, TOPLEY WILSONS PRINC, V2, P531; SMIBERT RM, 1978, ANNU REV MICROBIOL, V32, P673, DOI 10.1146/annurev.mi.32.100178.003325; TUMMURU MKR, 1993, P NATL ACAD SCI USA, V90, P7265, DOI 10.1073/pnas.90.15.7265; TUMMURU MKR, 1992, J BACTERIOL, V174, P5916, DOI 10.1128/jb.174.18.5916-5922.1992; WANG EZ, 1993, J BACTERIOL, V175, P4979, DOI 10.1128/JB.175.16.4979-4984.1993; WINTER AJ, 1978, INFECT IMMUN, V22, P963, DOI 10.1128/IAI.22.3.963-971.1978; YANG LY, 1992, J BACTERIOL, V174, P1258, DOI 10.1128/jb.174.4.1258-1267.1992	36	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15093	15101		10.1074/jbc.270.25.15093	http://dx.doi.org/10.1074/jbc.270.25.15093			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797493	hybrid			2022-12-27	WOS:A1995RE66600039
J	PASTI, L; POZZAN, T; CARMIGNOTO, G				PASTI, L; POZZAN, T; CARMIGNOTO, G			LONG-LASTING CHANGES OF CALCIUM OSCILLATIONS IN ASTROCYTES - A NEW FORM OF GLUTAMATE-MEDIATED PLASTICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AMINO-ACID RECEPTOR; CULTURED ASTROCYTES; NITRIC-OXIDE; GLIAL-CELLS; TERM POTENTIATION; VISUAL-CORTEX; FREE CA-2+; ACTIVATION; NEURONS	Long-term changes of synaptic strength in the central nervous system are mediated by an increase of cytosolic calcium concentration ([Ca2+](i)) following activation of excitatory neurotransmitter receptors. These phenomena, which represent a possible cellular basis for learning and memory processes in eukaryotes, are believed to be restricted to neurons. Here we provide evidence for a long-term change of the response elicited by the excitatory neurotransmitter glutamate in a non-neuronal cell population of the central nervous system, i.e. visual cortical astrocytes in culture. Stimulation with glutamate induces in astrocytes a regular pattern of [Ca2+](i) oscillations. A second stimulation, after an interval ranging from 2 to 60 min, induces an oscillatory response characterized by an increased frequency. Induction of this change in the astrocyte response is abolished by a specific inhibitor of the nitric oxide synthase and recovers upon exogenous nitric oxide generation or addition of a permeant cGMP analogue. Local brief pulses of glutamate to individual astrocytes, at a rate of 1 Hz, also elicit [Ca2+](i) oscillations whose frequency increases following a second series of pulses. The long-lasting modification in the [Ca2+](i) oscillatory response induced by glutamate in astrocytes demonstrates that in the central nervous system cellular memory is not a unique feature of neurons.	UNIV PADUA, DEPT BIOMED SCI, I-35121 PADUA, ITALY; UNIV PADUA, CNR, CTR BIOMEMBRANES, I-35121 PADUA, ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Carmignoto, Giorgio/A-8375-2018	Carmignoto, Giorgio/0000-0003-3063-6774				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; Bevan S., 1990, SEMIN NEUROSCI, V2, P467; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME E, 1984, ADV CYCLIC NUCL PROT, V17, P259; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BRENDT DS, 1990, P NATL ACAD SCI USA, V87, P682; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; CONN PJ, 1991, DRUG DEVELOP RES, V24, P207, DOI 10.1002/ddr.430240303; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1994, SOC NEUR ABSTR, V20; CSERR HF, 1986, ANN NY ACAD SCI, V481, P1, DOI 10.1111/j.1749-6632.1986.tb27134.x; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GARTHWAITE J, 1993, SEMIN NEUROSCI, V5, P171, DOI 10.1016/S1044-5765(05)80050-8; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MIKI N, 1977, BIOCHEM BIOPH RES CO, V75, P851, DOI 10.1016/0006-291X(77)91460-7; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PETERS A, 1991, FINE STRUCTURE NERVO, P276; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; SCHUMAN EM, 1993, SEMIN NEUROSCI, V5, P207, DOI 10.1016/S1044-5765(05)80054-5; SINGELBAUM SA, 1991, CURR OPIN NEUROBIOL, V1, P113; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; TATSUYA T, 1991, METHOD ENZYMOL, V201, P340; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; VITADELLO M, 1990, BRAIN RES, V509, P47, DOI 10.1016/0006-8993(90)90307-W; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WILKIN GP, 1991, ANN NY ACAD SCI, V633, P475; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; ZAFRA F, 1992, J NEUROSCI, V12, P4793	66	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15203	15210		10.1074/jbc.270.25.15203	http://dx.doi.org/10.1074/jbc.270.25.15203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797504	hybrid			2022-12-27	WOS:A1995RE66600055
J	RICHIERI, GV; OGATA, RT; KLEINFELD, AM				RICHIERI, GV; OGATA, RT; KLEINFELD, AM			THERMODYNAMICS OF FATTY-ACID-BINDING TO FATTY-ACID-BINDING PROTEINS AND FATTY-ACID PARTITION BETWEEN WATER AND MEMBRANES MEASURED USING THE FLUORESCENT-PROBE ADIFAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REFINEMENT; RESOLUTION; APOPROTEIN; DIVERSITY; VESICLES; FORCES; LIVER	Using the fluorescent probe ADIFAB (acrylodan-derivatized intestinal fatty acid-binding protein) to determine the equilibrium concentration of the free (unbound) fatty acid (FFA), dissociation constants were measured between 10 and 50 degrees C for the interaction of five different long chain fatty acids (FA) with fatty acid-binding proteins (FABP) from adipocyte, intestine, and heart. Gibbs free energies (Delta G) determined from the dissociation constants were between about -9 and -11 kcal/mol at 25 degrees C. Thermodynamic parameters for binding were determined using van't Hoff plots of the dissociation constants, which range, over the entire temperature region, between 2 and 3000 nM. For all the unlabeled FABPs, free energies of binding were dominated by large negative enthalpies that ranged from -7 to -12 kcal/mol, and the enthalpies tended to decrease with increasing FA unsaturation, The entropic contributions (-T Delta S) at 25 degrees C ranged between -4 and +2 kcal/ mol and tended to increase with increasing FA unsaturation. To assess the role of FA aqueous solubility in FABP binding, measurements of the partition of FA between unilamellar lipid vesicles and water were also done using ADIFAB; the lipid/water partition coefficients (K-p) determined from these measurements were found to be independent of temperature. The binding of FA to FABP is governed by the sum of contributions of various interactions between FA, water, and FABP. An analysis of the individual contributions suggests that the net free energy of binding results from the canceling in part of a number of separate quite large contributions. The entropic contributions sum almost to zero for most FA and FABPs as a result of the canceling of a large increase in bulk solvent entropy by decreases in configurational entropy upon FA binding to FABP. The net, approximately -10 kcal/mol enthalpy of binding, probably results from an increase in FA configurational enthalpy upon binding to FABP plus a large negative enthalpy from the interaction between the FA and the FABP. This large enthalpy of the FA-FABP interaction suggests that in addition to previously identified specific interactions between the carboxylate portion of the FA and charged amino acids within the binding cavity, other significantly larger enthalpic interactions, presumably involving the hydrocarbon portion of the FA, must contribute to the binding energy.	MED BIOL INST,LA JOLLA,CA 92037						NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46931] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BENNAIM A, 1994, BIOPHYS CHEM, V51, P203, DOI 10.1016/0301-4622(94)00041-7; BURTON PBJ, 1994, BIOCHEM BIOPH RES CO, V205, P1822, DOI 10.1006/bbrc.1994.2882; CANTOR CR, 1980, BIOPHYSICAL CHEM, P857; CHAN HS, 1994, J CHEM PHYS, V101, P7007, DOI 10.1063/1.468327; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JAHNIG F, 1983, P NATL ACAD SCI-BIOL, V80, P3691, DOI 10.1073/pnas.80.12.3691; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; JONES JD, 1994, BIOPHYS J, V67, P1546, DOI 10.1016/S0006-3495(94)80628-9; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MAATMAN RGHJ, 1994, BBA-LIPID LIPID MET, V1214, P1, DOI 10.1016/0005-2760(94)90002-7; MISHKIN S, 1975, AM J PHYSIOL, V228, P1634, DOI 10.1152/ajplegacy.1975.228.6.1634; MIYAZAKI J, 1992, BIOCHIM BIOPHYS ACTA, V1103, P62, DOI 10.1016/0005-2736(92)90057-S; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; PIETZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1989, J MOL BIOL, V208, P827; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHA RS, 1993, J BIOL CHEM, V268, P7885; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SITKOFF D, 1994, BIOPHYS CHEM, V51, P397, DOI 10.1016/0301-4622(94)00062-X; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; TANFORD C, 1973, HYDROPHOBIC EFFECT F, P14; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WIMLEY WC, 1993, BIOCHEMISTRY-US, V32, P6307, DOI 10.1021/bi00076a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	47	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15076	15084		10.1074/jbc.270.25.15076	http://dx.doi.org/10.1074/jbc.270.25.15076			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797491	hybrid			2022-12-27	WOS:A1995RE66600037
J	ABRAMS, CS; WU, H; ZHAO, W; BELMONTE, E; WHITE, D; BRASS, LF				ABRAMS, CS; WU, H; ZHAO, W; BELMONTE, E; WHITE, D; BRASS, LF			PLECKSTRIN INHIBITS PHOSPHOINOSITIDE HYDROLYSIS INITIATED BY G-PROTEIN-COUPLED AND GROWTH-FACTOR RECEPTORS - A ROLE FOR PLECKSTRINS PH DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; HUMAN-PLATELETS; SIGNALING PROTEINS; PHORBOL ESTER; FEEDBACK-REGULATION; MOLECULAR-CLONING; THROMBIN RECEPTOR; KINASE-C; PHOSPHORYLATION	Pleckstrin is a 40-kDa protein present in platelets and leukocytes that contains two PH domains separated by a 150-residue intervening sequence. Pleckstrin is a major substrate for protein kinase C, but its function is unknown. The present studies examine the effects of pleckstrin on second messenger generation. When expressed in cos-1 or HEK-293 cells, pleckstrin inhibited 1) the G(alpha)-mediated activation of phospholipase C-beta initiated by thrombin, M1-muscarinic acetylcholine, and angiotensin II receptors, 2) the stimulation of phospholipase C-beta by constitutively active G(q alpha), 3) the G(beta gamma)-mediated activation of phospholipase C-beta caused by alpha(2A)-adrenergic receptors, and 4) the tyrosine phosphorylation-media ted activation of phospholipase C-gamma caused by Trk A. However, pleckstrin had no effect on either the stimulation or inhibition of adenylyl cyclase, The inhibition of phosphoinositide hydrolysis caused by pleckstrin was similar in magnitude to that caused by activating protein kinase C with phorbol 12-myristate 13-acetate (PMA). When combined, pleckstrin and PMA had an additive effect, inhibiting phosphoinositide hydrolysis by as much as 90%, Structure-function analysis highlighted the role of pleckstrin's N-terminal PH domain in these events. Although deleting the C-terminal PH domain had no effect, deleting the N-terminal PH domain abolished activity (but not expression) and mutating a highly conserved tryptophan residue within the N-terminal PH domain decreased activity by one-third, Notably, however, a pleckstrin variant in which the N-terminal PH domain was replaced with a second copy of the C-terminal PH domain was nearly as active as native pleckstrin, These results show that: 1) pleckstrin can inhibit pathways leading to both phospholipase C-beta- and phospholipase C-gamma-mediated phosphoinositide hydrolysis, 2) this inhibition affects activation of phospholipase C-beta mediated by either G(alpha) or G(beta gamma) but does not affect the regulation of adenylyl cyclase activity by G(alpha) or G(beta gamma), 3) although pleckstrin is a substrate for protein kinase C, the effects of pleckstrin and PMA are at least partially independent, 4) the inhibition caused by pleckstrin appears to be mediated by the PH domain at the N terminus, rather than the C terminus of the molecule, and 5) location of the two PH domains within the molecule clearly contributes to their individual activity, These results do not appear to be readily attributable to an interaction between pleckstrin and G(beta gamma), but they are consistent with a recent report showing an association between PH domains and phosphatidylinositol 4,5-bisphosphate in vitro.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, K11HL002464] Funding Source: NIH RePORTER; NHLBI NIH HHS [5K11 HL02464, P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CONTRERAS ML, 1993, J NEUROCHEM, V61, P1035, DOI 10.1111/j.1471-4159.1993.tb03617.x; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JENKINS AL, 1994, J BIOL CHEM, V269, P17104; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIANG M, 1991, J BIOL CHEM, V266, P13342; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MORRIS JF, 1991, ONCOGENE, V6, P2339; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; RYU SH, 1990, J BIOL CHEM, V265, P17941; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; YANG LJ, 1993, J BIOL CHEM, V268, P3739; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	47	46	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14485	14492		10.1074/jbc.270.24.14485	http://dx.doi.org/10.1074/jbc.270.24.14485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782310	hybrid			2022-12-27	WOS:A1995RD45500040
J	CABISCOL, E; LEVINE, RL				CABISCOL, E; LEVINE, RL			CARBONIC ANHYDRASE-III - OXIDATIVE MODIFICATION IN-VIVO AND LOSS OF PHOSPHATASE-ACTIVITY DURING AGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDATION; S-THIOLATION; GLUTAMINE-SYNTHETASE; PROTEIN OXIDATION; HYDROGEN-PEROXIDE; RAT-LIVER; ISCHEMIA-REPERFUSION; CATALYZED OXIDATION; OXIDIZED PROTEINS; CREATINE-KINASE	Oxidative modification of DNA, lipids, and proteins occurs as a consequence of reaction with free radicals and activated oxygen. Oxidative modification of total cellular proteins has been described under many pathologic and experimental conditions, but no specific proteins have been identified as in vivo targets for oxidative modification. Utilizing an immunochemical method for detection of oxidatively modified proteins, we identified a protein in rat Liver that was highly oxidized. It was purified to homogeneity and identified as carbonic anhydrase, isozyme III. Its characteristics match those previously described for a protein that was lost during aging of the rat, senescence marker protein-1. Carbonic anhydrase III was purified from rats aged 2, 10, and 18 months, and the proteins were characterized. All three preparations were highly oxidatively modified as assessed by their carbonyl content. The enzyme has three known catalytic activities, and the specific activities for carbon dioxide hydration and for ester hydrolysis decreased during aging by similar to 30%. However, the third activity, that of a phosphatase, was virtually lost during aging. While the physiologic role of carbonic anhydrase III is unknown, we suggest that it functions in an oxidizing environment, which leads to its own oxidative modification.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levine, Rodney L/D-9885-2011; Cabiscol, Elisa/A-4584-2009	Cabiscol, Elisa/0000-0003-2795-7999				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AYENE IS, 1993, ARCH BIOCHEM BIOPHYS, V303, P307, DOI 10.1006/abbi.1993.1288; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BERLETT BS, 1984, P NATL ACAD SCI USA, V87, P398; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; CHATTERJEE B, 1981, J BIOL CHEM, V256, P939; CLIMENT I, 1991, ARCH BIOCHEM BIOPHYS, V289, P371, DOI 10.1016/0003-9861(91)90425-I; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; COLLISON MW, 1986, BIOCHIM BIOPHYS ACTA, V885, P58, DOI 10.1016/0167-4889(86)90038-8; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Jeffery S, 1991, CARBONIC ANHYDRASES, P289; KARSEKSTAPLES JA, 1993, FREE RADICAL BIO MED, V14, P115; KELLER RJ, 1993, CHEM RES TOXICOL, V6, P430, DOI 10.1021/tx00034a007; KELLY CD, 1988, BIOSCIENCE REP, V8, P401, DOI 10.1007/BF01121636; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOESTER MK, 1981, ARCH BIOCHEM BIOPHYS, V211, P632, DOI 10.1016/0003-9861(81)90499-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; MILLER RM, 1989, ARCH BIOCHEM BIOPHYS, V276, P355; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; PARK Y, 1991, FREE RADICAL RES COM, V14, P179, DOI 10.3109/10715769109088947; POSTON JM, 1992, ARCH BIOCHEM BIOPHYS, V295, P35, DOI 10.1016/0003-9861(92)90484-E; REDDY VY, 1994, J BIOL CHEM, V269, P4683; ROKUTAN K, 1989, EUR J BIOCHEM, V179, P233, DOI 10.1111/j.1432-1033.1989.tb14546.x; Rothstein M., 1984, P209; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; SHIELS A, 1983, BIOCHIM BIOPHYS ACTA, V760, P335, DOI 10.1016/0304-4165(83)90370-7; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Stadtman ER, 1994, OXIDATIVE PROCESSES, P117; STARKE PE, 1987, FASEB J, V1, P36, DOI 10.1096/fasebj.1.1.2886388; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Tashian RE, 1991, CARBONIC ANHYDRASES, P247, DOI DOI 10.1007/978-1-4899-0750-9_21; TASHIAN RE, 1990, BIOESSAYS, V10, P186; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221; WILBUR KM, 1948, J BIOL CHEM, V176, P147; YIM MB, 1990, P NATL ACAD SCI USA, V87, P394, DOI 10.1073/pnas.87.1.394; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZSNAGY I, 1984, BIOCHIM BIOPHYS ACTA, V790, P238, DOI 10.1016/0167-4838(84)90028-1; 1994, PROTEIN IDENTIFICATI	63	133	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14742	14747		10.1074/jbc.270.24.14742	http://dx.doi.org/10.1074/jbc.270.24.14742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782339	Green Published, hybrid			2022-12-27	WOS:A1995RD45500076
J	GUERINI, D; SCHRODER, S; FOLETTI, D; CARAFOLI, E				GUERINI, D; SCHRODER, S; FOLETTI, D; CARAFOLI, E			ISOLATION AND CHARACTERIZATION OF A STABLE CHINESE-HAMSTER OVARY CELL-LINE OVEREXPRESSING THE PLASMA-MEMBRANE CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP; CALCIUM-PUMP; MOLECULAR CHARACTERIZATION; LIMITED PROTEOLYSIS; MESSENGER-RNAS; MUSCLE-CELLS; RAT-BRAIN; EXPRESSION; ATPASE; ISOFORMS	Stable Chinese hamster ovary (CHO) cell lines overexpressing the human plasma membrane Ca2+-ATPase (PMCA) were generated, and three independent cell clones were characterized in details. They ovel expressed high amounts of active PMCA pump (15-20 times over the amount of endogenous PMCA) as indicated by experiments in which the formation of the phosphoenzyme intermediate and the uptake of Ca2+ by microsomes were measured. Immunocytochemistry experiments coupled to the biotinylation of the pump in the intact cells indicated the correct delivery of the expressed pump to the plasma membrane. The expressed pump was purified by affinity chromatography on calmodulin sepharose. The PMCA of transfected CHO cells promoted an increase of Ca2+ into the medium, after induction of Ca2+ release from the internal stores by activation of a purinergic receptor. An evident decrease of the activity of the endogenous sarcoplasmic reticulum Ca2+-ATPase pump was observed, probably related to the down-regulation of its expression. The cells overexpressing the PMCA pump had delayed recovery after trypsinization and plating. Their doubling time was, however, the same as CHO cells.	ETH ZENTRUM,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BLAUSTEIN MP, 1991, SODIUM CALCIUM EXCHA; BOBE R, 1994, J BIOL CHEM, V269, P1417; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FESCHENKO MS, 1992, J BIOL CHEM, V267, P4097; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HEIM R, 1992, J BIOL CHEM, V267, P24476; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KEETON TP, 1993, J BIOL CHEM, V268, P2740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRYL CR, 1981, ANAL BIOCHEM, V110, P680; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V250, P1086; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WRZOSEK A, 1992, CELL CALCIUM, V13, P281, DOI 10.1016/0143-4160(92)90063-X; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZVARITCH E, 1992, 8TH INT S CALC BIND	41	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14643	14650		10.1074/jbc.270.24.14643	http://dx.doi.org/10.1074/jbc.270.24.14643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782327	hybrid			2022-12-27	WOS:A1995RD45500062
J	JAKOB, U; MEYER, I; BUGL, H; ANDRE, S; BARDWELL, JCA; BUCHNER, J				JAKOB, U; MEYER, I; BUGL, H; ANDRE, S; BARDWELL, JCA; BUCHNER, J			STRUCTURAL ORGANIZATION OF PROKARYOTIC AND EUKARYOTIC HSP90 - INFLUENCE OF DIVALENT-CATIONS ON STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CONFORMATIONAL CHANGE; ESCHERICHIA-COLI; BINDING; QUANTITATION; PURIFICATION; RECEPTOR; KINASE; CELL	Hsp90 is a very abundant molecular chaperone that apparently helps to protect cellular proteins from denaturation upon temperature upshift. The unusual ability of Hsp90 to function under conditions where other proteins unfold prompted us to investigate the stability and structural organization of Hsp90 itself. Both procaryotic and eucaryotic members of the Hsp90 family were found to have very similar physicochemical properties: (i) they are stable against thermal unfolding up to at least 50 degrees C, (ii) they show biphasic, reversible unfolding transitions in guanidinium chloride, and (iii) their oligomerization state is strongly and rapidly affected by millimolar concentrations of divalent cations. In the presence of MnCl2 and MgCl2 defined changes in the quaternary structure of Hsp90 could be observed which resulted in a decrease in thermostability and an increased tendency to form larger aggregates. The addition of divalent cations also almost completely abolished the chaperone function of Hsp90 and induced release of folding intermediates of citrate synthase bound to Hsp90. These modulating effects of divalent cations on structure and function of Hsp90 in vitro represent a potential mechanism for regulation of Hsp90 chaperone action in vivo.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KAWAHARA J, 1992, ANAL BIOCHEM, V201, P94, DOI 10.1016/0003-2697(92)90178-A; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PAYOT P, 1975, EUR J BIOCHEM, V63, P263; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SPENCE J, 1989, J BIOL CHEM, V264, P4398; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	35	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14412	14419		10.1074/jbc.270.24.14412	http://dx.doi.org/10.1074/jbc.270.24.14412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782303	hybrid			2022-12-27	WOS:A1995RD45500030
J	MEYER, SC; FOX, JEB				MEYER, SC; FOX, JEB			INTERACTION OF PLATELET GLYCOPROTEIN-V WITH GLYCOPROTEIN-IB-IX REGULATES EXPRESSION OF THE GLYCOPROTEINS AND BINDING OF VON-WILLEBRAND-FACTOR TO GLYCOPROTEIN-IB-IX IN TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; LEUCINE-RICH GLYCOPROTEINS; AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE GLYCOPROTEINS; BERNARD-SOULIER PLATELETS; GEL-ELECTROPHORESIS; ALPHA-CHAIN; SHEAR RATE; GP-IB; COMPLEX	The goal of the present study was to determine whether platelet glycoprotein (GP) V interacts directly with the von Willebrand factor receptor GP Ib-IX and, if so, whether it affects the expression and function of this receptor. A melanoma cell line that does not contain actin-binding protein was transfected with the cDNAs coding for GP V and for each of the three subunits of GP Ib-IX. GP V co-immunoprecipitated and co-localized with GP Ib-IX. Although GP V could be expressed in the absence of GP Ib-IX, the amount incorporated in the membrane was markedly increased when GP Ib-IX was present. Similarly, there was an enhanced expression of GP Ib-IX on the cell surface in the presence of GP V. The binding affinity of botrocetin-induced von Willebrand factor to GP Ib-IX was unaffected by the presence or absence of GP V. However, the binding capacity was increased by the presence of GP V. We conclude that GP V interacts directly with GP Ib-IX, that GP V must associate with GP Ib-IX to be efficiently expressed in the membrane, and that GP V increases the binding capacity of the cells for von Willebrand factor by enhancing the surface expression of the GP Ib-IX complex.	CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, J BIOL CHEM, V256, P59; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1984, PROG HEMOST THROMB, V7, P111; BERNDT MC, 1983, BLOOD, V62, P8500; Booth W J, 1990, Platelets, V1, P169, DOI 10.3109/09537109009005485; CHOW TW, 1992, BLOOD, V80, P113; CLEMETSON JM, 1994, BLOOD, V84, P1124; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DU XP, 1987, BLOOD, V69, P1524; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDA M, 1986, J BIOL CHEM, V261, P2579; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MEYER S, 1993, J BIOL CHEM, V268, P20555; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOSHER DF, 1979, BLOOD, V53, P437; NURDEN AT, 1981, J CLIN INVEST, V67, P1431, DOI 10.1172/JCI110172; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTH GJ, 1991, BLOOD, V77, P5; SHIMOMURA T, 1990, BLOOD, V75, P2349; SIMSEK S, 1994, THROMB HAEMOSTASIS, V72, P444; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURITTO VT, 1977, ANN NY ACAD SCI, V283, P284, DOI 10.1111/j.1749-6632.1977.tb41775.x; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x	56	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14693	14699		10.1074/jbc.270.24.14693	http://dx.doi.org/10.1074/jbc.270.24.14693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782333	hybrid			2022-12-27	WOS:A1995RD45500069
J	OGASAWARA, Y; VOELKER, DR				OGASAWARA, Y; VOELKER, DR			ALTERED CARBOHYDRATE-RECOGNITION SPECIFICITY ENGINEERED INTO SURFACTANT PROTEIN-D REVEALS DIFFERENT BINDING MECHANISMS FOR PHOSPHATIDYLINOSITOL AND GLUCOSYLCERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; II CELLS; PHOSPHOLIPID SECRETION; PURIFICATION; CP4	Pulmonary surfactant protein D (SP-D) is a member of the collectin subgroup of the C-type lectin superfamily that binds glycosylated lipids such as phosphatidylinositol (PI) and glucosylceramide (GlcCer). We have previously reported that the carbohydrate recognition domain of SP-D plays an essential role in lipid binding. However, it is unclear how the carbohydrate binding property of SP-D contributes to the lipid binding. To clarify the relationship between the lectin property and the lipid binding activity of rat SP-D, we expressed wild-type recombinant rat SP-D (rSP-D) and a mutant form of the protein with substitutions Glu-321 --> Gln and Asn-323 --> Asp (SP-D-E321Q,D-N323D) in CHO-K1 cells. The indicated mutations have previously been shown to change the carbohydrate binding specificity of surfactant protein A and mannose-binding protein from mannose > galactose to the converse. rSP-D expressed in mammalian cells was essentially identical to native rat SP-D in its lipid and carbohydrate binding properties. In contrast, SP-D-E321Q,D-N323D was unable to bind GlcCer, but retained binding activity toward PI liposomes and solid-phase PI. The efficiency of SP-D-E321Q,D-N323D binding to PI liposome was similar to 50% of that of rSP-D in the presence of 5 mM Ca2+, but equivalent at 20 mM Ca2+. Carbohydrats competed for SP-D binding to PI such that maltose > galactose for rSP-D, and the order was reversed for SPDE321Q,N323D. Furthermore, SP-D-E321Q,D-N323D could bind to digalactosyldiacylglycerol more effectively than rSP-D. These results suggest the following. 1) The carbohydrate binding specificity of Sp-D-E321Q,D-N323D was changed from a mannose-glucose type to a galactose type; 2) the GlcCer binding property of SP-D is closely related to its sugar binding activity; and 3) the PI binding activity is not completely dependent on its carbohydrate binding specificity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,ANNA PERAHIA ADATTO CLIN LABS,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL29891, HL45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R37HL029891, R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888	33	48	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14725	14732		10.1074/jbc.270.24.14725	http://dx.doi.org/10.1074/jbc.270.24.14725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782337	hybrid			2022-12-27	WOS:A1995RD45500074
J	RATHOUZ, MM; VIJAYARAGHAVAN, S; BERG, DK				RATHOUZ, MM; VIJAYARAGHAVAN, S; BERG, DK			ACETYLCHOLINE DIFFERENTIALLY AFFECTS INTRACELLULAR CALCIUM VIA NICOTINIC AND MUSCARINIC RECEPTORS ON THE SAME POPULATION OF NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK CILIARY GANGLION; PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; ALPHA-BUNGAROTOXIN; CYTOSOLIC CALCIUM; CA2+ OSCILLATIONS; ENDOPLASMIC-RETICULUM; CA-2+ OSCILLATIONS; SIGNALING PATHWAYS; RELEASE	Multiple receptor subtypes activated by the same ligand but coupled to different second messengers can produce divergent signaling in a cell, while receptors activated by different ligands but sharing the same second messenger can produce convergent signaling, We show here that chick ciliary ganglion neurons have three classes of receptors activated by the same neurotransmitter, acetylcholine, and that all three regulate the same second messenger, intracellular free calcium, Activation of muscarinic receptors on the neurons stimulates phosphatidylinositol turnover and induces calcium oscillations that are initiated and maintained by calcium release from caffeine/ryanodine-insensitive intracellular stores, Extracellular calcium is required to sustain the oscillations, while cadmium abolishes them, Activation of either of two classes of nicotinic receptors, distinguished both by location on the neurons and by subunit composition, induces a single, rapid elevation in intracellular calcium without inducing phosphatidylinositol turnover, The nicotinic responses are entirely dependent on extracellular calcium, show no dependence on release from internal stores, and do not display oscillations, Low concentrations of the native agonist, acetylcholine, induce repetitive calcium spikes in the neurons characteristic of muscarinic receptors, while higher concentrations induce nonoscillating increases in intracellular calcium that include contributions from nicotinic receptors, The three classes of receptors also differ in the acetylcholine concentration required to elicit a response. These differences, together with differences in receptor location and sources of calcium mobilized, may enable the receptor subtypes to target different sets of calcium-dependent processes for regulation.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012601, P01NS025916] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS12601, P01 NS25916] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERRIDGE MJ, 1990, CELL REGUL, V1, P675, DOI 10.1091/mbc.1.9.675; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOWERS CW, 1992, DEV BIOL, V154, P410, DOI 10.1016/0012-1606(92)90079-V; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHIAPPINELLI VA, 1981, BRAIN RES, V211, P107, DOI 10.1016/0006-8993(81)90070-6; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEXTER F, 1994, AM J PHYSIOL, V266, pH298, DOI 10.1152/ajpheart.1994.266.1.H298; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; FURUKAWA K, 1994, BRAIN RES, V657, P185, DOI 10.1016/0006-8993(94)90966-0; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRAY DB, 1990, J NEUROSCI, V10, P2687; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB MH, 1984, P NATL ACAD SCI-BIOL, V81, P3223, DOI 10.1073/pnas.81.10.3223; JACOB MH, 1983, J NEUROSCI, V3, P260; LANDMESSER L, 1972, J PHYSIOL-LONDON, V222, P691, DOI 10.1113/jphysiol.1972.sp009822; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; MARGIOTTA JF, 1989, DEV BIOL, V135, P326, DOI 10.1016/0012-1606(89)90183-8; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEERING IR, 1984, NATURE, V309, P158, DOI 10.1038/309158a0; NISHI R, 1981, J NEUROSCI, V1, P505; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PUGH PC, 1994, J NEUROSCI, V14, P889; RATHOUZ MM, 1994, J NEUROSCI, V14, P6935; RAVDIN PM, 1981, J NEUROSCI, V1, P849; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHMID HA, 1992, NEUROPHARMACOLOGY, V31, P1001, DOI 10.1016/0028-3908(92)90101-T; SEGUELA P, 1993, J NEUROSCI, V13, P596; SORIMACHI M, 1993, BRAIN RES, V627, P34, DOI 10.1016/0006-8993(93)90745-9; SORIMACHI M, 1995, BRAIN RES, V669, P26, DOI 10.1016/0006-8993(94)01218-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOESCU EC, 1993, J BIOL CHEM, V268, P18654; TROUSLARD J, 1993, J PHYSIOL-LONDON, V468, P53, DOI 10.1113/jphysiol.1993.sp019759; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; VIJAYARAGHAVAN S, 1995, IN PRESS J NEUROSCI; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WISGIRDA ME, 1994, P NATL ACAD SCI USA, V91, P2858, DOI 10.1073/pnas.91.7.2858; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	68	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14366	14375		10.1074/jbc.270.24.14366	http://dx.doi.org/10.1074/jbc.270.24.14366			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782297	hybrid			2022-12-27	WOS:A1995RD45500023
J	SCHIFFER, SG; HEMLER, ME; LOBB, RR; TIZARD, R; OSBORN, L				SCHIFFER, SG; HEMLER, ME; LOBB, RR; TIZARD, R; OSBORN, L			MOLECULAR MAPPING OF FUNCTIONAL ANTIBODY-BINDING SITES OF ALPHA-4 INTEGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-ADHESION MOLECULE-1; PLATELET INTEGRIN; OVERLAP EXTENSION; I-DOMAIN; VLA-4; RECEPTOR; FIBRONECTIN; MURINE; IDENTIFICATION; DISTINCT	Integrin (alpha 4 beta 1 is a leukocyte receptor for fibronectin and vascular cell adhesion molecule-1 (VCAM-1). It is important in inflammatory recruitment of leukocytes, lymphopoiesis, and a number of developmental events. Here we have mapped a panel of functional monoclonal antibodies (mAbs) recognizing the integrin alpha 4 chain, using murine/human chimeric constructs expressed in COS7 cells. We find that: 1) mAbs that induce homotypic aggregation (epitope A mAbs) map to the most N-terminal 100 amino acids of the human alpha 4 chain; 2) mAbs that block adhesion of alpha 4 beta 1 to VCAM-1 and fibronectin (epitope B mAbs) map to a 52-amino-acid region between residues 152 and 203 of human alpha 4; 3) epitope B mAbs that do or do not induce aggregation (epitope B2 and B1 mAbs, respectively) map to the same regions and are therefore indistinguishable by this analysis; 4) mAbs that neither induce homotypic aggregation nor block adhesion (epitope C mAbs) map to a distinct region of the molecule comprising amino acids 422-606. The N-terminal region of the alpha 4 chain identified by functional A and B epitope mAbs does not correspond to ligand binding sites identified in other alpha subunits, such as cation binding sites or the ''I-domain,'' which alpha 4 lacks, and thus represents a novel site for epitope functionality among the integrins.	BIOGEN INC,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Biogen; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JAKUBOWSKI A, 1995, IN PRESS CELL ADH CO, V3; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOY P, 1993, J BIOL CHEM, V268, P8835; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PULIDO R, 1991, FEBS LETT, V294, P121, DOI 10.1016/0014-5793(91)81356-D; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; WANG JH, 1994, PROTEINS, V20, P287, DOI 10.1002/prot.340200310; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YANG JT, 1995, DEVELOPMENT, V121, P549; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	43	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14270	14273		10.1074/jbc.270.24.14270	http://dx.doi.org/10.1074/jbc.270.24.14270			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782282	hybrid			2022-12-27	WOS:A1995RD45500008
J	YOSHIDA, Y; KOJIMA, N; KUROSAWA, N; HAMAMOTO, T; TSUJI, S				YOSHIDA, Y; KOJIMA, N; KUROSAWA, N; HAMAMOTO, T; TSUJI, S			MOLECULAR-CLONING OF SIA-ALPHA-2,3GAL-BETA-1,4GLCNAC ALPHA-2,8-SIALYLTRANSFERASE FROM MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SIALYLTRANSFERASE GENE FAMILY; ALPHA-2,3-SIALYLTRANSFERASE; EXPRESSION; ADULT	A cDNA encoding a new alpha 2,8-sialyltransferase (ST8Sia III), which exhibits activity toward the Sia alpha 2,3Gal beta 1, 4GlcNAc sequences of N-linked oligosaccharides, was cloned from mouse brain by means of the polymerase chain reaction based approach. The predicted amino acid sequence of ST8Sia III showed 27.6 and 34.4% identity with those of so far cloned mouse alpha 2,8-sialyltransferases, i.e. G(D3) synthase (ST8Sia I) and STX (ST8Sia II), respectively. Transfection of the protein A-fused ST8Sia III gene into COS-7 cells led to alpha 2,8-sialyltransferase activity toward sialylated glycoproteins and alpha 2,3-sialylated glycosphingolipids, such as alpha 2,3-sialylparagloboside and G(M3). However, the kinetic properties of ST8Sia III revealed that it is much more specific to N-linked oligosaccharides of glycoproteins than glycosphingolipids. The expression pattern of the ST8Sia III gene was clearly different from those of other alpha 2,8-sialyltransferase genes. The expression of the ST8Sia III gene was tissue and stage specific. The ST8Sia III gene was expressed only in brain and testis, and it appeared first in 20 postcoitum embryonal brain and then decreased. Therefore, the new alpha 2,8-sialyltransferase is closely involved in brain development.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; KITAGAWA H, 1994, J BIOL CHEM, V268, P17872; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; ZUBER C, 1992, J BIOL CHEM, V267, P9965	18	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14628	14633		10.1074/jbc.270.24.14628	http://dx.doi.org/10.1074/jbc.270.24.14628			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782326	hybrid			2022-12-27	WOS:A1995RD45500060
J	MUKHERJI, S; SODERLING, TR				MUKHERJI, S; SODERLING, TR			MUTATIONAL ANALYSIS OF CA2+-INDEPENDENT AUTOPHOSPHORYLATION OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN-KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; CALMODULIN-BINDING; INTRASTERIC REGULATION; BASIC RESIDUES; SITE; ACTIVATION; DOMAIN	Previous studies with synthetic peptides indicate that residues 290-309, corresponding to the calmodulin (CaM)-binding domain of Ca2+/CaM-dependent protein kinase II interact with the catalytic core of the enzyme as a pseudosubstrate (Colbran, R. J., Smith, M. K., Schworer, C. M., Fong, Y. L., and Soderling, T. R. (1989) J. Biol. Chem. 264, 4800-4804). In the present study, we attempted to locate the pseudosubstrate motif by generation or removal of potential substrate recognition sequences (RXXS/T) at selected positions using site-directed mutagenesis. Based on previous results, Arg(297), Thr(305/306), and Ser(314) were selected as key residues. Single mutations such as N294S, K300S, A302R, A309R, and R311A were expressed, purified, and characterized. Several of the mutants exhibited decreased binding of and activation by CaM, not surprising since the mutations were within the CaM-binding domain. None of the mutants exhibited enhanced Ca2+-independent kinase activity toward exogenous substrate, but the K300S and N294S mutants showed a significant enhancement in the rate and stoichiometry of P-32 incorporation during Ca2+-independent autophosphorylation. Using two-dimensional peptide mapping and phosphoamino acid analyses, enhanced phosphorylation of the introduced Ser residue was demonstrated in the K300S mutant but not in the N294S mutant. This specific Ca2+-independent autophosphorylation of Ser(300) is consistent with the hypothesis that Arg(297) may occupy the P (-3) position in a pseudosubstrate autoinhibitory interaction with the catalytic core in the nonactivated state of the kinase.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HERRING BP, 1991, J BIOL CHEM, V266, P11838; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P130; ORR JW, 1994, J BIOL CHEM, V269, P8383; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1990, J BIOL CHEM, V265, P1823	27	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14062	14067		10.1074/jbc.270.23.14062	http://dx.doi.org/10.1074/jbc.270.23.14062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775466	hybrid			2022-12-27	WOS:A1995RC44800069
J	RAMAKERS, GMJ; DEGRAAN, PNE; URBAN, IJA; KRAAY, D; TANG, T; PASINELLI, P; OESTREICHER, AB; GISPEN, WH				RAMAKERS, GMJ; DEGRAAN, PNE; URBAN, IJA; KRAAY, D; TANG, T; PASINELLI, P; OESTREICHER, AB; GISPEN, WH			TEMPORAL DIFFERENCES IN THE PHOSPHORYLATION STATE OF PRESYNAPTIC AND POSTSYNAPTIC PROTEIN-KINASE-C SUBSTRATES B-50/GAP-43 AND NEUROGRANIN DURING LONG-TERM POTENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL SLICES; CALMODULIN-BINDING; B-50 GAP-43; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; TRANSMITTER RELEASE; AMINO-ACIDS; INDUCTION	The phosphorylation state of two identified neural-specific protein kinase C substrates (the presynaptic protein B-50 and the postsynaptic protein neurogranin) was monitored after the induction of long term potentiation in the CA1 field of rat hippocampus slices by quantitative immunoprecipitation following P-92(i) labeling in the recording chamber. B-50 phosphorylation was increased from 10 to 60 min, but no longer at 90 min after long term potentiation had been induced, neurogranin phosphorylation only at 60 min. increased phosphorylation was not found when long term potentiation was blocked with the N-methyl-D-aspartate receptor antagonist D-2-amino-5-phosphonovalerate, when only low frequency stimulation was applied or tetanic stimulation failed to induce long term potentiation. Our data show that both B-50 and neurogranin phosphorylation are increased following the induction of long term potentiation, thus providing strong evidence for pre- and postsynaptic protein kinase C activation during narrow, partially overlapping, time windows after the induction of long term potentiation.	UNIV UTRECHT, RUDOLF MAGNUS INST NEUROSCI, DEPT MED PHARMACOL, 3508 TA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center				Ramakers, Geert/0000-0001-7499-6996; Pasinelli, Piera/0000-0002-3385-2707				ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BEHNISCH T, 1994, SOC NEUR ABSTR, V20; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DEGRAAN PNE, 1988, NEUROSCI RES COMMUN, V3, P175; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEGRAAN PNE, 1993, BIOCHEM SOC T, V21, P406, DOI 10.1042/bst0210406; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GHIJSEN WEJM, 1992, J NEUROCHEM, V59, P482, DOI 10.1111/j.1471-4159.1992.tb09395.x; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; HENS JJH, 1993, J NEUROCHEM, V61, P1530, DOI 10.1111/j.1471-4159.1993.tb13649.x; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG YY, 1992, NEUROSCIENCE, V49, P819, DOI 10.1016/0306-4522(92)90359-A; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LEAHY JC, 1993, NEUROSCIENCE, V52, P563, DOI 10.1016/0306-4522(93)90406-6; LEE KS, 1983, J NEUROSCI, V3, P1369; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORDEN JJ, 1991, ANN NY ACAD SCI, V627, P75; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHAECHTER JD, 1993, J NEUROSCI, V13, P4361; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; VORONIN LL, 1991, NEUROSCI RES COMMUN, V8, P87; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WAXHAM MN, 1993, BRAIN RES, V609, P1; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0	61	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13892	13898		10.1074/jbc.270.23.13892	http://dx.doi.org/10.1074/jbc.270.23.13892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775448	Green Submitted, hybrid			2022-12-27	WOS:A1995RC44800047
J	ROUSSELLE, P; GOLBIK, R; VANDERREST, M; AUMAILLEY, M				ROUSSELLE, P; GOLBIK, R; VANDERREST, M; AUMAILLEY, M			STRUCTURAL REQUIREMENT FOR CELL-ADHESION TO KALININ (LAMININ-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA; MULTIDOMAIN PROTEIN; BASEMENT-MEMBRANES; GLOBULAR DOMAIN; COLLAGEN-IV; B2 CHAIN; LONG ARM; BINDING; ATTACHMENT; SITES	Laminin-5 (kalinin) was purified from spent cell culture media (SCC25 cells) by affinity chromatography on monoclonal antibody BM165. The protein was recovered as a mixture of the typical polypeptides of 165-155, 140, and 105 kDa as judged by SDS-polyacrylamide gel electrophoresis analysis under reducing conditions. The amino acid composition of purified laminin-5 was in agreement with that compiled from the recently published cDNA sequences of the alpha(3)-, beta(3)-, and gamma(2)-laminin chains. Moreover, the content of half-cystine residues in laminin-5 was about two-thirds that in laminin-1, which confirms the prediction of a smaller number of epidermal growth factor-like repeats in the amino-terminal portion of the three chains. The content of coiled-coil alpha-helices (27%) determined by CD spectroscopy was comparable to that reported for laminin-1, which indicates that the long arm portion of laminin-5 is equivalent to that of other laminin isoforms. The melting temperature was recorded at 72 degrees C by CD monitoring of unfolding and refolding of the coiled-coil structures during thermal denaturation and renaturation, respectively. The thermal stability of laminin-5 is therefore significantly higher than that of laminin-1 or alpha(2)-chain-containing laminins, which suggests higher ionic interactions between the three polypeptide chains of laminin-5. Cell adhesion-promoting activity of laminin 5 was found to be strictly and entirely dependent on the presence of coiled-coil structures, It decreased gradually after heat denaturation of the protein above 65 degrees C and was totally abrogated at 75 degrees C. This is in contrast to laminin-1, which contains both conformation-dependent and -independent cell-binding sites on the long and short arm domains, respectively.	INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE; MRC CTR,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	Centre National de la Recherche Scientifique (CNRS); MRC Laboratory Molecular Biology; University of Cambridge			Rousselle, Patricia/CAF-3915-2022; Rousselle, Patricia/J-5290-2019	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V5, P209; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GOODMAN SL, 1987, J CELL BIOL, V105, P589, DOI 10.1083/jcb.105.1.589; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HABER RM, 1985, J AM ACAD DERMATOL, V13, P252, DOI 10.1016/S0190-9622(85)70168-5; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HOOGERHEIDE JG, 1992, ANAL BIOCHEM, V201, P146, DOI 10.1016/0003-2697(92)90187-C; HUNTER I, 1992, J BIOL CHEM, V267, P6006; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; UTANI A, 1994, J BIOL CHEM, V269, P19167; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1991, LAB INVEST, V64, P85	42	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13766	13770		10.1074/jbc.270.23.13766	http://dx.doi.org/10.1074/jbc.270.23.13766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775432	hybrid			2022-12-27	WOS:A1995RC44800029
J	LEVY, AP; LEVY, NS; WEGNER, S; GOLDBERG, MA				LEVY, AP; LEVY, NS; WEGNER, S; GOLDBERG, MA			TRANSCRIPTIONAL REGULATION OF THE RAT VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; PERMEABILITY FACTOR; MAMMALIAN-CELLS; PHORBOL ESTER; PROTEIN; ENHANCER; MITOGEN; INVITRO; ANGIOGENESIS; EXPRESSION	Vascular endothelial growth factor (VEGF), a potent angiogenic factor and endothelial cell-specific mitogen, is up-regulated by hypoxia. However, the mechanism(s) responsible for hypoxic induction of VEGF has not been clearly delineated. We report that the steady state VEGF mRNA levels are increased 12 +/- 0.6-fold, but the transcriptional rate for VEGF is increased only 3.1 +/- O.6-fold by hypoxia in PC12 cells. In order to investigate cis-regulatory sequences which mediate this response to hypoxia, we cloned the rat genomic sequences encoding VEGF and identified a 28-base pair element in the 5' promoter that mediates hypoxia-inducible transcription in transient expression assays. This element has sequence and protein binding similarities to the hypoxia-inducible factor 1 binding site within the erythropoietin 3' enhancer. Post-transcriptional mechanisms have also been suggested to play a role in the hypoxic induction of VEGF. Evidence is provided that a frequently used polyadenylation site is 1.9 kilobases downstream from the translation termination codon for rat VEGF. This site is 1.5 kilobases further downstream from the polyadenylation site previously reported for VEGF. This new finding reveals sequence motifs in the 3'-untranslated region that may mediate VEGF mRNA stability.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007604, F32HL008838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07604, 1F32HL08838-02] Funding Source: Medline; NIDDK NIH HHS [DK45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AKASHI M, 1994, BLOOD, V83, P3182; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARROLL SM, 1994, CIRCULATION, V90, P521; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GILMAN M, 1994, CURRENT PROTOCOLS MO; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDWASSER E, 1989, CONTRIBUTIONS NEPHRO, P2; GONFURNINO M, 1991, P NATL ACAD SCI USA, V88, P2927; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LEVY AP, 1995, IN PRESS CIRC RES; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHARMA H, 1992, J MOL CELL CARDIO S5, V24; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TRIEZENBERG SJ, 1989, CURRENT PROTOCOLS MO; WANG GL, 1993, J BIOL CHEM, V268, P21513; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WU X, 1994, CIRCULATION, V90, pA1343	56	822	863	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13333	13340		10.1074/jbc.270.22.13333	http://dx.doi.org/10.1074/jbc.270.22.13333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768934	hybrid			2022-12-27	WOS:A1995RB43900059
J	MCKAY, RR; CHEN, DM; MILLER, K; KIM, SK; STARK, WS; SHORTRIDGE, RD				MCKAY, RR; CHEN, DM; MILLER, K; KIM, SK; STARK, WS; SHORTRIDGE, RD			PHOSPHOLIPASE-C RESCUES VISUAL DEFECT IN NORPA MUTANT OF DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL-PURIFICATION; NERVOUS-SYSTEM; RAT-LIVER; GENE; PHOTOTRANSDUCTION; PHOTORECEPTORS; EXPRESSION; PLATELETS; CASCADE; RETINA	Mutations in the norpA gene of Drosophila melanogaster severely affect the light evoked photoreceptor potential with strong mutations rendering the fly blind. The norpA gene has been proposed to encode phosphatidylinositol-specific phospholipase C (PLC), which enzymes play a pivotal role in one of the largest classes of signaling pathways known. A chimeric norpA minigene was constructed by placing the norpA cDNA behind an R1-6 photoreceptor cell-specific rhodopsin promoter. This minigene was transferred into norpA(P24) mutant by P-element-mediated germline transformation to determine whether it could rescue the phototransduction defect concomitant with restoring PLC activity. Western blots of head homogenates stained with norpA antiserum show that norpA protein is restored in heads of transformed mutants. Moreover, transformants exhibit a large amount of measurable PLC activity in heads, whereas heads of norpA(P24) mutant exhibit very little to none. Immunohistochemical staining of tissue sections using norpA antiserum confirm that expression of norpA protein in transformants localizes in the retina, more specifically in rhabdomeres of R1-6 photoreceptor cells, but not R7 or R8 photoreceptor cells. Furthermore, electrophysiological analyses reveal that transformants exhibit a restoration of Light-evoked photoreceptor responses in R1-6 photoreceptor cells, but not in R7 or RS photoreceptor cells. This is the strongest evidence thus far supporting the hypothesis that the norpA gene encodes phospholipase C that is utilized in phototransduction.	SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA; ST LOUIS UNIV, DEPT BIOL, ST LOUIS, MO 63103 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Saint Louis University					NEI NIH HHS [EY07192] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007192] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CHEN DM, 1992, VISUAL NEUROSCI, V9, P125, DOI 10.1017/S0952523800009585; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FERREIRA PA, 1994, J BIOL CHEM, V269, P3129; Gall JG, 1971, METHOD ENZYMOL, V21, P470; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HAKATA H, 1982, J BIOCHEM-TOKYO, V92, P929, DOI 10.1093/oxfordjournals.jbchem.a134008; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; INOUE H, 1988, J BIOCHEM-TOKYO, V103, P91, DOI 10.1093/oxfordjournals.jbchem.a122246; KAUPP UB, 1986, TRENDS BIOCHEM SCI, V11, P43, DOI 10.1016/0968-0004(86)90232-X; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE RD, 1994, THESIS ST LOUIS U; LONG JJ, 1994, J BIOL CHEM, V269, P2827; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MCKAY RR, 1994, NEUROSCIENCE, V61, P141, DOI 10.1016/0306-4522(94)90067-1; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Roberts D.B., 1986, P1; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STARK WS, 1976, J COMP PHYSIOL, V105, P15, DOI 10.1007/BF01380050; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; THUMMEL CS, 1991, DROS INFORMATION NEW, V2; WANG P, 1986, J BIOCHEM-TOKYO, V100, P1015, DOI 10.1093/oxfordjournals.jbchem.a121780; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13271	13276		10.1074/jbc.270.22.13271	http://dx.doi.org/10.1074/jbc.270.22.13271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768926	hybrid			2022-12-27	WOS:A1995RB43900050
J	KURLANDSKY, SB; XIAO, JH; DUELL, EA; VOORHEES, JJ; FISHER, GJ				KURLANDSKY, SB; XIAO, JH; DUELL, EA; VOORHEES, JJ; FISHER, GJ			BIOLOGICAL-ACTIVITY OF ALL-TRANS RETINOL REQUIRES METABOLIC CONVERSION TO ALL-TRANS-RETINOIC ACID AND IS MEDIATED THROUGH ACTIVATION OF NUCLEAR RETINOID RECEPTORS IN HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; CULTURED HUMAN KERATINOCYTES; HUMAN-SKIN KERATINOCYTES; BINDING-PROTEIN; VITAMIN-A; X-RECEPTORS; TERMINAL DIFFERENTIATION; RESPONSE ELEMENT; MOUSE EPIDERMIS; SERTOLI CELLS	The biological activity of all trans retinol, in human keratinocytes, was investigated through metabolic and functional analyses that assessed the capacity for retinol uptake and metabolism and the mechanism of retinol-induced activation of gene transcription, Human keratinocytes converted all-trans retinol predominantly to retinyl esters, which accounted for 60 and 90% of cell associated radiolabel after a 90-min pulse and a 48-h chase, respectively. Human keratinocytes also metabolized all-trans retinol to low levels of all-trans retinoic acid (11.47-131.3 ng/mg of protein) in a dose-dependent manner, between 0.3 and 10 mu M added retinol. Small amounts of 13-cis retinoic acid (5.47-8.62 ng/mg of protein) were detected, but 9-cis retinoic acid was detected only when keratinocytes were incubated with radiolabeled retinol, There was no accumulation of the oxidized catabolic metabolites 4-hydroxy- or 4-oxoretinoic acid; however, 5,6-epoxy retinoic acid was detected at pharmacological levels (10 and 30 mu M) of added retinol, Biological activity of retinol was assessed through analysis of two known retinoic acid-mediated responses: 1) reduction of type I epidermal transglutaminase and 2) activation of a retinoic acid receptor-dependent reporter gene, beta RARE(3)-tk-CAT. Both all-trans retinol and all-trans retinoic acid reduced type I epidermal transglutaminase in a dose-dependent manner; however, the ED(50) for all-trans retinol (10 nM) was 10 times greater than for all-trans retinoic acid (1 nM). All-trans retinol also stimulated beta RARE(3)-tk-CAT reporter gene activity in a dose-dependent manner, Half-maximal induction was observed at 30 nM retinol, which was again 10-fold greater than observed with all-trans retinoic acid, Cotransfection of human keratinocytes with expression vectors for dominant negative mutant retinoic acid and retinoid X receptors reduced retinol-induced beta RARE(3)-tk-CAT reporter gene activation by 80%. Inhibition of conversion of ah-trans retinol or all-trans retinaldehyde to all-traits retinoic acid by citral reduced beta RARE(3)-tk-CAT activity 98 and 86%, respectively, These data demonstrate that retinol-induced responses in human keratinocytes are mediated by its tightly regulated conversion to retinoic acid, which functions as a ligand to activate nuclear retinoic acid receptors.	UNIV MICHIGAN, MED CTR, DEPT DERMATOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007197] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07197-18] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ASTROM A, 1991, J BIOL CHEM, V266, P17662; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BORENFREUND E, 1981, J TISSUE CULTURE MET, V9, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CONNOR MJ, 1988, CANCER RES, V48, P7038; CREEK KE, 1993, J NUTR, V123, P356, DOI 10.1093/jn/123.suppl_2.356; CREEK KE, 1989, J INVEST DERMATOL, V92, P283, DOI 10.1111/1523-1747.ep12276867; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; ESKILD W, 1988, BIOCHEM BIOPH RES CO, V152, P1504, DOI 10.1016/S0006-291X(88)80456-X; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FOGH K, 1993, ARCH BIOCHEM BIOPHYS, V300, P751, DOI 10.1006/abbi.1993.1104; FROLIK CA, 1984, RETINOIDS, V2, P177; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIUDICE GJ, 1990, METHOD ENZYMOL, V190, P18; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GRIFFITHS CEM, 1992, J INVEST DERMATOL, V99, P283, DOI 10.1111/1523-1747.ep12616626; Groenendijk G W, 1980, Methods Enzymol, V67, P203; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODAM JR, 1991, J INVEST DERMATOL, V97, P298, DOI 10.1111/1523-1747.ep12480562; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; JETTEN AM, 1990, J INVEST DERMATOL, V95, pS44, DOI 10.1111/1523-1747.ep12505757; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KLIGMAN AM, 1993, J AM ACAD DERMATOL, V29, P25, DOI 10.1016/0190-9622(93)70147-L; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MICHEL S, 1991, ANAL BIOCHEM, V192, P232, DOI 10.1016/0003-2697(91)90213-D; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; Ong David E., 1994, P283; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; ROLLMAN O, 1993, BIOCHEM J, V293, P675, DOI 10.1042/bj2930675; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIEGENTHALER G, 1990, METHOD ENZYMOL, V189, P530; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SIEGENTHALLER G, 1989, PHARM RETINOIDS SKIN, V3, P52; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; TALWAR HS, 1993, J INVEST DERMATOL, V100, P800, DOI 10.1111/1523-1747.ep12476615; TANG GW, 1990, J LIPID RES, V31, P175; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; TORMA H, 1990, METHOD ENZYMOL, V190, P210; TORMA H, 1991, SKIN PHARMACOL, V4, P154; WANG XD, 1993, J NUTR, V123, P1277, DOI 10.1093/jn/123.7.1277	64	100	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32821	32827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806506				2022-12-27	WOS:A1994QA63800019
J	CLAESSONWELSH, L				CLAESSONWELSH, L			PLATELET-DERIVED GROWTH-FACTOR RECEPTOR SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PDGF BETA-RECEPTOR; FAMILY TYROSINE KINASES; SIMIAN SARCOMA-VIRUS; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; MITOGENIC SIGNAL; SH2 DOMAIN; ACTIVATION; TRANSDUCTION				CLAESSONWELSH, L (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, UPPSALA BRANCH, BOX 595, S-75124 UPPSALA, SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BENENTT AM, 1994, P NATL ACAD SCI USA, V91, P7335; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOWENPOPE DF, 1991, TRENDS GENET, V7, P413, DOI 10.1016/0168-9525(91)90222-C; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CLAESSONWELSH L, 1993, BIOL PLATELET DERIVE, V5, P31; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COOPER J, 1993, BIOL PLATELET DERIVE, V5, P44; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1994, IN PRESS MOL CELLULA; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1993, J BIOL CHEM, V268, P577; MORI S, 1994, J BIOL CHEM, V269, P4917; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RAINES EW, 1993, BIOL PLATELET DERIVE, V5, P74; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; TWAMLEY GM, 1993, ADV SEC MESS PHOSPH, V28, P187; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WELSH M, 1994, ONCOGENE, V9, P19; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WESTERMARK B, 1993, BIOL PLATELET DERIVE, V5, P146; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	517	530	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32023	32026						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798193				2022-12-27	WOS:A1994PX30400001
J	ZHAO, LJ; WANG, LL; MUKHERJEE, S; NARAYAN, O				ZHAO, LJ; WANG, LL; MUKHERJEE, S; NARAYAN, O			BIOCHEMICAL-MECHANISM OF HIV-1 VPR FUNCTION - OLIGOMERIZATION MEDIATED BY THE N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRION-ASSOCIATED PROTEIN; DNA-BINDING; PRODUCTIVE INFECTION; HUMAN MACROPHAGES; TYPE-1; GENE; ENCODES; REGION; CELLS	The human immunodeficiency virus, type 1 (HIV-1) genome encodes a 15-kDa accessory gene product, Vpr, that is essential for virus replication in primary monocytes/macrophages. Being present in the virion, Vpr is believed to function in the early phases of HIV-1 replication, including nuclear migration of the pre-integration complex and/or transcription of the provirus genome. By gel filtration analysis of highly purified Vpr protein and its mutants, we demonstrate that HIV-1 Vpr exists as an oligomer, The N-terminal domain of Vpr (amino acids (aa) 1-42) is sufficient for oligomerization; however deletion of aa 36-76 from Vpr disrupts oligomerization, suggesting that aa 36-42 are critical for Vpr oligomerization, As a result of Vpr oligomerization, basic aa residues within Vpr aa 1-73 are highly resistant to trypsin digestion, while those within Vpr aa 74-96 are easily accessible, Mutations within the leucine-/isoleucine-rich domain (aa 60-81), which was previously identified to be involved in Vpr interaction with a host cellular protein, rendered Arg(62) more susceptible to trypsin digestion, Thus, the Vpr oligomeric structure must be extended into this domain. These results suggest a novel feature of HIV-1 Vpr that may be important for its functions.			ZHAO, LJ (corresponding author), UNIV KANSAS,MED CTR,MARION MERRELL DOW FDN,DEPT MICROBIOL MOLEC GENET & IMMUNOL,VIRAL PATHOG,KANSAS CITY,KS 66160, USA.				NCRR NIH HHS [RR06753] Funding Source: Medline; NINDS NIH HHS [NS32203] Funding Source: Medline; PHS HHS [A129382] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032203] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LORI F, 1992, J VIROL, V66, P5553, DOI 10.1128/JVI.66.9.5553-5560.1992; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	35	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32131	32137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798208				2022-12-27	WOS:A1994PX30400020
J	TAKAHASHI, S; SUZUKI, J; KOHNO, M; OIDA, K; TAMAI, T; MIYABO, S; YAMAMOTO, T; NAKAI, T				TAKAHASHI, S; SUZUKI, J; KOHNO, M; OIDA, K; TAMAI, T; MIYABO, S; YAMAMOTO, T; NAKAI, T			ENHANCEMENT OF THE BINDING OF TRIGLYCERIDE-RICH LIPOPROTEINS TO THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BY APOLIPOPROTEIN-E AND LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT ATHEROSCLEROTIC LESIONS; MOUSE PERITONEAL-MACROPHAGES; CHOLESTERYL ESTER SYNTHESIS; CULTURED HUMAN FIBROBLASTS; SMOOTH-MUSCLE CELLS; FAMILIAL HYPERCHOLESTEROLEMIA; HEPARAN-SULFATE; MEDIATED UPTAKE; APOPROTEIN-E; FOAM CELLS	The low density lipoprotein (LDL) receptor plays a crucial role in cholesterol metabolism, A related protein, designated the very low density lipoprotein (VLDL) receptor, that specifically binds apolipoprotein (ape) E has recently been characterized and shown to be expressed in heart, muscle and adipose tissue and the human monocyte-macrophage cell line THP-1, The VLDL receptor binds and internalizes VLDL and intermediate density lipoprotein from Watanabe heritable hyperlipidemic (WHHL) rabbits as well as beta-migrating VLDL from cholesterol-fed rabbits but not LDL from WHHL rabbits, Chinese hamster ovary (CHO) cells transfected with the rabbit VLDL receptor cDNA have now been shown to bind or internalize VLDL (d < 1.006 g/ml) isolated from fasted normolipidemic human subjects with lower affinity than WHHL-VLDL or rabbit beta-VLDL, However, binding and internalization were markedly enhanced when fasted human VLDL was preincubated with either recombinant human apoE (3/3) or lipoprotein lipase (LPL) in CHO cells overexpressing the rabbit or human VLDL receptor, CHO cells transfected with both the rabbit VLDL receptor cDNA and the human LPL cDNA effectively bound, internalized, and degraded fasted human VLDL without pretreatment. Treatment of heparinase reduced the effect of LPL-mediated binding at 4 degrees C, but the inhibitory effect was lower at 37 degrees C, Pseudomonas LPL also enhanced the binding of human fasted VLDL to the VLDL receptor at 37 degrees C in CHO cells overexpressing the human VLDL receptor, Taken together, LPL causes the enhancement of triglyceride-rich lipoproteins binding to the VLDL receptor via both the formation of bridge between lipoproteins and heparan sulfate proteoglycans and its lipolytic effect, Ligand blot analysis showed that the apparent molecular mass of the VLDL receptor is 118 kDa, which is smaller than that of the LDL receptor, These results indicate that the VLDL receptor recognizes both triglyceride-rich lipoproteins that are also relatively rich in apoE, as well as the remnants of triglyceride-rich lipoproteins after catabolism and the interaction with heparan sulfate proteoglycans by LPL, The VLDL receptor may thus function as a receptor for remnants of triglyceride-rich lipoproteins in extrahepatic tissues.	TOHOKU UNIV,CTR GENE RES,SENDAI,MIYAGI 981,JAPAN	Tohoku University	TAKAHASHI, S (corresponding author), FUKUI MED SCH,DEPT INTERNAL MED 3,MATSUOKA,FUKUI 91011,JAPAN.							BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVER.G, 1991, EUR J BIOCHEM, V106, P557; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO P, 1992, BIOCHEM BIOPH RES CO, V183, P514, DOI 10.1016/0006-291X(92)90512-J; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; FLEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOTODA T, 1989, NUCLEIC ACIDS RES, V17, P2351, DOI 10.1093/nar/17.6.2351; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFMANN SL, 1989, J BIOL CHEM, V264, P8260; IKEDA Y, 1990, J LIPID RES, V31, P1911; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAWAMURA M, 1994, ARTERIOSCLER THROMB, V14, P235, DOI 10.1161/01.ATV.14.2.235; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KITA T, 1986, J CLIN INVEST, V77, P1460, DOI 10.1172/JCI112458; KOKUSHO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1743, DOI 10.1080/00021369.1982.10865342; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRAEMER FB, 1983, J BIOL CHEM, V258, P2190; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MAHLEY RW, 1980, J LIPID RES, V21, P970; MAHLEY RW, 1979, ATHER REV, V5, P1; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NOZAKI S, 1984, CLIN CHEM, V30, P748; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OKA K, 1994, EUR J BIOCHEM, V244, P975; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SHIBUI T, 1991, J BIOTECHNOL, V17, P109, DOI 10.1016/0168-1656(91)90002-D; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANLENTEN BJ, 1985, J BIOL CHEM, V260, P8783; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINDLER E, 1985, J LIPID RES, V26, P556; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143	60	203	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15747	15754		10.1074/jbc.270.26.15747	http://dx.doi.org/10.1074/jbc.270.26.15747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797576	hybrid			2022-12-27	WOS:A1995RG53800049
J	DELPINO, MMS; PETERSON, DR; HAWKINS, RA				DELPINO, MMS; PETERSON, DR; HAWKINS, RA			NEUTRAL AMINO-ACID-TRANSPORT CHARACTERIZATION OF ISOLATED LUMINAL AND ABLUMINAL MEMBRANES OF THE BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMS; CELLS; RAT; CAPILLARIES; VESICLES; POLARITY	The neutral amino acid carrier composition of luminal and abluminal membranes of the blood-brain barrier has been studied using isolated membrane vesicles. Phenylalanine was carried almost exclusively by a high affinity (K-m = 10 +/- 2 mu M), Na+-independent amino acid transport system, presumably L1 system, that was found to be symmetrically distributed between luminal and abluminal membranes. Inhibition of phenylalanine uptake was used to determine the affinities (K-i values) toward leucine (17 +/- 3 mu M), tryptophan (8 +/- 1), 2-aminobicyclo(2,2,1)-heptane-2-carboxylic acid (BCH) (11 +/- 2), alanine (628 +/- 117), and glutamine (228 +/- 51). Alanine was found to be transported by two Na+-dependent transport systems that were located exclusively on the abluminal membrane. Kinetic and inhibition experiments indicated that one of these activities was due to system A, which is probably the main route for Na+-dependent alanine transport (K-m = 0.6 +/- 0.2 mM) under physiological conditions. The other Na+-dependent activity was attributed to a B-o,B-+-like system based on its sensitivity toward BCH. This latter system showed greater affinity for large neutral amino acids. The affinities of these two transport systems for several other amino acids were also studied.	CHICAGO MED SCH, DEPT PHYSIOL & BIOPHYS, N CHICAGO, IL 60064 USA	Chicago Medical School			del Pino, Manuel M. Sánchez/I-3977-2015	del Pino, Manuel M. Sánchez/0000-0001-9696-7600	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42331] Funding Source: Medline; NINDS NIH HHS [NS 16389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CORNFORD EM, 1992, CANCER RES, V52, P138; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14907, DOI 10.1074/jbc.270.25.14907; HOPFER U, 1989, METHOD ENZYMOL, V172, P313; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; Lever J E, 1980, CRC Crit Rev Biochem, V7, P187, DOI 10.3109/10409238009105462; MILLER LP, 1985, J NEUROCHEM, V45, P1427, DOI 10.1111/j.1471-4159.1985.tb07209.x; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94, DOI 10.1152/ajplegacy.1976.230.1.94; PARDRIDGE WM, 1983, PHYSIOL REV, V63, P1481, DOI 10.1152/physrev.1983.63.4.1481; ROSENBERG R, 1980, BIOCHIM BIOPHYS ACTA, V598, P375, DOI 10.1016/0005-2736(80)90015-2; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; SMITH QR, 1991, ADV EXP MED BIOL, V291, P55; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; Takakura Y, 1991, Adv Pharmacol, V22, P137, DOI 10.1016/S1054-3589(08)60034-4; TAYARANI I, 1987, J CEREBR BLOOD F MET, V7, P585, DOI 10.1038/jcbfm.1987.109; TOVAR A, 1988, J NEUROCHEM, V51, P1285, DOI 10.1111/j.1471-4159.1988.tb03098.x; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P225, DOI 10.1016/0005-2736(90)90101-S; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WESTERGREN I, 1994, J NEUROCHEM, V62, P159	25	93	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14913	14918		10.1074/jbc.270.25.14913	http://dx.doi.org/10.1074/jbc.270.25.14913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797470	hybrid			2022-12-27	WOS:A1995RE66600014
J	OFFERMANNS, S; SIMON, MI				OFFERMANNS, S; SIMON, MI			G-ALPHA(15) AND G-ALPHA(16) COUPLE A WIDE VARIETY OF RECEPTORS TO PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; SIGNAL-TRANSDUCTION; HL-60 CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; SF9 CELLS; GQ-ALPHA; EXPRESSION; ACTIVATION; ISOZYMES	The murine G-protein alpha-subunit G alpha(15) and its human counterpart G alpha(16) are expressed in a subset of hematopoietic cells, and they have been shown to regulate beta-isoforms of inositide-specific phospholipase C. We studied the ability of a variety of receptors to interact with G alpha(15) and G alpha(16) by cotransfecting receptors and G-protein alpha-subunits in COS-7 cells. Activation of beta(2) adrenergic and muscarinic M(2) receptors in cells expressing the receptors alone or together with G alpha(q), G alpha(11), or G alpha(14) led to a very small stimulation of endogenous phospholipase C. However, when the receptors were coexpressed with G alpha(15) and G alpha(16), addition of appropriate ligands caused a severalfold increase in inositol phosphate production which was time- and dose-dependent. A similar activation of phospholipase C was observed when several other receptors which were previously shown to couple to members of the G(i) and G(s) family were coexpressed with G alpha(15/16). In addition, stimulation of inositol phosphate formation via receptors naturally coupled to phospholipase C was enhanced by cotransfection of G alpha(15) and G alpha(16). These data demonstrate that G alpha(15) and G alpha(16) are unique in that they can be activated by a wide variety of G-protein-coupled receptors. The ability of G alpha(15) and G alpha(16) to bypass the selectivity of receptor G-protein interaction can be a useful tool to understand the mechanism of receptor-induced G-protein activation. In addition, the promiscuous behavior of G alpha(15) and G alpha(16) toward receptors may be helpful in finding ligands corresponding to orphan receptors whose signaling properties are unknown.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER M, 1992, NATURE, V357, P383; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Gilman A G, 1974, Methods Enzymol, V38, P49; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LEE CH, 1995, MOL PHARMACOL, V47, P218; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAPARA MY, 1994, BLOOD, V84, pA572; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEREZ HD, 1992, J BIOL CHEM, V267, P358; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHNABEL P, 1992, BIOCHEM BIOPH RES CO, V188, P1018, DOI 10.1016/0006-291X(92)91333-L; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VANEK M, 1994, MOL PHARMACOL, V46, P832; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	51	435	497	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15175	15180		10.1074/jbc.270.25.15175	http://dx.doi.org/10.1074/jbc.270.25.15175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797501	hybrid, Green Accepted			2022-12-27	WOS:A1995RE66600051
J	SHAH, S; HYDE, DR				SHAH, S; HYDE, DR			2 DROSOPHILA GENES THAT ENCODE THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF THE BRAIN SOLUBLE GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ACTIVITY REQUIRES; ENZYME SUBUNITS; CDNA CLONES; EXPRESSION; PROTEIN; PURIFICATION; SYSTEM; RECEPTOR; DOMAIN	We identified two Drosophila genes (dgc alpha 1 and dgc beta 1) that encode the soluble guanylyl cyclase alpha and beta subunits, respectively. The putative Dgc alpha 1 protein is 76 kDa, has 35% amino acid identity with previously isolated alpha subunits, and was immunolocalized to the adult retina, to the optic lobes, and throughout the brain neuropil. The Dgc beta 1 protein is 86 kDa and exhibits 59% amino acid identity with the rat beta 1 protein. However, the Dgc beta 1 protein has an additional 118 amino acids inserted near the amino terminus, which makes it significantly larger than the rat beta 1. The Dgc beta 1 protein was immunolocalized to the optic lobes and throughout the brain neuropil, with no detectable expression in the retina. The Dgc alpha 1 and Dgc beta 1 cDNAs were stably transfected into human kidney 293 cells. Expression of the individual subunits and mixing of the individually expressed subunits failed to generate significant guanylyl cyclase activity. Only coexpression of the subunits resulted in significant guanylyl cyclase activity. Our results indicate that Dgc alpha 1 and Dgc beta 1 are soluble guanylyl cyclase alpha and beta subunits that are capable of forming a functional guanylyl cyclase heterodimer.	UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA	University of Notre Dame					NEI NIH HHS [EY08058] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008058] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; Catty D., 1988, ANTIBODIES, V1, P19; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARBERS DL, 1992, CELL, V71, P1; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HORIO Y, 1991, BIOCHIM BIOPHYS ACTA, V1133, P81, DOI 10.1016/0167-4889(91)90244-R; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LIU WC, 1995, J BIOL CHEM, V270, P12418, DOI 10.1074/jbc.270.21.12418; MAYER B, 1993, ADV SEC MESS PHOSPH, V28, P111; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PALAZZOLO MJ, 1989, NEURON, V3, P527, DOI 10.1016/0896-6273(89)90211-0; Sambrook J, 1989, MOL CLONING LABORATO; Schultz G., 1984, METHOD ENZYMAT AN, P379; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WALDMAN SA, 1982, J CYCLIC NUCL PROT, V8, P359; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; YOSHIKAWA S, 1993, J NEUROCHEM, V60, P1570, DOI 10.1111/j.1471-4159.1993.tb03324.x; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; YUEN PST, 1994, J BIOL CHEM, V269, P791; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016	38	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15368	15376		10.1074/jbc.270.25.15368	http://dx.doi.org/10.1074/jbc.270.25.15368			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797526	hybrid			2022-12-27	WOS:A1995RE66600078
J	FESCHENKO, MS; SWEADNER, KJ				FESCHENKO, MS; SWEADNER, KJ			STRUCTURAL BASIS FOR SPECIES-SPECIFIC DIFFERENCES IN THE PHOSPHORYLATION OF NA,K-ATPASE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; CATALYTIC SUBUNIT; NA+/K+-ATPASE; MAMMALIAN KIDNEY; ALPHA-SUBUNIT; NA+,K+-ATPASE; ISOZYME; ENZYME; PURIFICATION; STIMULATION	There is considerable evidence that protein kinases play a role in regulation of the activity of the Na,K-ATPase, but the characteristics of direct kinase phosphorylation of Na,K-ATPase subunits are still not well understood. There are 36 sites that could qualify as protein kinase C motifs in rat alpha 1. Here we have used protein fragmentation with trypsin to localize the site of phosphorylation of the rat Na,K-ATPase alpha 1 subunit to within the first 32 amino acids of the N terminus and then used direct sequencing of the phosphorylated protein to determine which of two candidate serine residues was modified. The result was that at most 25% of the P-32 was found on Ser-11, a site that is well conserved in Na,K-ATPase alpha 1 subunits. The remaining 75% or more of the P-32 was found on Ser-18, a site that is absent in many Na,K-ATPase alpha subunit sequences. This accounts for the observation that dog and pig alpha 1 subunits can be phosphorylated by protein kinase C only to much lower levels than can rat alpha 1. It is also likely to be relevant to other known species specific effects of protein kinase C on Na,K-ATPase.	MASSACHUSETTS GEN HOSP, CTR NEUROSCI, MEMBRANE BIOL LAB, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS 27653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; DALY SE, 1994, J BIOL CHEM, V269, P23944; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JORGENSEN PL, 1979, BIOCHIM BIOPHYS ACTA, V555, P485, DOI 10.1016/0005-2736(79)90401-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1978, BIOCHIM BIOPHYS ACTA, V507, P8, DOI 10.1016/0005-2736(78)90369-3; JORGENSEN PL, 1980, BIOCHIM BIOPHYS ACTA, V597, P305, DOI 10.1016/0005-2736(80)90108-X; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAIRUZ PB, 1991, FEBS LETT, V290, P83; LOPINA OD, 1995, BIOPHYS J, V68, P308; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON JP, 1993, J BIOL CHEM, V268, P18958; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; XIE ZJ, 1994, SODIUM PUMP, P49	37	122	123	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14072	14077		10.1074/jbc.270.23.14072	http://dx.doi.org/10.1074/jbc.270.23.14072			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775468	hybrid			2022-12-27	WOS:A1995RC44800071
J	MEDVED, LV; ORTHNER, CL; LUBON, H; LEE, TK; DROHAN, WN; INGHAM, KC				MEDVED, LV; ORTHNER, CL; LUBON, H; LEE, TK; DROHAN, WN; INGHAM, KC			THERMAL-STABILITY AND DOMAIN-DOMAIN INTERACTIONS IN NATURAL AND RECOMBINANT PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; DISSEMINATED INTRAVASCULAR COAGULATION; INVITRO ANTICOAGULANT ACTIVITY; PROTEOLYTIC FORMATION; PURPURA FULMINANS; CALCIUM-BINDING; CA2+ BINDING; FACTOR-XA; CONCENTRATE; EXPRESSION	Scanning microcalorimetry and spectrofluorimetry were applied to a study of the thermal stability and interaction of the modules within natural human protein C (PC) and recombinant protein C (rPC), a potential therapeutic anticoagulant expressed in transgenic pigs. Upon heating in the presence of 2 mM EDTA, pH 8.5, each protein exhibited a similar heat absorption peak with a T-m of similar to 62 degrees C corresponding to the melting of the serine protease (SP) module. Deconvolution of this peak indicated that the SP module consists of two domains that unfold independently. At pH below 3.8, a second peak appeared at extremely high temperature corresponding to the unfolding of the two interacting epidermal growth factor-like (EGF) domains. This second peak occurred at a temperature about 20 degrees C lower in rPC than in PC indicating that the EGF domains in the recombinant protein are less stable. The isolated 6-kDa gamma-carboxyglutamic acid-rich (Gla) fragment as well as a 25-kDa Gla-(EGF)(2) fragment both exhibited a sigmoidal fluorescence-detected denaturation transition in the same temperature region as the SP domains, but only in the presence of Ca2+. In 2 mM Ca2+, the first heat absorption peak in both intact proteins became biphasic, indicating Ca2+-induced structural changes. By contrast, Ca2+ had very little effect on the melting of Gla-domainless protein C. This indicates that not Ca2+ itself but the Ca2+-loaded Gla domain is responsible for conformational changes in the SP domain of the parent protein. Detailed analysis of the shape of the endotherms obtained in Ca2+ and EDTA suggests that Ca2+ induces compact structure in the Gla domain which appears to interact strongly with the SP domain(s) of protein C.			MEDVED, LV (corresponding author), AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.			Medved, Leonid/0000-0002-3665-9849				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ALTSCHUH D, 1994, PROTEIN ENG, V7, P769, DOI 10.1093/protein/7.6.769; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Filimonov V V, 1982, Mol Biol (Mosk), V16, P551; FISHER CL, 1994, PROTEIN SCI, V3, P588; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GERSON WT, 1993, PEDIATRICS, V91, P418; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; HOGG PJ, 1992, J BIOL CHEM, V267, P703; HOYER LW, 1994, VOX SANG, V67, P217, DOI 10.1111/j.1423-0410.1994.tb04579.x; INGHAM KC, 1995, ARCH BIOCHEM BIOPHYS, V316, P235, DOI 10.1006/abbi.1995.1033; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; MANCOJOHNSON M, 1992, AM J HEMATOL, V40, P69, DOI 10.1002/ajh.2830400116; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NOVOKHATNY V, 1992, J BIOL CHEM, V67, P3878; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; NOVOKHATNY VV, 1993, J BIOL CHEM, V268, P17211; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12194; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OKAJIMA K, 1990, AM J HEMATOL, V33, P277, DOI 10.1002/ajh.2830330413; ORTHNER CL, 1988, BIOCHEMISTRY-US, V27, P2558, DOI 10.1021/bi00407a043; ORTHNER CL, 1989, J BIOL CHEM, V24, P18781; ORTHNER CL, 1995, IN PRESS VOX SANG; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Privalov P L, 1986, Methods Enzymol, V131, P4; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WALLS JD, 1989, GENE, V81, P139, DOI 10.1016/0378-1119(89)90344-2; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13652	13659		10.1074/jbc.270.23.13652	http://dx.doi.org/10.1074/jbc.270.23.13652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775416	hybrid			2022-12-27	WOS:A1995RC44800013
J	NAGAHASHI, S; SUDOH, M; ONO, N; SAWADA, R; YAMAGUCHI, E; UCHIDA, Y; MIO, T; TAKAGI, M; ARISAWA, M; YAMADAOKABE, H				NAGAHASHI, S; SUDOH, M; ONO, N; SAWADA, R; YAMAGUCHI, E; UCHIDA, Y; MIO, T; TAKAGI, M; ARISAWA, M; YAMADAOKABE, H			CHARACTERIZATION OF CHITIN SYNTHASE-2 OF SACCHAROMYCES-CEREVISIAE - IMPLICATION OF 2 HIGHLY CONSERVED DOMAINS AS POSSIBLE CATALYTIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-ALBICANS; PHENOTYPIC SELECTION; NUCLEOTIDE-SEQUENCE; SYNTHESIS INVIVO; GENE; YEAST; RHIZOBIUM; EXPRESSION; NODC; CLONING	Chitin synthase 2 of Saccharomyces cerevisiae was characterized by means of site-directed mutagenesis and subsequent expression of the mutant enzymes in yeast cells. Chitin synthase 2 shares a region whose sequence is highly conserved in all chitin synthases. Substitutions of conserved amino acids in this region with alanine (alanine scanning) identified two domains in which any conserved amino acid could not be replaced by alanine to retain enzyme activity. These two domains contained unique sequences, Glu(561)-Asp(562)-Arg(563) and Gln(601)-Arg(602)-Arg-(603)-Arg(604)-Trp(605), that were conserved in all types of chitin synthases. Glu(561) or arginine at 563, 602, and 603 could be substituted by glutamic acid and lysine, respectively, without significant loss of enzyme activity. However, even conservative substitutions of Asp(562) with glutamic acid, Gln(601) with asparagine, Arg(604) with lysine, or Trp(605) with tyrosine drastically decreased the activity, but did not affect apparent K-m values for the substrate significantly. In addition to these amino acids, Asp(441) Was also found in all chitin synthase. The mutant harboring a glutamic acid substitution for Asp(441) severely lost activity, but it showed a similar apparent K-m value for the substrate, Amounts of the mutant enzymes in total membranes were more or less the same as found in the wild type. Furthermore, Asp(441), Asp(562), Gln(601), Arg(604), and Trp(605) are completely conserved in other proteins possessing N-acetylglucosaminyltransferase activity such as NodC proteins of Rhizobium bacterias. These results suggest that Asp(441), Asp(562), Gln(601), Arg(604),,and Trp(605) are located in the active pocket and that they function as the catalytic residues of the enzyme.	NIPPON ROCHE RES CTR, DEPT MYCOL, KAMAKURA, KANAGAWA 247, JAPAN; UNIV TOKYO, DEPT AGR CHEM, BUNKYO KU, TOKYO 113, JAPAN	Roche Holding; University of Tokyo								ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BGOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; CHOI WJ, 1994, P NATL ACAD SCI USA, V91, P4727, DOI 10.1073/pnas.91.11.4727; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DEBELLE F, 1992, MOL PLANT MICROBE IN, V5, P443, DOI 10.1094/MPMI-5-443; DIN AB, 1994, MICROBIOL-UK, V140, P2189, DOI 10.1099/13500872-140-9-2189; DURAN A, 1978, J BIOL CHEM, V253, P4419; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; KANG MS, 1984, J BIOL CHEM, V259, P4966; KRISHNAN HB, 1991, MOL PLANT MICROBE IN, V4, P512, DOI 10.1094/MPMI-4-512; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MOTOYAMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P1685, DOI 10.1271/bbb.58.1685; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; PIWNICAWERMS H, 1990, CURRENT PROTOCOLS MO; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSSEN L, 1984, NUCLEIC ACIDS RES, V12, P9497, DOI 10.1093/nar/12.24.9497; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SBURLATI A, 1986, J BIOL CHEM, V261, P5147; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SILVERMAN SJ, 1988, P NATL ACAD SCI USA, V85, P4735, DOI 10.1073/pnas.85.13.4735; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; Szaniszlo P. J., 1993, Molecular biology and its application to medical mycology., P229; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	43	142	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13961	13967		10.1074/jbc.270.23.13961	http://dx.doi.org/10.1074/jbc.270.23.13961			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775457	hybrid			2022-12-27	WOS:A1995RC44800056
J	LINDSEY, LA; CROW, AJ; GARCIABLANCO, MA				LINDSEY, LA; CROW, AJ; GARCIABLANCO, MA			A MAMMALIAN ACTIVITY REQUIRED FOR THE 2ND STEP OF PREMESSENGER RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 2ND STEP; SACCHAROMYCES-CEREVISIAE; DEPENDENT ATPASE; SPLICEOSOME; INVITRO; PROTEIN; YEAST; U5; PRP16	Splicing of precursors to messenger RNAs occurs via a two-step mechanism. In the first step, the 5'-exon is released concomitant with the production of a lariat intermediate, and in the second step, the exons are joined, releasing the intron in the form of a lariat product. Several gene products of the yeast Saccharomyces cerevisiae have been shown to be required exclusively for the second step. Although mammalian proteins have been implicated in the second step of splicing, none have been shown to act only at this step. We identify here the first mammalian activity shown to be exclusively required far the second step. The activity was shown to increase by 5-fold the rate for this splicing step, whereas it had no effect on the rate of the first step. The activity was not affected by treatment with micrococcal nuclease, whereas it is sensitive to heating to 55 degrees C, suggesting that it is not dependent on an RNA, but more likely is a protein. The second step activity was separated from other factors required for the first step and from PSF, a splicing factor thought to have a second step activity. The activity does not require ATP hydrolysis, suggesting that it acts at a late stage of the second step of splicing.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University			Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; CECH TR, 1993, RNA WORLD, P239; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1988, P NATL ACAD SCI USA, V85, P5459, DOI 10.1073/pnas.85.15.5459; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13415	13421		10.1074/jbc.270.22.13415	http://dx.doi.org/10.1074/jbc.270.22.13415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768943	hybrid			2022-12-27	WOS:A1995RB43900069
J	CLERK, A; BOGOYEVITCH, MA; ANDERSSON, MB; SUGDEN, PH				CLERK, A; BOGOYEVITCH, MA; ANDERSSON, MB; SUGDEN, PH			DIFFERENTIAL ACTIVATION OF PROTEIN-KINASE-C ISOFORMS BY ENDOTHELIN-1 AND PHENYLEPHRINE AND SUBSEQUENT STIMULATION OF P42 AND P44 MITOGEN-ACTIVATED PROTEIN-KINASES IN VENTRICULAR MYOCYTES CULTURED FROM NEONATAL RAT HEARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; CARDIAC GENE-TRANSCRIPTION; ATRIAL-NATRIURETIC-FACTOR; PHORBOL ESTERS; MYOCARDIAL-CELLS; PHOSPHOINOSITIDE HYDROLYSIS; ADRENERGIC-STIMULATION; SMOOTH-MUSCLE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE	The translocation of protein kinase C (PKC) isoforms PKC-alpha, PKC-delta, PKC-epsilon, and PKC-zeta from soluble to particulate fractions was studied in ventricular cardiomyocytes cultured from neonatal rats, Endothelin-1 (ET-1) caused a rapid, ET(A) receptor-mediated translocation of PKC-delta and PKC-epsilon (complete in 0.5-1 min). By 3-5 min, both isoforms were returning to the soluble fraction, but a greater proportion of PKC-epsilon remained associated with the particulate fraction, The EC(50) of translocation for PKC-delta was 11-15 nM ET-1 whereas that for PKC-epsilon was 1.4-1.7 nM. Phenylephrine caused a rapid translocation of PKC-epsilon (EC(50) = 0.9 mu M), but the proportion lost from the soluble fraction was less than with ET-1. Translocation of PKC-delta was barely detectable with phenylephrine. Neither agonist caused any consistent translocation of PKC-alpha or PKC-zeta. Activation of p42 and p44 mitogen-activated protein kinase (MAPK) by ET-1 or phenylephrine followed more slowly (complete in 3-5 min), Phosphorylation of p42-MAPK occurred simultaneously with its activation, The proportion of the total p42-MAPK pool phosphorylated in response to ET-1 (50%) was greater than with phenylephrine (20%), In addition to activation of MAPK, an unidentified p85 protein kinase was activated by ET-1 in the soluble fraction whereas an unidentified p58 protein kinase was activated in the particulate fraction.	UNIV LONDON, NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London; University of London				Bogoyevitch, Marie/0000-0001-9745-3716; Clerk, Angela/0000-0002-5658-0708	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHURCH DJ, 1993, BIOCHEM J, V290, P477, DOI 10.1042/bj2900477; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; HA KS, 1993, J BIOL CHEM, V268, P10534; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HIRATA Y, 1989, BIOCHEM BIOPH RES CO, V160, P1438, DOI 10.1016/S0006-291X(89)80165-2; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KHALIL RA, 1991, CIRC RES, V69, P1626, DOI 10.1161/01.RES.69.6.1626; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; KRAMER BK, 1992, CIRCULATION, V85, P350, DOI 10.1161/01.CIR.85.1.350; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LAZOU A, 1994, AM J PHYSIOL, V267, pH970, DOI 10.1152/ajpheart.1994.267.3.H970; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, J CARDIOVASC PHARM, V17, pS20, DOI 10.1097/00005344-199117002-00005; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MISCHAK H, 1993, FEBS LETT, V326, P51, DOI 10.1016/0014-5793(93)81759-S; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKUMURA K, 1990, MOL CELL BIOCHEM, V93, P173; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; POGGIOLI J, 1986, FEBS LETT, V206, P292, DOI 10.1016/0014-5793(86)80999-1; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; PUCEAT M, 1994, PROTEIN KINASE C, P249; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOZERI O, 1992, ONCOGENE, V7, P2259; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STEINBERG SF, 1987, ENDOCRINOLOGY, V120, P1889, DOI 10.1210/endo-120-5-1889; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TAKANASHI M, 1991, N-S ARCH PHARMACOL, V343, P669; TERZIC A, 1993, PHARMACOL REV, V45, P147; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANHEUGTEN HAA, 1993, J MOL CELL CARDIOL, V25, P41, DOI 10.1006/jmcc.1993.1006; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOODCOCK EA, 1987, CIRC RES, V61, P625, DOI 10.1161/01.RES.61.5.625	96	255	258	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32848	32857						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806510				2022-12-27	WOS:A1994QA63800023
J	HARTZOG, PE; CAIN, BD				HARTZOG, PE; CAIN, BD			2ND-SITE SUPPRESSOR MUTATIONS AT GLYCINE-218 AND HISTIDINE-245 IN THE A SUBUNIT OF F1F0 ATP SYNTHASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; A-SUBUNIT; PROTON TRANSLOCATION; ALPHA-SUBUNIT; MUTAGENIC ANALYSIS; F0F1-ATPASE; PORE; F0; F1FO-ATPASE; REGION	The a-like subunits of F1F0 ATP synthases share primary structural homology in two segments near their carboxyl termini, However, the amino acids at the functionally important positions occupied by a(Gly-218) and a(His-245) in Escherichia coli vary depending upon organism and organelle, The a(G218-->D,H245-->G) and a(G218-->K,H245-->G) double mutations were constructed in the E. coli uncB(a) gene to model the chloroplast ATPase IV subunit and alkaliphilic bacterial a subunit, respectively. Strains carrying each of the single mutations, a(G218-->D), a(G218-->K), and a(H245-->G), had marked reductions in F1F0 ATP synthase function. The a(G218-->K) mutation was alone sufficient to virtually eliminate enzyme function, Membranes prepared from the a(G218-->D) mutant exhibited increased levels of ATP hydrolysis activity without a corresponding increase in active proton transport, suggesting a mechanistic uncoupling of catalytic activity and proton translocation, However, much of the lost F1F0 ATP synthase activity was restored in the a(G218-->D,H245-->G) and a(G218-->K,H245-->G) double mutant strains demonstrating that these mutations act as mutual intragenic second-site suppressors. The evidence is consistent with a close spatial interaction between a(Gly-218) and a(His-245).	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1985, J BIOL CHEM, V260, P1207; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cross RL, 1992, MOL MECHANISMS BIOEN, P317; EYA S, 1988, J BIOL CHEM, V263, P10056; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HOWITT SM, 1993, BIOCHIM BIOPHYS ACTA, V1144, P17, DOI 10.1016/0005-2728(93)90025-B; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; Miller J. H., 1972, EXPT MOL GENETICS, P431; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STACK AE, 1994, J BACTERIOL, V176, P540, DOI 10.1128/JB.176.2.540-542.1994; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; WANG S, 1994, J BIOL CHEM, V269, P3095	35	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32313	32317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798232				2022-12-27	WOS:A1994PX30400047
J	INOUE, T; KIMURA, T; AZUMA, C; INAZAWA, J; TAKEMURA, M; KIKUCHI, T; KUBOTA, Y; OGITA, K; SAJI, F				INOUE, T; KIMURA, T; AZUMA, C; INAZAWA, J; TAKEMURA, M; KIKUCHI, T; KUBOTA, Y; OGITA, K; SAJI, F			STRUCTURAL ORGANIZATION OF THE HUMAN OXYTOCIN RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; DNA-BINDING; EXPRESSION; RAT; PREGNANCY; PROTEINS; UTERUS; HYBRIDIZATION	We isolated and charactarized the human oxytocin receptor gene, Southern blots indicated that the human genome has a single copy of the gene, Chromosomal localization by fluorescence in situ hybridization also showed that the gene was a single copy, assigned to 3p26,2 of the human chromosome, The gene spans approximately 17 kilobases and contains 3 introns and 4 exons, Exons 1 and 2 correspond to the 5'-non-coding region, followed by exons 3 and 4 encoding the amino acids of the receptor, Intron 3, which is the largest at 12 kilobases, separates the coding region immediately after the putative sixth transmembrane-spanning domain. The transcription start sites, demonstrated by primer extension analysis, lie 618 and 621 base pairs upstream of the methionine initiation codon, Near these putative transcription start sites, we found a TATA-like motif and a potential SP-l binding site at about 30 and 65 base pairs, respectively. We also found other known binding sites of transcription regulating factors, such as AP-1, AP-2, GATA-1, Myb, nucleofactor-interleukin 6 binding consensus sequence, and an acute phase reactant-responsive element. No estrogen-responsive element was observed except three half-palindromic estrogen-responsive element motifs. Our findings of the oxytocin receptor gene structure should help to elucidate the mechanism by which the gene expression is induced drastically at parturition in the uterus and how the gene is regulated in other organs such as the mammary gland or central nervous system.	OSAKA UNIV, SCH MED, DEPT OBSTET & GYNECOL, SUITA, OSAKA 565, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KYOTO 602, JAPAN	Osaka University; Kyoto Prefectural University of Medicine								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGIOLAS A, 1991, NEUROSCI BIOBEHAV R, V15, P217, DOI 10.1016/S0149-7634(05)80002-8; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DAWOOD MY, 1979, J CLIN ENDOCR METAB, V49, P429, DOI 10.1210/jcem-49-3-429; FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734, DOI 10.1016/0002-9378(84)90677-X; GUYTON AC, 1991, TXB MED PHYSL, P915; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOLTORF AP, 1989, ENDOCRINOLOGY, V125, P2612, DOI 10.1210/endo-125-5-2612; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KIMURA T, 1992, J STEROID BIOCHEM, V42, P253, DOI 10.1016/0960-0760(92)90127-5; LEAKE RD, 1981, J CLIN ENDOCR METAB, V53, P730, DOI 10.1210/jcem-53-4-730; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MANN EA, 1991, J BIOL CHEM, V266, P16931; NUSING RM, 1993, J BIOL CHEM, V268, P25253; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; ROMERO R, 1993, PRETERM BIRTH CAUSES, P97; RUZYCKY AL, 1988, CAN J PHYSIOL PHARM, V66, P10, DOI 10.1139/y88-002; SAMBROOK J, 1992, MOL CLONING LABORATO; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; SOLOFF MS, 1974, J BIOL CHEM, V249, P1376; TAKEMURA M, 1994, J CLIN INVEST, V93, P2319, DOI 10.1172/JCI117236; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YOSHIMURA R, 1993, ENDOCRINOLOGY, V133, P1239, DOI 10.1210/en.133.3.1239	36	210	214	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32451	32456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798245				2022-12-27	WOS:A1994PX30400066
J	TANAKA, Y; TAO, W; BLANCHARD, JS; HEHRE, EJ				TANAKA, Y; TAO, W; BLANCHARD, JS; HEHRE, EJ			TRANSITION-STATE STRUCTURES FOR THE HYDROLYSIS OF ALPHA-D-GLUCOPYRANOSYL FLUORIDE BY RETAINING AND INVERTING REACTIONS OF GLYCOSYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL FLUORIDE; CARBOHYDRASE ACTION; MECHANISM; GLUCOSIDASE; GLUCOAMYLASE; GLUCANASES; TREHALASE; ENZYME; SCOPE	Secondary tritium and primary C-14 kinetic isotope effects were measured for the hydrolysis of alpha-D-glucopyranosyl fluoride catalyzed by sugar beet seed alpha-D-glucosidase, forming alpha-D-glucose, and by Rhizopus niveus glucoamylase forming beta-D-glucose. The data provided a novel opportunity to model and directly compare the transition state structures for the hydrolysis of a substrate promoted with retention or inversion of configuration according to the enzyme catalyst. The isotope effects for the reaction catalyzed by each enzyme are most consistent with an S(N)1 rather than an S(N)2 mechanism, The modeled transition state structures for the hydrolysis promoted by the alpha-glucosidase and the glucoamylase both bear significant oxocarbonium ion character, with the D-glucosyl residue having a flattened C-4(1) conformation and a C-1-O-5 bond order of 1.92, even though opposite D-glucose anomers were produced from the substrate. The transition states show some modest differences, but their general similarity strongly suggests that the stereochemical outcome of glycosylase reactions does not predict the transition state structure, nor does the transition state structure of such reactions predict the stereochemical outcome. The results support previously reported evidence for the separate topological control of product configuration by protein structures in these and other glycosylases.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Tanaka, Yoshimasa/0000-0002-5024-0614	NIGMS NIH HHS [GM 33449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANAIT NS, 1991, J AM CHEM SOC, V113, P7951, DOI 10.1021/ja00021a021; BARNETT JEG, 1971, BIOCHEM J, V123, P607, DOI 10.1042/bj1230607; CHIBA S, 1978, AGR BIOL CHEM TOKYO, V42, P241, DOI 10.1080/00021369.1978.10862964; CHIBA S, 1979, J BIOCHEM-TOKYO, V85, P1135; CHIBA S, 1988, BIOCHEMISTRY-US, V27, P1564, DOI 10.1021/bi00405a025; CHIBA S, 1988, HDB AMYLASES RELATED, P112; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; Cleland W W, 1979, Methods Enzymol, V63, P103; COGOLI A, 1975, J BIOL CHEM, V250, P7802; EVELEIGH DE, 1969, CARBOHYD RES, V10, P87, DOI 10.1016/S0008-6215(00)81090-3; FERRIER WG, 1962, ACTA CRYSTALLOGR, V16, P1023; HEHRE EJ, 1990, CARBOHYD RES, V198, P123, DOI 10.1016/0008-6215(90)84282-Y; HEHRE EJ, 1979, J BIOL CHEM, V254, P5942; HEHRE EJ, 1969, ARCH BIOCHEM BIOPHYS, V135, P75, DOI 10.1016/0003-9861(69)90518-9; HEHRE EJ, 1982, BIOCHEMISTRY-US, V21, P3090, DOI 10.1021/bi00256a009; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10799; IGAKI S, 1989, ANN M JAP AGR SOC NI, P292; KASUMI T, 1987, BIOCHEMISTRY-US, V26, P3010, DOI 10.1021/bi00385a009; KERR JA, 1985, CRC HDB CHEM PHYSICS, pF165; KITA A, 1984, APR ANN M JAP AGR CH, P545; KITAHATA S, 1981, J BIOL CHEM, V256, P6017; KONSTANTINIDIS A, 1991, BIOCHEM J, V279, P587, DOI 10.1042/bj2790587; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LIU W, 1991, BIOCHEMISTRY-US, V30, P1419, DOI 10.1021/bi00219a036; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MATSUI H, 1989, J BIOL CHEM, V264, P8714; MATSUI H, 1993, CARBOHYD RES, V250, P45, DOI 10.1016/0008-6215(93)84153-W; NAKANO M, 1989, CARBOHYD RES, V194, P139, DOI 10.1016/0008-6215(89)85013-X; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; PARKIN DW, 1991, BIOCHEMISTRY-US, V30, P4586, DOI 10.1021/bi00232a032; SIMS LB, 1984, ISOTOPES ORGANIC CHE, V6, P161; SIMS LB, 1974, SPECIAL PUBLICATION, V1; SIMS LB, 1977, 337 IND U QUANT CHEM; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STERN MJ, 1971, J CHEM PHYS, V55, P2007, DOI 10.1063/1.1676366; TSUJISAKA Y, 1960, B OSAKA MUNICIPAL TE, V23, P1; Wilson Jr E. B., 1955, MOL VIBRATIONS; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; AMPAC506 QUANT CHEM	40	69	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32306	32312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798231				2022-12-27	WOS:A1994PX30400046
J	SUTHERLAND, C; OBRIEN, RM; GRANNER, DK				SUTHERLAND, C; OBRIEN, RM; GRANNER, DK			PHOSPHATIDYLINOSITOL 3-KINASE, BUT NOT P70/P85 RIBOSOMAL S6 PROTEIN-KINASE, IS REQUIRED FOR THE REGULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK) GENE-EXPRESSION BY INSULIN - DISSOCIATION OF SIGNALING PATHWAYS FOR INSULIN AND PHORBOL ESTER REGULATION OF PEPCK GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION; ACTIVATION; SEQUENCE; 3,4,5-TRISPHOSPHATE; ASSOCIATION; INHIBITION; DOMAINS	Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the rate limiting step in hepatic gluconeogenesis. Glucagon (via the second messenger cAMP) and glucocorticoids stimulate the transcription of the PEPCK gene, whereas insulin and phorbol esters inhibit, in a dominant fashion, these effects, Wortmannin, an inhibitor of phosphatidylinositol 3-kinase, prevents the stimulation of glycogen synthesis, glucose transport, mitogen-activated protein kinase, and p70/p85 ribosomal S6 protein kinase by insulin, We now show that wortmannin can also block the inhibition of glucocorticoid- and cAMP-stimulated PEPCK gene expression by insulin, PEPCK-chloramphenico1 acetyltransferase fusion gene experiments demonstrate that wortmannin blocks an activity that is required for insulin signaling to elements within the PEPCK promoter. Phorbol esters mimic the action of insulin on the regulation of PEPCK gene expression, but wortmannin does not block the effect of these agents, Thus, phosphatidylinositol 3-kinase is required for the regulation of PEPCK gene expression by insulin, but not by phorbol esters, The immunosuppressant rapamycin, a potent inhibitor of insulin or phorbol. ester stimulation of p70/p85 ribosomal S6 protein kinase, has no significant effect on the regulation of PEPCK gene expression by insulin or phorbol esters. Thus, p70/p85 ribosomal S6 protein kinase does not have a role in signaling to the PEPCK promoter by insulin or phorbol esters.	VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University				Sutherland, Calum/0000-0003-4398-7434	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P30DK020593, P60DK020593, R37DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEALE EG, 1985, J BIOL CHEM, V260, P748; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOU T, 1991, MOL CELL ENDOCRINOL, V75, P181, DOI 10.1016/0303-7207(91)90159-P; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENTON RM, 1986, ADV CYCLIC NUCLEOTID, V20, P289; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FILLAT C, 1993, FEBS LETT, V318, P287, DOI 10.1016/0014-5793(93)80530-8; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GOULD GW, 1994, J BIOL CHEM, V269, P26622; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; MOLERO C, 1992, EXP CELL RES, V200, P295, DOI 10.1016/0014-4827(92)90175-8; MYUERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TOKER A, 1994, J BIOL CHEM, V269, P32358; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	55	146	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15501	15506		10.1074/jbc.270.26.15501	http://dx.doi.org/10.1074/jbc.270.26.15501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797543	hybrid			2022-12-27	WOS:A1995RG53800013
J	TOGAWA, K; ISHIGURO, T; KAYA, S; SHIMADA, A; IMAGAWA, T; TANIGUCHI, K				TOGAWA, K; ISHIGURO, T; KAYA, S; SHIMADA, A; IMAGAWA, T; TANIGUCHI, K			REVERSIBLE PHOSPHORYLATION OF BOTH TYR(7) AND TYR(10) IN THE ALPHA-CHAIN OF PIG STOMACH H+,K+-ATPASE BY A MEMBRANE-BOUND KINASE AND A PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; CDNA CLONING; GASTRIC (H+; SEQUENCE; SUBUNIT; NA+,K+-ATPASE; PARIETAL; HISTAMINE; CLEAVAGE; PROTEINS	When pig stomach membrane H+,K+-ATPase preparations were incubated with [gamma-P-32]ATP and Mg2+ with vanadate, P-32 was incorporated into the oc chain of H+,K+-ATPase to a steady-state level of approximately 0.7 mol of phosphotyrosine (Tyr(P))/mol of phosphoenzyme intermediates. The addition of a membrane H+,K+ ATPase preparation with Mg2+ accelerated the liberation of P-32 from Tyr(P) residues in the alpha-chain, Mild tosylphenylalanyl chloromethyl ketone-trypsin treatment solubilized P-32-containing peptides from the ct-chain almost completely. A reverse-phase column chromatography of the supernatant gave two peaks of P-32-peptide with similar total radioactivities. The amino acid sequence of both peaks was shown to be Gly Lys Ala-Glu-Asn-Tyr-Glu-Leu-Tyr-Gln-, which is consistent with the amino-terminal sequence of the alpha-chain of H+,K+-ATPase deduced from cDNA from pig stomach except that the initial Met was absent. The comparison of the recovery of amino acid from each Edman cycle showed that the phosphorylation of Tyr(10) occurred preceding the phosphorylation of Tyr(7). These data and others suggested the presence of a novel membrane-bound enzyme system to participate in reversible phosphorylation of both Tyr residues in the alpha-chain of H+,K+-ATPase.	HOKKAIDO UNIV,FAC SCI,GRAD SCH SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Imagawa, Toshiaki/A-4255-2012					BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CARLSSON T, 1979, ACTA CHEM SCAND B, V33, P607, DOI 10.3891/acta.chem.scand.33b-0607; CHANG H, 1977, BIOCHIM BIOPHYS ACTA, V464, P313, DOI 10.1016/0005-2736(77)90006-2; CHEW CS, 1986, BIOCHIM BIOPHYS ACTA, V888, P116, DOI 10.1016/0167-4889(86)90077-7; CHEW CS, 1980, AM J PHYSIOL, V238, pG312, DOI 10.1152/ajpgi.1980.238.4.G312; EGUCHI H, 1993, BIOCHEM BIOPH RES CO, V196, P294, DOI 10.1006/bbrc.1993.2248; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1986, BIOCHEM BIOPH RES CO, V138, P185, DOI 10.1016/0006-291X(86)90264-0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SOLL AH, 1979, AM J PHYSIOL, V237, pE444, DOI 10.1152/ajpendo.1979.237.5.E444; TSUNODA Y, 1993, AM J PHYSIOL, V264, pG351, DOI 10.1152/ajpgi.1993.264.2.G351	22	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15475	15478		10.1074/jbc.270.26.15475	http://dx.doi.org/10.1074/jbc.270.26.15475			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797539	hybrid			2022-12-27	WOS:A1995RG53800009
J	ZIEMIENOWICZ, A; ZYLICZ, M; FLOTH, C; HUBSCHER, U				ZIEMIENOWICZ, A; ZYLICZ, M; FLOTH, C; HUBSCHER, U			CALF THYMUS HSC70 PROTEIN PROTECTS AND REACTIVATES PROKARYOTIC AND EUKARYOTIC ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; STRESS PROTEINS; DNA-REPLICATION; RNA-POLYMERASE; MOLECULAR CHAPERONES; BINDING-SPECIFICITY; PEPTIDE-BINDING; ATP HYDROLYSIS; HSP70	The heat-shock 70 protein (Hsp 70) chaperone family is very conserved and its prokaryotic homologue, the DnaK protein, is assumed to form one of the cellular systems for the prevention and restoration of heat-induced protein denaturation. By using anti-DnaK antibodies we purified the DnaK homologue heat-shock cognate protein (Hsc70) from calf thymus to apparent homogeneity, This protein was classified as an eukaryotic Hsc70, since (i) monoclonal antibodies against eukaryotic Hsc70 recognized it, (ii) its amino terminal sequence showed strong homology to Hsp70s from eukaryotes and, (iii) it had an intrinsic weak ATPase activity that was stimulated by various peptide substrates, We show that this calf thymus Hsc70 protein protected calf thymus DNA polymerases alpha and epsilon as well as Escherichia coli DNA polymerase III and RNA polymerase from heat inactivation and could reactivate these heat-inactivated enzymes in an ATP-hydrolysis dependent manner, likely leading to the dissociation of aggregates formed during heat inactivation, In contrast to this, DnaK protein was exclusively able to protect and to reactivate the enzymes from E. coli but not from eukaryotic cells, Finally, the addition of calf thymus DnaJ cochaperone homologue reduced the amount of Hsc70 required for reactivation at least 10-fold.	UNIV ZURICH,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; UNIV GDANSK,DEPT BIOL MOLEC,DIV BIOPHYS,PL-80822 GDANSK,POLAND	University of Zurich; Fahrenheit Universities; University of Gdansk								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V129, P95; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISER T, 1991, J BIOL CHEM, V266, P10420; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	35	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15479	15484		10.1074/jbc.270.26.15479	http://dx.doi.org/10.1074/jbc.270.26.15479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797540	Green Accepted, hybrid			2022-12-27	WOS:A1995RG53800010
J	DAGOSTARO, GAF; ZINGONI, A; MORITZ, RL; SIMPSON, RJ; SCHACHTER, H; BENDIAK, B				DAGOSTARO, GAF; ZINGONI, A; MORITZ, RL; SIMPSON, RJ; SCHACHTER, H; BENDIAK, B			MOLECULAR-CLONING AND EXPRESSION OF CDNA-ENCODING THE RAT UDP-N-ACETYLGLUCOSAMINE-ALPHA-6-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; ASPARAGINE-LINKED OLIGOSACCHARIDES; EUKARYOTIC MESSENGER-RNAS; 3' UNTRANSLATED REGION; ALPHA-MANNOSIDASE-II; SEQUENCE-ANALYSIS; GLYCOPROTEIN-SYNTHESIS; MEMBRANE-PROTEINS; GOLGI-APPARATUS; GLYCOSYLATION	UDP-N-acetyl-D-glucosamine:alpha-6-D-mannoside beta-1,2-N-acetylglucosaminyltransferase II (EC 2.4.1.143) (GnT II) is a Golgi resident enzyme that catalyzes an essential step in the biosynthetic pathway leading from high mannose to complex N-linked oligosaccharides. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the enzyme purified from rat liver revealed a polypeptide of 42 kDa. Amino acid sequences were obtained from the N terminus and a tryptic peptide. Overlapping cDNA clones coding for the full-length rat GnT II were obtained. The complete nucleotide sequence revealed a 1326-base pair open reading frame that codes for a polypeptide of 442 amino acids, including a presumptive N-terminal membrane-anchoring domain. The region of cDNA coding for the C-terminal 389 amino acids of rat GnT II was linked in frame to a cDNA segment encoding the cleavable signal sequence of the human interleukin-2 receptor and transiently expressed in COS-7 cells. A 77-fold enhancement of GnT II activity over a control carrying the GnT II cDNA out-of-frame was detected in the culture medium at 72 h after transfection. H-1-NMR spectroscopy confirmed that the oligosaccharide synthesized in vitro by the recombinant enzyme was the product of GnT II activity. These data verify the identity of the cloned GnT II cDNA and demonstrate that the C-terminal region of the protein includes the catalytic domain.	BIOMEMBRANE INST,SEATTLE,WA 98119; UNIV WASHINGTON,SEATTLE,WA 98119; ENEA,BIOPHYS LAB,I-00060 CASACCIA,ITALY; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA	University of Washington; University of Washington Seattle; Italian National Agency New Technical Energy & Sustainable Economics Development; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Zingoni, Alessandra/AAC-5481-2022; Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BENDIAK B, 1985, CARBOHYD RES, V144, P1, DOI 10.1016/0008-6215(85)85001-1; BENDIAK B, 1988, ANAL BIOCHEM, V175, P96, DOI 10.1016/0003-2697(88)90366-1; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BINDER R, 1989, J BIOL CHEM, V264, P16910; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; FUKUDA M N, 1990, Glycobiology, V1, P9, DOI 10.1093/glycob/1.1.9; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; GREGO B, 1985, EUR J BIOCHEM, V148, P485, DOI 10.1111/j.1432-1033.1985.tb08865.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; POWNALL S, 1992, GENOMICS, V12, P699, DOI 10.1016/0888-7543(92)90297-6; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; VANHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WARD LD, 1990, J CHROMATOGR, V519, P199, DOI 10.1016/0021-9673(90)85148-O	56	46	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15211	15221		10.1074/jbc.270.25.15211	http://dx.doi.org/10.1074/jbc.270.25.15211			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797505	hybrid			2022-12-27	WOS:A1995RE66600056
J	GLOVER, S; BAYBURT, T; JONAS, M; CHI, E; GELB, MH				GLOVER, S; BAYBURT, T; JONAS, M; CHI, E; GELB, MH			TRANSLOCATION OF THE 85-KDA PHOSPHOLIPASE A(2) FROM CYTOSOL TO THE NUCLEAR-ENVELOPE IN RAT BASOPHILIC LEUKEMIA-CELLS STIMULATED WITH CALCIUM IONOPHORE OR IGE/ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONATE-MOBILIZING PHOSPHOLIPASE-A2; MOUSE PERITONEAL-MACROPHAGES; PRODUCT-CONTAINING VESICLES; MEMBRANE ASSOCIATION; ACID RELEASE; MAST-CELLS; HYDROLYZING PHOSPHOLIPASE-A2; SUBSTRATE SPECIFICITIES; HUMAN PLATELETS	The rat mast cell line RBL-2H3,1 contains an 85-kDa cytosolic phospholipase A(2) (cPLA(2)) that is very likely involved in liberating arachidonate from membrane phospholipid for the synthesis of eicosanoids following stimulation with either calcium ionophore or IgE/antigen. In this study, the intracellular location of cPLA(2) was determined using immunofluorescence microscopy and immuno-goId electron microscopy. In nonstimulated cells, cPLA(2) is distributed throughout the cytosol and is excluded from the nucleoplasm. Following cell activation with calcium ionophore, most of the cPLA(2) translocates to the nuclear envelope, and the enzyme remains there during the entire period that ionophore is present. With IgE/antigen stimulation for 5 min, approximately 20-30% of the cPLA(2) translocates to the nuclear envelope, and after 30 min of stimulation, most of the enzyme returns to the cytosol. Measurement of intracellular calcium using the dye Fura-2/AM shows that the level of calcium rises immediately after antigen is added, remains high for about 30 s, and then declines back to resting levels. Activation with calcium ionophore produces a 10-fold larger release of arachidonate than does stimulation with IgE/antigen. Thus, the results suggest that the extent of membrane binding of cPLA(2) correlates with the release of arachidonate and that the site of arachidonate liberation is the nuclear envelope where many of the enzymes that oxygenate this fatty acid are located.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017758] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL50040] Funding Source: Medline; NIAID NIH HHS [AI17758] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BINGHAM BR, 1994, J BIOL CHEM, V269, P19300; BOLE DG, 1989, J HISTOCHEM CYTOCHEM, V37, P1817, DOI 10.1177/37.12.2685110; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHI EY, 1982, LAB INVEST, V47, P579; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOD BJ, 1968, BIOCHIM BIOPHYS ACTA, V150, P397, DOI 10.1016/0005-2736(68)90138-7; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FONTEH AN, 1994, J IMMUNOL, V154, P5438; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; ISHIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1084, P53, DOI 10.1016/0005-2760(91)90055-M; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; KEENAN TW, 1970, BIOCHIM BIOPHYS ACTA, V203, P547, DOI 10.1016/0005-2736(70)90191-4; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAUSE H, 1991, EUR J BIOCHEM, V199, P3555; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEI ZM, 1992, ENDOCRINOLOGY, V130, P861, DOI 10.1210/en.130.2.861; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCGIVNEY A, 1981, ARCH BIOCHEM BIOPHYS, V212, P572, DOI 10.1016/0003-9861(81)90400-8; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL DE, 1991, PROSTAG LEUKOTR ESS, V43, P1, DOI 10.1016/0952-3278(91)90125-O; MONK PN, 1993, RECEPTOR, V3, P77; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NAKATANI Y, 1994, BIOL PHARM BULL, V17, P47; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NATSUI K, 1991, BIOCHIM BIOPHYS ACTA, V1085, P241, DOI 10.1016/0005-2760(91)90100-V; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OKANO Y, 1985, BIOCHEM BIOPH RES CO, V127, P726, DOI 10.1016/S0006-291X(85)80003-6; OROURKE AM, 1992, MOL IMMUNOL, V29, P1299, DOI 10.1016/0161-5890(92)90166-U; ORTEGA E, 1989, EUR J IMMUNOL, V19, P2251, DOI 10.1002/eji.1830191211; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SAHARA N, 1990, J HISTOCHEM CYTOCHEM, V38, P975, DOI 10.1177/38.7.1693935; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STEINER MR, 1991, ARCH BIOCHEM BIOPHYS, V286, P293, DOI 10.1016/0003-9861(91)90043-I; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TANAKA Y, 1991, CHEM PHARM BULL, V39, P2072; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; XING MZ, 1994, J BIOL CHEM, V269, P3117; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; ZOR U, 1991, BIOCHIM BIOPHYS ACTA, V1091, P385, DOI 10.1016/0167-4889(91)90204-B; ZOR U, 1990, BIOCHIM BIOPHYS ACTA, V1091, P385	74	315	318	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15359	15367		10.1074/jbc.270.25.15359	http://dx.doi.org/10.1074/jbc.270.25.15359			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797525	hybrid			2022-12-27	WOS:A1995RE66600077
J	KALMAN, VK; ERDMAN, RA; MALTESE, WA; ROBISHAW, JD				KALMAN, VK; ERDMAN, RA; MALTESE, WA; ROBISHAW, JD			REGIONS OUTSIDE OF THE CAAX MOTIF INFLUENCE THE SPECIFICITY OF PRENYLATION OF G-PROTEIN GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA; RAS PROTEINS; POSTTRANSLATIONAL MODIFICATION; BACULOVIRUS SYSTEM; TERMINAL CYSTEINE; ALPHA-SUBUNITS; AMINO-ACID; FARNESYLTRANSFERASE; CELLS	A family of GTP-binding regulatory proteins (G proteins) transduces signals across the plasma membrane from a large number of receptors to a smaller number of effecters. Recent studies indicate that a series of post-translational modifications are required for their association with the plasma membrane and for their function. In the case of the G protein gamma subunits, the post-translational modifications include the prenylation of a cysteine residue within a carboxyl-terminal CAAX motif. Although prenylation has been shown to involve the addition of either a C-15 farnesyl or a C-20 geranylgeranyl group to proteins, the structural requirements and functional consequences of adding different types of prenyl groups to various members of the gamma subunit family have not been examined. In the present study, we have employed the baculovirus expression system to study the structural requirements for attaching different types of prenyl groups to various members of the gamma subunit family. We show that the gamma(2) subunit is modified by a C-20 geranylgeranyl group, consistent with the presence of a geranylgeranylation target sequence in this protein. However, we found that the gamma(1) and mutant gamma(2(ser-71)) subunits are modified by both C-15 farnesyl and C-20 geranylgeranyl groups, despite the presence of an accepted farnesylation target sequence in both of these proteins. Using chimeras of the gamma(1) and gamma(2) subunits, we provide evidence indicating that structural elements upstream of the carboxyl-terminal CAAX motif play a role in the recognition of members of the gamma subunit family by the appropriate insect and mammalian prenyltransferases.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center					NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039867, R29GM039867] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline; NIGMS NIH HHS [GM39867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS JB, 1991, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWE PN, 1990, ONCOGENE, V5, P1045; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; REISS Y, 1991, J BIOL CHEM, V266, P10672; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; UEDA N, 1994, J BIOL CHEM, V269, P4388; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14835	14841		10.1074/jbc.270.24.14835	http://dx.doi.org/10.1074/jbc.270.24.14835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782351	hybrid			2022-12-27	WOS:A1995RD45500089
J	KAZANIETZ, MG; BARCHI, JJ; OMICHINSKI, JG; BLUMBERG, PM				KAZANIETZ, MG; BARCHI, JJ; OMICHINSKI, JG; BLUMBERG, PM			LOW-AFFINITY FINDING OF PHORBOL ESTERS TO PROTEIN-KINASE-C AND ITS RECOMBINANT CYSTEINE-RICH REGION IN THE ABSENCE OF PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							12,13-DIBUTYRATE BINDING; CAENORHABDITIS-ELEGANS; REGULATORY DOMAIN; UNC-13 GENE; ACTIVATION; RECEPTOR; BRAIN; PHOSPHATIDYLSERINE; SEQUENCE; PRODUCT	Binding of phorbol esters to protein kinase C (PKC) has been regarded as dependent on phospholipids, with phosphatidylserine being the most effective for reconstituting binding. By using a purified single cysteine-rich region from PKC delta expressed in Escherichia coli we were able to demonstrate that specific binding of [H-3]phorbol 12,13-dibutyrate to the receptor still takes place in the absence of the phospholipid cofactor. However, [H-3]phorbol 12,13-dibutyrate bound to the cysteine rich region with 80-fold lower affinity in the absence than in the presence of 100 mu g/ml phosphatidlylserine. Similar results were observed with the intact recombinant PRC delta isolated from insect cells. When different phorbol derivatives were examined, distinct structure-activity relations for the cysteine-rich region were found in the presence and absence of phospholipid. Our results have potential implications for PKC translocation, for inhibitor design, and for PKC structural determination.	NCI,MED CHEM LAB,BETHESDA,MD 20892; NIDDK,CHEM PHYS LAB,BETHESDA,MD 20892; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Barchi, Joseph J/N-3784-2014	Barchi, Joseph/0000-0001-9906-0799				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; ARECESLB, 1994, J BIOL CHEM, V269, P19553; BLUMBERG PM, 1988, CANCER RES, V48, P1; BLUMBERG PM, 1984, MECHANISMS TUMOR PRO, V3, P143; DASILVA C, 1990, CANCER RES, V50, P2081; DUNPHY WG, 1981, CANCER RES, V41, P2640; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; LUO JH, 1993, J BIOL CHEM, V268, P3715; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NAKADATE T, 1987, CANCER RES, V47, P6537; Nakakuma H, 1989, Cancer Commun, V1, P127; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; SHARKEY NA, 1985, CANCER RES, V45, P19; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; TURNER JT, 1987, J PHARMACOL EXP THER, V242, P873; WENDER PA, 1995, P NATL ACAD SCI USA, V92, P239, DOI 10.1073/pnas.92.1.239	27	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14679	14684		10.1074/jbc.270.24.14679	http://dx.doi.org/10.1074/jbc.270.24.14679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782331	hybrid			2022-12-27	WOS:A1995RD45500067
J	KOSTER, JC; BLANCO, G; MERCER, RW				KOSTER, JC; BLANCO, G; MERCER, RW			A CYTOPLASMIC REGION OF THE NA,K-ATPASE ALPHA-SUBUNIT IS NECESSARY FOR SPECIFIC ALPHA/ALPHA ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENOSINE-TRIPHOSPHATASE; PERFORMANCE GEL CHROMATOGRAPHY; LASER-LIGHT SCATTERING; INFECTED INSECT CELLS; (NA+ + K+)-ATPASE; BETA-UNITS; MOLECULAR-CLONING; ATPASE ACTIVITY; RAT-BRAIN; K+-ATPASE	While most structural studies of the Na,K-ATPase support a subunit stoichiometry of one alpha subunit to one beta-subunit, the exact quaternary structure of the Na,K-ATPase and its relevance to enzyme function is the subject of much debate. Formation of a higher order enzyme complex is supported by our previous study demonstrating specific alpha/alpha interactions among the rat Na,K-ATPase isoforms (alpha 1, alpha 2, alpha 3), expressed in virally infected Sf-9 insect cells and among native alpha isoforms in rat brain (1). This detergent-resistant association was not observed in insect cells coexpressing the homologous gastric H,B-ATPase alpha-subunit, nor was it dependent on the coexpression of the beta-subunit. To delineate domains necessary for alpha/alpha assembly, a series of H,K-ATPase-Na,K-ATPase chimeras were constructed by combining the N-terminal, cytoplasmic midregion and C-terminal segments derived hom the Na,K-ATPase (N) and the H,K-ATPase (H) alpha-polypeptides (HNN, HNH, NHH, NHN, and HHN), The alpha-subunit chimeras were coexpressed with the Na,R-ATPase alpha 1-subunit in Sf-9 cells using the baculovirus expression system. Specific and detergent-stable association is observed between the Na,R-ATPase alpha-subunit and the HNN and HNH chimeras, but not with the NHH, NHN, or HHN chimeras. Consistent with the Na,K-ATPase cytoplasmic domain as being necessary for alpha/alpha interactions, the full-length alpha-subunit stably associates with an alpha N-terminal deletion mutant (Delta Gly(2)-Leu(273)), but not with an alpha cytoplasmic deletion mutant (Delta Arg(350)-Pro(785)). In addition, the naturally occurring C-terminal truncated alpha 1 isoform, alpha 1T (Delta Gly(554) to, C terminus), does not associate with the alpha 1-subunit in Sf-9 cells coexpressing both polypeptides. Thus, a cytoplasmic region in the alpha-subunit (Gly(554)-Pro(785)) is necessary for specific alpha/alpha association. The same cytoplasmic region contains a strongly hydrophobic segment that, by analogy with oligomerization of water-soluble proteins, may form the interface of the extramembranous alpha/alpha contact site.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039746, R29GM039746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; Blanco G, 1988, Prog Clin Biol Res, V268A, P271; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1994, SODIUM PUMP, P82; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; ELLORY JC, 1979, J PHYSIOL-LONDON, V295, P10; ESMANN M, 1980, BIOCHIM BIOPHYS ACTA, V603, P1, DOI 10.1016/0005-2736(80)90386-7; GANJEIZADEH M, 1992, BIOPHYS J, V61, P122; GANJEIZADEH M, 1991, BIOPHYS J, V59, P343; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HAYASHI Y, 1983, BIOCHIM BIOPHYS ACTA, V748, P153, DOI 10.1016/0167-4838(83)90291-1; HEBERT H, 1982, BIOCHIM BIOPHYS ACTA, V689, P571, DOI 10.1016/0005-2736(82)90316-9; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KLASSEN CHW, 1993, FEBS LETT, V329, P277; KOSTER JC, 1994, SODIUM PUMP, P90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MEDFORD RM, 1991, J BIOL CHEM, V266, P18308; Mercer Robert W., 1993, V137C, P139; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MODYANOV N, 1991, SOC GEN PHY, V46, P99; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; NORBY JG, 1991, SOC GEN PHY, V46, P173; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHONER W, 1994, SODIUM PUMP, P332; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SKRIVER E, 1981, FEBS LETT, V131, P219, DOI 10.1016/0014-5793(81)80371-7; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VILSEN B, 1987, J BIOL CHEM, V262, P10511; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332	49	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14332	14339		10.1074/jbc.270.24.14332	http://dx.doi.org/10.1074/jbc.270.24.14332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782292	hybrid			2022-12-27	WOS:A1995RD45500018
J	NAIDOO, N; COOPERMAN, BS; WANG, ZM; LIU, XZ; RUBIN, H				NAIDOO, N; COOPERMAN, BS; WANG, ZM; LIU, XZ; RUBIN, H			IDENTIFICATION OF LYSINES WITHIN ALPHA-1-ANTICHYMOTRYPSIN IMPORTANT FOR DNA-BINDING - AN UNUSUAL COMBINATION OF DNA-BINDING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; GEL-ELECTROPHORESIS; ELASTASE INHIBITOR; CDNA CLONES; PROTEIN; ALPHA-1-ANTITRYPSIN; SEQUENCE; PLASMA; TRANSCRIPTION; PURIFICATION	The human serum serine protease inhibitor (serpin) alpha 1-antichymotrypsin (ACT) appears to be unique among serpins in its ability to bind to double-stranded DNA. Using site-directed mutagenesis and chemical modification, a tri-lysine sequence (residues 210-212) falling within a solvent exposed loop and the C-terminal peptide containing two lysines (residues 391 and 396) were shown to be important for DNA binding. Mutation of residues 210-212 from lysines to either glutamates or threonines abolished DNA binding. The Lys(210)-Thr(211)-Lys(212) and Thr(210)-Th4(211)-Lys(212) variants displayed reduced affinity for DNA, especially at higher ionic strength. Limited acetylation of rACT with acetic anhydride led to loss of DNA binding and, conversely, DNA protected rACT from acetylation. A combination of CNBr digestion, peptide separation, and peptide sequencing identified Lys(396), two residues from the C terminus, as the most reactive lysine in rACT. Acetylation of Lys(396) is strongly decreased in the presence of DNA. The double mutant K391T/K396T-rACT had very little affinity for DNA. The epsilon-amines of lysines 210-212 are 8-15 Angstrom across a cleft from the epsilon-amines in Lys(391) adn Lys(396), and together these two elements may form an unusual DNA binding domain. Attempts to isolate a DNA sequence to which ACT binds specifically have been unsuccessful to date, raising the possibility that nonspecific binding of ACT to DNA suffices to account for the ACT found in certain cell nuclei. ACT variants not binding to double stranded DNA retain ACT protease inhibitory activity, a potentially important result for the use of ACT variants as therapeutic agents.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Naidoo, Nirinjini/0000-0002-7463-2559	NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ADDISON C, 1990, ONCOGENE, V5, P423; BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23626; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUBIN A, 1992, J BIOL CHEM, V267, P6576; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GROSS E, 1962, J BIOL CHEM, V237, P1856; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMILTON WDO, 1987, J GEN VIROL, V68, P2563, DOI 10.1099/0022-1317-68-10-2563; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANZON L, 1990, EMBO J, V5, P1391; JOHNSON JL, 1990, THESIS U PENNSYLVANI; KATSUNUMA T, 1980, BIOCHEM BIOPH RES CO, V93, P552, DOI 10.1016/0006-291X(80)91112-2; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; LINDMARK BE, 1985, CLIN CHIM ACTA, V152, P261, DOI 10.1016/0009-8981(85)90101-9; Maniatis T., 1982, MOL CLONING; NAIDOO N, 1994, THESIS U PENNSYULVAN; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; POTEMPA J, 1991, BIOCHEM J, V274, P465, DOI 10.1042/bj2740465; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROBSON CN, 1991, NUCLEIC ACIDS RES, V20, P4417; ROWLAND SJ, 1989, EMBO J, V8, P2761, DOI 10.1002/j.1460-2075.1989.tb08418.x; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; STRAUSS HS, 1980, BIOCHEMISTRY-US, V19, P3496, DOI 10.1021/bi00556a014; STRUCK JCR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P80, DOI 10.1016/0167-4781(90)90145-R; SUZUKI Y, 1990, J BIOCHEM, V108, P344, DOI 10.1093/oxfordjournals.jbchem.a123204; TAHARA E, 1984, HUM PATHOL, V15, P957, DOI 10.1016/S0046-8177(84)80125-2; TAKADA S, 1982, GANN, V73, P742; TAKADA S, 1986, CANCER RES, V46, P3688; TAKADA S, 1988, BIOCHEM INT, V16, P949; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUDA M, 1987, BIOCHEM BIOPH RES CO, V144, P409, DOI 10.1016/S0006-291X(87)80525-9; TSUDA M, 1986, CANCER RES, V46, P6139; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEI A, 1994, NAT STRUCT BIOL, V1, P250; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1	56	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14548	14555		10.1074/jbc.270.24.14548	http://dx.doi.org/10.1074/jbc.270.24.14548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782318	hybrid			2022-12-27	WOS:A1995RD45500049
J	DRACHEVA, S; KOONIN, EV; CRUTE, JJ				DRACHEVA, S; KOONIN, EV; CRUTE, JJ			IDENTIFICATION OF THE PRIMASE ACTIVE-SITE OF THE HERPES-SIMPLEX VIRUS TYPE-1 HELICASE-PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; PROTEIN; ALIGNMENT; REGION; EXPRESSION; SEQUENCE	Herpes simplex virus type 1 (HSV-1) encodes a heterotrimeric helicase-primase composed of the products of the three DNA replication-specific genes UL5, UL8, and UL52 (Crute, J. J., and Lehman, I. R. (1991) J. Biol. Chem. 266, 4484-4488). The UL5 and UL52 products constitute a heterodimeric subassembly of the holoenzyme that contains both helicase and primase activities (Calder, J. M., and Stow, N. D. (1990) Nucleic Acids Res. 18, 3573-3578; Dodson, M. S., and Lehman, I. R. (1991) Proc. Natl. Bead. Sci. U.S.A. 88, 1105-1109). The role of the UL52 product in the active HSV-1 helicase-primase was examined. A sequence located between residues 610 and 636 on the UL52 protein was found to be conserved among the UL52 homologues of eight herpesviruses. The carboxyl-terminal portion of this conserved sequence consisted of two Asp residues separated by a variable hydrophobic amino acid residue and is analogous to the divalent metal-binding site of DNA polymerases and several DNA primases. This motif has been designated the herpesvirus primase DXD motif. To study the role of the HSV-1 primase DXD motif in primase action, three site-directed changes were introduced into the UL52 gene. The helicase activity of the recombinant holoenzymes was unaffected by any of the introduced changes. Changing either of the two Asp residues that constitute the divalent metal-binding site (Asp(628) or, Asp(630)) to Ala dramatically reduced the primase activity of the HSV-1 helicase-primase holoenzyme in vitro, whereas alteration of the nearby conserved residue Asn(624) to Gly had minimal effect. Therefore, in the three-subunit HSV-1 helicase-primase, the UL52 product provides at least a part of the primase catalytic site.	BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT IMMUNOL DIS, RIDGEFIELD, CT 06877 USA; NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	Boehringer Ingelheim; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker T. A., 1992, DNA REPLICATION; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DODSON MS, 1993, J BIOL CHEM, V268, P1213; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Sambrook J, 1989, MOL CLONING LABORATO; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	27	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14148	14153		10.1074/jbc.270.23.14148	http://dx.doi.org/10.1074/jbc.270.23.14148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775476	hybrid			2022-12-27	WOS:A1995RC44800081
J	PANJWANI, N; ZHAO, Z; AHMAD, S; YANG, ZT; JUNGALWALA, F; BAUM, J				PANJWANI, N; ZHAO, Z; AHMAD, S; YANG, ZT; JUNGALWALA, F; BAUM, J			NEOLACTOGLYCOSPHINGOLIPIDS, POTENTIAL MEDIATORS OF CORNEAL EPITHELIAL-CELL MIGRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC ANTIGEN; WOUND CLOSURE; A-BINDING; GLYCOLIPIDS; EXPRESSION; CULTURE; CHAIN; NEOLACTOGLYCOLIPIDS; GLYCOSPHINGOLIPIDS; SULFOGLUCURONYL	Cell migration is a fundamental process of wound repair in biological systems. In an attempt to identify plasma membrane glycoconjugates which mediate cell migration, migrating and nonmigrating rabbit corneal epithelia were analyzed for reactivity with monoclonal antibodies (mAbs) specific for unsubstituted N-acetyl-lactosamine (mAb 1B2), Le(x) (mAbs 7A and MMA), and sialyl Le(x) (mAb CSLEX1) carbohydrate chains of neolactoglycoconjugates. Immunohistochemical analyses indicated that regardless of whether the epithelia analyzed were from corneas of animals in vivo, corneas in organ culture, or cells in tissue culture, migrating cells stained intensely with mAb 1B2, whereas nonmigrating cells either did not stain or stained only weakly. mAbs MMA and 7A stained migrating epithelium as well as basal and middle cell layers of normal, nonmigrating epithelium. mAb CSLEX1 did not stain wounded corneas but stained the superficial cell layer of normal corneal epithelium. Biochemical analyses by TLC immunostaining revealed the presence of three mAb 1B2-reactive glycosphingolipids (GSL), neolactotetraosyl-(nLc(4), paragloboside), neolactohexaosyl- (nLc(6)), and neolacto-octaosylceramide (nLc(8)) in migrating epithelia. In contrast, nonmigrating epithelia contained only trace amounts of these glycolipids. Exogenous addition of nLc(4), but not various other GSLs including a Le(x)-GSL (SSEA-1), stimulated re-epithelialization of wounds in an experimental model of corneal epithelial wound healing. More-over, re-epithelialization of wounds was significantly inhibited by mAb 1B2 but not by mAb MMA. The data suggest that neolacto-GSLs of corneal epithelium may be among the molecules which mediate healing of corneal epithelial wounds by influencing cell migration.	TUFTS UNIV, SCH MED, NEW ENGLAND EYE CTR, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, WALTHAM, MA 02254 USA	Tufts University; Tufts University	PANJWANI, N (corresponding author), TUFTS UNIV, SCH MED, DEPT OPHTHALMOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.				NATIONAL EYE INSTITUTE [R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EY07088, EY09349] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD S, 1992, INVEST OPHTH VIS SCI, V33, P892; BASU M, 1972, J BIOL CHEM, V247, P1489; CAVANAGH HD, 1976, T AM ACAD OPHTHALMOL, V81, P754; CAVANAGH HD, 1979, OCULAR SURFACE INT O, V19, P197; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIPSON IK, 1980, INVEST OPHTH VIS SCI, V19, P341; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HAKOMORI SI, 1938, HDB LIPID RES, V3, P353; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; JORNA A, 1993, INVEST OPHTH VIS SCI, V34, P1553; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; JUMBLATT MM, 1986, INVEST OPHTH VIS SCI, V27, P8; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MACHER BA, 1981, J BIOL CHEM, V256, P1968; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; MATSUSHITA Y, 1990, LAB INVEST, V63, P780; MCLAUGHLIN BJ, 1986, CURR EYE RES, V5, P601, DOI 10.3109/02713688609015125; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; MYOGA A, 1988, CANCER RES, V48, P1512; PANJWANI N, 1986, INVEST OPHTH VIS SCI, V27, P1280; PANJWANI N, 1990, INVEST OPHTH VIS SCI, V31, P689; PANJWANI N, 1995, INVEST OPHTH VIS SCI, V36, P365; PFISTER RR, 1975, INVEST OPHTH VISUAL, V14, P648; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOONG HK, 1989, ARCH OPHTHALMOL-CHIC, V107, P1052, DOI 10.1001/archopht.1989.01070020114042; STULTS C, 1993, ARCH BIOCHEM BIOPHYS, V303, P25; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SUNDSMO JS, 1976, BIOCHEM BIOPH RES CO, V68, P799, DOI 10.1016/0006-291X(76)91216-X; TAKI T, 1985, J BIOCHEM-TOKYO, V98, P887, DOI 10.1093/oxfordjournals.jbchem.a135368; TRINKAUSRANDALL V, 1988, CELL TISSUE RES, V251, P315, DOI 10.1007/BF00215839; WATANABE H, 1995, INVEST OPHTH VIS SCI, V36, P337; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WILLIAMS MA, 1988, J LIPID RES, V29, P1613; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; YOUNG WW, 1981, J BIOL CHEM, V256, P967; ZHAO Z, 1992, INVEST OPHTH VIS SCI, V33, P891; ZIESKE JD, 1986, INVEST OPHTH VIS SCI, V27, P1205	48	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14015	14023		10.1074/jbc.270.23.14015	http://dx.doi.org/10.1074/jbc.270.23.14015			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775461	hybrid			2022-12-27	WOS:A1995RC44800063
J	JOLY, M; KAZLAUSKAS, A; CORVERA, S				JOLY, M; KAZLAUSKAS, A; CORVERA, S			PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY IS REQUIRED AT A POSTENDOCYTIC STEP IN PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; MEDIATED ENDOCYTOSIS; TYROSINE KINASES; BINDING-SITE; SRC FAMILY; INTERNALIZATION; SUBUNIT; EGF; IDENTIFICATION; MOLECULES	We have previously reported that platelet-derived growth factor (PDGF) receptor mutants that lack high affinity binding sites for phosphatidylinositol 3-kinase (PI 3-kinase) fail to concentrate in juxtanuclear vesicular structures after activation with PDGF. We have now identified the point in the endocytic pathway at which PI S-kinase binding sites are required. Receptor internalization from the plasma membrane, measured as the acquisition of acid resistance of prebound I-125-PDGF, was only slightly decreased in cells expressing a PDGF receptor mutant (F5) lacking PI 3-kinase, GTPase-activating protein (GAP), phospholipase C gamma, and Syp binding sites but not expressing mutants where any of these individual sites were restored nor expressing a mutant lacking exclusively PI 3-kinase binding sites. In contrast, the extent of down-regulation of PDGF binding sites from the cell surface after prolonged incubation with PDGF as well as the degradation of [S-35]methionine-labeled receptor were markedly reduced in cells expressing the F5 mutant, mutants restored in GAP, phospholipase C gamma, or Syp binding sites or expressing the mutant exclusively lacking PI 3-kinase binding sites but not in cells expressing the mutant where PI 3-kinase binding sites were restored. Inhibition of PI 8-kinase activity with wortmannin caused a dramatic decrease in the rates of down-regulation and degradation of wildtype receptors. These results suggest that PI 3-kinase binding sites are not required for internalization of PDGF receptor but are required to divert the PDGF receptor to a degradative pathway. Furthermore, the requirement for PI 3-kinase binding sites on the receptor appears to be due to a requirement for PI 8-kinase catalytic activity.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; NATL JEWISH HOSP IMMUNOL & RESP MED,DENVER,CO 80206	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Jewish Health					NIDDK NIH HHS [DK-40330] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1990, J BIOL CHEM, V265, P16450; BACKER JM, 1991, J CELL BIOL, V115, P1525; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ESCOBEDO J, 1991, CELL, V33, P75; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOLY M, 1994, SCIENCE, V263, P581; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KOCH CA, 1991, SCIENCE, V252, P669; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1994, J BIOL CHEM, V269, P4917; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OKADA T, 1994, J BIOL CHEM, V269, P3568; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YANO H, 1993, J BIOL CHEM, V268, P25846	36	167	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13225	13230		10.1074/jbc.270.22.13225	http://dx.doi.org/10.1074/jbc.270.22.13225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768921	hybrid			2022-12-27	WOS:A1995RB43900044
J	ONRUST, R; FINKELSTEIN, J; NAKTINIS, V; TURNER, J; FANG, LH; ODONNELL, M				ONRUST, R; FINKELSTEIN, J; NAKTINIS, V; TURNER, J; FANG, LH; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .1. ORGANIZATION OF THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; GAMMA-SUBUNIT; SIZE CLASSES; IDENTIFICATION; PURIFICATION; CHI; PSI; OVEREXPRESSION; MECHANISM	The gamma complex of DNA polymerase III holoenzyme, the replicase of Escherichia coli, couples ATP hydrolysis to the loading of beta sliding clamps onto primed DNA. The beta sliding clamp tethers the holoenzyme replicase to DNA for rapid and processive synthesis. In this report, the gamma complex has been constituted hom its five different subunits. Size measurements and subunit stoichiometry studies show a composition of gamma(2) delta(1) delta'(1) chi(1) psi(1). Strong intersubunit contacts have been identified by gel filtration, and weaker contacts were identified by surface plasmon resonance measurements. An analogous tau complex has also been constituted and characterized; it is nearly as active as the gamma complex in clamp loading activity, but as shown in the fourth report of this series, it is at a disadvantage in binding the delta, delta', chi, and psi subunits when core is present (Xiao, Il., Naktinis, V., and O'Donnell, M. (1995) J. Biol. Chem. 270, 13378-13383). The single copy subunits within the gamma complex provide the basis for the structural asymmetry inherent within DNA polymerase III holoenzyme.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5294; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CARTER JR, 1993, MOL GEN GENET, V241, P399, DOI 10.1007/BF00284693; CARTER JR, 1993, J BACTERIOL, V174, P7013; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG A, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1993, THESIS CORNELL U; ROWEN L, 1978, J BIOL CHEM, V253, P758; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TURNER J, 1995, IN PRESS METHODS ENZ, V262; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773	44	112	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13348	13357		10.1074/jbc.270.22.13348	http://dx.doi.org/10.1074/jbc.270.22.13348			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768936	hybrid			2022-12-27	WOS:A1995RB43900061
J	CAI, DY; KLINMAN, JP				CAI, DY; KLINMAN, JP			EVIDENCE FOR A SELF-CATALYTIC MECHANISM OF 2,4,5-TRIHYDROXYPHENYLALANINE QUINONE BIOGENESIS IN YEAST COPPER AMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVE-SITE; COORDINATION CHEMISTRY; SUBSTRATE; COFACTOR; EXCHANGE; WATER; STATE	Copper amine oxidases are representative of a new class of redox enzymes that contain a peptide-bound quinone cofactor, generated by posttranslational modification of amino acid side chain(s). We have investigated the mechanism for the biogenesis of 2,4,5-trihydroxyphenylalanine quinone (TPQ) in amine oxidase with two site-specific mutants of the yeast methylamine oxidase, Our results show that the capacity for TPQ formation in vivo is abolished when a putative ligand to copper, His-456, is changed to Asp; this H456D mutant binds copper at a low level (similar to 4.1%), relative to the wildtype protein, In contrast, altering the active site consensus sequence that contains the precursor tyrosine does not affect TPQ production. The data implicate a self-catalysis mechanism for TPQ biogenesis, in which the protein-bound copper plays a key role, We propose that the minimal information required for TPQ biogenesis lies in a structural motif consisting of the copper site and the precursor tyrosine.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; COLLISON D, 1989, BIOCHEM J, V264, P663, DOI 10.1042/bj2640663; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DOOLEY DM, 1991, J AM CHEM SOC, V113, P754, DOI 10.1021/ja00003a004; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1989, J AM CHEM SOC, V111, P102, DOI 10.1021/ja00183a018; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MCCRACKEN J, 1992, J AM CHEM SOC, V114, P3715, DOI 10.1021/ja00036a021; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; PAZ MA, 1991, J BIOL CHEM, V266, P689; SCOTT RA, 1985, J AM CHEM SOC, V107, P4348, DOI 10.1021/ja00300a055; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	21	133	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32039	32042						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798196				2022-12-27	WOS:A1994PX30400005
J	JOCKERS, R; LINDER, ME; HOHENEGGER, M; NANOFF, C; BERTIN, B; STROSBERG, AD; MARULLO, S; FREISSMUTH, M				JOCKERS, R; LINDER, ME; HOHENEGGER, M; NANOFF, C; BERTIN, B; STROSBERG, AD; MARULLO, S; FREISSMUTH, M			SPECIES-DIFFERENCE IN THE G-PROTEIN SELECTIVITY OF THE HUMAN AND BOVINE A(1)-ADENOSINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; A1 ADENOSINE RECEPTORS; BETA-GAMMA-SUBUNITS; ESCHERICHIA-COLI; ALPHA-SUBUNITS; MOLECULAR-CLONING; HUMAN BRAIN; ADRENERGIC-RECEPTORS; RADIOLIGAND BINDING; 2 FORMS	The purified bovine brain A(1)-adenosine receptor has previously been shown to discriminate among closely related G protein alpha-subunits. To obtain analogous information for the human receptor, the cDNA coding for the human A(1)-adenosine receptor was inserted into a plasmid placing the synthesis of the receptor protein under the control of the MalE promoter, Following induction by maltose, active receptor accumulated in Escherichia coli membranes, Binding of the antagonist 8-[H-3]cyclopentyl-1,3-dipropylxanthine to E. coli membranes (K-D similar to 2 nM, B-max similar to 0.2-0.4 pmol/mg) showed the appropriate pharmacological profile, Incubation of E. coli membranes with purified G(o,i)-reconstituted guanine nucleotide-sensitive high affinity binding of the agonist (-)[I-125] N-6-3-(iodo-4-hydroxyphenylisopropyl) adenosine to the receptor (K-D similar to 1 nM), In the presence of purified beta gamma-subunit, the recombinant receptor interacted equally well with the recombinant G protein alpha-subunits G(i alpha-1), G(i alpha-2), G(i alpha-3), G(o alpha) displayed a lower affinity for the receptor while G(5 alpha) was inactive, Parallel experiments were carried out in bovine and human brain membranes pretreated with N-ethylmaleimide to inactivate the endogenous G(o)/G(i) proteins; G(i alpha-3) was most potent in reconstituting I-125-HPIA binding to bovine membranes, while G(i alpha-1), G(i alpha-2), and G(o alpha) displayed similar affinities, However, in human membranes, G(i alpha-1), G(i alpha-2), and G(i alpha-3), were equipotent and high concentrations of G(o alpha) were required to promote I-125-HPIA binding. These observations show (i) that functional human A(1)-adenosine receptors were synthesized in E. coli; (ii) that the pattern of G protein coupling is identical, for the recombinant human A(1)-receptor and its counterpart in the native membrane; (iii) and that species differences between bovine and human receptor exist not only in their pharmacological profile but also in their G protein specificity suggesting that species homologues of receptors may use different signaling mechanisms.	UNIV VIENNA,INST PHARMACOL,A-1090 VIENNA,AUSTRIA; INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE; WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	University of Vienna; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL)			Marullo, Stefano/C-6142-2008; Jockers, Ralf/P-2272-2017; Linder, Maurine/AAU-9999-2021; Hohenegger, Martin/AAF-6479-2020; Jockers, Ralf/Q-2100-2019	Marullo, Stefano/0000-0001-9604-9973; Jockers, Ralf/0000-0002-4354-1750; Linder, Maurine/0000-0003-2202-9712; Jockers, Ralf/0000-0002-4354-1750; Freissmuth, Michael/0000-0001-9398-1765; Hohenegger, Martin/0000-0001-6537-9574; nanoff, christian/0000-0002-8857-2470	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTIN B, 1992, J BIOL CHEM, V267, P8200; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; ENSEN CJ, 1994, MOL PHARMACOL, V45, P294; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; FREISSMUTH M, 1991, BIOCHEM J, V275, P651, DOI 10.1042/bj2750651; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FREISSMUTH M, 1987, N-S ARCH PHARMACOL, V335, P438, DOI 10.1007/BF00165560; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GALEN PJM, 1991, MED RES REV, V12, P423; GARWINS P, 1992, J BIOL CHEM, V267, P16081; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; INUIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KLOTZ KN, 1991, N-S ARCH PHARMACOL, V343, P196, DOI 10.1007/BF00168610; LEE E, 1992, J BIOL CHEM, V267, P1212; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1984, MOL PHARMACOL, V26, P414; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LINDER ME, 1994, METHOD ENZYMOL, V237, P254; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MARULLO S, 1989, BIO-TECHNOL, V7, P923, DOI 10.1038/nbt0989-923; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUNSHI R, 1990, MOL PHARMACOL, V38, P170; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NAKATA H, 1992, EUR J BIOCHEM, V206, P171, DOI 10.1111/j.1432-1033.1992.tb16914.x; NAKATA H, 1989, J BIOL CHEM, V264, P16545; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STILES GL, 1992, J BIOL CHEM, V267, P6451; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	53	99	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32077	32084						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798201				2022-12-27	WOS:A1994PX30400013
J	MOREN, A; OLOFSSON, A; STENMAN, G; SAHLIN, P; KANZAKI, T; CLAESSONWELSH, L; TENDIJKE, P; MIYAZONO, K; HELDIN, CH				MOREN, A; OLOFSSON, A; STENMAN, G; SAHLIN, P; KANZAKI, T; CLAESSONWELSH, L; TENDIJKE, P; MIYAZONO, K; HELDIN, CH			IDENTIFICATION AND CHARACTERIZATION OF LTBP-2, A NOVEL LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; MARFAN-SYNDROME; TGF-BETA; HUMAN-PLATELETS; FIBRILLIN GENES; MESSENGER-RNA; RECEPTOR; FACTOR-BETA-1; EXPRESSION; SECRETION	Latent transforming growth factor-beta (TGF-beta)-binding protein (LTBP) is a component of the latent TGF-beta complex in human platelets. LTBP is composed of two different cysteine-rich repeat sequences, i.e. epidermal growth factor (EGF)-like repeats and a repeat containing 8 cysteine residues. The overall structure of LTBP is similar to those of the microfibrillar proteins fibrillin-1 and fibrillin-2. Here we report the identification of a novel protein termed LTBP-2, which is structurally related to LTBP. cDNA for LTBP-2 was obtained from human foreskin fibroblast cDNA libraries using a fragment of the LTBP cDNA as a probe. LTBP-2 is composed of 20 EGF-like repeats and four copies of the 8-cysteine repeat. The amino acid sequence of LTBP-2 is 41% identical to that of LTBP and 25% identical to that of fibrillin-1. LTBP-2 is synthesized as a 240-kDa protein by human foreskin fibroblasts and also by COS cells transfected with the isolated LTBP-2 cDNA Similar to LTBP, a considerable part of LTBP-2 was found to be associated with extracellular matrix. Co-transfection of cDNAs for LTBP-2 and TGF-beta 1 revealed that LTBP-2 forms a high molecular weight complex with the TGF-beta 1 precursor. The LTBP-S gene was assigned to chromosome 14q24. These results indicate that different forms of latent TGF-beta complexes occur and suggest that the different associated proteins may function to target the complexes to specific sites.	LUDWIG INST CANC RES, CTR BIOMED, S-75124 UPPSALA, SWEDEN; SAHLGRENS UNIV HOSP, DEPT PATHOL, CANC GENET LAB, S-41345 GOTHENBURG, SWEDEN	Ludwig Institute for Cancer Research; Sahlgrenska University Hospital			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Claesson-Welsh, Lena/0000-0003-4275-2000				BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COLOSETTI P, 1993, FEBS LETT, V320, P140, DOI 10.1016/0014-5793(93)80079-A; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DAVIS C G, 1990, New Biologist, V2, P410; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIZOI T, 1993, CANCER RES, V53, P183; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STENMAN G, 1994, CYTOGENET CELL GENET, V66, P117, DOI 10.1159/000133680; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TENDIJKE P, 1988, ONCOGENE, V3, P721; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WALTENBERGER J, 1993, AM J PATHOL, V142, P71; YAMAZAKI M, 1994, AM J PATHOL, V144, P221; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	42	162	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32469	32478						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798248				2022-12-27	WOS:A1994PX30400069
J	TORRE, E; MCNIVEN, MA; URRUTIA, R				TORRE, E; MCNIVEN, MA; URRUTIA, R			DYNAMIN-1 ANTISENSE OLIGONUCLEOTIDE TREATMENT PREVENTS NEURITE FORMATION IN CULTURED HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; REVERSIBLE BLOCKAGE; GTPASE; PROTEINS; MICROTUBULES; ENDOCYTOSIS; DOMAINS; SHIBIRE	Dynamin 1 (D100) is a microtubule-activated GTPase that is believed to play a role in the early steps of receptor-mediated endocytosis. Previous studies on the characterization of the Drosophila dynamin gene homolog, known as shibire, suggest that this protein may also participate in the formation of neuronal processes. To understand the role of rat brain dynamin 1 in neuronal morphogenesis, we correlated the intracellular levels of dynamin with the formation of neurites in rat hippocampal neurons and neuroblastoma N1E-115 cells in vitro. Quantitative Western and Northern blot analyses show that dynamin levels increase during neurite formation in both the hippocampal neurons and N1E-115 cells and decrease in N1E-115 cells during serum-induced neurite retraction. Furthermore, using antisense technology, we investigated the effect of decreased intracellular levels of dynamin on neurite formation in cultured embryonic hippocampal neurons. Antisense oligonucleotides against sequences surrounding the initiation codon of the rat brain dynamin gene (D100) reduce the intracellular levels of dynamin by approximately 90% and impair the formation of the minor and axon-like processes in a dose-dependent manner. Taken together, these results suggest that dynamin-mediated processes are necessary for normal neuronal morphogenesis.	MAYO CLIN & MAYO FDN,DEPT MOLEC NEUROSCI,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905; UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908	Mayo Clinic; Mayo Clinic; University of Virginia					NIAAA NIH HHS [AA09227] Funding Source: Medline; NIDDK NIH HHS [DK 44650] Funding Source: Medline; NINDS NIH HHS [1R29 NS 32882-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044650, R29DK044650, R01DK044650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009227] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Banker G., 1991, CULTURING NERVE CELL; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANSEN SH, 1991, EXP CELL RES, V199, P19; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KIM YT, 1987, J NEUROSCI, V7, P3245; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH HN, 1993, J NEUROSCI, V13, P4282; MASUR S, 1989, J NEUROGENET, V6, P191; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; PRASAD KN, 1975, BIOL REV, V50, P129, DOI 10.1111/j.1469-185X.1975.tb01055.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773	37	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32411	32417						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798241				2022-12-27	WOS:A1994PX30400060
J	AKASHI, M; HACHIYA, M; PAQUETTE, RL; OSAWA, Y; SHIMIZU, S; SUZUKI, G				AKASHI, M; HACHIYA, M; PAQUETTE, RL; OSAWA, Y; SHIMIZU, S; SUZUKI, G			IRRADIATION INCREASES MANGANESE SUPEROXIDE-DISMUTASE MESSENGER-RNA LEVELS IN HUMAN FIBROBLASTS - POSSIBLE MECHANISMS FOR ITS ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR GENE-EXPRESSION; LONG TERMINAL REPEAT; IONIZING-RADIATION; MESSENGER-RNA; PHORBOL ESTER; INTERLEUKIN-1 PRECURSOR; NUCLEOTIDE-SEQUENCE; OXYGEN RADICALS; GM-CSF	Irradiation induces the production of superoxide radicals (O O-2)((radical) (anion)), which play an important causative role in radiation damage. Manganese superoxide dismutase (MnSOD) is a mitochondrial enzyme involved in scavenging O-2((radical) (anion)). This study examined MnSOD gene regulation by irradiation in WI38 human fibroblasts. Unstimulated fibroblasts constitutively expressed MnSOD activity and mRNA; irradiation markedly increased MnSOD activity and mRNA levels. The increase in MnSOD transcripts by irradiation was both time- and dose dependent. WI38 fibroblasts constitutively produce low levels of interleukin-1 (IL-1). The induction of MnSOD mRNA by irradiation was partially blocked by anti-IL-1 antibodies, and treatment of cells with IL-1 also increased MnSOD mRNA levels. Inhibition of the cyclo-oxygenase pathway with indomethacin augmented the induction MnSOD mRNA by irradiation and prostaglandin E(2) inhibited the accumulation of MnSOD mRNA by irradiation. Transcriptional run-on analysis showed that irradiation increased the rate of MnSOD transcription 2-fold. Stability studies of MnSOD mRNA in these cells showed that the half-life increased from <1.5 h in unirradiated cells to >4 h in irradiated cells. These results suggest that induction of the MnSOD gene after irradiation is regulated, at least in part, by IL-1 production and that increased levels of MnSOD transcripts also occur through a pathway of endogenous prostaglandin E(2) production. Our data indicate that the increase in MnSOD mRNA observed after irradiation occurs through both transcriptional and post-transcriptional mechanisms.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	AKASHI, M (corresponding author), NATL INST RADIOL SCI,DIV RADIAT HLTH,INAGE KU,4-9-1 ANAGAWA,CHIBA 263,JAPAN.							AKASHI M, 1994, BLOOD, V83, P3182; AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; AKASHI M, 1989, BLOOD, V74, P2383; AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; AKASHI M, 1992, HEMATOLOGY BLOOD TRA, P83; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAVARD C, 1990, J CLIN INVEST, V86, P1369, DOI 10.1172/JCI114849; CLARK IA, 1985, MED RES REV, V5, P297, DOI 10.1002/med.2610050303; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DAVIES KJA, 1983, FEBS LETT, V153, P227, DOI 10.1016/0014-5793(83)80153-7; DAVIES KJA, 1985, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUJII J, 1991, J BIOL CHEM, V266, P23142; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HACHIYA M, 1994, EXP CELL RES, V214, P343, DOI 10.1006/excr.1994.1266; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P10; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HARRIS CA, 1990, J IMMUNOL, V147, P149; HARTMAN JR, 1988, Patent No. 881048805; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND SL, 1984, RADIAT RES, V100, P115, DOI 10.2307/3576527; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MELTZER MS, 1977, J IMMUNOL, V118, P77; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; VALERIE K, 1987, NATURE, V333, P78; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WESLEY MB, 1979, P NATL ACAD SCI USA, V76, P1967; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1992, TUMOR NECROSIS FACTO, P473; YAMATO K, 1989, J CELL PHYSIOL, V139, P610, DOI 10.1002/jcp.1041390322; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512	57	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15864	15869		10.1074/jbc.270.26.15864	http://dx.doi.org/10.1074/jbc.270.26.15864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797591	hybrid			2022-12-27	WOS:A1995RG53800065
J	DONG, LJ; HSIEH, JC; CHUNG, AE				DONG, LJ; HSIEH, JC; CHUNG, AE			2 DISTINCT CELL ATTACHMENT SITES IN ENTACTIN ARE REVEALED BY AMINO-ACID SUBSTITUTIONS AND DELETION OF THE RGD SEQUENCE IN THE CYSTEINE-RICH EPIDERMAL GROWTH-FACTOR REPEAT-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN ENTACTIN; COLLAGEN TYPE-IV; PHENOTYPIC SELECTION; ADHESION; PROTEINS; INTEGRIN; MUTAGENESIS; RECEPTORS; LAMININ; BINDING	The basement membrane glycoprotein, entactin, has previously been shown to promote cell attachment and chemotaxis. We have constructed a panel of glutathione S-transferase fusion proteins that encompasses the four major structural domains of entactin, G1, G2, E, and G3. These proteins have been synthesized in bacteria and purified by affinity chromatography, The connecting stalk of entactin, E, which contains four cysteine-rich EGF homology repeats and the integrin receptor RGD recognition sequence, has been modified by deletion of the RGD sequence and substituting glutamic acid for aspartic acid. Attachment assays reveal that the RGD sequence is one of the major cell attachment sites in entactin and that this sequence is recognized by the alpha(v) beta(3) integrin receptor, Analysis of cell attachment on mutant forms of full-length entactin expressed in the baculovirus expression system revealed a second attachment site that was independent of the RGD sequence. This second site was localized to a peptide of 39 amino acid residues in the second globular G2 domain of entactin. This peptide represents a cysteine-rich EGF repeat, Inhibition of cell attachment by anti-integrin receptor antibodies indicates that the second attachment site is recognized by a member of the beta(1) family of integrin receptors, possibly alpha(3) beta(1).	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NIGMS NIH HHS [GM-25690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025690] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHUNG AE, 1993, KIDNEY INT, V43, P13, DOI 10.1038/ki.1993.4; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GRESHAM HD, 1993, MOL BIOL CELL S, V4, P285; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HSIEH JC, 1994, BIOCHEM BIOPH RES CO, V199, P1509, DOI 10.1006/bbrc.1994.1402; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO T, 1990, J BIOL CHEM, V265, P5188; WU CY, 1991, J BIOL CHEM, V266, P18802; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YELIAN FD, 1993, J CELL BIOL, V121, P923, DOI 10.1083/jcb.121.4.923	30	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15838	15843		10.1074/jbc.270.26.15838	http://dx.doi.org/10.1074/jbc.270.26.15838			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797588	hybrid			2022-12-27	WOS:A1995RG53800061
J	NIXON, PJ; KOMENDA, J; BARBER, J; DEAK, Z; VASS, I; DINER, BA				NIXON, PJ; KOMENDA, J; BARBER, J; DEAK, Z; VASS, I; DINER, BA			DELETION OF THE PEST-LIKE REGION OF PHOTOSYSTEM-2 MODIFIES THE Q(B)-BINDING POCKET BUT DOES NOT PREVENT RAPID TURNOVER OF D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; HERBICIDE-RESISTANT MUTANTS; II REACTION CENTER; THERMO-LUMINESCENCE; ORNITHINE DECARBOXYLASE; MANGANESE CLUSTER; DEGRADATION; PROTEIN; CHLOROPLASTS; POLYPEPTIDE-D1	The rapid turn-over of the D1 polypeptide of the photosystem two complex has been suggested to be due to the presence of a ''PEST''-like sequence located between putative transmembrane helices IV and V of D1 (Greenberg, B. M., Gaba, V., Mattoo, A. K. and Edelman, M. (1987) EMBO J. 6, 2865-2869). We have tested this hypothesis by constructing a deletion mutant (Delta 226-233) of the cyanobacterium Synechocystis sp. PCC 6803 in which residues 226-233 of the D1 polypeptide, containing the PEST-like sequence, have been removed. The resulting mutant, Delta PEST, is able to grow photoautotrophically and give light-saturated rates of oxygen at wild type levels. However electron transfer on the acceptor side of the complex is perturbed. Analysis of cells by thermoluminescence and by monitoring the decay in quantum yield of variable fluorescence following saturating flash excitation indicates that Q(B)(-), but not Q(A)(-), is destabilized in this mutant. Electron transfer on the donor side of photosystem two remains largely unchanged in the mutant. Turnover of the D1 polypeptide as examined by pulse-chase experiments using [S-35]methionine was enhanced in the Delta PEST mutant compared to strain TC31 which is the wild type control. We conclude that the PEST sequence is not absolutely required for turnover of the D1 polypeptide in vivo although deletion of residues 226-233 does have an effect on the redox equilibrium between Q(A) and Q(B).	HUNGARIAN ACAD SCI, BIOL RES CTR, H-6701 SZEGED, HUNGARY; DUPONT CO INC, DEPT CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA	Hungarian Academy of Sciences; Hungarian Biological Research Center; DuPont	NIXON, PJ (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, WOLFSON LABS, PHOTOSYNTHESIS RES GRP, LONDON SW7 2AY, ENGLAND.		Komenda, Josef/H-4083-2014; Vass, Imre/AAS-6171-2021	Komenda, Josef/0000-0003-4588-0382; Vass, Imre/0000-0003-4987-7842; Nixon, Peter/0000-0003-1952-6937				BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BOICHENKO VA, 1993, Z NATURFORSCH C, V48, P224; CANOVAS PM, 1993, FEBS LETT, V324, P341, DOI 10.1016/0014-5793(93)80147-M; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; DALLACHIESA M, 1994, THESIS U LONDON; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEME, 1993, LJU, V336, P852; DEMETER S, 1982, PHOTOBIOCH PHOTOBIOP, V4, P163; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DEMETER S, 1985, BIOCHIM BIOPHYS ACTA, V806, P16, DOI 10.1016/0005-2728(85)90077-5; Edelman M., 1978, CHLOROPLAST DEV, P641; ERICKSON JM, 1992, PHOTOSYSTEMS STRUCTU, P101; ETIENNE AL, 1990, BIOCHIM BIOPHYS ACTA, V1015, P435, DOI 10.1016/0005-2728(90)90076-G; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GLEITER HM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P135, DOI 10.1016/0005-2728(92)90002-J; GRAAN T, 1986, BIOCHIM BIOPHYS ACTA, V852, P320, DOI 10.1016/0005-2728(86)90238-0; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; JOHNSON BM, 1994, EMBO J, V1184, P85; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; KIM J, 1994, J BIOL CHEM, V269, P17918; KIM JM, 1991, J BIOL CHEM, V266, P14931; KLESS H, 1992, BIOCHEMISTRY-US, V31, P11065, DOI 10.1021/bi00160a016; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; PACKHAM NK, 1988, FEBS LETT, V231, P284, DOI 10.1016/0014-5793(88)80835-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; TANG XS, 1990, FEBS LETT, V273, P257, DOI 10.1016/0014-5793(90)81098-9; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; TELFER A, 1994, J BIOL CHEM, V269, P13244; TYYSTJARVI T, 1994, PLANT MOL BIOL, V25, P517, DOI 10.1007/BF00043879; VASS I, 1981, BIOCHIM BIOPHYS ACTA, V634, P140, DOI 10.1016/0005-2728(81)90134-1; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V764, P24; VASS I, 1992, PHOTOSYSTEMS STRUCTU, V11, P269; WETTERN M, 1983, METHOD ENZYMOL, V97, P554; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	47	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14919	14927		10.1074/jbc.270.25.14919	http://dx.doi.org/10.1074/jbc.270.25.14919			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797471	hybrid			2022-12-27	WOS:A1995RE66600015
J	YANG, WL; CARMAN, GM				YANG, WL; CARMAN, GM			PHOSPHORYLATION OF CTP SYNTHETASE FROM SACCHAROMYCES-CEREVISIAE BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MUTANTS; GENE; IDENTIFICATION; PURIFICATION; ACTIVATION; ENZYME	Phosphorylation of CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) from Saccharomyces cerevisiae by protein kinase C was examined. Using pure CTP synthetase as a substrate, protein kinase C activity was dose- and time-dependent and required calcium, diacyl-glycerol, and phosphatidylserine for full activation. Protein kinase C activity was also dependent on the concentration of CTP synthetase. Protein kinase C phosphorylated CTP synthetase on serine and threonine residues in vitro whereas the enzyme was primarily phosphorylated on serine residues in vivo. Phosphopeptide mapping analysis of CTP synthetase phosphorylated in vitro and in vivo indicated that the enzyme was phosphorylated on more than one site. Most of the phosphopeptides derived from CTP synthetase phosphorylated in vivo were the same as those derived from CTP synthetase phosphorylated by protein kinase C in vitro. The stoichiometry of the phosphorylation of native CTP synthetase was 0.4 mol of phosphate/mol of enzyme whereas the stoichiometry of the phosphorylation of alkaline phosphatase-treated CTP synthetase was 2.2 mol of phosphate/mol of enzyme. This indicated that CTP synthetase was purified in a phosphorylated state. Phosphorylation of CTP synthetase resulted in a 3-fold activation in enzyme activity whereas alkaline phosphatase treatment of CTP synthetase resulted in a 5-fold decrease in enzyme activity. Overall, the results reported here were consistent with the conclusion that CTP synthetase was regulated by protein kinase C phosphorylation.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50679, R01 GM050679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679, R01GM063109] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ARONOW B, 1987, J BIOL CHEM, V262, P5106; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PIKULA S, 1994, J BIOL CHEM, V269, P27566; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	40	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14983	14988		10.1074/jbc.270.25.14983	http://dx.doi.org/10.1074/jbc.270.25.14983			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797479	Green Accepted, hybrid			2022-12-27	WOS:A1995RE66600024
J	STARLING, AP; EAST, JM; LEE, AG				STARLING, AP; EAST, JM; LEE, AG			PHOSPHATIDYLINOSITOL 4-PHOSPHATE INCREASES THE RATE OF DEPHOSPHORYLATION OF THE PHOSPHORYLATED CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; ADENOSINE-TRIPHOSPHATASE; ATPASE; CALCIUM; (CA2+-MG2+)-ATPASE; MECHANISM; PHOSPHOLIPIDS; PHOSPHOLAMBAN; HYDROLYSIS; MICROSCOPY	Incubation of the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum with ATP in the absence of Ca2+ leads to phosphorylation of phosphatidylinositol (PtdIns) to phosphatidylinositol 4-phosphate (PtdIns-4P) and to a doubling of ATPase activity. Similarly, reconstitution of the ATPase with mixtures of dioleoylphosphatidylcholine and PtdIns-4P also led to a doubling of activity; ATPase activity increased with increasing PtdIns-4P content, up to 10% beyond which no further increase was observed. Reconstitution with PtdIns had a much smaller effect on activity. Changes in the Ca2+ affinity of the ATPase following incubation with ATP or reconstitution with PtdIns-4P were small. The rates of phosphorylation of the ATPase by ATP rind of the Ca2+ transport step were unaffected, but the rate of dephosphorylation of the phosphorylated ATPase increased by a factor of 2 either following incubation with ATP or following reconstitution with PtdIns-4P. Activation of the ATPase led to a decrease in the level of phosphorylation of the ATPase by P-i corresponding to a 10-fold decrease in the equilibrium constant E2PMg/E2P(i)Mg.			STARLING, AP (corresponding author), UNIV SOUTHAMPTON,DEPT BIOCHEM,BASSETT CRESCENT E,SOUTHAMPTON SO9 3TU,HANTS,ENGLAND.							BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; Bird I M, 1994, Methods Mol Biol, V27, P227; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; DEMEIS L, 1981, SARCOPLASMIC RETICUL; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GOULD GW, 1986, BIOCHEM J, V237, P217, DOI 10.1042/bj2370217; HARDWICKE PM, 1974, EUR J BIOCHEM, V42, P183; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; LEE AG, 1993, PROTEIN LIPID INTERA, P259; MICHELANGELI F, 1991, BIOCHEMISTRY-US, V30, P342, DOI 10.1021/bi00216a006; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P8307, DOI 10.1021/bi00488a015; MILTING H, 1994, FEBS LETT, V345, P211, DOI 10.1016/0014-5793(94)00440-4; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFER M, 1987, BIOCHEM J, V247, P579, DOI 10.1042/bj2470579; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STARLING AP, 1993, BIOCHEMISTRY-US, V32, P1593, DOI 10.1021/bi00057a025; STARLING AP, 1995, BIOCHEMISTRY-US, V34, P3084, DOI 10.1021/bi00009a040; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VARSANYI M, 1989, EUR J BIOCHEM, V179, P473, DOI 10.1111/j.1432-1033.1989.tb14577.x; VARSANYI M, 1983, EMBO J, V2, P1543, DOI 10.1002/j.1460-2075.1983.tb01621.x; WARREN GB, 1974, BIOCHEMISTRY-US, V13, P5501, DOI 10.1021/bi00724a008	29	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14467	14470		10.1074/jbc.270.24.14467	http://dx.doi.org/10.1074/jbc.270.24.14467			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782308	hybrid			2022-12-27	WOS:A1995RD45500037
J	TIMMERMANSHEREIJGERS, JLPM; SNOEK, GT; WIRTZ, KWA				TIMMERMANSHEREIJGERS, JLPM; SNOEK, GT; WIRTZ, KWA			A SPHINGOMYELIN-TRANSFERRING PROTEIN FROM CHICKEN LIVER - USE OF PYRENE-LABELED PHOSPHOLIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; BOVINE BRAIN; EXCHANGE PROTEINS; BINDING-SITES; BEEF-LIVER; PURIFICATION; PHOSPHATIDYLCHOLINE; FRACTIONS; SN-1	A phospholipid transfer protein was purified from chicken liver which, in addition to phosphatidylinositol (PI) and phosphatidylcholine (PC), carries sphingomyelin (SM) between membranes. For comparison, the PI-transfer protein from chicken liver only carries PI and PC. Specificity was established by use of phospholipids that carry a pyrene-labeled acyl chain. Based on the N-terminal sequence and Western blot analysis we conclude that this protein is an isoform of the PI-transfer protein. At increasing length of the pyrene-labeled acyl chain, the isoform expresses a high activity toward SM, a low activity toward PI, and virtually no activity toward PC.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3508 TB UTRECHT,NETHERLANDS; HELSINKI UNIV,DEPT BASIC CHEM,SF-00014 HELSINKI,FINLAND	Utrecht University; University of Helsinki								AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BLOJ B, 1977, J BIOL CHEM, V252, P1613; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; DYATLOVITSKAYA EV, 1978, EUR J BIOCHEM, V82, P463, DOI 10.1111/j.1432-1033.1978.tb12040.x; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; KADER JC, 1975, BIOCHIM BIOPHYS ACTA, V380, P31, DOI 10.1016/0005-2760(75)90042-9; KAMP HH, 1973, BIOCHIM BIOPHYS ACTA, V318, P313, DOI 10.1016/0005-2736(73)90196-X; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KASURINEN J, 1992, J BIOL CHEM, V267, P6563; KOUMANOV K, 1982, BIOCHIM BIOPHYS ACTA, V713, P23, DOI 10.1016/0005-2760(82)90162-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; POORTHUIS BJH, 1983, METHOD ENZYMOL, V54, P592; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANAMERONGEN A, 1987, BIOCHIM BIOPHYS ACTA, V919, P149, DOI 10.1016/0005-2760(87)90201-3; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14263	14266		10.1074/jbc.270.24.14263	http://dx.doi.org/10.1074/jbc.270.24.14263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782280	hybrid			2022-12-27	WOS:A1995RD45500006
J	EMIG, S; SCHMALZ, D; SHAKIBAEI, M; BUCHNER, K				EMIG, S; SCHMALZ, D; SHAKIBAEI, M; BUCHNER, K			THE NUCLEAR-PORE COMPLEX PROTEIN P62 IS ONE OF SEVERAL SIALIC ACID-CONTAINING PROTEINS OF THE NUCLEAR-ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM AGGLUTININ; N-ACETYLGLUCOSAMINE; SUGAR CHAINS; GLYCOPROTEINS; CELLS; IMPORT; IDENTIFICATION; GLYCOSYLATION; INHIBITION; TRANSPORT	While investigating the glycosylation of nuclear envelope proteins of neuroblastoma cells, we found several proteins that bound the sialic acid-specific Sambucus nigra agglutinin, The strongest signals were obtained for proteins with apparent molecular masses of 66 and 180 kDa, The specificity of the lectin binding was checked by acylneuraminyl hydrolase treatment of nuclear envelope proteins, which prohibited S. nigra agglutinin binding, Digestion of nuclear envelope proteins with the N-glycosidase F revealed that sialic acid was N-glycosidically linked to the 180-kDa protein and very probably O-glycosidically linked to the 66-kDa protein, Upon extraction, the latter behaved like the nucleoporin p62 in that it was partly extracted by high ionic strength buffers, could not be solubilized by nonionic detergent, and was completely removed from the nuclear envelope with urea, Two-dimensional gel electrophoretic comparison showed that the S. nigra agglutinin-binding protein and p62 have an identical isoelectric point of about 5.0 and an identical apparent molecular mass of 66 kDa, This, together with the binding of the anti-nucleoporin antibody, demonstrated the identity of the 66-kDa sialoprotein and p62, S. nigra agglutinin inhibits nuclear protein transport in neuroblastoma cells, strongly suggesting a functional significance of sialylation of p62.	FREE UNIV BERLIN,INST BIOCHEM,ARBEITSGRP NEUROCHEM,D-14195 BERLIN,GERMANY; FREE UNIV BERLIN,INST ANAT,D-14195 BERLIN,GERMANY	Free University of Berlin; Free University of Berlin			Prof. Dr. Shakibaei, Mehdi/AAA-7004-2020	Prof. Dr. Shakibaei, Mehdi/0000-0002-6304-7506				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAROLL SM, 1981, J BIOL CHEM, V256, P8357; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HOLT GD, 1987, J CELL BIOL, V107, P1157; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KLJAJIC Z, 1987, EUR J BIOCHEM, V169, P97, DOI 10.1111/j.1432-1033.1987.tb13585.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS RK, 1976, BIOCHIM BIOPHYS ACTA, V451, P465, DOI 10.1016/0304-4165(76)90141-0; MILLER MW, 1994, J BIOL CHEM, V269, P9289; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; NEWMEYER DD, 1993, CURR OPIN CELL BIOL, V4, P335; OTTO H, 1992, NEUROCHEM INT, V21, P409, DOI 10.1016/0197-0186(92)90192-T; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; RODRIGUEZAPARIC.LB, 1992, J BIOL CHEM, V267, P9257; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271; STODDART RW, 1979, BIOL REV, V54, P199, DOI 10.1111/j.1469-185X.1979.tb01010.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TAKASAKI S, 1979, J BIOL CHEM, V254, P8548; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	39	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13787	13793		10.1074/jbc.270.23.13787	http://dx.doi.org/10.1074/jbc.270.23.13787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775435	hybrid			2022-12-27	WOS:A1995RC44800033
J	HOWE, JR; SKRYABIN, BV; BELCHER, SM; ZERILLO, CA; SCHMAUSS, C				HOWE, JR; SKRYABIN, BV; BELCHER, SM; ZERILLO, CA; SCHMAUSS, C			THE RESPONSIVENESS OF A TETRACYCLINE-SENSITIVE EXPRESSION SYSTEM DIFFERS IN DIFFERENT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; GLUTAMATE RECEPTORS; MESSENGER-RNA; GENE; PHOSPHORYLATION; ACTIVATION; MODULATION; CLONING; SUBUNIT	A tetracycline-sensitive inducible expression system was used to regulate the expression of neurotransmitter receptor genes in two mammalian cell lines. The dopamine D-3-receptor was stably expressed in GH3 cells, and GluR6 (a glutamate receptor subunit) was stably expressed in human embryonic kidney (HEK 293) cells. Three striking differences were found. 1) In the inactive state, virtually no D-3-receptor expression was found in GH3 cells, whereas substantial levels of GluR6 expression were found in HER 293 cells. 2) The induction of expression obtained upon removal of tetracycline was robust in GH3 cells but only modest in HEK 293 cells. 3) Whereas in each clonal cell line, the expression of a co-transfected hybrid transactivator is clearly regulated in a tetracycline-responsive manner, in the induced state, its mRNA levels were found to be very low in GH3 cells and very high in HEK 293 cells. The results indicate that, in contrast to GH3 cells, HEK 293 cells do not provide a cellular environment in which the expression of a heterologous gene can be tightly controlled in a tetracycline-responsive manner.	MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Yale University			Skryabin, Boris/AAL-3100-2020	Skryabin, Boris/0000-0002-4392-185X; Belcher, Scott/0000-0002-1196-3705	NINDS NIH HHS [NS 30996] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030996] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU K, 1994, J BIOL CHEM, V269, P29220; MARSHALL J, 1994, BIOPHYS J, V66, pA436; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; NOUER L, 1991, HEAT SHOCK RESPONSE, P167; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; RUETHER JE, 1986, MOL CELL BIOL, V6, P123, DOI 10.1128/MCB.6.1.123; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOKOLOFF P, 1992, EUR J PHARM-MOLEC PH, V225, P331, DOI 10.1016/0922-4106(92)90107-7; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377	29	104	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14168	14174		10.1074/jbc.270.23.14168	http://dx.doi.org/10.1074/jbc.270.23.14168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775477	hybrid			2022-12-27	WOS:A1995RC44800084
J	KIM, JH; WESS, J; VANRHEE, AM; SCHONEBERG, T; JACOBSON, KA				KIM, JH; WESS, J; VANRHEE, AM; SCHONEBERG, T; JACOBSON, KA			SITE-DIRECTED MUTAGENESIS IDENTIFIES RESIDUES INVOLVED IN LIGAND RECOGNITION IN THE HUMAN A(2A) ADENOSINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RADIOLIGAND BINDING; ADENYLATE-CYCLASE; RAT-BRAIN; EXPRESSION; CLONING; AGONIST; ACTIVATION; INHIBITION; CELLS	The A(2a) adenosine receptor is a member of the G-protein coupled receptor family, and its activation stimulates cyclic AMP production. To determine the residues which are involved in ligand binding, several residues in transmembrane domains 5-7 were individually replaced with alanine and other amino acids, The binding properties of the resultant mutant receptors were determined in transfected COS-7 cells. To study the expression levels in COS-7 cells, mutant receptors were tagged at their amino terminus with a hemagglutinin epitope, which allowed their immunological detection in the plasma membrane by the monoclonal antibody 12CA5. The functional properties of mutant receptors were determined by measuring stimulation of adenylate cyclase. Specific binding of [H-3]CGS 21680 (15 nM) and [H-3]XAC (4 nM), an A(2a) agonist and antagonist, respectively, was absent in the following Ala mutants: F182A, H250A, N253A, I274A, H278A, and S281A, although they were well expressed in the plasma membrane. The hydroxy group of Ser-277 is required for high affinity binding of agonists, but not antagonists. An N181S mutant lost affinity for adenosine agonists substituted at N-6 or C-2, but not at C-5 '. The mutant receptors I274A, S277A, and H278A showed full stimulation of adenylate cyclase at high concentrations of CGS 21680. The functional agonist potencies at mutant receptors that lacked radioligand binding were >30-fold less than those at the wild type receptor. His-250 appears to be a required component of a hydrophobic pocket, and H-bonding to this residue is not essential. On the other hand, replacement of His-278 with other aromatic residues was not tolerated in ligand binding. Thus, some of the residues targeted in this study may be involved in the direct interaction with ligands in the human A(2a) adenosine receptor. A molecular model based on the structure of rhodopsin, in which the 5 '-NH in NECA is hydrogen bonded to Ser-277 and His-278, was developed in order to visualize the environment of the ligand binding site.	NIDDK, MOLEC RECOGNIT SECT, BETHESDA, MD 20892 USA; NIDDK, BIOORGAN CHEM LAB, DRUG RECEPTOR INTERACT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20, Z99 DK999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ASKALAN R, 1994, J NEUROCHEM, V63, P1477; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARRACO RA, 1994, PROG NEURO-PSYCHOPH, V18, P545, DOI 10.1016/0278-5846(94)90011-6; BARRINGTON WW, 1989, P NATL ACAD SCI USA, V86, P6572, DOI 10.1073/pnas.86.17.6572; CBLUML K, 1994, J BIOL CHEM, V269, P18870; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; ENJALBERT A, 1983, MOL PHARMACOL, V23, P576; FERRE S, 1994, NEUROSCIENCE, V63, P765, DOI 10.1016/0306-4522(94)90521-5; FONG TM, 1994, J BIOL CHEM, V269, P2728; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HIDE I, 1992, MOL PHARMACOL, V41, P352; Higuchi R., 1989, PCR TECHNOLOGY, P61; IJzerman A P, 1992, Drug Des Discov, V9, P49; IJZERMAN AP, 1994, EUR J PHARM-MOLEC PH, V268, P95, DOI 10.1016/0922-4106(94)90124-4; JACOBSON KA, 1992, MOL PHARMACOL, V42, P123; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; JACOBSON M, 1995, ADENOSINE ADENINE NU; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; JI XD, 1992, J RECEPTOR RES, V12, P149, DOI 10.3109/10799899209074789; KANDA T, 1994, EUR J PHARMACOL, V256, P263, DOI 10.1016/0014-2999(94)90551-7; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MARTIN GE, 1993, PHARMACOL BIOCHEM BE, V45, P951, DOI 10.1016/0091-3057(93)90146-K; NIKODIJEVIC O, 1993, DRUG DEVELOP RES, V30, P121, DOI 10.1002/ddr.430300304; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, J BIOL CHEM, V269, P18016; OLSSON RA, 1990, PHARMACOL REV, V3, P761; PIERSEN CE, 1994, MOL PHARMACOL, V45, P871; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STRADER CD, 1989, J BIOL CHEM, V264, P13572; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; VANGALEN PJM, 1994, MOL PHARMACOL, V45, P1101; VANRHEE AM, 1994, 208TH NAT M WASH; WEISS S, 1985, MOL PHARMACOL, V27, P595; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	42	204	206	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13987	13997		10.1074/jbc.270.23.13987	http://dx.doi.org/10.1074/jbc.270.23.13987			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775460	hybrid, Green Accepted			2022-12-27	WOS:A1995RC44800060
J	SMULDERS, RHPH; VANGEEL, IG; GERARDS, WLH; BLOEMENDAL, H; DEJONG, WW				SMULDERS, RHPH; VANGEEL, IG; GERARDS, WLH; BLOEMENDAL, H; DEJONG, WW			REDUCED CHAPERONE-LIKE ACTIVITY OF ALPHA-A(INS)-CRYSTALLIN, AN ALTERNATIVE SPLICING PRODUCT CONTAINING A LARGE INSERT PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; HEAT-SHOCK PROTEINS; B-CRYSTALLIN; QUATERNARY STRUCTURE; NONLENTICULAR TISSUES; MOLECULAR CHAPERONE; AINS-CRYSTALLIN; EXPRESSION; MODEL; GENE	alpha-Crystallin is a multimeric protein complex which is constitutively expressed at high levels in the vertebrate eye lens, where it serves a structural role, and at low levels in several non-lenticular tissues. Like other members of the small heat shock protein family, alpha-crystallin has a chaperone-like activity in suppressing nonspecific aggregation of denaturing proteins in vitro. Apart from the major alpha A- and alpha B-subunits, alpha-crystallin of rodents contains an additional minor subunit resulting from alternative splicing, alpha A(ins)-crystallin. This polypeptide is identical to normal alpha A-crystallin except for an insert peptide of 23 residues. To explore the structural and functional consequences of this insertion, we have expressed rat alpha A- and alpha A(ins)-crystallin in Escherichia coli. The multimeric particles formed by alpha A(ins) are larger and more disperse than those of alpha A, but they are native-like and display a similar thermostability and morphology, as revealed by gel permeation chromatography, tryptophan fluorescence measurements, and electron microscopy, However, as compared with alpha A, the alpha A(ins)-particles display a diminished chaperone-like activity in the protection of heat-induced aggregation of beta(low)-crystallin. Our experiments indicate that alpha A(ins)-multimers have a 3-4-fold reduced substrate binding capacity, which might be correlated to their increased particle size and to a shielding of binding sites by the insert peptides. The structure-function relationship of the natural mutant alpha A(ins)-crystallin may shed light on the mechanism of chaperone-like activity displayed by all small heat shock proteins.	UNIV NIJMEGEN, DEPT BIOCHEM, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen					NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER; NEI NIH HHS [EY09683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; Bloemendal H., 1981, MOL CELLULAR BIOL EY; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURNSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; COHEN LH, 1978, EUR J BIOCHEM, V89, P259, DOI 10.1111/j.1432-1033.1978.tb20921.x; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEJONG WW, 1980, BIOCHEM BIOPH RES CO, V96, P648, DOI 10.1016/0006-291X(80)91404-7; DEJONG WW, 1984, EUR J BIOCHEM, V39, P207; DERETIC D, 1994, J BIOL CHEM, V269, P16853; DURO G, 1991, ANAL BIOCHEM, V195, P111, DOI 10.1016/0003-2697(91)90304-C; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; HENDRIKS W, 1990, BIOCHIM BIOPHYS ACTA, V1037, P58, DOI 10.1016/0167-4838(90)90101-K; HENDRIKS W, 1988, EUR J BIOCHEM, V174, P133, DOI 10.1111/j.1432-1033.1988.tb14072.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1986, ADV AGE RES EUROPE, P227; IWAKI T, 1993, AM J PATHOL, V143, P487; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAWORSKI C J, 1990, Investigative Ophthalmology and Visual Science, V31, P507; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO S, 1993, NEUROPATH APPL NEURO, V19, P436, DOI 10.1111/j.1365-2990.1993.tb00466.x; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KING CR, 1984, J BIOL CHEM, V259, P1822; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KOENIG SH, 1993, BIOPHYS J, V64, P1178, DOI 10.1016/S0006-3495(93)81483-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; OHNO S, 1985, TRENDS GENET, V1, P160, DOI 10.1016/0168-9525(85)90070-8; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Sambrook J, 1989, MOL CLONING LABORATO; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENHEUVEL R, 1985, J MOL BIOL, V185, P273, DOI 10.1016/0022-2836(85)90403-6; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; XIA JZ, 1994, BIOPHYS J, V66, P861, DOI 10.1016/S0006-3495(94)80862-8	56	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13916	13924		10.1074/jbc.270.23.13916	http://dx.doi.org/10.1074/jbc.270.23.13916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775451	hybrid			2022-12-27	WOS:A1995RC44800050
J	ZHOU, MJ; LUBLIN, DM; LINK, DC; BROWN, EJ				ZHOU, MJ; LUBLIN, DM; LINK, DC; BROWN, EJ			DISTINCT TYROSINE KINASE ACTIVATION AND TRITON-X-100 INSOLUBILITY UPON FC-GAMMA-RII OR FC-GAMMA-RIIIB LIGATION IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES - IMPLICATIONS FOR IMMUNE-COMPLEX ACTIVATION OF THE RESPIRATORY BURST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN-NEUTROPHILS; MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; RECEPTOR-III; PHAGOCYTOSIS; PROTEIN; IDENTIFICATION; EXPRESSION; CELLS	Two tyrosine kinase dependent pathways exist for activation of the respiratory burst by polymorphonuclear leukocyte (PMN) immunoglobulin G Fc receptors. Direct ligation of Fc gamma RII activates the respiratory burst, but ligation of the glycan phosphoinositol-linked Fc gamma RIIIB does not. Instead, this receptor and the integrin complement receptor CR3 synergize in activation of the respiratory burst (Zhou, M.-J., and Brown, E. J. (1994) J, Cell Biol. 125, 1407-1416). Here we show that direct ligation of Fc gamma RIII leads to activation and Triton X-100 insolubility of the Src family kinase Fgr, without effect on the related myeloid Src family member Hck. In contrast, adhesion of PMN via Fc gamma RIIIB leads to activation and Triton X-100 insolubility of Hck but not Fgr. The exclusive association of Fc gamma RIIIB with Hck activation and Triton insolubility is not solely a result of its glycan phosphoinositol anchor, since decay accelerating factor (CD55), another prominent glycan phosphoinositol-anchored PMN protein, is associated with Fgr insolubility to a greater extent than Hck. Ligation of decay accelerating factor, with or without coligation of CR3, does not activate the PMN respiratory burst. Coligation of Fc gamma RIIIB with Fc gamma RII overcomes the pertussis toxin inhibition of H2O2 production in response to direct ligation of Fc gamma RII. These data support the hypothesis that activation of Hck upon Fc gamma RIIIB ligation has a role in generation of the synergistic respiratory burst.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI24674, AI35811] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811, R01AI024674, R37AI024674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P393; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BLACKBURN WD, 1989, BIOCHEM BIOPH RES CO, V164, P983, DOI 10.1016/0006-291X(89)91766-X; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; CONNOR J, 1992, J BIOL CHEM, V267, P26050; COYNE KE, 1992, J IMMUNOL, V149, P2906; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; DUSI S, 1994, BIOCHEM BIOPH RES CO, V201, P30, DOI 10.1006/bbrc.1994.1665; EDBERG JC, 1994, J IMMUNOL, V152, P5826; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; LIEBL EC, 1992, ONCOGENE, V7, P2417; LINK DC, 1995, IN PRESS BLOOD; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOONEY RJ, 1986, J EXP MED, V163, P826, DOI 10.1084/jem.163.4.826; MICHL J, 1979, J EXP MED, V150, P607, DOI 10.1084/jem.150.3.607; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROSALES C, 1993, NEUTROPHIL, P23; SALMON JE, 1991, J IMMUNOL, V146, P997; SEHGAL G, 1993, J IMMUNOL, V150, P4571; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	45	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13553	13560		10.1074/jbc.270.22.13553	http://dx.doi.org/10.1074/jbc.270.22.13553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768958	hybrid			2022-12-27	WOS:A1995RB43900088
J	DONNADIEU, E; TRAUTMANN, A; MALISSEN, M; TRUCY, J; MALISSEN, B; VIVIER, E				DONNADIEU, E; TRAUTMANN, A; MALISSEN, M; TRUCY, J; MALISSEN, B; VIVIER, E			RECONSTITUTION OF CD3-ZETA COUPLING TO CALCIUM MOBILIZATION VIA GENETIC COMPLEMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; ZETA-CHAIN; CYTOPLASMIC TAIL; LYMPHOCYTES-T; ACTIVATION; MESSENGER; PHOSPHORYLATION; HYBRIDOMAS	The integrity of the T cell receptor complex (CD3-TCR) transduction machinery is central to T cell development and to T cell effector function, Molecular dissection of the multimeric CD3-TCR complex revealed that at least two associated polypeptides, CD3 zeta and CD3 epsilon, autonomously couple antigenic recognition event to early and late events of the intracytoplasmic activation cascade, A 18-amino acid motif based on a tandem YXXL stretch, the activation receptor homology sequence 1 (ARH-1) motif, is necessary and sufficient to the transducing properties of both CD3 zeta and CD3 epsilon. Stimulation of chimeric molecules made of ecto- and transmembrane domains of various cell surface proteins and intracytoplasmic domains of CD3 epsilon or CD3 zeta leads to an increase in the intracellular Ca2+ concentration ([Ca2+](i)) in Jurkat cells, We describe here that a similar CD25/zeta chimeric molecule was unable to induce a detectable [Ca2+](i) rise upon CD25 cross-linking once expressed in the murine thymoma BW-. A Ca2+ influx could, however, be triggered in BW- cells by thapsigargin, i.e. following depletion of Ca2+ stores, Somatic cell hybrids made from BW- and either thymocytes or mature lymph node T cells reconstituted the coupling of CD3 zeta to the Ca2+ signal via an ARH-1 motif-dependent pathway, However, pervanadate-induced Ca2+ mobilization, a phenomenon attributed to tyrosine phosphorylation, was impaired in BW- cells and reconstituted in hybridomas, In contrast to the Ca2+ response, IL-2 production was induced in both BW- and hybrids cells, which ques-tions the functional relevance of [Ca2+](i) augmentation in T cell activation, In conclusion, the properties of the BW- thymoma, which define a novel group of CD3 zeta transduction cell mutants, as well as its complementation by somatic cell fusion demonstrate that this cell line represents a useful model to dissect the signaling pathway that couples CD3 zeta to Ca2+ mobilization by genetic reconstitution.	FAC SCI LUMINY,CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 09,FRANCE; ECOLE NORMALE SUPER,NEUROBIOL LAB,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Malissen, Bernard/AAK-4659-2020; Vivier, Eric/F-8939-2010; Donnadieu, Emmanuel/P-4566-2017	Vivier, Eric/0000-0001-7022-8287; Malissen, Marie/0000-0003-2331-1445				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; DONNADIEU E, 1993, PFLUG ARCH EUR J PHY, V424, P448, DOI 10.1007/BF00374907; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HOEVELER A, 1993, MOL IMMUNOL, V30, P755, DOI 10.1016/0161-5890(93)90147-4; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MILLS GB, 1985, J IMMUNOL, V134, P1640; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1992, COLD SPRING HARB SYM, V67, P107; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WHITE J, 1989, J IMMUNOL, V143, P1822	40	18	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32828	32834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806507				2022-12-27	WOS:A1994QA63800020
J	RAHUEL, C; ELOUET, JF; CARTRON, JP				RAHUEL, C; ELOUET, JF; CARTRON, JP			POSTTRANSCRIPTIONAL REGULATION OF THE CELL-SURFACE EXPRESSION OF GLYCOPHORIN-A, GLYCOPHORIN-B, AND GLYCOPHORIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; MESSENGER-RNA; STRUCTURAL ORGANIZATION; MAMMALIAN-CELLS; CDNA CLONES; K562 CELLS; PROMOTER; SEQUENCE; LINE; ELEMENTS	GYPA, GYPB, and GYPE represent a small gene family localized on chromosome 4q28-q31 that encodes the major red cell membrane glycophorins, GPA and GPB, and a new but as yet uncharacterized glycoprotein, GPE. There are 3-4 times more copies of GPA as compared with GPB on human erythrocytes (10(6) versus 2 x 10(5) copies/cell), whereas GPE is absent or poorly represented, Whether these quantitative differences reflect a transcriptional or post-transcriptional regulation was investigated, We found the functional activities of the glycophorin promoters to be similar, as shown by DNase I footprinting, gel retardation, methylation interference, and deletion analysis, Run-on analysis indicated that the transcription rate of each glycophorin gene in K562 cells was also very similar. However, large differences in mRNA decay were found in actinomycin-treated K562 cells, GPA transcripts were very stable (at least 24 h), whereas GPB transcripts were severely reduced after 17 h, The GPE transcripts were barely detectable and disappeared completely after 1 h. These results suggest that a difference in stability of the GPA, GPB, and GPE transcripts rather than a transcriptional regulation may predominantly account for the different levels of glycophorin expression on erythrocytes.	INST NATL TRANSFUS SANGUINE,INSERM,U76,F-75015 PARIS,FRANCE; INSERM,U91,CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)								ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BLANCHARD D, 1990, Transfusion Medicine Reviews, V4, P170, DOI 10.1016/S0887-7963(90)70263-5; CARTRON J-P, 1992, Transfusion Medicine Reviews, V6, P63, DOI 10.1016/S0887-7963(92)70158-8; CARTRON JP, 1992, PROTEIN BLOOD GROUP, P101; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIN Y, 1986, J BIOL CHEM, V261, P229; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FUKUDA M, 1984, CELL SURFACE GLYCOPR, P183; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; GAHMBERG CG, 1979, J BIOL CHEM, V254, P7442; GARDNER B, 1989, IMMUNOLOGY, V68, P283; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMID J, 1990, NUCLEIC ACIDS RES, V18, P5829, DOI 10.1093/nar/18.19.5829; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LEONARD M, 1993, BLOOD, V82, P1071; LITTAUER UZ, 1982, PROG NUCLEIC ACID RE, V27, P53, DOI 10.1016/S0079-6603(08)60597-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MORLE F, 1992, BLOOD, V79, P3094; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; ONDA M, 1994, J BIOL CHEM, V269, P13013; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; RAHUEL C, 1989, GENE, V85, P471, DOI 10.1016/0378-1119(89)90441-1; RAICH N, 1993, STEM CELLS, V11, P95, DOI 10.1002/stem.5530110204; SAMBROOK J, 1989, MOL CLONING LABORATO, P1420; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SIEBERT PD, 1986, J BIOL CHEM, V261, P2433; SILVER RE, 1987, ARCH BIOCHEM BIOPHYS, V256, P285, DOI 10.1016/0003-9861(87)90448-6; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	53	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32752	32758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806496				2022-12-27	WOS:A1994QA63800009
J	DESJARDINS, M; CELIS, JE; VAN MEER, G; DIEPLINGER, H; JAHRAUS, A; GRIFFITHS, G; HUBER, LA				DESJARDINS, M; CELIS, JE; VAN MEER, G; DIEPLINGER, H; JAHRAUS, A; GRIFFITHS, G; HUBER, LA			MOLECULAR CHARACTERIZATION OF PHAGOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; PLASMA-MEMBRANE; CELLS; MACROPHAGES; TRANSPORT; CLATHRIN; BINDING; IDENTIFICATION; TRANSLOCATION; PHAGOCYTOSIS	The transformation of newly formed phagosomes into mature phagolysosomes is a process that involves a complex series of interactions between phagosomes and other vacuolar organelles. The machinery required by phagosomes to mediate these interactions is poorly understood. In this study, we allowed human and various rodent cells to take up latex beads whose density facilitates a simple purification of phagosomes using discontinuous sucrose gradients. With this system, we initiated a systematic study of phagosome proteins using two-dimensional gel electrophoresis and the currently available two-dimensional gel protein data bases. By this approach, we were able to recognize a group of polypeptides associated with mouse J774 phagosomes-phagolysosomes including annexin II, annexin VI, the beta-1 and beta-2 subunits of trimeric G proteins, and a group of actin-binding proteins. While the amount of annexin II associated to phagosomes was similar at all times of latex internalization, the levels of annexin VI were higher on late phagosomes. Phospholipid analysis of J774 phagosomes isolated at early and late time points during phagolysosome formation also revealed significant differences in their lipid composition. In the human phagosomes, we resolved over 200 polypeptides on the two-dimensional gels. These included the proteins described in the mouse, as well as 32 polypeptides that were found to be highly enriched in phagosomes, 15 of which are not present in the current data bases. The results demonstrate that the use of latex bead phagosomes is a powerful system to identify key molecules involved in phagolysosome biogenesis.	DANISH CTR HUMAN GENOME RES, DK-8000 AARHUS C, DENMARK; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Aarhus University; Utrecht University	DESJARDINS, M (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Huber, Lukas Alfons/AAM-3499-2021; van Meer, Gerrit/AAH-1560-2021	Desjardins, Michel/0000-0002-5684-5980; van Meer, Gerrit/0000-0002-5976-6436; Huber, Lukas Alfons/0000-0003-1116-2120				AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; BROWN EJ, 1987, J IMMUNOL, V139, P3777; CELIS JE, 1993, J ELECTROPH, V14, P1091; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNSTER LM, 1994, VIROLOGY, V198, P265, DOI 10.1006/viro.1994.1029; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVANS WH, 1985, BIOCHEM J, V232, P33, DOI 10.1042/bj2320033; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; HONING S, 1994, J CELL SCI, V107, P1185; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JACKLE S, 1994, J BIOL CHEM, V269, P1026; JAHRAUS A, 1994, J CELL SCI, V107, P145; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MCMURRAY WC, 1972, ANNU REV BIOCHEM, V41, P129, DOI 10.1146/annurev.bi.41.070172.001021; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; PIZON V, 1994, J CELL SCI, V107, P1661; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; ZHANG LS, 1992, CANCER RES, V52, P4634	48	226	230	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32194	32200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798218				2022-12-27	WOS:A1994PX30400030
J	VILLENA, JA; MARTIN, I; VINAS, O; CORMAND, B; IGLESIAS, R; MAMPEL, T; GIRALT, M; VILLARROYA, F				VILLENA, JA; MARTIN, I; VINAS, O; CORMAND, B; IGLESIAS, R; MAMPEL, T; GIRALT, M; VILLARROYA, F			ETS TRANSCRIPTION FACTORS REGULATE THE EXPRESSION OF THE GENE FOR THE HUMAN MITOCHONDRIAL ATP SYNTHASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ENHANCER-BINDING PROTEIN; LONG TERMINAL REPEAT; OXIDATIVE-PHOSPHORYLATION; PROMOTER SEQUENCES; DIFFERENTIAL EXPRESSION; MAMMALIAN-CELLS; NUCLEAR GENES; RAT-LIVER; IV GENE	Elements responsible for the transcriptional activity of the human ATP synthase beta-subunit (ATPsyn beta) gene promoter have been studied through transient expression in HepG2 hepatoma cells of a CAT gene connected with various 5'-deletion mutants of the 5'-flanking region, Promoter activity was mostly dependent upon a single CCAAT motif as well as a nearby Ets domain binding region. This last region contains two sites that bind Ets-related proteins present in liver nuclear extracts as well as recombinant purified Ets-1 protein. The ATPsyn beta promoter was trans-activated by Ets-1 and Ets-2 expression vectors, and this effect was lost when the Ets binding region was deleted, The Ets binding region of the ATPsyn beta promoter increased basal expression and conferred Ets-1- and Ets-2-dependent trans-activation to the herpes symplex thymidine kinase minimal promoter, A double-point mutation of the main Ets-binding site, which suppresses Ets binding, blocks Ets-dependent trans-activation. It is concluded that the gene for the mitochondrial ATPsyn beta is a target of transcriptional activation by members of the Ets family of transcription factors, It is suggested that Ets transcription factors may be involved in the enhanced expression of the ATPsyn beta gene in highly proliferating cells and in the coordinate transcription of nuclear genes for mitochondrial proteins.	UNIV BARCELONA,DEPT BIOQUIM & FISIOL,UNITAT BIOQUIM & BIOL MOLEC B,E-08071 BARCELONA,SPAIN	University of Barcelona			Mampel, Teresa/C-5571-2017; Villarroya, Francesc/K-4357-2014; Iglesias, Roser/C-5561-2017; Villena, Josep A/H-1597-2015; Cormand, Bru/H-5338-2015; Giralt, Marta/A-4756-2013	Iglesias, Roser/0000-0002-7107-8097; Cormand, Bru/0000-0001-5318-4382; Giralt, Marta/0000-0001-7968-4190; Villena, Josep A/0000-0002-2200-2985; Villarroya, Francesc/0000-0003-1266-9142				ASANO M, 1990, J VIROL, V64, P5927, DOI 10.1128/JVI.64.12.5927-5938.1990; ASCIONE R, 1992, INT J ONCOL, V1, P631; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; FABRIZI GM, 1992, GENE, V119, P307, DOI 10.1016/0378-1119(92)90288-Z; FARRELL LB, 1987, BIOCHEM BIOPH RES CO, V144, P1257, DOI 10.1016/0006-291X(87)91446-X; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GLAICHENHAUS N, 1986, EMBO J, V5, P1251; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x; NAGINO M, 1989, CANCER RES, V49, P4913; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHTA S, 1988, J BIOL CHEM, V263, P11257; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	50	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32649	32654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798271				2022-12-27	WOS:A1994PX30400093
J	GRABER, P; PROUDFOOT, AEI; TALABOT, F; BERNARD, A; MCKINNON, M; BANKS, M; FATTAH, D; SOLARI, R; PEITSCH, MC; WELLS, TNC				GRABER, P; PROUDFOOT, AEI; TALABOT, F; BERNARD, A; MCKINNON, M; BANKS, M; FATTAH, D; SOLARI, R; PEITSCH, MC; WELLS, TNC			IDENTIFICATION OF KEY CHARGED RESIDUES OF HUMAN INTERLEUKIN-5 IN RECEPTOR-BINDING AND CELLULAR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-5; COLONY-STIMULATING FACTOR; HUMAN GROWTH-HORMONE; GM-CSF; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION	Interleukin-5 (IL-5) is a cytokine that plays a major role in the differentiation and activation of eosinophils. In order to identify which charged residues of human IL-5 are important in binding to its receptor and subsequent cellular activation, we have systematically replaced all of the clusters of charged amino acids with alanine residues. The mutants have been expressed in Escherichia coli, renatured, and purified. They were assayed for ability to cause proliferation of the erythro-leukaemic cell line TF-1 and the up-regulation of eosinophil adhesion to ICAM-1. In addition, we studied receptor binding using either immobilized recombinant IL-5 receptor alpha-chain or the alpha/beta-receptor complex expressed on TF-2 cells. The key charged residue is Glu-12. This residue is in an identical position to those previously identified in IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) involved in binding to the receptor beta-chain. The alpha-chain binding site is shown to involve the side chains Arg-90 and Glu-109, located in the second beta sheet and after the end of the fourth helix, respectively. It is unique to IL-5 and does not occur in IL-3 or GM-CSF. Understanding the topology of the interaction of IL-5 with its receptor chains will help in the search for rationally designed antagonists of IL-5 function.	GLAXO INST MOLEC BIOL SA,CH-1228 GENEVA,SWITZERLAND; GLAXO RES & DEV,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline; GlaxoSmithKline			Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Wells, Timothy/0000-0001-9796-847X				BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1993, EUR J BIOCHEM, V212, P751, DOI 10.1111/j.1432-1033.1993.tb17714.x; GRENFELL S, 1991, BIOCHEM J, V280, P111, DOI 10.1042/bj2800111; HASSELL AM, 1993, J MOL BIOL, V229, P1150, DOI 10.1006/jmbi.1993.1110; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HERCUS TR, 1994, BLOOD, V83, P3500; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KODAMA S, 1991, BIOCHEM BIOPH RES CO, V178, P514, DOI 10.1016/0006-291X(91)90137-V; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1992, EMBO J, V11, P3137; LEATHERBARROW RJ, 1992, GRAFIT VERSION 3 01; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOKS T, 1987, BIOTECHNOLOGY, V5, P37; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAKATSU K, 1992, CURR OPIN IMMUNOL, V4, P299, DOI 10.1016/0952-7915(92)90080-X; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; WEIR MP, 1988, BIOCHEMISTRY-US, V27, P6883, DOI 10.1021/bi00418a034; ZURAWSKI SM, 1989, EMBO J, V8, P2583, DOI 10.1002/j.1460-2075.1989.tb08397.x	43	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15762	15769		10.1074/jbc.270.26.15762	http://dx.doi.org/10.1074/jbc.270.26.15762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797578	hybrid			2022-12-27	WOS:A1995RG53800051
J	KAUFMAN, DL; KEITH, DE; ANTON, B; TIAN, J; MAGENDZO, K; NEWMAN, D; TRAN, TH; LEE, DS; WEN, C; XIA, YR; LUSIS, AJ; EVANS, CJ				KAUFMAN, DL; KEITH, DE; ANTON, B; TIAN, J; MAGENDZO, K; NEWMAN, D; TRAN, TH; LEE, DS; WEN, C; XIA, YR; LUSIS, AJ; EVANS, CJ			CHARACTERIZATION OF THE MURINE MU-OPIOID RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; RAT-BRAIN; CLONING; CDNA; AUTORADIOGRAPHY; MOUSE; DNA	The analgesic and addictive properties of morphine and other opioid drugs are thought to result from their interaction with mu opioid receptors, Using a delta opioid receptor cDNA as a probe, we have isolated a murine mu opioid receptor cDNA clone (mMOR), Stable expression of mMOR in Chinese hamster ovary cells conferred high binding affinity for mu receptor ligands including morphine and [D-Ala(2),N-methyl-Phe(4),Gly(5)-ol]-enkephalin and low affinity for delta and kappa preferring ligands, Treatment of these cell lines with morphine and other mu agonists inhibited forskolin-induced cAMP accumulation, demonstrating a functional coupling of mMOR to the inhibition of adenylate cyclase, The predicted amino acid sequence of mMOR shares approximate to 55% overall amino acid identity with the delta receptor and approximate to 97% identity with the recently reported rat mu opioid receptor, Expression of the mu receptor in mouse brain as revealed by in situ hybridization parallels the reported pattern of distribution of mu-selective ligand binding sites, Chromosomal localization (to mouse chromosome 10) and Southern analysis are consistent with a single mu opioid receptor gene in the mouse genome, suggesting that the various pharmacologically distinct forms of the mu receptor arise from alternative splicing, post-translational events, or from a highly divergent gene(s).	UNIV CALIF LOS ANGELES,NPI,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC & MED PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042488, R01HL042488, P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL42488] Funding Source: Medline; NIDA NIH HHS [P50 DA005010, DA05010] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; BELKNAP JK, 1990, BEHAV GENET, V20, P333, DOI 10.1007/BF01067800; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DIETRICH W, 1992, GENETICS, V131, P423; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LOGEL J, 1992, BIOTECHNIQUES, V13, P604; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MANSOUR A, 1987, J NEUROSCI, V7, P2445; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; MINAMI M, 1994, NEUROSCI RES, V18, P315, DOI 10.1016/0168-0102(94)90167-8; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARIF NA, 1989, PEPTIDES, V10, P499, DOI 10.1016/0196-9781(89)90135-6; TEMPEL A, 1987, P NATL ACAD SCI USA, V84, P4308, DOI 10.1073/pnas.84.12.4308; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; WOLLEMANN M, 1990, J NEUROCHEM, V54, P1095, DOI 10.1111/j.1471-4159.1990.tb01934.x; ZASTAWNY RL, 1994, J NEUROCHEM, V62, P2099	27	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15877	15883		10.1074/jbc.270.26.15877	http://dx.doi.org/10.1074/jbc.270.26.15877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797593	hybrid			2022-12-27	WOS:A1995RG53800067
J	TRIEU, VN; MCCONATHY, WJ				TRIEU, VN; MCCONATHY, WJ			A 2-STEP MODEL FOR LIPOPROTEIN(A) FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSING HUMAN APOLIPOPROTEIN(A); B-CONTAINING LIPOPROTEINS; PLASMA; LP(A); ASSOCIATION; PLASMINOGEN; CYSTEINE; DISEASE; BINDING	Lipoprotein(a) (Lp(a)), a risk factor for coronary artery disease, is a LDL-like particle with apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B (apoB), the main protein component of LDL. Apo(a) is highly homologous to plasminogen and its gene probably arose by duplication of the plasminogen gene. It has many repeats of kringle- 4-like domain, classified as type 1 through type 10 (T1-T10). T9 is responsible for the covalent linkage between apo(a) and LDL. However, we found that T9 has no affinity for LDL. Therefore, an initial noncovalent interaction between apo(a) and LDL is necessary to bring T9 and LDL together. T6 and possibly T7 of apo(a) were identified as the kringles which mediate this initial interaction. With these findings, a two step model for Lp(a) formation is proposed. This model should be useful in the design of Lp(a) formation inhibitors. These inhibitors are potential anti-hyperlipoprotein(a) drugs.	UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM,FT WORTH,TX 76107	University of North Texas System; University of North Texas Health Science Center	TRIEU, VN (corresponding author), UNIV N TEXAS,HLTH SCI CTR,DEPT MED,DIV CLIN RES,3500 CAMP BOWIE BLVD,FT WORTH,TX 76107, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DURRINGTON PN, 1988, LANCET, V1, P1070; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GABEL B, 1994, FEBS LETT, V350, P71; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; LAW A, 1990, J LIPID RES, V31, P1109; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STEYRER E, 1994, J CLIN INVEST, V94, P2330, DOI 10.1172/JCI117598; TREXLER M, 1983, FEBS LETT, V154, P311, DOI 10.1016/0014-5793(83)80173-2; TRIEU VN, 1995, BIOCHEM J, V307, P17, DOI 10.1042/bj3070017; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; TRIEU VN, 1995, IN PRESS BIOCH J; VANDERHOEK YY, 1994, CAN J PHYSIOL PHARM, V72, P304, DOI 10.1139/y94-046; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; YE SQ, 1988, J BIOL CHEM, V263, P6337	29	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15471	15474		10.1074/jbc.270.26.15471	http://dx.doi.org/10.1074/jbc.270.26.15471			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797538	hybrid			2022-12-27	WOS:A1995RG53800008
J	AXELSON, M; LARSSON, O				AXELSON, M; LARSSON, O			LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL IS CONVERTED TO 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS - EVIDENCE THAT 27-HYDROXYCHOLESTEROL CAN BE AN IMPORTANT INTRACELLULAR MEDIATOR BETWEEN LDL AND THE SUPPRESSION OF CHOLESTEROL PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; OXYSTEROL-BINDING-PROTEIN; STEROL CARRIER PROTEIN-2; BILE-ACID BIOSYNTHESIS; HUMAN LIVER-MICROSOMES; CULTURED MOUSE CELLS; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CEREBROTENDINOUS XANTHOMATOSIS; OXYGENATED STEROLS; FAMILIAL HYPERCHOLESTEROLEMIA	The formation of oxysterols in cultured human fibroblasts and their physiological roles as intracellular regulators of cholesterol production have been investigated, In the presence of low density lipoproteins (LDL) normal fibroblasts converted LDL cholesterol to the oxysterol 27-hydroxycholesterol in quantities apparently sufficient to down-regulate 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The production of 27-hydroxycholesterol started 5-8 h after the addition of LDL to the incubation medium, and during this time the activity of HMG-CoA reductase decreased by 73%. For formation of other biologically active oxysterols such as 7 alpha-hydroxycholesterol, 24-hydroxycholesterol, and 25-hydroxycholesterol was not observed, When 27-hydroxylation of LDL cholesterol in mitochondria was selectively prevented by treating normal fibroblasts with cyclosporin A or by using fibroblasts genetically lacking sterol 27-hydroxylase, the suppressive effect of LDL on HMG-CoA reductase was reduced by a factor of about 10. In the absence of LDL or when the fibroblasts lacked LDL-receptors, the cells did not produce detectable amounts of 27-hydroxycholesterol, and HMG-CoA reductase was up-regulated. The results provide strong evidence that 27-hydroxycholesterol is an important intracellular mediator between LDL and the suppression of HMG-CoA reductase in human fibroblasts. The mitochondrial uptake/metabolism of LDL cholesterol seems to be a biologically important extension of the LDL pathway in human cells, since the mitochondrial products of LDL cholesterol may regulate cholesterol homeostasis or be precursors of steroid hormones or bile acids. This pathway, which has now been demonstrated in fibroblasts, may link together the two 22-year-old observations that LDL as well as oxysterols can down-regulate HMG-CoA reductase in cells.	KAROLINSKA HOSP,DEPT TUMOUR PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	AXELSON, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN CHEM,S-17176 STOCKHOLM,SWEDEN.							AXELSON M, 1995, J LIPID RES, V36, P290; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1991, J BIOL CHEM, V266, P17770; AXELSON M, 1981, ANAL LETT PT B, V14, P771, DOI 10.1080/00032718108055481; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BELL JJ, 1976, J BIOL CHEM, V251, P1745; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BJORKHEM I, 1992, J LIPID RES, V32, P455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDLER HN, 1983, J LEARN DISABIL, V16, P491, DOI 10.1177/002221948301600813; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHANG TY, 1981, J BIOL CHEM, V256, P6174; Dahl K. D., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P181; DAHLBACKSJOBERG H, 1993, BIOCHEM J, V293, P203, DOI 10.1042/bj2930203; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; EDWARDS PA, 1979, J LIPID RES, V20, P40; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; GIBBONS GF, 1983, BIOCHEM SOC T, V11, P649, DOI 10.1042/bst0110649; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GOWR DB, 1988, HORMONES THEIR ACT 1, P3; GUPTA A, 1986, J BIOL CHEM, V261, P8348; Hornsby P.J., 1988, HORMONES THEIR ACT 2, P193; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; JANNE O, 1969, CLIN CHIM ACTA, V23, P405, DOI 10.1016/0009-8981(69)90340-4; JAVITT NB, 1990, J LIPID RES, V31, P1527; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KESAV S, 1992, BIOCHEM SOC T, V20, P818, DOI 10.1042/bst0200818; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LORENZO JL, 1987, FEBS LETT, V218, P77, DOI 10.1016/0014-5793(87)81022-0; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; MYANT NB, 1990, CHOLESTEROL METABOLI, P33; NICOLAU G, 1974, J LIPID RES, V15, P94; ORAM JF, 1992, HIGH DENSITY LIPOPRO, V3, P125; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PHILLIPS MC, 1992, HIGH DENSITY LIPOPRO, V3, P117; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; RODGWAY ND, 1992, J CELL BIOL, V116, P307; ROMMERTS FFG, 1988, HORMONES THEIR ACT 2, P163; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SHODA J, 1993, HEPATOLOGY, V17, P395; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; SINENSKY M, 1981, ARCH BIOCHEM BIOPHYS, V209, P321, DOI 10.1016/0003-9861(81)90287-3; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TINT GS, 1989, J LIPID RES, V30, P633; TORNVALL P, 1990, ATHEROSCLEROSIS, V84, P219, DOI 10.1016/0021-9150(90)90094-Y; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; Warnick G.R., 1983, SELECTED METHODS CLI, V10, P91; WEINSTEIN DB, 1979, CIRCULATION S2, V54, P59	65	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15102	15110		10.1074/jbc.270.25.15102	http://dx.doi.org/10.1074/jbc.270.25.15102			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797494	hybrid			2022-12-27	WOS:A1995RE66600040
J	KRAVCHENKO, VV; PAN, ZX; HAN, JH; HERBERT, JM; ULEVITCH, RJ; YE, RD				KRAVCHENKO, VV; PAN, ZX; HAN, JH; HERBERT, JM; ULEVITCH, RJ; YE, RD			PLATELET-ACTIVATING-FACTOR INDUCES NF-KAPPA-B ACTIVATION THROUGH A G-PROTEIN-COUPLED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION MECHANISMS; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR RECEPTOR; TRANSCRIPTION FACTOR; SURFACE EXPRESSION; EPITHELIAL-CELLS; BINDING PROTEINS; LIGAND-BINDING; T-CELLS; LIPOPOLYSACCHARIDE	The capability of platelet activating factor (PAF) to induce transcription factor activation was examined. In stably transfected Chinese hamster ovary cells expressing the PAF receptor (CHO PAFR), PAF stimulation resulted in the nuclear expression of a DNA binding activity with specificity to the kappa B sequence. The p50 and p65 proteins, constituents of the prototypic nuclear factor kappa B (NF-kappa B), were identified as components of the DNA . protein complexes by antipeptide antibodies in gel supershift as well as UV cross-linking experiments. PAF induced an initial decrease and subsequent increase of cytoplasmic I kappa B alpha levels, accompanied by up-regulation of the I kappa B alpha messenger RNA, a feature of NF-kappa B activation. PAF-induced kappa B binding activity was detected within 15 min after agonist stimulation, peaked at 30-40 min, and remained detectable by 2.5 h. SR 27417, a PAF receptor antagonist, blocked PAF-induced kappa B binding activity but not that induced by tumor necrosis factor-alpha (TNF alpha). Cholera toxin treatment markedly reduced PAF-induced kappa B binding activity, whereas pertussis toxin had no significant inhibitory effect. Neither of the two toxins affected the kappa B binding activity induced by TNF alpha in the same cells. In addition to the CHO-PAFR cells, PAF stimulated kappa B binding activity in the murine P388D(1) macrophage and the human ASK.0 B cell lines that express endogenous PAF receptors. These results imply a potential role of PAF in the regulation of gene expression through a G protein-coupled transcription factor activation pathway.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SANOFI RECH, HAEMOBIOL RES DEPT, TOULOUSE, FRANCE	Scripps Research Institute; Sanofi-Aventis; Sanofi France			Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020; Han, J/G-4671-2010	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; 	NIAID NIH HHS [AI33503, AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033503, R01AI015136, R01AI033503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEPFELBACHER M, 1992, J IMMUNOL, V148, P2186; AVODONIN PV, 1985, BIOCHEM BIOPH RES CO, V131, P307; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAZAN HEP, 1993, P NATL ACAD SCI USA, V90, P8678, DOI 10.1073/pnas.90.18.8678; BEG AA, 1994, ONCOGENE, V9, P1487; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRASER JK, 1994, BLOOD, V84, P2523; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERBERT JM, 1992, BIOCHEM J, V284, P201, DOI 10.1042/bj2840201; HERBERT JM, 1991, J PHARMACOL EXP THER, V259, P44; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1991, BIOCHEM BIOPH RES CO, V180, P1318, DOI 10.1016/S0006-291X(05)81339-7; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU HL, 1992, J BIOL CHEM, V267, P20811; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SCHLONDORFF D, 1989, AM J PHYSIOL, V256, pF171, DOI 10.1152/ajprenal.1989.256.1.F171; SCHULAM PG, 1991, J IMMUNOL, V146, P1642; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SQUINTO SP, 1990, J MOL NEUROSCI, V2, P79, DOI 10.1007/BF02876914; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TAN X, 1993, FASEB J, V7, pA216; TRIPATHI YB, 1992, BIOCHEM J, V286, P27; VALONE FH, 1988, J IMMUNOL, V140, P2389; WEISSMAN D, 1993, P NATL ACAD SCI USA, V90, P2537, DOI 10.1073/pnas.90.6.2537; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	58	147	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14928	14934		10.1074/jbc.270.25.14928	http://dx.doi.org/10.1074/jbc.270.25.14928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797472	hybrid			2022-12-27	WOS:A1995RE66600016
J	KWAK, EL; LAROCHELLE, DA; BEAUMONT, C; TORTI, SV; TORTI, FM				KWAK, EL; LAROCHELLE, DA; BEAUMONT, C; TORTI, SV; TORTI, FM			ROLE FOR NF-KAPPA-B IN THE REGULATION OF FERRITIN-H BY TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HEAVY-CHAIN; MESSENGER-RNAS; PROMOTER; BINDING; IRON; EXPRESSION; ACTIVATION; GENE; INTERLEUKIN-1	Ferritin is a ubiquitously distributed iron-binding protein that plays a key role in cellular iron homeostasis. It is composed of two subunits, termed H (heavy or heart) and L (light or liver), In fibroblasts and other cells, the cytokine tumor necrosis factor-alpha (TNF) specifically induces synthesis of the ferritin H subunit. Using nuclear run-off assays, we demonstrate that this TNF-dependent increase in ferritin H is mediated by a selective increase in ferritin H transcription. Transfection of murine fibroblasts with chimeric genes containing the 5'-flanking region of murine ferritin H fused to the human growth hormone reporter gene reveals that the cia-acting element that mediates this response is located similar to 4.8 kilobases distal to the start site of transcription. Deletion analyses delimit the TNF-responsive region to a 40-nucleotide sequence located between nucleotides -4776 and -4736, which we term FER-2. Electrophoretic mobility shift assays and site-specific mutations indicate that this region contains two independent elements: one contains a sequence that binds a member of the NF-kappa B family of transcription factors, and a second contains a novel sequence that partially conforms to the NF-kappa B consensus sequence and may bind a different member of the NF-kappa B/Rel transcription factor family, Thus, effects of an inflammatory cytokine on ferritin are mediated by a family of transcription factors responsive to oxidative stress.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT CANC BIOL,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305; FAC XAVIER BICHAT,INSERM,U409,F-75018 PARIS,FRANCE	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLA G, 1992, J BIOL CHEM, V267, P18148; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; CERMAK J, 1993, CANCER RES, V53, P5308; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JAIN SK, 1985, J BIOL CHEM, V260, P1762; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MUKAIDA N, 1991, ADV EXP MED BIOL, V305, P31; MUROI M, 1993, J BIOL CHEM, V268, P19534; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; ROESER HP, 1980, IRON BIOCH MED, V2, P605; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TSUJI Y, 1992, CYTOKINES HLTH DISEA, P131; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6	39	163	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15285	15293		10.1074/jbc.270.25.15285	http://dx.doi.org/10.1074/jbc.270.25.15285			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797515	hybrid			2022-12-27	WOS:A1995RE66600066
J	KANG, D; NISHIDA, J; IYAMA, A; NAKABEPPU, Y; FURUICHI, M; FUJIWARA, T; SEKIGUCHI, M; TAKESHIGE, K				KANG, D; NISHIDA, J; IYAMA, A; NAKABEPPU, Y; FURUICHI, M; FUJIWARA, T; SEKIGUCHI, M; TAKESHIGE, K			INTRACELLULAR-LOCALIZATION OF 8-OXO-DGTPASE IN HUMAN-CELLS, WITH SPECIAL REFERENCE TO THE ROLE OF THE ENZYME IN MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT LIPID-PEROXIDATION; DNA-SYNTHESIS; DEGENERATIVE DISEASES; MUTAGENIC SUBSTRATE; OXIDATIVE DAMAGE; MUTT PROTEIN; PARTICLES; HYDROLYZES; EXPRESSION; UBIQUINONE	We examined the intracellular distribution of 8-oxo-dGTPase (8-oxo-7,8-dihydrodeoxyguanosine triphosphatase) encoded by the MTH1 gene, a human mutator homologue. The activity of 8-oxo-dGTPase mainly located in cytosolic and mitochondrial soluble fractions of Jurkat cells, a human T-cell leukemia line. Electron microscopic immunocytochemistry, using a specific antibody against MTH1 protein, showed localization of MTH1 protein in the mitochondrial matrix. Activity in the mitochondria accounted for about 4% of the total activity. The specific activity in the mitochondrial soluble fraction (8093 units/mg protein) was as high as that in the cytosolic fraction (8111 unit/mg protein). The 8-oxo-dGTPase activities in cytosolic and mitochondrial soluble fractions co-eluted with MTH1 protein by anion-exchange chromatography, and the molecular mass of the mitochondrial MTH1 protein was much the same as that of the cytosolic MTH1 protein (about 18 kDa). HeLa cells expressing MTH1 cDNA showed an increased cytoplasmic signal together with a weak signal in the nucleus in in situ immunostaining of MTH1 protein, and the overexpressed MTH1 protein was recovered from both cytosolic and mitochondrial fractions. Thus, the 8-oxo-dGTPase encoded by MTH1 gene is localized. in mitochondria and cytosol.	KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN; FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81401,JAPAN	Kyushu University; Fukuoka University	KANG, D (corresponding author), KYUSHU UNIV,SCH MED,DEPT BIOCHEM,3-1-1 MAIDASHI,FUKUOKA 812,JAPAN.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CHEN C, 1987, MOL CELL BIOL, V7, P751; DEMAY J, 1981, CELL BIOL INT REP, V5, P889; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; ETO Y, 1992, ARCH BIOCHEM BIOPHYS, V295, P101, DOI 10.1016/0003-9861(92)90493-G; Fleischer S, 1974, Methods Enzymol, V31, P6; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; GELLERA C, 1990, NEUROLOGY, V40, P495, DOI 10.1212/WNL.40.3_Part_1.495; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HRUSZKEWYCZ AM, 1990, MUTAT RES, V244, P123, DOI 10.1016/0165-7992(90)90060-W; ISHIBASHI T, 1994, J BIOL CHEM, V269, P7645; ISHIBASHI T, 1994, MUTAT RES-DNA REPAIR, V315, P199, DOI 10.1016/0921-8777(94)90032-9; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KASAI H, 1984, JPN J CANCER RES, V75, P1037; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; TAJIRI T, 1995, IN PRESS MUTAT RES; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TREFFERS HP, 1954, P NATL ACAD SCI USA, V32, P1064; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146	45	156	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14659	14665		10.1074/jbc.270.24.14659	http://dx.doi.org/10.1074/jbc.270.24.14659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782328	hybrid			2022-12-27	WOS:A1995RD45500064
J	YANG, AJ; KNAUER, M; BURDICK, DA; GLABE, C				YANG, AJ; KNAUER, M; BURDICK, DA; GLABE, C			INTRACELLULAR A-BETA-1-42 AGGREGATES STIMULATE THE ACCUMULATION OF STABLE, INSOLUBLE AMYLOIDOGENIC FRAGMENTS OF THE AMYLOID PRECURSOR PROTEIN IN TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; SENILE PLAQUES; PEPTIDE; BRAIN; IMMUNOREACTIVITY; IDENTIFICATION; NEUROTOXICITY; DERIVATIVES; LYSOSOMES	We have analyzed the effect of internalized amyloid beta-protein (A beta) 1-42 aggregates on the metabolism of the amyloid precursor protein (APP) in stably transfected 293 cells. The amount of potentially amyloidogenic fragments of APP immunoprecipitatedby anti-carboxyl-terminal APP and anti-A beta antibodies is dramatically enhanced by the treatment of the cells with A beta 1-42, which is resistant to degradation, but not A beta 1-28, which does not accumulate in cells. This accumulation of amyloidogenic carboxyl-terminal fragments is specific, since there is relatively little effect of A beta 1-42 on the amount of the nonamyloidogenic alpha-secretase carboxyl-terminal fragment. The amyloidogenic fragments accumulate in the same nonionic detergent-insoluble fraction of the cell that contains the internalized A beta 1-42. Western analysis indicates that a subset of the amyloidogenic fragments react with antibodies that recognize a conformation of A beta that is specifically associated with aggregated forms of A beta, suggesting that the adoption of this aggregation-related conformation may be an early event which precedes the final processing that produces A beta. Pulse-chase analysis of the [S-35]Met-labeled 16-kDa amyloidogenic fragment indicates that it is relatively stable in A beta 1-42-treated cells, with a half-life of approximately 50 h. This fragment is degraded with a half-life of 30 min in control cells treated with A beta 1-28. In contrast, the turnover of the nonamyloidogenic alpha-secretase product is not significantly altered by the presence of A beta 1-42, The continuous uptake of A beta 1-42 from the medium is not required for the stimulation of amyloidogenic fragment accumulation, suggesting that the presence of intracellular A beta 1-42 aggregates establishes a new pathway for APP catabolism in cells which leads to the long term stability of the fragments. If these amyloidogenic fragments of APP ultimately give rise to A beta, then the production of A beta may be an autocatalytic, ''runaway'' process in cells containing A beta 1-42 nuclei. It is conceivable that the accumulation of insoluble APP and amyloidogenic fragments of APP in response to A beta 1-42 aggregates may mimic the pathophysiology of dystrophic neurites, where the accumulation of intracellular APP and APP fragments has been documented by immunohistochemistry.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT CELL & DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHER C, 1989, NEUROBIOL AGING, V10, P125, DOI 10.1016/0197-4580(89)90021-3; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; COLE G, 1989, NEUROSCI LETT, V100, P340, DOI 10.1016/0304-3940(89)90710-6; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; COLE GM, 1989, NEUROCHEM RES, V10, P933; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRACKOWIAK J, 1994, J NEUROPATH EXP NEUR, V53, P637, DOI 10.1097/00005072-199411000-00011; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; FUKUCHI KI, 1993, ANN NY ACAD SCI, V695, P217, DOI 10.1111/j.1749-6632.1993.tb23055.x; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; ISHII T, 1989, NEUROPATH APPL NEURO, V15, P135, DOI 10.1111/j.1365-2990.1989.tb01216.x; IVERFELDT K, 1993, P NATL ACAD SCI USA, V90, P4146, DOI 10.1073/pnas.90.9.4146; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOTO A, 1994, BBA-MOL BASIS DIS, V1225, P304, DOI 10.1016/0925-4439(94)90011-6; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SUZUKI N, 1994, SCIENCE, V264, P336; WISNIEWSKI HM, 1995, NEUROSCI LETT, V183, P120, DOI 10.1016/0304-3940(94)11129-7; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YASUHARA O, 1994, NEUROSCI LETT, V171, P73, DOI 10.1016/0304-3940(94)90608-4	46	111	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14786	14792		10.1074/jbc.270.24.14786	http://dx.doi.org/10.1074/jbc.270.24.14786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782344	hybrid			2022-12-27	WOS:A1995RD45500082
J	JIANG, SW; EBERHARDT, NL				JIANG, SW; EBERHARDT, NL			INVOLVEMENT OF A PROTEIN DISTINCT FROM TRANSCRIPTION ENHANCER FACTOR-I (TEF-1) IN MEDIATING HUMAN CHORIONIC SOMATOMAMMOTROPIN GENE ENHANCER FUNCTION THROUGH THE GT-IIC ENHANSON IN CHORIOCARCINOMA AND COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL-LACTOGEN; FACTOR-I TEF-1; SV40 ENHANCER; COLLAGEN PROMOTER; BINDING; EVOLUTION; SEQUENCE; SPECIFICITY; ACTIVATION; EXPRESSION	Previous studies suggested that transcription enhancer factor-1 (TEF-1) was involved in mediating the human chorionic somatomammotropin (hCS) gene enhancer (CSEn) function (Jiang, S.-W., and Eberhardt, N. L. (1994) J. Biol. Chem. 269, 10384-10392). We now show that an unrelated protein (CSEF-1) found in BeWo and COS-1 cells binds to the GT-IIC enhanson in CSEn and is correlated with CSEn activity in these cells. TEF-1 and CSEF-1 were distinguished by differential migration as GT-IIC complexes, thermal stability, molecular mass, and cross-reactivity with chicken TEF-1 antibodies. TEF-1 and CSEF-1 bound to the GT-IIC and Sph-I/Sph-II enhansons with identical binding properties, and in vitro generated TEF-1 competed with CSEF-1 binding to the GT-IIC motif, suggesting that their actions might be mutually exclusive. Up- and down-regulation of TEF-1 levels by expression systems and antisense oligonucleotides demonstrated that TEF-1 inhibited the hCS promoter in a manner independent of the enhancer or a known TEF-1 DNA binding site. The data suggest that TEF-1 may provide a counter-regulatory stimulus to the actions of CSEF-1, which may be involved in mediating enhancer stimulatory activity.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK41206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FORSBERG M, 1991, EMBO J, V10, P2543, DOI 10.1002/j.1460-2075.1991.tb07794.x; HATAMOCHI A, 1993, FEBS LETT, V327, P325, DOI 10.1016/0014-5793(93)81014-Q; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LYTRAS A, 1994, MOL ENDOCRINOL, V8, P478, DOI 10.1210/me.8.4.478; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647, DOI 10.1093/nar/14.19.7647; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SNEDECOR GW, 1994, STATISTICAL METHODS, P116; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WALKER WH, 1990, J BIOL CHEM, V265, P12940; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13906	13915		10.1074/jbc.270.23.13906	http://dx.doi.org/10.1074/jbc.270.23.13906			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775450	hybrid			2022-12-27	WOS:A1995RC44800049
J	TAM, SSC; LEE, DHS; WANG, EY; MUNROE, DG; LAU, CY				TAM, SSC; LEE, DHS; WANG, EY; MUNROE, DG; LAU, CY			TEPOXALIN, A NOVEL DUAL INHIBITOR OF THE PROSTAGLANDIN-H SYNTHASE CYCLOOXYGENASE AND PEROXIDASE-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; PERFUSED-RAT-LIVER; ENDOPEROXIDE SYNTHASE; BIOSYNTHESIS; SYNTHETASE; HYDROPEROXIDE; MECHANISM; ASSAY; ACID	Prostaglandin-H synthase-1, the rate-limiting enzyme in prostaglandin synthesis, has both cyclooxygenase (CO) and peroxidase (PO) activities. While most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit only the CO activity, we describe an inhibitor, tepoxalin, that inhibits both the CO (IC50 = 0.1 mu M) and the PO (IC50 = 4 mu M) activities. Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme. Moreover, inhibition of the PO activity by tepoxalin is not dependent on the enzymatic turnover of the CO activity. The hydroxamic acid of tepoxalin is responsible for the PO inhibition since a carboxylic acid derivative of tepoxalin retains full CO but not PO inhibition. We postulated that the hydroxamic group might confer the ability to inhibit PO on conventional CO inhibitors. This idea was supported by the observation that naproxen hydroxamic acid, but not naproxen showed PO inhibition. Furthermore, tepoxalin's carboxylic acid analogue and naproxen each competitively relieved PO inhibition by their respective hydroxamic acids. The intracellular activity of PO as monitored by the release of reactive oxygen species was also inhibited by both tepoxalin and naproxen hydroxamic acid. These observations suggest a strategy for design of novel compounds to inhibit prostaglandin synthase PO. The therapeutic implications of these novel PO inhibitors are discussed.	RW JOHNSON PHARMACEUT RES INST,DISCOVERY RES,DON MILLS,ON M3C 1L9,CANADA									AKERBOOM TPM, 1982, J BIOL CHEM, V257, P4248; ARGENTIERI DC, 1994, J PHARMACOL EXP THER, V271, P1399; BASS DA, 1983, J IMMUNOL, V130, P1910; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BURK RF, 1978, J BIOL CHEM, V253, P43; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHARKRABORTI S, 1993, BIOCHEM J, V292, P585; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1981, J BIOL CHEM, V256, P375; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Egan R W, 1980, Adv Prostaglandin Thromboxane Res, V6, P153; FERRO MP, 1992, Patent No. 5164381; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1989, ARCH BIOCHEM BIOPHYS, V193, P340; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMSEN H, 1977, J BIOL CHEM, V252, P1752; KASMI SMI, 1995, J CELLBIOCH, V57, P299; KUEHL FA, 1977, NATURE, V265, P170, DOI 10.1038/265170a0; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1976, ADV PROSTAG THROMB R, V1, P7; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1982, J BIOL CHEM, V257, P6957; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PLE P, 1989, J BIOL CHEM, V264, P13983; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROBAK J, 1978, BIOCHEM PHARMACOL, V27, P393, DOI 10.1016/0006-2952(78)90367-2; ROBISON TW, 1990, PROSTAGLANDINS, V40, P13, DOI 10.1016/0090-6980(90)90053-X; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SMITH RC, 1987, FREE RADICAL BIO MED, V3, P251, DOI 10.1016/S0891-5849(87)80032-1; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6	52	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13948	13955		10.1074/jbc.270.23.13948	http://dx.doi.org/10.1074/jbc.270.23.13948			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775455	hybrid			2022-12-27	WOS:A1995RC44800054
J	WENG, HQ; CHOI, SY; FALLER, DV				WENG, HQ; CHOI, SY; FALLER, DV			THE MOLONEY LEUKEMIA RETROVIRAL LONG TERMINAL REPEAT TRANS-ACTIVATES AP-1-INDUCIBLE GENES AND AP-1 TRANSCRIPTION FACTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; JUN DNA-BINDING; MURINE RETROVIRUS; DISEASE SPECIFICITY; SIGNAL TRANSDUCTION; ENHANCER ELEMENT; MAMMALIAN-CELLS; PHOSPHORYLATION; VIRUS; FOS	Moloney murine leukemia virus (Mo-MuLV) is a thymotropic and leukemogenic retrovirus which causes T lymphomas. The long terminal repeat (LTR) of Mo-MuLV affects the regulation of a number of cellular genes, including collagenase IV, monocyte chemoattractant protein-1, and c-jun genes, all of which contain 12-O-tetradecanoylphorbol-13-acetate-responsive element consensus sites within their promoters. We report here that Mo-MuLV stimulates the collagenase IV gene through transcription factor AP-1, and that the expression of a subgenomic portion of Mo-MuLV LTR alone is sufficient for this effect. Transient or stable expression of the viral LTR increases cellular AP-1 DNA binding activity. The collagenase IV 12-O-tetradecanoylphorbol-13-acetate-responsive element consensus sequence was shown to be required for this trans-activation. Deletions or mutations of this consensus site which abolished AP-1 binding also abolished trans activation by the LTR. Transient or stable transfection of the viral LTR into cells stimulated c-jun gene expression, suggesting one mechanism whereby the viral LTR may induce cellular AP-1 activity. Thus, the Mo-MuLV LTR, through activation of the transcription factor AP-1, is capable of regulating cellular gene expression, including the induction of proto-oncogenes. This activity may be relevant to the mechanisms whereby retroviruses which do not contain oncogenes induce neoplasia.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,MED LAB,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University					NCI NIH HHS [R01-CA50459, R01-CA65420] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459, R01CA065420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRIGHTMAN BK, 1991, P NATL ACAD SCI USA, V88, P2264, DOI 10.1073/pnas.88.6.2264; CHOI SY, 1994, J BIOL CHEM, V269, P19691; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLYER DC, 1985, J IMMUNOL, V135, P2287; FLYER DC, 1983, NATURE, V305, P315; FRAME MC, 1991, ONCOGENE, V6, P205; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKAFLIPOT I, 1992, J VIROL, V66, P7201, DOI 10.1128/JVI.66.12.7201-7210.1992; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HOLLAND CA, 1985, J VIROL, V53, P158, DOI 10.1128/JVI.53.1.158-165.1985; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOKA P, 1991, J IMMUNOL, V146, P2417; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MUNDSCHAU LJ, 1991, MOL CELL BIOL, V11, P3148, DOI 10.1128/MCB.11.6.3148; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPAVASSILIOU AG, 1992, P NATL ACAD SCI USA, V89, P11562, DOI 10.1073/pnas.89.23.11562; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WILSON LD, 1987, MOL CELL BIOL, V7, P2406, DOI 10.1128/MCB.7.7.2406; YAMITHEZI A, 1994, ONCOGENE, V9, P1065	48	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13637	13644		10.1074/jbc.270.23.13637	http://dx.doi.org/10.1074/jbc.270.23.13637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775415	hybrid			2022-12-27	WOS:A1995RC44800011
J	YAMANO, Y; OHYAMA, K; KIKYO, M; SANO, T; NAKAGOMI, Y; INOUE, Y; NAKAMURA, N; MORISHIMA, I; GUO, DF; HAMAKUBO, T; INAGAMI, T				YAMANO, Y; OHYAMA, K; KIKYO, M; SANO, T; NAKAGOMI, Y; INOUE, Y; NAKAMURA, N; MORISHIMA, I; GUO, DF; HAMAKUBO, T; INAGAMI, T			MUTAGENESIS AND THE MOLECULAR MODELING OF THE RAT ANGIOTENSIN-II RECEPTOR (AT(1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TYPE-1 RECEPTOR; EXPRESSION CLONING; LIGAND-BINDING; SMOOTH-MUSCLE; CDNA; PROTEIN; IDENTIFICATION; DISTINCT; SUBTYPE	The molecular interaction involved in the ligand binding of the rat angiotensin II receptor (AT(1A)) was studied by site-directed mutagenesis and receptor model building. The three-dimensional structure of AT(1A) was constructed on the basis of a multiple amino acid sequence alignment of seven transmembrane domain receptors and angiotensin II receptors and after the beta 2 adrenergic receptor model built on the template of the bacteriorhodopsin structure. These data indicated that there are conserved residues that are actively involved in the receptor-ligand interaction. Eleven conserved residues in AT(1), His(166), Arg(167), Glu(173), His(183), Glu(185), Lys(199), Trp(253), His(256), Phe(259), Thr(260), and Asp(263), were targeted individually for site-directed mutation to Ala. Using COS-7 cells transiently expressing these mutated receptors, we found that the binding of angiotensin II was not affected in three of the mutations in the second extracellular loop, whereas the Ligand binding affinity was greatly reduced in mutants Lys(199) --> Ala, Trp(253) --> Ala, Phe(259) --> Ala, Asp(263), Ala, and Arg(167), Ala. These amino acid residues appeared to provide binding sites for Ang II. The molecular modeling provided useful structural information for the peptide hormone receptor AT(1A). Binding of EXP985, a nonpeptide angiotensin II antagonist, was found to be involved with Arg(167) but not Lys(199).	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; TOTTORI UNIV,FAC AGR,METAB BIOCHEM LA,TOTTORI 680,JAPAN; YAMANASKI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; GREEN CROSS CO,HIRAKATA,OSAKA 573,JAPAN	Vanderbilt University; Tottori University; University of Yamanashi; Green Cross Corporation					NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1993, MOL PHARMACOL, V44, P277; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1991, HYPERTENSION, V17, P720, DOI 10.1161/01.HYP.17.5.720; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; BURNS KD, 1993, AM J PHYSIOL, V269, pF645; BURNS L, 1994, FEBS LETT, V343, P146, DOI 10.1016/0014-5793(94)80307-2; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P1260, DOI 10.1006/bbrc.1993.1552; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HUMBLET C, 1992, ANNU REP MED CHEM, V27, P291; HUSS KM, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; INAGAMI T, 1993, ARZNEIMITTEL-FORSCH, V43-1, P226; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; JI H, 1993, BIOCHEM BIOPH RES CO, V194, P756, DOI 10.1006/bbrc.1993.1886; JI H, 1994, J BIOL CHEM, V269, P16533; JOESTEN MD, 1974, HYDROGEN BONDING; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KHOLA MC, 1993, J MED CHEM, V16, P829; KHOSLA MC, 1992, J MED CHEM, V15, P792; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIE J, 1994, J BIOL CHEM, V299, P20815; MARSHALL GR, 1970, P NATL ACAD SCI USA, V67, P1624, DOI 10.1073/pnas.67.3.1624; MAUZY CA, 1992, BIOCHEM BIOPH RES CO, V186, P277, DOI 10.1016/S0006-291X(05)80804-6; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOORE GJ, 1991, COMPR MED CHEM, V3, P961; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NIKIFOROVICH GV, 1993, BIOCHEM BIOPH RES CO, V195, P222, DOI 10.1006/bbrc.1993.2033; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; OLIVEIRA L, 1993, J COMPUT AID MOL DES, V7, P649, DOI 10.1007/BF00125323; PANDEY KN, 1988, J BIOL CHEM, V263, P13406; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PIERSON ME, 1992, PEPTIDE RES, V5, P102; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SPEAR KL, 1990, J MED CHEM, V33, P1935, DOI 10.1021/jm00169a019; STEINBERG MI, 1993, CARDIOVASC DRUG REV, V11, P312, DOI 10.1111/j.1527-3466.1993.tb00194.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SUGG EE, 1990, PEPTIDES CHEM STRUCT, P305; TAKAYANAGI R, 1992, BIOCHEM BIOPH RES CO, V183, P910, DOI 10.1016/0006-291X(92)90570-B; TEETER MM, 1994, J MED CHEM, V37, P2874, DOI 10.1021/jm00044a008; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YOSHIDA H, 1992, BIOCHEM BIOPH RES CO, V86, P1942	72	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14024	14030		10.1074/jbc.270.23.14024	http://dx.doi.org/10.1074/jbc.270.23.14024			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775462	hybrid			2022-12-27	WOS:A1995RC44800064
J	HENSON, JW; SCHNITKER, BL; LEE, TS; MCALLISTER, J				HENSON, JW; SCHNITKER, BL; LEE, TS; MCALLISTER, J			CELL-SPECIFIC ACTIVATION OF THE GLIAL-SPECIFIC JC VIRUS EARLY PROMOTER BY LARGE T-ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BRAIN; TRANSCRIPTIONAL ACTIVATION; TATA; EXPRESSION; ENHANCER; MULTIPLE; ELEMENTS; BINDS	JC virus causes the human demyelinating disease progressive multifocal leukoencephalopathy by selective infection of glial cells. This cell specificity results from glial-specific expression of viral early genes (large and small T antigens). Analysis of transcriptional regulation by the MH1 JC virus early promoter demonstrates that glial specificity is directed by the basal promoter. Because T antigen regulates the basal region of several viral and cellular promoters, we investigated whether it controls the JC virus basal promoter in a glial-specific manner. A JC virus T antigen expression plasmid generated a 95-kDa protein which exhibited nuclear localization and physical association with p53. T antigen repressed the JC virus and SV40 early promoters 4- to 5-fold in glioma cells. Conversely, T antigen induced 100- to 200-fold activation of the JC virus early promoter in nonglial cells, whereas the SV40 promoter was repressed. Activation required the JC virus TATA box sequence and a pentanucleotide repeat immediately upstream of the TATA box, but was independent of the upstream enhancer region. These data demonstrate that the JC virus basal promoter is responsible for glial-specific gene expression and suggest a mechanism for this regulation.			HENSON, JW (corresponding author), MASSACHUSETTS GEN HOSP EAST,MOLEC NEUROONCOL LAB,149 13TH ST,BOSTON,MA 02129, USA.			, Taek Seung/0000-0002-3943-1145	NINDS NIH HHS [NS 01605] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001605] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEGGS AH, 1988, P NATL ACAD SCI USA, V85, P7632, DOI 10.1073/pnas.85.20.7632; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GILINGER G, 1993, J VIROL, V67, P6682, DOI 10.1128/JVI.67.11.6682-6688.1993; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HENSON J, 1992, ANN NEUROL, V32, P72, DOI 10.1002/ana.410320112; HENSON JW, 1994, J BIOL CHEM, V269, P1046; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOYAMA Y, 1981, ANN NEUROL, V11, P396; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KUMAR G, 1994, VIROLOGY, V203, P116, DOI 10.1006/viro.1994.1461; PADGETT BL, 1971, LANCET, V1, P1257; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; RICE PW, 1993, J VIROL, V76, P6689; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SHARMA AK, 1991, FEBS LETT, V281, P272, DOI 10.1016/0014-5793(91)80409-V; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TAYLOR ICA, 1989, J BIOL CHEM, V264, P16160; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13240	13245		10.1074/jbc.270.22.13240	http://dx.doi.org/10.1074/jbc.270.22.13240			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768922	hybrid			2022-12-27	WOS:A1995RB43900046
J	KNUDSEN, BS; FELLER, SM; HANAFUSA, H				KNUDSEN, BS; FELLER, SM; HANAFUSA, H			4 PROLINE-RICH SEQUENCES OF THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR C3G BIND WITH UNIQUE SPECIFICITY TO THE FIRST SRC HOMOLOGY-3 DOMAIN OF CRK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; INSULIN-RECEPTOR SUBSTRATE-1; EPIDERMAL GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; SH3 DOMAINS; V-CRK; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; ONCOGENE PRODUCT; TYROSINE KINASE	The widely expressed cellular Crk protein has the domain structure SH2-SH3-SH3. We have previously demonstrated that the more N-terminal SH3 domain of Crk (CrkSH3(N)) specifically binds several cytoplasmic proteins. A cDNA encoding one of these proteins was isolated and found to have two different splice forms. The sequence is virtually identical to C3G, a guanine-nucleotide exchange factor. The center region of the 145-155-kDa protein contains four similar proline-rich sequences which are capable of binding individually to the SH3(N) domains of c-Crk and v-Crk. Comparison of these sequences in C3G to proline-rich sequences in other Crk-binding proteins suggests that positively charged amino acids following the prolines play an important role in the binding to the CrkSH3(N) domain. The endogenous C3G could be coprecipitated with Crk from cell lysates of cells expressing high levels of c-Crk or v-Crk, suggesting high binding affinity and a possible interaction in vivo. Unlike many other SH3-binding proteins which interact with multiple SH3 domains, C3G from cell lysates binds preferentially to the CrkSH3(N) domain. This unique binding specificity supports the idea that C3G plays an important role in Crk signaling pathways.	ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356, CA09673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHOU M, 1993, THESIS ROCKEFELLER U; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METHODS ENZ; FINAN P, 1994, J BIOL CHEM, V269, P13752; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYANJ, 1993, CURR OPIN STRUC BIOL, V3, P828; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIM WA, 1994, STRUCT BIOL, V1, P221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, J BIOL CHEM, V265, P12000; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; REICHMAN C, 1993, THESIS ROCKEFELLER U; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOBE K, 1993, J BIOL CHEM, V268, P11167; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	194	201	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32781	32787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806500				2022-12-27	WOS:A1994QA63800013
J	MCGEEHAN, GM; BICKETT, DM; GREEN, M; KASSEL, D; WISEMAN, JS; BERMAN, J				MCGEEHAN, GM; BICKETT, DM; GREEN, M; KASSEL, D; WISEMAN, JS; BERMAN, J			CHARACTERIZATION OF THE PEPTIDE SUBSTRATE SPECIFICITIES OF INTERSTITIAL COLLAGENASE AND 92-KDA GELATINASE - IMPLICATIONS FOR SUBSTRATE OPTIMIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; FIBROBLAST COLLAGENASE; ENZYME SPECIFICITY; EXPRESSION; SYNOVIUM; STROMELYSIN; INHIBITOR; PROTEASE; KINETICS; SITE	The peptide substrate specificities of two matrix metalloproteinases (MMPs), interstitial collagenase (MMP-1), and 92-kDa gelatinase (MMP-9), have been examined, Starting with the parent substrate, Dnp-Pro-Leu-Gly similar to Leu-Trp-Ala-D-Arg-NH2, four separate substrate mixtures were synthesized at subsites P-2(Leu) through P-2'(Trp), These mixtures contained either naturally occurring L-amino acids, D-amino acids, or either of two distinct sets of miscellaneous amino acids, Combined, these mixtures gave 88 unique substitutions at each position and, over the four subsites, represented 352 potential substrates, Optimal substrates were identified using a combined high performance liquid chromatography/mass spectrometry analysis as previously reported, The results gave an extended profile of the substrate specificities for both MMP-1 and MMP-9 at subsites P-2(Leu) through P-2'(Trp), Using the data obtained from the mapping, a new peptide substrate, Dnp-Pro-Cha-Abu similar to Smc-His-Ala-D-Arg-NH2 (where Dnp is 2,4-dinitrophenyl, Cha is cyclohexylalanine, Abu is cr aminobutyric acid, and Smc is S-methylcysteine) was designed and characterized, This peptide showed a 36-fold improvement in turnover (k(cat)/K-m) versus the parent substrate by interstitial collagenase, In addition, some collagenase subsite specificities described here were found to be different from those previously reported, Experimental data show that the observed selectivity is dependent on the original peptide template employed, which has broader implications for substrate specificity studies.			MCGEEHAN, GM (corresponding author), GLAXO INC, RES INST, DEPT BIOCHEM, 5 MOORE DR, RES TRIANGLE PK, NC 27709 USA.							ABELES RH, 1960, J BIOL CHEM, V235, P853; ABELES RH, 1960, J BIOL CHEM, V235, P6; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; DICKENS J, 1986, Patent No. 4599361; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4344, DOI 10.1021/bi00067a025; STACK MS, 1989, J BIOL CHEM, V264, P4277; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	22	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32814	32820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806505				2022-12-27	WOS:A1994QA63800018
J	BAJORATH, J; ARUFFO, A				BAJORATH, J; ARUFFO, A			MOLECULAR-MODEL OF THE EXTRACELLULAR LECTIN-LIKE DOMAIN IN CD69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY ACTIVATION ANTIGEN; T-CELL ACTIVATION; LYMPHOCYTE-ACTIVATION; HOMOLOGOUS PROTEINS; P-SELECTIN; EXPRESSION; RECOGNITION; SEQUENCES; AIM/CD69; CRITERIA	CD69 is described as a T cell activation antigen, but the ligand and physiological function of CD69 are currently unknown. The sequence of the extracellular domain of CD69 shows some similarity with that of calcium-dependent (C-type) lectins, Using comparative computer modeling and inverse folding calculations, we have generated and analyzed a detailed three-dimensional model of the extracellular domain of CD69 based on the crystal structure of the mannose binding protein. The sequence of CD69 appears to be highly compatible with the C-type lectin fold, and assessment of the model using inverse folding calculations suggests its overall correctness. Compared with mannose binding protein and the selectins, CD69 displays significant deletions in loop regions. In addition, residues that form conserved calcium binding sites found in the C-type lectin family are not conserved in CD69. This suggests the presence of structural features in CD69 that depart from some of the conserved motifs seen in two crystal structures of C-type lectins. The CD69 model shows cavity-shaped hydrophobic regions surrounded by charged residues. One of these cavities is proximal to a potential low affinity calcium binding site and may be implicated in specific interactions with ligands.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb			Bajorath, Jürgen/F-7493-2014					BAJORATH J, 1993, PROTEIN SCI, V2, P1798, DOI 10.1002/pro.5560021103; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAJORATH J, 1992, IMMUNOMETHODS, V1, P137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEBER T, 1992, J INVEST DERMATOL, V98, P771, DOI 10.1111/1523-1747.ep12499948; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; DAMBROSIO D, 1993, EUR J IMMUNOL, V23, P2993, DOI 10.1002/eji.1830231140; DELIA D, 1988, IMMUNOLOGY, V64, P593; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FETROW JS, 1993, BIO-TECHNOL, V11, P479, DOI 10.1038/nbt0493-479; GAVIOLI R, 1992, CELL IMMUNOL, V142, P186, DOI 10.1016/0008-8749(92)90279-X; GEROSA F, 1991, MOL IMMUNOL, V28, P159, DOI 10.1016/0161-5890(91)90100-X; GODZIK A, 1993, J COMPUT AID MOL DES, V7, P397, DOI 10.1007/BF02337559; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREER J, 1991, METHOD ENZYMOL, V202, P239; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; NOVOTNY J, 1988, PROTEINS, V4, P19, DOI 10.1002/prot.340040105; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; SCHWARTING R, 1989, LEUCOCYTE TYPING, V4, P428; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TUGORES A, 1992, J IMMUNOL, V148, P2300; WEIS WI, 1994, STRUCTURE, V2, P147, DOI 10.1016/S0969-2126(00)00016-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WODAK SJ, 1993, CURR OPIN STRUC BIOL, V3, P247, DOI 10.1016/S0959-440X(05)80160-5; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	46	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32457	32463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798246				2022-12-27	WOS:A1994PX30400067
J	PETERSEN, CCH; BERRIDGE, MJ				PETERSEN, CCH; BERRIDGE, MJ			THE REGULATION OF CAPACITATIVE CALCIUM-ENTRY BY CALCIUM AND PROTEIN-KINASE-C IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PAROTID ACINAR-CELLS; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; LAEVIS OOCYTES; TUMOR PROMOTER; MAST-CELLS; THAPSIGARGIN; INFLUX; ACTIVATION	Agonists linked to the phosphoinositide signaling pathway evoke capacitative calcium entry in Xenopus oocytes. This entry pathway can also be activated by injection of inositol 2,4,5-trisphosphate, application of thapsigargin, or incubation in calcium-free medium. A variety of protocols revealed highly nonlinear behavior of the calcium entry in thapsigargin-treated oocytes suggestive of positive and negative feedback by calcium at the level of its own entry. These feedback mechanisms may account for the highly damped calcium oscillations we observed in thapsigargin-treated oocytes. Low level activation of protein kinase C potentiated calcium influx in thapsigargin-treated oocytes, apparently by blocking the inactivation of the calcium influx. Higher levels of protein kinase C activity inhibited capacitative calcium entry.			PETERSEN, CCH (corresponding author), UNIV CAMBRIDGE,BABRAHAM INST,DEPT ZOOL,MOLEC SIGNALLING LAB,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Petersen, Carl/M-5123-2017	Petersen, Carl/0000-0003-3344-4495	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IINO M, 1990, J GEN PHYSIOL, V101, P67; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MONTERO M, 1993, J BIOL CHEM, V268, P13055; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; PARKER I, 1992, AM J PHYSIOL, V263, pC154, DOI 10.1152/ajpcell.1992.263.1.C154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PETERSEN CCH, 1994, CELL CALCIUM, V16, P391, DOI 10.1016/0143-4160(94)90032-9; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKEMURA H, 1989, BIOCHEM J, V259, P125; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	38	144	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32246	32253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798225				2022-12-27	WOS:A1994PX30400038
J	AUSTIN, CA; MARSH, KL; WASSERMAN, RA; WILLMORE, E; SAYER, PJ; WANG, JC; FISHER, LM				AUSTIN, CA; MARSH, KL; WASSERMAN, RA; WILLMORE, E; SAYER, PJ; WANG, JC; FISHER, LM			EXPRESSION, DOMAIN-STRUCTURE, AND ENZYMATIC-PROPERTIES OF AN ACTIVE RECOMBINANT HUMAN DNA TOPOISOMERASE II-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NIH-3T3 CELLS; 2 FORMS; YEAST; GENE; PROTEIN; SEQUENCE; PURIFICATION; LOCALIZATION; HOMOLOGY	Human cells express two genetically distinct isoforms of DNA topoisomerase II, alpha and beta, which catalyze ATP-dependent DNA strand passage and are an important antitumor drug target, Here we report for the first time the successful overexpression of human topoisomerase II beta in yeast by cloning a topoisomerase II beta cDNA in a yeast shuttle vector under the control of a galactose inducible promoter, Recombinant human topoisomerase II beta (residues 46-1621 fused to the first 5 residues of yeast topoisomerase II) was purified to homogeneity, yielding an enzymatically active polypeptide in sufficient quantity to allow analysis of its domain structure and comparison with that of recombinant human topoisomerase II alpha. Partial digestion of beta with either trypsin or protease SV8 generated fragments of approximately 130, 90, 62, and 45-50 kDa, arising from cleavage at three limited and discrete regions of the protein (A, B, and C) indicating the presence of at least four structural domains, Recombinant human topoisomerase II alpha and beta induced DNA breakage which was promoted by a variety of agents, Isoform differences in drug-induced DNA breakage were observed, These studies of human topoisomerase II beta in concert with alpha should aid the determination of their individual roles in cancer chemotherapy and should facilitate the design, targeting, and testing of cytotoxic antitumor agents.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,MOLEC GENET GRP,LONDON SW17 0RE,ENGLAND	Harvard University; St Georges University London	AUSTIN, CA (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Willmore, Elaine/B-4350-2009	Willmore, Elaine/0000-0002-4762-094X; West, Katherine/0000-0002-5994-8969; Fisher, Larry Mark/0000-0002-2172-3369; Austin, Caroline/0000-0002-1921-5947				AUSTIN CA, 1990, BIOCHEM BIOPH RES CO, V170, P763, DOI 10.1016/0006-291X(90)92156-T; AUSTIN CA, 1990, FEBS LETT, V266, P115, DOI 10.1016/0014-5793(90)81520-X; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PETROV P, 1993, EXP CELL RES, V204, P73, DOI 10.1006/excr.1993.1010; PFLUGFELDER MT, 1988, P NATL ACAD SCI USA, V85, P7177; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TAN KB, 1992, CANCER RES, V52, P231; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006	40	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15739	15746		10.1074/jbc.270.26.15739	http://dx.doi.org/10.1074/jbc.270.26.15739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797575	hybrid			2022-12-27	WOS:A1995RG53800048
J	BERG, DT; CALNEK, DS; GRINNELL, BW				BERG, DT; CALNEK, DS; GRINNELL, BW			THE HUMAN APOLIPOPROTEIN-E GENE IS NEGATIVELY REGULATED IN HUMAN LIVER HEPG2 CELLS BY THE TRANSCRIPTION FACTOR BEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							E MESSENGER-RNA; TRANSGENIC MICE; A-I; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; EXPRESSION; PROTEIN; ELEMENT; LINES	Apolipoprotein E (apoE) is a major constituent of plasma lipoprotein that functions in lipid transport and redistribution (reverse cholesterol transport) and probably plays an important role in inhibiting the development and/or progression of atherosclerosis, While cis-acting regions involved in basal and tissue-specific control of the apoE gene have been identified by promoter mapping studies, much less is known about factors that regulate the gene. In this study, we demonstrate that the region between -94 and -84 upstream of transcriptional start site of the human apoE gene contains a binding site for the transcriptional repressor factor BEF-1, a tyrosine-phosphorylated nuclear protein that was first identified in HeLa cells, Using gel retar dation assays, we show that HeLa cell derived BEF-1 binds the apoE BEF-1 homology, and this binding can be competed with the prototype BEF-1 sequence, but not by a mutated sequence, Furthermore, we demonstrate that the apoE- producing human liver HepG2 cell produces significant levels of BEF-1, which could bind to both the prototype BEF-1 sequence and the apoE homology, and be competed equivalently with cold BEF-1 or apoE homology, To determine if BEF-1 affected the expression of apoE, we performed competition experiments using plasmids containing the intact or mutated BEF-1 homology, The introduction of the intact BEF I site into HepG2 cells resulted in an induction of apoE mRNA, whereas control and mutated BEF-1-containing plasmids had no significant effect, We also found that increasing the level of nuclear BEF-1 by treatment of cells with orthovanadate resulted in a reduction in the level of apoE mRNA Overall, our data suggest that the endogenous apoE gene in the human HepG2 cell hue is repressed by the trans-acting influence of nuclear factor BEF-1.	ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES,INDIANAPOLIS,IN 46285	Eli Lilly								AZROLAN N, 1990, J LIPID RES, V31, P1141; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS HK, 1985, J BIOL CHEM, V260, P6240; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIO S, 1994, J LIPID RES, V35, P408; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PAIK YK, 1988, J BIOL CHEM, V264, P13340; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; ROSES AD, 1994, NEUROPSYCHOPHARMACOL, V10, P5; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SIMONET WS, 1985, J BIOL CHEM, V266, P8651; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WEISGRABER KH, 1990, ANN NY ACAD SCI, V598, P37, DOI 10.1111/j.1749-6632.1990.tb42274.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15447	15450		10.1074/jbc.270.26.15447	http://dx.doi.org/10.1074/jbc.270.26.15447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797534	hybrid			2022-12-27	WOS:A1995RG53800002
J	MALABA, L; SMELAND, S; SENOO, H; NORUM, KR; BERG, T; BLOMHOFF, R; KINDBERG, GM				MALABA, L; SMELAND, S; SENOO, H; NORUM, KR; BERG, T; BLOMHOFF, R; KINDBERG, GM			RETINOL-BINDING PROTEIN AND ASIALO-OROSOMUCOID ARE TAKEN UP BY DIFFERENT PATHWAYS IN LIVER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-RECEPTOR; STELLATE CELLS; RAT-LIVER; VITAMIN-A; TRANSPORT; ENDOCYTOSIS; CAVEOLAE; SURFACE; MOLECULES; COMPONENT	The intracellular transport and degradation of in vivo endocytosed retinol-binding protein was compared with that of asialo-orosomucoid, a marker for receptor-mediated endocytosis through coated pits, The transport pathways were studied in rat liver cells by means of subcellular fractionation in Nycodenz and sucrose density gradients and by immunoelectron microscopy, Retinol-binding protein and asialo orosomucoid were labeled by covalent attachment of radioiodinated tyramine cellobiose, an adduct which is incapable of crossing cellular membranes and thus provides a marker for the organelles where the protein has been taken up and degraded. The data obtained from subcellular fractionation studies, as well as from immunoelectron microscopy, showed that retinol-binding protein and asialo-orosomucoid were initially localized in different endocytic vesicles, Retinol-binding protein co-localized in density gradients with markers for potocytosis, an alternative endocytic pathway which uses internalization through caveolae instead of clathrin-coated pits. Later, retinol-binding protein and asialo-orosomucoid comigrated in the gradients and they were also observed in the same larger vesicles by immunoelectron microscopy. These data suggest that retinol-binding protein is taken up by Liver cells by potocytosis and that a fraction of the retinol-binding protein is later transferred to larger vesicles located deeper in the cytoplasm where degradation takes place.	UNIV OSLO, SCH MED, INST NUTR RES, N-0316 OSLO, NORWAY	University of Oslo								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P46; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BLOMHOFF R, 1990, METHOD ENZYMOL, V190, P58; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EL-AASER A A, 1969, Histochemical Journal, V1, P417, DOI 10.1007/BF01086983; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GENZE HJ, 1987, J CELL BIOL, V104, P1715; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KINDBERG GM, 1987, CELLS MEMBRANES DISE, P315; MALABA L, 1993, BIOCHEM J, V291, P187, DOI 10.1042/bj2910187; MCGUIRE BW, 1981, ENDOCRINOLOGY, V108, P658, DOI 10.1210/endo-108-2-658; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; RICKWOOD D, 1983, PROPERTIES IODINATED, P1; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SENOO H, 1990, J LIPID RES, V31, P1229; SENOO H, 1993, P NATL ACAD SCI USA, V90, P3616, DOI 10.1073/pnas.90.8.3616; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STANG E, 1988, J MICROSC-OXFORD, V149, P77, DOI 10.1111/j.1365-2818.1988.tb04564.x; Tokuyasu K. T., 1984, IMMUNOLABELLING ELEC, P71; TOLLESHAUG H, 1980, H-S Z PHYSIOL CHEM, V361, P1155, DOI 10.1515/bchm2.1980.361.2.1155; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WEBSTER P, 1993, J MICROSC-OXFORD, V169, P85, DOI 10.1111/j.1365-2818.1993.tb03281.x; WIDNELL CC, 1982, CELL, V28, P61, DOI 10.1016/0092-8674(82)90375-0; WISSE E, 1970, J ULTRA MOL STRUCT R, V31, P125, DOI 10.1016/S0022-5320(70)90150-4	43	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15686	15692		10.1074/jbc.270.26.15686	http://dx.doi.org/10.1074/jbc.270.26.15686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797569	hybrid			2022-12-27	WOS:A1995RG53800040
J	TINKER, RL; SANDERS, GM; SEVERINOV, K; KASSAVETIS, GA; GEIDUSCHEK, EP				TINKER, RL; SANDERS, GM; SEVERINOV, K; KASSAVETIS, GA; GEIDUSCHEK, EP			THE COOH-TERMINAL DOMAIN OF THE RNA-POLYMERASE ALPHA-SUBUNIT IN TRANSCRIPTIONAL ENHANCEMENT AND DEACTIVATION AT THE BACTERIOPHAGE-T4 LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL MAP; DNA; ACTIVATION; PROTEIN; BINDING; REGION; COMMUNICATION; INHIBITION; APPARATUS	Many activator proteins generate their positive control of transcription through interactions with the COOH-terminal domain of the Escherichia coli RNA polymerase alpha subunit. We have examined the participation of this alpha-domain in transcriptional enhancement and suppression at bacteriophage T4 late promoters, Enhancement is generated by the T4 gene 45 protein, which is the DNA-tracking processivity factor of viral DNA replication; suppression of unenhanced transcription is generated by the RNA polymerase-binding coactivator T4 gene 33 protein. Enhanced and unenhanced transcription by RNA polymerase reconstituted with intact and truncated alpha subunits and by RNA polymerase containing ADP-ribosylated alpha has been compared; the internal structures of transcription complexes formed with these RNA polymerases have also been analyzed by footprinting and photocross-linking. Comparison of these structural and functional analyses suggests that enhancement of T4 late transcription by gp45 is not compatible with any significant role of the COOH-terminal domain of the RNA polymerase core a subunit in transcriptional initiation. Suppression of unenhanced T4 late transcription by the gene 33 protein also does not require the COOH-terminal domain of alpha.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of California System; University of California San Diego; Rockefeller University	TINKER, RL (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92093, USA.		Severinov, Konstantin/C-8545-2016					BARTHOLOMEW B, 1995, IN PRESS METHODS ENZ, V262; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COPPO A, 1975, J MOL BIOL, V96, P601, DOI 10.1016/0022-2836(75)90141-2; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1995, IN PRESS CURR OPIN G; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; EPSTEIN RH, 1964, COLD SPRING HARB SYM, V28, P375; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; KARAM J, 1994, MOL BIOL BACTERIOP T, V4; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; MAILHAMMER R, 1975, P NATL ACAD SCI USA, V72, P4828; Maniatis T., 1982, MOL CLONING; Mathews C.K., 1983, BACTERIOPHAGE T; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P3956, DOI 10.1128/JB.176.13.3956-3965.1994; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; STEVENS A, 1977, BIOCHIM BIOPHYS ACTA, V475, P193, DOI 10.1016/0005-2787(77)90355-0; STITT B, 1994, MOL BIOL BACTERIOP T, V4, P142; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; WILKENS K, 1994, MOL BIOL BACTERIOP T, V4, P132; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	42	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15899	15907		10.1074/jbc.270.26.15899	http://dx.doi.org/10.1074/jbc.270.26.15899			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797594	hybrid			2022-12-27	WOS:A1995RG53800070
J	CRANMER, SL; CONANT, AR; GUTTERIDGE, WE; HALESTRAP, AP				CRANMER, SL; CONANT, AR; GUTTERIDGE, WE; HALESTRAP, AP			CHARACTERIZATION OF THE ENHANCED TRANSPORT OF L-LACTATE AND D-LACTATE INTO HUMAN RED-BLOOD-CELLS INFECTED WITH PLASMODIUM-FALCIPARUM SUGGESTS THE PRESENCE OF A NOVEL SATURABLE LACTATE PROTON COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTES; MALARIA PARASITES; INVITRO CULTURES; MONOCARBOXYLATE TRANSPORT; PLASMA-MEMBRANES; HOST ERYTHROCYTE; DIRECT ACCESS; PYRUVATE; CARRIER; PERMEABILITY	Human erythrocytes parasitized with the malarial protozoan Plasmodium falciparun showed rates of L-lactate, D-lactate, and pyruvate uptake many fold greater than control cells. Thus it was necessary to work at 0 degrees C to resolve true initial rates of transport. Studies on the dependence of the rate of transport on substrate concentration implied the presence in parasitized cells of both a saturable mechanism blocked by alpha-cyano-4-hydroxycinnamate (CHC) and a nonsaturable mechanism insensitive to CHC. The former was dominant at physiological substrate concentrations with K-m values for pyruvate and D-lactate of 2.3 and 5.2 mM, respectively, with no stereoselectivity for L- over D-lactate. CHC was significantly less effective as an inhibitor of lactate transport in parasitized erythrocytes than in uninfected cells, whereas p-chloromercuribenzenesulfonate, a potent inhibitor in control cells, gave little or no inhibition of lactate transport into parasitized erythrocytes. Inhibition of transport into infected cells was also observed with phloretin, furosemide, niflumic acid, stilbenedisulfonate derivatives, and 5-nitro-2-(3-phenylpropylamino)benzoic acid at concentrations similar to those that inhibit the lactate carrier of control erythrocytes. These compounds were more effective inhibitors of the rapid transport of chloride into infected cells than of lactate transport, whereas CHC was more effective against lactate transport. This implies that different pathways are involved in the parasite-induced transport pathways for lactate and chloride. The transport of L-lactate into infected erythrocytes was also inhibited by D-lactate, pyruvate, 2-oxobutyrate, and 2-hydroxybutyrate, The intracellular accumulation of L-lactate at equilibrium was dependent on the transmembrane pH gradient, suggesting a protogenic transport mechanism. Our data are consistent with lactate and pyruvate having direct access to the malarial parasite, perhaps via the proposed parasitophorous duct or some close contact between the host cell and parasite plasma membranes, with transport across the latter by both a proton-linked carrier (CHC-sensitive, saturable, and the major route) and free diffusion of the undissociated acid (CHC-insensitive, unsaturable, and a minor route).	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	University of Bristol; GlaxoSmithKline; Wellcome Research Laboratories			Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANCELIN ML, 1992, BIOCHEM J, V283, P619, DOI 10.1042/bj2830619; ANCELIN ML, 1991, BIOCHEM J, V273, P701, DOI 10.1042/bj2730701; BARNARD JP, 1993, J BIOL CHEM, V268, P3654; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; CABANTCHIK ZI, 1983, MOL PHARMACOL, V23, P92; CABANTCHIK ZI, 1990, UCLA SYM BI, V118, P267; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; EDLUND GL, 1988, BIOCHEM J, V249, P117, DOI 10.1042/bj2490117; ELFORD BC, 1992, BIOCHEM SOC T, V20, P790, DOI 10.1042/bst0200790; FUJIOKA H, 1993, EXP PARASITOL, V76, P302, DOI 10.1006/expr.1993.1036; GATI WP, 1990, BIOCHEM J, V272, P277, DOI 10.1042/bj2720277; GERO AM, 1992, PARASITOL TODAY, V8, P283, DOI 10.1016/0169-4758(92)90147-T; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GINSBURG H, 1987, BIOSCIENCE REP, V7, P455, DOI 10.1007/BF01116501; GOODYER ID, 1994, ANN TROP MED PARASIT, V88, P209, DOI 10.1080/00034983.1994.11812859; GOODYER ID, 1993, 5TH BRIT SOC PAR MAL, P7; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; GUTTERIDGE WE, 1991, IMMUNOL LETT, V30, P261, DOI 10.1016/0165-2478(91)90035-9; GUTTERIDGE WE, 1993, MODERN PARASITOLOGY; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HALESTRAP AP, 1976, BIOCHEM J, V156, P193, DOI 10.1042/bj1560193; HALESTRAP AP, 1979, TECHNIQUES METABOL B, V206, P1; JONES TR, 1994, CLIN MICROBIOL REV, V7, P303, DOI 10.1128/CMR.7.3.303-310.1994; KANAANI J, 1991, J CELL PHYSIOL, V149, P469, DOI 10.1002/jcp.1041490316; KANAANI J, 1992, ANTIMICROB AGENTS CH, V36, P1102, DOI 10.1128/AAC.36.5.1102; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; KIRK K, 1994, J BIOL CHEM, V269, P3339; KIRK K, 1991, BIOCHIM BIOPHYS ACTA, V1061, P305, DOI 10.1016/0005-2736(91)90296-K; KNAPP B, 1991, PARASITOL RES, V77, P277, DOI 10.1007/BF00930901; KUTNER S, 1987, BIOCHEM PHARMACOL, V36, P123, DOI 10.1016/0006-2952(87)90389-3; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; LORD R, 1994, PARASITOL TODAY, V10, P434, DOI 10.1016/0169-4758(94)90174-0; LOYEVSKY M, 1994, MOL PHARMACOL, V45, P446; LOYEVSKY M, 1993, J CLIN INVEST, V91, P218, DOI 10.1172/JCI116174; LYTTON SD, 1993, BLOOD, V81, P214; MATTEI D, 1992, GENE, V110, P71, DOI 10.1016/0378-1119(92)90446-V; NEWBOLD CI, 1990, PARASITOL TODAY, V6, P320, DOI 10.1016/0169-4758(90)90175-4; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PFALLER MA, 1982, EXP PARASITOL, V54, P391, DOI 10.1016/0014-4894(82)90048-0; POOLE RC, 1991, BIOCHEM J, V275, P307, DOI 10.1042/bj2750307; POOLE RC, 1988, BIOCHEM J, V254, P385, DOI 10.1042/bj2540385; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POOLE RC, 1990, BIOCHEM J, V269, P827, DOI 10.1042/bj2690827; POOLE RC, 1989, BIOCHEM J, V264, P409, DOI 10.1042/bj2640409; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; SHERMAN IW, 1990, PARASITOL TODAY, V6, P317, DOI 10.1016/0169-4758(90)90174-3; SHERMAN IW, 1992, PARASITOL TODAY, V8, P2, DOI 10.1016/0169-4758(92)90294-C; SILFEN J, 1988, BIOCHEM PHARMACOL, V37, P4269, DOI 10.1016/0006-2952(88)90606-5; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TANABE K, 1990, PARASITOL TODAY, V6, P225, DOI 10.1016/0169-4758(90)90199-E; TARASCHI TF, 1994, PARASITOL TODAY, V10, P399, DOI 10.1016/0169-4758(94)90232-1; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; WANG XM, 1993, BIOCHEM J, V290, P249, DOI 10.1042/bj2900249; WIEMER EAC, 1992, BIOCHEM BIOPH RES CO, V184, P1028, DOI 10.1016/0006-291X(92)90694-G	62	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15045	15052		10.1074/jbc.270.25.15045	http://dx.doi.org/10.1074/jbc.270.25.15045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797486	hybrid			2022-12-27	WOS:A1995RE66600032
J	EDMONDS, BT; MURRAY, J; CONDEELIS, J				EDMONDS, BT; MURRAY, J; CONDEELIS, J			PH REGULATION OF THE F-ACTIN BINDING-PROPERTIES OF DICTYOSTELIUM ELONGATION-FACTOR 1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CYTOPLASMIC PH; MESSENGER-RNA; PROTEIN-SYNTHESIS; CYTOSKELETAL FRAMEWORK; HELA-CELLS; DISCOIDEUM; DIFFERENTIATION; FACTOR-1-ALPHA; IDENTIFICATION	ABP50, an F-actin bundling protein from Dictyostelium, is also the protein synthesis co-factor, elongation factor 1 alpha (EF1 alpha). Concomitant with cAMP stimulation in Dictyostelium is a cytoplasmic alkalinization (Aerts, R. J., DeWit, R. J. W., and Van Lookeren Campagne, M. M. (1987) FEES Lett. 220, 366-370) and a redistribution of EF1 alpha (Dharmawardhane, S., Demma, M., Yang, F., and Condeelis, J. (1991) Cell Motil. Cytoskel. 20, 279-288). In addition, others have shown a correlation between intracellular pH and the level of protein synthesis in Dictyostelium (Aerts, R. J., Durston, A. J., and Moolenaar, W. H. (1985) Cell 43, 653-657). The present study investigates the relationship between pH and the F-actin binding properties of EF1 alpha. We found that increasing pH over the physiological range 6.2-7.8 causes a loss of EF1 alpha-mediated F-actin bundling and single filament binding, with corresponding increases in the amount of free EF1 alpha in vitro. Similar results also were obtained by cell fractionation and confocal immunofluorescence microscopy. The EF1 alpha binding constant (K-d) for F-actin is increased from 0.2 mu M to > 2.2 mu M over the same pH range. In addition, EF1 alpha-induced actin bundle formation is freely reversible by changes in pH. Thus, pH may be a potent modulator of cytoarchitecture in Dictyostelium and may also influence mRNA translation rates by modifying the interactions between the protein synthetic machinery and the actin cytoskeleton.			EDMONDS, BT (corresponding author), ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25813] Funding Source: Medline; NINDS NIH HHS [NS08864] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; AERTS RJ, 1987, FEBS LETT, V220, P366, DOI 10.1016/0014-5793(87)80848-7; ALTON TH, 1977, CELL, V12, P301, DOI 10.1016/0092-8674(77)90208-2; Brenowitz M., 1989, CURRENT PROTOCOLS MO; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHI KF, 1992, GASTROENTEROLOGY, V103, P98, DOI 10.1016/0016-5085(92)91101-9; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Condeelis John, 1993, Trends in Cell Biology, V3, P371, DOI 10.1016/0962-8924(93)90085-F; CONDEELIS JS, 1977, J CELL BIOL, V74, P901, DOI 10.1083/jcb.74.3.901; COOK RK, 1992, J BIOL CHEM, V267, P9430; COTTER DA, 1992, BIOCHEM CELL BIOL, V70, P892, DOI 10.1139/o92-137; DEMMA M, 1990, J BIOL CHEM, V265, P2286; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; EDMONDS B, 1987, BRAIN RES, V406, P288, DOI 10.1016/0006-8993(87)90794-3; EDMONDS BT, 1993, J CELL BIOCHEM, V52, P134, DOI 10.1002/jcb.240520204; FECHHEIMER M, 1982, CELL MOTIL CYTOSKEL, V2, P287, DOI 10.1002/cm.970020308; FECHHEIMER M, 1986, EUR J CELL BIOL, V40, P242; FINNEY RE, 1985, DEV BIOL, V110, P171, DOI 10.1016/0012-1606(85)90074-0; FURUKAWA R, 1988, J CELL BIOL, V107, P2541, DOI 10.1083/jcb.107.6.2541; FURUKAWA R, 1990, J CELL BIOL, V110, P1947, DOI 10.1083/jcb.110.6.1947; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HESKETH JE, 1991, BIOCHEM J, V277, P1; HOWE JG, 1984, CELL, V37, P85; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; PATTERSON DJ, 1980, BIOL REV, V55, P1, DOI 10.1111/j.1469-185X.1980.tb00686.x; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POGGEVONSTRANDM.R, 1984, FEBS LETT, V175, P422; POTEL MJ, 1979, J CELL SCI, V36, P281; RAMAGOPAL S, 1981, P NATL ACAD SCI-BIOL, V78, P3083, DOI 10.1073/pnas.78.5.3083; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHMIDT JM, 1993, BIOCHEM BIOPH RES CO, V197, P660, DOI 10.1006/bbrc.1993.2530; SHELDON E, 1995, IN PRESS J CELL SCI; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SHESTAKOVA EA, 1993, CELL BIOL INT, V17, P409, DOI 10.1006/cbir.1993.1079; SIMCHOWITZ L, 1986, J BIOL CHEM, V261, P6492; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; VANDUIJN B, 1991, P NATL ACAD SCI USA, V88, P4951, DOI 10.1073/pnas.88.11.4951; WEEKS G, 1991, BIOCHEM CELL BIOL, V69, P608, DOI 10.1139/o91-090; WINKLER MM, 1980, NATURE, V287, P558, DOI 10.1038/287558a0; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG WN, 1993, J BIOL CHEM, V268, P392	55	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15222	15230		10.1074/jbc.270.25.15222	http://dx.doi.org/10.1074/jbc.270.25.15222			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797506	hybrid			2022-12-27	WOS:A1995RE66600057
J	GRAHAM, LA; HILL, KJ; STEVENS, TH				GRAHAM, LA; HILL, KJ; STEVENS, TH			VMA8 ENCODES A 32-KDA V-1 SUBUNIT OF THE SACCHAROMYCES-CEREVISIAE VACUOLAR H+-ATPASE REQUIRED FOR FUNCTION AND ASSEMBLY OF THE ENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; YEAST VACUOLE; GENE ENCODES; MEMBRANE; PROTEIN; BIOSYNTHESIS; BIOGENESIS; MUTANTS	The isolated Saccharomyces cerevisiae vacuolar proton-translocating ATPase (V-ATPase) is composed of at least 10 subunits. We have identified VMA8, the gene encoding the 32-kDa subunit of the V-ATPase, by 100% match between the sequences of tryptic peptides and the predicted protein sequence of ORF11. The VMA8 gene contains a 768-base pair open reading frame encoding a 256 amino acid protein with a predicted molecular mass of 29,176 Da. Disruption of VMA8 resulted in a mutant exhibiting pH-sensitive growth, slowed growth under all conditions, and an inability to grow on nonfermentable carbon sources. Vacuolar membranes isolated from vma8 Delta yeast cells exhibited no V-ATPase activity, Immunoblot analysis of vma8 Delta cells revealed normal levels of both V-1 and V-0 subunits. Whereas the V-1 subunits failed to associate with the vacuolar membrane in vma8 Delta cells, the V-0 polypeptides were transported to and stable in the vacuolar membrane. Density gradient fractionation revealed that Vma8p associated only with the fully assembled V-ATPase and did not associate with a separate lower density V-0 subcomplex fraction. Finally, Vma8p was unable to assemble onto the vacuolar membranes in the absence of other V-1 subunits.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DENDA K, 1990, J BIOL CHEM, V265, P21509; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARRISON MA, 1994, EUR J BIOCHEM, V221, P111, DOI 10.1111/j.1432-1033.1994.tb18719.x; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; PAUL MF, 1994, J BIOL CHEM, V269, P26158; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKASE K, 1994, J BIOL CHEM, V269, P11037; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	36	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15037	15044		10.1074/jbc.270.25.15037	http://dx.doi.org/10.1074/jbc.270.25.15037			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797485	hybrid			2022-12-27	WOS:A1995RE66600031
J	JANSEN, E; AYOUBI, TAY; MEULEMANS, SMP; VANDEVEN, WJM				JANSEN, E; AYOUBI, TAY; MEULEMANS, SMP; VANDEVEN, WJM			NEUROENDOCRINE-SPECIFIC EXPRESSION OF THE HUMAN PROHORMONE CONVERTASE-1 GENE - HORMONAL REGULATION OF TRANSCRIPTION THROUGH DISTINCT CAMP RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN PROCESSING ENZYME; MESSENGER-RNA; SUBTILISIN FAMILY; PRIMARY SEQUENCE; RAT-BRAIN; PC2; IDENTIFICATION; FURIN; CDNA; PITUITARY	Prohormone convertases are involved in the tissue-specific endoproteolytic processing of prohormones and neuopeptide precursors within the secretory pathway. In the present study, we have isolated genomic clones comprising the 5'-terminal region of the human prohormone convertase 1 (PC1) gene and identified and characterized the PC1 promoter region. We found multiple transcription start sites located within a 15-base pair region, 205 base pairs upstream of the translation start codon. The promoter region is not G+C-rich and does not contain a canonical TATA box nor a CAAT box. Transient expression assays with a set of human PC1 gene fragments containing progressive 5' deletions demonstrate that the proximal promoter region is capable of directing high levels of neuroendocrine-specific expression of reporter gene constructs. In addition, the proximal promoter region confers both basal and hormone-regulated promoter activity. Site-specific mutagenesis experiments demonstrate that two closely spaced cAMP response elements within the proximal promoter region direct cAMP-mediated hormonal regulation of transcription of the PC1 gene.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; FLANDERS INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM	KU Leuven; Flanders Institute for Biotechnology (VIB)								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1992, DNA CELL BIOL, V11, P791, DOI 10.1089/dna.1992.11.791; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; BORELLI E, 1992, CRIT REV ONCOGENESIS, V3, P321; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FTOUHI N, 1994, DNA CELL BIOL, V13, P395, DOI 10.1089/dna.1994.13.395; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; JEANNOTTE L, 1987, MOL CELL BIOL, V7, P4058, DOI 10.1128/MCB.7.11.4058; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MINEO I, 1995, BIOCHEM BIOPH RES CO, V207, P646, DOI 10.1006/bbrc.1995.1236; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; PRESTRIDGE DS, 1993, COMPUT APPL BIOSCI, V9, P113; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SAMBROOOK J, 1989, MOL CLONING LABORATO; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x	46	54	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15391	15397		10.1074/jbc.270.25.15391	http://dx.doi.org/10.1074/jbc.270.25.15391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797529	hybrid			2022-12-27	WOS:A1995RE66600081
J	TISSOT, C; MECHTI, N				TISSOT, C; MECHTI, N			MOLECULAR-CLONING OF A NEW INTERFERON-INDUCED FACTOR THAT REPRESSES HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CONSTITUTIVE EXPRESSION; REGULATED EXPRESSION; INFLUENZA-VIRUS; IFN-GAMMA; T-CELLS; ACTIVATION	Transcriptional induction of genes is an essential part of the cellular response to interferons. To isolate yet unidentified IFN-regulated genes we have performed a differential screening on a cDNA library prepared from human lymphoblastoid Daudi cells treated for 16 h with human alpha/beta interferon (Hu-alpha/beta IFN). In the course of these studies we have isolated a human cDNA which codes for a protein sharing homology with the mouse Rpt-1 gene; it will be referred as Staf-50 for Stimulated Trans-Acting Factor of 50 kDa. Amino acid sequence analysis revealed that Staf-50 is a member of the Ring finger family and contains all the features of a transcriptional regulator able to initiate a second cascade of gene induction (secondary response). Staf-50 is induced by both type I and type II IFN in various cell lines and down-regulates the transcription directed by the long terminal repeat promoter region of human immunodeficiency virus type 1 in transfected cells. These data are consistent with a role of Staf-50 in the mechanism of transduction of the IFN antiviral action.	INST MOLEC GENET,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRON M, 1993, J GEN VIROL, V64, P2641; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HENGEL H, 1994, J VIROL, V68, P289, DOI 10.1128/JVI.68.1.289-297.1994; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATZE MG, 1986, MOL CELL BIOL, V6, P1741, DOI 10.1128/MCB.6.5.1741; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; LEIB DA, 1989, J VIROL, V63, P759, DOI 10.1128/JVI.63.2.759-768.1989; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V33, P1362; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; POPIK W, 1991, P NATL ACAD SCI USA, V88, P9573, DOI 10.1073/pnas.88.21.9573; PORTER ACG, 1989, EMBO J, V8, P831; RECH J, 1994, J CELL SCI, V107; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RYSIECKI G, 1989, J INTERFERON RES, V99, P649; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CE, 1992, INTERFERON PRINCIPLE, P225; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VLACH J, 1993, J VIROL, V67, P4427, DOI 10.1128/JVI.67.7.4427-4431.1993; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x	58	176	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14891	14898		10.1074/jbc.270.25.14891	http://dx.doi.org/10.1074/jbc.270.25.14891			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797467	Green Published, hybrid			2022-12-27	WOS:A1995RE66600011
J	MONKAWA, T; MIYAWAKI, A; SUGIYAMA, T; YONESHIMA, H; YAMAMOTOHINO, M; FURUICHI, T; SARUTA, T; HASEGAWA, M; MIKOSHIBA, K				MONKAWA, T; MIYAWAKI, A; SUGIYAMA, T; YONESHIMA, H; YAMAMOTOHINO, M; FURUICHI, T; SARUTA, T; HASEGAWA, M; MIKOSHIBA, K			HETEROTETRAMERIC COMPLEX-FORMATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; DEPENDENT PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; FUNCTIONAL-CHARACTERIZATION; PERIPHERAL-TISSUES; MOLECULAR-CLONING; MOUSE CEREBELLUM; CALCIUM-RELEASE; INSP3 RECEPTOR; PURKINJE-CELL	The inositol 1,4,5-trisphosphate receptor (IP(3)R) exists as a tetrameric complex to form a functional inositol 1,4,5-trisphosphate-gated Ca2+ channel. Molecular cloning studies have shown that there are at least three types of IP(3)R subunits, designated type 1, type 2, and type 3. The levels of expression of IP(3)R subunits in various cell lines were investigated by Western blot analysis using type-specific antibodies against 15 C-terminal amino acids of each IP(3)R subunit. We found that all the three types of IP(3)R subunits were expressed in each cell line examined, but their levels of expression varied. To determine whether IP(3)Rs form heterotetramers, we employed immunoprecipitation experiments using Chinese hamster ovary cells (CHO-K1 cells), in which all three types are abundantly expressed. Each type-specific antibody immunoprecipitated not only the respective cognate type but also the other two types. This result suggests that distinct types of IP(3)R subunits assemble to form heterotetramers in CHO-K1 cells. We also detected heterotetramers in rat liver, in which IP(3)R type 1 and type 2 are expressed abundantly. Previous studies have shown some functional differences among IP(3)R types, suggesting the possibility that various compositions of subunits show distinct channel properties. The diversity of IP(3)R channels may be further increased by the co-assembly of different IP(3)R subunits to form home- or heterotetramers.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 160,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,IBARAKI 305,OSAKA,JAPAN	University of Tokyo; Keio University; Kyowa Kirin Ltd; RIKEN			Miyawaki, Atsushi/K-3569-2014; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014; Monkawa, Toshiaki/F-2361-2010	Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888; Monkawa, Toshiaki/0000-0002-7876-7661				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NHAKADE S, 1994, J BIOL CHEM, V269, P6735; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; YAMADA M, 1995, IN PRESS BIOCH J; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	40	193	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14700	14704		10.1074/jbc.270.24.14700	http://dx.doi.org/10.1074/jbc.270.24.14700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782334	hybrid			2022-12-27	WOS:A1995RD45500070
J	BOLLINGER, JM; KWON, DS; HUISMAN, GW; KOLTER, R; WALSH, CT				BOLLINGER, JM; KWON, DS; HUISMAN, GW; KOLTER, R; WALSH, CT			GLUTATHIONYLSPERMIDINE METABOLISM IN ESCHERICHIA-COLI - PURIFICATION, CLONING, OVERPRODUCTION, AND CHARACTERIZATION OF A BIFUNCTIONAL GLUTATHIONYLSPERMIDINE SYNTHETASE/AMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRYPANOTHIONE REDUCTASE; CRITHIDIA-FASCICULATA; GLUTATHIONE SYNTHETASE; TRYPANOSOMA-CRUZI; PHYSICAL MAP; D-ALANINE; INHIBITION; SPERMIDINE; DEFICIENT	Glutathionylspermidine (GSP) synthetases of Trypanosomatidae and Escherichia coli couple hydrolysis of ATP (to ADP and P-i) with formation of an amide bond between spermidine (N-(3-aminopropyl)-1,4-diamino-butane) and the glycine carboxylate of glutathione (gamma-Glu-Cys-Gly). In the pathogenic trypanosomatids, this reaction is the penultimate step in the biosynthesis of the antioxidant metabolite, trypanothione (N-1,N-8-bis-(glutathionyl)spermidine), and is a target for drug design. In this study, GSP synthetase was purified to near homogeneity from E. coli B, the gene encoding it was isolated and sequenced, the enzyme was overexpressed and purified in quantity, and the recombinant enzyme was characterized. The 70-kDa protein was found to have an unexpected second catalytic activity, glutathionylspermidine amide bond hydrolysis. Thus, the bifunctional GSP synthetase/amidase catalyzes opposing amide bond-forming and -cleaving reactions, with net hydrolysis of ATP. The synthetase activity is selectively abrogated by proteolytic cleavage 81 residues from the C terminus, suggesting that the two activities reside in distinct domains (N-terminal amidase and C-terminal synthetase). Proteolysis at this site is facile in the absence of substrates, but is inhibited in the presence of ATP, glutathione, and Mg2+. A series of analogs was used to probe the spermidine-binding site of the synthetase activity. The activity of diaminopropane as a substrate, inactivity of the C-4-C-8 diaminoalkanes, and greater loss of specificity for analogs modified in the 3-aminopropyl moiety than for those modified in the 4-aminobutyl moiety indicate that the enzyme recognizes predominantly the diaminopropane portion of spermidine and corroborate N-1 (the aminopropyl N) as the site of glutathione linkage (Tabor, H. and Tabor, C. W. (1975) J. Biol. Chem. 250, 2648-2654). Trends in K-m and k(cat) for a set of difluoro-substituted spermidine derivatives suggest that the enzyme may bind the minor, deprotonated form of the amine nucleophile.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Bollinger, Joseph/C-1425-2016	Huisman, Gjalt/0000-0003-1955-1120	NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P10, DOI 10.1016/0304-4165(75)90206-8; BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; COLANDUONI J, 1987, J BIOL CHEM, V262, P3037; CONNELL N, 1987, MOL MICROBIOL, V1, P195, DOI 10.1111/j.1365-2958.1987.tb00512.x; DUBIN DT, 1959, BIOCHEM BIOPH RES CO, V1, P262, DOI 10.1016/0006-291X(59)90034-8; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; ELVIN CM, 1986, MOL GEN GENET, V204, P477, DOI 10.1007/BF00331028; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FAIRLAMB AH, 1987, HOST PARASITE CELLUL, P29; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; FUCHS JA, 1975, J BACTERIOL, V124, P140, DOI 10.1128/JB.124.1.140-148.1975; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HENDERSON GB, 1988, P NATL ACAD SCI USA, V85, P5374, DOI 10.1073/pnas.85.15.5374; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOCKERSSCHERUBL MC, 1989, EUR J BIOCHEM, V180, P267, DOI 10.1111/j.1432-1033.1989.tb14643.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1974, ENZYMES, V10, P699; Meister A., 1974, ENZYMES, V10, P671; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHAMES SL, 1988, BIOCHEMISTRY-US, V27, P5014, DOI 10.1021/bi00414a010; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; Stadtman E.R., 1974, ENZYMES, V10, P755; SULLIVAN FX, 1991, BIOCHEMISTRY-US, V30, P2761, DOI 10.1021/bi00225a004; SULLIVAN FX, 1989, BIOCHEMISTRY-US, V28, P4986, DOI 10.1021/bi00438a013; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; TABOR CW, 1970, BIOCHEM BIOPH RES CO, V41, P232, DOI 10.1016/0006-291X(70)90493-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1978, J BIOL CHEM, V253, P3671; TABOR CW, 1966, FED PROC, V25, P709; TABOR H, 1975, J BIOL CHEM, V250, P2648; TABOR H, 1966, FED PROC, V25, P879; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; WALSH C, 1991, TRENDS BIOCHEM SCI, V16, P305, DOI 10.1016/0968-0004(91)90124-E; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; YANG TP, 1992, J BACTERIOL, V174, P1700, DOI 10.1128/jb.174.5.1700-1701.1992	56	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14031	14041		10.1074/jbc.270.23.14031	http://dx.doi.org/10.1074/jbc.270.23.14031			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775463	hybrid			2022-12-27	WOS:A1995RC44800065
J	GONZALEZFLECHA, B; DEMPLE, B				GONZALEZFLECHA, B; DEMPLE, B			METABOLIC SOURCES OF HYDROGEN-PEROXIDE IN AEROBICALLY GROWING ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; OXIDATIVE STRESS; DEHYDROGENASE; MITOCHONDRIA; GENERATION; OXIDASE; DISEASE; PROTEIN; OXYGEN; DAMAGE	Exposure of cells to hydrogen peroxide (H2O2) mediates adaptive responses or oxidative damage, depending on the magnitude of the challenge. Determining the threshold for peroxide-mediated oxidative stress thus requires quantitation of the changes in endogenous H2O2 production. The intracellular steady-state concentrations of H2O2 were measured in intact Escherichia coli under different conditions. Compounds that block electron transport at NADH dehydrogenase (rotenone) or between ubiquinone and cytochrome b (antimycin) showed that univalent reduction of O-2 can occur at these sites in vivo to form superoxide anion (O-2(-)), in agreement with reports for mammalian mitochondria. Mutational inactivation of different components of the respiratory chain showed that H2O2 production also depended on the energy status of the cell and on the arrangement of respiratory chain components corresponding to particular growth conditions. Production rates for O-2(-) and H2O2 were linearly related to the number of active respiratory chains that reached maximal values during exponential growth. In the strains defective in respiratory chain components, catalase activity was regulated to compensate for changes in the H2O2 production rates, which maintained intracellular H2O2 at 0.1-0.2 mu M during aerobic growth over a wide range of cell densities. The expression of a katG'::lacZ fusion (reporting transcriptional control of the catalase-hydroperoxidase I gene) was increased by H2O2 given either as a pulse or as a steady production. This response not only depended on the type and severity of the stimulus but was also strongly influenced by the growth phase of the cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NCI NIH HHS [CA37831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BABIOR BM, 1991, AM J HEMATOL, V37, P263, DOI 10.1002/ajh.2830370410; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; CALHOUN MW, 1993, J BACTERIOL, V175, P3020, DOI 10.1128/JB.175.10.3020-3025.1993; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623; GONZALEZFLECHA B, 1994, J BACTERIOL, V176, P2293; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GREEN GN, 1988, J BIOL CHEM, V263, P13138; HARMAN D, 1991, P NATL ACAD SCI USA, V88, P5360, DOI 10.1073/pnas.88.12.5360; HASSAN HM, 1978, J BIOL CHEM, V253, P6445; HAYASHI M, 1989, BIOCHIM BIOPHYS ACTA, V977, P62, DOI 10.1016/S0005-2728(89)80009-X; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HIDALGO E, 1995, REGULATION GENE EXPR; HOLMBERG K, 1973, ARCH ORAL BIOL, V18, P423, DOI 10.1016/0003-9969(73)90167-2; IMLAY JA, 1991, FREE RADICAL RES COM, V12-3, P59, DOI 10.3109/10715769109145768; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; IVANOVA A, 1994, MOL MICROBIOL, V12, P571, DOI 10.1111/j.1365-2958.1994.tb01043.x; JAMIESON DJ, 1994, MICROBIOLOGY, V150, P3277; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; Miller JH., 1992, EXPT MOL GENETICS; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; SCHULTZEOSTHOFF K, 1995, IN PRESS ADV MOL CEL; Sies H., 1991, OXIDATIVE STRESS OXI, pxv; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	45	247	263	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13681	13687		10.1074/jbc.270.23.13681	http://dx.doi.org/10.1074/jbc.270.23.13681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775420	hybrid			2022-12-27	WOS:A1995RC44800017
J	BUSHKINHARAV, I; GARTY, NB; LITTAUER, UZ				BUSHKINHARAV, I; GARTY, NB; LITTAUER, UZ			DOWN-REGULATION OF A 67-KDA YIGSR-BINDING PROTEIN UPON DIFFERENTIATION OF HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; LAMININ-A-CHAIN; AMINO-ACID-SEQUENCE; RETINOIC ACID; SYNTHETIC PEPTIDE; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; CARCINOMA-CELLS; MELANOMA-CELLS; CYCLIC-AMP	Differentiated human neuroblastoma LA-N1 cells that were exposed to dibutyryl adenosine 3',5'-cyclic monophosphate for 5 days (primed cells) showed increased adhesion to laminin-, fibronectin-, and collagen type I-coated plates as compared to unprimed cells. Moreover, primed cells seemed to adhere best to laminin. The binding site in laminin, mediating cell attachment, was identified as containing the YIGSR sequence, a known cell binding motif, located in the short arm of the B1 chain of laminin. The synthetic peptide amide, C(YIGSR)(3)-NH2, containing a repeat of this binding motif, inhibited the attachment of neuroblastoma cells to laminin in a competitive manner, and its inhibitory activity was inversely dependent on laminin concentrations. Affinity chromatography of membrane-extracted proteins over an Affi-Gel 10 column conjugated to C(YIGSR)(3)-NH2, revealed a major YIGSR-binding protein with an apparent molecular mass of 67 kDa. The 67-kDa surface membrane protein was specifically eluted from the column with the soluble C(YIGSR)(3)-NH2 peptide, but not with an unrelated peptide. Furthermore, no 67-kDa laminin-binding protein was recovered from an unrelated peptide matrix with the free C(YIGSR)(3)-NH2 peptide. Ligand blot overlay assays with biotin-labeled C(YIGSR)(3)-NH2 peptide demonstrated that the 67-kDa receptor is indeed a YIGSR-binding protein. This 67-kDa laminin-binding protein appeared to be down-regulated upon differentiation of LA-N1 cells, as indicated by the level of this protein and its mRNA.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BUSHKINHARAV I, 1994, 8TH INT C INT SOC DI, P177; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; EDGAR D, 1989, TRENDS NEUROSCI, V12, P248, DOI 10.1016/0166-2236(89)90020-9; GARTY NB, 1991, 15TH INT C BIOCH JER, P229; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GINZBURG I, 1990, REGULATION GENE EXPR, P305; GLICK MC, 1980, ADV NEUROBLASTOMA RE, P171; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROSS N, 1987, INT J CANCER, V39, P521, DOI 10.1002/ijc.2910390420; HADLEY MA, 1990, DEV BIOL, V140, P318, DOI 10.1016/0012-1606(90)90082-T; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KIRSCH J, 1990, J NEUROCHEM, V55, P1031, DOI 10.1111/j.1471-4159.1990.tb04593.x; KIRSCH J, 1991, ADV NEUROBLASTOMA RE, V3, P327; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KRAMER RH, 1989, CANCER RES, V49, P393; LAURIE GW, 1991, DIFFERENTIATION, V46, P173, DOI 10.1111/j.1432-0436.1991.tb00879.x; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LITTAUER UZ, 1979, BIOCHEM BIOPH RES CO, V88, P933, DOI 10.1016/0006-291X(79)91498-0; LITTAUER UZ, 1980, J BIOL CHEM, V255, P5448; LITTAUER UZ, 1990, BASIC CLIN THERAPEUT, V1, P117; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MAFUNE K, 1990, CANCER RES, V50, P3888; MARCHETTI D, 1987, J NEUROCHEM, V49, P475, DOI 10.1111/j.1471-4159.1987.tb02889.x; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NOMIZU M, 1993, CANCER RES, V53, P3459; PONZONI M, 1992, CANCER RES, V52, P931; PRASAD KN, 1975, CANCER, V36, P1338, DOI 10.1002/1097-0142(197510)36:4<1338::AID-CNCR2820360422>3.0.CO;2-1; RAMOS DM, 1990, CANCER RES, V50, P728; RAO NC, 1983, BIOCHEM BIOPH RES CO, V111, P804, DOI 10.1016/0006-291X(83)91370-0; REICHARDT LF, 1989, DEV NEUROSCI-BASEL, V11, P332, DOI 10.1159/000111910; RESCAN PY, 1991, HEPATOLOGY, V13, P289, DOI 10.1016/0270-9139(91)92442-B; ROSS RA, 1988, ADV NEUROBLASTOMA RE, V2, P277; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; RUPNIAK HT, 1984, CANCER RES, V44, P2600; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SOREQ H, 1983, DEV BRAIN RES, V7, P257, DOI 10.1016/0165-3806(83)90182-7; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; TSOKOS M, 1987, AM J PATHOL, V128, P484; VONDERMARK K, 1985, BIOCHIM BIOPHYS ACTA, V823, P147; WEEKS BS, 1991, AM J PHYSIOL, V261, pF688, DOI 10.1152/ajprenal.1991.261.4.F688; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; YAMAMURA K, 1993, CANCER RES, V53, P423; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	67	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13422	13428		10.1074/jbc.270.22.13422	http://dx.doi.org/10.1074/jbc.270.22.13422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768944	hybrid			2022-12-27	WOS:A1995RB43900070
J	NAKTINIS, V; ONRUST, R; FANG, LH; ODONNELL, M				NAKTINIS, V; ONRUST, R; FANG, LH; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .2. INTERMEDIATE COMPLEX BETWEEN THE CLAMP LOADER AND ITS CLAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; PRIMED DNA; SUBUNIT; CHI; PSI; ATP	The Escherichia coli replicase, DNA polymerase III holoenzyme, derives its processivity from the beta subunit sliding clamp that encircles DNA and tethers the replicase to the template. The beta dimer is assembled around DNA by the gamma complex clamp loader in an ATP-dependent reaction. In this report, the essential contact between the clamp loader and beta is identified as mediated through the delta subunit of the gamma complex. The delta subunit appears to contact the face of the beta dimer ring that contains the two C termini. Surprisingly, ATP is required for the gamma complex to bind beta, but not for delta to bind p. This indicates that delta is buried in the gamma complex and suggests a role for ATP in exposing delta for interaction with p. A protease protection assay has been developed to specifically probe the delta subunit within the gamma complex. The results of the assay are consistent with an ATP-induced conformational change in the gamma complex that alters the state of the delta subunit within it. The implication of these key features to the clamp loading mechanism of the gamma complex is discussed.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LEE SH, 1991, J BIOL CHEM, V266, P594; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, BIOL CHEM, V270, P13348; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	24	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13358	13365		10.1074/jbc.270.22.13358	http://dx.doi.org/10.1074/jbc.270.22.13358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768937	hybrid			2022-12-27	WOS:A1995RB43900062
J	HEVEKER, N; BONNAFFE, D; ULLMANN, A				HEVEKER, N; BONNAFFE, D; ULLMANN, A			CHEMICAL FATTY ACYLATION CONFERS HEMOLYTIC AND TOXIC ACTIVITIES TO ADENYLATE-CYCLASE PROTOXIN OF BORDETELLA-PERTUSSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALMODULIN; ACTIVATION; PURIFICATION; PENETRATION; PROTEIN; BINDING; CYAC	Adenylate cyclase toxin (ACT), a virulence factor of Bordetella pertussis, acquires hemolytic and toxic activities after post-translational modification of the cyaA gene product, CyaA. The exact nature of this modification is unknown, but homology to the related repeat toxin cu-hemolysin of Escherichia coli suggests that fatty acylation of a lysine residue may be involved, In the present study, we used an in, vitro chemical approach to acylate unmodified, inactive adenylate cyclase protoxin by using a new water soluble compound, acylpyrophosphate. We show that undirected transfer of lauric, myristic, or palmitic acid chains to the CyaA protoxin is able to confer both hemolytic and toxic activities to ACT. The chemically modified protoxin shows a specific requirement for Ca2+ ions for toxic activity, as does the wild type toxin. However, the toxic and hemolytic activities of chemically modified ACT are low in comparison to ACT modified in vivo, suggesting that in vitro fatty acylation of the protoxin involves random modification of nucleophilic residues present in the toxin in contrast to the in vivo modification of specific sites.	INST PASTEUR, DEPT BIOCHIM & GENET MOLEC, UNITE CHIM ORGAN, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HEVEKER, N (corresponding author), INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, 28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE.		Heveker, Nikolaus/G-5306-2012					BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; HANSKI E, 1985, J BIOL CHEM, V260, P5526; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOSEPH E, 1982, MOL GEN GENET, V185, P262, DOI 10.1007/BF00330796; LADANT D, 1986, J BIOL CHEM, V261, P6264; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; RYU EK, 1979, J LIPID RES, V20, P561; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834	16	5	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32844	32847						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806509				2022-12-27	WOS:A1994QA63800022
J	ABRUZZO, LV; REITMAN, M				ABRUZZO, LV; REITMAN, M			ENHANCER ACTIVITY OF UPSTREAM HYPERSENSITIVE SITE-2 OF THE CHICKEN BETA-GLOBIN CLUSTER IS MEDIATED BY GATA SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; STAGE SELECTOR ELEMENT; HUMAN ERYTHROID-CELLS; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATION; GENE-TRANSCRIPTION; TRANSGENIC MICE; ACTIVATION REGION; MAMMALIAN-CELLS; BINDING-PROTEIN	Upstream of the chicken beta-globin gene cluster are four DNase I-hypersensitive sites (HS1-4), Hypersensitive sites located upstream of the mammalian beta-globin clusters have enhancer activity and mediate position-independent gene expression, In contrast, a region inside the chicken cluster has enhancer activity and mediates position-independent expression, Here we investigate the function of the chicken upstream sites, which are different from the mammalian ones in sequence, number, and distance from the genes, Each was tested for its effect on reporter gene expression in transfected primary erythroid cells, HS2 and HS3 (4.4 and 6.4 kilobases upstream of rho-globin) showed significant enhancer activity while HS1 and HS4 (1.6 and 11 kilobases upstream of rho-globin) did not, A 237-base pair region of HS2 contained the sequences necessary for enhancer activity. Proteins from erythroid extracts bound HS2 in seven different regions; six of these sites were characterized, GATA-1 bound to four of the sites, Each site contributed to the enhancer activity of HS2, Two Other sequences bound proteins that may be related to Spl and erythroid krup-pel-like factor. Surprisingly, mutations in these elements, which disrupted protein binding, did not affect enhancer activity, Thus, the observed enhancer activity of HS2 is due to the four GATA sites, The existence of multiple GATA sites in both chicken HS2 and the mammalian upstream sites may be due to evolution from a common element with preservation of only very short sequences or to convergent evolution. These observations highlight the crucial role for GATA proteins in globin regulation.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LIEBER MR, 1987, J CELL BIOL, V105, P1055, DOI 10.1083/jcb.105.3.1055; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOON AM, 1991, BLOOD, V77, P2272; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; REITMAN M, 1993, GENOMICS, V18, P616, DOI 10.1016/S0888-7543(05)80364-7; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STALDER J, 1980, CELL, V20, P451, DOI 10.1016/0092-8674(80)90631-5; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	55	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32565	32571						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798259				2022-12-27	WOS:A1994PX30400081
J	SCHOENWAELDER, SM; JACKSON, SP; YUAN, YP; TEASDALE, MS; SALEM, HH; MITCHELL, CA				SCHOENWAELDER, SM; JACKSON, SP; YUAN, YP; TEASDALE, MS; SALEM, HH; MITCHELL, CA			TYROSINE KINASES REGULATE THE CYTOSKELETAL ATTACHMENT OF INTEGRIN ALPHA(IIB)BETA(3) (PLATELET GLYCOPROTEIN IIB/IIIA) AND THE CELLULAR RETRACTION OF FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-STIMULATED PLATELETS; PROTEIN-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE SKELETON; IIB-IIIA; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; HERBIMYCIN-A; GPIIB-IIIA; AGGREGATION	Integrins promote cell-substratum and cell-cell adhesion by acting as transmembrane linker molecules between extracellular adhesion proteins and the actin-rich cytoskeleton. The integrin alpha(IIb)beta(3) (platelet glycoprotein IIb/IIIa) is essential for platelet spreading, aggregation, fibrin clot retraction, and for the transduction of extracellular signals. We examined the effect of the specific tyrosine kinase inhibitor herbimycin A on integrin and cytoskeletal-mediated events in thrombin-stimulated platelets. Incubation of washed platelets for 24 h with herbimycin A (5 mu M) abolished the thrombin-stimulated cytoskeletal enzyme activity of pp60(c-src) in parallel with a reduction in the tyrosine phosphorylation of multiple platelet proteins, as assessed with anti-phosphotyrosine immunoblots. However, thrombin-induced activation of protein kinase C and the production of thromboxane A(2) were not altered by herbimycin A. Despite the absence of cytoskeletal pp60(c-src) enzyme activity, platelet shape change, aggregation, and serotonin release were unaltered following platelet stimulation with thrombin (0.05-1.0 unit/ml). Herbimycin A-treated platelets also demonstrated normal platelet aggregation in response to collagen (5 mu g/ml), ionophore A23187 (2 mu M), and ADP/adrenaline (10 pat each). However, the ability of herbimycin A-treated platelets to retract fibrin gels was significantly reduced. This defect in clot retraction was associated with reduced incorporation of integrin alpha(IIb)beta(3) into the cytoskeletal fraction of thrombin-aggregated platelets. Our studies suggest that tyrosine kinases in platelets regulate the cytoskeletal attachment of alpha(IIb)beta(3), as an essential process for the transmission of cellular contractile forces to fibrin polymers.	BOX HILL HOSP, MONASH MED SCH, DEPT MED, BOX HILL, VIC 3128, AUSTRALIA	Box Hill Hospital; Monash University			Schoenwaelder, Simone/E-9506-2011; Jackson, Shaun P/E-9633-2011	Mitchell, Christina A/0000-0001-9372-3192; Jackson, Shaun/0000-0002-4750-1991; Schoenwaelder, Simone/0000-0003-0465-5840				ARDLIE NG, 1974, BRIT J HAEMATOL, V26, P331, DOI 10.1111/j.1365-2141.1974.tb00477.x; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; Baenziger N L, 1974, Methods Enzymol, V31, P149; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FINDIK D, 1990, FEBS LETT, V262, P1, DOI 10.1016/0014-5793(90)80138-9; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1993, BIOCHEM J, V292, P851, DOI 10.1042/bj2920851; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; ODA A, 1992, J BIOL CHEM, V267, P20075; PEERSCHKE EIB, 1989, BLOOD, V74, P682; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P881, DOI 10.1016/0006-2952(92)90119-4; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SMYTH SS, 1993, BLOOD, V81, P2827; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TUSZYNSKI GP, 1987, PLATELET RESPONSES M, V2, P187; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEISS RH, 1992, J BIOL CHEM, V267, P5608; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHANG J, 1992, J BIOL CHEM, V267, P4686	52	56	57	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32479	32487						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798249				2022-12-27	WOS:A1994PX30400070
J	CHRISTENSEN, S; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV; NIELSEN, HR; ROEPSTORFF, P; ENGHILD, JJ				CHRISTENSEN, S; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV; NIELSEN, HR; ROEPSTORFF, P; ENGHILD, JJ			SODIUM DODECYL SULFATE-STABLE COMPLEXES BETWEEN SERPINS AND ACTIVE OR INACTIVE PROTEINASES CONTAIN THE REGION COOH-TERMINAL TO THE REACTIVE-SITE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE INHIBITOR; ANTITHROMBIN-III; ALPHA-1-PROTEINASE INHIBITOR; MECHANISM; THROMBIN; ALPHA-2-ANTIPLASMIN; ALPHA-1-ANTITRYPSIN; SUBSTRATE; KINETICS; TRYPSIN	Recently inhibitors of the serpin family were shown to form complexes with dichloroisocoumarine (DCI)-inactivated proteinases under native conditions (Enghild, J. J., Valnickova, Z., Thogersen I., and Pizzo, S. V. (1994) J. Biol. Chem. 269, 20159-20166). This study demonstrates that serpin-DCI/proteinase complexes resist dissociation when analyzed in reduced SDS-polyacrylamide gel electrophoresis. Previously, SDS-stable serpin-proteinase complexes have been observed only between serpins and catalytically active proteinases. The stability of these complexes is believed to result from an acyl-ester bond between the active site Ser(195) of the proteinase and the alpha-carbonyl group of the scissile bond in the reactive site loop. We have further analyzed the structure of the SDS-stable serpin-proteinase and serpin-DCI/proteinase complexes. The results of these studies demonstrate the presence of the COOH-terminal region of the serpin in both complexes. Since (i) modification of Ser(195) does not prevent formation of SDS-stable complexes and (ii) COOH-terminal peptides are present in both complexes, the previously described mechanism does not sufficiently explain the formation of SDS-stable complexes.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; ODENSE UNIV,DEPT MOLEC BIOL,DK-5230 ODENSE M,DENMARK	Duke University; University of Southern Denmark				Christensen, Soren/0000-0003-2500-0085; Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL49542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BODE W, 1902, EUR J BIOCHEM, V204, P433; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; DEAGOSTINI A, 1988, J CLIN INVEST, V82, P700, DOI 10.1172/JCI113650; ENGHILD JJ, 1994, J BIOL CHEM, V269, P20159; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOROI M, 1977, BIOCHIM BIOPHYS ACTA, V482, P412, DOI 10.1016/0005-2744(77)90255-8; OWEN WG, 1977, BIOCHIM BIOPHYS ACTA, V494, P182, DOI 10.1016/0005-2795(77)90146-5; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; POWERS JC, 1994, METHOD ENZYMOL, V244, P442; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; TOMONO T, 1986, ACTA HAEMATOL JAPON, V49, P969	28	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14859	14862		10.1074/jbc.270.25.14859	http://dx.doi.org/10.1074/jbc.270.25.14859			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797463	hybrid			2022-12-27	WOS:A1995RE66600005
J	SATO, M; KATAOKA, R; DINGUS, J; WILCOX, M; HILDEBRANDT, JD; LANIER, SM				SATO, M; KATAOKA, R; DINGUS, J; WILCOX, M; HILDEBRANDT, JD; LANIER, SM			FACTORS DETERMINING SPECIFICITY OF SIGNAL-TRANSDUCTION BY G-PROTEIN-COUPLED RECEPTORS - REGULATION OF SIGNAL TRANSFER FROM RECEPTOR TO G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; HAMSTER OVARY CELLS; ALPHA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; BETA-GAMMA; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; GUANINE-NUCLEOTIDES; AGONIST BINDING; PHOSPHOLIPASE-C	Among subfamilies of G-protein-coupled receptors, agonists initiate several cell signaling events depending on the receptor subtype (R) and the type of G-protein (G) or effector molecule (E) expressed in a particular cell, Determinants of signaling specificity/efficiency may operate at the R-G interface, where events are influenced by cell architecture or accessory proteins found in the receptor's microenvironment, This issue was addressed by characterizing signal transfer from R to G following stable expression of the alpha(2A/D) adrenergic receptor in two different membrane environments (NIH-3T3 fibroblasts and the pheochromocytoma cell line, PC-12), Receptor coupling to endogenous Gr-proteins in both cell types was eliminated by pertussis toxin pretreatment and R-G signal transfer restored by reconstitution of cell membranes with purified brain G-protein, Thus, the receptor has access to the same population of G-proteins in the two different environments, In this signal restoration assay, agonist-induced activation of G was 3-9-fold greater in PC-12 as compared with NIH-3T3 alpha(2)-adrenergic receptor transfectants. The cell-specific differences in signal transfer were observed over a range of receptor densities or G-protein concentration, The augmented signal transfer in PC-12 versus NIH-3T3 transfectants occurred despite a BS-fold lower level of receptors existing in the R-G-coupled state (high affinity, guanyl-5'-yl imidodiphosphate-sensitive agonist binding), suggesting the existence of other membrane factors that influence the nucleotide binding behavior of G-protein in the two cell types, Detergent extraction of PC-12 but not NIH-3T3 membranes yielded a heat-sensitive, macromolecular entity that increased S-35-labeled guanosine 5'-O-(thiotriphosphate) binding to brain G-protein in a concentration-dependent manner. These data indicate that the transfer of signal from R to G is regulated by a cell type-specific, membrane-associated protein that enhances the agonist-induced activation of G.	MED UNIV S CAROLINA, DEPT PHARMACOL, CHARLESTON, SC 29425 USA	Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CHABRE O, 1994, J BIOL CHEM, V269, P5730; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GRAESER D, 1993, MOL PHARMACOL, V43, P434; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LEE NH, 1993, J BIOL CHEM, V268, P7949; LEIBER D, 1993, J BIOL CHEM, V268, P3833; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MAH SJ, 1992, MOL PHARMACOL, V42, P217; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PILC A, 1986, J PHARMACOL EXP THER, V237, P725; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUPRENANT A, 1992, SCIENCE, V257, P977; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; TIAN WN, 1994, MOL PHARMACOL, V45, P524; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; VAZIRI C, 1992, J BIOL CHEM, V267, P22973	50	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15269	15276		10.1074/jbc.270.25.15269	http://dx.doi.org/10.1074/jbc.270.25.15269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797513	hybrid			2022-12-27	WOS:A1995RE66600064
J	KASUYA, J; GOKO, H; FUJITAYAMAGUCHI, Y				KASUYA, J; GOKO, H; FUJITAYAMAGUCHI, Y			MULTIPLE TRANSCRIPTS FOR THE HUMAN CARDIAC FORM OF THE CGMP-INHIBITED CAMP-PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMP PHOSPHODIESTERASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; HUMAN-PLATELETS; TRANSFER-RNA; FAT-CELLS; YEAST INVERTASE; MESSENGER-RNAS; GENE ENCODES	cDNAs for two distinct Type III cGMP-inhibited (cGI) cyclic nucleotide phosphodiesterases (PDE), designated cGIP1 and cGIP2, were previously cloned from rat adipose and human cardiac cDNA libraries, respectively. In this study, another cDNA (similar to 4.0 kilobase (kb)) encoding a cGI-PDE of 74 kDa (658 amino acids) was isolated from a human placental cDNA library, The nucleotide sequence of its open reading frame was virtually identical to a corresponding region in the 3' portion of the cardiac cGIP2 cDNA (similar to 7,6 kb) which encoded a similar to 125-kDa cGI-PDE (1141 amino acid). Northern blots and RNase protection assays revealed a prominent 4.4-kb transcript and a 7.6-kb transcript in human placenta. The transcription start site of the 4.4-kb transcript was assigned to cardiac cDNA nucleotide 1292, the putative beginning of exon 3 of the human cGIP2 gene, with a potential translation initiation site 183 bases downstream, as determined by RNase protection assay. The 5'-flanking region of the 4.4-kb transcript exhibited promoter activity in HeLa cells which expressed the 4.4-kb transcript, amd contained a TATAA sequence 35 base pairs upstream from the tentative transcription start site. Recombinant cGI-PDEs, expressed in Sf9 cells from the 7.6- and 4.0-kb cDNA, exhibited differences in their subcellular localization and K-m for cGMP. Thus, in human tissues, alternative transcription may contribute to generating at least two cGIP2 isoforms, cytosolic and membrane-associated cGI-PDEs with different K-m values for cGMP.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT MOLEC GENET,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIDDK NIH HHS [DK27790] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BUTCHER RW, 1966, J BIOL CHEM, V241, P1651; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHEUNG P, 1994, FASEB J 1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU MI, 1992, GENETICS, V132, P987; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; DEGERMAN E, 1989, ADV SEC MESS PHOSPH, V12, P171; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; GRANT PG, 1984, BIOCHEMISTRY-US, V23, P1801, DOI 10.1021/bi00303a034; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KHOO JC, 1973, J BIOL CHEM, V248, P3823; KONO T, 1975, J BIOL CHEM, V250, P7826; KONO T, 1973, J BIOL CHEM, V248, P7417; KOZAK M, 1986, CELL, V46, P481; KOZAK M, 1986, J CELL BIOL, V108, P229; KOZAK M, 1987, CELL, V44, P283; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBON TR, 1992, ENDOCRINOLOGY, V130, P3265, DOI 10.1210/en.130.6.3265; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOPEZAPARICIO P, 1992, BIOCHEM BIOPH RES CO, V186, P517, DOI 10.1016/S0006-291X(05)80838-1; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; LOTEN EG, 1970, BIOCHEM J, V120, P193; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P87; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MONACO L, 1994, J BIOL CHEM, V269, P347; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PERLMAN D, 1981, CELL, V25, P525, DOI 10.1016/0092-8674(81)90071-4; PILLAI R, 1994, J BIOL CHEM, V269, P30676; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; RASCON A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P149, DOI 10.1016/0167-4889(92)90038-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAKUR Y, 1993, BIOCHEM J, V292, P6577; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V170, P533, DOI 10.1016/0006-291X(90)92124-I; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; TAIRA M, 1993, J BIOL CHEM, V268, P18573; WEBER HW, 1982, J BIOL CHEM, V257, P5339; WU M, 1987, J BIOL CHEM, V262, P12275; XIONG LM, 1990, ENDOCRINOLOGY, V126, P2102, DOI 10.1210/endo-126-4-2102; YAN PF, 1993, J BIOL CHEM, V268, P22444; ZINMAN B, 1974, J BIOL CHEM, V249, P2182; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	65	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14305	14312		10.1074/jbc.270.24.14305	http://dx.doi.org/10.1074/jbc.270.24.14305			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782288	hybrid			2022-12-27	WOS:A1995RD45500014
J	PUMIGLIA, KM; LEVINE, H; HASKE, T; HABIB, T; JOVE, R; DECKER, SJ				PUMIGLIA, KM; LEVINE, H; HASKE, T; HABIB, T; JOVE, R; DECKER, SJ			A DIRECT INTERACTION BETWEEN G-PROTEIN BETA-GAMMA-SUBUNITS AND THE, RAF-1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYTIC SUPPORT; ADP-RIBOSYLATION; RAS; PHOSPHORYLATION; ACTIVATION; INHIBITION; DELETION; REGION; ALPHA	Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade. Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G(beta 2) subunit of heterotrimeric G-proteins. In vitro, purified G(beta gamma) subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330). Binding assays with truncation mutants of GST-Raf indicate that the region located. between amino acids 136 and 239 is a primary determinant for interaction with G(beta gamma). In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G(beta gamma) to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect. Scatchard analysis of in vitro binding between Raf/330 and G(beta gamma) revealed an affinity of interaction (K-d = 163 +/- 36 nM), similar to that seen between G(beta gamma) and beta ARK (K-d = 87 +/- 24 nM), The formation of native heterotrimeric G(alpha beta gamma) complexes, as measured by pertussis toxin ADP-ribosylation of G(alpha), could be disrupted by increasing amounts of Raf/330, with an EC(50) of approximately 200 nM, in close agreement with the estimated binding affinity. In vivo complexes of Raf-1 and G(beta gamma) were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G(beta 2). The identification and characterization of this novel interaction raises several possibilities for signaling cross-talk between growth factor receptors and those receptors coupled to heterotrimeric G-proteins.	UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; PARKE DAVIS PHARMACEUT, DIV RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48106 USA; PARKE DAVIS PHARMACEUT, DIV RES, DEPT NEUROSCI, ANN ARBOR, MI 48106 USA	University of Michigan System; University of Michigan; Pfizer; Pfizer				Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABIB T, 1994, J BIOL CHEM, V269, P25243; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARPER JW, 1993, CELL, V75, P805; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HONDA Z, 1994, J BIOL CHEM, V269, P2307; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RON D, 1994, J BIOL CHEM, V269, P21395; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOKOE D, 1994, SCIENCE, V264, P1468; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14251	14254		10.1074/jbc.270.24.14251	http://dx.doi.org/10.1074/jbc.270.24.14251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782277	hybrid			2022-12-27	WOS:A1995RD45500003
J	COLEMAN, RA; TAGGART, AKP; BENJAMIN, LR; PUGH, BF				COLEMAN, RA; TAGGART, AKP; BENJAMIN, LR; PUGH, BF			DIMERIZATION OF THE TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; TFIID BINDS; TBP; SUFFICIENT; INITIATION; ELEMENT	The TATA binding protein (TBP) is a central component of all eukaryotic transcription machineries. The recruitment of TBP to the promoter is slow and possibly rate limiting in transcription complex assembly. In an effort to understand the nature of this potential rate-limiting step, we have investigated the physical state of TBP prior to DNA binding. By chemical cross-linking, gel filtration chromatography, and protein affinity chromatography, we find that the conserved carboxyl-terminal DNA binding domain of human TBP dimerizes when not bound to DNA. The data completely support the proposed dimeric structure of plant TBP, previously determined by x-ray crystallography. TBP dimers are quite stable, having an approximate equilibrium dissociation constant (K-D) in the low nanomolar range. The dimerization interface appears to be dominated by hydrophobic forces, as predicted by the crystal structure. TBP dimers do not bind DNA, but they must dissociate into monomers before stably binding to the TATA box. Dissociation of TBP dimers appears to be relatively slow, and as such has the potential to dictate the kinetics of DNA binding.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JUPP R, 1993, J BIOL CHEM, V268, P16105; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LU T, 1993, ANAL BIOCHEM, V213, P318, DOI 10.1006/abio.1993.1427; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1995, IN VITRO TRANSCRIPTI, V37, P359; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3	25	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13842	13849		10.1074/jbc.270.23.13842	http://dx.doi.org/10.1074/jbc.270.23.13842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775442	hybrid			2022-12-27	WOS:A1995RC44800041
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			TRIACYLGLYCEROL SYNTHESIS BY PURIFIED TRIACYLGLYCEROL SYNTHETASE OF RAT INTESTINAL-MUCOSA - ROLE OF ACYL-COA ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; DIACYLGLYCEROL ACYLTRANSFERASE; COENZYME-A; RADIATION INACTIVATION; PARTIAL-PURIFICATION; POLYACRYLAMIDE GELS; LIVER MICROSOMES; FUNCTIONAL SIZE; Z-PROTEIN; HYDROLASE	The activities of the proposed triacylglycerol synthetase complex, acyl-CoA Ligase, acyl-CoA acyltransferase (AAT), monoacylglycerol acyltransferase (MGAT), and diacylglycerol acyltransferase (DGAT), coeluted upon Cibacron blue 3GA-agarose affinity chromatography of detergent-solubilized rat intestinal microsomes. The AAT activity is associated with a 54-kDa protein, that binds covalently an acyl group from acyl-CoA via a thiol ester linkage (Lehner, R. and Kuksis, A. (1993) J. Biol. Chem. 268, 24726-24733). Reagents that prevent the acyl-AAT formation inhibit triacylglycerol synthesis as does the removal of AAT from the complex by immunoprecipitation. In the absence of mono- and diacylglycerol accepters, the acyl group is transferred to water. It is proposed that triacylglycerol synthesis proceeds via a sequential transfer of acyl groups from acyl-CoA ligase to the AAT, from which they are passed to the mono- and diacylglycerol acyltransferases for incorporation into the di- and triacylglycerols depending on the availability of the acyl acceptors.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				ANDERSSON M, 1994, J LIPID RES, V35, P535; BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BRINDLEY DN, 1965, BIOCHIM BIOPHYS ACTA, V106, P495, DOI 10.1016/0005-2760(65)90066-4; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; FERSHT A, 1985, ENZYME STRUCTURE MEC, P115; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOFFMAN AGD, 1979, CAN J PHYSIOL PHARM, V57, P832, DOI 10.1139/y79-127; HOFFMAN AGD, 1982, BIOCHIM BIOPHYS ACTA, V710, P53, DOI 10.1016/0005-2760(82)90189-8; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; KUKSIS A, 1986, FAT ABSORPTION, V1, P233; KWANYUEN P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P67, DOI 10.1016/0167-4838(90)90227-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P385, DOI 10.1016/0005-2760(80)90086-7; LARSON JD, 1985, ARCH BIOCHEM BIOPHYS, V273, P27; LEHNER R, 1993, J BIOL CHEM, V268, P24726; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P107, DOI 10.1139/o85-016; MANLEY ER, 1974, BIOCHEM BIOPH RES CO, V58, P229, DOI 10.1016/0006-291X(74)90916-4; MENTLEIN R, 1985, BIOCHEM J, V232, P479, DOI 10.1042/bj2320479; MISHKIN S, 1974, BIOCHEM BIOPH RES CO, V60, P376; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; NIMMO GA, 1984, BIOCHEM J, V224, P101, DOI 10.1042/bj2240101; ODOHERTY PJA, 1975, FEBS LETT, V60, P256, DOI 10.1016/0014-5793(75)80725-3; OZASA S, 1989, J LIPID RES, V30, P1759; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; POLOKOFF MA, 1980, BIOCHIM BIOPHYS ACTA, V618, P129, DOI 10.1016/0005-2760(80)90060-0; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SANJANWALA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P299, DOI 10.1016/0003-9861(87)90348-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x	43	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13630	13636		10.1074/jbc.270.23.13630	http://dx.doi.org/10.1074/jbc.270.23.13630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775414	hybrid			2022-12-27	WOS:A1995RC44800010
J	TEZAPSIDIS, N; NOCTOR, S; KANNAN, R; KRIEGER, TJ; MENDEMUELLER, L; HOOK, VYH				TEZAPSIDIS, N; NOCTOR, S; KANNAN, R; KRIEGER, TJ; MENDEMUELLER, L; HOOK, VYH			STIMULATION OF PROHORMONE THIOL PROTEASE (PTP) AND [MET]ENKEPHALIN BY FORSKOLIN - BLOCKADE OF ELEVATED [MET]ENKEPHALIN BY A CYSTEINE PROTEASE INHIBITOR OF PTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-PROCESSING ENZYME; LOBE SECRETORY VESICLES; ENKEPHALIN PRECURSOR; CHROMAFFIN CELLS; CYCLIC-AMP; SUBTILISIN FAMILY; CONVERTING ENZYME; ADRENAL-MEDULLA; MESSENGER-RNA; PURIFICATION	Proenkephalin and other prohormones require proteolytic processing at paired basic and monobasic residues for the biosynthesis of active neuropeptides. The novel ''prohormone thiol protease'' (PTP) has been proposed as a candidate proenkephalin processing enzyme for the production of [Met]enkephalin in chromaffin granules (Krieger, T. J., and Hook, V. Y. H. (1991) J. Biol. Chem. 266, 88376-8383). In this study, PTP was examined during elevation of cellular [Met]enkephalin by forskolin, a direct activator of adenylate cyclase that produces cAMP. Treatment of chromaffin cells with forskolin for 72 h increased enkephalin precursor cleaving activity (measured by following the conversion of the model substrate [S-35-Met]preproenkephalin to trichloroacetic acid-soluble radioactivity) in isolated chromaffin granules by 170-180% over controls (100%). The increased activity was associated with the membrane fraction, rather than the soluble fraction, of chromaffin granules. The elevated activity was inhibited by E-64c, which is a potent inhibitor of PTP and cysteine proteases; however, the activity was not inhibited by serine or aspartic protease inhibitors. The elevated activity was identified as PTP based on immunoprecipitation by anti-PTP immunoglobulins. Stimulation of PTP synthesis was involved in the forskolin-induced increase in PTP activity, as demonstrated by a 10 fold increase in [S-35]PTP pulse labeling in forskolin-treated chromaffin cells. Forskolin elevation of PTP protein levels within chromaffin granules was also detected in Western blots. Importantly, the forskolin-mediated rise in cellular [Met]enkephalin levels was completely blocked when cells were preincubated with the cysteine protease inhibitor Ep453, which is known to be converted by intracellular esterases to the more effective inhibitor E-64c (Buttle, D. J., Saklatvala, J., Tamai, M., and Barrett, A. J. (1992) Biochem. J. 281, 175-177). Both E-64c and Ep453 inhibit PTP, with E-64c being more potent (Azaryan, A. V., and Hook, V. Y. H. (1994b) Arch. Biochem. Biophys. 314, 171-177). These results demonstrate a role for PTP in proenkephalin processing in chromaffin cells and indicate that [Met] enkephalin formation and PTP are both regulated by cAMP.	UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103; UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	University of California System; University of California San Diego; Uniformed Services University of the Health Sciences - USA; Medical College of Wisconsin								AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; AZARYAN AV, 1995, IN PRESS J NEUROCHEM; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BUTTLE DJ, 1992, BIOCHEM J, V281, P175, DOI 10.1042/bj2810175; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EIDEN LE, 1984, P NATL ACAD SCI-BIOL, V81, P3949, DOI 10.1073/pnas.81.13.3949; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LOH YP, 1985, J BIOL CHEM, V260, P7194; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; PARISH DC, 1986, J BIOL CHEM, V261, P4392; POLLARD HB, 1978, J BIOL CHEM, V254, P1170; SCHILLER MR, 1995, IN PRESS BIOCHEMISTR; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; STEINER DF, 1992, J BIOL CHEM, V267, P23435; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; WAN DC, 1991, MOL BRAIN RES, V9, P135, DOI 10.1016/0169-328X(91)90138-N; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	29	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13285	13290		10.1074/jbc.270.22.13285	http://dx.doi.org/10.1074/jbc.270.22.13285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768928	hybrid			2022-12-27	WOS:A1995RB43900052
J	SAKAI, R; IWAMATSU, A; HIRANO, N; OGAWA, S; TANAKA, T; NISHIDA, J; YAZAKI, Y; HIRAI, H				SAKAI, R; IWAMATSU, A; HIRANO, N; OGAWA, S; TANAKA, T; NISHIDA, J; YAZAKI, Y; HIRAI, H			CHARACTERIZATION, PARTIAL-PURIFICATION, AND PEPTIDE SEQUENCING OF P130, THE MAIN PHOSPHOPROTEIN ASSOCIATED WITH V-CRK ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SRC HOMOLOGY REGION-2; SH3 DOMAINS; SARCOMA-VIRUS; TRANSFORMING ACTIVITY; CYTOPLASMIC PROTEIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; ONCOGENE PRODUCT; PHOSPHOLIPASE-C	The transforming gene v-crk found in CT10 and ASV-1 avian sarcoma viruses induces marked phosphorylation of several proteins in cells expressing p47(v-crk) (v-Crk), In this work, the main tyrosine-phosphorylated proteins in ASV-1-infected chicken cells and v-crk transfected rat cells were characterized biochemically, Both these proteins have a molecular mass of about 130 kDa and are tightly associated with v-Crk in vivo, Two-dimensional gel electrophoresis revealed that they are both essentially single proteins (p130) with modifications that result in a broad spot in an acidic region, The broad band of semi-purified p130 became sharp at an elevated position in the gel upon treatment with orthovanadate in vivo or with c-Src kinase produced using a baculovirus vector in vitro, whereas it shifted at a lower position upon treatment with alkaline phosphatase in vitro, These results suggest multiple phosphorylation states of p130, which result in a broad band of p130. Two procedures of immunoaffinity purification were used to purify p130 from SY1 cells transfected with v-crk. Approximately 30 pmol of purified p130 was obtained in an immobilized form on a filter starting from 3 x 10(10) cells, Peptide mapping of p130 digested in situ by peptidase revealed that the purity and quantity of the final material were enough for peptide sequencing, Several stretches of partial amino acid sequences were determined, and they indicated that p130 is a novel protein.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOLEC BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KIRIN BREWERY CO LTD, CENT LAB KEY TECHNOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	University of Tokyo; Jichi Medical University; Kirin Brewery Company Limited			Tanaka, Tomoyuki U/A-4775-2008	Sakai, Ryuichi/0000-0001-6833-1103				AOYAMA H, 1988, J PROTEIN CHEM, V7, P191; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DECUE JE, 1987, P NATL ACAD SCI USA, V84, P9064; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POTTS WM, 1987, VIROLOGY, V160, P494, DOI 10.1016/0042-6822(87)90024-9; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIE H, 1989, ONCOGENE, V4, P1281; WIRTH PJ, 1987, CANCER RES, V47, P2839; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32740	32746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806494				2022-12-27	WOS:A1994QA63800007
J	SUNDARAMOORTHY, M; KISHI, K; GOLD, MH; POULOS, TL				SUNDARAMOORTHY, M; KISHI, K; GOLD, MH; POULOS, TL			THE CRYSTAL-STRUCTURE OF MANGANESE PEROXIDASE FROM PHANEROCHAETE-CHRYSOSPORIUM AT 2.06-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN-DEGRADING BASIDIOMYCETE; CYTOCHROME-C PEROXIDASE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; CRYSTALLOGRAPHIC REFINEMENT; OXIDIZED STATES; OXIDATION; BIODEGRADATION; COMPOUND; MODEL	The crystal structure of manganese peroxidase (MnP) from the lignin degrading basidiomycetous fungus Phanerochaete chrysosporium has been solved using molecular replacement techniques and refined to R = 0.20 at 2.06 Angstrom. The overall structure is similar to that of two other fungal peroxidases, lignin peroxidase from P. chrysosporium and Arthromyces ramosus peroxidase. Like the other fungal peroxidases, MnP has two structural calcium ions. MnP also has two N-acetylglucosamine residues N-linked to Asn(131) that are readily visible in the electron density map. The active site, consisting of a proximal His ligand H-bonded to an Asp residue and a distal side peroxide binding pocket consisting of a catalytic His and Arg, is the same as in the aforementioned fungal peroxidases as well as yeast cytochrome c peroxidase. MnP differs in having five rather than four disulfide bonds. The additional disulfide bond, Cys(341)-Cys(348), is located near the C terminus of the polypeptide chain. Importantly, a new cation binding site, which we propose is the manganese-binding site of MnP, was located in the crystal structure. The ligands constituting the Mn2+-binding site include Asp(179), Glu(35), Glu(39), a heme propionate, and two water molecules. Electron transfer from Mn2+ to the heme edge or iron center is envisioned to occur through a sigma-bonded pathway along a heme propionate.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291	University of California System; University of California Irvine; University of California System; University of California Irvine								ALIC M, 1987, APPL ENVIRON MICROB, V53, P1464, DOI 10.1128/AEM.53.7.1464-1469.1987; ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BANCI L, 1991, P NATL ACAD SCI USA, V88, P6956, DOI 10.1073/pnas.88.16.6956; BROWN JA, 1990, J BACTERIOL, V172, P3125, DOI 10.1128/jb.172.6.3125-3130.1990; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, SYSTEM XRAY REFINEME; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; DEMMER H, 1980, COORDINATION COMPOUN, V56, P1; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1989, ACS SYM SER, V389, P127; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOLD MH, 1993, PLANT PEROXIDASES BI, P87; Greppin H., 1993, PLANT PEROXIDASES BI, P35; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HIGUCHI T, 1990, WOOD SCI TECHNOL, V24, P23, DOI 10.1007/BF00225306; JOHNSON F, 1993, PLANT PEROXIDASES BI, P31; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LI HY, 1994, STRUCTURE, V2, P461, DOI 10.1016/S0969-2126(00)00046-0; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MAYFIELD MB, 1994, APPL ENVIRON MICROB, V60, P4303, DOI 10.1128/AEM.60.12.4303-4309.1994; MINO Y, 1988, J BIOL CHEM, V263, P7029; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; POULOS TL, 1994, PEROXIDASES STRUCTUR, V30, P25; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SCHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SUNDARAMOORTHY M, 1994, J MOL BIOL, V238, P845, DOI 10.1006/jmbi.1994.1338; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; [No title captured]	54	341	360	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32759	32767						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806497				2022-12-27	WOS:A1994QA63800010
J	BLAIKIE, P; IMMANUEL, D; WU, J; LI, NX; YAJNIK, V; MARGOLIS, B				BLAIKIE, P; IMMANUEL, D; WU, J; LI, NX; YAJNIK, V; MARGOLIS, B			A REGION IN SHC DISTINCT FROM THE SH2 DOMAIN CAN BIND TYROSINE-PHOSPHORYLATED GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGF RECEPTOR; EXPRESSION CLONING; KINASES; PROTEINS; RAS; ASSOCIATION; GRB2; SITE; SRC; GAP	Shc is a ubiquitously expressed Src homology 2 (SH2) domain protein that can transform fibroblasts and differentiate PC12 cells in a Ras dependent fashion, Shc binds a variety of tyrosine-phosphorylated growth factor receptors presumably via its carboxyl-terminal SH2 domain, We cloned a fragment of She when screening a bacterial expression library with tyrosine-phosphorylated epidermal growth factor (EGF) receptor. Surprisingly, this fragment encodes the amino terminus of She, a region that has no significant similarity to an SH2 domain, When expressed as a glutathione S-transferase fusion protein, this amino-terminal domain binds to autophosphorylated EGF receptor, as web as HER2/neu and TrkA receptors, This fragment acts like an SH2 domain in that it does not bind non-phosphorylated EGF receptor or EGF receptor with all tyrosine phosphorylation sites mutated or deleted, Our data define a novel domain in She that has the potential to interact with growth factor receptors and other tyrosine-phosphorylated proteins.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LI N, 1994, IN PRESS ONCOGENE; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2	28	310	324	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32031	32034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798194				2022-12-27	WOS:A1994PX30400003
J	GU, LY; HUANG, SM; SANDER, M				GU, LY; HUANG, SM; SANDER, M			SINGLE AMINO-ACID CHANGES ALTER THE REPAIR SPECIFICITY OF DROSOPHILA RRP1 - ISOLATION OF MUTANTS DEFICIENT IN REPAIR OF OXIDATIVE DNA-DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; COLI EXONUCLEASE-III; ENZYME APEX NUCLEASE; ESCHERICHIA-COLI; 3'-5' EXONUCLEASE; POLYMERASE-I; CDNA; MUTAGENESIS; EXPRESSION; HOMOLOGY	Drosophila Rrp1 has several tightly associated enzymatic activities, including double-strand DNA 3'-exo-nuclease, apurinic/apyrimidinic endonuclease, 3'-phosphatase, and 3'-phosphodiesterase. The carboxyl-terminal third of Rrp1, homologous to Escherichia coli exonuclease III, is sufficient to repair oxidative and alkylation-induced DNA damage in vivo. Using a screen for partial complementation of repair-deficient E., coli, we isolated three mutants of the nuclease domain of Rrp1: T462A, K463Q, and L484P, that protect against methyl methanesulfonate (MMS)-induced but not t-BuO(2)H-induced DNA damage, Thr-462 and Lys-463 are highly conserved residues found in a cluster of 5 conserved amino acids (LQETK), while Leu-484 is poorly conserved. Gln-460 Glu-461, Thr-462, and Lys-463 and Leu-484 were altered by site-directed mutagenesis using a plasmid including the entire Rrp1 gene and mutant proteins were purified, Mutants of the three residues Glu-461, Thr-462, and Lys-463 demonstrate 8-200-fold lower phosphodiesterase specific activity than wild-type Rrp1., E46lA has a 30-fold reduction in AP endonuclease and is MMS-sensitive, but all other mutants have near-normal AP endonuclease and are MMS-resistant, Glu-461 appears to be essential for the nuclease function of Rrp1. Lys-463 and, to a lesser extent, Thr-462 influence the substrate specificity of the Rrp1 nuclease.	NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								[Anonymous], 1985, DNA REPAIR; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; BOYD JB, 1987, J CELL SCI, P39; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; GU LY, 1993, NUCLEIC ACIDS RES, V21, P4788, DOI 10.1093/nar/21.20.4788; HENRICH B, 1986, GENE, V42, P345, DOI 10.1016/0378-1119(86)90239-8; IZUMI T, 1992, J BACTERIOL, V174, P7711, DOI 10.1128/JB.174.23.7711-7716.1992; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1993, J MOL BIOL, V229, P239, DOI 10.1006/jmbi.1993.1021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; NUGENT M, 1993, BIOCHEMISTRY-US, V32, P11445, DOI 10.1021/bi00093a023; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1993, J BIOL CHEM, V268, P2075; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Von Sontag C., 1987, CHEM BASIS RAD BIOL, P221; WILSON TM, 1994, NUCLEIC ACIDS RES, V22, P530, DOI 10.1093/nar/22.3.530; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32685	32692						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798276				2022-12-27	WOS:A1994PX30400099
J	MONNET, V; NARDI, M; CHOPIN, A; CHOPIN, MC; GRIPON, JC				MONNET, V; NARDI, M; CHOPIN, A; CHOPIN, MC; GRIPON, JC			BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF PEPF, AN OLIGOPEPTIDASE FROM LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-CREMORIS H61; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; PZ-PEPTIDASE; NATURAL PEPTIDES; SIGNAL PEPTIDE; RAT TESTES; DCP GENE; PURIFICATION	Lactococcus lactis possesses a complex proteolytic system which is essential for its growth in milk. me characterized one of the peptidases of this system, oligopeptidase PepF, together with its structural gene. PepF hydrolyzed peptides containing between 7 and 17 amino acids with a rather wide specificity. It was purified to homogeneity. The N-terminal sequences of PepF and of peptides resulting from tryptic digestion of PepF were determined and used to design degenerate oligonucleotides which served to amplify a DNA fragment internal to pepF. This fragment was used as a probe to screen a lactococcal genomic library in Escherichia coli and to clone the entire gene pepF. The gene coded for a 70 kDa protein and was located on a 55-kilobase lactose-protease plasmid. A motif His-Glu-X-X-His, characteristic of metallopeptidases was evidenced. Two regions of PepF were found similar, first to a stretch of 43 amino acids around the zinc-binding site of several other peptidases, second to a stretch of 33 amino acids well conserved among creatine and arginine kinases. Preliminary results suggest the presence of a second copy of pepF.	INRA,GENET MICROBIENNE LAB,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay	MONNET, V (corresponding author), INRA,RECH LAITIERES STN,ENZYMOL GRP,F-78352 JOUY EN JOSAS,FRANCE.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARRETT AJ, 1990, BIOL CHEM H-S, V371, P311; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CONLIN CA, 1992, J BACTERIOL, V174, P5881, DOI 10.1128/jb.174.18.5881-5887.1992; CONLIN CA, 1992, J BACTERIOL, V174, P1631, DOI 10.1128/jb.174.5.1631-1640.1992; DANIELSEN EM, 1980, BIOCHEM J, V191, P645, DOI 10.1042/bj1910645; DESMAZEAUD MJ, 1976, ANN BIOL ANIM BIOCH, V16, P851, DOI 10.1051/rnd:19760608; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSSANTOS ALL, 1987, FEMS MICROBIOL LETT, V42, P209, DOI 10.1111/j.1574-6968.1987.tb02074.x; DUMAS C, 1993, J BIOL CHEM, V268, P21599; GIBSON TJ, 1984, THESIS U CAMBRIDGE E; HAMILTON S, 1992, J BACTERIOL, V174, P1626, DOI 10.1128/jb.174.5.1626-1630.1992; HENRICH B, 1993, J BACTERIOL, V175, P7290, DOI 10.1128/JB.175.22.7290-7300.1993; HUANG DC, 1991, FEMS MICROBIOL LETT, V77, P101, DOI [10.1111/j.1574-6968.1991.tb04329.x, 10.1016/S0378-1097(99)00297-9]; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KIRSCHNER RJ, 1981, METHOD ENZYMOL, V80, P702; KIWAKI M, 1989, MOL MICROBIOL, V3, P359, DOI 10.1111/j.1365-2958.1989.tb00181.x; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENHOUTS KJ, 1994, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1995, APPL ENVIRON MICROB, V57, P2562; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAYO B, 1993, APPL ENVIRON MICROB, V59, P2049, DOI 10.1128/AEM.59.7.2049-2055.1993; MIERAU I, 1993, J BACTERIOL, V175, P2087, DOI 10.1128/JB.175.7.2087-2096.1993; MILLS OE, 1978, NEW ZEAL J DAIRY SCI, V13, P209; MONNET V, IN PRESS METHODS ENZ; MORALES TI, 1977, J BIOL CHEM, V252, P4855; MORIYAMA A, 1988, BIOCHIM BIOPHYS ACTA, V956, P151, DOI 10.1016/0167-4838(88)90261-0; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; RABIER D, 1973, BIOCHIMIE, V55, P389, DOI 10.1016/S0300-9084(73)80204-4; RAUCH PJG, 1990, NUCLEIC ACIDS RES, V18, P4253, DOI 10.1093/nar/18.14.4253; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIMON D, 1985, FEMS MICROBIOL LETT, V26, P239, DOI 10.1111/j.1574-6968.1985.tb01598.x; TAN PST, 1991, APPL ENVIRON MICROB, V57, P3593, DOI 10.1128/AEM.57.12.3593-3599.1991; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; VANDEGUCHTE M, 1991, MOL GEN GENET, V227, P65, DOI 10.1007/BF00260708; VIMR ER, 1983, J BACTERIOL, V153, P1259, DOI 10.1128/JB.153.3.1259-1265.1983; YAN TR, 1987, EUR J BIOCHEM, V163, P259, DOI 10.1111/j.1432-1033.1987.tb10796.x; YAN TR, 1987, APPL ENVIRON MICROB, V53, P2296, DOI 10.1128/AEM.53.10.2296-2302.1987	58	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32070	32076						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798200				2022-12-27	WOS:A1994PX30400012
J	TOKER, A; MEYER, M; REDDY, KK; FALCK, JR; ANEJA, R; ANEJA, S; PARRA, A; BURNS, DJ; BALLAS, LM; CANTLEY, LC				TOKER, A; MEYER, M; REDDY, KK; FALCK, JR; ANEJA, R; ANEJA, S; PARRA, A; BURNS, DJ; BALLAS, LM; CANTLEY, LC			ACTIVATION OF PROTEIN-KINASE-C FAMILY MEMBERS BY THE NOVEL POLYPHOSPHOINOSITIDES PTDINS-3,4-P-2 AND PTDINS-3,4,5-P-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-SUBSPECIES BLOCKS; NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; PHOSPHOINOSITIDE 3-KINASE; ACTIN POLYMERIZATION; MITOGENIC SIGNAL; HUMAN-PLATELETS	The effect of phosphoinositides on the activity of protein kinase C (PKC) isotypes was investigated. PKC alpha, beta I, beta II, gamma, delta, epsilon, eta, and zeta were expressed in baculovirus-infected insect cells and purified by column chromatography. The calcium-activated PKC isotypes alpha, beta I, beta II, and gamma were not significantly activated by any of the phosphoinositides investigated (phosphatidylinositol-4-phosphate (PtdIns-4-P), PtdIns-3-P, PtdIns-4,5-P-2, PtdIns-3,4-P-2, and PtdIns-3,4,5-P-3) when added in the presence of concentrations of phosphatidylserine that give maximal stimulation. The calcium-insensitive PKC isotypes delta, epsilon, and eta also showed little response to PtdIns3-P, PtdIns-4-P, or PtdIns-4,5-P-2 when these lipids were added in the presence of phosphatidylserine. In contrast, PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 caused a 5-15-fold stimulation of these enzymes compared with phosphatidylserine alone. 50 % maximal stimulation of PKC epsilon by PtdIns-3,4,5-P-3 occurred when this lipid was present at about 1% of the carrier PtdIns-4,5-P-2 (about 100 nM). These lipids had little effect on baculovirus-expressed PKC zeta, which was constitutively active. A short chain version of PtdIns-3,4,5-P-3, dioctanoyl-PtdIns-3,4,5-P-3, activated PKC delta, epsilon, and eta in the absence of other lipids, whereas a short chain version of PtdIns-4,5-P-2, dihexanoyl-PtdIns-4,5-P-2, did not. Since PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 are nominally absent in unstimulated cells and appear within seconds to minutes of stimulation by various cell activators, these Lipids could act as second messengers to activate PHC delta, epsilon, or eta in vivo.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; SPHINX PHARMACEUT, DURHAM, NC 27717 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; CORNELL UNIV, DIV FUNCT LIPIDS, LANGMUIR LAB, ITHACA, NY 14850 USA	Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cornell University	TOKER, A (corresponding author), BETH ISRAEL HOSP, DEPT MED,DIV SIGNAL TRANSDUCT,WARREN ALPERT BLDG, RM 146, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM049594, R44GM049594, R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37361, GM41890, GM49594, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ANEJA R, 1970, BIOCHIM BIOPHYS ACTA, V218, P102, DOI 10.1016/0005-2760(70)90097-4; ANEJA R, 1974, Biochemical Society Transactions, V2, P38; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLAS LM, 1993, FASEB J S, P35; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CACACE AM, 1993, ONCOGENE, V8, P2095; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHOUINARD PM, 1986, J ORG CHEM, V51, P75, DOI 10.1021/jo00351a015; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DREEF CE, 1988, TETRAHEDRON LETT, V29, P6513, DOI 10.1016/S0040-4039(00)82387-4; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FALCK JR, 1993, BIOORG MED CHEM LETT, V3, P717, DOI 10.1016/S0960-894X(01)81261-0; FALCK JR, 1991, ACS SYM SER, V463, P145; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIGGINS JA, 1978, BIOCHEM J, V174, P563, DOI 10.1042/bj1740563; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KOCHS G, 1993, BIOCHEM J, V291, P627, DOI 10.1042/bj2910627; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LIMATOLA C, 1993, 34TH INT C BIOCH LIP; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; NAHAS N, 1989, FEBS LETT, V246, P30, DOI 10.1016/0014-5793(89)80247-9; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1991, METHOD ENZYMOL, V200, P228; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; RANKL NB, 1994, IN PRESS PROTEIN EXP; RAY TK, 1969, J BIOL CHEM, V244, P5528; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WENNSTROM S, 1994, ONCOGENE, V9, P651; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686	83	563	572	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32358	32367						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798235				2022-12-27	WOS:A1994PX30400053
J	ARAVINDA, S; GOPALAKRISHNAN, B; DEY, CS; TOTEY, SM; PAWSHE, CH; SALUNKE, D; KAUR, K; SHAHA, C				ARAVINDA, S; GOPALAKRISHNAN, B; DEY, CS; TOTEY, SM; PAWSHE, CH; SALUNKE, D; KAUR, K; SHAHA, C			A TESTICULAR PROTEIN IMPORTANT FOR FERTILITY HAS GLUTATHIONE-S-TRANSFERASE ACTIVITY AND IS LOCALIZED EXTRACELLULARLY IN THE SEMINIFEROUS TUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SPERM; MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; HUMAN TESTIS; RAT TESTES; EXPRESSION; ANTIGENS; BINDING; MOUSE; CELLS	A 24-kDa protein isolated by preparative gel electrophoresis from rat testes was reported by us as an active immunogen in rats. Anti-24-kDa antibodies inhibited murine sperm-oocyte binding in vitro. Here, we show similarity at the NH2 terminus shared by this protein purified on Sephadex G-75 followed by anion exchange high performance liquid chromatography with glutathione S-transferase (GST)-mu subunits. This protein purified by glutathione affinity chromatography also demonstrated similarity to GST-mu NH2 terminus in a 30-amino-acid overlap. Both proteins showed activity toward the GST substrate 1-chloro-2,4-dinitrobenzene (K-m of 33 mu M and 50 mu M) which was inhibited by 17 beta-estradiol 3-sulfate. Antisera against both proteins recognized liver GST-mu on Western blots and sperm acrosome of multiple species immunocytochemically. Both antisera significantly inhibited in vitro fertilization of goat oocytes by sperm preincubated with them while anti-liver GST sera did not. GST activity was localized on rat sperm, seminiferous tubular fluid, and Sertoli cells. Seminiferous tubular fluid 24-kDa protein shared similarity to the NH2 terminus of GST-mu subunits in a 20-amino-acid overlap. Time dependent accumulation of GST was detected in the spent culture medium of seminiferous tubules from rats of different ages suggesting secretion.	NATL INST IMMUNOL, NEW DELHI 110067, INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				ADACHI Y, 1991, Hokkaido Journal of Medical Science, V66, P818; AWONIYI CA, 1990, ENDOCRINOLOGY, V127, P177, DOI 10.1210/endo-127-1-177; Bardin C.W., 1988, P933; BOGGARDS JJP, 1992, BIOCHEM J, V286, P383; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; GONDOS B, 1993, SERTOLI CELL, P116; HERR JC, 1990, BIOL REPROD, V42, P181, DOI 10.1095/biolreprod42.1.181; HINTON BT, 1993, SERTOLI CELL, P250; ISHIKAWA T, 1988, EUR J BIOCHEM, V176, P551, DOI 10.1111/j.1432-1033.1988.tb14313.x; JOHNSON JA, 1992, BIOCHEM J, V252, P279; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KLYS HS, 1992, BRIT J CANCER, V66, P589, DOI 10.1038/bjc.1992.319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE MG, 1993, J NEUROCHEM, V61, P533; Listowsky Irving, 1993, P397; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MATHER JP, 1984, METHODS SERUM FREE C, P29; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MUKHTAR H, 1978, BIOCHEM BIOPH RES CO, V83, P1093, DOI 10.1016/0006-291X(78)91507-3; NAZ RK, 1993, IMMUNOLOGY REPRODUCT, P37; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAWSHE CH, 1994, THERIOGENOLOGY, V42, P117, DOI 10.1016/0093-691X(94)90668-9; RAM PA, 1989, GAMETE RES, V22, P321, DOI 10.1002/mrd.1120220309; Ritzen EM, 1981, TESTIS COMPREHENSIVE, P171; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; SHAHA C, 1991, MOL REPROD DEV, V29, P302, DOI 10.1002/mrd.1080290314; SHAHA C, 1994, MOL REPROD DEV, V38, P393, DOI 10.1002/mrd.1080380407; SHAHA C, 1990, INT J ANDROL, V13, P17, DOI 10.1111/j.1365-2605.1990.tb00956.x; SHAHA C, 1988, INT J ANDROL, V11, P479, DOI 10.1111/j.1365-2605.1988.tb01022.x; SHAHA C, 1993, HYBRIDOMA, V12, P709, DOI 10.1089/hyb.1993.12.709; SHAHA C, 1990, CONRAD W S, P75; SHAHA C, 1989, HYBRIDOMA, V8, P647, DOI 10.1089/hyb.1989.8.647; SHUR BD, 1979, DEV BIOL, V71, P243, DOI 10.1016/0012-1606(79)90167-2; SNEDECOR GW, 1967, STATISTICAL METHODS, P329; SURI A, 1993, SCI BAS FER, P427; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG PS, 1990, BIOL REPROD, V42, P351, DOI 10.1095/biolreprod42.2.351; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P998; VITALE R, 1973, ANAT REC, V176, P333, DOI 10.1002/ar.1091760309; WARHOLM M, 1985, METHOD ENZYMOL, V113, P499; WHEAT TE, 1985, MOL IMMUNOL, V22, P643, DOI 10.1016/0161-5890(85)90093-8; WHEAT TE, 1985, ANN NY ACAD SCI, V438, P156; YOGANATHAN T, 1989, BIOCHEM INT, V19, P667; ZWAIN IH, 1992, ENDOCRINOLOGY, V131, P1511, DOI 10.1210/en.131.3.1511	48	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15675	15685		10.1074/jbc.270.26.15675	http://dx.doi.org/10.1074/jbc.270.26.15675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797568	hybrid			2022-12-27	WOS:A1995RG53800039
J	CHEN, CY; SCHWARTZ, RJ				CHEN, CY; SCHWARTZ, RJ			IDENTIFICATION OF NOVEL DNA-BINDING TARGETS AND REGULATORY DOMAINS OF A MURINE TINMAN HOMEODOMAIN FACTOR, NKX-2.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; DROSOPHILA; PROTEIN; HEART; SEQUENCE; COMPLEX; CELLS; MYOD	A murine cardiac-specific homeodomain gene named csx (Komuro, I., and Izumo, S, (1993) Proc. Natl. Acad, Sci, U, S, A. 90, 8145-8149) and nkx-2.5 (Lints, T, J,, Parsons, L, M,, Hartley, L,, Lyons, I,, and Harvey, R. P, (1993) Development 119, 419-431) was identified as a potential vertebrate homologue of Drosophila tinman, a mesoderm determination factor required for insect heart formation (Bodmer, R, (1993) Development 118, 719-729), Bacterial expression of the nkx-2.5 homeodomain allowed us to identify downstream DNA targets from a library of randomly generated oligonucleotides. High affinity nkx-2.5 DNA binding sites, 5'-TNNAGTG-3', represented novel binding sequences, whereas intermediate and weaker affinity sites, 5'-C(APT)TTAATTN-3', contained the typical 5'-TAAT-3' core required by most homeodomain factors for DNA binding, We also ob served that nkx-2.5 served as a modest transcription activator in transfection assays done in 10T1/2 fibroblasts with multimerized binding sites linked to a luciferase reporter gene, Functional dissection of nkx-2.5 revealed a COOH-terminal inhibitory domain composed mainly of clusters of alanines and prolines, which appeared to mask a potent activation domain composed of hydrophobic and highly charged amino acids.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHANG KS, 1985, NUCLEIC ACIDS RES, V13, P1223, DOI 10.1093/nar/13.4.1223; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GAUZZI S, 1990, EMBO J, V9, P3631; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARVEY RP, 1994, J CELL BIOCHEM, V18, P477; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LEE TC, 1994, ONCOGENE, V9, P1047; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOSS JB, 1994, J BIOL CHEM, V269, P12731; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; OTTING G, 1991, EMBO J, V9, P3085; SASSOON D, 1989, NATURE, V34, P303; SATORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	33	183	185	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15628	15633		10.1074/jbc.270.26.15628	http://dx.doi.org/10.1074/jbc.270.26.15628			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797561	hybrid			2022-12-27	WOS:A1995RG53800031
J	GROSS, RW; RUDOLPH, AE; WANG, JA; SOMMERS, CD; WOLF, MJ				GROSS, RW; RUDOLPH, AE; WANG, JA; SOMMERS, CD; WOLF, MJ			NITRIC-OXIDE ACTIVATES THE GLUCOSE-DEPENDENT MOBILIZATION OF ARACHIDONIC-ACID IN A MACROPHAGE-LIKE CELL-LINE (RAW-264.7) THAT IS LARGELY MEDIATED BY CALCIUM-INDEPENDENT PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYZING PHOSPHOLIPASE-A2; CANINE MYOCARDIUM; SERUM-ALBUMIN; PURIFICATION; MECHANISM; INHIBITION; IDENTIFICATION; MEMBRANE; RELEASE; ADDUCT	Herein, we demonstrate that nitric oxide is a potent (>20% release) and highly selective inducer of [H-3]arachidonic acid mobilization in the macrophage-like cell line RAW 264.7. Treatment of RAW 264.7 cells with (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran -2-one resulted in the inhibition of the large majority (86%) of nitric oxide-induced [H-3]arachidonic acid release into the medium (IC50 <0.5 mu M) and the concomitant inhibition of in vitro measurable calcium-independent phospholipase A(2) activity (92% inhibition) without demonstrable effects on calcium-dependent phospholipase A(2) activity. Since nitric oxide is a potent stimulator of glycolysis (and therefore glycolytically derived ATP) and since cytosolic calcium-independent phospholipase A(2) exists as a catalytic complex comprised of ATP-modulated phosphofructokinase-like regulatory polypeptides and a catalytic subunit, we examined the role of glucose in facilitating nitric oxide-mediated arachidonic acid release. Nitric oxide-induced release of [H-3]arachidonic acid possessed an obligatory requirement for glucose, was highly correlated with the concentration of glucose in the medium, and was dependent on the metabolism of glucose. Thus, [H-3]arachidonic acid release is coupled to cellular glucose metabolism through alterations in the activity of calcium-independent phospholipase A(2). Collectively, these results identify a unifying metabolic paradigm in which the generation of lipid second messengers is coordinately linked to the signalstimulated acceleration of glycolytic flux, thereby facilitating integrated metabolic responses to cellular stimuli.	WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	GROSS, RW (corresponding author), WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED CHEM & MOLEC BIOL, ST LOUIS, MO 63110 USA.		WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852				ALBINA JE, 1993, AM J PHYSIOL, V264, pC1594, DOI 10.1152/ajpcell.1993.264.6.C1594; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BROOKS SPJ, 1988, AM J PHYSIOL, V255, pR289, DOI 10.1152/ajpregu.1988.255.2.R289; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAZEN SL, 1991, METHOD ENZYMOL, V197, P400; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; KRAFFT GA, 1981, J AM CHEM SOC, V103, P5459, DOI 10.1021/ja00408a030; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1986, BIOCHEM J, V236, P251, DOI 10.1042/bj2360251; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PORTILLA D, 1994, J CLIN INVEST, V93, P1609, DOI 10.1172/JCI117141; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	33	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14855	14858		10.1074/jbc.270.25.14855	http://dx.doi.org/10.1074/jbc.270.25.14855			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797462	hybrid			2022-12-27	WOS:A1995RE66600004
J	KIM, D; OUYANG, HH; YANG, SH; NUSSENZWEIG, A; BURGMAN, P; LI, GC				KIM, D; OUYANG, HH; YANG, SH; NUSSENZWEIG, A; BURGMAN, P; LI, GC			A CONSTITUTIVE HEAT-SHOCK ELEMENT-BINDING FACTOR IS IMMUNOLOGICALLY IDENTICAL TO THE KU AUTOANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DNA-BINDING; GENE-TRANSCRIPTION; MOLECULAR-CLONING; HUMAN-CELLS; ANTIGEN; ACTIVATION; STRESS; OLIGOMERIZATION; PURIFICATION	Analysis of the heat shock element (HSE)-binding proteins in extracts of rodent cells, during heat shock and their post-heat shock recovery, indicates that the regulation of heat shock response involves a constitutive HSE-binding factor (CHEF), in addition to the heat-inducible heat shock factor HSF1. We purified the CHEF to apparent homogeneity from HeLa cells using column chromatographic techniques including an HSE oligonucleotide affinity column. The purified CHEF consists of two polypeptides with apparent molecular masses of 70 and 86 kDa. Immunoblot and gel mobility shift analysis verify that CHEF is identical or closely related to the Ku autoantigen. The DNA binding characteristics of CHEF to double-stranded or single-stranded DNA are similar to that of Ku autoantigen. In gel mobility shift analysis using purified CHEF and recombinant human HSF1, CHEF competes with HSF1 for the binding of DNA sequences containing HSEs in vitro. Furthermore, when Rat-1 cells were co-transfected with human Ku expression vectors and the hsp70-promoter-driven luciferase reporter gene, thermal induction of luciferase is significantly suppressed relative to cells transfected with only the hsp70-luciferase construct, These data suggest a role of CHEF (or Ku protein) in the regulation of heat response in vivo.	MEM SLOAN KETTERING CANC CTR,DEPT MED PHYS,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA56909, CA 31397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056909, R01CA031397, R37CA031397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMABIS JM, 1990, CHROMOSOMA, V99, P102, DOI 10.1007/BF01735325; AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIER PR, 1993, J BIOL CHEM, V268, P7594; DVIR A, 1993, J BIOL CHEM, V268, P10440; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1963, BIOCHEM BIOPH RES CO, V190, P747; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; LIU RY, 1993, P NATL ACAD SCI USA, V90, P3078, DOI 10.1073/pnas.90.7.3078; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; PIRITY M, 1992, EUR J BIOCHEM, V210, P793, DOI 10.1111/j.1432-1033.1992.tb17482.x; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; Sambrook J, 1989, MOL CLONING LABORATO; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407	43	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15277	15284		10.1074/jbc.270.25.15277	http://dx.doi.org/10.1074/jbc.270.25.15277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797514	hybrid			2022-12-27	WOS:A1995RE66600065
J	KUROKI, K; ENG, F; ISHIKAWA, T; TURCK, C; HARADA, F; GANEM, D				KUROKI, K; ENG, F; ISHIKAWA, T; TURCK, C; HARADA, F; GANEM, D			GP180, A HOST-CELL GLYCOPROTEIN THAT BINDS DUCK HEPATITIS-B VIRUS-PARTICLES, IS ENCODED BY A MEMBER OF THE CARBOXYPEPTIDASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN HEPATOCYTES; DIMETHYL-SULFOXIDE; INFECTION; RECEPTOR; CLONING; CDNA	Duck hepatitis B virus particles bearing the L and S envelope proteins bind a cellular glycoprotein of 180 kDa (gp180) with high affinity and specificity. Binding is mediated by the pre-S region of the L protein and is blocked by neutralizing but not by non-neutralizing monoclonal antibodies to the virus. These and other properties have suggested that gp180 may be a component of the viral entry machinery. Here we report the purification of gp180 from duck liver and the isolation and characterization of cDNA encoding it. DNA sequence analysis of this cDNA indicates that gp180 is a novel member of the basic carboxypeptidase gene family.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KUROKI, K (corresponding author), KANAZAWA UNIV,CANC RES INST,DEPT BIOPHYS,13-1 TAKARAMACHI,KANAZAWA,ISHIKAWA 920,JAPAN.				NIAID NIH HHS [AI 31973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRIPON P, 1993, VIROLOGY, V192, P534, DOI 10.1006/viro.1993.1069; GRIPON P, 1988, J VIROL, V62, P4136, DOI 10.1128/JVI.62.11.4136-4143.1988; HSIEH S, 1990, J VIROL, P3192; ISHIKAWA T, 1994, VIROLOGY, V202, P1061, DOI 10.1006/viro.1994.1440; KLINGMULLER U, 1993, J VIROL, V67, P7414; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARION PL, 1988, PROG MED VIROL, V35, P43; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PUGH JC, 1989, VIROLOGY, V172, P564, DOI 10.1016/0042-6822(89)90199-2; PUGH JC, 1987, J VIROL, V61, P1384, DOI 10.1128/JVI.61.5.1384-1390.1987; SCHLICHT HJ, 1987, J VIROL, V61, P2280, DOI 10.1128/JVI.61.7.2280-2285.1987; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAN FL, 1989, J BIOL CHEM, V264, P13165; TUTTLEMAN JS, 1986, J VIROL, V58, P17, DOI 10.1128/JVI.58.1.17-25.1986; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E	20	120	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15022	15028		10.1074/jbc.270.25.15022	http://dx.doi.org/10.1074/jbc.270.25.15022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797483	hybrid			2022-12-27	WOS:A1995RE66600029
J	LACRONIQUE, V; LOPEZ, S; MIQUEROL, L; PORTEU, A; KAHN, A; RAYMONDJEAN, M				LACRONIQUE, V; LOPEZ, S; MIQUEROL, L; PORTEU, A; KAHN, A; RAYMONDJEAN, M			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF AN ERYTHROID-SPECIFIC ENHANCER IN THE L-TYPE PYRUVATE-KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; PORPHOBILINOGEN DEAMINASE GENE; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GLOBIN GENE; BETA-GLOBIN; REGULATORY ELEMENT; DNA INTERACTIONS; INVIVO PROTEIN; CACCC ELEMENT	The rat L-type pyruvate kinase gene is transcribed either from promoter L in the liver or promoter L' in erythroid cells. We have now cloned and functionally characterized an erythroid-specific enhancer, mapped in the fetal liver as hypersensitive site B (HSSB) at 3.7 kilobases upstream from the promoter L'. Protein-DNA interactions were examined in the 200-base pair core of the site by in vivo footprinting experiments. In the fetal liver, footprints were revealed at multiple GATA and CACC/GT motifs, whose association is the hallmark of erythroid-specific regulatory sequences. Functional analysis of the HSSB element in transgenic mice revealed properties of a cell-restricted enhancer. Indeed, this element was able to activate the linked ubiquitous herpes simplex virus thymidine kinase promoter in erythroid tissues. The activation was also observed in a variety of nonerythroid tissues known to synthesize GATA-binding factors. In the context of L'-PK transgenes, HSSB was not needed for an erythroid-specific activation of the L' promoter, while it was required to stimulate the L' promoter activity to a proper level. Finally, HSSB cannot be replaced by strong ubiquitous viral or cellular enhancers, suggesting a preferential interaction of the HSSB region with the L' promoter.	UNIV PARIS 05,INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Penard-Lacronique, Virginie/R-1938-2019; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BOQUET D, 1992, EUR J BIOCHEM, V207, P13, DOI 10.1111/j.1432-1033.1992.tb17013.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CARTIER N, 1992, ONCOGENE, V7, P1413; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; FISHER KD, 1993, J BIOL CHEM, V268, P23915; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GALLARDA JL, 1989, GENE DEV, V3, P845; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KELLEY C, 1993, DEVELOPMENT, V118, P817; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1992, BLOOD, V80, P575; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; SHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90; SON HJ, 1991, MOL CELL BIOL, V11, P4244, DOI 10.1128/MCB.11.8.4244; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1989, NATURE, V338, P1384; TREMP GL, 1989, J BIOL CHEM, V264, P19904; TSAI SF, 1994, NATURE, V371, P221; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG ZY, 1994, J BIOL CHEM, V269, P10079	51	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14989	14997		10.1074/jbc.270.25.14989	http://dx.doi.org/10.1074/jbc.270.25.14989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797480	hybrid			2022-12-27	WOS:A1995RE66600025
J	MILTON, NGN; BESSIS, A; CHANGEUX, JP; LATCHMAN, DS				MILTON, NGN; BESSIS, A; CHANGEUX, JP; LATCHMAN, DS			THE NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTOR ALPHA-2 SUBUNIT GENE PROMOTER IS ACTIVATED BY THE BRN-3B POU FAMILY TRANSCRIPTION FACTOR AND NOT BY BRN-3A OR BRN-3C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; DISTINCT; CELLS	The regulatory region of the neuronal nicotinic acetylcholine receptor alpha 2 subunit gene, which contains six copies of the octamer-related sequence CCCCATGCAAT, is activated by the Brn-3b POU family transcription factor but not by the closely related factors Brn-3a and Brn-3c. This effect is in contrast to the previously documented inhibitory effect of Brn-3b on octamer-containing promoters that are activated by Brn-3a and Brn-3c. Activation of the alpha 2 gene by Brn-3b requires that both the POU domain and other N-terminal sequences are derived from Brn-3b and is dependent on the intactness of the alpha 2 gene regulatory region, being lost in truncated derivatives containing one, two, or four copies of the octamer-related sequence. Surprisingly, however, these truncated derivatives are activated by Brn-3c. These effects are discussed in terms of both the influence of the target sequence and its context in the promoter on activation by the various forms of Brn-3 as well as of the processes that restrict expression of the alpha 2 subunit gene to a few cells in the nervous system.	UCL, SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND; INST PASTEUR, MOLEC NEUROBIOL LAB, F-75724 PARIS, FRANCE	University of London; University College London; UCL Medical School; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Milton, Nathaniel Gavin Nicolas/GON-7735-2022; Milton, Nathaniel G N/E-8522-2012	Milton, Nathaniel Gavin Nicolas/0000-0002-7431-9060; Milton, Nathaniel G N/0000-0002-7431-9060; Bessis, Alain/0000-0001-8362-6874				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BAUKNECHT T, 1995, J VIROL, V69, P1; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; DAUBAS P, 1990, NEURON, V5, P49, DOI 10.1016/0896-6273(90)90032-B; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; LATCHMAN DS, 1995, GENE REGULATION; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7	23	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15143	15147		10.1074/jbc.270.25.15143	http://dx.doi.org/10.1074/jbc.270.25.15143			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797498	hybrid			2022-12-27	WOS:A1995RE66600046
J	PALCZEWSKI, K; OHGURO, H; PREMONT, RT; INGLESE, J				PALCZEWSKI, K; OHGURO, H; PREMONT, RT; INGLESE, J			RHODOPSIN KINASE AUTOPHOSPHORYLATION - CHARACTERIZATION OF SITE-SPECIFIC MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; COUPLED RECEPTOR KINASES; PHOTOEXCITED RHODOPSIN; SCANNING MUTAGENESIS; 48-KDA PROTEIN; PHOSPHORYLATION; PURIFICATION; ISOPRENYLATION; IDENTIFICATION; PHOSPHATASES	Upon illumination, rhodopsin kinase (RE) phosphorylates the visual pigment rhodopsin, which is thought to partially terminate the biochemical events that follow photon absorption. Rh enzymology was explored by mutagenesis of the residues Sem(488), Thr(489) (major autophosphorylation sites), and Lys(491) (a distal residue). We found the following to be true. (i) Double mutations at residues Ser(488) and Thr(489) to Ala or Asp decrease autophosphorylation to substoichiometrical levels, while single mutations at either residue independently reduce autophosphorylation by half. (ii) Phosphorylation of residue Ser(488) influences the affinity of RR for heparin-Sepharose only moderately, whereas Thr(489) and Lys(491) are important for this interaction RK K491A does not phosphorylate acidic peptides, suggesting that this residue participates in substrate binding. (iii) Mutations in the autophosphorylation region affect the K-m for ATP, suggesting that this region is involved in binding of ATP to the catalytic site. (iv) RH mutants S488A or S488D and RR S488A and T489A have an increased ability to phosphorylate Rho in the dark. (v) Mutations at the autophosphorylation region change the initial site of phosphorylation on photolyzed rhodopsin (Rho*), implying that this region may regulate selectivity of the site of phosphorylation.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; DUKE UNIV,HOWARD HUGHES MED INST,DEPT MED CARDIOL,DURHAM,NC 27710; DUKE UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	University of Washington; University of Washington Seattle; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	PALCZEWSKI, K (corresponding author), UNIV WASHINGTON,SCH MED,DEPT OPHTHALMOL,RJ-10,SEATTLE,WA 98195, USA.			Premont, Richard/0000-0002-8053-5026	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NEI NIH HHS [EY08061] Funding Source: Medline; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEE RH, 1982, BIOCHEMISTRY-US, V21, P3303, DOI 10.1021/bi00257a009; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PALCZEWSKI K, 1993, METH NEUROSCI, V15, P217; PAULSEN R, 1984, NATURE, V302, P417; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Segel I.H., 1975, ENZYME KINETICS; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	37	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15294	15298		10.1074/jbc.270.25.15294	http://dx.doi.org/10.1074/jbc.270.25.15294			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797516	hybrid			2022-12-27	WOS:A1995RE66600067
J	SMALHEISER, NR; KIM, E				SMALHEISER, NR; KIM, E			PURIFICATION OF CRANIN, A LAMININ-BINDING MEMBRANE-PROTEIN - IDENTITY WITH DYSTROGLYCAN AND REASSESSMENT OF ITS CARBOHYDRATE MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; CENTRAL-NERVOUS-SYSTEM; L-SELECTIN; AXONAL GROWTH; CELL-ADHESION; NEURAL CELLS; P-SELECTIN; ASSOCIATION; DOMAIN; OLIGOSACCHARIDES	Cranin was described in 1987 as a membrane glocoprotein expressed in brain and many other tissues, which binds laminin with high affinity in a calcium-dependent manner. Dystrophin-associated glycoprotein (''dystroglycan'') is a laminin-binding protein cloned in 1992 whose relation to cranin has remained uncertain. Here we describe the purification of cranin to homogeneity from sheep brain, show cranin to be a form of dystroglycan, and localize the N terminus of beta-dystroglycan to amino acid residue 654. We find that brain alpha-dystroglycan is tightly associated with membranes, and localizes to regions of synaptic contact as assessed by immunocytochemistry of rat cerebellum. Brain alpha-dystroglycan expresses high mannose/hybrid N-linked saccharides, terminal GalNAc residues, and the HNK-1 epitope. Although dystroglycan has previously been presumed to be a proteoglycan, the amino acid sequence, pI, O-sialoglycoprotease susceptibility, lectin-binding profile, and laminin-binding properties of brain dystroglycan are more typical of mucin-like proteins. Furthermore, using CHO mutant cell lines deficient in xylosyltransferase and galactosyltransferase I, which are required for glycosaminoglycan biosynthesis, it is shown that chondroitin sulfate and heparan sulfate are not critical for laminin binding, and indeed are apparently not expressed at all in dystroglycan from CHO cells.			SMALHEISER, NR (corresponding author), UNIV CHICAGO,DEPT PEDIAT,MC 5058,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.			Smalheiser, Neil/0000-0003-1079-3406	NICHD NIH HHS [HD 09402] Funding Source: Medline; NINDS NIH HHS [NS 26055] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026055] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BOWE M, 1994, NEURON, V12, P1; BRESOLIN N, 1994, NEUROMUSCULAR DISORD, V4, P359, DOI 10.1016/0960-8966(94)90072-8; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3367; DICKSON G, 1992, J CELL SCI, V103, P1223; DOWBENKO D, 1993, J CLIN INVEST, V92, P952, DOI 10.1172/JCI116671; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GORECKI DC, 1994, HUM MOL GENET, V3, P1589; GRAVEL P, 1994, ANAL BIOCHEM, V221, P66, DOI 10.1006/abio.1994.1380; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; IBRAGHIMOVBESKR.O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LIDOV HGW, 1993, NEUROSCIENCE, V54, P167, DOI 10.1016/0306-4522(93)90392-S; MA JY, 1993, J BIOL CHEM, V268, P25108; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; SANTOSBENITO FF, 1992, J EXP MED, V176, P915, DOI 10.1084/jem.176.3.915; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; Smalheiser N. R., 1994, Society for Neuroscience Abstracts, V20, P1693; Smalheiser Neil R., 1992, Developmental Brain Research, V69, P215, DOI 10.1016/0165-3806(92)90162-P; Smalheiser Neil R., 1992, Developmental Brain Research, V69, P225, DOI 10.1016/0165-3806(92)90163-Q; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	53	137	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15425	15433		10.1074/jbc.270.25.15425	http://dx.doi.org/10.1074/jbc.270.25.15425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797531	hybrid			2022-12-27	WOS:A1995RE66600086
J	APTE, SS; OLSEN, BR; MURPHY, G				APTE, SS; OLSEN, BR; MURPHY, G			THE GENE STRUCTURE OF TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP)-3 AND ITS INHIBITORY ACTIVITIES DEFINE THE DISTINCT TIMP GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; DEVELOPMENTAL EXPRESSION; TERMINAL DOMAIN; TRANSFORMATION; PURIFICATION; FLUID	Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a critical role in extracellular matrix homeostasis. We have previously cloned human and mouse TIMP-3 cDNAs and mapped their chromosomal loci (Apte, S. S., Mattei, M-G., and Olsen, B. R. (1994) Genomics 19, 86-90; Apte, S. S., Hayashi, K., Seldin, M. F., Mattei, M-G;., Hayashi, M., and Olsen, B. R. (1994) Dev. Dynam. 200, 177-197); the identification of TIMP3 mutations in Sorsby's fundus dystrophy has underscored the functional importance! of TIMP-3. We now report that TIMP-3 is encoded by five exons spanning over 30 kilobase pairs of mouse genomic DNA. In the attribution of protein domains to specific exons, as well as exon structures, the Timp-3 and Timp-1 genes are similar, confirming the common evolutionary origin of the TIMPs and defining a distinct gene family. We have expressed human and mouse TIMP-3 in mouse NSO myeloma cells. In each case, an N-glycosylated. 27-kDa protein was generated, that, like TIMP-1 and TIMP-2, inhibited collagenase-1, stromelysin-1, and gelatinases A and B. TIMP-3 and TIMP-1 inhibition were quantitatively similar, implying that all TIMPs are equally efficient in MMP inhibition. Instead, differential regulation of the TIMP genes or divergent C-terminal protein sequences may underlie distinct biological functions for each TIMP.	STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND		APTE, SS (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Apte, Suneel/0000-0001-8441-1226	NHLBI NIH HHS [HL33014] Funding Source: Medline; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036819, R37AR036820, R56AR036819, R01AR036820, R37AR036819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V839, P214, DOI 10.1016/0304-4165(85)90039-X; NOMURA S, 1989, DEVELOPMENT, V105, P575; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PELLETIER JP, 1990, ARTHRITIS RHEUM, V33, P1466, DOI 10.1002/art.1780331003; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; SUN Y, 1994, CANCER RES, V54, P1139; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Werb Z, 1992, Matrix Suppl, V1, P337; WICK M, 1994, J BIOL CHEM, V269, P18953; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	35	279	289	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14313	14318		10.1074/jbc.270.24.14313	http://dx.doi.org/10.1074/jbc.270.24.14313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782289	hybrid			2022-12-27	WOS:A1995RD45500015
J	BOUABOULA, M; BOURRIE, B; RINALDICARMONA, M; SHIRE, D; LEFUR, G; CASELLAS, P				BOUABOULA, M; BOURRIE, B; RINALDICARMONA, M; SHIRE, D; LEFUR, G; CASELLAS, P			STIMULATION OF CANNABINOID RECEPTOR CB1 INDUCES KROX-24 EXPRESSION IN HUMAN ASTROCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; RAT-BRAIN; MESSENGER-RNA; INHIBITION; PROTEIN; MARIJUANA; DIFFERENTIATION; LOCALIZATION; INVOLVEMENT; MEMBRANES	The recent isolation and cloning of the G protein-coupled central cannabinoid receptor (CB1) from brain tissue has provided a molecular basis to elucidate how cannabinoid compounds may mediate their psychoactive effects. Here we report the high expression of cannabinoid receptors in human astrocytoma tumors of different grades, in the astrocytoma cell lines U373 MG and GL-15, as well as in normal astrocytes. From an analysis of the coupling mechanisms of functional CB1 receptors in U373 MG, we show that, in addition to the inhibition of adenylyl cyclase, activation by the cannabinoid agonist CP-55940 induces the expression of the immediate-early gene krox-24, also known as NGFI-A, zif/268, egr-1, and TIS8. The amount of Krox-24 protein and the level of Krox-24 DNA binding activity, as measured by Western blot and electrophoretic mobility shift assay, respectively, were also increased by the addition of CP-55940. These effects were blocked by incubation with pertussis toxin but not by treatment with hydrolysis-resistant cAMP analogues, suggesting that the transduction pathway between the cannabinoid receptor and krox-24 involves a pertussis toxin-sensitive GTP-binding protein and is independent of cARIP metabolism. The specific involvement of CB1 in Krox-24 induction was demonstrated in Chinese hamster ovary cells transfected with the human CB1 receptor and also in experiments using the CB1-selective cannabinoid antagonist SR 141716A.	SANOFI RECH,F-34184 MONTPELLIER,FRANCE; SANOFI RECH,F-75008 PARIS,FRANCE; SANOFI RECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CAO XM, 1993, J BIOL CHEM, V268, P16949; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAUMASDUPORT C, 1988, CANCER, V15, P2152; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DORNAND J, 1992, J CELL PHYSIOL, V151, P71, DOI 10.1002/jcp.1041510112; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FELDER CC, 1992, MOL PHARMACOL, V42, P838; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HISANAGA K, 1990, MOL BRAIN RES, V8, P69, DOI 10.1016/0169-328X(90)90011-2; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HOWLETT AC, 1987, NEUROPHARMACOLOGY, V26, P507, DOI 10.1016/0028-3908(87)90035-9; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legoux P, 1992, Eur Cytokine Netw, V3, P553; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAILLEUX P, 1992, NEUROSCIENCE, V48, P355; MARX J, 1990, SCIENCE, V249, P624, DOI 10.1126/science.2166339; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PREISSIG SH, 1979, ACTA CYTOL, V23, P412; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SHIRE G, 1995, J BIOL CHEM, V270, P3726; TAHIR SK, 1991, PHARMACOL BIOCHEM BE, V40, P617, DOI 10.1016/0091-3057(91)90372-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBOXEL JA, 1974, NATURE, V251, P443, DOI 10.1038/251443a0; WATZL B, 1991, INT J IMMUNOPHARMACO, V13, P1091, DOI 10.1016/0192-0561(91)90160-9	46	150	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13973	13980		10.1074/jbc.270.23.13973	http://dx.doi.org/10.1074/jbc.270.23.13973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775459	hybrid			2022-12-27	WOS:A1995RC44800058
J	CHE, MX; ORTIZ, DF; ARIAS, IM				CHE, MX; ORTIZ, DF; ARIAS, IM			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING THE BILE CANALICULAR, PURINE-SPECIFIC NA+-NUCLEOSIDE COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							XENOPUS-LAEVIS OOCYTES; RAT; TRANSPORT; MEMBRANE; ADENOSINE; RABBIT; CELLS; ATP	We previously characterized a purine-specific Na+- nucleoside cotransport system in bile canalicular membrane. The function of this transport system may be related to conserving nucleosides and preventing cholestasis. We report here the isolation of a cDNA encoding a Na+-dependent nucleoside transporter from rat liver using an expression cloning strategy. The substrate specificities and kinetic characteristics of the cloned cotransporter are consistent with the properties of the Na+-dependent, purine-selective nucleoside transporter in bile canalicular membranes. The nucleotide sequence predicts a protein of 659 amino acids (72 kDa) with 14 putative membrane-spanning domains. Northern blot analysis showed that the transcripts are present in liver and several other tissues. Data base searches indicate significant sequence similarity to the pyrimidine-selective nucleoside transporter (cNT1) of rat jejunum. Although these two subtypes of Na+-nucleoside cotransporter have different substrate specificities and tissue localizations, they are members of a single gene family.			CHE, MX (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, R01DK035652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERHFELD G, 1989, J PHYSIOL-LONDON, V418, P88; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; DOIN R, 1985, SCIENCE, V227, P1296; FORRESTER T, 1990, J PHYSIOL-LONDON, V268, P371; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN SH, 1989, J BIOL CHEM, V264, P14403; LINDEN J, 1994, J BIOL CHEM, V269, P27900; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PALACIN M, 1990, J BIOL CHEM, V265, P7142; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; SHIMA S, 1990, JPN J PHARMACOL, V53, P473, DOI 10.1254/jjp.53.473; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WU XC, 1992, J BIOL CHEM, V267, P8813	22	147	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13596	13599		10.1074/jbc.270.23.13596	http://dx.doi.org/10.1074/jbc.270.23.13596			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775409	hybrid			2022-12-27	WOS:A1995RC44800005
J	CORNEL, MJ; WILLIAMS, TA; LAMANGO, NS; COATES, D; CORVOL, P; SOUBRIER, F; HOHEISEL, J; LEHRACH, H; ISAAC, RE				CORNEL, MJ; WILLIAMS, TA; LAMANGO, NS; COATES, D; CORVOL, P; SOUBRIER, F; HOHEISEL, J; LEHRACH, H; ISAAC, RE			CLONING AND EXPRESSION OF AN EVOLUTIONARY CONSERVED SINGLE-DOMAIN ANGIOTENSIN-CONVERTING ENZYME FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HOMOLOGOUS DOMAINS; MOLECULAR-BIOLOGY; MESSENGER-RNAS; GENE; SITES; TRANSCRIPTION; SPECIFICITIES; PEPTIDES; ISOZYMES; FORMS	Mammalian somatic angiotensin converting enzyme (EC 3.4.15.1, ACE) consists of two highly homologous (N- and C-) domains encoded by a duplicated gene. We have identified an apparent single-domain (67 kDa) insect angiotensin converting enzyme (AnCE) in embryos of Drosophila melanogaster which converts angiotensin I to angiotensin II (K-m, 365 mu M), removes Phe-Arg from the C terminus of bradykinin (K-m, 22 mu M), and is inhibited by ACE inhibitors, captopril (IC50 = 1.1 x 10(-9) M) and trandolaprilat (IC50 = 1.6 x 10(-8) M). We also report the cloning and expression of a Drosophila AnCE cDNA which codes for a single-domain 615-amino acid protein with a predicted 17-amino acid signal peptide and regions with high levels of homology to both the N- and C-domains of mammalian somatic ACE, especially around the active site consensus sequence. Northern analysis identified a single 2.1-kilobase mRNA in Drosophila embryos, and Southern analysis of Drosophila genomic DNA indicates that the insect gene is not duplicated. When expressed in COS-7 cells, the AnCE protein is a secreted enzyme, which converts angiotensin I to angiotensin II and is inhibited by captopril (IC50 = 5.6 x 10(-9) M) and trandolaprilat (IC50 = 2 x 10(-8) M). The evolutionary significance of these results is discussed.	UNIV LEEDS, DEPT PURE & APPL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; IMPERIAL CANC RES FUND, GENOME ANAL LAB, LONDON WC2A 3PX, ENGLAND; COLL FRANCE, EXPTL MED LAB, INSERM, U36, F-75005 PARIS, FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM, MOLEC GENET GENOME ANAL LAB, D-69120 HEIDELBERG, GERMANY	University of Leeds; Cancer Research UK; The Genome Analysis Centre (TGAC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Helmholtz Association; German Cancer Research Center (DKFZ)			Williams, Tracy/K-5604-2013; Lamango, Nazarius/W-8459-2019	Williams, Tracy Ann/0000-0002-2388-6444				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; DAS M, 1975, J BIOL CHEM, V250, P6762; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; DEDDISH PA, 1994, P NATL ACAD SCI USA, V91, P7807, DOI 10.1073/pnas.91.16.7807; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Jowett T., 1986, DROSOPHILA, P275; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; KENNY AJ, 1991, DEGRADATION BIOACTIV, P47; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V198, P380, DOI 10.1006/bbrc.1994.1053; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAMANGO NS, 1994, BIOCHEM J, V299, P651, DOI 10.1042/bj2990651; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; Sambrook J, 1989, MOL CLONING LABORATO; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; SOFFER RL, 1976, ANNU REV BIOCHEM, V45, P73, DOI 10.1146/annurev.bi.45.070176.000445; SOUBRIER F, 1993, J HYPERTENS, V11, P599, DOI 10.1097/00004872-199306000-00003; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; TURNER AJ, 1987, J NEUROCHEM, V48, P910, DOI 10.1111/j.1471-4159.1987.tb05603.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; 1991, PROGRAM MANUAL GCG P	43	136	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13613	13619		10.1074/jbc.270.23.13613	http://dx.doi.org/10.1074/jbc.270.23.13613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775412	hybrid			2022-12-27	WOS:A1995RC44800008
J	KOZYAVKIN, SA; PUSHKIN, AV; EISERLING, FA; STETTER, KO; LAKE, JA; SLESAREV, AI				KOZYAVKIN, SA; PUSHKIN, AV; EISERLING, FA; STETTER, KO; LAKE, JA; SLESAREV, AI			DNA ENZYMOLOGY ABOVE 100-DEGREES-C - TOPOISOMERASE V UNLINKS CIRCULAR DNA AT 80-120-DEGREES-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXTREMELY THERMOPHILIC ARCHAEBACTERIA; DESULFUROCOCCUS-AMYLOLYTICUS; PYROCOCCUS-FURIOSUS; ELECTRON-MICROSCOPY; POLYMERASE; ARCHAEA; TEMPERATURE; BACTERIA; AMPLIFICATION; SEQUENCES	The widespread application of polymerase chain reaction and related techniques in biology and medicine has led to a heightened interest in thermophilic enzymes of DNA metabolism. Some of these enzymes are stable for hours at 100 degrees C, but no enzymatic activity on duplex DNA at temperatures above 100 degrees C has so far been demonstrated. Recently, we isolated topoisomerase V from the hyperthermophile Methanopyrus kandleri, which grows up to 110 degrees C. This novel enzyme is similar to eukaryotic topoisomerase I and acts on duplex DNA regions. We now show that topoisomerase V catalyzes the unlinking of double-stranded circular DNA at temperatures up to 122 degrees C. In this in vitro system, maximal DNA unlinking occurs at 108 degrees C and corresponds to complementary strands being linked at most once. These results further imply that in the presence of sufficient positive supercoiling DNA can exist as a double helix even at 122 degrees C.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV REGENSBURG,W-8400 REGENSBURG,GERMANY; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Regensburg; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Kozyavkin, Sergei/0000-0001-5605-5113				ACHENBACHRICHTE.L, 1987, SYST APPL MICROBIOL, V9, P34; ADAMS W, 1992, BIOCATALYSIS EXTREME; COWAN DA, 1987, BIOCHEM J, V247, P121, DOI 10.1042/bj2470121; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DANSON J, 1992, BIOCH SOC S, V58; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; GAGUA AV, 1981, NATURE, V294, P662, DOI 10.1038/294662a0; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; JOHNSON D, 1975, NUCLEIC ACIDS RES, V2, P2049, DOI 10.1093/nar/2.11.2049; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; KONG HM, 1993, J BIOL CHEM, V268, P1965; KOZYAVKIN SA, 1994, J BIOL CHEM, V269, P11081; Kristjansson Jakob K., 1992, P1; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LOWE SE, 1993, MICROBIOL REV, V57, P451, DOI 10.1128/MMBR.57.2.451-509.1993; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PUSHKIN AV, 1993, FEMS MICROBIOL LETT, V113, P167; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEN Y, 1993, NATURE, V366, P48, DOI 10.1038/366048a0; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1994, J BIOL CHEM, V269, P3295; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VOLOGODSKII AV, 1992, TOPOLOGY PHYSICS CIR; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	41	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13593	13595		10.1074/jbc.270.23.13593	http://dx.doi.org/10.1074/jbc.270.23.13593			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775408	hybrid			2022-12-27	WOS:A1995RC44800004
J	WEISS, C; GOLOUBINOFF, P				WEISS, C; GOLOUBINOFF, P			A MUTANT AT POSITION-87 OF THE GROEL CHAPERONIN IS AFFECTED IN PROTEIN-BINDING AND ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK GENES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; COOPERATIVITY; MORPHOGENESIS; PURIFICATION; STRESS; HSP60	The highly conserved aspartic acid residue at position 87 of the Escherichia coli chaperonin GroEL was mutated to glutamic acid. When expressed in an E. coli groEL mutant strain deficient for phage morphogenesis, plasmid-encoded GroEL mutant D87E restored T-4 phage morphogenesis. It did not, however, reactivate the transcription of a recombinant luciferase operon from Vibrio fischeri. In vitro, GroEL mutant D87E was found to be impaired in the ability to bind nonnative proteins and to hydrolyze ATP, resulting in less efficient refolding of urea-denatured ribulose-1,5-bisphosphate carboxylase/oxygenase. Mutant oligomer D87E GroEL(14) was able to bind GroES(7) as efficiently as wild-type GroEL(14). The conserved aspartic acid residue at position 87 located in the equatorial domain of GroEL (Braig, K., Otwinowski, Z., Hegde, R., Boisvert, D. C., Joachimiak, A., Horwich, A. L., and Sigler, P. B. (1994) Nature 371, 578-586) is thus inferred to have a dual effect on the binding of nonnative proteins to the GroEL(14) core chaperonin and on ATP hydrolysis.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				ADAR YY, 1992, J BACTERIOL, V174, P7138, DOI 10.1128/jb.174.22.7138-7143.1992; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BLOOM M, 1986, J BACTERIOL, V166, P380, DOI 10.1128/jb.166.2.380-384.1986; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P278; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GREENER T, 1993, EMBO J, V12, P889, DOI 10.1002/j.1460-2075.1993.tb05729.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEATHERBARROW RJ, 1987, ENZFITTER PROGRAM; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; ULITZUR S, 1988, J BIOLUM CHEMILUM, V2, P81, DOI 10.1002/bio.1170020205; VIITANEN PV, 1992, PROTEINSCI, V7, P363	45	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13956	13960		10.1074/jbc.270.23.13956	http://dx.doi.org/10.1074/jbc.270.23.13956			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775456	hybrid			2022-12-27	WOS:A1995RC44800055
J	DARMON, AJ; EHRMAN, N; CAPUTO, A; FUJINAGA, J; BLEACKLEY, RC				DARMON, AJ; EHRMAN, N; CAPUTO, A; FUJINAGA, J; BLEACKLEY, RC			THE CYTOTOXIC T-CELL PROTEINASE GRANZYME-B DOES NOT ACTIVATE INTERLEUKIN-1-BETA-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TOXIC LYMPHOCYTES-T; SERINE PROTEASES; MOLECULAR-CLONING; CONVERTING ENZYME; APOPTOSIS; CYTOLYSIS; SUBSTRATE; GRANULES; GENES; ACID	Murine granzyme B (cytotoxic cell proteinase-1 (CCP1)) is a member of a family of seven serine proteases found in cytoplasmic granules of cytotoxic T lymphocytes (CTLs). Evidence has suggested that it is involved in target cell DNA fragmentation during CTL-mediated cytotoxicity, although intracellular substrates for granzyme B have not yet been identified. The substrate specificity of granzyme B, requiring an aspartic acid residue at site P1, is unique among eukaryotic serine proteases and is shared with only one other known eukaryotic protease, interleukin-1 beta-converting enzyme (ICE). ICE is responsible for processing pro-interleukin-1 beta to produce biologically active interleukin-1 beta and is itself synthesized as an inactive precursor. Recent evidence has suggested a role for ICE in programmed cell death, which led to a model for CTL-mediated cytotoxicity. In this proposal granzyme B activates ICE in the target cell by proteolytically processing the ICE precursor, resulting in active ICE heterodimer that induces apoptosis in the target cell. We have isolated the cDNA encoding murine ICE and generated in vitro translated ICE precursor. Using lysates from COS cells expressing granzyme B we show that ICE precursor is not a substrate for granzyme B and propose an alternate mechanism for CTL-mediated cytotoxicity.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA	University of Alberta								BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NETT MA, 1992, J IMMUNOL, V149, P3254; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	27	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32043	32046						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798197				2022-12-27	WOS:A1994PX30400006
J	DING, Y; CASEY, JR; KOPITO, RR				DING, Y; CASEY, JR; KOPITO, RR			THE MAJOR KIDNEY AE1 ISOFORM DOES NOT BIND ANKYRIN (ANK1) IN-VITRO - AN ESSENTIAL ROLE FOR THE 79 NH2-TERMINAL AMINO-ACID-RESIDUES OF BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANION-EXCHANGER; CYTOPLASMIC DOMAIN; INTERCALATED CELLS; COLLECTING DUCT; RAT-KIDNEY; MEMBRANE-CYTOSKELETON; TRANSPORT PROTEIN; EPITHELIAL-CELLS; SPECTRIN; LOCALIZATION	The AE1 (band 3) protein mediates the exchange of anions across the erythrocyte plasma membrane and, via association with the adapter molecule, ankyrin (Ank1), forms the major link between the membrane and the underlying spectrin cytoskeleton. The major kidney isoform of AE1 (kAE1), a protein that is otherwise identical to erythroid AE1 but lacks the NH2-terminal 79 amino acids, is localized to the basolateral plasma membrane of acid-secreting (alpha-type) intercalated cells of distal nephron. It has been proposed that this polarized distribution of kAE1 is due, at least in part, to its association with the ankyrin-spectrin cytoskeleton. In this study, we have used cell-free binding assays to investigate the interaction of anion exchangers with an Ank1 fragment, R13-H, that contains the AE1 binding site. Microsomes from cells expressing full-length erythroid AE1 bound I-125-labeled R13-H, revealing the presence of both high (K-d = 12.5 nM) and low (K-d = 166 nM) affinity sites. This binding was specific, as evidenced by the failure to observe high affinity binding of I-125-R13-H to microsomes from cells transfected with vector alone or with AE1m, a mutant lacking the similar to 400 amino acid NH2-terminal cytoplasmic ankyrin binding domain, Using this assay, we could detect no high affinity association between kAE1 and I-125-R13-H. We conclude that the NH2-terminal 79 amino acids play an essential role in high affinity and specific binding of AE1 to Ank1.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056	NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BECKER PS, 1985, CLIN HAEMATOL, V14, P15; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DRENCKHAHN D, 1993, RENAL PHYSIOL BIOCH, V16, P6; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; DRENCKHAHN D, 1987, AM J PHYSIOL, V252, pC570, DOI 10.1152/ajpcell.1987.252.5.C570; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1988, CELL PHYSL BLOOD, P151; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1989, ANION TRANSPORT PROT, P103; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MORGANS CW, 1993, J CELL SCI, V105, P1137; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OGEL ZB, 1992, PROTEIN ENG, V5, P467, DOI 10.1093/protein/5.5.467; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	49	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32201	32208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798219				2022-12-27	WOS:A1994PX30400031
J	JANMEY, PA; HVIDT, S; KAS, J; LERCHE, D; MAGGS, A; SACKMANN, E; SCHLIWA, M; STOSSEL, TP				JANMEY, PA; HVIDT, S; KAS, J; LERCHE, D; MAGGS, A; SACKMANN, E; SCHLIWA, M; STOSSEL, TP			THE MECHANICAL-PROPERTIES OF ACTIN GELS - ELASTIC-MODULUS AND FILAMENT MOTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUASIELASTIC LIGHT-SCATTERING; F-ACTIN; BINDING PROTEIN; NUCLEOTIDE EXCHANGE; POLYMERIZED ACTIN; ALPHA-ACTININ; NETWORKS; LENGTH; MACROPHAGES; MOBILITY	To address large discrepancies reported in the literature, the viscoelastic properties of gels formed by purified actin filaments have been measured by five different techniques and five different instruments using actin preparations purified separately in four different laboratories, These measurements consistently showed that the elastic shear modulus of 2 mg/ml F-actin is on the order of several hundred pascals, and depends very strongly on the length of the filaments and on the history of the sample prior to measurement. Shortening of actin filaments with gelsolin and mechanical perturbations reduce the shear modulus to low values identical to some reported in the literature, indicating that such perturbations account for low shear moduli and poor responsiveness to filament modifying treatments reported previously, The structures of individual actin filaments within gels very similar or identical to those studied rheometrically were also examined by dynamic light scattering and fluorescence microscopy. Dynamic light scattering data were analyzed by a new method to confirm that actin filaments have no stable associations with each other and fluctuate in solution at a rate governed by the filament bending modulus or persistence length, determined to be approximately 10 mu m. Fluorescence microscopy confirmed that applying even small shear stresses to F-actin can orient and rupture the filaments, and that in a minimally perturbed viscoelastic gel, long actin filaments are free to diffuse within a limit of constraints formed by their neighbors, These findings confirm that relatively isotropic F-actin networks are sufficiently strong to stabilize cells.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOMED & BIOL SCI, BOSTON, MA 02115 USA; ROSKILDE UNIV CTR, DEPT CHEM, DK-4000 ROSKILDE, DENMARK; HUMBOLDT UNIV BERLIN, FAK MED CHARITE, INST MED PHYS & BIOPHYS, O-1040 BERLIN, GERMANY; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEORET GRP, PARIS 06, FRANCE; TECH UNIV MUNICH, DEPT PHYS, D-85748 GARCHING, GERMANY; UNIV MUNICH, INST ZELLBIOL, D-80336 MUNICH 2, GERMANY	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Roskilde University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Technical University of Munich; University of Munich	JANMEY, PA (corresponding author), BRIGHAM & WOMENS HOSP, DIV EXPTL MED, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.			Kas, Josef A./0000-0003-3158-2480; Hvidt, Soren/0000-0002-7315-3089	NHLBI NIH HHS [HL07680, HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almdal K., 1993, POLYM GELS NETW, V1, P5, DOI [10.1016/0966-7822(93)90020-I, DOI 10.1016/0966-7822(93)90020-I]; BALE MD, 1988, THROMB RES, V52, P565, DOI 10.1016/0049-3848(88)90129-6; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; Brown W., 1993, DYNAMIC LIGHT SCATTE, P272; BURLACU S, 1992, AM J PHYSIOL, pC569; BUXBAUM RE, 1987, SCIENCE, V235, P1511, DOI 10.1126/science.2881354; CASELLA JF, 1993, CYTOSKELETON CELL FU, P44; COPPIN CM, 1992, BIOPHYS J, V63, P794, DOI 10.1016/S0006-3495(92)81647-8; CORTESE JD, 1988, J CELL BIOL, V107, P1477, DOI 10.1083/jcb.107.4.1477; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; Doi M., 1988, THEORY POLYM DYNAMIC; ELSON EL, 1988, ANNU REV BIOPHYS BIO, V17, P397; EVANS E, 1993, J CELL BIOL, V122, P1295, DOI 10.1083/jcb.122.6.1295; FARGE E, 1993, MACROMOLECULES, V26, P5041, DOI 10.1021/ma00071a009; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FERRY JD, 1983, ANN NY ACAD SCI, V408, P1, DOI 10.1111/j.1749-6632.1983.tb23229.x; FUJIME S, 1971, J MOL BIOL, V62, P251, DOI 10.1016/0022-2836(71)90144-6; FURUKAWA R, 1993, BIOCHEMISTRY-US, V32, P12346, DOI 10.1021/bi00097a010; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HASKELL J, 1994, BIOPHYS J, V66, pA196; HVIDT S, 1990, PHYSICAL NETWORKS PO, P195; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; JANMEY PA, 1986, J BIOL CHEM, V261, P8357; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; KAS J, 1994, NATURE, V368, P226, DOI 10.1038/368226a0; KAS J, 1993, EUROPHYS LETT, V21, P865, DOI 10.1209/0295-5075/21/8/012; KERST A, 1990, P NATL ACAD SCI USA, V87, P4241, DOI 10.1073/pnas.87.11.4241; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LARCHE D, 1993, J PHYS III, V3, P1283; LUBYPHELPS K, 1993, CURR OPIN CELL BIOL, V6, P3; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MIYAMOTO S, 1993, BIOPHYS J, V64, P1139, DOI 10.1016/S0006-3495(93)81480-2; MULLER O, 1991, MACROMOLECULES, V24, P3111; NEWMAN J, 1993, BIOPHYS J, V64, P1559, DOI 10.1016/S0006-3495(93)81525-X; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; OTT A, 1993, PHYS REV E, V48, pR1642, DOI 10.1103/PhysRevE.48.R1642; PACAUD M, 1987, EUR J BIOCHEM, V165, P139, DOI 10.1111/j.1432-1033.1987.tb11204.x; PACAUD M, 1987, J CELL SCI, V88, P81; PIEKENBROCK T, 1992, BIOPOLYMERS, V32, P1471, DOI 10.1002/bip.360321107; PIEKENBROCK T, 1991, AIP CONF PROC, V226, P282; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; Ruddies R., 1993, Biochemical Society Transactions, V21, p37S; SACKMANN E, 1994, MACROMOL CHEM PHYSIC, V195, P7, DOI 10.1002/macp.1994.021950103; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; SATO M, 1985, J BIOL CHEM, V260, P8585; SCHMIDT CF, 1989, MACROMOLECULES, V22, P3638, DOI 10.1021/ma00199a023; SIMON SI, 1990, J BIOMECH ENG-T ASME, V112, P303, DOI 10.1115/1.2891188; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUZUKI A, 1991, BIOPHYS J, V59, P25, DOI 10.1016/S0006-3495(91)82194-4; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WEGNER A, 1988, J BIOL CHEM, V263, P13739; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; ZANER KS, 1986, J BIOL CHEM, V261, P7615; ZANER KS, 1988, J BIOL CHEM, V263, P4532; ZIEMANN F, 1994, BIOPHYS J, V66, P2210, DOI 10.1016/S0006-3495(94)81017-3	68	223	225	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32503	32513						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798252				2022-12-27	WOS:A1994PX30400073
J	KOJIMA, R; FUJIMORI, T; KIYOTA, N; TORIYA, Y; FUKUDA, T; OHASHI, T; SATO, T; YOSHIZAWA, Y; TAKEYAMA, K; MANO, H; MASUSHIGE, S; KATO, S				KOJIMA, R; FUJIMORI, T; KIYOTA, N; TORIYA, Y; FUKUDA, T; OHASHI, T; SATO, T; YOSHIZAWA, Y; TAKEYAMA, K; MANO, H; MASUSHIGE, S; KATO, S			IN-VIVO ISOMERIZATION OF RETINOIC ACIDS - RAPID ISOMER EXCHANGE AND GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; BINDING-PROTEIN; THYROID-HORMONE; X-RECEPTORS; ALL-TRANS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; MESSENGER-RNA; VITAMIN-D; II GENE	The in vivo isomerization of all-trans- and 9-cis-retinoic acids (RAs) was evaluated by high performance Liquid chromatography after oral administration to rats. Ah-trans (2 ng/ml)- and 13-cis (1.8 ng/ml)-RAs, but not 9-cis-RA, were detected in the serum of normal rats. When an excess of either ah-trans-HA or 9-cis-RA (100 mu g/rat) was intragastrically administered to the retinoid-depleted rats, a rapid isomer exchange between 9-cis- and all-trans-RAs along with appearance of the administered RA occurred shortly after the dose (30 min). RA rapidly isomerized when an excess of either all-trans- or 9-cis-RA (1 mg/rat) was administered to normal rats. To examine whether the isomerized RAs elicit biological actions in vivo, the induction of target genes-[cellular retinol-binding protein type II (CRBP II) for 9-cis-RA and all-trans-retinoic acid receptor beta (RAR beta) for 9-cis- and all-trans-RAs] was determined. The degree of induction of the two genes did not differ 4 h after administration of either 9-cis-RA or all-trans-Rk However, unlike all-trans-RA, the RAR-specific synthetic retinoids did not induce the CRBP II gene. These results suggested that the apparent actions of 9-cis- and all-trans-RAs on gene expression in vivo may be mediated to some extent by the converted stereoisomer.	TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN	Tokyo University of Agriculture								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLUM ME, 1985, J BIOL CHEM, V260, P590; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3828; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KTO S, 1994, J NUTR SCI VITAMINOL, V39, P545; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIVREA MA, 1993, RETINOIDS; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MANO H, 1994, J BIOL CHEM, V269, P1591; MATSUURA T, 1993, ARCH BIOCHEM BIOPHYS, V301, P221, DOI 10.1006/abbi.1993.1137; NINOMIYA Y, 1992, BIOCHEM BIOPH RES CO, V187, P1374, DOI 10.1016/0006-291X(92)90454-S; OLSON JA, 1992, J NUTR, V122, P615, DOI 10.1093/jn/122.suppl_3.615; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; TANG GW, 1990, J LIPID RES, V31, P175; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WOLF G, 1992, NUTR REV, V50, P197, DOI 10.1111/j.1753-4887.1992.tb01325.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	53	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32700	32707						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798278				2022-12-27	WOS:A1994PX30400101
J	LUO, GX; HOROWITZ, PM				LUO, GX; HOROWITZ, PM			THE STABILITY OF THE MOLECULAR CHAPERONIN CPN60 IS AFFECTED BY SITE-DIRECTED REPLACEMENT OF CYSTEINE-518	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GROEL; RHODANESE; PROTEINS; ATP; PURIFICATION; CARBOXYLASE; POLYMERASE; DNA	Cysteine 518 of the molecular chaperonin cpn60 (groEL) has been replaced with serine (C518S) by site directed mutagenesis. The resulting mutant chaperonin protein is still functional and it can: (a) arrest the spontaneous folding of rhodanese in the absence of GroES and ATP, (b) assist refolding of the enzyme rhodanese in the presence of GroES and ATP/Mg2+, and (c) permit the urea-induced release and refolding of rhodanese from its complex with cpn60, ATP/Mg2+, alone, could discharge active rhodanese from cpn60 complexes formed with either wild type or C518S, In contrast with wild type cpn60, C518S has: (a) reduced stability of its quaternary structure, (b) reduced ability to reassemble tetradecamers after dissociation by urea; (c) reduced ATPase activity; and (d) more easily exposed hydrophobic surfaces, The data suggest that replacement of Cys-518 with Ser in cpn60 destabilizes its oligomeric structure, but there is no significant effect on cpn60 function or the stability of the monomers formed in urea.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROVITZ A, 1994, J MOL BIOL, V238, P133, DOI 10.1006/jmbi.1994.1275; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32151	32154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798211				2022-12-27	WOS:A1994PX30400023
J	MCCANCE, SG; MENHART, N; CASTELLINO, FJ				MCCANCE, SG; MENHART, N; CASTELLINO, FJ			AMINO-ACID-RESIDUES OF THE KRINGLE-4 AND KRINGLE-5 DOMAINS OF HUMAN PLASMINOGEN THAT STABILIZE THEIR INTERACTIONS WITH OMEGA-AMINO ACID LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; RECOMBINANT KRINGLE-1; H-1-NMR SPECTROSCOPY; ACTIVATOR; FIBRIN; PURIFICATION; FRAGMENTS; REGIONS; COMPLEX	Regions of the human plasminogen (Pg) cDNA containing its kringle 4 (K4) and K5 domains have been expressed in Escherichia coli, and binding constants of omega-amino acid ligands for recombinant (r)-[R4(Pg)] and r-[K5(Pg)] have been obtained. In each case, the results showed that of a series of aliphatic alpha,omega-amino acid analogues, g-aminohexanoic acid showed maximal affinity for these modules, and all ligands interacted more strongly with r-[K4(Pg)] than with r-[K5(Pg)]. Site-directed mutagenesis investigations demonstrated that the major amino acid side chain contributors to ligand binding were similar for each of these kringles. Ligand binding was stabilized by charged groups at Asp(56) of r-[K4(Pg)] and Asp(57) of r-[K5(Pg)] as well as by Arg(69) Of both r-[K4(Pg)] and r-[K5(Pg)]. Some hydrophobic amino acids that contributed significantly to the binding strength of the ligands were identified. These were provided by homologous residues in each of the domains, viz. Trp(60) and Trp(70) of r-[K4(Pg)] and Trp(62) and Tyr(72) of r-[K5(Pg)]. Tyr(74) of r-[K5(Pg)] also substantially contributed to its ligand binding energy,	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R37HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BYEON IJL, 1989, BIOCHEMISTRY-US, V28, P9350, DOI 10.1021/bi00450a016; BYEON IJL, 1991, EUR J BIOCHEM, V197, P155, DOI 10.1111/j.1432-1033.1991.tb15894.x; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321; DEMARCO A, 1989, BIOCHIM BIOPHYS ACTA, V994, P121, DOI 10.1016/0167-4838(89)90151-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DESERRANO VS, 1994, BIOCHEMISTRY-US, V33, P3509, DOI 10.1021/bi00178a007; DESERRANO VS, 1993, BIOCHEMISTRY-US, V32, P3540, DOI 10.1021/bi00065a004; DESERRANO VS, 1992, ARCH BIOCHEM BIOPHYS, V292, P206, DOI 10.1016/0003-9861(92)90069-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P11698, DOI 10.1021/bi00162a005; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; HOCHSCHWENDER SM, 1981, J BIOL CHEM, V256, P1172; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; NIELSEN PR, 1993, BIOCHEMISTRY-US, V32, P13019, DOI 10.1021/bi00211a010; NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6; PETROS AM, 1989, BIOCHEMISTRY-US, V28, P1368, DOI 10.1021/bi00429a064; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; THEWES T, 1990, J BIOL CHEM, V265, P3906; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TREXLER M, 1982, J BIOL CHEM, V257, P7401; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; URANO T, 1987, J BIOL CHEM, V262, P15959; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	33	50	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32405	32410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798240				2022-12-27	WOS:A1994PX30400059
J	TAM, LY; LOO, TW; CLARKE, DM; REITHMEIER, RAF				TAM, LY; LOO, TW; CLARKE, DM; REITHMEIER, RAF			IDENTIFICATION OF AN INTERNAL TOPOGENIC SIGNAL SEQUENCE IN HUMAN BAND-3, THE ERYTHROCYTE ANION-EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE-PROTEIN TOPOLOGY; ENDOPLASMIC-RETICULUM; TRANSPORT PROTEIN; MICROSOMAL-MEMBRANES; RECOGNITION PARTICLE; ALKALINE-PHOSPHATASE; GLUCOSE TRANSPORTER; XENOPUS-LAEVIS; BETA-LACTAMASE	The insertion of Band 3, the human erythrocyte anion exchanger, into microsomal membranes was studied in an in vitro reticulocyte lysate translation system. Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642. Insertion of truncated Band 3 molecules into microsomal membranes was assayed by glycosylation, resistance to alkaline extraction, and tryptic removal of the cytosolic domain. Truncations containing either the first four or the last eight putative transmembrane segments were stably integrated into microsomes showing that an intact membrane domain was not required for membrane integration. Furthermore, the extracytosolic domain following the seventh transmembrane segment was properly translocated across the microsomal membrane and glycosylated whether the seventh transmembrane segment was the first, last, or the only transmembrane segment in the construct. The ability of the entire membrane domain, the truncated domain beginning with the seventh transmembrane segment, or the seventh transmembrane segment to insert into microsomes was dependent on the presence of the signal recognition particle receptor. The seventh transmembrane segment in Band 3 therefore has the topogenic properties of an internal signal sequence.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA	University of Toronto	TAM, LY (corresponding author), UNIV TORONTO, DEPT MED, MRC, MEMBRANE BIOL GRP, TORONTO M5S 1A8, ON, CANADA.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRAELL WA, 1982, CELL, V28, P23, DOI 10.1016/0092-8674(82)90371-3; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; BROCK CJ, 1983, BIOCHEM J, V213, P577, DOI 10.1042/bj2130577; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CASEY JR, 1993, BIOCHEMISTRY-US, V32, P1172, DOI 10.1021/bi00055a023; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1982, NATURE, V318, P338; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GOMEZ S, 1993, J BIOL CHEM, V268, P19593; GROVES JD, 1992, J BIOL CHEM, V267, P22163; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JAY DG, 1986, BIOCHEMISTRY-US, V25, P554, DOI 10.1021/bi00351a006; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1986, NATURE, V322, P549, DOI 10.1038/322549a0; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARBAN E, 1981, J CELL BIOL, V91, P637; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	66	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32542	32550						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798256				2022-12-27	WOS:A1994PX30400078
J	AUTHIER, F; MORT, JS; BELL, AW; POSNER, BI; BERGERON, JJM				AUTHIER, F; MORT, JS; BELL, AW; POSNER, BI; BERGERON, JJM			PROTEOLYSIS OF GLUCAGON WITHIN HEPATIC ENDOSOMES BY MEMBRANE-ASSOCIATED CATHEPSIN-B AND CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ISOLATED CANINE HEPATOCYTES; RAT PROCATHEPSIN-B; MACROPHAGE ENDOSOMES; LYSOSOMAL-ENZYMES; MICROSOMAL-MEMBRANES; LIVER ENDOSOMES; RECEPTOR KINASE; HEPG2 CELLS; INSULIN	The acidic glucagon-degrading activity of hepatic endosomes has been attributed to membrane-bound forms of cathepsins B and D. Endosomal lysates processed full-length nonradiolabeled glucagon to 32 different peptides that were identified by amino acid analysis and full-length sequencing, These indicated C-terminal carboxypeptidase, endopeptidase as well as N-terminal tripeptidyl-aminopeptidase activities in endosomes. Glucagon proteolysis was inhibited 95% by E-64 and pepstatin A, inhibitors of cathepsins B and D, respectively. This was confirmed by the pH 6-dependent chemical cross-linking of [I-125]iodoglucagon to a polypeptide of 30 kDa, which was immunodepleted by polyclonal anti cathepsin B antibody, and the removal of greater than 80% of glucagon-degrading activity by polyclonal antibodies to cathepsins B and D, By similar criteria, insulin-degrading enzyme was ruled out as a candidate enzyme for endosomal proteolysis of glucagon. Lysosomal contamination was unlikely since all forms of cathepsin B in endosomes, i.e. the major 45-kDa inactive precursor as well as the lesser amounts of the 32- and 28-kDa active forms, were tightly bound to endosomal membranes. Furthermore the mature 29-kDa single-chain and 22-kDa heavy-chain forms of cathepsin L were undetectable in endosomes, although high levels of the 37-kDa preform were observed. Membrane association of the cathepsins B and D was not to the mannose g-phosphate receptor since association was unaffected by mannose B-phosphate and/or EDTA, thereby indicating a distinct endosomal receptor. Hence, a pool of active cathepsins B and D as well as a poorly defined tripeptidyl aminopeptidase is maintained in endosomes by selective membrane retention. These hydrolases degrade glucagon internalized into Liver parenchyma early in endocytosis.	MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,SHELDON BIOTECHNOL CTR,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL,PQ H3G 1A6,CANADA	McGill University; McGill University; McGill University; McGill University	AUTHIER, F (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U30,F-75015 PARIS,FRANCE.		Bergeron, John/AAW-1893-2021; Posner, Barry/B-6733-2008					AFTING EG, 1981, BIOCHEM J, V197, P519, DOI 10.1042/bj1970519; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; AUTHIER F, 1990, BIOCHEM J, V272, P703, DOI 10.1042/bj2720703; AUTHIER F, 1991, BIOCHEM J, V280, P211, DOI 10.1042/bj2800211; AUTHIER F, 1992, ENDOCRINOLOGY, V131, P447, DOI 10.1210/en.131.1.447; AUTHIER F, 1994, CELLULAR PROTEOLYTIC, V15, P89; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BLACHE P, 1990, J BIOL CHEM, V265, P21514; Blum J S, 1993, Subcell Biochem, V19, P69; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FIANI ML, 1993, ARCH BIOCHEM BIOPHYS, V307, P225, DOI 10.1006/abbi.1993.1583; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAGOPIAN WA, 1987, J CLIN INVEST, V79, P409, DOI 10.1172/JCI112827; HAGOPIAN WA, 1984, J BIOL CHEM, V259, P8986; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; JASPAN LJ, 1981, AM J PHYSIOL, V240, P233; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUO WL, 1994, J BIOL CHEM, V269, P22599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATRISIAN LM, 1984, J BIOL CHEM, V259, P3047; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OU WJ, 1992, J BIOL CHEM, V267, P23789; PLANCK SR, 1984, J BIOL CHEM, V259, P3053; POLGAR L, 1987, J BIOL CHEM, V262, P14448; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; RODMAN JS, 1990, J LEUKOCYTE BIOL, V48, P116, DOI 10.1002/jlb.48.2.116; ROSE K, 1988, BIOCHEM J, V256, P847, DOI 10.1042/bj2560847; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SHEETZ MJ, 1988, J BIOL CHEM, V263, P8509; SHEETZ MJ, 1988, J BIOL CHEM, V263, P19210; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILEY HS, 1985, J BIOL CHEM, V260, P5290	59	76	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15798	15807		10.1074/jbc.270.26.15798	http://dx.doi.org/10.1074/jbc.270.26.15798			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797582	hybrid			2022-12-27	WOS:A1995RG53800055
J	LAKIN, ND; MORRIS, PJ; THEIL, T; SATO, TN; MOROY, T; WILSON, MC; LATCHMAN, DS				LAKIN, ND; MORRIS, PJ; THEIL, T; SATO, TN; MOROY, T; WILSON, MC; LATCHMAN, DS			REGULATION OF NEURITE OUTGROWTH AND SNAP-25 GENE-EXPRESSION BY THE BRN-3A TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN PROTEIN; ANTISENSE OLIGONUCLEOTIDES; NEURONAL CELLS; RNASE-H; I-POU; DIFFERENTIATION; HOMEODOMAIN; REDISTRIBUTION; SECRETION; DISTINCT	SNAP-25 is a presynaptic nerve terminal protein which is also essential for the process of neurite outgrowth in vivo and in vitro. However the processes regulating its expression have not been characterized previously. We show that the gene encoding this protein, SNAP, is strongly activated by the Brn-3a POU (Pit-Oct-Unc) family transcription factor. Expression of both Brn-3a and SNAP-25 increases when ND7 neuronal cells are induced to extend neurite processes by serum removal. Inhibition of Brn-3a expression in these cells inhibits SNAP-25 expression and abolishes the neurite outgrowth that normally occurs in response to serum removal. These results identify Brn-3a as the first transcription factor having a role in process outgrowth in neuronal cells acting, at least in part, via the activation of SNAP-25 gene expression.	UNIV COLL & MIDDLESEX SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	University of London; University College London; Philipps University Marburg; Scripps Research Institute			Moroy, Tarik/D-9923-2011	Theil, Thomas/0000-0001-6590-8309	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048989] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 48989] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAMILLI P, 1993, NATURE, V364, P387; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; FALKNER FG, 1986, NUCLEIC ACIDS RES, V13, P7847; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HESS EJ, 1992, J NEUROSCI, V12, P2865; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WHEATLEY SC, 1992, NEUROSCIENCE, V51, P575, DOI 10.1016/0306-4522(92)90297-F; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; [No title captured]	38	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15858	15863		10.1074/jbc.270.26.15858	http://dx.doi.org/10.1074/jbc.270.26.15858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797590	hybrid			2022-12-27	WOS:A1995RG53800064
J	LI, QT; KARAM, SM; GORDON, JI				LI, QT; KARAM, SM; GORDON, JI			SIMIAN-VIRUS-40 T-ANTIGEN-INDUCED AMPLIFICATION OF PRE-PARIETAL CELLS IN TRANSGENIC MICE - EFFECTS ON OTHER GASTRIC EPITHELIAL CELL LINEAGES AND EVIDENCE FOR A P53-INDEPENDENT APOPTOTIC MECHANISM THAT OPERATES IN A COMMITTED PROGENITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING PROTEIN; GROWTH-FACTOR-ALPHA; MOUSE STOMACH; DUODENAL MUCOSA; BETA-SUBUNIT; CORPUS; DYNAMICS; GENE; TRANSFORMATION; EXPRESSION	Gastric units in the glandular epithelium of the mouse stomach contain several types of continuously renewing epithelial cells. Acid-producing parietal cells are derived from a multipotent stem cell that also gives rise to mucus producing pits cells and pepsinogen- and intrinsic factor-producing zymogenic cells. We used nucleotides -1035 to +24 of the mouse H+/K+-ATPase beta subunit gene (H+/K+-ATPase beta subunit (-1035) (to) (+24)) to examine the consequences of expressing simian virus 40 T antigen (SV 40 TAg) in the normally rare, nonproliferating, short-lived pre-parietal cell progenitor. Light and electron microscopic morphologic studies plus multilabel immunohistochemical analyses of postnatal day (P) 14-80-day transgenic mice revealed that SV 40 TAg produces a 50-70-fold amplification of pre-parietal cells which become the predominant cell type in gastric units. Differentiation to mature parietal cells is blocked, resulting in hypochlorhydria and an associated systemic iron deficiency. SV 40 TAg-induced pre-parietal proliferation is accompanied by apoptosis. Examination of adult transgenic mice homozygous for p53 wild type or p53 null alleles established that the apoptosis occurs through a p53-independent pathway. H+/K+-ATPase beta subunit(-1035) (to) (+24)/SV40 Tag is not expressed during differentiation of the zymogenic lineage. Nonetheless, P28-P80 transgenic mice exhibit an apparent block in the conversion of pre-zymogenic to zymogenic cells. This neck to neck cells and neck to pre-zymogenic cells is not affected. Comparison of normal and transgenic mice that are p53(+/+) or p53(-/-) confirmed that the loss of mature zymogenic cells is not dependent upon p53. Although H+/K+-ATPase beta subunit-(-1035) (to) (+24) is not active in pit cell progenitors or their differentiated descendants, there is a 2-3-fold increase in mature pit cells in transgenic animals. Our findings (i) demonstrate an approach for amplifying and characterizing pre-parietal or other progenitor cell populations in gastric units, (ii) reveal an SV 40 Tag-inducible, p53-independent apoptotic mechanism that operates in a committed epithelial progenitor cell, and (ii) provide a transgenic mouse model for defining factors that may mediate progression through specific points in the differentiation programs of the parietal and zymogenic cell lineages or that may influence decisions about allocation to the pit cell lineage.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; KUWAIT UNIV,FAC MED,DEPT ANAT,SAFAT 13110,KUWAIT	Washington University (WUSTL); Kuwait University					NIDDK NIH HHS [DK33487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANFIELD VA, 1991, P NATL ACAD SCI USA, V88, P8247, DOI 10.1073/pnas.88.18.8247; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEW CS, 1994, ANNU REV PHYSIOL, V56, P445; COHN SM, 1984, J BIOL CHEM, V259, P2456; CONRAD ME, 1991, GASTROENTEROLOGY, V100, P129, DOI 10.1016/0016-5085(91)90592-9; CONRAD ME, 1987, J LAB CLIN MED, V110, P418; CONRAD ME, 1992, BLOOD, V79, P244, DOI 10.1182/blood.V79.1.244.bloodjournal791244; CONRAD ME, 1990, J BIOL CHEM, V265, P5273; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1995, AM J PHYSIOL-GASTR L, V268, pG553, DOI 10.1152/ajpgi.1995.268.4.G553; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUGLIETTA A, 1994, DIGEST DIS SCI, V49, P177; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HOGAN B, 1986, MANIPULATING MOUSE E; KAKEI N, 1983, BIOCHEM BIOPH RES CO, V197, P310; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1994, AM J PHYSIOL, V266, pG745, DOI 10.1152/ajpgi.1994.266.4.G745; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LEE EY, 1989, GASTROENTEROLOGY, V97, P1171, DOI 10.1016/0016-5085(89)91687-9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; Luna L.G., 1968, MANUAL HISTOLOGIC ST, P184; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORLEY GP, 1992, J BIOL CHEM, V267, P1165; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; RHODES JA, 1986, P NATL ACAD SCI USA, V83, P3844, DOI 10.1073/pnas.83.11.3844; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; Sambrook J., 1989, MOL CLONING LAB MANU; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHARP R, 1995, DEVELOPMENT, V121, P149; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU W, 1994, P NATL ACAD SCI USA, V91, P3602	51	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15777	15788		10.1074/jbc.270.26.15777	http://dx.doi.org/10.1074/jbc.270.26.15777			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797580	hybrid			2022-12-27	WOS:A1995RG53800053
J	REHLI, M; KRAUSE, SW; KREUTZ, M; ANDREESEN, R				REHLI, M; KRAUSE, SW; KREUTZ, M; ANDREESEN, R			CARBOXYPEPTIDASE-M IS IDENTICAL TO THE MAX.1 ANTIGEN AND ITS EXPRESSION IS ASSOCIATED WITH MONOCYTE TO MACROPHAGE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND CARBOXYPEPTIDASE; CELL-LINE HL-60; MATURATION; INDUCTION; PROTEINS; ENZYME; 1,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; HETEROGENEITY; SARCOIDOSIS	The two monoclonal antibodies MAX.1 and MAX.11 recognize cell surface antigens that are almost undetectable on monocytes but highly expressed on differentiated macrophages. Biochemical characterization revealed that both antibodies detect the same 58-64-kDa glycoprotein anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. We purified the MAX.1/11 antigen by immunoaffinity chromatography using monoclonal antibody MAX.11. The NH2-terminal amino acid sequence was determined and turned out to be identical to the NH2-terminal sequence of the membrane-bound carboxypeptidase M. By precipitation with antibodies MAX.1 and MAX.11, membrane preparations of macrophages and placental microvilli were almost completely depleted of enzyme activity, indicating that the two antibodies indeed recognize carboxypeptidase M. Immunoreactivity of both antibodies correlates with the reported tissue distribution of enzyme activity. Expression of carboxypeptidase M on mRNA level and enzymatic activity markedly increase during in vitro differentiation of monocytes, according to the described increase in MAX.1 and MAX.11 antigen expression. Moreover, in vitro differentiated macrophages show the highest specific activity yet described in any tissue. In addition, carboxypeptidase M expression could be detected in HL-60, U937, and THP-1 myeloid cell lines. Vitamin D-3-induced monocytic differentiation resulted in an increased carboxypeptidase M expression in all three cell lines. Further studies are needed to elucidate the functional role of carboxypeptidase M during monocytic differentiation and activation.	UNIV REGENSBURG, DEPT HEMATOL & ONCOL, D-93042 REGENSBURG, GERMANY	University of Regensburg			Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Krause, Stefan/0000-0002-5259-4651				ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; ANDREESEN R, 1986, BLOOD, V67, P1257; ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2; ANDREESEN R, 1988, CELL TISSUE RES, V253, P271; ANDREESEN R, 1994, ERNST SCHERING RES F, V11, P9; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; CHODIMELLA V, 1991, AM REV RESPIR DIS, V144, P869, DOI 10.1164/ajrccm/144.4.869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; DESMAZES N, 1992, AM J RESP CELL MOL, V7, P477, DOI 10.1165/ajrcmb/7.5.477; DRAGOVIC T, 1993, AM REV RESPIR DIS, V147, P1491, DOI 10.1164/ajrccm/147.6_Pt_1.1491; GORDON S, 1992, CURR OPIN IMMUNOL, V4, P25, DOI 10.1016/0952-7915(92)90119-Y; KRAUSE SW, 1992, ANN HEMATOL, V64, P190, DOI 10.1007/BF01696222; KREUTZ M, 1990, BLOOD, V76, P2449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN J, 1989, CLIN LAB MED, V9, P745, DOI 10.1016/S0272-2712(18)30602-4; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MUSSON RA, 1983, AM J PATHOL, V111, P331; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NAGAE A, 1992, J NEUROCHEM, V59, P2201; OLSSON I, 1983, CANCER RES, V43, P5862; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUTHERFORD MS, 1993, J LEUKOCYTE BIOL, V53, P602, DOI 10.1002/jlb.53.5.602; SHAPIRO AL, 1967, BIOCHEM BIOPH RES CO, V126, P155; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; SKIDGEL RA, 1991, METHODS NEUROSCIENCE, V6, P373; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAN FL, 1989, J BIOL CHEM, V264, P13165; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERSCHOOT CE, 1989, LEUCOCYTE TYPING, V4, P887; VANFURTH R, 1982, IMMUNOBIOLOGY, V161, P178, DOI 10.1016/S0171-2985(82)80072-7; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	41	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15644	15649		10.1074/jbc.270.26.15644	http://dx.doi.org/10.1074/jbc.270.26.15644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797563	hybrid			2022-12-27	WOS:A1995RG53800034
J	MISRAPRESS, A; RIM, CS; YAO, H; ROBERSON, MS; STORK, PJS				MISRAPRESS, A; RIM, CS; YAO, H; ROBERSON, MS; STORK, PJS			A NOVEL MITOGEN-ACTIVATED PROTEIN-KINASE PHOSPHATASE - STRUCTURE, EXPRESSION, AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; MAP KINASE; PC12 CELLS; PHOSPHORYLATION; DIFFERENTIATION; SPECIFICITY; RECEPTOR; RAS	Mitogen-activated protein (MAP) kinase lies at the convergence of various extracellular ligand-mediated signaling pathways. It is activated by the dual-specificity kinase, MAP kinase kinase or MEK. MAP kinase inactivation is mediated by dephosphorylation via specific MAP kinase phosphatases (MKPs). One MKP (MKP-1 (also known as 3CH134, Erp, or CL100)) has been reported to be expressed in a wide range of tissues and cells. We report the identification of a second widely expressed MKP, termed MKP-2, isolated from PC12 cells. MKP-2 showed significant homology with MKP-1 (58.8% at the amino acid level) and, like MKP-1, displayed vanadate-sensitive phosphatase activity against MAP kinase in vitro. Overexpression of MKP-2 in vive inhibited MAP kinase-dependent gene transcription in PC12 cells. MKP-2 differed from MKP-1 in its tissue distribution and in its extent of induction by growth factors sind agents that induce cellular stress, suggesting that these MKPs may have distinct physiological functions.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALLESSI DR, 1993, ONCOGENE, V8, P2015; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARLES CH, 1992, ONCOGENE, V7, P187; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRUKER B, 1992, BLOOD, V79, P2215; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LLOYD ED, 1992, J NEUROCHEM, V59, P1099, DOI 10.1111/j.1471-4159.1992.tb08352.x; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MISRAPRESS A, 1994, J BIOL CHEM, V269, P23220; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PENNYPACKER KR, 1993, J NEUROCHEM, V60, P204, DOI 10.1111/j.1471-4159.1993.tb05839.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORK P, 1995, IN PRESS METHODS NEU; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CEHM, V268	52	215	218	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14587	14596		10.1074/jbc.270.24.14587	http://dx.doi.org/10.1074/jbc.270.24.14587			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782322	hybrid			2022-12-27	WOS:A1995RD45500055
J	EMILI, A; INGLES, CJ				EMILI, A; INGLES, CJ			PROMOTER-DEPENDENT PHOTOCROSS-LINKING OF THE ACIDIC TRANSCRIPTIONAL ACTIVATOR E2F-1 TO THE TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; RETINOBLASTOMA PROTEIN; FACTOR-TFIIB; CLONING; YEAST; GENE; TRANSACTIVATION; INTERACTS; SEQUENCE; INVITRO	Sequence-specific transcriptional activators, such as the human factor E2F-1, increase the rate of initiation of transcription by RNA polymerase II, possibly by contacting one or more of the RNA polymerase II-associated general initiation factors. One candidate target of transactivators is the TATA-binding protein (TBP), which, when bound to a promoter, nucleates the formation of a preinitiation complex. Previous studies using affinity chromatography techniques have shown that the activation domains of certain activators, including the acidic activation domain of E2F-1, can interact with TBP in the absence of DNA Using a site directed photoaffinity cross-linking approach, we demonstrate here that the activation domain of the chimeric activator LexA-E2F-1 can be cross-linked to TBP when both factors are bound to a transcriptionally responsive RNA polymerase II promoter. Mutations within the activation domain of LexA-E2F-1 that impaired its ability to activate transcription in vitro were found to reduce cross-linking of LexA-E2F-1 to TBP. The association of initiation factor TFIIB with the TBP-promoter complex did not preclude this promoter-dependent cross-linking of LexA-E2F-1 to TBP. TFIIB itself could also be crosslinked to LexA-E2F-1; however, this cross-linking was promoter-independent. In contrast, TFIIA strongly inhibited the promoter-dependent cross-linking of LexA-E2F-1 to TBP. These results directly demonstrate that acidic activators such as E2F-1 can interact with TBP during the earliest stages in the assembly of an RNA polymerase II preinitiation complex.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORII T, 1981, CELL, V23, P689, DOI 10.1016/0092-8674(81)90432-3; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISB JA, 1992, SCIENCE, V256, P1127; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SN X, 1994, GENE DEV, V8, P2336; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; YOUNG KC, 1994, GENE DEV, V8, P2097; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13674	13680		10.1074/jbc.270.23.13674	http://dx.doi.org/10.1074/jbc.270.23.13674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775419	hybrid			2022-12-27	WOS:A1995RC44800016
J	HABIB, GM; CARTER, BZ; SEPULVEDA, AR; SHI, ZZ; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW				HABIB, GM; CARTER, BZ; SEPULVEDA, AR; SHI, ZZ; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW			IDENTIFICATION OF A 6TH PROMOTER THAT DIRECTS THE TRANSCRIPTION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE TYPE-III RNA IN MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNAS; TRANSFERASE TRANSPEPTIDASE; EPITHELIAL-CELLS; POLYMERASE-II; 5' ENDS; RAT; GENE; TRANSFECTION; SEQUENCES	We have previously identified five promoters in the 5'-flanking region of the mouse gamma-glutamyl transpeptidase (gamma GT) gene. We now report the localization of a sixth promoter that supports the transcription of type III RNA, the major gamma GT RNA in fetal liver. We made a fetal liver cDNA library enriched for gamma GT RNA and obtained 12 gamma GT type III-specific clones. The longest clone is consistent with a transcription start site for type III RNA at a position 5' to the type IV promoter and about 5 kilobase(s) (kb) 5' to the first coding exon. We estimated by ribonuclease protection assay that about 80% of the gamma GT mRNA in fetal liver was type III. Primer extension and nuclease protection analyses mapped the 5' end of type III mRNA in fetal liver and kidney to a single cluster of potential major and minor transcription start sites. Deletion analysis using transient expression of chloramphenicol acetyltransferase constructs of the type III promoter region revealed the greatest activity with a 1-kb 5'-flanking fragment in mouse kidney proximal tubular cells and no detectable activity in NIH-3T3 fibroblasts. These studies demonstrate that the type III 5' region of the mouse gamma GT gene is organized into two distinct exons (IIIa and IIIb) and that type III RNA is expressed under the control of its own promoter.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER; NCI NIH HHS [CA39392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT Z, 1961, NATURE, V191, P767, DOI 10.1038/191767a0; BRAUN L, 1987, CANCER RES, V47, P4116; BROUILLET A, 1994, J BIOL CHEM, V269, P14878; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARTER BZ, 1994, J BIOL CHEM, V269, P24581; CHASSANDE O, 1994, J BIOL CHEM, V269, P14484; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GHUSH D, 1990, NUCLEIC ACIDS RES, V18, P1749; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JBILO O, 1994, J BIOL CHEM, V269, P20829; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; MUKAI T, 1986, J BIOL CHEM, V261, P3347; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; Ruoslahti E, 1979, Adv Cancer Res, V29, P275, DOI 10.1016/S0065-230X(08)60849-0; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1981, METHOD ENZYMOL, V113, P400; TATEISHI N, 1976, GANN, V67, P215; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; UENO T, 1988, BIOCHIM BIOPHYS ACTA, V950, P411, DOI 10.1016/0167-4781(88)90138-8; VOCI A, 1994, HORM METAB RES, V26, P133, DOI 10.1055/s-2007-1000793; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WULHRICH RP, 1990, KIDNEY INT, V37, P783	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13711	13715		10.1074/jbc.270.23.13711	http://dx.doi.org/10.1074/jbc.270.23.13711			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775425	hybrid			2022-12-27	WOS:A1995RC44800022
J	LESUFFLEUR, T; ROCHE, F; HILL, AS; LACASA, M; FOX, M; SWALLOW, DM; ZWEIBAUM, A; REAL, FX				LESUFFLEUR, T; ROCHE, F; HILL, AS; LACASA, M; FOX, M; SWALLOW, DM; ZWEIBAUM, A; REAL, FX			CHARACTERIZATION OF A MUCIN CDNA CLONE ISOLATED FROM HT-29 MUCUS-SECRETING CELLS - THE 3' END OF MUC5AC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTESTINAL MUCIN; MONOCLONAL-ANTIBODIES; EXPRESSION; GENE; SEQUENCE; DIFFERENTIATION; HYBRIDIZATION; LOCALIZATION; ADAPTATION	HT-29 cells resistant to 10(-6) M methotrexate (HT29-MTX) secrete mucins with gastric immunoreactivity (Lesuffleur, T., Barbat, A., Dussaulx, E., and Zweibaum, A. (1990) Cancer Res. 50, 6334-6343). A 3310-base pair mucin cDNA clone (L31) was isolated from an HT29-MTX expression library using a polyclonal serum specific for normal gastric mucosa. It shows a high level of identity (98.6%) to clone NP3a isolated from a nasal polyp cDNA library (Meerzaman, D., Charles, P., Daskal, E., Polymeropoulos, M. H., Martin, B. M., and Rose, M. C. (1994) J. Biol. Chem. 269, 12932-12939). However, as a result of changes in reading frame, the 1042-amino acid deduced peptide contains four regions of a low similarity to the NP3a peptide. The amino acid sequence shows 36.3% similarity to part of the carboxyl-terminal sequence of MUC2 including the so called D4 domain and 21.3% to the pro von Willebrand factor. A short amino acid sequence is similar to cysteine-rich sequences repeated in tracheobronchial, gastric, and colonic mucin cDNAs. The gene corresponding to L31 is located in the mucin gene cluster on chromosome 11p15.5. The patterns of mRNA expression were indistinguishable from those revealed with the JER58 probe (MUC5AC). Southern blot analysis indicates that the L31 and JER 58 sequences are within 20 kilobase pairs of each other. Together, these results suggest that L31 clone is the 3' end of MUC5AC.	UNIV AUTONOMA BARCELONA, INST MUNICIPAL INVEST MED, E-08003 BARCELONA, SPAIN; UNIV LONDON UNIV COLL, GALTON LAB, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; UNIV PARIS 06, F-75005 PARIS, FRANCE	Autonomous University of Barcelona; University of London; University College London; UDICE-French Research Universities; Sorbonne Universite	LESUFFLEUR, T (corresponding author), INSERM, U178, 16 AVE PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Arribas, Francisco X Real/H-5275-2015; lesuffleur, thecla/AAC-2980-2020	Arribas, Francisco X Real/0000-0001-9501-498X; 				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BARA J, 1986, CANCER RES, V46, P3983; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CHAMBERS JA, 1994, J CELL SCI, V107, P413; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONG NV, 1990, HUM GENET, V86, P167; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; GAMBUS G, 1993, GASTROENTEROLOGY, V104, P93; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUYONNETDUPERAT V, 1995, BIOCHEM J, V304, P211; HARVEY CB, 1993, ANN HUM GENET, V57, P179, DOI 10.1111/j.1469-1809.1993.tb01593.x; HO SB, 1993, CANCER RES, V53, P641; KITAMURA H, 1994, GASTROENTEROLOGY, V106, pA403; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; ORIOL R, 1977, IMMUNOLOGY, V32, P131; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; ROSE MC, 1989, J BIOL CHEM, V264, P8193; RYSAVY FR, 1992, COMPUT APPL BIOSCI, V8, P149; SHELTONINLOES BB, 1987, BIOCHEM BIOPH RES CO, V144, P657, DOI 10.1016/S0006-291X(87)80016-5; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502; ZWEIBAUM A, 1975, TISSUE ANTIGENS, V6, P121; ZWEIBAUM A, 1969, NATURE, V223, P84, DOI 10.1038/223084a0	41	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13665	13673		10.1074/jbc.270.23.13665	http://dx.doi.org/10.1074/jbc.270.23.13665			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775418	hybrid			2022-12-27	WOS:A1995RC44800015
J	YU, JX; CHAO, L; CHAO, J				YU, JX; CHAO, L; CHAO, J			MOLECULAR-CLONING, TISSUE-SPECIFIC EXPRESSION, AND CELLULAR-LOCALIZATION OF HUMAN PROSTASIN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; BOAR SPERM ACROSIN; 4 TANDEM REPEATS; SERINE PROTEASE; COAGULATION FACTOR; CONVERTING ENZYME; DISULFIDE BONDS; APPLE DOMAINS; FACTOR-XI; CDNA	We have purified a novel human serine proteinase, designated as prostasin, from seminal fluid (Yu ct al., 1994). In the present study, we have cloned and characterized the full-length cDNA encoding prostasin and identified its tissue-specific expression and cellular localization. A cDNA fragment was obtained by polymerase chain reaction using degenerate oligonucleotide primers derived from the NH2-terminal and internal amino acid sequences. A fall-length cDNA sequence encoding prostasin was obtained by amplification of the 5'- and 3'-ends of the cDNA. It contains a 1,032-base coding region a 572-base 3'-noncoding region and a 138-base 5'-noncoding sequence. Prostasin cDNA encodes a protein of 343 amino acids, which consists of a 32-amino acid signal peptide and a 311-amino acid proprostasin. Proprostasin is then cleaved between Arg(12) and Ile(13) to generate a 12-amino acid light chain and a 299-amino acid heavy chain, which are associated through a disulfide bond. The deduced amino acid sequence of the heavy chain has 34-42% identity to human acrosin, plasma kallikrein, and hepsin. A potential N-glycosylation site at Asn(127) and the catalytic triad of His(53), Asp(102), and Ser(206) have been identified. The deduced prostasin has a unique 19-amino acid hydrophobic portion at the COOH terminus, which makes it suitable to anchor in the cell membrane. Carboxyl-terminal sequencing of purified prostasin indicates that the hydrophobic portion is removed and that there is a cleavage between Arg(290) and pro(291) during secretion. Southern blot analysis, following a reverse transcription polymerase chain reaction, indicates that prostasin mRNA is expressed in prostate, liver, salivary gland, kidney, lung, pancreas, colon, bronchus, renal proximal tubular cells, and prostate carcinoma LNCaP cells. Cellular localization of prostasin mRNA was identified within epithelial cells of the human prostate gland by in situ hybridization histochemistry.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425	Medical University of South Carolina					NHLBI NIH HHS [HL 29397] Funding Source: Medline; NIDCR NIH HHS [DE 09731] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009731] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADHAM IM, 1990, HUM GENET, V84, P125; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BELDENT V, 1993, J BIOL CHEM, V268, P26428; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; JONES R, 1988, DEVELOPMENT, V102, P781; KLEMM U, 1991, HUM GENET, V87, P635; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LILIA H, 1985, J CLIN INVEST, V76, P1899; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; Shivaji S, 1990, PROTEINS SEMINAL PLA; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; TOPFERPETERSEN E, 1990, FEBS LETT, V275, P139, DOI 10.1016/0014-5793(90)81458-Z; TOPFERPETERSEN E, 1988, BIOL CHEM H-S, V369, P69, DOI 10.1515/bchm3.1988.369.1.69; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEI L, 1991, J BIOL CHEM, V266, P5540; YOUNG CL, 1978, ATLAS PROTEIN SEQ S3, V5, P73; YU JX, 1994, J BIOL CHEM, V269, P18843	27	111	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13483	13489		10.1074/jbc.270.22.13483	http://dx.doi.org/10.1074/jbc.270.22.13483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768952	hybrid			2022-12-27	WOS:A1995RB43900078
J	OHNISHI, Y; NISHIYAMA, M; HORINOUCHI, S; BEPPU, T				OHNISHI, Y; NISHIYAMA, M; HORINOUCHI, S; BEPPU, T			INVOLVEMENT OF THE COOH-TERMINAL PRO-SEQUENCE OF SERRATIA-MARCESCENS SERINE-PROTEASE IN THE FOLDING OF THE MATURE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; DENATURED SUBTILISIN; PRECURSOR; EXCRETION; CHAPERONE; PROTEINS; CLONING; GENE	The serine protease (SSP) from a Gram-negative organism, Serratia marcescens, is excreted even from Escherichia coli, The protease is synthesized as a 1045-amino-acid precursor (preproSSP) composed of three functional portions, a typical NH2-terminal signal peptide of 27 amino acids, the mature protease part of 618 amino acids, and a large COOH-terminal part of 400 amino acids. After the mature part (Ala(28) to Asp(645)) has been liberated into the medium, most of the COOH-terminal part (Phe(717) to Phe(1045)) remains stably in the outer membrane, When a mutated gene encoding the preproSSP with deletion of the junction region (Ser(646) to Gly(716)) between the mature protease and the processed COOH-terminal protein was expressed in E. coli, the SSP protein was not detected in any fractions of the cells nor in the medium, whereas a processed COOH-terminal protein was found in the outer membrane, However, when the outer membrane fraction prepared from the transformant exhibiting the junction region (Ser(646) to Gly(716)) probably on the cell surface was co cultured with the transformant, SSP was found in the medium. Furthermore, a significant portion of the SSP protein denatured with guanidine hydrochloride was correctly refolded in vitro into the active protease, only in the presence of the outer membrane preparation from the transformant exhibiting the junction region, These results suggest that the junction region is exposed outside the cells, and it plays a role for guiding the folding of SSP in the correct conformation.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo				Ohnishi, Yasuo/0000-0001-7633-9236				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CORNELIS P, 1982, MOL GEN GENET, V186, P507, DOI 10.1007/BF00337957; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; HAGIHARA B, 1958, J BIOCHEM-TOKYO, V45, P185, DOI 10.1093/oxfordjournals.jbchem.a126856; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUBARA M, 1994, FEBS LETT, V342, P193, DOI 10.1016/0014-5793(94)80499-0; Miller J.H., 1972, EXPT MOL GENETICS; MIURA T, 1969, BIOCHIM BIOPHYS ACTA, V193, P268; MIYAZAKI H, 1989, J BACTERIOL, V171, P6566, DOI 10.1128/jb.171.12.6566-6572.1989; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SHIKATA S, 1992, J BIOCHEM-TOKYO, V111, P627, DOI 10.1093/oxfordjournals.jbchem.a123809; SHIKATA S, 1993, J BIOCHEM, V114, P723, DOI 10.1093/oxfordjournals.jbchem.a124244; SHIMADA K, 1994, J BIOCHEM-TOKYO, V116, P327, DOI 10.1093/oxfordjournals.jbchem.a124527; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	21	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32800	32806						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806503				2022-12-27	WOS:A1994QA63800016
J	NOLAND, TD; FRIDAY, BB; MAULIT, MT; GERTON, GL				NOLAND, TD; FRIDAY, BB; MAULIT, MT; GERTON, GL			THE SPERM ACROSOMAL MATRIX CONTAINS A NOVEL MEMBER OF THE PENTAXIN FAMILY OF CALCIUM-DEPENDENT BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG SPERM; OLIGOSACCHARIDE SIDE-CHAINS; C-REACTIVE PROTEIN; INITIAL CHARACTERIZATION; EPIDIDYMAL SPERMATOZOA; 2-DIMENSIONAL ANALYSIS; POLYACRYLAMIDE GELS; SECRETORY GRANULES; TISSUE PROTEINS; CELL FRACTIONS	The sperm acrosome is a regulated secretory granule that undergoes exocytosis during fertilization, To elucidate the structural organization of the contents within the acrosome, guinea pig sperm acrosomal apical segments were isolated and mapped by two-dimensional polyacrylamide gel electrophoresis (PAGE), Although complex, the two-dimensional PAGE map was dominated by two M(r) 50,000 polypeptides (p50 and proacrosin), a M(r) 67,000 polypeptide (p67), and a M(r) 32,000 polypeptide (sp32), Proacrosin (pi >8.0), p67, and sp32 were extracted from apical segments by 1 M NaCl. Protein p50, a relatively acidic polypeptide, was not extracted in 1 M NaCl and/or 1% Triton X-100 at 4 degrees C, but was solubilized with 6 M urea, Protein p50 was purified from the urea extract by elution from DEAE-Sephacel with 100 mM guanidine HCl and appeared homogeneous by SDS-PAGE, Antibodies to p50 were monospecific as judged by Western blot analysis, Indirect immunofluorescence indicated that p50 was restricted to the acrosomal apical segment, Incubation of apical segments at pH 7.5 in the presence of 1 mM EDTA at 37 degrees C resulted in the release of p50 into the 200,000 x g supernatant fluid, a process that was reversed by a subsequent incubation with 1.5 mM CaCl2 but not with MgCl2. The Ca2+-dependent reassociation of p50 with the acrosomal apical segments was reversed by the addition of 2.0 mM EGTA, indicating that p50 binding is dependent on free Ca2+ concentrations. When acrosomal matrices were purified following Triton X-100 extraction, p50 was the major component, with p67, proacrosin, and sp32 as less prominent constituents. Molecular cloning demonstrated that p50 is a unique, testis-specific member of the pentaxin family of calcium-dependent binding proteins.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	University of Pennsylvania; University of Pennsylvania; Vanderbilt University			Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274, R01HD022899] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22899, HD06274] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADEKUNLE AO, 1987, BIOL REPROD, V37, P201, DOI 10.1095/biolreprod37.1.201; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANAKWE OO, 1991, MOL REPROD DEV, V29, P294, DOI 10.1002/mrd.1080290313; ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BABA T, 1994, J BIOL CHEM, V269, P10133; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; CHIDGEY MAJ, 1993, BIOESSAYS, V15, P317, DOI 10.1002/bies.950150505; COURTENS JL, 1978, J ULTRA MOL STRUCT R, V65, P182, DOI 10.1016/S0022-5320(78)90055-2; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEVRIES JWA, 1985, EUR J CELL BIOL, V37, P81; DICARLANTONIO G, 1988, GAMETE RES, V21, P425, DOI 10.1002/mrd.1120210410; EDDY EM, 1993, PHYSL REPROD, P29; FAWCETT DW, 1963, Z ZELLFORSCH MIK ANA, V60, P276, DOI 10.1007/BF00350481; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FAWCETT DW, 1975, FUNCTIONAL ANATOMY S, P199; FLAHERTY SP, 1988, ANAT REC, V220, P267, DOI 10.1002/ar.1092200307; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; FULLER SA, 1991, CURRENT PROTOCOLS MO; GREEN DPL, 1978, J CELL SCI, V32, P153; GREEN DPL, 1978, J CELL SCI, V32, P177; HARDY DM, 1987, BIOL REPROD, V37, P189, DOI 10.1095/biolreprod37.1.189; HARDY DM, 1991, BIOCHEM J, V275, P759, DOI 10.1042/bj2750759; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HUANG TTF, 1985, BIOL REPROD, V32, P451, DOI 10.1095/biolreprod32.2.451; JONES R, 1990, DEVELOPMENT, V109, P41; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KOLBBACHOFEN V, 1991, IMMUNOBIOLOGY, V183, P133, DOI 10.1016/S0171-2985(11)80193-2; KOPF GS, 1991, ELEMENTS MAMMALIAN F, V1, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GW, 1993, J IMMUNOL, V150, P1804; NOLAND TD, 1990, BIOL REPROD, V42, P252, DOI 10.1095/biolreprod42.2.252; NOLAND TD, 1989, J BIOL CHEM, V264, P13586; NOLAND TD, 1987, BIOL REPROD, V37, P171, DOI 10.1095/biolreprod37.1.171; NUZZO NA, 1990, MOL REPROD DEV, V25, P52, DOI 10.1002/mrd.1080250110; OLSON GE, 1987, GAMETE RES, V17, P77, DOI 10.1002/mrd.1120170109; OLSON GE, 1985, BIOL REPROD, V33, P761, DOI 10.1095/biolreprod33.3.761; REID MS, 1994, J BIOL CHEM, V269, P32615; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGER TA, 1991, CURRENT PROTOCOLS MO; STOJANOFF A, 1987, GAMETE RES, V17, P321, DOI 10.1002/mrd.1120170405; TALBOT P, 1985, J HISTOCHEM CYTOCHEM, V33, P1169, DOI 10.1177/33.11.4056380; TALBOT P, 1974, J REPROD FERTIL, V39, P429, DOI 10.1530/jrf.0.0390429; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; Tooze S A, 1992, Semin Cell Biol, V3, P357, DOI 10.1016/1043-4682(92)90021-M; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESTBROOKCASE VA, 1994, BIOL REPROD, V51, P1, DOI 10.1095/biolreprod51.1.1; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	60	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32607	32614						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798265				2022-12-27	WOS:A1994PX30400087
J	KANG, CH; FROMM, HJ				KANG, CH; FROMM, HJ			IDENTIFICATION OF AN ESSENTIAL 2ND METAL-ION IN THE REACTION-MECHANISM OF ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE; COMPLEXES; PURIFICATION; PURA; ACID	This study reports that two Mg2+ ions are required for Escherichia coli adenylosuccinate synthetase activity, The first metal ion is presumably coordinated with beta-and gamma-phosphoryl groups of GTP to provide an electron sink, and the second one seems to interact with aspartate in the enzyme active site, Regarding the latter metal ion, kinetic studies show that aspartate and the second Mg2+ ion bind to the enzyme active site randomly with a k(cat) value of 1.47 s(-1) and with K-m values for cat aspartate and Mg2+ of 225 and 114 mu M, respectively, The dissociation constants for aspartate and Mg2+ of the enzyme . GTP . IMP (aspartate or Mg2+) complex are 79.2 and 40.0 mu M, respectively. However, variable amounts of aspartate or Mg2+ did not show any significant changes in the K-m values for GTP and IMP, Kinetic studies using Mn2+ and Ca2+ ions indicate that the k(cat) values (0.930 and 0.235 s(-1), respectively) were slightly decreased compared with the value obtained using Mg2+; however, the K-m values for aspartate and GTP in the presence of Mn2+ and Ca2+ were significantly decreased compared with those obtained using Mg2+ ion (4.5 and 4.6 times for Mn2+ ion and 5.6 and 5.8 times for Ca2+ ion, respectively), On the other hand, the K-m values for IMP were not significantly changed (1.9 and 1.8 times for Mn2+ and Ca2+ ions, respectively), Taken together, these kinetic results imply that aspartate may interact with Mg2+ to form a Mg aspartate complex in the enzyme active site, An inhibition study of the enzyme with ZnCl2 (its K-i Value is 29 nM) also suggested that Zn2+ competes with aspartate as well as Mg2+, implying that Zn2+ might form a complex with aspartate in the active site, On the basis of these results, it is suggested that Mg . aspartate complex formation in the active site of adenylosuccinate synthetase may be important in activation of the protonated amino group of aspartate, enhancement of the enzyme's binding affinity, and its specificity for aspartate.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS 10548] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BUCHANAN JM, 1959, ADV ENZYMOL REL S BI, V21, P199; CHEN M, 1994, J BIOL CHEM, V269, P5554; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; COOPER BF, 1982, FED PROC, V41, P742; EVANS CA, 1979, MET IONS BIOL SYST, V9, P41; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GLASS E., 1956, Zeitschrift fur Botanik, V44, P1; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HAUGLAND PR, 1992, HDB FLUORESCENT PROB, P145; Hsie AW, 1979, TRACE METALS HLTH DI, P55; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MARKHAM GD, 1977, ARCH BIOCHEM BIOPHYS, V184, P24, DOI 10.1016/0003-9861(77)90322-8; MARKHAM GD, 1977, THESIS U PENNSYLVANI; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; Pettit L.D., 1979, MET IONS BIOL SYST, V9, P174; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; SARIBAS AS, 1994, J BIOL CHEM, V269, P6313; SCHMIDBAUR H, 1986, ANGEW CHEM INT EDIT, V25, P1013, DOI 10.1002/anie.198610131; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; TU AT, 1971, MET IONS BIOL SYST, V1, P1; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; WAGNER FW, 1988, METHOD ENZYMOL, V158, P21, DOI 10.1016/0076-6879(88)58045-X; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	41	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15539	15544		10.1074/jbc.270.26.15539	http://dx.doi.org/10.1074/jbc.270.26.15539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797548	hybrid			2022-12-27	WOS:A1995RG53800018
J	CESTELE, S; KHALIFA, RB; PELHATE, M; ROCHAT, H; GORDON, D				CESTELE, S; KHALIFA, RB; PELHATE, M; ROCHAT, H; GORDON, D			ALPHA-SCORPION TOXINS BINDING ON RAT-BRAIN AND INSECT SODIUM-CHANNELS REVEAL DIVERGENT ALLOSTERIC MODULATIONS BY BREVETOXIN AND VERATRIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED ANTIBODIES; NERVE ENDING PARTICLES; RECEPTOR-SITES; SELECTIVE NEUROTOXINS; MEMBRANES; VENOM; BATRACHOTOXININ; SYNAPTOSOMES; 20-ALPHA-BENZOATE; PURIFICATION	At least six topologically separated neurotoxin receptor sites have been identified on sodium channels that reveal strong allosteric interactions among them. We have studied the allosteric modulation induced by veratridine, binding to receptor site 2, and brevetoxin PbTx-1, occupying receptor site 5, on the binding of alpha-scorpion toxins at receptor site 3, on three different neuronal sodium channels: rat brain, locust, and cockroach synaptosomes. We used I-125-AaH II, the most active cu scorpion toxin on vertebrates, and I-125-Lqh alpha IT, shown to have high activity on insects, as specific probes for receptor site 3 in rat brain and insect sodium channels. Our results reveal that brevetoxin PbTx-1 generates three types of effects at receptor site 3: 1) negative allosteric modulation in rat brain sodium channels, 2) positive modulation in locust sodium channels, and 3) no effect on cockroach sodium channel. However, PbTx-1 activates sodium channels in cockroach axon similarly to its activity in other preparation. Veratridine positively modulates both rat brain and locust sodium channels but had no effect on alpha-toxin binding in cockroach, The dramatic differences in allosteric modulations in each sodium channel subtype suggest structural differences in receptor sites for PbTx-1 and/or at the coupling regions with alpha-scorpion toxin receptor sites in the different sodium channels, which can be detected by combined application of specific channel modifiers and may elucidate the dynamic gating activity and the mechanism of allosteric interactions among various neurotoxin receptors.	FAC MED NORD,INST FEDERAT RECH JEAN ROCHE,BIOCHEM LAB,CNRS,URA 1455,F-13916 MARSEILLE 20,FRANCE; UNIV ANGERS,NEUROPHYSIOL LAB,CNRS,URA 611,F-49045 ANGERS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite d'Angers								AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; BARNES S, 1988, J GEN PHYSIOL, V91, P421, DOI 10.1085/jgp.91.3.421; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1977, J BIOL CHEM, V252, P8669; CATTERALL WA, 1979, J GEN PHYSIOL, V74, P375, DOI 10.1085/jgp.74.3.375; CATTERALL WA, 1985, TOXICON, V23, P497, DOI 10.1016/0041-0101(85)90034-0; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; CATTERALL WA, 1980, MOL PHARMACOL, V19, P345; CHURCH CJ, 1993, COMP BIOCHEM PHYS C, V104, P279, DOI 10.1016/0742-8413(93)90036-K; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; DONG K, 1993, PESTIC BIOCHEM PHYS, V46, P141, DOI 10.1006/pest.1993.1045; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; GAWLEY RE, 1992, TOXICON, V30, P780, DOI 10.1016/0041-0101(92)90014-V; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1993, ARCH INSECT BIOCHEM, V22, P41, DOI 10.1002/arch.940220106; GORDON D, 1985, BIOCHIM BIOPHYS ACTA, V821, P130, DOI 10.1016/0005-2736(85)90163-4; GORDON D, 1990, BIOCHIM BIOPHYS ACTA, V1026, P80, DOI 10.1016/0005-2736(90)90335-L; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG JMC, 1984, J PHARMACOL EXP THER, V229, P615; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; JOVER E, 1980, BIOCHEMISTRY-US, V19, P463, DOI 10.1021/bi00544a010; LESTER D, 1982, BIOCHIM BIOPHYS ACTA, V701, P370, DOI 10.1016/0167-4838(82)90240-0; LIMA ME, 1989, INSECT BIOCHEM, V19, P413; LIMA ME, 1986, BIOCHEM BIOPH RES CO, V139, P296; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; MOSKOWITZ H, 1991, NEUROSCI LETT, V124, P148, DOI 10.1016/0304-3940(91)90081-4; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PARMENTIER JL, 1978, TOXICON, V16, P235, DOI 10.1016/0041-0101(78)90084-3; PAURON D, 1985, BIOCHEM BIOPH RES CO, V131, P1226, DOI 10.1016/0006-291X(85)90222-0; PELHATE M, 1982, J INSECT PHYSIOL, V28, P889, DOI 10.1016/0022-1910(82)90104-4; PELHATE M, 1982, J EXP BIOL, V97, P67; PICHON Y, 1967, J EXP BIOL, V47, P343; PICHON Y, 1983, STRUCTURE FUNCTION E, P211; POLI MA, 1986, MOL PHARMACOL, V30, P129; QUANDT FN, 1982, P NATL ACAD SCI-BIOL, V79, P6732, DOI 10.1073/pnas.79.21.6732; RAY R, 1978, J BIOL CHEM, V253, P7307; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; SODERLUND DM, 1989, COMP BIOCHEM PHYS C, V94, P255, DOI 10.1016/0742-8413(89)90175-8; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WESTERFIELD M, 1977, AM J PHYSIOL, V232, pC23, DOI 10.1152/ajpcell.1977.232.1.C23; WILLOW M, 1982, MOL PHARMACOL, V22, P627; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1994, J TOXICOL-TOXIN REV, V13, P25, DOI 10.3109/15569549409006479; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1987, ENDEAVOUR, V11, P168, DOI 10.1016/0160-9327(87)90280-8	60	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15153	15161		10.1074/jbc.270.25.15153	http://dx.doi.org/10.1074/jbc.270.25.15153			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797499	hybrid			2022-12-27	WOS:A1995RE66600048
J	HRUSKOVAHEIDINGSFELDOVA, O; ANDREANSKY, M; FABRY, M; BLAHA, I; STROP, P; HUNTER, E				HRUSKOVAHEIDINGSFELDOVA, O; ANDREANSKY, M; FABRY, M; BLAHA, I; STROP, P; HUNTER, E			CLONING, BACTERIAL EXPRESSION, AND CHARACTERIZATION OF THE MASON-PFIZER MONKEY VIRUS PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYELOBLASTOSIS-ASSOCIATED VIRUS; ESCHERICHIA-COLI; TRANSMEMBRANE GLYCOPROTEIN; RETROVIRAL PROTEINASE; SUBSITE SPECIFICITY; SYNTHETIC PEPTIDES; VIRAL INFECTIVITY; HIV-1 PROTEINASE; MATRIX PROTEIN	We have cloned and expressed the 3' region of the Mason-Pfizer monkey virus pro gene in Escherichia coli. The recombinant 26-kDa precursor undergoes rapid self-processing both in E. coli and in vitro at the NH2 terminus, yielding a proteolytically active 17-kDa protein, p17. This initial cleavage is followed in vitro by a much slower self-processing that leads to emergence of proteolytically active p12 and a COOH-terminal cleavage product p5. We have found the NH2-terminal processing site of both the p17 and p12 to be identical and similar to the amino terminus of the mouse mammary tumor virus proteinase. We have also identified the COOH-terminal processing site of the p12 form. Using purified recombinant proteins and synthetic oligopeptide substrates based on naturally occurring retroviral processing sites, we have determined the enzymatic activity and specificity of the Mason-Pfizer monkey virus proteinase to be more closely related to that of myeloblastosis-associated virus proteinase rather than that of the Human immunodeficiency virus type 1 proteinase. Inhibition studies using peptide inhibitors support these results.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA; ACAD SCI CZECH REPUBL, INST ORGAN CHEM & BIOCHEM, CR-16610 PRAGUE, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST MOLEC GENET, CR-16637 PRAGUE, CZECH REPUBLIC	University of Alabama System; University of Alabama Birmingham; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences			HruskovaHeidingsfeld, Olga/B-2429-2009; Fabry, Milan/G-3602-2014	HruskovaHeidingsfeld, Olga/0000-0001-9881-8473; 	FOGARTY INTERNATIONAL CENTER [R03TW000050] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA027834, R01CA027834] Funding Source: NIH RePORTER; FIC NIH HHS [TW00050] Funding Source: Medline; NCI NIH HHS [CA27834] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREANSKY M, 1991, FEBS LETT, V287, P129, DOI 10.1016/0014-5793(91)80032-X; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; BILLICH S, 1988, J BIOL CHEM, V263, P17905; BRODY BA, 1992, P NATL ACAD SCI USA, V89, P3443, DOI 10.1073/pnas.89.8.3443; BURSTEIN H, 1992, J VIROL, V66, P1781, DOI 10.1128/JVI.66.3.1781-1785.1992; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; Hayashi R, 1977, Methods Enzymol, V47, P84; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONVALINKA J, 1991, FEBS LETT, V282, P73, DOI 10.1016/0014-5793(91)80447-B; KONVALINKA J, 1990, FEBS LETT, V268, P35, DOI 10.1016/0014-5793(90)80966-M; KOPPE B, 1994, J VIROL, V68, P2813; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P24134; PARK JS, 1991, J VIROL, V65, P5111, DOI 10.1128/JVI.65.9.5111-5117.1991; PAVLICKOVA L, 1992, ARCH BIOCHEM BIOPHYS, V298, P753, DOI 10.1016/0003-9861(92)90476-D; RHEE SS, 1991, EMBO J, V10, P535, DOI 10.1002/j.1460-2075.1991.tb07980.x; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHOEMAKER JM, 1981, J GEN MICROBIOL, V123, P323; SOMMERFELT MA, 1992, J VIROL, V66, P4220, DOI 10.1128/JVI.66.7.4220-4227.1992; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; STEWART L, 1994, VIROLOGY, V204, P45, DOI 10.1006/viro.1994.1509; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANESE N, 1986, J VIROL, V59, P743, DOI 10.1128/JVI.59.3.743-745.1986; URBAN J, 1992, FEBS LETT, V298, P9, DOI 10.1016/0014-5793(92)80010-E; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; ZYBARTH G, 1994, J VIROL, V68, P240, DOI 10.1128/JVI.68.1.240-250.1994	36	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15053	15058		10.1074/jbc.270.25.15053	http://dx.doi.org/10.1074/jbc.270.25.15053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797487	hybrid			2022-12-27	WOS:A1995RE66600033
J	SAWAI, ET; BAUR, AS; PETERLIN, BM; LEVY, JA; CHENGMAYER, C				SAWAI, ET; BAUR, AS; PETERLIN, BM; LEVY, JA; CHENGMAYER, C			A CONSERVED DOMAIN AND MEMBRANE TARGETING OF NEF FROM HIV AND SIV ARE REQUIRED FOR ASSOCIATION WITH A CELLULAR SERINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OPEN READING FRAME; HUMAN T-CELLS; TYPE-1 NEF; MUTATIONAL ANALYSIS; DOWN-REGULATION; LTR TRANSCRIPTION; SURFACE CD4; PROTEIN; EXPRESSION	Among the primate lentiviruses (human immunodeficiency virus (HPV) -1, HIV-2, and simian immunodeficiency virus (SIV)), the nef gene is highly conserved and encodes a myristylated protein of similar to 27 kDa (HIV-1) or similar to 34 kDa (HIV-2, SIV). Previously, we found Nef expressed either as a CDS-Nef fusion protein or as a native protein in virally infected T cell lines associates with a cellular serine kinase. This kinase activity phosphorylated two proteins of 62 and 72 kDa that coimmunoprecipitate with Nef in in vitro kinase assays. Using transient expression, various Nef alleles and mutants have been analyzed for association with the cellular kinase activity. The ability of Nef to associate with the kinase activity is conserved among several alleles of HIV-1 as well as SIVmac239 and is observed in non-lymphoid cell lines of simian and murine origins. Two separate regions of HIV-1(SF2) Nef are critical for the associated kinase activity. One domain overlaps with a central highly conserved region found in all primate lentivirus nef genes and has been provisionally mapped to amino acids 45-127. Because membrane localization of Nef is important for the associated cellular kinase activity, the second domain represents a membrane targeting signal. Moreover, point mutations within the central region that abrogate the Nef-associated kinase activity in HIV-1(SF2) Nef have the same effect when introduced into SIVmac239open Nef.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	SAWAI, ET (corresponding author), UNIV CALIF SAN FRANCISCO,CANC RES INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025284] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI25284] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANDRES JC, 1994, VIROLOGY, V201, P157, DOI 10.1006/viro.1994.1278; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; COLOMBINI S, 1989, P NATL ACAD SCI USA, V86, P4813, DOI 10.1073/pnas.86.13.4813; DE SK, 1994, J BIOL CHEM, V269, P6656; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; FREUND J, 1994, EUR J BIOCHEM, V221, P811, DOI 10.1111/j.1432-1033.1994.tb18795.x; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GURGO C, 1988, VIROLOGY, V164, P531, DOI 10.1016/0042-6822(88)90568-5; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; INOUE M, 1993, INT IMMUNOL, V5, P1067, DOI 10.1093/intimm/5.9.1067; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIENZLE N, 1993, EUR J BIOCHEM, V214, P451, DOI 10.1111/j.1432-1033.1993.tb17941.x; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; KOHLEISEN B, 1992, AIDS, V6, P1427, DOI 10.1097/00002030-199212000-00002; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MAITRA RK, 1991, VIROLOGY, V182, P522, DOI 10.1016/0042-6822(91)90593-Z; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; MEYERS G, 1993, HUMAN RETROVIRUSES A; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MUNIS JR, 1992, J GEN VIROL, V73, P1899, DOI 10.1099/0022-1317-73-8-1899; MURTI KG, 1993, P NATL ACAD SCI USA, V90, P11895, DOI 10.1073/pnas.90.24.11895; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1186; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; RHEE SS, 1994, J IMMUNOL, V152, P5128; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANFRIDSON A, 1994, J BIOL CHEM, V269, P3917; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; TSUMETSUGUYOKOT.Y, 1992, VIROLOGY, V191, P960; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; ZAZOPOULOS E, 1993, J VIROL, V67, P1676, DOI 10.1128/JVI.67.3.1676-1680.1993; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634	54	111	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15307	15314		10.1074/jbc.270.25.15307	http://dx.doi.org/10.1074/jbc.270.25.15307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797518	hybrid			2022-12-27	WOS:A1995RE66600069
J	SUZUKI, T; KITAJIMA, K; INOUE, Y; INOUE, S				SUZUKI, T; KITAJIMA, K; INOUE, Y; INOUE, S			CARBOHYDRATE-BINDING PROPERTY OF PEPTIDE-N-GLYCANASE FROM MOUSE FIBROBLAST L-929 CELLS AS EVALUATED BY INHIBITION AND FINDING EXPERIMENTS USING VARIOUS OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFERTILIZED EGGS; ORYZIAS-LATIPES; FREE SIALOOLIGOSACCHARIDES; 1ST DEMONSTRATION; GLYCOSIDASE-F; STORAGE POOL; MEDAKA FISH; IDENTIFICATION; GLYCOSYLATION; GLYCOPROTEINS	Carbohydrate binding to peptide:N-glycanase from mouse fibroblast L-929 cells (L-929 PNGase) and inhibition by oligosaccharides of its catalytic activity were studied. L-929 PNGase was found to bind strongly with oligosaccharides having triomannosido-,N'-diacetylchitobiosyl (Man,GlcNAc(2)) structure (K-d = similar to 10 mu M). This binding was inhibited by mannotriose (Man(3); Man alpha 1--> 3[Man alpha 1-->6]Man) but not by N,N'-diacetylchitobiose (GlcNAc(2); GlcNAc beta 1-->4GlcNAc). Scatchard analysis indicated that there exist two binding sites for Man(3) on a homodimeric form of a 105-kDa subunit. Oligosaccharides having Man(3) GlcNAc(2) structure were also shown to be strong inhibitors for the PNGase-catalyzed reaction (K-i = similar to 10 mu M). The minimum structural requirements for inhibition of the PNGase activity were Man(3) and GlcNAc(2). Enzyme kinetic studies showed that the mechanism of inhibition by the oligosaccharides and Man(3) fits well with a model wherein two inhibitor binding sites reside on L-929 PNGase. The conformity of K-d with IC50 values may be taken as an evidence for inhibition of the catalytic activity by the oligosaccharides and Man(3) through the occupation of the binding sites with these molecules. On the other hand, inhibition by GlcNAc(2) followed the simple competitive mode. Since the minimum substrate for the L-929 PNGase was shown to be Man beta 1-->4GlcNAc beta 1-->4GlcNAc beta-->peptide, GlcNAc(2) may be directly accessible to the catalytic site in competition with substrate. Interestingly, alkylation of -SH group in L-999 PNGase caused complete loss of the catalytic activity, but the carbohydrate binding activity was completely retained, indicating that the catalytic site(s) is discriminated from the carbohydrate-binding sites in the active site of this enzyme. The carbohydrate-binding property seems to be unique to soluble PNGases from mammals and may be associated not only with regulation of the enzyme activity, but also with receptor and carrier functions for glycoconjugates in certain intracellular processes.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN	University of Tokyo; Showa University			Suzuki, Tadashi/I-4536-2014; Suzuki, Tadashi/AAX-5707-2021	Suzuki, Tadashi/0000-0003-1030-7631				CHU FK, 1986, J BIOL CHEM, V261, P172; DIXON M, 1956, BIOCHEM J, V55, P171; DRICKAMER K, 1994, ANN REV CELL BIOL, V9, P237; INOUE S, 1989, J BIOL CHEM, V264, P18520; INOUE S, 1993, GLYCOCONJUGATE J, V10, P223, DOI 10.1007/BF01209812; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1992, J BIOL CHEM, V267, P24287; KITAJIMA K, 1995, IN PRESS ARCH BIOCH, V319; MAYNARD Y, 1982, J BIOL CHEM, V257, P3788; NOMOTO H, 1992, BIOSCI BIOTECH BIOCH, V56, P1090, DOI 10.1271/bbb.56.1090; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; SEKO A, 1991, BIOCHEM BIOPH RES CO, V180, P1165, DOI 10.1016/S0006-291X(05)81318-X; SEKO A, 1989, J BIOL CHEM, V264, P15922; SEKO A, 1991, J BIOL CHEM, V266, P22110; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; SUZUKI T, 1995, IN PRESS GLYCOCONJUG, V12; SUZUKI T, 1994, 17TH INT CARB S OTT, P430; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; YET MG, 1988, J BIOL CHEM, V263, P118	25	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15181	15186		10.1074/jbc.270.25.15181	http://dx.doi.org/10.1074/jbc.270.25.15181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797502	hybrid			2022-12-27	WOS:A1995RE66600052
J	ANANT, S; MACGINNITIE, AJ; DAVIDSON, NO				ANANT, S; MACGINNITIE, AJ; DAVIDSON, NO			APOBEC-1, THE CATALYTIC SUBUNIT OF THE MAMMALIAN APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME, IS A NOVEL RNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTESTINE; SITE	Apolipoprotein B (apoB) mRNA editing is mediated by an enzyme complex which includes the catalytic subunit, apobec-1. Recombinant GST/APOBEC-1 binds with high specificity to a rat apoB RNA template as demonstrated by UV cross-linking and electrophoretic mobility shift assay (ERISA), ApoB RNA binding was competed by poly(U), poly(A,U), and tRNA, but not by poly(A) or other homopolymeric ribonucleotides, UV cross-linking of GST/APOBEC-1 to an apoB RNA template was uninfluenced by the binding of proteins of similar to 60 and similar to 44 kDa, present in S100 extracts prepared from different sources, The binding of these proteins was similarly uninfluenced by the simultaneous binding of GST/APO-BEC-1. Moreover, the inclusion of heterologous S100 extracts in the RNA binding reactions completely abrogated the competitive displacement of GST/APOBEC-1 by tRNA. EMSA revealed the onset of RNA binding within 1-2 min, and its specificity was confirmed by a supershift with anti-GST/APOBEC-1 antisera. The structural specificity for apoB RNA binding, as inferred from EMSA, appears to be distinct from apoB RNA editing since wild-type chicken apoB RNA,which is not editable, and several mutant chicken apoB RNAs containing clustered mutations within the minimal apoB RNA editing cassette, bound with efficiency similar to the rat apoB RNA template. In conclusion, while the data suggest that apobec-1 binds AU-rich templates, the importance of this observation in the context of mammalian apoB mRNA editing remains unknown.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Anant, Shrikant/AAF-8020-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, P01HL018577, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1994, TRENDS CARDIOVAS MED, V4, P231, DOI 10.1016/1050-1738(94)90039-6; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1991, NUCLEIC ACIDS RES, V18, P5817; LU PP, 1994, P NATL ACAD SCI USA, V91, P8522; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1993, SCIENCE, V264, P1816; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	26	104	108	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14762	14767		10.1074/jbc.270.24.14762	http://dx.doi.org/10.1074/jbc.270.24.14762			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782342	hybrid			2022-12-27	WOS:A1995RD45500079
J	HRMOVA, M; GARRETT, TPJ; FINCHER, GB				HRMOVA, M; GARRETT, TPJ; FINCHER, GB			SUBSITE AFFINITIES AND DISPOSITION OF CATALYTIC AMINO-ACIDS IN THE SUBSTRATE-BINDING REGION OF BARLEY 1,3-BETA-GLUCANASES - IMPLICATIONS IN PLANT-PATHOGEN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE; ALPHA-AMYLASES; ACTION PATTERN; ENZYMES; PURIFICATION; ENDO-1,4-BETA-XYLANASE; OLIGOSACCHARIDES; PARAMETERS; EVOLUTION; SITE	Oligo-1,3-beta-glucosides with degrees of polymerization of 2-9 were labeled at their reducing terminal residues by catalytic tritiation. These substrates were used in detailed kinetic and thermodynamic analyses to examine substrate binding in 1,3-beta-D-glucan glucanohydrolase (EC 3.2,1.39) isoenzymes GI, GII, and GIII from young seedlings of barley (Hordeum vulgare). Bond-cleavage frequencies, together with the kinetic parameter k(cat)/K-m, have been calculated as a function of substrate chain length to define the number of subsites that accommodate individual beta-glucosyl residues and to estimate binding energies at each subsite, Each isoenzyme has eight beta-glucosyl-binding subsites. The catalytic amino acids are located between the third and fourth subsite from the nonreducing terminus of the substrate. Negative binding energies in subsites adjacent to the hydrolyzed glycosidic linkage suggest that some substrate distortion may occur in this region during binding and that the resultant strain induced in the substrate might facilitate hydrolytic cleavage. If the 1,3-beta-glucanases exert their function as pathogenesis-related proteins by hydrolyzing the branched or substituted 1,3; 1,6-beta-glucans of fungal walls, it is clear that relatively extended regions of the cell wall polysaccharide must fit into the substrate-binding cleft of the enzyme.	UNIV ADELAIDE,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA; BIOMOLEC RES INST,PARKVILLE,VIC 3052,AUSTRALIA	University of Adelaide			Hrmova, Maria/AAH-3951-2020	Hrmova, Maria/0000-0002-3545-0605				AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; Allen J D, 1980, Methods Enzymol, V64, P248; ALLEN JD, 1976, BIOCHEM J, V159, P121, DOI 10.1042/bj1590121; BIELY P, 1983, BIOCHIM BIOPHYS ACTA, V743, P155, DOI 10.1016/0167-4838(83)90429-6; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; BRAY MR, 1992, EUR J BIOCHEM, V204, P191, DOI 10.1111/j.1432-1033.1992.tb16623.x; BRUCKNER J, 1955, BIOCHEM J, V60, P200; CHEN L, 1993, J MOL BIOL, V234, P888, DOI 10.1006/jmbi.1993.1635; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; COLE FE, 1964, BIOCHIM BIOPHYS ACTA, V81, P122, DOI 10.1016/0926-6569(64)90342-6; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; EVANS EA, 1974, J LABELLED COMPD, V10, P569, DOI 10.1002/jlcr.2590100407; HAHN MG, 1992, MOL PLANT PATHOL, V2, P103; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; HIROMI K, 1973, BIOCHIM BIOPHYS ACTA, V302, P362, DOI 10.1016/0005-2744(73)90164-2; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MACGREGOR EA, 1994, CARBOHYD RES, V257, P249, DOI 10.1016/0008-6215(94)80039-1; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MOREAU A, 1994, EUR J BIOCHEM, V219, P261, DOI 10.1111/j.1432-1033.1994.tb19937.x; NAZAROVA NI, 1982, BIOORG KHIM+, V8, P1189; Nelson N, 1944, J BIOL CHEM, V153, P375; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; SAMUELS ML, 1991, STATISTICS LIFE SCI; SHIBAOKA T, 1974, J BIOCHEM-TOKYO, V76, P475, DOI 10.1093/oxfordjournals.jbchem.a130591; SKRIVER K, 1991, P NATL ACAD SCI USA, V88, P7266, DOI 10.1073/pnas.88.16.7266; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stone BA, 1993, CHEM BIOL 1 3 BETA G; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SUGANUMA T, 1991, CARBOHYD RES, V212, P201, DOI 10.1016/0008-6215(91)84057-L; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; THOMA JA, 1976, CARBOHYD RES, V48, P105, DOI 10.1016/S0008-6215(00)83518-1; THOMA JA, 1971, J BIOL CHEM, V246, P5621; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; WESSELS JGH, 1993, NEW PHYTOL, V123, P397, DOI 10.1111/j.1469-8137.1993.tb03751.x; WONG YS, 1977, J BIOL CHEM, V252, P1402; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8	45	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14556	14563		10.1074/jbc.270.24.14556	http://dx.doi.org/10.1074/jbc.270.24.14556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782319	hybrid			2022-12-27	WOS:A1995RD45500050
J	TANAKA, S; NEFF, L; BARON, R; LEVY, JB				TANAKA, S; NEFF, L; BARON, R; LEVY, JB			TYROSINE PHOSPHORYLATION AND TRANSLOCATION OF THE C-CBL PROTEIN AFTER ACTIVATION OF TYROSINE KINASE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; V-CBL; RECEPTOR; GRB2; TRANSFORMATION; ONCOGENE; TRANSDUCTION; ASSOCIATION; TRUNCATION; BINDING	The c-cbl protooncogene product (c-Cbl) is a 120-kDa protein that has been shown to bind to the Src homology 3 domains of various proteins, suggesting its involvement in signal transduction pathways. We identified one of the most prominent tyrosine-phosphorylated proteins in Fc gamma receptor (Fc gamma R)-stimulated macrophages; to be c-Cbl. Tyrosine phosphorylation of c-Cbl occurred within 20 s after stimulation and reached maximum levels within 3-5 min. c-Cbl was also tyrosine-phosphorylated in epidermal growth factor (EGF) receptor-over-expressing cells upon EGF stimulation, in macrophages in response to CSF-1 treatment, and in v-src transformed cells. Furthermore, we found that c-Cbl associated with these kinases in vivo. In vitro, c-Cbl bound to the Src homology 3 domains of Src, Fyn, and Lyn in both unstimulated and Fc gamma R-stimulated macrophages. Examination of cells by immunofluorescence revealed that c-Cbl is diffusely distributed in the cytoplasm in both unstimulated macrophages and EGF receptor-overexpressing cells and translocated to a more specific compartment of the cell, consistent with the trans-Golgi region, following Fc gamma R clustering and EGF stimulation, respectively. These results suggest that c-Cbl is involved in the signaling pathways utilized by different types of tyrosine kinases.	YALE UNIV,SCH MED,DEPT ORTHOPED,NEW HAVEN,CT 06510	Yale University	TANAKA, S (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	21	166	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14347	14351		10.1074/jbc.270.24.14347	http://dx.doi.org/10.1074/jbc.270.24.14347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782294	hybrid			2022-12-27	WOS:A1995RD45500020
J	LUJAN, HD; MOWATT, MR; WU, JJ; LU, Y; LEES, A; CHANCE, MR; NASH, TE				LUJAN, HD; MOWATT, MR; WU, JJ; LU, Y; LEES, A; CHANCE, MR; NASH, TE			PURIFICATION OF A VARIANT-SPECIFIC SURFACE PROTEIN OF GIARDIA-LAMBLIA AND CHARACTERIZATION OF ITS METAL-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY ABSORPTION-SPECTROSCOPY; ANTIGENIC VARIATION; ZINC-BINDING; FINE-STRUCTURE; EXAFS; SITES; CLEAVAGE; GENE; TOOL; DNA	Giardia lamblia, an intestinal parasite of humans and other vertebrates, undergoes surface antigenic variation by modulating the expression of different variant-specific surface proteins (VSP). VSPs are cysteine-rich surface proteins that bind zinc and other heavy metals in vitro. We developed an immunoaffinity chromatographic method to purify a VSP in order to determine its biochemical properties. The sequences of two different proteolytic fragments agreed with the sequence deduced from the cloned gene, and amino-terminal sequence indicated the removal of a 14 residue signal peptide, consistent with the transport of VSP to the cell surface, The protein is not glycosylated and has an isoelectric point of 5.3. X-ray microanalyses indicated that the major metals in Giardia trophozoites, as well as purified VSP, are zinc and iron. The zinc concentration in Giardia cells was found to be 0.43 mM and the iron concentration 0.80 mM when compared with standard samples (zinc) or calculated hom a known physical constants (iron), We propose that metal coordination stabilizes VSPs, rendering them resistant to proteolytic attack in the upper small intestine. Moreover, the ability to bind ions by Giardia may play a role in nutritional deficiency and/or malabsorption in heavily infected persons.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814	Yeshiva University; Albert Einstein College of Medicine; Uniformed Services University of the Health Sciences - USA	LUJAN, HD (corresponding author), NIAID,PARASIT DIS LAB,9000 ROCKVILLE PIKE,BLDG 4,RM 126,BETHESDA,MD 20892, USA.			Lees, Andrew/0000-0002-8370-4876				ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; AGGARWAL A, 1989, MOL BIOCHEM PARASIT, V32, P39, DOI 10.1016/0166-6851(89)90127-8; ALEY SB, 1993, EXP PARASITOL, V77, P295, DOI 10.1006/expr.1993.1087; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACHMAYE.H, 1967, P NATL ACAD SCI USA, V57, P122, DOI 10.1073/pnas.57.1.122; BERTINI I, 1994, BIOINORG CHEM, V1, P37; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10041, DOI 10.1073/pnas.89.21.10041; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DAS S, 1991, J BIOL CHEM, V266, P21318; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; ELLIS JE, 1993, FEBS LETT, V325, P196, DOI 10.1016/0014-5793(93)81072-8; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUJIWARA K, 1988, J IMMUNOL METHODS, V112, P77, DOI 10.1016/0022-1759(88)90036-1; GABRIEL O, 1992, GLYCOBIOLOGY, V2, P437, DOI 10.1093/glycob/2.5.437; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; GOTTSTEIN B, 1990, PARASITE IMMUNOL, V12, P659, DOI 10.1111/j.1365-3024.1990.tb00995.x; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; LUJAN HD, 1994, J EUKARYOT MICROBIOL, V41, P169, DOI 10.1111/j.1550-7408.1994.tb01491.x; LYTLE FW, 1989, PHYSICA B, V158, P701; MANTEI N, 1992, ANALYZESIGNALASE; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; NASH TE, 1992, MOL BIOCHEM PARASIT, V51, P219, DOI 10.1016/0166-6851(92)90072-R; NASH TE, 1990, J IMMUNOL, V144, P4362; NASH TE, 1990, EXP PARASITOL, V71, P415, DOI 10.1016/0014-4894(90)90067-M; NASH TE, 1993, P NATL ACAD SCI USA, V90, P5489, DOI 10.1073/pnas.90.12.5489; NASH TE, 1988, J IMMUNOL, V141, P636; PEISACH J, 1982, BIOPHYS J, V38, P277, DOI 10.1016/S0006-3495(82)84559-1; PIMENTA PFP, 1991, INFECT IMMUN, V59, P3989, DOI 10.1128/IAI.59.11.3989-3996.1991; ROWLETT RS, 1994, BIOCHEMISTRY-US, V36, P13967; SAGI I, 1990, J AM CHEM SOC, V112, P8639, DOI 10.1021/ja00180a001; SCHEURING EM, 1994, BIOCHEMISTRY-US, V33, P6310, DOI 10.1021/bi00186a034; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; THIEL EC, 1994, BIOINORG CHEM, V1, P1; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSON SM, 1994, EUR J BIOCHEM, V220, P439, DOI 10.1111/j.1432-1033.1994.tb18641.x; UDOMKESMALEE E, 1992, AM J CLIN NUTR, V56, P50, DOI 10.1093/ajcn/56.1.50; VAUGH D, 1986, XRAY DATA BOOKLET; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHANG YY, 1993, INFECT IMMUN, V61, P520, DOI 10.1128/IAI.61.2.520-524.1993	45	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13807	13813		10.1074/jbc.270.23.13807	http://dx.doi.org/10.1074/jbc.270.23.13807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775437	hybrid			2022-12-27	WOS:A1995RC44800036
J	TANG, AH; TU, CPD				TANG, AH; TU, CPD			PENTOBARBITAL-INDUCED CHANGES IN DROSOPHILA GLUTATHIONE-S-TRANSFERASE D21 MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; EXTRAHEPATIC TISSUES; MULTIGENE FAMILY; INTRONLESS GENE; CYTOCHROME-P-450; SEQUENCE; LIVER; EXPRESSION; INDUCTION	The Drosophila glutathione S-transferase (gstD) genes are a family of divergently transcribed, intronless genes and pseudogenes. Under control conditions, the steady-state level of gstD1 mRNA is 20-fold higher than that of the gstD21 mRNA despite a lower transcription rate of the gstD1 gene, The GST D1 protein level is four times as abundant as the GST D21 protein. The gstD1 and gstD21 genes responded rapidly to pentobarbital (PB) as changes in mRNA levels were detectable within 30 min of treatment. Maximal induction of gstD1 and gstD21 resulted in 3-fold and 20-fold elevation of their respective mRNA levels, The major mechanism for the increase in gstD1 mRNAs appears to be transcriptional activation, The 2-fold increase in the rate of gstD21 transcription, however, cannot fully account for the 20-fold increase in the steady-state level of gstD21 mRNA Therefore, post-transcriptional mechanism(s) should also be responsible for the increase of gstD21 mRNA by PB, Because the gstD21 mRNA is relatively unstable under control conditions, induction of the intronless gstD21 mRNA by PB occurs mainly at the level of enhanced mRNA stability, The GST D1 protein level in adult Drosophila was increased approximately 2-fold after PB treatment, whereas the GST D21 level remained relatively the same, Thus, an increase in gstD21 mRNA stability by PB treatment is probably coupled to a regulatory effect at the translational level.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878	NCRR NIH HHS [2S07 RR07082] Funding Source: Medline; NIEHS NIH HHS [ES 05661] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005661] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADESNIK M, 1986, CRIT REV BIOCHEM MOL, V19, P247, DOI 10.3109/10409238609084657; ATCHISON M, 1983, J BIOL CHEM, V258, P1285; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; Belasco J.G., 2012, CONTROL MESSENGER RN; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHEN RT, 1994, P NATL ACAD SCI USA, V91, P6069, DOI 10.1073/pnas.91.13.6069; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; COCHRANE BJ, 1987, INSECT BIOCHEM, V17, P731, DOI 10.1016/0020-1790(87)90043-6; COCHRANE BJ, 1992, ACS SYM SER, V505, P53; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GOODMANGILMAN A, 1990, GOODMAN GILMANS PHAR, P358; Habig W H, 1981, Methods Enzymol, V77, P398; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAYAOKA T, 1982, PESTIC BIOCHEM PHYS, V17, P113, DOI 10.1016/0048-3575(82)90015-3; HAYES JD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P3; HE JS, 1991, J BIOL CHEM, V266, P7864; HO IK, 1981, ANNU REV PHARMACOL, V21, P83, DOI 10.1146/annurev.pa.21.040181.000503; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; LOVE JD, 1985, ANAL BIOCHEM, V150, P429, DOI 10.1016/0003-2697(85)90532-9; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MULLIN CA, 1992, MOL MECHANISMS INSEC; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OTTEA JA, 1981, PESTIC BIOCHEM PHYS, V15, P10, DOI 10.1016/0048-3575(81)90029-8; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIKE SF, 1985, BIOCHEM PHARMACOL, V34, P2489, DOI 10.1016/0006-2952(85)90531-3; REDDY CC, 1983, ARCH BIOCHEM BIOPHYS, V224, P87, DOI 10.1016/0003-9861(83)90192-3; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROUSH RT, 1987, ANNU REV ENTOMOL, V32, P361, DOI 10.1146/annurev.en.32.010187.002045; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; TANG AH, 1994, J BIOL CHEM, V269, P27876; TANG AH, 1994, THESIS PENNSYLVANIA; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P379; TU CPD, 1985, J BIOL CHEM, V260, P9961; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; YAMAZOE Y, 1987, J BIOL CHEM, V262, P7423	53	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13819	13825		10.1074/jbc.270.23.13819	http://dx.doi.org/10.1074/jbc.270.23.13819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775439	hybrid			2022-12-27	WOS:A1995RC44800038
J	PLUMMER, TH; TARENTINO, AL; HAUER, CR				PLUMMER, TH; TARENTINO, AL; HAUER, CR			NOVEL, SPECIFIC O-GLYCOSYLATION OF SECRETED FLAVOBACTERIUM-MENINGOSEPTICUM PROTEINS - ASP-SER-ASTERISK AND ASP-THR-ASTERISK-THR CONSENSUS SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; MOLECULAR-CLONING; PRIMARY SEQUENCE; GLYCOPROTEIN; LINKAGE	A new type of O-linked oligosaccharide has been discovered on several proteins secreted by the Gram-negative bacterium Flavobacterium meningosepticum, including Endo F-2 (three sites), Endo F-3 (one site), and a P40 protease (one site). The oligosaccharide moiety is covalently attached via a mannose residue to a serine or threonine at consensus sites corresponding to Asp-Ser* or Asp-Thr*-Thr. Preliminary characterization by mass spectroscopy revealed an oligosaccharide of 1244 Da at each of the proposed glycosylation sites. Collision-associated dissociation analysis showed a characteristic daughter ion series of m/z 218, 394, and 556, indicative of a common Flavobacterium oligosaccharide. Compositional analysis demonstrated an unusual profile of monosaccharides, including hexoses, methylated hexoses, and uronic acid derivatives.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	PLUMMER, TH (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOLEC MED,ALBANY,NY 12201, USA.			Hauer, Christoph/0000-0001-8704-2198	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [1-P41-RR05351-05] Funding Source: Medline; PHS HHS [30471] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARLSON DM, 1968, J BIOL CHEM, V243, P616; CLARKE AJ, 1991, ANAL BIOCHEM, V199, P68, DOI 10.1016/0003-2697(91)90270-4; DUBIOS M, 1956, ANAL CHEM, V28, P350, DOI DOI 10.1021/AC60111A017; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GRIMWOOD BG, 1994, ARCH BIOCHEM BIOPHYS, V311, P127, DOI 10.1006/abbi.1994.1217; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KARCHER U, 1993, J BIOL CHEM, V268, P26821; MERKLE RK, 1994, METHOD ENZYMOL, V231, P1; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; REINHOLD BB, 1995, J BIOL CHEM, V270, P13197, DOI 10.1074/jbc.270.22.13197; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1993, J BIOL CHEM, V268, P9702; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1995, IN PRESS ARCH BIOCH; TOWNSEND RR, 1991, CARBOHYD RES, V215, P211, DOI 10.1016/0008-6215(91)84021-6; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; YORK WS, 1986, METHOD ENZYMOL, V118, P3	21	49	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13192	13196		10.1074/jbc.270.22.13192	http://dx.doi.org/10.1074/jbc.270.22.13192			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768916	hybrid			2022-12-27	WOS:A1995RB43900039
J	BRAKEBUSCH, C; VARFOLOMEEV, EE; BATKIN, M; WALLACH, D				BRAKEBUSCH, C; VARFOLOMEEV, EE; BATKIN, M; WALLACH, D			STRUCTURAL REQUIREMENTS FOR INDUCIBLE SHEDDING OF THE P55 TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR TNF RECEPTOR; FACTOR-BINDING PROTEIN; MOLECULAR-CLONING; CELL-SURFACE; SOLUBLE FORM; MONOCLONAL-ANTIBODIES; PHORBOL ESTER; GENE-PRODUCT; EXPRESSION	Induced shedding of the p55 tumor necrosis factor receptor (p55-R) was previously shown 60 be independent of the amino acid sequence properties of the intracellular domain of this receptor. We now find it also independent of the sequence properties of the transmembrane domain and of the cysteine-rich region that constitutes most of the extracellular domain of the receptor. The shedding is shown to depend solely on the sequence properties of a small region within the spacer that Links the cysteine-rich region in the extracellular domain to the transmembrane domain. Detailed tests of effects of mutations in the spacer on the shedding indicate that the process is independent of the amino acid side-chain identity in this region except for a limited dependence on the identity of 1 residue (Val-173), located downstream to the putative major cleavage site of the receptor. It is strongly affected, however, by some mutations that seem to change the conformation of the spacer region. These findings suggest that a short amino acid sequence in the p55-R is essential and sufficient for its shedding and that the shedding is mediated either by a protease with limited sequence specificity or by several different proteases that recognize different amino acid sequences, yet it strictly depends on some conformational features of the cleavage region in the receptor.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Brakebusch, Cord/0000-0002-9342-1634				ADERKA D, 1991, CANCER RES, V51, P5602; ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ADERKA D, 1993, TUMOR NECROSIS FACTO, V4, P191; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; AVIVI A, 1991, ONCOGENE, V6, P673; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1993, TUMOR NECROSIS FACTO, V4, P40; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENDLY BM, 1990, CANCER RES, V50, P1550; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; ISRAEL S, 1986, IMMUNOL LETT, V12, P217, DOI 10.1016/0165-2478(86)90007-6; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LITTLEFIELD JW, 1964, NATURE, V203, P1142, DOI 10.1038/2031142a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOSSALAYI MD, 1991, B I PASTEUR, V89, P139; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SELDEN RF, 1994, CURRENT PROTOCOLS MO, V1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUNADA H, 1985, ANAL BIOCHEM, V149, P438, DOI 10.1016/0003-2697(85)90595-0; TAGA T, 1989, CELL, V58, P578; ULRICH A, 1984, NATURE, V309, P418; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; WALLACH D, 1991, TUMOR NECROSIS FACTO, V3, P47; WARE CF, 1991, J IMMUNOL, V147, P4229; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	55	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32488	32496						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798250				2022-12-27	WOS:A1994PX30400071
J	CARRIER, F; SMITH, ML; BAE, I; KILPATRICK, KE; LANSING, TJ; CHEN, CY; ENGELSTEIN, M; FRIEND, SH; HENNER, WD; GILMER, TM; KASTAN, MB; FORNACE, AJ				CARRIER, F; SMITH, ML; BAE, I; KILPATRICK, KE; LANSING, TJ; CHEN, CY; ENGELSTEIN, M; FRIEND, SH; HENNER, WD; GILMER, TM; KASTAN, MB; FORNACE, AJ			CHARACTERIZATION OF HUMAN GADD45, A P53-REGULATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; KINASE-C; P53; ACTIVATION; CELLS; RNA; RADIATION; INDUCTION; ARREST	GADD45 (growth arrest and DNA damage) is a DNA-damage-inducible gene regulated in part by the tumor suppressor p53. A role in negative growth control has recently been suggested based on significant (more than 75%) reduction of colony formation following over expression of Gadd45. To better understand the role of Gadd45, we have developed specific rabbit and murine antibodies raised against the human recombinant protein. Using these antibodies, we have found that in ML-1 cells Gadd45 is predominantly a nuclear protein. MyD118, a protein induced by terminal differentiation sharing 57% homology with Gadd45, does not cross-react with any of the antibodies produced. As expected, the induction of Gadd45 protein by ionizing radiation (IR) was also found to be dependent on a mild type p53 phenotype. Interestingly, WI-L2-NS, a human lymphoid cell line, showed very high basal levels of Gadd45 mRNA and protein in addition to a high constitutive level of a mutated p53 protein. In this cell Line, the high levels of GADD45 did not inhibit cellular growth in spite of the fact that no mutations were found in GADD45 sequence. These results indicate that some cell line(s) can tolerate high levels of Gadd45 and abrogate its growth suppression function.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; OREGON HLTH SCI UNIV,SCH MED,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129	GlaxoSmithKline; GlaxoSmithKline; Oregon Health & Science University	CARRIER, F (corresponding author), NCI,DCT,DTP,MOLEC PHARMACOL LAB,BETHESDA,MD 20892, USA.		Carrier, France/C-3063-2008	Carrier, France/0000-0002-5517-5284				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JA, 1968, CANCER-AM CANCER SOC, V22, P517, DOI 10.1002/1097-0142(196809)22:3<517::AID-CNCR2820220305>3.0.CO;2-A; LORD KA, 1990, ONCOGENE, V5, P387; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	23	111	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32672	32677						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798274				2022-12-27	WOS:A1994PX30400097
J	CHEN, DW; SWENSON, RP				CHEN, DW; SWENSON, RP			CLONING, SEQUENCE-ANALYSIS, AND EXPRESSION OF THE GENES ENCODING THE 2 SUBUNITS OF THE METHYLOTROPHIC BACTERIUM W3A1 ELECTRON-TRANSFER FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS ORS571; AMINO-ACID-SEQUENCE; FAD-BINDING SITE; TRIMETHYLAMINE DEHYDROGENASE; METHYLOPHILUS-METHYLOTROPHUS; PARACOCCUS-DENITRIFICANS; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; MOLECULAR-CLONING; ESCHERICHIA-COLI	The genes encoding the two different subunits of the electron transfer flavoprotein (ETF) from the methylotrophic bacterium W3A1 have been identified, cloned, and sequenced. A 0.8-kilobase pair DNA fragment was generated for use as a molecular probe by the amplification of genomic sequences using the polymerase chain reaction and a primer pair with degenerate sequences derived from the NH2-terminal amino acid sequences determined for the ETF subunits purified hom W3A1, The screening of a partial genomic minilibrary containing size-selected BamHI-SalI fragments using this probe identified a 2.2-kilobase pair insert containing the complete coding sequences for both W3A1 ETF subunits, The genes are arranged in tandem in the genomic DNA with only 2 bases between the TAG translation termination codon of the small subunit and the ATG translation initiation codon of the large subunit, The deduced amino acid sequences of each of the W3A1 ETF subunits exhibit only similar to 30% identity with the corresponding subunits of the ETF from human, rat, and Paracoccus denitrificans, which as a group are greater than 50% identical, Thus, the ETF from W3A1 may exhibit some unique structural features that, like other differences in some of its physical and functional properties, may distinguish this ETF from others in this family. A highly homologous region near the COOH terminus of the large subunit in all the ETF proteins was found to contain a sequence that matches in several ways the ADP-binding motif of flavoproteins and other dinucleotide-binding proteins, suggesting that the large subunit forms a portion of the FAD (or AMP) binding site in these proteins. Under control of the tac promoter, the cloned ETF subunit genes were co-expressed in Escherichia coli producing the heterodimeric holoprotein with physical, spectral, and electron-accepting properties essentially identical to the ETF isolated from W3A1, The recombinant ETF serves as the electron acceptor for W3A1 trimethylamine dehydrogenase in vitro, accumulating as the air-stable anionic semiquinone in the presence of excess trimethylamine, Fully reduced ETF could not be obtained even after prolonged enzymatic reduction.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Ohio State University					NIGMS NIH HHS [GM36490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMAN E, 1983, GENE, V25, P167; ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; BACHMANN BJ, 1983, MICROBIOL REV, V47, P180, DOI 10.1128/MMBR.47.2.180-230.1983; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CROSS AR, 1980, BIOCHEM J, V192, P429, DOI 10.1042/bj1920429; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; EARL CD, 1987, J BACTERIOL, V169, P1127, DOI 10.1128/jb.169.3.1127-1136.1987; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FRERMAN FE, 1987, T BIOCH SOC, V16, P416; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORELICK RJ, 1986, BIOCHEMISTRY-US, V25, P7092, DOI 10.1021/bi00370a050; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMS LR, 1990, BIOCHEM BIOPH RES CO, V168, P809, DOI 10.1016/0006-291X(90)92393-E; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1990, METHOD ENZYMOL, V188, P309; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; JOH T, 1987, J BIOL CHEM, V262, P15127; JORNVALL H, 1977, EUR J BIOCHEM, V72, P443, DOI 10.1111/j.1432-1033.1977.tb11268.x; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM LW, 1986, J BIOL CHEM, V261, P5140; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; RYAN T, 1983, J BIOL CHEM, V258, P4690; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIMO SS, 1969, J BACTERIOL, V98, P368, DOI 10.1128/JB.98.2.368-374.1969; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHINZAWA K, 1988, BIOCHEM BIOPH RES CO, V155, P300, DOI 10.1016/S0006-291X(88)81084-2; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; SWENSON RP, 1991, FLAVINS AND FLAVOPROTEINS 1990, P415; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; VOGT VM, 1970, J BIOL CHEM, V245, P4760; WALLER JP, 1963, J MOL BIOL, V7, P483, DOI 10.1016/S0022-2836(63)80096-0; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	57	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32120	32130						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798207				2022-12-27	WOS:A1994PX30400019
J	CHEN, WN; LIM, L				CHEN, WN; LIM, L			THE CAENORHABDITIS-ELEGANS SMALL GTP-BINDING PROTEIN RHOA IS ENRICHED IN THE NERVE RING AND SENSORY NEURONS DURING LARVAL DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; SACCHAROMYCES-CEREVISIAE; ADP-RIBOSYLTRANSFERASE; REGULATORY PROTEIN; RAS SUPERFAMILY; GENE FAMILY; EXPRESSION; CLONING; ENCODES; SEQUENCE	p21 Res has been implicated in vulval differentiation in Caenorhabditis elegans. We now describe the characteristics during nematode development of the related p21 RhoA which has been ascribed a morphological role in mammals. The CeRhoA cDNA isolated in this study encodes a sequence of 192 amino acids residues with 87.6% identity to human RhoA Genomic Southern analysis indicates the presence of a single Rho gene in C. elegans. Its 2-kilobase mRNA is expressed at the highest levels during embryogenesis and decreases gradually thereafter. However, the level of the 24-kDa protein detected by the anti-CeRhoA antibody is high at the larval stages but low in embryos. The glutathione S-transferase/CeRhoA fusion protein expressed in Escherichia coli displays conserved biochemical activities. Unlike its counterpart in mammalian cells which is predominantly cytosolic, most of CeRhoA is associated with the membrane and the cytoskeleton throughout development. Indirect immunofluorescence analysis indicates an ubiquitous expression of CeRhoA throughout development with a particular enrichment at larval stages in the pharyngeal nerve ring and at the tip of the head containing chemosensory and mechanosensory neurons. This suggests a stage specific role for p21 RhoA in mediating the signaling pathway underlying the sensory circuitry in C. elegans post-embryonic development.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	CHEN, WN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, GLAXO IMCB GRP, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.			, Yang/0000-0002-6620-8897				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHEN WN, 1994, J BIOL CHEM, V269, P820; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HAFEN E, 1993, DEVELOPMENT, P41; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; ISOMURA M, 1991, ONCOGENE, V6, P119; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; LAND M, 1994, J BIOL CHEM, V269, P9234; LU XY, 1990, J BIOL CHEM, V265, P3293; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PERONA R, 1993, ONCOGENE, V8, P1285; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMAS JH, 1994, SCIENCE, V264, P1698, DOI 10.1126/science.7911601; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILLIAMSON KC, 1990, J BIOL CHEM, V265, P20807; WOLINSKY E, 1990, BEHAV GENET, V20, P169, DOI 10.1007/BF01067789; Wood WB, 1988, NEMATODE CAENORHABDI; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	56	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32394	32404						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798239				2022-12-27	WOS:A1994PX30400058
J	ENDO, K; ICHIKAWA, F; UCHIYAMA, Y; KATSUMATA, K; OHKAWA, H; KUMAKI, K; OGATA, E; IKEDA, K				ENDO, K; ICHIKAWA, F; UCHIYAMA, Y; KATSUMATA, K; OHKAWA, H; KUMAKI, K; OGATA, E; IKEDA, K			EVIDENCE FOR THE UPTAKE OF A VITAMIN-D ANALOG (OCT) BY A HUMAN CARCINOMA AND ITS EFFECT OF SUPPRESSING THE TRANSCRIPTION OF PARATHYROID HORMONE-RELATED PEPTIDE GENE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D ENDOCRINE SYSTEM; INFECTED T-CELLS; HUMORAL HYPERCALCEMIA; PROTEIN; EXPRESSION; IDENTIFICATION; MALIGNANCY; RECEPTOR; CANCER; GROWTH	The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D-3 (22-oxa-1,25-(OH)(2)D-3, OCT), a vitamin D-3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia. FA-6 tumor expressed vitamin D receptor (VDR) mRNA, and its nuclear extract contained a specific and saturable 1,25-(OH)(2)D-3 binding activity. Although [H-3]OCT administered intravenously into FA-6 tumor-bearing nude mice was cleared from the circulation more rapidly than [H-3]1,25-(OH)(2)D-3, the uptake of [H-3]OCT into the tumor tissue, relative to the radioactivity in the circulation, was greater than that of [H-3]1,25-(OH)(2)D-3. Intravenous or oral administration of OCT reduced the steady-state levels of PTHRP mRNA in FA-6 tumor, and nuclear run off assays demonstrated that the effect of OCT on PTHRP gene expression occurred at a transcriptional level. RNase mapping analysis revealed that both upstream and downstream promoters of the human PTHRP gene were down-regulated by OCT. Finally, OCT exerted a preventive as well as therapeutic effect on cancer-associated hypercalcemia with a marked prolongation of the survival time in tumor-bearing animals. These results suggest that OCT is effectively taken up by a VDR-positive human carcinoma in vivo and has a therapeutic potential for cancer-associated hypercalcemia through suppression of PTHRP gene transcription.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,DIV ENDOCRINOL,BUNKYO KU,TOKYO 112,JAPAN; CHUGAI PHARMACEUT CO LTD,BONE DIS LAB,SHIZUOKA 412,JAPAN; CANC INST HOSP,JAPANESE FDN CANC RES,TOKYO 115,JAPAN	University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Japanese Foundation for Cancer Research								ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1993, CANCER RES, V53, P2534; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROWN AJ, 1993, ENDOCRINOLOGY, V133, P1158, DOI 10.1210/en.133.3.1158; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; IKEDA K, 1993, J BIOL CHEM, V268, P1174; IKEDA K, 1989, J BIOL CHEM, V264, P15743; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1990, J BIOL CHEM, V265, P5398; INOUE D, 1993, J BIOL CHEM, V268, P16730; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOBAYASHI T, 1994, J BIOCHEM-TOKYO, V115, P373, DOI 10.1093/oxfordjournals.jbchem.a124346; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1927, DOI 10.1210/endo-128-4-1927; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; MANGIN M, 1988, MOL ENDOCRINOL, V2, P1049, DOI 10.1210/mend-2-11-1049; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MURAYAMA E, 1986, CHEM PHARM BULL, V34, P4410; NAGATA N, 1989, ENDOCRINOL JAPON, V36, P75; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; PIERCE EA, 1987, J BIOL CHEM, V262, P17092; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; STREWLER GJ, 1990, ANNU REV MED, V41, P35; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WATANABE H, 1992, STEROIDS, V57, P444, DOI 10.1016/0039-128X(92)90098-T; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32693	32699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798277				2022-12-27	WOS:A1994PX30400100
J	HERRICK, KR; SALAZAR, D; GOODMAN, SI; FINOCCHIARO, G; BEDZYK, LA; FRERMAN, FE				HERRICK, KR; SALAZAR, D; GOODMAN, SI; FINOCCHIARO, G; BEDZYK, LA; FRERMAN, FE			EXPRESSION AND CHARACTERIZATION OF HUMAN AND CHIMERIC HUMAN PARACOCCUS-DENITRIFICANS ELECTRON-TRANSFER FLAVOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; ACIDEMIA TYPE-II; UBIQUINONE OXIDOREDUCTASE; PIG-LIVER; NUCLEOTIDE-SEQUENCE; CIRCULAR-DICHROISM; MOLECULAR-CLONING; ALPHA-SUBUNIT	Electron transfer flavoprotein (ETF) is a heterodimer that contains a single equivalent of FAD and accepts electrons from nine flavoprotein dehydrogenases in the mitochondrial matrix, Human ETF was expressed in Escherichia coli using the expression vector previously employed to express Paracoccus denitrificans ETF (Bedzyk, L. A., Escudero, K. A., Gill, R. E., Griffin, K. J., and Frerman, F. E. (1993) J. Biol. Chem. 268, 20211-20217). cDNAs encoding the beta and alpha subunits of the human protein were inserted into the vector, mimicking the arrangement of the P. denitrificans genes in which coding sequences are joined by overlapping termination and initiation codons, A human ETF containing 30% P. denitrificans sequence at the amino terminus of the beta subunit was also expressed and purified, This chimeric ETF has 64% sequence identity with the human sequence in the substituted region, Kinetic constants of medium chain and short chain acyl-CoA dehydrogenases for the chimeric ETFs were slightly changed from those of human ETF; but, there are marked differences in the kinetic constants of sarcosine dehydrogenase and electron transfer flavoprotein-ubiquinone oxidoreductase with the two ETFs, Absorption spectra of the three redox states of human, chimeric, and P. denitrificans ETF flavins are identical, However, the flavin circular dichroism spectra of the three ETFs are characteristic for each species, The spectrum of the chimeric ETF has both human and P. denitrificans ETF features, The amplitude of the 436 nm band is identical to that of the of the human ETF flavin, but the amplitude of the 375 nm band is identical to that of the P. denitrificans ETF flavin, Thus, flavin in the chimeric ETF appears to be exposed to dipoles in the protein framework provided by human and bacterial sequences, These spectral data indicate that the flavin is located in the vicinity of the amino-terminal region of the beta subunit, The kinetic data suggest that the amino-terminal region of the beta subunit comprises part of the docking site for some primary dehydrogenases and electron transfer flavoprotein-ubiquinone oxidoreductase.	UNIV COLORADO, SCH MED, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, PROGRAM CELLULAR & DEV BIOL, DENVER, CO 80262 USA; IST NAZL NEUROL CE BESTA, BIOCHIM & GENET LAB, I-20133 MILAN, ITALY	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Finocchiaro, Gaetano/0000-0003-3583-4040	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD004024, T32HD007385] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08315, T32 HD07385, HD04024] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUER HE, 1980, J BIOL CHEM, V255, P8157; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BEINERT H, 1962, J BIOL CHEM, V237, P2988; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P133; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FRENEAUX E, 1992, J CLIN INVEST, V90, P1679, DOI 10.1172/JCI116040; FRERMAN FE, 1990, PROG CLIN BIOL RES, V321, P79; FRERMAN FE, 1988, BIOCHEM SOC T, V16, P416, DOI 10.1042/bst0160416; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; GORLICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830; GORLICK RJ, 1986, BIOCHEMISTRY-US, V25, P7092; HALL C, 1982, J BIOL CHEM; HAUGE JG, 1956, J AM CHEM SOC, V78, P5266, DOI 10.1021/ja01601a032; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSU MC, 1971, J AM CHEM SOC, V93, P3515; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; IZAI K, 1992, J BIOL CHEM, V267, P1027; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MCKEAN MC, 1979, J BIOL CHEM, V254, P2730; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; SCOLANAG.G, 1972, Z NATURFORSCH PT B, VB 27, P1044; SONG PS, 1972, Z NATURFORSCH PT B, VB 27, P1011, DOI 10.1515/znb-1972-0901; STEENKAMP DJ, 1988, BIOCHEM J, V255, P869, DOI 10.1042/bj2550869; STEENKAMP DJ, 1987, BIOCHEM J, V243, P519, DOI 10.1042/bj2430519; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; WATMOUGH NJ, 1991, BIOCHEMISTRY-US, V30, P1317, DOI 10.1021/bi00219a023; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102	36	24	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32239	32245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798224				2022-12-27	WOS:A1994PX30400037
J	RAO, GN; BAAS, AS; GLASGOW, WC; ELING, TE; RUNGE, MS; ALEXANDER, RW				RAO, GN; BAAS, AS; GLASGOW, WC; ELING, TE; RUNGE, MS; ALEXANDER, RW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES BY ARACHIDONIC-ACID AND ITS METABOLITES IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MAP KINASE; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; MESANGIAL CELLS; ANGIOTENSIN-II; MESSENGER-RNA; LINOLEIC-ACID; DNA-SYNTHESIS; 3T3 CELLS	Previous studies from this laboratory and others suggest that arachidonic acid and its metabolites play important roles in a variety of biological processes such as signal transduction, contraction, chemotaxis, and cell growth and differentiation. Here we studied the effect of arachidonic acid on mitogen-activated protein (MAP) kinases in vascular smooth muscle cells (VSMC). Arachidonic acid activated MAP kinases in VSMC in a time-and dose-dependent manner. Nordihydroguaiaretic acid (NDGA), a potent inhibitor of the Lipoxygenase system, significantly blocked the arachidonic acid-induced activation of MAP kinases, whereas indomethacin, an inhibitor of cyclooxygenase, had no effect. In VSMC, arachidonic acid was converted to 15-hydroxyeicosatetraenoic acid (15-HETE); NDGA inhibited the formation of this HETE. Exogenous addition of 15-HETE to VSMC caused stimulation of MAP kinases. Depletion of protein kinase C attenuated both the arachidonic acid- and 15-HETE-induced activation of MAP kinases in VSMC. Together these results suggest that 1) arachidonic acid activates MAP kinases in VSMC; 2) 15-HETE, a 15-lipoxygenase product of arachidonic acid, at least in part, mediates the arachidonic acid effect on MAP kinases; and 3) protein kinase C appears to be important in arachidonic acid activation of MAP kinases, Therefore, MAP kinases may play an important role in arachidonic acid signaling of VSMC growth and function.	EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322; NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709	Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CL, 1985, CIRC RES, V56, P97, DOI 10.1161/01.RES.56.1.97; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DELL KR, 1989, BIOCHEM J, V258, P171, DOI 10.1042/bj2580171; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOW CE, 1984, J LIPID RES, V25, P1090; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; PALMBERG L, 1987, J CELL SCI, V88, P151; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PORTER NA, 1975, J ORG CHEM, V40, P3614, DOI 10.1021/jo00912a037; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1994, J BIOL CHEM, V269, P7180; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SIEGEL MI, 1982, BIOCHEM BIOPH RES CO, V104, P874, DOI 10.1016/0006-291X(82)91330-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	62	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32586	32591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798262				2022-12-27	WOS:A1994PX30400084
J	SCHMID, RM; LIPTAY, S; BETTS, JC; NABEL, GJ				SCHMID, RM; LIPTAY, S; BETTS, JC; NABEL, GJ			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF NF-KAPPA-B - DETERMINANTS OF DNA-BINDING SPECIFICITY AND PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; REL ONCOGENE; SUBUNIT; P50; INHIBITION; CLONING; ONCOPROTEIN; ENCODES; MOTIFS; GENE	The NF-kappa B transcription factors display a high degree of sequence conservation in a domain initially described in the rel oncogene. Two family members, NF-kappa B1 and NF-kappa B2, have distinct DNA binding properties and functionally distinct effects on different enhancers. NF-kappa B1, for example, binds to the kappa B Site from the human immunodeficiency virus (HIV) with similar to 15-fold higher affinity than NF-kappa B2. In this study, we have defined regions within the Rel domain which determine DNA binding specificity and interaction with other proteins. We find that the COOH-terminal putative Rel dimerization domain of NF-kappa B1 is required for preferential binding to the HIV KB site. In contrast, preferential stimulation of the HIV enhancer by NF-kappa B2 with RelA(p65) is determined by both the NH2- and COOH-terminal Rel domains of NF-kappa B2. These two regions of NF-kappa B2 also mediate preferential synergy with Bcl3. These data suggest that a specific subdomain of the Rel conserved region has evolved to control the fine specificity of DNA binding, and two distinct subregions within the Rel domain determine the specificity of interaction with other transcription factors. These specific Rel-conserved domains therefore determine the specificity of NF-kappa B interactions and contribute to selective gene activation.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852	29	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32162	32167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798213				2022-12-27	WOS:A1994PX30400025
J	TAKAHARA, K; LYONS, GE; GREENSPAN, DS				TAKAHARA, K; LYONS, GE; GREENSPAN, DS			BONE MORPHOGENETIC PROTEIN-1 AND A MAMMALIAN TOLLOID HOMOLOG (MTLD) ARE ENCODED BY ALTERNATIVELY SPLICED TRANSCRIPTS WHICH ARE DIFFERENTIALLY EXPRESSED IN SOME TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; CELLS; GENE; PROTEASE; PATTERN; PRODUCT; DOMAIN; EMBRYO; BMP-1	Bone morphogenetic protein-1 (BMP-1) is a metalloprotease purified from extracts capable of inducing ectopic bone formation. In humans, it has a domain structure similar to that of the Drosophila dorsal-ventral patterning gene-product tolloid (Tld), but is considerably shorter. Here we show that, in humans and mice, alternatively spliced transcripts encode BMP-1 and a longer protein, designated mammalian tolloid (mTld), with a domain structure identical to that of Drosophila Tld. A third alternatively spliced product, in which a novel domain is inserted near the BMP-1 C terminus, is also reported. Low levels of transcripts for mTld were found in all adult human tissues surveyed, while BMP-1 transcripts were detectable in all adult tissues except brain. This differential expression was mirrored in embryonic mouse tissues where in situ hybridization found high levels of mTld transcripts, but was unable to detect BMP-1 transcripts, in the floor plate of the neural tube of the developing central nervous system. The third alternatively spliced form was not detected in adult human tissues. In situ hybridizations found punctate signals for all three forms localized to trophoblast giant cells in 17.5-day mouse placenta, with highest levels of expression, especially for BMP-1, near the maternal interface.	UNIV WISCONSIN, SCH MED, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT ANAT, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, CELL & MOLEC BIOL PROGRAM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Greenspan, Daniel/0000-0001-8096-7446	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029471] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-29471] Funding Source: Medline; NIGMS NIH HHS [GM-46846] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; LEE ST, 1988, J BIOL CHEM, V263, P13414; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; PLACZEK M, 1991, DEVELOPMENT, P105; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SOARES MJ, 1993, TROPHOBLAST CELLS PA, P46; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1990, J CELL SCI, P149	26	140	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32572	32578						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798260				2022-12-27	WOS:A1994PX30400082
J	SUKEGAWA, J; BLOBEL, G				SUKEGAWA, J; BLOBEL, G			A PUTATIVE MAMMALIAN RNA HELICASE WITH AN ARGININE-SERINE-RICH DOMAIN COLOCALIZES WITH A SPLICING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; PROTEIN; DNA; IDENTIFICATION; COMPONENTS; ENCODES; CLONING; YEAST	We have cloned a rat cDNA whose deduced primary structure yields a protein of 117.4 kDa. Because this protein contains RNA helicase consensus motifs, among them a ''DEAD'' box, we have termed it HEL117 (for helicase of 117.4 kDa). Besides the helicase consensus motifs, HEL117 contains an arginine-serine (RS)-rich domain, which occurs in some proteins involved in RNA splicing. Moreover, the COOH-terminal region of 78 residues of HEL117 is 38.5% identical and 59% similar to the COOH-terminal region of a yeast PRP5 protein that is involved in RNA splicing. Rabbit antibodies generated against a synthetic peptide of HEL117 identified a single polypeptide not only in rat cells but also in cells of other mammals as well as chicken. The antibodies revealed a finely punctate and speckled intranuclear staining in immunofluorescence microscopy. A monoclonal antibody against a human splicing factor containing an RS domain (SC35) showed, in double immunofluorescence microscopy, largely overlapping staining consistent with HEL117 being involved in RNA splicing.			SUKEGAWA, J (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; LEE CG, 1993, J BIOL CHEM, V268, P13472; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; 1991, PROGRAM MANUAL GCG P	28	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15702	15706		10.1074/jbc.270.26.15702	http://dx.doi.org/10.1074/jbc.270.26.15702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797571	hybrid			2022-12-27	WOS:A1995RG53800042
J	FISH, KJ; CEGIELSKA, A; GETMAN, ME; LANDES, GM; VIRSHUP, DM				FISH, KJ; CEGIELSKA, A; GETMAN, ME; LANDES, GM; VIRSHUP, DM			ISOLATION AND CHARACTERIZATION OF HUMAN CASEIN KINASE I-EPSILON (CKI), A NOVEL MEMBER OF THE CKI GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG INITIATOR CODON; PROTEIN-KINASES; SUBSTRATE DETERMINANTS; MOLECULAR-CLONING; BUDDING YEAST; DNA; EXPRESSION; CELLS; HYBRIDIZATION; LOCALIZATION	The casein kinase I (CKI) gene family is a rapidly enlarging group whose members have been implicated in the control of cytoplasmic and nuclear processes, including DNA replication and repair. We report here the cloning and characterization of a novel isoform of CKI from a human placental cDNA library. The cDNA for this isoform, hCKI epsilon, predicts a basic polypeptide of 416 amino acids and a molecular mass of 47.3 kDa. It encodes a core kinase domain of 285 amino acids and a carboxyl-terminal tail of 123 amino acids. The kinase domain is 53-98% identical to the kinase domains of other CKI family members and is most closely related to the delta isoform. Localization of the hCKI epsilon gene to chromosome 22q12-13 and the hCKI delta gene to chromosome 17q25 confirms that these are distinct genes in the CKI family. Northern blot analysis shows that hCKI epsilon is expressed in multiple human cell lines. Recombinant hCKI epsilon is an active enzyme that phosphorylates known CKI substrates including a CKI-specific peptide substrate and is inhibited by CKI-7, a CKI-specific inhibitor. A budding yeast isoform of CKI, HRR25, has been implicated in DNA repair responses. Expression of hCKI epsilon but not hCKI alpha rescued the slow-growth phenotype of a Saccharomyces cerevisiae strain with a deletion of HRR25. Human CKI epsilon is a novel CKI isoform with properties that overlap those of previously described CKI isoforms.	UNIV UTAH, PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT ONCOL SCI, DIV MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA; INTEGRATED GENET INC, DEPT HUMAN GENET, FRAMINGHAM, MA 01701 USA; WORCESTER POLYTECH INST, WORCESTER, MA 01609 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Worcester Polytechnic Institute			Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [5 P30 CA42014] Funding Source: Medline; NHGRI NIH HHS [5P30 HG00199] Funding Source: Medline; NIAID NIH HHS [R01 AI31657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDROV IA, 1988, CHROMOSOMA, V96, P443, DOI 10.1007/BF00303039; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CURRAN ME, 1992, GENOMICS, V12, P729, DOI 10.1016/0888-7543(92)90302-9; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KEARNEY PH, 1994, BIOCHEM BIOPH RES CO, V203, P231, DOI 10.1006/bbrc.1994.2172; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANDES GM, 1995, IN PRESS CYTOGEN CEL; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; REALINI C, 1994, FEBS LETT, V348, P10; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; Sherman F., 1986, METHODS YEAST GENETI; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAPIA C, 1994, FEBS LETT, V349, P307, DOI 10.1016/0014-5793(94)00679-2; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014; YUROV YB, 1987, HUM GENET, V76, P157, DOI 10.1007/BF00284914; 1994, MIM156100 OMIM J HOK	42	162	175	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14875	14883		10.1074/jbc.270.25.14875	http://dx.doi.org/10.1074/jbc.270.25.14875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797465	hybrid			2022-12-27	WOS:A1995RE66600009
J	BAJZAR, L; MANUEL, R; NESHEIM, ME				BAJZAR, L; MANUEL, R; NESHEIM, ME			PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C; PLASMINOGEN-ACTIVATOR; ENZYME COMPLEXES; FACTOR-VA; BLOOD; SYSTEM; PROTHROMBIN; MECHANISM; PLASMA; EXPRESSION	Previous studies demonstrated that tissue plasminogen activator-induced fibrinolysis in vitro is retarded in the presence of prothrombin (II) activation and that the anticoagulant-activated protein C appears profibrinolytic by preventing the formation of thrombin (IIa)-like activity during fibrinolysis. To disclose the molecular connection between the generation of IIa and the inhibition of fibrinolysis, a lysis assay that is sensitive to the antifibrinolytic effect of II activation was developed tend was used to purify a 60-kDa single-chain protein from human plasma. Because the lysis of a clot, produced from purified components, is retarded when this protein is present and when II activation occurs in situ, the protein was named TAFI (thrombin-activatable fibrinolysis inhibitor). TAFI is cleaved by IIa yielding 35-, 25-, and 14-kDa products. Amino-terminal sequence analyses identified TAFI as a precursor of a plasma carboxypeptidase B (CPB). Formation of the 35-kDa product correlates with both prolongation of lysis time and CPB-like activity. Prolongation of lysis time saturates at about 125 nM TAFI. Activated TAFI inhibits the activation of Glu-plasminogen but does not prolong the lysis of clots formed in the presence of Lys-plasminogen. 2-Guanidinoethylmercaptosuccinic acid, a competitive inhibitor of CPB, completely inhibits prolongation of lysis by activated TAFI in a purified system and the prolongation induced by II activation in barium-adsorbed plasma. This suggests that TAFI accounts for the antifibrinolytic effect that accompanies prothrombin activation and that activated protein C appears profibrinolytic by attenuating TAFI activation.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada								BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; COTE HCF, 1994, J BIOL CHEM, V269, P11374; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; Damus P S, 1976, Methods Enzymol, V45, P653; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; EATON DL, 1991, J BIOL CHEM, V266, P21833; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ESMON NL, 1982, J BIOL CHEM, V257, P859; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FREDEMNBURGH JC, 1992, FIBRINOLYSIS S2, V6, P68; GAFFNEY PJ, 1993, FIBRINOLYSIS, V7, P2, DOI 10.1016/0268-9499(93)90039-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKAY TJ, 1978, BIOCHEMISTRY-US, V17, P401, DOI 10.1021/bi00596a003; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1983, J BIOL CHEM, V245, P14708; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; SAKATA Y, 1986, BLOOD, V68, P1218; SMITH RAG, 1986, BIOCHEM J, V239, P477, DOI 10.1042/bj2390477; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAYLOR FB, 1981, FED PROC, V40, P2092; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WANG W, 1994, J BIOL CHEM, V269, P15937; WEINSTEIN RE, 1993, SEMIN THROMB HEMOST, V19, P368, DOI 10.1055/s-2007-993288; WEINSTEIN RE, 1991, THROMB RES, V63, P123, DOI 10.1016/0049-3848(91)90275-2; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	41	595	619	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14477	14484		10.1074/jbc.270.24.14477	http://dx.doi.org/10.1074/jbc.270.24.14477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782309	hybrid			2022-12-27	WOS:A1995RD45500039
J	BREVET, A; CHEN, J; LEVEQUE, F; BLANQUET, S; PLATEAU, P				BREVET, A; CHEN, J; LEVEQUE, F; BLANQUET, S; PLATEAU, P			COMPARISON OF THE ENZYMATIC-PROPERTIES OF THE 2 ESCHERICHIA-COLI LYSYL-TRANSFER-RNA SYNTHETASE SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; TRYPSIN-MODIFIED ENZYMES; RELEASE FACTOR-II; DECARBOXYLASE GENES; REGULATORY PROTEIN; GLOBAL RESPONSE; CAD OPERON; EXPRESSION; LEUCINE	In Escherichia coli, lysyl-tRNA synthetase activity is encoded by either a constitutive lysS gene or an inducible one, lysU, The two corresponding enzymes could be purified at homogeneity from a Delta lysU and a Delta lysS strain, respectively, Comparison of the pure enzymes, LysS and LysU, indicates that, in the presence of saturating substrates, LysS is about twice more active than LysU in the ATP-PPi exchange as well as in the tRNA(Lys) aminoacylation reaction. Moreover, the dissociation constant of the LysU-lysine complex is 8-fold smaller than that of the LysS-lysine complex, In agreement with this difference, the activity of LysU is less sensitive than that of LysS to the addition of cadaverine, a decarboxylation product of lysine and a competitive inhibitor of lysine binding to its synthetase, This observation points tla a possible useful role of LysU, under physiological conditions causing cadaverine accumulation in the bacterium. Remarkably, these conditions also induce lysU expression. Homogeneous LysU and LysS were also compared in Ap,A synthesis. LysU is only 8-fold more active than LysS in the production of this dinucleotide, This makes unlikely that the heat-inducible LysU species could be preferentially involved in the accumulation of Ap(4)A inside stressed Escherichia coli cells, This conclusion could be strengthened by determining the concentrations of Ap(4)N (N = A, C, G, or U) in a Delta lysU as well as in a lysU(+) strain, before and after a 1-h temperature shift at 48 degrees C. The measured concentration values were the same in both strains.	ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 240,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AUGER EA, 1989, MOL MICROBIOL, V3, P609, DOI 10.1111/j.1365-2958.1989.tb00208.x; BLANQUET S, 1974, EUR J BIOCHEM, V44, P343, DOI 10.1111/j.1432-1033.1974.tb03491.x; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; BUKLAD NE, 1973, J BACTERIOL, V116, P1477, DOI 10.1128/JB.116.3.1477-1478.1973; CHAKRABURTTY K, 1975, NUCLEIC ACIDS RES, V2, P2069, DOI 10.1093/nar/2.11.2069; CHARLIER J, 1987, BIOCHEM J, V248, P43, DOI 10.1042/bj2480043; CLARK RL, 1990, J BACTERIOL, V172, P3237, DOI 10.1128/jb.172.6.3237-3243.1990; COLE FX, 1970, BIOCHEMISTRY-US, V9, P480, DOI 10.1021/bi00805a005; COULONDRE C, 1977, J MOL BIOL, V117, P525, DOI 10.1016/0022-2836(77)90056-0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; FROMANT M, 1981, BIOCHIMIE, V63, P541, DOI 10.1016/S0300-9084(81)80087-9; FURANO AV, 1977, J BIOL CHEM, V252, P2154; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; GAZEAU M, 1992, FEBS LETT, V300, P254, DOI 10.1016/0014-5793(92)80857-D; HASSANI M, 1992, APPL ENVIRON MICROB, V58, P2704, DOI 10.1128/AEM.58.8.2704-2707.1992; HASSANI M, 1991, J BACTERIOL, V173, P1965, DOI 10.1128/jb.173.6.1965-1970.1991; HICKEY EW, 1990, APPL ENVIRON MICROB, V56, P1038, DOI 10.1128/AEM.56.4.1038-1045.1990; HIRSHFIE.IN, 1973, J BACTERIOL, V113, P167, DOI 10.1128/JB.113.1.167-177.1973; HIRSHFIELD IN, 1975, P NATL ACAD SCI USA, V72, P1364, DOI 10.1073/pnas.72.4.1364; HIRSHFIELD IN, 1976, BIOCHIM BIOPHYS ACTA, V435, P306, DOI 10.1016/0005-2787(76)90111-8; HIRSHFIELD IN, 1972, BIOCHIM BIOPHYS ACTA, V259, P330, DOI 10.1016/0005-2787(72)90308-5; HIRSHFIELD IN, 1984, J BACTERIOL, V158, P615, DOI 10.1128/JB.158.2.615-620.1984; HIRSHFIELD IN, 1981, J BACTERIOL, V146, P345, DOI 10.1128/JB.146.1.345-351.1981; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO K, 1993, P NATL ACAD SCI USA, V90, P302, DOI 10.1073/pnas.90.1.302; ITO K, 1994, J BACTERIOL, V176, P7383, DOI 10.1128/JB.176.23.7383-7386.1994; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KAWAKAMI K, 1989, MOL GEN GENET, V219, P333, DOI 10.1007/BF00259604; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P5620, DOI 10.1073/pnas.85.15.5620; KISSELEV LL, 1972, FEBS LETT, V22, P231, DOI 10.1016/0014-5793(72)80052-8; Kitzler J.W., 1992, AP4A OTHER DINUCLEOS, P135; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LAWRENCE F, 1973, EUR J BIOCHEM, V36, P234, DOI 10.1111/j.1432-1033.1973.tb02905.x; LEVEQUE F, 1991, J BACTERIOL, V173, P7903, DOI 10.1128/jb.173.24.7903-7910.1991; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; MENG SY, 1992, J BACTERIOL, V174, P2659, DOI 10.1128/jb.174.8.2659-2669.1992; Miller JH., 1992, EXPT MOL GENETICS; NEIDHARDT FC, 1981, BIOCHEM BIOPH RES CO, V100, P894, DOI 10.1016/S0006-291X(81)80257-4; NEWMAN EB, 1992, CELL, V68, P617, DOI 10.1016/0092-8674(92)90135-Y; PLATEAU P, 1981, BIOCHIMIE, V63, P827; PLATEAU P, 1992, AP4A OTHER DINUCLEOS, P63; RYMO L, 1972, J BIOL CHEM, V247, P3888; SHI XL, 1993, J BACTERIOL, V175, P1182, DOI 10.1128/JB.175.4.1182-1186.1993; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; STEFFES C, 1992, J BACTERIOL, V174, P3242, DOI 10.1128/jb.174.10.3242-3249.1992; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR H, 1980, J BACTERIOL, V144, P952, DOI 10.1128/JB.144.3.952-956.1980; WADA M, 1986, J BACTERIOL, V168, P213, DOI 10.1128/jb.168.1.213-220.1986; WATSON N, 1992, J BACTERIOL, V174, P530, DOI 10.1128/jb.174.2.530-540.1992; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2	53	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14439	14444		10.1074/jbc.270.24.14439	http://dx.doi.org/10.1074/jbc.270.24.14439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782306	hybrid			2022-12-27	WOS:A1995RD45500033
J	HAWKINS, MG; MCGHEE, JD				HAWKINS, MG; MCGHEE, JD			ELT-2, A 2ND GATA FACTOR FROM THE NEMATODE CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ZINC FINGER; TRANSCRIPTION FACTOR GATA-1; NITROGEN REGULATORY GENE; DNA-BINDING DOMAIN; LEADER SEQUENCE; EXPRESSION; PROTEIN; FAMILY; ACTIVATION; ESTERASE	We have previously shown that a tandem pair of (A/T)GATA(A/G) sequences in the promoter region of the Caenorhabditis elegans gut esterase gene (ges-1) controls the tissue specificity of ges-1 expression in vivo. The ges-1 GATA region was used as a probe to screen a C. elegans cDNA expression library, and a gene for a new C. elegans GATA-factor (named elt-2) was isolated. The longest open reading frame in the elt-2 cDNA codes for a protein of M(r) 47,000 with a single zinc finger domain, similar (approximately 75% amino acid identity) to the C-terminal fingers of all other two-fingered GATA factors isolated to date. A similar degree of relatedness is found with the single-finger DNA binding domains of GATA factors identified in invertebrates. An upstream region in the ELT 8 protein with the sequence C-X(2)-C-X(16)-C-X(2)-C has some of the characteristics of a zinc finger domain but is highly diverged from the zinc finger domains of other GATA factors. The elt-2 gene is expressed as an SL1 trans-spliced message, which can be detected at all stages of development except oocytes; however, elt-2 message levels are 5-10-fold higher in embryos than in other stages. The genomic clone for elt-2 has been characterized and mapped near the center of the C. elegans X chromosome. ELT-2 protein, produced by in. vitro transcription-translation, binds to ges-1 GATA-containing oligonucleotides similar to a factor previously identified in C. elegans embryo extracts, both as assayed by electrophoretic migration and by competition with wild type and mutant oligonucleotides. However, there is as yet no direct evidence that elt-2 does or does not control ges-1.	UNIV CALGARY,HLTH SCI CTR,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba				McGhee, James/0000-0001-7266-7275				AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ABEL T, 1993, DEVELOPMENT, V119, P623; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BRENNER S, 1974, GENETICS, V77, P71; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EGAN CR, 1995, IN PRESS DEV BIOL; ENGEL JD, 1991, SEMIN HEMATOL, V28, P158; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V268, P23177; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; ORKIN SH, 1992, BLOOD, V80, P575; RAMAIN P, 1993, DEVELOPMENT, V118, P1277; SAMBROOK J, 1989, LABORATORY MANUAL; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; STROEHER VL, 1994, DEV BIOL, V163, P367, DOI 10.1006/dbio.1994.1155; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WINNICK J, 1993, DEVELOPMENT, V119, P1055; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	35	71	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14666	14671		10.1074/jbc.270.24.14666	http://dx.doi.org/10.1074/jbc.270.24.14666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782329	hybrid			2022-12-27	WOS:A1995RD45500065
J	WALKER, PK; LEONG, LEC; PORTER, AG				WALKER, PK; LEONG, LEC; PORTER, AG			SEQUENCE AND STRUCTURAL DETERMINANTS OF THE INTERACTION BETWEEN THE 5'-NONCODING REGION OF PICORNAVIRUS RNA AND RHINOVIRUS PROTEASE 3C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; COMMON COLD VIRUS; POLIOVIRUS RNA; CYSTEINE PROTEASES; SERINE PROTEASES; VIRAL-RNA; EXPRESSION; DISTINCT; GENE	It has previously been established that human rhinovirus 14 protease 3C binds specifically to the 5'-noncoding region of the viral RNA. A series of mutants of protease 3C and deletion or point mutants of the 5'-noncoding region of the viral RNA were analyzed to elucidate the sites of interaction between the protease and the RNA. Amino acids in protease SC essential for RNA binding were found to be discontinuous in the amino acid sequence, and mutations which destroyed RNA binding did not affect the catalytic (proteolytic) activity of protease 3C. Based on the three-dimensional structure of rhinovirus 14 protease 3C, the RNA binding region is located in an extended area distinct from the catalytic triad. A single stem-loop structure of 27 nucleotides (stem-loop d) in the 5'-noncoding region was necessary and sufficient to bind protease 3C. Mutagenesis of either the base-paired stem or unpaired loop or bulge regions of stem-loop d suggested that the base-paired stem, but not the loop or bulge, carries important determinants of protease 3C binding. This conclusion is strengthened by the observation that rhinovirus 14 protease 3C bound specifically to the 5'-noncoding region of poliovirus RNA, and only the base-paired stem of stem-loop d is conserved between poliovirus and rhinovirus RNAs.			WALKER, PK (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.							ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1992, J VIROL, V66, P6028; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; LEONG LEC, 1992, J CRYST GROWTH, V122, P246, DOI 10.1016/0022-0248(92)90253-F; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PORTER AG, 1993, J VIROL, V67, P6917, DOI 10.1128/JVI.67.12.6917-6921.1993; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAENGER W, 1990, PRINCIPLES NUCLEIC A, P116; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; 1991, PROGRAM MANUAL GCG P	27	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14510	14516		10.1074/jbc.270.24.14510	http://dx.doi.org/10.1074/jbc.270.24.14510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782313	hybrid			2022-12-27	WOS:A1995RD45500044
J	ZHUANG, HM; NIU, ZT; HE, TC; PATEL, SV; WOJCHOWSKI, DM				ZHUANG, HM; NIU, ZT; HE, TC; PATEL, SV; WOJCHOWSKI, DM			ERYTHROPOIETIN-DEPENDENT INHIBITION OF APOPTOSIS IS SUPPORTED BY CARBOXYL-TRUNCATED RECEPTOR FORMS AND BLOCKED BY DOMINANT-NEGATIVE FORMS OF JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-MYC; TYROSINE KINASE(S); CYTOSOLIC DOMAINS; PROGENITOR CELLS; PROTEIN-KINASE; EXPRESSION; BCL-2; SURVIVAL; LINE	Apoptosis, or programmed cell death (PCD), recently has emerged as an important homeostatic mechanism within several hematopoietic lineages. This process is subject to both positive and negative modulation by cytokines and within the erythroid lineage is inhibited by interleukin-3, stem cell factor, and erythropoietin (Epo). Through the expression of carboxyl-truncated Epo receptor mutants in FDC-P1 cells, a receptor form possessing 80 membrane-proximal cytoplasmic residues is shown to efficiently mediate Epo-dependent inhibition of PCD. This is in contrast to previous studies that attributed this activity to a distal carboxyl-terminal receptor subdomain (and/or heterodimerization of wild type Epo receptors with a truncated non-functional receptor form). Epo-dependent inhibition of PCD also is shown to be blocked by ectopic expression of kinase-deficient dominant-negative forms of Jak2 (Jak2 Delta VIII and Jak2-829), further underlining a role of this membrane-proximal subdomain of the Epo receptor in the inhibition of PCD. To our knowledge, this comprises the first direct evidence for an essential role for a Jak tyrosine kinase (Jak2) in this apoptotic response pathway.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT VET SCI, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NHLBI NIH HHS [HL44491, HL03042] Funding Source: Medline; NIDDK NIH HHS [DK40242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242, R29DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BULLOCK G, 1993, EXP HEMATOL, V21, P1640; Cohen J J, 1992, Semin Immunol, V4, P363; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; HE TC, 1994, J BIOL CHEM, V269, P18291; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IWAI K, 1994, BLOOD, V84, P1201; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LOURY MJ, 1990, TRANSFUSION BETHESDA, V30, P673; MANABE A, 1994, BLOOD, V83, P1731, DOI 10.1182/blood.V83.7.1731.bloodjournal8371731; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAY WS, 1993, EXP HEMATOL, V21, P1029; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; OTANI H, 1993, J BIOL CHEM, V268, P22733; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SCHWALL R, 1993, SCIENCE, V259, P696, DOI 10.1126/science.8430322; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SPIVAK JL, 1991, BLOOD, V77, P1228; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WANG L, 1994, NUCLEIC ACIDS RES, V22, P1774, DOI 10.1093/nar/22.9.1774; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; ZHUANG HM, 1994, BIOCHEM BIOPH RES CO, V204, P278, DOI 10.1006/bbrc.1994.2456	56	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14500	14504		10.1074/jbc.270.24.14500	http://dx.doi.org/10.1074/jbc.270.24.14500			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782312	hybrid			2022-12-27	WOS:A1995RD45500042
J	DOTSON, GD; DUA, RK; CLEMENS, JC; WOOTEN, EW; WOODARD, RW				DOTSON, GD; DUA, RK; CLEMENS, JC; WOOTEN, EW; WOODARD, RW			OVERPRODUCTION AND ONE-STEP PURIFICATION OF ESCHERICHIA-COLI 3-DEOXY-D-MANNO-OCTULOSONIC ACID 8-PHOSPHATE SYNTHASE AND OXYGEN-TRANSFER STUDIES DURING CATALYSIS USING ISOTOPIC-SHIFTED HETERONUCLEAR NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; RABBIT MUSCLE; PHOSPHOENOLPYRUVATE; SYNTHETASE; MECHANISM; ANALOGS; STEREOCHEMISTRY	The enzyme 3-deoxy-D-manno-octulosonic acid 8-phosphhate synthase catalyzes the condensation of D-arabinose 5-phosphate with phosphoenolpyruvate to give the unique 8-carbon acidic sugar 3-deoxy-D-manno-octulosonic acid 8-phosphate (KDO 8-P) found only in Gramnegative bacteria and required for lipid A maturation and cellular growth. The Escherichia coli gene kdsA that encodes KDO 8-P synthase has been amplified by polymerase chain reaction methodologies and subcloned into the expression vector, pT7-7. A simple one-step purification yields 200 mg of homogeneous KDO 8-P synthase per liter of cell culture. [2-C-13,O-18]Phosphoenolpyruvate (PEP) was prepared by first, exchange of [2-C-13]-3-bromopyruvate with H-2(2) O-18 followed by reaction of the labeled bromopyruvate with trimethylphosphite. The fate of the enolic oxygen in this multilabeled PEP, during the course of the KDO 8-P synthase-catalyzed reaction with D-arabinose 5-phosphate, was monitored by C-13 and P-31 NMR spectroscopy. The inorganic phosphate formed during the reaction was further analyzed via mass spectral analysis of its trimethyl ester derivative. The C-13 NMR spectrum of an incubation mixture of [2-C-13]PEP and D-arabinose 5-phosphate in H-2(2) O-18 in the presence of KDO 8-P synthase was also recorded, [2-C-13]KDO 8-P was utilized to determine the extent of nonenzymatic incorporation of O-18 into the C-2 position of KDO 8-P. The results indicate that the enolic oxygen of the PEP is recovered with the inorganic phosphate, and the C-2 oxygen of KDO 8-P originates from the solvent, H2O2.	UNIV MICHIGAN,COLL PHARM,INTERDEPARTMENTAL PROGRAM MED CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOCHEM,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Woodard, Ronald/0000-0002-7472-3653	NCRR NIH HHS [2507RR0557-28] Funding Source: Medline; NIGMS NIH HHS [T32 GM07767, GM 42544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM042544, T32GM007767] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; ANTON DL, 1983, BIOCHEMISTRY-US, V22, P5903, DOI 10.1021/bi00294a033; BANERJEE RV, 1988, BIOCHEMISTRY-US, V27, P9062, DOI 10.1021/bi00425a027; BONDINELL WE, 1971, J BIOL CHEM, V246, P6191; CLARK VM, 1963, J AM CHEM SOC, V85, P3705, DOI 10.1021/ja00905a043; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; HANSEN DE, 1981, J BIOL CHEM, V256, P5967; HANSEN DE, 1982, J BIOL CHEM, V257, P4795; HANSEN PE, 1983, ANN REPORTS NMR SPEC, V15, P118; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHLBRENNER WE, 1987, J BIOL CHEM, V262, P4534; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARQUARDT JL, 1993, J AM CHEM SOC, V115, P10393; METZLER DE, 1977, BIOCH CHEM REACTIONS, P418; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; STUBBE JA, 1972, BIOCHEMISTRY-US, V11, P338, DOI 10.1021/bi00753a005; STUBBE JA, 1971, BIOCHEMISTRY-US, V10, P2669; TABOR S, 1990, CURRENT PROTOCOLS MO; WOISETSCHLAGER M, 1987, MOL GEN GENET, V207, P369, DOI 10.1007/BF00331603; WOOTEN EW, 1994, J MAGN RESON SER A, V107, P50, DOI 10.1006/jmra.1994.1046; ZEMELL RI, 1975, J BIOL CHEM, V250, P4959	25	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13698	13705		10.1074/jbc.270.23.13698	http://dx.doi.org/10.1074/jbc.270.23.13698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775423	hybrid			2022-12-27	WOS:A1995RC44800020
J	GOLD, L				GOLD, L			OLIGONUCLEOTIDES AS RESEARCH, DIAGNOSTIC, AND THERAPEUTIC AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AFFINITY RNA LIGANDS; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; SELECTION; RECOGNITION; SEQUENCES; BINDING				GOLD, L (corresponding author), NEXSTAR PHARMACEUT INC,BOULDER,CO 80301, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; DVORAK HF, 1991, J EXP MED, V174, P275; EATON BE, 1995, ANNU REV BIOCHEM, V64, P837, DOI 10.1146/annurev.bi.64.070195.004201; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L., 1993, RNA WORLD, P497; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JELLINEK D, 1993, BIOCHEMISTRY-US, V90, P10450; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; Judson HF., 1979, 8 DAY CREATION; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229; LOUHON CT, 1995, J AM CHEM SOC, V117, P1246; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SCHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452; SWITZER CY, 1993, BIOCHEMISTRY-US, V32, P10489, DOI 10.1021/bi00090a027; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	37	233	284	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13581	13584		10.1074/jbc.270.23.13581	http://dx.doi.org/10.1074/jbc.270.23.13581			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775406	hybrid			2022-12-27	WOS:A1995RC44800001
J	ROUSSO, I; BRODSKY, I; LEWIS, A; SHEVES, M				ROUSSO, I; BRODSKY, I; LEWIS, A; SHEVES, M			THE ROLE OF WATER IN RETINAL COMPLEXATION TO BACTERIOOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE; PURPLE MEMBRANE; BACTERIORHODOPSIN; RESONANCE; CHROMOPHORE; HYDRATION; MECHANISM; RHODOPSIN; PROTEINS; EXCHANGE	A system is described that allows for the delineation of the factors that effect the complexation of retinal to the apoprotein of bacteriorhodopsin. This complexation is investigated in various states of hydration, in H2O and D2O, at a variety of pH levels, with mutant membranes and labeled retinals. The complexation reaction was also investigated using absorption spectroscopy and vibrational spectra using difference Fourier transform infrared spectroscopy. The results demonstrate the crucial role of water in controlling the protein conformations that lead to protein/ligand binding reactions and begin to shed new Light on the protein control of a reaction that normally cannot take place in an aqueous medium.	WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, DEPT APPL PHYS, IL-91904 JERUSALEM, ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem			Rousso, Itay/A-7662-2013	Rousso, Itay/0000-0002-4399-9171				BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343; DEGRIP WJ, 1985, BIOCHIM BIOPHYS ACTA, V809, P97, DOI 10.1016/0005-2728(85)90172-0; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DOUKAS AG, 1981, BIOPHYS J, V33, P275, DOI 10.1016/S0006-3495(81)84889-8; DUPUIS P, 1980, REV CAN BIOL EXPTL, V39, P247; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; EHRENBERG B, 1980, P NATL ACAD SCI-BIOL, V77, P6571, DOI 10.1073/pnas.77.11.6571; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; GARTNER W, 1983, BIOCHEMISTRY-US, V22, P2637, DOI 10.1021/bi00280a007; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; GAT Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P371, DOI 10.1111/j.1751-1097.1994.tb05050.x; HILDEBRANDT P, 1984, BIOCHEMISTRY-US, V23, P5539, DOI 10.1021/bi00318a025; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; KORENSTEIN R, 1977, NATURE, V270, P184, DOI 10.1038/270184a0; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LUGTENBURG J, 1985, PURE APPL CHEM, V57, P759; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PAJARES MA, 1989, J BIOL CHEM, V264, P6804; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; RUDIGER A, 1993, JUL INT BIOPH SOC M, P196; RUPLEY JA, 1991, ADV PROTEIN CHEM, V41, P37; SAMPOGNA RV, 1994, BIOPHYS J, V66, P1341, DOI 10.1016/S0006-3495(94)80925-7; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHRECKENBACH T, 1978, BIOCHEMISTRY-US, V17, P5353, DOI 10.1021/bi00618a005; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; VARO G, 1983, BIOPHYS J, V43, P47, DOI 10.1016/S0006-3495(83)84322-7	32	17	17	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13860	13868		10.1074/jbc.270.23.13860	http://dx.doi.org/10.1074/jbc.270.23.13860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775444	hybrid			2022-12-27	WOS:A1995RC44800043
J	CADENE, M; BOUDIER, C; DEMARCILLAC, GD; BIETH, JG				CADENE, M; BOUDIER, C; DEMARCILLAC, GD; BIETH, JG			INFLUENCE OF LOW-MOLECULAR-MASS HEPARIN ON THE KINETICS OF NEUTROPHIL ELASTASE INHIBITION BY MUCUS PROTEINASE-INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; 2-STEP REACTION-MECHANISM; HUMAN-LEUKOCYTE ELASTASE; AMINO-ACID SEQUENCE; ALPHA-1-PROTEINASE INHIBITOR; ANTI-THROMBIN; PROTEASE INHIBITOR; BINDING; ANTITHROMBIN; SECRETIONS	Commercial low molecular mass heparin accelerates the inhibition of neutrophil elastase by mucus proteinase inhibitor, the predominant antielastase of lung secretions (Faller, B., Mely, Y., Gerard, D., and Bieth, J. G. (1992) Biochemistry 31, 8285-8290). To study the kinetic mechanism of this rate enhancement, we have isolated a 4.5-kDa heparin fragment from commercial heparin. This compound is fairly monodisperse as shown by analytical ultracentrifugation. It binds elastase and inhibitor with a 1:1 stoichiometry and an equilibrium dissociation constant of 3 and 210 nar, respectively. It also forms a tight complex with EI. Flow calorimetry shows that the inhibitor-heparin interaction is characterized by a large negative enthalpy change (Delta H-o = -45.2 kJ mol(-1)) and a small entropy change (Delta S = -23.7 J K-1 mol(-1)). Stopped-flow kinetics run under pseudo-first-order conditions ( I-o much greater than E(o) ) show that in the absence of heparin the inhibition conforms to a simple bimolecular reaction, GRAPHICS where, k(a) = 3.1 x 10(6) m(-1)s(-1), k(d) = 10(-4) s(-1), and K-i = 33 pm, whereas in the presence of heparin, E and I react via a two-step mechanism, GRAPHICS where K-i* = 86 nnr, k(2) = 2.2 s(-1), k(-2) = 10(-3) s(-1), and K-i = 37 pM. Thus, heparin increases both the rate of inhibition by promoting the formation of a high affinity EI* intermediate and the rate of EI dissociation. Since the dissociation is negligible in bronchial secretions where the inhibitor concentration is much higher than K-i, it may be concluded that heparin significantly potentiates the inhibitor's antielastase potential in vivo.	UNIV LOUIS PASTEUR STRASBOURG 1,FAC PHARM,INSERM,U392,ENZYMOL LAB,F-67400 ILLKIRCH GRAFFENS,FRANCE; INST BIOL MOLEC PLANTES,CNRS,F-67000 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Boudier, Christian/N-3841-2018	Boudier, Christian/0000-0002-5534-6389; Cadene, Martine/0000-0003-4936-2662				AHMED T, 1992, AM REV RESPIR DIS, V145, P566, DOI 10.1164/ajrccm/145.3.566; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bieth J., 1974, BAYER S, P463; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; BIETH JG, 1974, BIOCH MED, V32, P387; BJORK I, 1982, J BIOL CHEM, V257, P9487; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOUDIER C, 1989, BIOCHIM BIOPHYS ACTA, V995, P36, DOI 10.1016/0167-4838(89)90230-6; CAMPBELL EJ, 1986, AM REV RESPIR DIS, V134, P984; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; CASU B, 1990, HAEMOSTASIS, V20, P62; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CLARK JG, 1983, INT REV CONNECTIVE T, P249; DANIELSSON A, 1981, BIOCHEM J, V193, P427; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DELAUDER S, 1992, BIOCHIM BIOPHYS ACTA, V1159, P141, DOI 10.1016/0167-4838(92)90018-9; EISENBERG SP, 1990, J BIOL CHEM, V265, P976; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Jacques L. B., 1967, CAN J PHYSIOL PHARM, V45, P787; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959; LANE DL, 1989, HEPARIN CHEM BIOL PR; LAURENT TC, 1961, ARCH BIOCHEM BIOPHYS, V92, P224, DOI 10.1016/0003-9861(61)90341-1; LI EHH, 1974, BIOCHEMISTRY-US, V13, P5012, DOI 10.1021/bi00721a023; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MELLET P, 1995, BIOCHEMISTRY-US, V34, P2645, DOI 10.1021/bi00008a031; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V61, P201; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; SALLENAVE JM, 1992, BIOL CHEM H-S, V373, P27, DOI 10.1515/bchm3.1992.373.1.27; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; STEPHANO C, 1988, ANN CHIM, V78, P55; Taylor JC, 1987, PULMONARY EMPHYSEMA; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TOURNIER JM, 1983, ANAL BIOCHEM, V131, P345, DOI 10.1016/0003-2697(83)90181-1; TYLERCROSS R, 1993, ARCH BIOCHEM BIOPHYS, V306, P528, DOI 10.1006/abbi.1993.1548	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13204	13209		10.1074/jbc.270.22.13204	http://dx.doi.org/10.1074/jbc.270.22.13204			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768918	hybrid			2022-12-27	WOS:A1995RB43900041
J	LIPKIND, G; GONG, QM; STEINER, DF				LIPKIND, G; GONG, QM; STEINER, DF			MOLECULAR MODELING OF THE SUBSTRATE-SPECIFICITY OF PROHORMONE CONVERTASES SPC2 AND SPC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROCESSING ENZYME; CRYSTAL-STRUCTURE; SUBTILISIN BPN'; YEAST KEX2; EGLIN-C; ENDOPROTEASE FAMILY; CONSENSUS SEQUENCE; SERINE PROTEASES; GENE-PRODUCT	In this paper we describe the results of molecular modeling of the structures of the active sites of two subtilisin-like prohormone convertases (SPCs), SPC2 (PC2) and SPC3 (PC1/PC3). These enzymes are members of a recently discovered family of cellular proteases involved in the processing of precursor proteins. Although these proteases all possess catalytic domains similar to the bacterial subtilisins no tertiary structural data from x-ray analysis are yet available. We have shown that despite the high structural homology of the subtilisins and the SPCs, the structure of the loop which lies immediately below the active sites differs due to the presence of a cis-peptide bond (Tyr(167)-pro(168)) in this loop in the subtilisins and its absence in the SPCs. Accordingly, we have proposed a new alignment for the amino acid sequences of the SPCs in this region. Both SPC2 and SPC3 participate in the processing of prohormones at dibasic cleavage sites, typically Lys-Arg or Arg-Arg. To investigate the structural basis of the substrate specificity of these SPCs, we have carried out molecular mechanic calculations of the optimal arrangement and interactions of peptide substrates containing several residues of arginine or lysine, i.e. Arg, Ala-Ala Ala-Arg, Arg-AZa-Ala-Arg, Arg-Ala-Arg-Arg, Arg-Ala-Lys-Arg, in the putative active sites. Such subtilisin-based modeling has allowed us to identify those negatively charged residues, Asp and Glu, in the S1, S2, and S4 subsites, which can directly interact with basic residues in the substrates via formation of salt bridges and thereby contribute to the substrate selectivity of the SPCs.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago					NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R37DK013914, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BODE W, 1986, EMBO J, V5, P813, DOI 10.1002/j.1460-2075.1986.tb04286.x; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Creighton T. E., 1993, PROTEINS STRUCTURES; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HIRONO S, 1984, J MOL BIOL, V178, P389, DOI 10.1016/0022-2836(84)90150-5; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; MATTHEWS DA, 1975, J BIOL CHEM, V250, P7120; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; RHEINNECKER M, 1993, BIOCHEMISTRY-US, V32, P1199, DOI 10.1021/bi00056a001; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHERAGA HA, 1971, CHEM REV, V71, P195, DOI 10.1021/cr60270a003; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, PROG BRAIN RES, V92, P235, DOI 10.1016/S0079-6123(08)61179-6; Steiner D F, 1969, Recent Prog Horm Res, V25, P207; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1994, ENDOCRINOLOGY, P1296; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P5167, DOI 10.1073/pnas.84.15.5167; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; WELLS JA, 1995, J CELL BIOCH B, V19, P233; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0	46	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13277	13284		10.1074/jbc.270.22.13277	http://dx.doi.org/10.1074/jbc.270.22.13277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768927	hybrid			2022-12-27	WOS:A1995RB43900051
J	CHAN, HC; KAETZEL, MA; GOTTER, AL; DEDMAN, JR; NELSON, DJ				CHAN, HC; KAETZEL, MA; GOTTER, AL; DEDMAN, JR; NELSON, DJ			ANNEXIN-IV INHIBITS CALMODULIN-DEPENDENT PROTEIN-KINASE II-ACTIVATED CHLORIDE CONDUCTANCE - A NOVEL MECHANISM FOR ION-CHANNEL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS; BINDING PROTEIN; LINE T84; CALCIUM; ANTIBODY; PURIFICATION; CURRENTS	Ca2+-activated Cl- current (I-Cl,I-Ca) in colonic T84 cells is inhibited by the specific peptide inhibitor of Ca2+/calmodulin-dependent Kinase II (CaM KII). Annexin IV, a Ca2+-dependent phospholipid binding protein also inhibits Ca2+-dependent anion current activation (Kaetzel, M, A, Chan, H.-C., Dubinsky, W. P., Dedman, J. R, and Nelson, D, J, (1994) J. Biol. Chem. 269, 5297-5302). Intracellular injection of antibodies against annexin IV enhances current activation; this activation is inhibited by the peptide inhibitor of CaM KII, Intracellular application of autonomously active CaM KII in the presence of ATP induced a Cl- current similar to that activated by the Ca2+ ionophore A23187, Current activation by the exogenous kinase was completely inhibited in the presence of purified annexin IV. In vitro, annexin IV does not inhibit CaM KII activity nor does it act as a substrate for CaM KII. Thus, it appears that annexin IV inhibits phosphorylation-dependent anion conductance activation by preventing CaM KII-ion channel interaction rather than by direct interaction with the enzyme itself. These findings suggest a novel mechanism by which Ca2+-dependent membrane binding proteins, cytoplasmic kinases, and ion channels interact to regulate membrane conductance, The characterization of unique channel regulatory pathways in Cl- transporting epithelia may identify potential avenues of alternate therapy to compensate for the loss of functional Cl- channels in the disease of cystic fibrosis.	UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; CHINESE UNIV HONG KONG,DEPT PHYSIOL,SHA TIN,HONG KONG; UNIV CINCINNATI,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,CINCINNATI,OH 45267	University of Chicago; University of Chicago; Chinese University of Hong Kong; University System of Ohio; University of Cincinnati			Chan, Hsiao Chang/E-1507-2016		NIDDK NIH HHS [DK41740, DK44840] Funding Source: Medline; NIGMS NIH HHS [GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740, P01DK044840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; DEDMAN JR, 1978, J BIOL CHEM, V253, P7515; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; KAETZEL MA, 1989, BIOCHEM BIOPH RES CO, V160, P1233, DOI 10.1016/S0006-291X(89)80135-4; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; MILLS JW, 1994, J EXP ZOOL, V268, P111, DOI 10.1002/jez.1402680207; Moss S. E, 1992, ANNEXINS; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SEATON BA, 1990, J BIOL CHEM, V265, P4567; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	23	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32464	32468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798247				2022-12-27	WOS:A1994PX30400068
J	HRESKO, RC; MURATA, H; MARSHALL, BA; MUECKLER, M				HRESKO, RC; MURATA, H; MARSHALL, BA; MUECKLER, M			DISCRETE STRUCTURAL DOMAINS DETERMINE DIFFERENTIAL ENDOPLASMIC-RETICULUM TO GOLGI TRANSIT TIMES FOR GLUCOSE-TRANSPORTER ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-TARGET SIZE; XENOPUS-OOCYTES; HUMAN-ERYTHROCYTES; INTRACELLULAR SEQUESTRATION; MEMBRANE-GLYCOPROTEINS; FUNCTIONAL EXPRESSION; CELL-SURFACE; PROTEIN; INSULIN; GLUT1	The rate of movement of the glucose transporter isoforms Glut1 and Glut4 from the endoplasmic reticulum (ER) to the Golgi apparatus was investigated by pulse labeling and monitoring endoglycosidase H resistance in mRNA-injected Xenopus oocytes and in 3T3-L1 adipocytes, a cell line that naturally expresses both transporter isoforms. Despite their high degree of sequence identity, Glut1 and Glut4 exhibited dramatically different transit times. The t(1/2) values for ER to Golgi transit for Glut1 and Glut4 were < 1 and 24 h, respectively, in oocytes and similar to 5 and 20 min, respectively, in 3T3-L1 adipocytes. Pulse-chase in conjunction with sucrose density gradient analysis revealed that the rate-limiting step in the ER to Golgi processing of Glut4 was exit from the ER and not retention in an early Golgi compartment. We analyzed the biosynthesis of Glut1/Glut4 chimeric transporters in Xenopus oocytes in order to determine whether specific domains in Glut1 and Glut4 were responsible for their distinct transit times. The first exofacial glycosylated loop and the cytoplasmic carboxyl-terminal domain of Glut4 were crucial for its delayed exit from the ER. The first transmembrane, the first exofacial, and the cytoplasmic COOH-terminal domains of Glut1 were largely responsible for Glut1's rapid processing in the ER Some of the chimeric transporters were not fully processed. Approximately 50% of chimeric molecules containing the cytoplasmic COOH-terminal domain of Glut1 and either the first transmembrane or first exofacial domain of Glut4 were retained in early Golgi compartments and prevented from complete maturation, Normal processing of these chimeras was achieved by replacing the cytoplasmic COOH-terminal domain of Glut1 with that of Glut4. These data suggest that amino acid residues within the glycosylated exofacial loop and the cytoplasmic COOH terminus participate in a rate-limiting step in the folding of both Glut1 and Glut4 or could act as transient ER retention signals. Additionally, these results show that even chimeric molecules constructed from two highly homologous proteins can exhibit aberrant folding and post-translational processing.			HRESKO, RC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CUPPOLETTI J, 1981, J BIOL CHEM, V256, P1305; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DAVIES A, 1990, BIOCHEM J, V266, P799; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGUCHI R, 1990, RECOMBINANT PCR; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JARVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V855, P312, DOI 10.1016/0005-2736(86)90179-3; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JUNG CY, 1980, J BIOL CHEM, V255, P361; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KELLER K, 1989, J BIOL CHEM, V264, P18884; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW SH, 1994, J BIOL CHEM, V269, P1985; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SOGIN DC, 1978, J SUPRAMOL STR CELL, V8, P447, DOI 10.1002/jss.400080407; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725	48	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32110	32119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798206				2022-12-27	WOS:A1994PX30400018
J	LO, TWC; WESTWOOD, ME; MCLELLAN, AC; SELWOOD, T; THORNALLEY, PJ				LO, TWC; WESTWOOD, ME; MCLELLAN, AC; SELWOOD, T; THORNALLEY, PJ			BINDING AND MODIFICATION OF PROTEINS BY METHYLGLYOXAL UNDER PHYSIOLOGICAL CONDITIONS - A KINETIC AND MECHANISTIC STUDY WITH N-ALPHA-ACETYLARGININE, N-ALPHA-ACETYLCYSTEINE, AND N-ALPHA-ACETYLLYSINE, AND BOVINE SERUM-ALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYOXALASE SYSTEM; DIABETES-MELLITUS; ALDOSE REDUCTASE; AMINO-ACIDS; PHENYLGLYOXAL; COMPLICATIONS; 1,2-DIAMINO-4,5-DIMETHOXYBENZENE; REAGENTS; ASSAY	The physiological alpha-oxoaldehyde methylglyoxal binds and modifies arginine, lysine, and cysteine residues in proteins. The kinetics and mechanism of these reactions were investigated with N alpha-acetylamino acids and bovine serum albumin at pH 7.4 and 37 degrees C. The reaction of methylglyoxal with N alpha-acetylarginine involved the initial reversible formation of glycosylamine and 4,5-dihydroxy-5-methylimidazolidine derivatives, with further slow irreversible conversion to an imidazolone, N alpha-acetyl-N delta-(5-methyl-4-imidazolon-2-yl) ornithine. The imidazolone was fluorescent with an excitation lambda(max), value of 320 nn and an emission lambda(max) value of 398 nm. Methylglyoxal reacted reversibly with N alpha-acetyllysine to form glycosylamine and bisglycosylamine derivatives. Further reaction of these glycosylamines occurred to form brown, fluorescent oligomers that were not characterized, Methylglyoxal reacted rapidly and reversibly with N alpha-acetylcysteine to farm the hemithioacetal adduct. The reaction of methylglyoxal with bovine serum albumin (BSA) at pH 7.4 and 37 degrees C involved the reversible and irreversible formation of methylglyoxal-BSA adducts. Irreversible modification of BSA occurred mainly on arginine residues to form imidazolone, The formation of methylglyoxal-modified proteins involves glycoxidation leading to advanced glycation end product-like fluorescence. It is expected to be increased in diabetes mellitus and may be linked to the development of diabetic complications.	UNIV ESSEX,DEPT CHEM & BIOL CHEM,COLCHESTER CO4 3SQ,ESSEX,ENGLAND	University of Essex			Lo, Theodore/AAE-5275-2020	Thornalley, Paul/0000-0001-7659-443X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; CLELLAND JD, 1990, J LABELLED COMPDS RA, V28, P1454; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; KATO H, 1986, J NUTR SCI VITAMINOL, V32, P55, DOI 10.3177/jnsv.32.55; KWON CH, 1991, J MED CHEM, V34, P1845, DOI 10.1021/jm00110a013; LEE T-H, 1989, Korean Journal of Biochemistry, V21, P75; LEONCINI G, 1980, FEBS LETT, V117, P17, DOI 10.1016/0014-5793(80)80903-3; LEONCINI G, 1981, EXPERIENTIA, V37, P443, DOI 10.1007/BF01986121; Lo TWC, 1993, AMINO ACIDS, V5, P172; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2, P1; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MIGLIETTA A, 1985, CELL BIOCHEM FUNCT, V3, P9, DOI 10.1002/cbf.290030104; MIGLIETTA A, 1986, RES COMMUN PATHOL PH, V51, P249; MIRA ML, 1991, BIOCHIM BIOPHYS ACTA, V1060, P257, DOI 10.1016/S0005-2728(05)80315-9; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; RAE C, 1990, EUR J BIOCHEM, V193, P83, DOI 10.1111/j.1432-1033.1990.tb19307.x; Selwood Trevor, 1993, Biochemical Society Transactions, V21, p170S; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P395, DOI 10.1093/oxfordjournals.jbchem.a131471; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P403, DOI 10.1093/oxfordjournals.jbchem.a131472; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293	32	589	625	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32299	32305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798230				2022-12-27	WOS:A1994PX30400045
J	MARSTON, SB; FRASER, IDC; HUBER, PAJ				MARSTON, SB; FRASER, IDC; HUBER, PAJ			SMOOTH-MUSCLE CALDESMON CONTROLS THE STRONG BINDING INTERACTION BETWEEN ACTIN-TROPOMYOSIN AND MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; THIN-FILAMENTS; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; COOPERATIVE BINDING; CALMODULIN-BINDING; REGULATED ACTIN; SKELETAL; COMPLEX; DISSOCIATION	We have demonstrated that caldesmon does not alter the affinity of weak binding actomyosin complexes when it inhibits actin-tropomyosin activation at physiological ratios (1 per 14 actins), and we proposed that it acts upon the strong binding complexes in the same way that troponin-tropomyosin does. We therefore compared the effect of caldesmon, caldesmon fragments, and troponin upon the interaction of the strongly bound complexes S-1 ADP, S-1 adenylyl imidodiphosphate (AMP-PNP), and N-ethylmaleimide-treated myosin subfragment-1 (NEM-S1) with actin-tropomyosin. In 0.17 M ionic strength buffer [C-14]iodoacetamide-labeled S1-ADP bound to actin-smooth muscle tropomyosin with no evidence of cooperativity; K-d = 0.8 +/- 0.3 mu M (n = 5). Inhibitory concentrations of sheep aorta caldesmon or rabbit skeletal muscle troponin made the binding highly cooperative. At low levels of saturation the apparent K-d was 10-40 mu M with 10 mu M caldesmon and 8-20 mu M with 6 mu M troponin; at > 50% saturation the binding was indistinguishable from actin-tropomyosin alone. A similar result was obtained for the binding of [C-14]iodoacetamide-labeled S-1.AMP.PNP to actin-smooth muscle tropomyosin at 0.03 M ionic strength (K-d = 0.47 +/- 0.05 mu M). Binding was slightly cooperative and became highly cooperative in the presence of inhibitory concentrations of troponin, caldesmon, and the human caldesmon fragments H7 (amino acids 622-767) and H9 (amino acids 726-793). We conclude that caldesmon and troponin both act as allosteric effecters of the ''on''/''off'' equilibrium of actin-tropomyosin. 0.1 NEM-S-1/actin potentiated actin-smooth muscle tropomyosin activation of myosin MgATPase 7-fold at 0.03 M ionic strength. Caldesmon inhibited the ATPase in the presence and absence of 0.5 mu M NEM-S-1. NEM-S-1 reactivated actin-tropomyosin, which had been inhibited by troponin, caldesmon, H7, or H9. This is compatible with opposing effects of NEM-S-1 and caldesmon or troponin upon the actin-tropomyosin on/off equilibrium.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907; Marston, Steven/0000-0001-6054-6070; Huber, Pia AJ/0000-0001-9823-7863				BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUBER PAJ, 1993, J MUSCLE RES CELL M, V14, P385, DOI 10.1007/BF00121289; HUBER PAJ, 1994, BIOPHYS J, V66, P197; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; ISCHII Y, 1987, BIOCHEMISTRY-US, V26, P4922; LEHMAN W, 1993, BIOCHIM BIOPHYS ACTA, V1203, P53, DOI 10.1016/0167-4838(93)90035-P; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1976, J MOL BIOL, V104, P263, DOI 10.1016/0022-2836(76)90012-7; MARSTON SB, 1980, BIOCHEM J, V185, P355, DOI 10.1042/bj1850355; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1982, J MOL BIOL, V157, P275, DOI 10.1016/0022-2836(82)90234-0; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022	55	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32104	32109						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798205				2022-12-27	WOS:A1994PX30400017
J	FURMAN, E; GLITZ, DG				FURMAN, E; GLITZ, DG			PURIFICATION OF THE SPLICEOSOME A-COMPLEX AND ITS VISUALIZATION BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; SPLICING COMPLEXES; U2 SNRNP; 2'-OME RNA; AFFINITY-CHROMATOGRAPHY; ASSEMBLY PATHWAY; PARTICLES; U5; OLIGONUCLEOTIDES	Pre-mRNA splicing occurs on splceosomes, a family of ribonucleoprotein particles. Spliceosome assembly on exogenous adenovirus pre-mRNA was blocked at the A-complex (or pre-spliceosome) stage, either by destruction of the small nuclear ribonucleoproteins (snRNPs) that comprise the U4/U5/U6 tri-snRNP complex, or by interference in tri-snRNP assembly and interactions. The A-complex was isolated by size exclusion chromatography; homogeneity was shown by electrophoresis in nondenaturing polyacrylamide gels, gradient sedimentation, and electron microscopy. Northern hybridization showed UI and U2 snRNAs to be present in the preparation, but not U4, U5, or U6. Antibodies specific for a component of the U1 snRNP or for a component that is common to all snRNPs (except U6) each precipitated an A-complex containing pre-mRNA, U1 and U2 snRNPs. Electron micrographs showed 230 x 270-Angstrom particles whose two components appear similar to individual U1 and U2 snRNPs. Electron micrographs of an A-complex-5'-biotinyl oligonucleotide streptavidin-gold composite allowed identification of the U2 snRNP within the structure and the localization of the 5'-segment of U2 snRNA at a unique site in the A-complex. This region of U2 RNA is adjacent to the developing catalytic center of the spliceosome.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 51195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051195, R55GM051195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; Baserga S., 1993, RNA WORLD, P359; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; CIRSPINO J, 1994, SCIENCE, V265, P1866; CLARK MW, 1988, EMBO J, V7, P3829, DOI 10.1002/j.1460-2075.1988.tb03268.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GRABOWSKI PJ, 1990, METHOD ENZYMOL, V184, P319; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; KASTNER B, 1989, EMBO J, V8, P277, DOI 10.1002/j.1460-2075.1989.tb03374.x; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LASATER LS, 1988, BIOCHEMISTRY-US, V27, P4687, DOI 10.1021/bi00413a016; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MATTER L, 1982, ARTHRITIS RHEUM, V25, P1278, DOI 10.1002/art.1780251102; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MONTESANORODITIS L, 1994, J BIOL CHEM, V269, P6458; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1994, CURR OPIN CELL BIOL, V6, P360, DOI 10.1016/0955-0674(94)90027-2; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; OLSON HM, 1988, J BIOL CHEM, V263, P15196; OLSON HM, 1991, J BIOL CHEM, V266, P1896; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; SIBBALD MJ, 1993, J STRUCT BIOL, V110, P111, DOI 10.1006/jsbi.1993.1011; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	59	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15515	15522		10.1074/jbc.270.26.15515	http://dx.doi.org/10.1074/jbc.270.26.15515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797545	hybrid			2022-12-27	WOS:A1995RG53800015
J	BROWN, HA; GUTOWSKI, S; KAHN, RA; STERNWEIS, PC				BROWN, HA; GUTOWSKI, S; KAHN, RA; STERNWEIS, PC			PARTIAL-PURIFICATION AND CHARACTERIZATION OF ARF-SENSITIVE PHOSPHOLIPASE-D FROM PORCINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; ADENYLATE-CYCLASE; REGULATORY COMPONENT; HYDRODYNAMIC PROPERTIES; CHOLERA-TOXIN; BINDING; HYDROLYSIS; ACTIVATION; CGMP	Phospholipase D (PLD) activity from membranes of cultured cells can be activated by guanosine 5'-O-(3-thiotriphosphate) and the small GTP-dependent protein, Arf. While this activity was readily apparent in membranes from HL60 cells, it was much lower or not observable in membranes from various mammalian tissues. However, extraction of porcine brain membranes with detergent and subsequent chromatography with SP-Sepharose revealed a large peak of Arf-sensitive PLD activity. This activity has been enriched through several steps of chromatography and characterized with respect to size, nucleotide specificity, and sensitivity to different Arf and Arf-like proteins. Hydrodynamic analysis indicated that the enriched PLD had an s(20,w) of 5.1 and a Stokes radius of 4.3 nm. These parameters indicate that the enzyme has an apparent molecular mass of 95,000 Da. Effective stimulation of the enriched enzyme was achieved with GTP as well as nonhydrolyzable analogs. All of the Arf subtypes tested were effective activators of PLD activity. Arf derived from yeast could activate mammalian PLD but with lower potency. The Arf-related Arl proteins were ineffective. PLD that has been highly enriched retained a requirement for phosphatidylinositol 4,5-bisphosphate for efficient expression of activity. Additionally, the ability of recombinant or purified porcine brain Arf to stimulate PLD activity was reduced relative to impure fractions of Arf activity. Thus, porcine PLD that has been purified about 5,000-10,000-fold is synergistically activated by Arf in combination with other cytosolic components that are described in the accompanying paper (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950). Taken together, these data suggest that physiological regulation of Arf-sensitive PLD may involve the coordinate assembly of several interacting regulatory subunits.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM15817, GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015817, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTIA NJ, 1970, CAN J BIOCHEM CELL B, V48, P643, DOI 10.1139/o70-103; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; EINSET E, 1958, J BIOL CHEM, V231, P703; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALCK JR, 1991, ACS SYM SER, V463, P145; HAGA T, 1977, J BIOL CHEM, V252, P5776; Heller M, 1978, Adv Lipid Res, V16, P267; HOWLETT AC, 1980, J BIOL CHEM, V255, P2861; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1993, HDB EXPT PHARM GTPAS, P529; KOBAYASHI M, 1991, METHOD ENZYMOL, V197, P575; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PAGES F, 1992, J BIOL CHEM, V267, P22018; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TAKI T, 1979, J BIOL CHEM, V254, P9761; TERUI T, 1994, J BIOL CHEM, V269, P28130; WANG XM, 1994, J BIOL CHEM, V269, P20312	45	130	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14935	14943		10.1074/jbc.270.25.14935	http://dx.doi.org/10.1074/jbc.270.25.14935			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797473	hybrid			2022-12-27	WOS:A1995RE66600017
J	LENTING, PJ; TERMAAT, H; CLIJSTERS, PPFM; DONATH, MJSH; VANMOURIK, JA; MERTENS, K				LENTING, PJ; TERMAAT, H; CLIJSTERS, PPFM; DONATH, MJSH; VANMOURIK, JA; MERTENS, K			CLEAVAGE AT ARGININE-145 IN HUMAN BLOOD-COAGULATION FACTOR-IX CONVERTS THE ZYMOGEN INTO A FACTOR-VIII BINDING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-X ACTIVATION; PLASMA THROMBOPLASTIN ANTECEDENT; RUSSELLS VIPER VENOM; CHRISTMAS-FACTOR; PLASMINOGEN-ACTIVATOR; FACTOR-XIA; EXTRINSIC PATHWAY; INHIBITOR TYPE-1; PROTEIN-S	The transition of the factor IX zymogen into the enzyme factor IXa beta was investigated. For this purpose, the activation intermediate factors IX alpha and IXa alpha were purified after cleavage of the Arg(145)-Ala(146) and Arg(180)-Val(181) bonds, respectively. These intermediates were compared for a number of functional properties with factor IXa beta, which is cleaved at both positions. Factor IXa alpha was equal to factor IXa beta in hydrolyzing the synthetic substrate CH3SO2-Leu-Gly-Arg-p-nitroanilide (k(cat)/K-m approximate to 120 s(-1) M(-1)) but was less efficient in factor X activation. Factor IX alpha was incapable of generating factor Xa but displayed reactivity toward p-nitrophenol p-guanidino-benzoate and the peptide substrate. The catalytic efficiency, however, was 4-fold lower compared with factor IXa alpha and factor IXa beta. Factor IX alpha and factor IXa beta had similar affinity for the inhibitor benzamidine (K-i approximate to 2.5 mM), and amidolytic activity of both species was inhibited by Glu-Gly-Arg-chloromethyl ketone and antithrombin III. Unlike factor IXa beta, factor IX alpha was unable to form SDS stable complexes with antithrombin III. Moreover, inhibition of factor IXa beta and factor IX alpha by Glu-Gly-Arg-chloromethyl ketone followed distinct pathways, because factor IX alpha was inhibited in a nonirreversible manner and displayed only minor incorporation of the dansylated inhibitor into its catalytic site. These data demonstrate that the catalytic site of factor IX alpha differs from that of the fully activated factor IXa beta. Factor IX and its derivatives were also compared with regard to complex assembly with factor VIII in direct binding studies employing the immobilized factor VIII light chain. Factor IX alpha and factor IXa beta displayed a 30-fold higher affinity for the factor VIII light chain (K-d approximate to 12 nM) than the factor IX zymogen. Factor IXa alpha showed lower affinity (K-d approximate to 50 nM) than factor IX alpha and factor IXa beta, which may explain the lower efficiency of factor X activation by factor IXa alpha. Collectively, our data indicate that cleavage of the Arg(180)-Val(181) bond develops full amidolytic activity but results in suboptimal binding to the factor VIII light chain. With regard to cleavage of the Arg(145)-Ala(146) bond, we have demonstrated that this results in the transition of the factor IX zymogen into an enzyme that lacks proteolytic activity. Moreover, the same cleavage fully exposes the binding site for the factor VIII light chain, suggesting that cleavage of the Arg(145)-Ala(146) bond serves a previously unrecognized role in the assembly of the factor IX-factor VIII complex.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,1066 CX AMSTERDAM,NETHERLANDS				Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1983, BIOCHEMISTRY-US, V22, P4047, DOI 10.1021/bi00286a009; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE R, 1980, J BIOL CHEM, V255, P5336; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ELDERING E, 1992, J BIOL CHEM, V267, P7013; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GERATZ JD, 1979, ARCH BIOCHEM BIOPHYS, V197, P551, DOI 10.1016/0003-9861(79)90279-0; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KREUTTER K, 1994, BIOCHEMISTRY-US, V33, P13792, DOI 10.1021/bi00250a033; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LIU LW, 1991, J BIOL CHEM, V266, P23632; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MERTENS K, 1990, THROMB HAEMOSTASIS, V64, P138; MERTENS K, 1982, THROMB HAEMOSTASIS, V47, P96; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MERTENS K, 1994, Patent No. 5692; MERTENS K, 1995, THROMB HAEMOSTASIS, V54, P654; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; NEUENSCHWANDER P, 1990, ANAL BIOCHEM, V184, P347, DOI 10.1016/0003-2697(90)90692-3; PATTSON PA, 1990, J BIOL CHEM, V265, P17086; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PERSSON E, 1993, J BIOL CHEM, V268, P22531; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PROROK M, 1994, BIOCHEMISTRY-US, V33, P9784, DOI 10.1021/bi00198a050; RAWALASHEIKH R, 1992, BLOOD, V79, P398; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SPERLING R, 1978, J BIOL CHEM, V253, P3898; STEIN RL, 1986, BIOCHEMISTRY-US, V25, P5414, DOI 10.1021/bi00367a011; STEL HV, 1984, THESIS U AMSTERDAM, P51; STENFLO J, 1991, BLOOD, V78, P1637; TANS G, 1987, EUR J BIOCHEM, V164, P637, DOI 10.1111/j.1432-1033.1987.tb11174.x; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WALSH PN, 1982, J CLIN INVEST, V73, P1392; WU QY, 1994, J BIOL CHEM, V269, P3725	55	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14884	14890		10.1074/jbc.270.25.14884	http://dx.doi.org/10.1074/jbc.270.25.14884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797466	hybrid			2022-12-27	WOS:A1995RE66600010
J	SCHWENK, U; SCHRODER, JM				SCHWENK, U; SCHRODER, JM			5-OXO-EICOSANOIDS ARE POTENT EOSINOPHIL CHEMOTACTIC FACTORS - FUNCTIONAL-CHARACTERIZATION AND STRUCTURAL REQUIREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-EICOSATETRAENOIC ACIDS; MAJOR BASIC-PROTEIN; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-NEUTROPHILS; IDENTIFICATION; MIGRATION; STIMULATION; GENERATION; CYTOKINE	Human eosinophils produce upon treatment with 5-oxo-eicosatetraenoic acid or (5S,15S)-dihydroxyeicosatetraenoic acid a potent eosinophil-chemotactic eicosanoid, 5-oxo-15-hydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5-oxo-15-HETE). 5-Oxo-15-HETE induces human eosinophil (Eo) chemotaxis at nanomolar concentrations with an efficacy in vitro comparable to that seen for platelet activating factor. Comparison of Eo chemotactic activities of several structurally related eicosanoids with different substituents and/or double bound geometry led to the conclusion that maximal potency and efficacy of eosinophil-chemotactic and chemokinetic activity is present in 5-oxo-(6E,8Z,11Z,14Z)-eieosatetraenoic acid (5-oxo-ETE). The presence of a hydroxyl group at position C-15 is not necessary for potent chemotactic activity, whereas a geometric isomer having trans instead of cis double bond at C-atom 8, as well as esterified 5-oxo-ETE usually show a 5-10-fold lower potency. 5-Oxo-eicosanoids elicit a dose-dependent transient rise of intracellular Ca2+ levels in human Eos, however, in contrast to some other Eo chemotaxins do not induce degranulation. Cross-desensitization of Ca2+ mobilization and Eo chemotaxis revealed that the geometric isomers of 5-oxo-eicosanoids, 5(S)-HETE, and (5S,15S)-di-HETE cross-deactivate Eo responses to each other, whereas other, unrelated stimuli did not interfere with these lipids indicating that 5-oxo-eicosanoids activate Eos via a separate receptor.	CHRISTIAN ALBRECHTS UNIV KIEL, DEPT DERMATOL, KLIN FORSCHERGRP, D-24105 KIEL, GERMANY	University of Kiel			Schroeder, Jens M/B-3994-2009					BORGEAT P, 1979, J BIOL CHEM, V254, P2643; COEFFIER E, 1991, INT J IMMUNOPHARMACO, V13, P273, DOI 10.1016/0192-0561(91)90108-J; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; FIESER LF, 1968, ORG CHEM, P464; FILLEY WV, 1982, LANCET, V2, P11; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOETZL EJ, 1979, J EXP MED, V150, P406, DOI 10.1084/jem.150.2.406; GOETZL EJ, 1980, J IMMUNOL, V124, P926; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GOETZL EJ, 1980, IMMUNOLOGY, V39, P491; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAY AB, 1973, IMMUNOLOGY, V24, P969; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; MORITA E, 1990, J IMMUNOL, V144, P1893; MORITA E, 1989, SCAND J IMMUNOL, V29, P709, DOI 10.1111/j.1365-3083.1989.tb01175.x; NOSO N, 1994, BIOCHEM BIOPH RES CO, V200, P1470, DOI 10.1006/bbrc.1994.1616; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; PREISSNER WC, 1983, BRIT J DERMATOL, V109, P1, DOI 10.1111/j.1365-2133.1983.tb03984.x; PRETSCH E, 1976, TABELLEN STRUKTURAUF, pU25; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TURK J, 1982, J BIOL CHEM, V257, P7068; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WISEMAN JS, 1988, BIOCHEM BIOPH RES CO, V154, P544, DOI 10.1016/0006-291X(88)90174-X	33	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15029	15036		10.1074/jbc.270.25.15029	http://dx.doi.org/10.1074/jbc.270.25.15029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797484	hybrid			2022-12-27	WOS:A1995RE66600030
J	MACGINNITIE, AJ; ANANT, S; DAVIDSON, NO				MACGINNITIE, AJ; ANANT, S; DAVIDSON, NO			MUTAGENESIS OF APOBEC-1, THE CATALYTIC SUBUNIT OF THE MAMMALIAN APOLIPOPROTEIN-B MESSENGER-RNA EDITING ENZYME, REVEALS DISTINCT DOMAINS THAT MEDIATE CYTOSINE NUCLEOSIDE DEAMINASE, RNA-BINDING, AND RNA EDITING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SITE	Apolipoprotein (apo) B48 is synthesized by mammalian small intestine as a result of post-transcriptional RNA editing. This process is mediated by an enzyme complex containing a catalytic subunit, apobec-1, which is homologous to other cytidine deaminases, particularly in a domain (H/C)-(A/V)-E-(X)(24-30)-P-C-(X)(2)-C which coordinates zinc. apobec-1, expressed as a glutathione S-transferase fusion protein, demonstrates both apoB RNA editing and cytidine deaminase activity. His(61) Cys(93), and Cys(96), the putative zinc-coordinating residues, were mutated to Arg, Ser, and Ser, respectively, with loss of RNA editing activity and either great reduction or abolition of cytidine deaminase activity. Mutation of the catalytically active Glu(63) residue to Gln and pro(92) to Leu abolished both cytidine deaminase and RNA editing activity. The conservative His(61) --> Cys mutation, which should coordinate zinc, retained both editing and cytidine deaminase activity. Thus, zinc binding is required for both apoB RNA editing and cytidine deaminase activity. Mutation of the first four leucines within the heptad repeat of the leucine-rich region (LRR) of apobec-1 resulted in reduced RNA editing but preservation of wild-type cytidine deaminase activity, GST/APOBEC-1 was also demonstrated to cross-link to apoB RNA. Mutation of His(61) --> Arg abolished RNA binding, while the Glu(63), Gln and Cys(96) --> Ser mutant proteins showed wild-type levels of RNA binding. The remaining mutants had reduced levels of activity. Overexpression of wild-type apobec-1 in McA 7777 cells resulted in a 5-6-fold increase in editing of endogenous apoB. Transfection of the His(61) --> Cys, LRR, and Cys(93) --> Ser mutants increased endogenous editing 23-fold, while Glu(63) --> Gln and His(61) --> Arg mutants acted as dominant negatives, reducing endogenous editing. These data suggest that apobec-1 has distinct functional domains which modulate activity in the context of the apoB mRNA editing enzyme.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago			Anant, Shrikant/AAF-8020-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; ANDERSSON S, 1992, J BIOL CHEM, V264, P8222; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BHAUMIK D, 1993, J BIOL CHEM, V268, P5464; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOYUM A, 1994, EXP HEMATOL, V22, P208; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROTH GJ, 1991, BLOOD, V77, P5; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TENG B, 1993, SCIENCE, V260, P1819; WILSON DK, 1991, SCIENCE, V25, P1278; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	111	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14768	14775		10.1074/jbc.270.24.14768	http://dx.doi.org/10.1074/jbc.270.24.14768			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782343	hybrid			2022-12-27	WOS:A1995RD45500080
J	MOLINARI, M; MAKI, M; CARAFOLI, E				MOLINARI, M; MAKI, M; CARAFOLI, E			PURIFICATION OF MU-CALPAIN BY A NOVEL AFFINITY-CHROMATOGRAPHY APPROACH - NEW INSIGHTS INTO THE MECHANISM OF THE INTERACTION OF THE PROTEASE WITH TARGETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; ERYTHROCYTE PLASMA-MEMBRANE; CALCIUM-DEPENDENT PROTEASE; HAND STRUCTURE-DOMAIN; BINDING; CALPASTATIN; CALMODULIN; DEGRADATION; PROTEINS; PHOSPHODIESTERASE	A calmodulin-binding motif is a common structural feature of a number of calpain substrates (1). Since a calmodulin-like domain has been identified in both subunits of the calpain molecule, the proposal was made that the domain(s) would recognize the calmodulin-binding motifs of the substrates prior to the enzymatic modification by calpain. In keeping with the proposal, a succesful attempt to purify mu-calpain hom human erythrocytes was made by using an affinity chromatography approach in which the synthetic peptide C49, containing the calmodulin-binding domain of the plasma membrane Ca2+-ATPase, was coupled to a Sepharose matrix. The calmodulin-like domain of the catalytic subunit of human mu-calpain expressed in Escherichia coli was also retained by the C49-Sepharose column. Both mu-calpain and tbe calmodulin-like domain interacted with C49 in a Ca2+-dependent way and were eluted from the column by Ca2+-chelating agents. The finding confirmed the interaction between the calmodulin-binding domain of the plasma membrane Ca2+-ATPase and the calmodulinlike domain of mu-calpain. Experiments were performed to establish whether irreversibly inactivated mu-calpain or its expressed C-terminal portion containing the calmodulin-like domain could activate the hydrolysis of ATP by the plasma membrane Ca2+ pump, in keeping with the evident ATPase stimulation of the same pump by calmodulin. A stimulation was observed, but it was much weaker than that induced by calmodulin.	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 60601, JAPAN; ETH ZURICH, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND	Kyoto University; Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016; Molinari, Maurizio/N-2587-2019; Maki, Masatoshi/AAM-6839-2021	Carafoli, Ernesto/0000-0002-7826-0094; Molinari, Maurizio/0000-0002-7636-5829; Maki, Masatoshi/0000-0001-9144-5491				ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P13936; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; GUNDERSEN RE, 1987, J BIOL CHEM, V262, P4602; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; INOMATA M, 1989, J BIOL CHEM, V264, P18838; INOMATA M, 1990, BIOCHEM BIOPH RES CO, V171, P625, DOI 10.1016/0006-291X(90)91192-U; JAMES P, 1989, J BIOL CHEM, V264, P8289; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; KAWASAKI H, 1993, ARCH BIOCHEM BIOPHYS, V305, P467, DOI 10.1006/abbi.1993.1448; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUBOKI M, 1990, J BIOCHEM-TOKYO, V107, P776, DOI 10.1093/oxfordjournals.jbchem.a123124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE WJ, 1990, BIOCHEM INT, V22, P163; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; SIMAN R, 1990, FID RES FDN, V4, P145; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; VORRHERR T, 1990, BIOCHEMISTRY-US, V29, P355; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348	47	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14576	14581		10.1074/jbc.270.24.14576	http://dx.doi.org/10.1074/jbc.270.24.14576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782321	hybrid			2022-12-27	WOS:A1995RD45500053
J	HALSTEAD, J; KEMP, A; IGNOTZ, RA				HALSTEAD, J; KEMP, A; IGNOTZ, RA			EVIDENCE FOR INVOLVEMENT OF PHOSPHATIDYLCHOLINE-PHOSPHOLIPASE-C AND PROTEIN-KINASE-C IN TRANSFORMING GROWTH-FACTOR-BETA SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TGF-BETA; MEDIATED HYDROLYSIS; CELLS; INHIBITION; ACTIVATION; RECEPTOR; TRANSDUCTION; STIMULATION; RAS	Transforming growth factor-beta (TGF-beta) is a multifunctional peptide that elicits a wide variety of responses in cells. TGF-beta binds to cell surface receptors that contain cytoplasmic serine/threonine kinase domains. Here we provide evidence that both phospholipase C and protein kinase C (pFC) are involved in the TGF-beta activation of transcription and luciferase expression from the p3TP-Lux plasmid. Down-regulation of PKC prevents TGF-beta 1 induction of luciferase expression. Staurosporin and Calphostin C, inhibitors of PKC, block the ability of TGF-beta 1 to initiate transcription of the luciferase gene. Further, D609, an inhibitor of phosphatidylcholine-phospholipase C (PC-PLC), and secondarily PKC also blocks TGF-1-induced transcription of the transgene in A549 cells while the phosphatidylinositol-PLC pathway inhibitor U73122 is without effect; TGF-beta elevates steady-state mRNA levels for the endogenous PAI-1 and fibronectin genes. Treatment of cells with calphostin C or D609 prevents the TGF-beta-induced increase in these mRNAs. Together, these results suggest that PC-PLC and PKC are in a TGF-beta signaling pathway that results in elevated gene expression.	UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester								BLEASDALE JE, 1993, NEUROPROTOCOLS, V3, P125; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DIAZMECO MT, 1992, MOL CELL BIOL, V12, P302, DOI 10.1128/MCB.12.1.302; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HOWE PH, 1989, CANCER RES, V49, P6024; IGNOTZ R A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P75; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TWARDZIK DR, 1989, J NATL CANCER I, V81, P1132; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1994, J BIOL CHEM, V269, P13231	33	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13600	13603		10.1074/jbc.270.23.13600	http://dx.doi.org/10.1074/jbc.270.23.13600			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775410	hybrid			2022-12-27	WOS:A1995RC44800006
J	WATANABE, K; FUKUCHI, T; HOSOYA, H; SHIRASAWA, T; MATUOKA, K; MIKI, H; TAKENAWA, T				WATANABE, K; FUKUCHI, T; HOSOYA, H; SHIRASAWA, T; MATUOKA, K; MIKI, H; TAKENAWA, T			SPLICING ISOFORMS OF RAT ASH/GRB2 - ISOLATION AND CHARACTERIZATION OF THE CDNA AND GENOMIC DNA CLONES AND IMPLICATIONS FOR THE PHYSIOLOGICAL ROLES OF THE ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; PROTEIN; GRB2; BINDS; SOS; SEVENLESS; ACTIVATOR; SEQUENCE	We obtained three types of cDNA clones homologous to Ash/Grb2(Ash-l) cDNA from rats. One of these clones, Ash-psi was an unusual transcribed gene having 93% identity in the nucleotide sequence to Ash-l. The other two clones, Ash-m and -s, had nucleotide sequences identical with Ash-l cDNA in the amino-terminal region. The coding sequence of Ash-m cDNA is 42 nucleotides shorter than that of Ash-l cDNA. The defective region of Ash-m cDNA encodes 14 amino acid residues (157 to 170 of Ash-l), which comprise the most conserved region of the second SH3 domain. On the other hand, the coding sequence of Ash-s terminated at the end of the first SH3 domain due to a stop codon at the boundary of the sequence, thereby differing from Ash-l cDNA Cloning of the genomic DNA of the Ash-l-encoding gene, determination of the gene organization, and nucleotide sequencing revealed that the two isoforms, as well as Ash-l, are generated from a single gene by unusual alternative splicings. The gene spans more than 16 kilobases and contains 6 exons and 5 introns. Ash-m and Ash-s mRNAs were detected in various tissues by reverse-transcribed polymerase chain reaction. Ash-m physically associated with dynamin, but the association with Sos was less effective than that of Ash-l in rat pheochromocytoma PC12 cell lysates, irrespective of treatment with nerve growth factor. In contrast, Ash-s formed a complex with dynamin and Sos in cell lysates. Moreover, the newly formed carboxyl-terminal SH3 of Ash-m by splicing bound different proteins from those bound to the carboxyl-terminal SH3 domain of Ash-l, suggesting that Ash-m generates different signals. Microinjection of Ash-m or Ash-s into Balb/c 3T3 cells inhibited DNA synthesis induced by platelet-derived growth factor. These results show that these isoforms act as dominant negative regulators of mitogenic signals by Ash-l.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT EXPTL BIOL,TOKYO 173,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT MOLEC PATHOL,TOKYO 173,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	University of Tokyo								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maniatis T., 1982, MOL CLONING; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MESSING J, 1981, NUCLEIC ACIDS RES, V10, P1755; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; WATANABE K, 1992, GENE, V114, P261, DOI 10.1016/0378-1119(92)90585-D	27	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13733	13739		10.1074/jbc.270.23.13733	http://dx.doi.org/10.1074/jbc.270.23.13733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775428	hybrid			2022-12-27	WOS:A1995RC44800025
J	BRUNEAU, N; LOMBARDO, D				BRUNEAU, N; LOMBARDO, D			CHAPERONE FUNCTION OF A GRP 94-RELATED PROTEIN FOR FOLDING AND TRANSPORT OF THE PANCREATIC BILE SALT-DEPENDENT LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; CHOLESTEROL ESTERASE; MEMBRANE-GLYCOPROTEINS; STIMULATED LIPASE; CDNA CLONING; PURIFICATION; CELL; GLYCOSYLATION; EXPRESSION; OLIGOSACCHARIDES	In its fundamental attributes, the secretion pathway of the pancreatic bile salt-dependent lipase (BSDL) followed that described for all enzymes involved in regulated secretion. This route was inhibited by drugs that affect protein synthesis and intracellular transport. In the presence of monensin, BSDL was solely detected in microsome membrane fractions. The association of BSDL with intracellular membranes involved a protein complex, formed by at least two proteins of 94 and 56 kDa. In cells experiencing the metabolic stress due to azetidine-2-carboxylic acid, BSDL was additionally associated with a protein of 46 kDa. Affinity blotting showed that BSDL bound directly to the 94-kDa protein (p94). It was suggested that p94 could be a molecular chaperone, further identified as related to the 94-kDa glucose regulated protein (Grp 94). The membrane-associated BSDL (i.e. BSDL bound to the Grp 94-related p94) was O- and N-glycosylated and consequently appeared released from membranes in the trans-Golgi compartment. Therefore and for the first time, it is suggested that a multiprotein complex including the chaperone Grp 94-related p94 protein may play an essential role in the folding and transport of BSDL. One hypothesis is that the association of BSDL with membrane via the Grp 94-related p94 along its secretion pathway is required for its complete O-glycosylation, which occurs on the extended mucin-like structures present on the C-terminal part of the protein.	FAC MED TIMONE,INSERM,U260,F-13385 MARSEILLE 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Bruneau, Nadine/O-2100-2016	Bruneau, Nadine/0000-0002-1523-3128				ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; ALBERS GHR, 1987, DIFFERENTIATION, V34, P210, DOI 10.1111/j.1432-0436.1987.tb00068.x; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BENNETT G, 1987, CELL TISSUE RES, V250, P355; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ESCRIBANO MJ, 1989, J BIOL CHEM, V264, P21865; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; FITTING T, 1982, J BIOL CHEM, V257, P4011; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSSON L, 1993, J BIOL CHEM, V268, P26692; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; MAS E, 1993, EUR J BIOCHEM, V216, P807, DOI 10.1111/j.1432-1033.1993.tb18201.x; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MIRALLES F, 1993, EUR J CELL BIOL, V60, P115; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; REGGIO HA, 1978, J CELL BIOL, V77, P288, DOI 10.1083/jcb.77.2.288; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; REUE K, 1991, J LIPID RES, V32, P267; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudd E.A., 1984, P185; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; STROUS GJA, 1980, CELL, V22, P709; SUGO T, 1993, EUR J BIOCHEM, V216, P799, DOI 10.1111/j.1432-1033.1993.tb18200.x; VELEZGRANELL CS, 1994, J CELL SCI, V107, P539	54	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13524	13533		10.1074/jbc.270.22.13524	http://dx.doi.org/10.1074/jbc.270.22.13524			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768954	hybrid			2022-12-27	WOS:A1995RB43900084
J	DODSON, ML; MICHAELS, ML; LLOYD, RS				DODSON, ML; MICHAELS, ML; LLOYD, RS			UNIFIED CATALYTIC MECHANISM FOR DNA GLYCOSYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							T4 ENDONUCLEASE-V; NUCLEOTIDE EXCISION REPAIR; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; NACL CONCENTRATION; BASE-PAIR; ENZYME; GENE; T4-ENDONUCLEASE-V; MUTY		UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; AMGEN CORP,THOUSAND OAKS,CA 91320	University of Texas System; University of Texas Medical Branch Galveston; Amgen				Lloyd, R. Stephen/0000-0001-7273-372X				AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; AUGUSTINE ML, 1991, BIOCHEMISTRY-US, V30, P8052, DOI 10.1021/bi00246a025; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOWD DR, 1990, J BIOL CHEM, V265, P3424; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FERSHT A, 1977, ENZYME STRUCTURE MEC, V2, P69; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GATES FT, 1977, J BIOL CHEM, V252, P2802; GERLT JA, 1993, NUCLEASES, V2, P1; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P111; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUO CF, 1992, J MOL BIOL, V227, P347, DOI 10.1016/0022-2836(92)90703-M; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHAM KA, 1994, BIOCHEMISTRY-US, V33, P9024, DOI 10.1021/bi00196a021; LATHAM KA, 1994, IN PRESS NUCLEIC ACI; LLOYD RS, 1987, MUTAT RES, V183, P109, DOI 10.1016/0167-8817(87)90052-6; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; LLOYD RS, 1993, NUCLEASES, V2, P263; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NICKELL C, 1992, BIOCHEMISTRY-US, V31, P4189, DOI 10.1021/bi00132a006; NICKELL C, 1991, BIOCHEMISTRY-US, V30, P8638, DOI 10.1021/bi00099a021; NICKELL C, 1991, J BIOL CHEM, V266, P5634; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WEST SC, 1993, NUCLEASES, V2, P145	45	234	239	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32709	32712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806489				2022-12-27	WOS:A1994QA63800001
J	TOHYAMA, Y; YANAGI, S; SADA, K; YAMAMURA, H				TOHYAMA, Y; YANAGI, S; SADA, K; YAMAMURA, H			TRANSLOCATION OF P72(SYK) TO THE CYTOSKELETON IN THROMBIN-STIMULATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SKELETON; ACTIN POLYMERIZATION; TYROSINE PHOSPHORYLATION; BLOOD-PLATELETS; PROTEIN; ASSOCIATION; IDENTIFICATION; AGGREGATION; PP60(C-SRC); PP60C-SRC	Thrombin stimulation induces a dramatic increase in the activity of p72(syk) in platelets. We have found that activated p72(syk), which is phosphorylated on tyrosine residue(s), translocates from the Triton X-100-soluble fraction to the Triton X-100-insoluble, cytoskeleton-rich fraction after thrombin stimulation. In addition, the redistribution of p72(syk) from the 100,000 x g Triton X-soluble fraction and the membrane skeleton was found to correlate with an increased level of p72(syk) in the cytoskeleton. Furthermore, the early phase of p72(syk) translocation (within 60 s) was significantly inhibited with cytochalasin D, whereas the late phase of p72(syk) translocation (after 90 s) was completely inhibited with RGDS tetrapeptide treatment. These results suggest that translocation of the activated p72(syk) to the cytoskeleton correlates with different phases of the platelet activation process through actin polymerization and glyco protein IIb/IIIa-fibrinogen-mediated aggregation of platelets and, hence, may have a regulatory role in tyrosine phosphorylation of platelets.	FUKUI MED SCH,DEPT BIOCHEM,MATSUOKA,FUKUI 91011,JAPAN; KOBE UNIV,BIOSIGNAL RES CTR,NADA KU,KOBE 657,JAPAN	University of Fukui; Kobe University			Sada, Kiyonao/H-7373-2015	Sada, Kiyonao/0000-0001-6124-3100				BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HORVATH AR, 1992, EMBO J, V11, P821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1992, J BIOL CHEM, V267, P20075; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686	22	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32796	32799						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806502				2022-12-27	WOS:A1994QA63800015
J	PILZ, RB; BERJIS, M; IDRISS, SD; SCHEELE, JS; SUHASINI, M; GAO, L; SCHEFFLER, IE; BOSS, GR				PILZ, RB; BERJIS, M; IDRISS, SD; SCHEELE, JS; SUHASINI, M; GAO, L; SCHEFFLER, IE; BOSS, GR			ISOLATION AND CHARACTERIZATION OF HL-60 CELLS RESISTANT TO NITROPRUSSIDE-INDUCED DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; DEPENDENT PROTEIN-KINASE; PROMYELOCYTIC LEUKEMIA-CELLS; NITRIC-OXIDE; MOLECULAR-CLONING; RAT LUNG; HUMAN-PLATELETS; C-MYC; TISSUE PREPARATIONS; LINE HL-60	Sodium nitroprusside and sodium nitrite, which generate nitric oxide and increase the intracellular cGMP concentration, and 8-bromo-cGMP, a membrane-permeable cGMP analog, induce myelomonocytic differentiation of HL-60 cells (Boss, G. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7174-7178). We have selected HL-60 cells resistant to nitroprusside-induced differentiation as assessed by acquisition of the OKM-1 antigen, reduction of nitro blue tetrazolium, and morphologic maturation. The variant cells were also resistant to differentiation induced by sodium nitrite and two cGMP analogs but still differentiated in response to other inducing agents such as dimethyl sulfoxide and cAMP analogs and showed the same changes in c-myc and c-fos expression in response to the latter drugs as occurred in parental cells. We studied the early steps of the NO/cGMP signal transduction pathway in the variant cells and found that basal and nitroprusside-stimulated guanylate cyclase activity was similar in parental and variant cell extracts and that nitroprusside increased the intracellular cGMP concentration to the same extent in parental and variant cells. As part of these studies we found that HL-60 cells expressed only alpha(2) and beta(2) guanylate cyclase mRNA; the abundance of these two mRNA species was similar in parental and variant cells. Neither nitroprusside nor 8-bromo-cGMP changed the intracellular calcium concentration in parental or variant cells. The data suggest that the defect in the variant cells is after guanylate cyclase activation in the NO/cGMP transduction pathway and that the cGMP and cAMP transduction pathways operate independently in inducing differentiation of HL-60 cells.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	PILZ, RB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018835, R01GM049360] Funding Source: NIH RePORTER; NCI NIH HHS [KO8 CA01548] Funding Source: Medline; NIGMS NIH HHS [R01 GM18835, R01 GM49360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; ASANO T, 1977, BIOCHEM BIOPH RES CO, V78, P910, DOI 10.1016/0006-291X(77)90509-5; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHHAJLANI V, 1989, BIOCHEM INT, V19, P1039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DOUGLAS SD, 1990, HEMATOLOGY, P859; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HIGUCHI M, 1991, MOL IMMUNOL, V28, P1039; IDRISS SD, 1992, BIOCHEM BIOPH RES CO, V183, P312, DOI 10.1016/0006-291X(92)91645-7; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; LANDER HM, 1993, J IMMUNOL, V150, P1509; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUELLER R, 1985, Nature (London), V314, P546; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; OKAZAKI T, 1986, CANCER RES, V46, P6059; PILZ RB, 1984, J BIOL CHEM, V259, P2927; PILZ RB, 1990, J BIOL CHEM, V265, P8880; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SPRENGER H, 1991, IMMUNOBIOLOGY, V183, P94, DOI 10.1016/S0171-2985(11)80189-0; TSUDA T, 1987, J BIOCHEM-TOKYO, V102, P1579, DOI 10.1093/oxfordjournals.jbchem.a122207; UJIIE K, 1993, J CLIN INVEST, V91, P730, DOI 10.1172/JCI116255; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; YEN A, 1987, CANCER RES, V47, P129; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; ZWILLER J, 1981, BIOCHIM BIOPHYS ACTA, V658, P64, DOI 10.1016/0005-2744(81)90250-3	52	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32155	32161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798212				2022-12-27	WOS:A1994PX30400024
J	SEKIYA, F; USUI, H; INOUE, K; FUKUDOME, K; MORITA, T				SEKIYA, F; USUI, H; INOUE, K; FUKUDOME, K; MORITA, T			ACTIVATION OF PROTHROMBIN BY A NOVEL MEMBRANE-ASSOCIATED PROTEASE - AN ALTERNATIVE PATHWAY FOR THROMBIN GENERATION INDEPENDENT OF THE COAGULATION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; FACTOR-X; ENZYMATIC-PROPERTIES; RECEPTOR ACTIVATION; NEURITE OUTGROWTH; FACTOR-VIIA; CELLS; COMPLEX; IDENTIFICATION; ANTITHROMBIN	We herein report that a novel membrane-associated protease capable of activating prothrombin is present in several mammalian cells, This protease can directly convert prothrombin to active thrombin and induces blood clotting both in vivo and in. vitro but is apparently different from coagulation factor Xa, which has been thought to be the only physiological activator of prothrombin, This protease activity was initially found and was very high in 8C feline kidney fibroblast cells, and we characterized its enzymological features using this cell Line, Activity was detected in neither the cytosolic fraction nor the culture medium but found in the membranes and identified on the surface of intact cells, The activation of prothrombin required Ca2+ ions, and the apparent K-m value for prothrombin was 0.2 mu M. The activity was irreversibly inhibited by exposure to EDTA, but various inhibitors for serine proteases including antithrombin III were without effect, Based on these results, we propose that this novel enzyme, membrane-associated prothrombin activator, catalyzes an alternative pathway for generation of thrombin, which is independent of the blood coagulation cascade, and that the thrombin generated is involved in certain pathological states and/or in activation of cells that are spatially separated from the bloodstream.	MEIJI COLL PHARM, DEPT BIOCHEM, TANASHI, TOKYO 188, JAPAN; SHIONOGI & CO LTD, SHIONOGI INST MED SCI, OSAKA 566, JAPAN	Meiji Pharmaceutical University; Shionogi & Company Limited								ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1990, J IMMUNOL, V145, P246; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; EDWARDS RL, 1993, THROMB HAEMOSTASIS, V69, P205; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GORDON SG, 1981, J CLIN INVEST, V67, P1665, DOI 10.1172/JCI110203; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JENKINS AL, 1993, J BIOL CHEM, V268, P21433; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KISIEL W, 1987, J BIOL CHEM, V262, P12607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MANN KG, 1990, BLOOD, V76, P1; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MORITA T, 1986, J BIOL CHEM, V261, P4008; MORITA T, 1974, J BIOCHEM, V76, P1031; ROSING J, 1992, TOXICON, V30, P1515, DOI 10.1016/0041-0101(92)90023-X; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; TAPPARELLI C, 1993, TRENDS PHARMACOL SCI, V14, P366, DOI 10.1016/0165-6147(93)90095-2; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32441	32445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798243				2022-12-27	WOS:A1994PX30400064
J	SHUMAN, S				SHUMAN, S			NOVEL-APPROACH TO MOLECULAR-CLONING AND POLYNUCLEOTIDE SYNTHESIS USING VACCINIA DNA TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; BINDING	Construction of chimaeric DNA molecules in vitro relies traditionally on two enzymatic steps catalyzed by separate protein components. Site-specific restriction endonucleases are used to generate linear DNAs with defined termini that can then be joined covalently at their ends via the action of DNA ligase. A novel approach to the synthesis of recombinant DNAs exploits the ability of a single enzyme, vaccinia DNA topoisomerase, to both cleave and rejoin DNA strands with extreme specificity at each step. Placement of the CCCTT cleavage motif for vaccinia topoisomerase near the end of a duplex DNA permits efficient generation of a stable, highly recombinogenic protein-DNA adduct that can religate only to acceptor DNAs that contain complementary single-strand extensions. Linear DNAs containing CCCTT cleavage sites at both ends (bivalent substrates) can be activated by topoisomerase and inserted into a plasmid vector in a simple and rapid in vitro procedure that is especially well suited to the molecular cloning of polymerase chain reaction-amplified DNAs. Activation of polyvalent (e.g. branched) DNA substrates by topoisomerase offers a potentially powerful method for the synthesis of two- and three dimensional polynucleotide networks.			SHUMAN, S (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.							CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043	13	122	177	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32678	32684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798275				2022-12-27	WOS:A1994PX30400098
J	TSUGA, H; KAMEYAMA, K; HAGA, T; KUROSE, H; NAGAO, T				TSUGA, H; KAMEYAMA, K; HAGA, T; KUROSE, H; NAGAO, T			SEQUESTRATION OF MUSCARINIC ACETYLCHOLINE-RECEPTOR M2 SUBTYPES - FACILITATION BY G-PROTEIN-COUPLED RECEPTOR KINASE (GRK2) AND ATTENUATION BY A DOMINANT-NEGATIVE MUTANT OF GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NEURO-BLASTOMA CELLS; 3RD CYTOPLASMIC LOOP; CHOLINERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; GAMMA-SUBUNITS; DEPENDENT PHOSPHORYLATION; CHICK HEART; DESENSITIZATION; AGONIST	Sequestration of m2 receptors (muscarinic acetylcholine receptor m2 subtypes), which was assessed as loss of N-[H-3]methylscopolamine ([H-3]NMS) binding activity from the cell surface, was examined in COS7 and BHK-21 cells that had been transfected with expression vectors encoding the m2 receptor and, independently, vectors encoding a G protein-coupled receptor kinase (GRK2) (beta-adrenergic receptor kinase 1) or a GRK2 dominant-negative mutant (DN-GRK2). The sequestration of m2 receptors became apparent when the cells were treated with 10(-5) M or higher concentrations of carbamylcholine. In this case, approximately 40% or 20-25% of the [H-3]NMS binding sites on COS 7 or BHK-21 cells, respectively, were sequestered with a half-life of 15-25 min. In cells in which GRK2 was also expressed, the sequestration became apparent in the presence of 10(-7) M carbamylcholine. Approximately 40% of the [H-3]NMS binding sites on both COS 7 and BHK-21 cells were sequestered in the presence of 10(-6) nr or higher concentrations of carbamylcholine. When DN-GRK2 was expressed in COS 7 cells, the proportion of [H-3]NMS binding sites sequestered in the presence of 10(-5) M or higher concentrations of carbamylcholine was reduced to 20-30%. These results indicate that the phosphorylation of m2 receptors by GRK2 facilitates their sequestration. These results are in contrast with the absence of a correlation between sequestration and the phosphorylation of beta-adrenergic receptors by the GRK2 and suggests that the consequences of phosphorylation by GRK2 are different for different receptors.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHARMACOL & TOXICOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	TSUGA, H (corresponding author), UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; FISHER SK, 1988, MOL PHARMACOL, V33, P414; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GALPER JB, 1982, J BIOL CHEM, V257, P344; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; IKEGAYA T, 1993, J NEUROCHEM, V60, P1143, DOI 10.1111/j.1471-4159.1993.tb03265.x; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1994, J BIOL CHEM, V269, P10093; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MALOTEAUX JM, 1983, FEBS LETT, V156, P103, DOI 10.1016/0014-5793(83)80257-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4	41	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32522	32527						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798253				2022-12-27	WOS:A1994PX30400075
J	LI, SW; OKAMOTO, T; CHUN, MY; SARGIACOMO, M; CASANOVA, JE; HANSEN, SH; NISHIMOTO, I; LISANTI, MP				LI, SW; OKAMOTO, T; CHUN, MY; SARGIACOMO, M; CASANOVA, JE; HANSEN, SH; NISHIMOTO, I; LISANTI, MP			EVIDENCE FOR A REGULATED INTERACTION BETWEEN HETEROTRIMERIC G-PROTEINS AND CAVEOLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; TRANS-GOLGI-NETWORK; ALPHA-SUBUNIT; GTP-BINDING; GUANINE-NUCLEOTIDES; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; RECEPTOR; INSULIN	Caveolae are flash-shaped plasma membrane specializations, A 22-kDa protein, caveolin, is a principal component of caveolar membranes in vivo, As recent evidence suggests that caveolae may participate in G protein-coupled signaling events, we have investigated the potential interaction of caveolin with heterotrimeric G proteins, Using cell fractionation techniques, we found that mutational or pharmacologic activation of G(s alpha) prevents its co-fractionation with caveolin, In a second independent approach, we directly examined the interaction of G proteins with caveolin, For this purpose, we recombinantly expressed caveolin as a glutathione S-transferase fusion protein, Using an in vitro binding assay, we found that caveolin interacts with G protein alpha subunits (G(s), G(o), and G(i)). Mutational or pharmacologic activation (with guanosine 5'-O-(thiotriphosphate)) of G(alpha) subunits prevents this interaction, indicating that the inactive GDP-bound form of G(alpha) subunits preferentially interacts with caveolin, This G protein binding activity is located within a 41-amino acid region of caveolin's cytoplasmic N-terminal. domain (residues 61-101), Further functional analysis shows that a polypeptide derived from this region of caveolin (residues 82-101) effectively suppresses the basal activity of purified G proteins, apparently by inhibiting GDP/GTP exchange, This caveolin sequence is homologous to a region of the Rab GDP dissociation inhibitor, a known inhibitor of GDP/GTP exchange for Rab proteins, These data suggest that caveolin could function to negatively regulate the activation state of heterotrimeric G proteins.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MASSACHUSETTS GEN HOSP EAST, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, DEPT PEDIAT GASTROENTEROL, DIV MUCOSAL IMMUNOL, BOSTON, MA 02129 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; li, wj/HGD-7322-2022; Li, Shengwen Calvin/H-1725-2012	Lisanti, Michael/0000-0003-2034-1382; Li, Shengwen Calvin/0000-0002-9699-9204; Hansen, Steen/0000-0002-9408-4676; Sargiacomo, Massimo/0000-0003-4040-706X	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIAID NIH HHS [AI-32991] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991, R29AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASALOVICH AM, 1987, DOKL AKAD NAUK SSSR+, V297, P470; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; OKAMOTO T, 1994, J BIOL CHEM, V269, P13756; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Raposo G, 1994, Trends Cell Biol, V4, P418, DOI 10.1016/0962-8924(94)90096-5; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	560	573	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15693	15701		10.1074/jbc.270.26.15693	http://dx.doi.org/10.1074/jbc.270.26.15693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797570	hybrid			2022-12-27	WOS:A1995RG53800041
J	YEH, CH; SHATKIN, AJ				YEH, CH; SHATKIN, AJ			A CIS-ACTING ELEMENT IN ROUS-SARCOMA VIRUS LONG TERMINAL REPEAT REQUIRED FOR PROMOTER REPRESSION BY HELA NUCLEAR-PROTEIN P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; C-FOS GENE; MAMMALIAN-CELLS; XENOPUS EMBRYOS; TRANSCRIPTION; IDENTIFICATION; EXPRESSION; ENHANCER; CARG	HeLa cell basic nuclear protein (p21), which represses Rous sarcoma virus long terminal repeat (RSV LTR) promoter activity, diminished v-src expression and the appearance at permissive temperature of the transformed phenotype in tsRSVLA23 Rat-1, a cell line transformed with a temperature-sensitive mutant of RSV. Nuclear run on analyses using COS-l cells cotransfected with p21 cDNA and chloramphenicol acetyltransferase reporter indicated that p21 inhibits transcription initiation by targeting a region in the RSV LTR promoter between positions -108 and -85 upstream of the cap site. Insertion of this 24-base pair sequence in place of one of the 72-base pair enhancers in the SV40 early promoter rendered it sensitive to pal repression. Electrophoretic mobility shift assays using a synthetic oligomer corresponding to the 24-base pair LTR promoter element revealed that p21 altered the pattern of protein . DNA complex formation apparently without binding DNA directly. Complex formation assayed by UV cross-linking and DNA affinity chromatography indicated further that a cellular factor which can interact with this element was decreased in cells transfected with p21 expression plasmid. The results indicate that p21 repression of RSV LTR is mediated by a cis-acting element and may occur by alteration of protein complexes formed on this promoter element.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854									ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; BOULDEN A, 1990, VIROLOGY, V174, P204, DOI 10.1016/0042-6822(90)90069-4; CARROLL RC, 1978, P NATL ACAD SCI USA, V75, P5015, DOI 10.1073/pnas.75.10.5015; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1985, MOL CELL BIOL, V5, P438, DOI 10.1128/MCB.5.3.438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMARTIN GM, 1983, MOL CELL BIOL, V3, P1834, DOI 10.1128/MCB.3.10.1834; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HABEL DE, 1993, J VIROL, V67, P1545, DOI 10.1128/JVI.67.3.1545-1554.1993; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAIMINS LA, 1984, NUCLEIC ACIDS RES, V12, P6427, DOI 10.1093/nar/12.16.6427; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NORTON PA, 1987, J VIROL, V61, P1171, DOI 10.1128/JVI.61.4.1171-1179.1987; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEH CH, 1994, GENE, V143, P285; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002; ZACHOW KR, 1992, J VIROL, V66, P1959, DOI 10.1128/JVI.66.4.1959-1970.1992	38	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15815	15820		10.1074/jbc.270.26.15815	http://dx.doi.org/10.1074/jbc.270.26.15815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797584	hybrid			2022-12-27	WOS:A1995RG53800057
J	ZHAO, XM; KOBAYASHI, T; MALAK, H; GRYCZYNSKI, I; LAKOWICZ, J; WADE, R; COLLINS, JH				ZHAO, XM; KOBAYASHI, T; MALAK, H; GRYCZYNSKI, I; LAKOWICZ, J; WADE, R; COLLINS, JH			CALCIUM-INDUCED TROPONIN FLEXIBILITY REVEALED BY DISTANCE DISTRIBUTION MEASUREMENTS BETWEEN ENGINEERED SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; FREQUENCY-DOMAIN FLUOROMETRY; AMINO-ACID SEQUENCE; PROTEOLYTIC FRAGMENTS; BIOLOGICAL-ACTIVITY; BINDING-SITES; ESCHERICHIA-COLI; ENERGY-TRANSFER; THIN-FILAMENTS; CA2+ BINDING	The contraction of vertebrate striated muscle is regulated by Ca2+ binding to troponin C (TnC). This causes conformational changes which alter the interaction of TnC with the inhibitory protein TnI and the tropomyosin-binding protein TnT. We have used the frequency domain method of fluorescence resonance energy transfer to measure TnT-TnC and TnT-TnI distances and distance distributions, in the presence of Ca2+, Mg2+, or EGTA, in TnC . TnI . TnT complexes. We reconstituted functional, ternary troponin complexes using the following recombinant subunits n- hose sequences were based on those of rabbit skeletal muscle: wild-type TnC; TnT(25), a mutant C-terminal 25-kDa fragment of TnT containing a single Trp(212) which was used as the sole donor for fluorescence energy transfer measurements; Trp-less TnI: mutants which contained either no Cys or a single Cys at position 9, 96, or 117. Energy acceptor groups were introduced into TnC or TnI by labeling with dansyl aziridine or N-(iodoacetyl)-N'-( 1-sulfo-5-naphthyl)ethylenediamine. Our results indicate that the troponin complex is relatively rigid in relaxed muscle, but becomes much more flexible when Ca2+ binds to regulatory sites in TnC. This increased flexibility may be propagated to the whole thin filament, releasing the inhibition of actomyosin ATPase activity and allowing the muscle to contract. This is the first report of distance distribution measurements between troponin subunits.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,INST BIOTECHNOL,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NCRR NIH HHS [RR-08119] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Cherry R J, 1978, Methods Enzymol, V54, P47; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V26, P268; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FUJIMORI K, 1990, NATURE, V344, P182; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HUDSON EN, 1972, BIOCHEMISTRY-US, V12, P4154; ISHIWATA S, 1972, J MOL BIOL, V68, P511, DOI 10.1016/0022-2836(72)90103-9; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; KLUWE L, 1993, FEBS LETT, V232, P83; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LAKOWICZ JR, 1987, CHEM PHYS LETT, V138, P587, DOI 10.1016/0009-2614(87)80130-6; LAKOWICZ JR, 1990, BIOPHYS CHEM, V36, P99, DOI 10.1016/0301-4622(90)85014-W; LAKOWICZ JR, 1994, PHOTOCHEM PHOTOBIOL, V59, P16, DOI 10.1111/j.1751-1097.1994.tb04996.x; LAKOWICZ JR, 1988, BIOCHEMISTRY-US, V27, P9149, DOI 10.1021/bi00426a012; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; OOSAWA F, 1972, COLD SPRING HARB SYM, V37, P177; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RAGGI A, 1989, BIOCHIM BIOPHYS ACTA, V997, P135, DOI 10.1016/0167-4838(89)90145-3; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SILVA ACR, 1993, EUR J BIOCHEM, V213, P599; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; WANG CK, 1986, J MOL BIOL, V190, P509; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; ZOT AS, 1987, J BIOL CHEM, V262, P15418; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	58	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15507	15514		10.1074/jbc.270.26.15507	http://dx.doi.org/10.1074/jbc.270.26.15507			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797544	hybrid			2022-12-27	WOS:A1995RG53800014
J	LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; FEY, GH; BAUMANN, H				LAI, CF; RIPPERGER, J; MORELLA, KK; WANG, YP; GEARING, DP; FEY, GH; BAUMANN, H			SEPARATE SIGNALING MECHANISMS ARE INVOLVED IN THE CONTROL OF STAT PROTEIN-ACTIVATION AND GENE-REGULATION VIA THE INTERLEUKIN-6 RESPONSE ELEMENT BY THE BOX-3 MOTIF OF GP130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; RECEPTOR	The cytoplasmic receptor sequences required for the transcriptional control via the IL-6 response element (IL-6RE) and the hematopoietin receptor response element (HRRE) in hepatoma cells were defined by transient expression of wild-type and mutant granulocyte-colony stimulating factor receptor-gp130 chimeric receptors. gp130 generated two separate transcriptional signals, one of which was directed to IL-6RE and required an intact box 3 motif, and another, which was directed to HRRE and was box 3-independent. The activation of DNA-binding of STAT3 required the same gp130 domains as the IL-6RE response. A box 3-independent activation of STAT proteins was achieved by overexpression of the kinases JAK2 or TYK2. The increase in the DNA-binding activity of STAT proteins, however, did not result in a corresponding increase in transcription via either IL-6RE or HRRE. The data indicate that activation of the DNA-binding potential of STAT proteins via gp130 is not sufficient to achieve transcriptional up-regulation of specific target genes.	SYSTEMIX,PALO ALTO,CA 94304; ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; UNIV ERLANGEN NURNBERG,CHAIR GENET,D-91058 ERLANGEN,GERMANY; CHILDRENS HOSP,DIV ENDOCRINOL,BUFFALO,NY 14222	Roswell Park Cancer Institute; University of Erlangen Nuremberg; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KUMAR G, 1994, J IMMUNOL, V153, P4436; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WARD LD, 1994, J BIOL CHEM, V269, P23286; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHUANG H, 1994, J BIOL CHEM, V269, P2411	27	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14847	14850		10.1074/jbc.270.25.14847	http://dx.doi.org/10.1074/jbc.270.25.14847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797460	hybrid			2022-12-27	WOS:A1995RE66600002
J	OTSU, M; URADE, R; KITO, M; OMURA, F; KIKUCHI, M				OTSU, M; URADE, R; KITO, M; OMURA, F; KIKUCHI, M			A POSSIBLE ROLE OF ER-60 PROTEASE IN THE DEGRADATION OF MISFOLDED PROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; PRE-GOLGI COMPARTMENT; DISULFIDE-ISOMERASE; PHOSPHOLIPASE-C; MOLECULAR-CLONING; RAPID DEGRADATION; CYSTEINE PROTEASE; T-CELL; SEQUENCE; RETENTION	Wild-type human lysozyme (hLZM) is secreted when expressed in mouse L cells, whereas misfolded mutant hLZMs are retained and eventually degraded in a pre-Golgi compartment (Omura, F., Otsu, M., Yoshimori, T., Tashiro, Y., and Kikuchi, M. (1992) Eur. J. Biochem. 210, 591-599). These misfolded mutant hLZMs are associated with protein disulfide isomerase (Otsu, M., Omura, F., Yoshimori, T., and Kikuchi, M. (1994) J. Biol. Chem. 269, 6874-6877). From the observation that this degradation is sensitive to cysteine protease inhibitors, such as N-acetyl-leucyl-leucyl-norleucinal and N-acetyl-leucyl-leucyl-methioninal, but not to the serine protease inhibitors, 1-chloro-3-tosylamido-7-amino-2-heptanone and (p-amidinophenyl)methanesulfonyl fluoride, it was suggested that some cysteine proteases are likely responsible for the degradation of abnormal proteins in the endoplasmic reticulum (ER). ER-60 protease (ER-60), an ER resident protein with cysteine protease activity (Urade, R., Nasu, M., Moriyama, T., Wada, K., and Kito, M. (1992) J. Biol. Chem. 267, 15152-15159), was found to associate with misfolded hLZMs, but not with the wildtype protein, in mouse L cells. Furthermore, denatured hLZM is degraded by ER-60 in vitro, whereas native hLZM is not. These results suggest that ER-60 could be a component of the proteolytic machinery for the degradation of misfolded mutant hLZMs in the ER.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DEGAN E, 1991, J CELL BIOL, V112, P1099; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; INOUE S, 1991, J BIOL CHEM, V266, P13311; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LE A, 1992, J BIOL CHEM, V267, P172; LIPPINCOTTSCHWA.J, 1988, CELL, V54, P209; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; OTSU M, 1994, J BIOL CHEM, V269, P6874; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SATO R, 1990, J BIOL CHEM, V265, P11880; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; WADA I, 1991, J BIOL CHEM, V266, P19599; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YOUNG J, 1993, J BIOL CHEM, V268, P19810; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	32	97	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14958	14961		10.1074/jbc.270.25.14958	http://dx.doi.org/10.1074/jbc.270.25.14958			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797475	hybrid			2022-12-27	WOS:A1995RE66600020
J	ARGETSINGER, LS; HSU, GW; MYERS, MG; BILLESTRUP, N; WHITE, MF; CARTERSU, C				ARGETSINGER, LS; HSU, GW; MYERS, MG; BILLESTRUP, N; WHITE, MF; CARTERSU, C			GROWTH-HORMONE, INTERFERON-GAMMA, AND LEUKEMIA INHIBITORY FACTOR PROMOTED TYROSYL PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3'-KINASE; FACTOR-I; GLUCOSE TRANSPORTERS; BINDING-PROTEIN; MESSENGER-RNA; KINASE; EXPRESSION; CELLS	The identification of JAK2 as a growth hormone (G:H) receptor-associated, GH-activated tyrosine kinase has established tyrosyl phosphorylation as a signaling mechanism for GH. In the present study, GH is shown to stimulate tyrosyl phosphorylation of insulin receptor substrate 1 (IRS-1), the principle substrate of the insulin receptor. Tyrosyl phosphorylation if IRS-1 is a critical step in insulin signaling and provides binding sites for proteins with the appropriate Src homology 2 domains, including the 85-kDa regulatory subunit of phosphatidylinositol (PI) 3'-kinase. In 3T3-F442A fibroblasts, GH-dependent tyrosyl phosphorylation of IRS-1 was detected by I min and at GH concentrations as low as 5 ng/ml (0.23 nM). Tyrosyl phosphorylation of IRS-1 was transient, with maximal stimulation detected at 30 rain and diminished signal detected at 60 min. The ability of GH receptor (GHR) to transduce the signal for IRS-1 tyrosyl phosphorylation is mediated by the intracellular region of GHR between amino acids 295 and 380 by a mechanism not involving the two tyrosines in this region. This region of GHR is required for GH-dependent JAK2 association and activation (VanderKuur, J. A., Wang, X., Zhang,L., Campbell, G. S., Allevato, G., Billestrup, N., Norstedt, G., and Carter-Su, C. (1994:) J. Biol. Chem. 269, 21709-21717). When other cytokines that activate JAK2 were tested for the ability to stimulate the tyrosyl phosphorylation of IRS-1, stimulation was detected with interferon-gamma and leukemia inhibitory factor. The correlation between JAK2 tyrosyl phosphorylation and IRS-1 tyrosyl phosphorylation in response to GH, interferon-gamma, and leukemia inhibitory factor rind in cells expressing different GHR mutants, provides evidence that IRS-1 may interact with JAK2 or an auxiliary molecule that binds to JAK2. GH is also shown to stimulate binding of IRS-1 to the 85-kDa regulatory subunit of PI 3'-kinase. The ability of GH to stimulate tyrosyl phosphorylation of IRS-1 and its association with PI 3'-kinase provides a biochemical basis for responses shared by insulin and GH including the well characterized insulin-like metabolic effects of GH observed in a variety of cell types.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067	NIDDK NIH HHS [R01-DK34171, R01 DK043808, R01 DK034171, DK36836, DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, P30DK036836, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; [Anonymous], 1994, PROGRAM MANUAL WISCO; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; BURNSIDE J, 1991, ENDOCRINOLOGY, V128, P3183, DOI 10.1210/endo-128-6-3183; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; JACOBS S, 1983, J BIOL CHEM, V258, P9581; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUMAR CS, 1989, J BIOL CHEM, V2264, P17939; LAM K, 1994, J BIOL CHEM, V269, P20648; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIURA O, 1994, J BIOL CHEM, V269, P614; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V114, P3577; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RUBIN JB, 1983, NATURE, V305, P438, DOI 10.1038/305438a0; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG XJ, 1993, J NEUROSCI, V13, P3006; YIN TG, 1994, J BIOL CHEM, V269, P26614; YIN TG, 1994, EXP HEMATOL, V22, P467; ZHANG J, 1993, J BIOL CHEM, V268, P22251	81	220	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14685	14692		10.1074/jbc.270.24.14685	http://dx.doi.org/10.1074/jbc.270.24.14685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782332	hybrid			2022-12-27	WOS:A1995RD45500068
J	KIMURA, K; WHITE, BH; SIDHU, A				KIMURA, K; WHITE, BH; SIDHU, A			COUPLING OF HUMAN D-1 DOPAMINE-RECEPTORS TO DIFFERENT GUANINE-NUCLEOTIDE-BINDING PROTEINS - EVIDENCE THAT D-1 DOPAMINE-RECEPTORS CAN COUPLE TO BOTH G(S) AND G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; RAT STRIATUM; ADENYLATE-CYCLASE; STIMULATION; ALPHA; EXPRESSION; INHIBITION; SUBUNITS; CHANNELS; AGONIST	Coupling between D-1 dopamine receptors and G proteins in cell lines expressing human D-1 receptors and different G proteins was examined. Pertussis toxin (PTX) treatment of rat pituitary GH(4)C(1) cells significantly reduced, but did not abolish, agonist high affinity binding sites of the D-1 dopamine receptor; in SK-N-MC neuroblastoma cells, PTX failed to have any effect on D-1 high affinity sites. Cholera toxin (CTX) treatment of GH(4)C(1) cells reduced but did not abolish the high affinity sites of D-1 receptors, while in SK-N-MC cells, treatment with CTX abolished all the high affinity sites. Western blot analyses with specific antisera indicated that G(s) alpha, Q(i1)alpha, G(i3)alpha and G(q) alpha were expressed in both cell lines, while G(i2)alpha and G(o) alpha were expressed in GH(4)C(1) but not SK-N-MC cells. Antisera NEI-805 (anti-G(s) alpha) and 9072 (anti-G(o) alpha) immunoprecipitated 24 +/- 4.3 and 34.4 +/- 6.9%, respectively, of G protein-associated D-1 dopamine receptors. Antisera 3646 (anti-G(i1)alpha), 1521 (anti-G(i2)alpha), 1518 (anti-G(i3)alpha), and 0941 (anti-G(q) alpha) failed to coimmunoprecipitate appreciable levels df soluble receptors. These data indicate that D-1 dopamine receptors are coupled to both G(s) alpha and G(o) alpha but not to G(q) alpha.	GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,WASHINGTON,DC 20007	Georgetown University			Kimura, Kazuhiro/A-5029-2012		NINDS NIH HHS [NS-30912, NS-29685] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029685, R01NS030912] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BERTORELLO A, 1988, ACTA PHYSIOL SCAND, V132, P441, DOI 10.1111/j.1748-1716.1988.tb08350.x; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF9; BIRNBAUMER L, 1990, FASEB J, V4, P3068; CALFIELD MP, 1994, J PHYSL, V477, P415; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; FELDER CC, 1989, J PHARMACOL EXP THER, V248, P171; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HUFF RM, 1985, J BIOL CHEM, V260, P864; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; KELLY E, 1988, J NEUROCHEM, V51, P918, DOI 10.1111/j.1471-4159.1988.tb01828.x; KIMURA K, 1995, J NEUROCHEM, V64, P2118; KIMURA K, 1994, J NEUROCHEM, V63, P2093; KITAI ST, 1993, ADV NEUROL, V60, P40; LATINEN JT, 1993, J NEUROCHEM, V61, P1461; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCMILLIAN MK, 1992, J NEUROCHEM, V58, P1308, DOI 10.1111/j.1471-4159.1992.tb11343.x; MOISES HC, 1994, J NEUROSCI, V14, P3842; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEER EJ, 1994, PROTEIN SCI, V3, P3; ODOWD BF, 1993, J NEUROCHEM, V60, P804, DOI 10.1111/j.1471-4159.1993.tb03224.x; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUBINSTEIN JE, 1990, BIOCHEM PHARMACOL, V39, P1965, DOI 10.1016/0006-2952(90)90616-S; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SCHULTZ G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P229; SIDHU A, 1990, J BIOL CHEM, V265, P10065; SIDHU A, 1991, J NEUROCHEM, V57, P1445, DOI 10.1111/j.1471-4159.1991.tb08312.x; SIDHU A, 1994, BIOCHEMISTRY-US, V33, P11246, DOI 10.1021/bi00203a021; SIDHU A, 1994, J NEUROCHEM, V63, P201; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P1849; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WALDO GL, 1992, J BIOL CHEM, V267, P25798; WALLACE MA, 1990, NEUROSCI LETT, V110, P155, DOI 10.1016/0304-3940(90)90804-I; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZHOU X-M, 1991, Molecular and Cellular Neuroscience, V2, P464	48	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14672	14678		10.1074/jbc.270.24.14672	http://dx.doi.org/10.1074/jbc.270.24.14672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782330	hybrid			2022-12-27	WOS:A1995RD45500066
J	LUTHRIA, DL; BAYKOUSHEVA, SP; SPRECHER, H				LUTHRIA, DL; BAYKOUSHEVA, SP; SPRECHER, H			DOUBLE-BOND REMOVAL FROM ODD-NUMBERED CARBONS DURING PEROXISOMAL BETA-OXIDATION OF ARACHIDONIC-ACID REQUIRES BOTH 2,4-DIENOYL-COA REDUCTASE AND DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RAT-LIVER PEROXISOMES; METABOLISM; PATHWAY; EXISTENCE; CELLS; COA; IDENTIFICATION; MITOCHONDRIA; DEGRADATION	The pathway for the peroxisomal beta-oxidation of arachidonic acid (5,8,11,14-20:4) was elucidated by comparing its metabolism with 4,7,10-hexadecatrienoic acid (4,7,10-16:3) and 5,8-tetradecadienoic acid (5,8-14:2) which are formed, respectively, after two and three cycles of arachidonic acid degradation. When [1-C-14]4,7,10-16:3 was incubated with peroxisomes in the presence of NAD(+) and NADPH, it resulted in a time-dependent increase in the production of acid-soluble radioactivity which was accompanied by the synthesis of 2-trans-4,7,10-hexadecatetraenoic acid and two 3,5,7,10-hexadecatetraenoic acid isomers. The formation of conjugated trienoic acids suggests that peroxisomes contain Delta(3.5),Delta(2,4)-dienoyl-CoA isomerase with the ability to convert 2-trans-4,7,10-hexadecatetraenoic acid to 3,5,7,10-hexadecatetraenoic acid. When 1-C-14-labeled 6,9,12-octadecatrienoic acid or 7,10,13,16-docosatetraenoic acid was incubated without nucleotides, the 3-hydroxy metabolites accumulated, since further degradation requires NAD(+)-dependent 3-hydroxyacyl-CoA dehydrogenase. When [1-C-14]5,8,11,14-20:4 was incubated under identical conditions, no polar metabolite was detected, but 2-trans-4,8,11,14-eicosapentaenoic acid accumulated. When NADPH was added to incubations, 3-hydroxy-8,11,14-eicosatrienoic, 2-trans-4,8,11,14-eicosapentaenoic, 2-trans-8,11,14-eicosatetraenoic, and 8,11,14-eicosatrienoic acids were produced. Analogous compounds were formed from [1-C-14]5,8-14:2. Our results show that the removal of double bonds from odd-numbered carbons in arachidonic acid thus requires both NADPH-dependent 2,4-dienoyl-CoA reductase and Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase. One complete cycle of 5,8-14:2 and 5,8,11,14-20:4 beta-oxidation yields, respectively, 6-dodecenoic and 6,9,12 octadecatrienoic acids.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			Baykoucheva, Svetla P/H-1969-2011	Baykoucheva, Svetla P/0000-0001-7066-058X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BARTLETT K, 1990, BIOCHEM J, V270, P175, DOI 10.1042/bj2700175; BAYKOUSHEVA SP, 1994, J BIOL CHEM, V269, P18390; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; CHEN LS, 1995, BIOCHEMISTRY-US, V34, P442, DOI 10.1021/bi00002a008; DAS AK, 1992, J BIOL CHEM, V267, P9724; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; DICZFALUSY U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P182, DOI 10.1016/0005-2760(90)90294-8; DOMMES V, 1981, J BIOL CHEM, V256, P8259; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GORDON JA, 1994, J BIOL CHEM, V269, P4103; GORDON JA, 1991, BIOCHIM BIOPHYS ACTA, V1085, P21, DOI 10.1016/0005-2760(91)90227-9; HADJIAGAPIOU C, 1987, PROSTAG OTH LIPID M, V34, P579, DOI 10.1016/0090-6980(87)90100-6; HADJIAGAPIOU C, 1990, J BIOL CHEM, V265, P4369; HADJIAGAPIOU C, 1991, ARCH BIOCHEM BIOPHYS, V292, P112; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; HOVIK R, 1987, BIOCHEM J, V247, P531, DOI 10.1042/bj2470531; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KATES M, 1972, TECHNIQUES LIPIDOLOG, P383; KUNAU WH, 1974, EUR J BIOCHEM, V48, P311, DOI 10.1111/j.1432-1033.1974.tb03770.x; LUO MJ, 1994, J BIOL CHEM, V269, P2384; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPRECHER H, 1982, METHOD ENZYMOL, V86, P357; SPRECHER HW, 1965, BIOCHEMISTRY-US, V4, P1856, DOI 10.1021/bi00885a024; STOFFEL W, 1967, J LIPID RES, V8, P196; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; WIGREN J, 1993, J LIPID RES, V34, P625	36	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13771	13776		10.1074/jbc.270.23.13771	http://dx.doi.org/10.1074/jbc.270.23.13771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775433	hybrid, Green Submitted			2022-12-27	WOS:A1995RC44800030
J	ITOH, H; KOBAYASHI, R; WAKUI, H; KOMATSUDA, A; OHTANI, H; MIURA, AB; OTAKA, M; MASAMUNE, O; ANDOH, H; KOYAMA, K; SATO, Y; TASHIMA, Y				ITOH, H; KOBAYASHI, R; WAKUI, H; KOMATSUDA, A; OHTANI, H; MIURA, AB; OTAKA, M; MASAMUNE, O; ANDOH, H; KOYAMA, K; SATO, Y; TASHIMA, Y			MAMMALIAN 60-KDA STRESS PROTEIN (CHAPERONIN HOMOLOG) - IDENTIFICATION, BIOCHEMICAL-PROPERTIES, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PURIFICATION; BACTERIAL; GROEL; HSP60; ELECTROPHORESIS; MITOCHONDRIA; FAMILY; CELL	Mammalian chaperonin homolog (HSP60) was purified from porcine livers cytosol using a tandem ATP-Sepharose column and Mono and column chromatography. A partial amino acid sequence (96 amino acid residues) of this protein was determined and coincided with those of human HSP60 with 96.9% homology, which was deduced from the nucleotide sequence of the cDNA. The sequence of the NH2 termini of the purified protein (5 amino acid residues) coincided with the signal sequence of HSP60. These facts led to the identification of the 60-kDa liver protein with the chaperonin homolog. Dihydrofolate reductase was able to form a stable complex with the liver chaperonin homolog. The liver chaperonin homolog was detected by at least five spots around pI = 5.6 on two-dimensional gel electrophoresis. Immunoblotting studies using an antibody against chaperonin homolog showed that the chaperonin homolog was localized in the cytosol, mitochondrial, and nuclear fractions of porcine Liver. The chaperonin homolog was localized both in the mitochondria and cytoplasm of rat kidneys at the electron microscopic level. The chaperonin homolog in the cytosol, but not in the other subcellular fractions, was cross-reacted with an antibody against the synthetic peptide corresponding to the signal peptide of HSP60 as well as the purified chaperonin homolog on immunoblotting. These results suggested that the functional chaperonin homolog in the cytosol may be transported into the mitochondria and the protein may be processed to mitochondrial HSP60 in the organella.	AKITA UNIV,SCH MED,DEPT INTERNAL MED 3,AKITA 010,JAPAN; AKITA UNIV,SCH MED,DEPT INTERNAL MED 1,AKITA 010,JAPAN; AKITA UNIV,SCH MED,DEPT SURG 1,AKITA 010,JAPAN; KAGAWA MED SCH,DEPT CHEM,KAGAWA 76107,JAPAN	Akita University; Akita University; Akita University; Kagawa University	ITOH, H (corresponding author), AKITA UNIV,SCH MED,DEPT BIOCHEM,1-1-1 HONDO,AKITA 010,JAPAN.							ANDERSEN KJ, 1977, ANAL BIOCHEM, V83, P703, DOI 10.1016/0003-2697(77)90075-6; BERNATH P, 1962, METHOD ENZYMOL, V5, P597, DOI 10.1016/S0076-6879(62)05283-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISH P, 1990, SCIENCE, V250, P1269; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1985, CAN J BIOCHEM CELL B, V63, P489, DOI 10.1139/o85-068; HORN T, 1979, J MOL BIOL, V129, P359; IKAWA S, 1992, P NATL ACAD SCI USA, V89, P2012, DOI 10.1073/pnas.89.6.2012; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; ITOH H, 1990, EUR J BIOCHEM, V193, P429, DOI 10.1111/j.1432-1033.1990.tb19356.x; ITOH H, 1993, INT J BIOCHEM, V25, P69; ITOH H, 1991, INT J BIOCHEM, V23, P1185; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; LAD PJ, 1983, ANAL BIOCHEM, V133, P350, DOI 10.1016/0003-2697(83)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTANI H, 1993, HISTOCHEMISTRY, V100, P423, DOI 10.1007/BF00267822; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; SANDERS BM, 1994, BIOCHEM J, V297, P21, DOI 10.1042/bj2970021; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WAKUI H, 1992, INT J BIOCHEM, V24, P1507; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063	34	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13429	13435		10.1074/jbc.270.22.13429	http://dx.doi.org/10.1074/jbc.270.22.13429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768945	hybrid			2022-12-27	WOS:A1995RB43900071
J	SOLWAY, J; SELTZER, J; SAMAHA, FF; KIM, S; ALGER, LE; NIU, Q; MORRISEY, EE; IP, HS; PARMACEK, MS				SOLWAY, J; SELTZER, J; SAMAHA, FF; KIM, S; ALGER, LE; NIU, Q; MORRISEY, EE; IP, HS; PARMACEK, MS			STRUCTURE AND EXPRESSION OF A SMOOTH-MUSCLE CELL-SPECIFIC GENE, SM22-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; ALPHA-ACTIN PROMOTER; 5'-FLANKING REGION; BINDING FACTOR; BLOOD-VESSELS; CHICK-EMBRYO; MYOD FAMILY; ENHANCER; TRANSCRIPTION; PROTEINS	SM22 alpha is expressed exclusively in smooth muscle-containing tissues of adult animals and is one of the earliest markers of differentiated smooth muscle cells (SMCs). To examine the molecular mechanisms that regulate SMC-specific gene expression, Foe have isolated and structurally characterized the murine SM22 alpha gene. SM22 alpha is a 6.2-kilobase single copy gene composed of five exons. SM22 alpha mRNA is expressed at high levels in the aorta, uterus, lung, and intestine, and in primary cultures of rat aortic SMCs, and the SMC line, A7r5. ln contrast to genes encoding SMC contractile proteins, SM22 alpha gene expression is not decreased in proliferating SMCs. Transient transfection experiments demonstrated that 441 base pairs of SM22 alpha 5'-flanking sequence was necessary and sufficient to program high level transcription of a luciferase reporter gene in both primary rat aortic SMCs and A7r5 cells. DNA sequence analyses revealed that the 441-base pair promoter contains two CArG/SRF boxes, a CACC box, and one potential MEF-2 binding site, cis-acting elements which are each important regulators of striated muscle transcription. Taken together, these studies have identified the murine SM22 alpha promoter as an excellent model system for studies of developmentally regulated, Lineage-specific gene expression in SMCs.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago			Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Parmacek, Michael/0000-0003-1449-4665; Ip, Hon/0000-0003-4844-7533	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051145, R01HL048257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034566] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL48257, R01HL51145] Funding Source: Medline; NIAID NIH HHS [U01 AI34566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BLANK RS, 1992, J BIOL CHEM, V267, P984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHAPONNIER C, 1990, EUR J BIOCHEM, V190, P559, DOI 10.1111/j.1432-1033.1990.tb15610.x; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FRID MG, 1993, J VASC RES, V30, P279, DOI 10.1159/000159007; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GONZALEZCRUSSI F, 1971, AM J ANAT, V130, P441, DOI 10.1002/aja.1001300406; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREPIN C, 1994, MOL CELL BIOL, V9, P5022; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HIRAKOW R, 1981, ANAT EMBRYOL, V163, P299, DOI 10.1007/BF00315706; HOOD LC, 1992, ANAT RECORD, V234, P291, DOI 10.1002/ar.1092340215; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSSE PRL, 1985, LAB INVEST, V53, P556; MURPHY ME, 1978, AM J ANAT, V151, P345, DOI 10.1002/aja.1001510304; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, AM J PATHOL, V143, P987; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; STRASSER P, 1992, GENBANK DIRECT SUBMI; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; ZANELLATO AMC, 1990, ARTERIOSCLEROSIS, V10, P996, DOI 10.1161/01.ATV.10.6.996	70	227	247	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13460	13469		10.1074/jbc.270.22.13460	http://dx.doi.org/10.1074/jbc.270.22.13460			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768949	hybrid			2022-12-27	WOS:A1995RB43900075
J	YAMAGATA, H; MASUZAWA, T; NAGAOKA, Y; OHNISHI, T; IWASAKI, T				YAMAGATA, H; MASUZAWA, T; NAGAOKA, Y; OHNISHI, T; IWASAKI, T			CUCUMISIN, A SERINE-PROTEASE FROM MELON FRUITS, SHARES STRUCTURAL HOMOLOGY WITH SUBTILISIN AND IS GENERATED FROM A LARGE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; DENATURED SUBTILISIN; PRO-SEQUENCE; GENE; EXPRESSION; PROTEINS; CLONING; SECRETION; PEPTIDE	Cucumisin is a thermostable alkaline serine protease that is found in the juice of melon fruits (Cucumis melo L.). We have determined the complete nucleotide sequence of a cucumisin cDNA (2,552 nucleotides) and deduced the corresponding amino acid sequence, The open reading frame of the cDNA consists of 731 codons and encodes a large precursor (molecular weight, 78,815) relative to the observed size of mature native cucumisin (67 kDa), Sequence comparisons reveal that cucumisin has several features in common with the microbial proteases of the subtilisin family, The highly conserved sequences to the proximal regions of the catalytic triad amino acids Asp, His, and Ser, together with the substrate binding site in subtilisin, can be found within the deduced amino acid sequence of the protease domain of the cucumisin precursor, Cucumisin is the first known plant protease with such characteristics. Examination of the primary structure of cucumisin revealed that it is synthesized as a precursor, consisting of four functional domains: a possible signal peptide (22 amino acid residues), an NH2-terminal pro-sequence (88 residues), a 54-kDa protease domain (505 residues), which is the active enzyme domain of the 67-kDa native cucumisin, and a 14-kDa COOH-terminal polypeptide (116 residues), which arises by limited autolysis of the 67-kDa native cucumisin, This structure of cucumisin suggests that it is probably synthesized as an inactive precursor.			YAMAGATA, H (corresponding author), KOBE UNIV,FAC AGR,BIOCHEM LAB,NADA KU,ROKKODAI CHO 1,KOBE,HYOGO 657,JAPAN.							BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHRISPEELS MJ, 1991, PLANT MOL BIOL, V2, P575; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; Glazer A., 1971, ENZYMES, P501; GRIERSON D, 1984, PLANT MOL BIOL, P22; GUNKEL FA, 1989, EUR J BIOCHEM, V179, P185, DOI 10.1111/j.1432-1033.1989.tb14539.x; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACOBS M, 1985, NUCLEIC ACIDS RES, V13, P8913, DOI 10.1093/nar/13.24.8913; KANEDA M, 1986, J BIOCHEM-TOKYO, V99, P569, DOI 10.1093/oxfordjournals.jbchem.a135513; KANEDA M, 1975, J BIOCHEM, V78, P1287, DOI 10.1093/oxfordjournals.jbchem.a131026; KANEDA M, 1977, PHYTOCHEMISTRY, V16, P345, DOI 10.1016/0031-9422(77)80061-7; KANEDA M, 1984, J BIOCHEM-TOKYO, V95, P825, DOI 10.1093/oxfordjournals.jbchem.a134674; KANEDA M, 1986, AGR BIOL CHEM TOKYO, V50, P2413, DOI 10.1080/00021369.1986.10867760; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROGERS SO, 1986, PLANT MOL BIOL, V5, P69; Ryan CA, 1981, BIOCH PLANTS, P321; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; TERADA I, 1990, J BIOL CHEM, V265, P6576; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; VERNET T, 1990, J BIOL CHEM, V265, P16661; VONHEIJNE G, 1991, PLANT MOL BIOL, V2, P583; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WU XC, 1990, J BIOL CHEM, V265, P6845; YAMAGATA H, 1989, AGR BIOL CHEM TOKYO, V53, P1009, DOI 10.1080/00021369.1989.10869404; YAMAGATA H, 1982, PLANT PHYSIOL, V70, P1094, DOI 10.1104/pp.70.4.1094; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	44	127	134	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32725	32731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806492				2022-12-27	WOS:A1994QA63800005
J	NAYERNIA, K; NIETER, S; KREMLING, H; OBERWINKLER, H; ENGEL, W				NAYERNIA, K; NIETER, S; KREMLING, H; OBERWINKLER, H; ENGEL, W			FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF THE TRANSCRIPTIONAL REGULATORY REGION OF THE PROACROSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; TRANSGENIC MICE; SPERMATOGENIC CELLS; FUSION GENES; ACROSIN; PROMOTER; DNA; PGK-2; LOCUS	Proacrosin, the zymogen form of the serine protease acrosin, is located within the acrosomal vesicle of mammalian spermatozoa and has been suggested to be involved in the fertilization process, In mouse and rat, expression of the proacrosin gene starts in pachytene spermatocytes and continues through the early stages of spermiogenesis, We have shown recently that 2.3 kilobase pairs of the 5'-flanking region of the rat proacrosin gene is sufficient to direct chloramphenicol acetyltransferase gene expression in a germ cell-specific and developmental stage-specific manner in the mouse, Additional transgenic lines have been generated which include two deletions in the 5'-flanking region and a tyrosinase minigene as marker for gene expression, Transgenic mice bearing these two truncated fragments showed different patterns of reporter gene expression, Transgenic lines (BM, B3, B2) harboring the 397-base pair (bp) fragment (from 45 to 442 bp upstream of ATG) showed no chloramphenicol acetyltransferase (CAT) activity in either testis or other tissues, but analysis via reverse transcription polymerase chain reaction confirmed low levels of reporter gene transcription in testis, Transgenic line TC bearing a longer fragment of 877 bp (from 45 to 922 bp upstream of ATG) showed a reporter gene expression and chloramphenicol acetyl-transferase enzyme activity which was identical to that found in mice harboring the 2.3-kilobase pair 5'-flanking region, The analysis of the CAT gene expression during testicular development showed diploid transcription and haploid translation, It can be concluded that all sequences required for a basic level of testis-specific transcription of transgene are present within the 397-bp fragment, and other DNA sequences located outside of the 397-bp fragment but present within the 877-bp fragment can function as enhancer elements. Two fragments within the 877-bp region were identified by gel retardation assays as binding exclusively to nuclear factor(s) from testis protein extracts. In both fragments we identified sequence elements which are present in the promoter region of the germ cell-specific genes for histone H2B and protamine 1, respectively.	UNIV GOTTINGEN,INST HUMAN GENET,D-37073 GOTTINGEN,GERMANY	University of Gottingen								BEERMANN F, 1991, NUCLEIC ACIDS RES, V19, P958, DOI 10.1093/nar/19.4.958; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CUNLIFFE V, 1990, GENOMICS, V8, P331, DOI 10.1016/0888-7543(90)90290-B; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EWULONU UK, 1993, DEVELOPMENT, V117, P89; FLORKE S, 1983, DIFFERENTIATION, V24, P250, DOI 10.1111/j.1432-0436.1983.tb01328.x; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANDEL MA, 1987, SPERMATOGENESIS GENE, P1; HANNAUER A, 1983, NUCLEIC ACIDS RES, V11, P3505; HOGAN B, 1986, MANIPULATING MOUSE E, P151; KALLAJOKI M, 1986, BIOL REPROD, V35, P157, DOI 10.1095/biolreprod35.1.157; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KLEMM U, 1991, HUM GENET, V87, P635; KREMER EJ, 1992, GENE, V110, P167, DOI 10.1016/0378-1119(92)90644-5; KREMLING H, 1991, GENOMICS, V11, P828, DOI 10.1016/0888-7543(91)90005-Y; Kremling H, 1991, DNA Seq, V2, P57, DOI 10.3109/10425179109008440; LATCHMAN DS, 1992, EUKARYOTIC TRANSCRIP, P16; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NAYERNIA K, 1992, MOL REPROD DEV, V31, P241, DOI 10.1002/mrd.1080310403; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SALEHIASHTIANI K, 1993, P NATL ACAD SCI USA, V90, P8886, DOI 10.1073/pnas.90.19.8886; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAMURA T, 1989, TECHNIQUE, V1, P33; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6761; WATANABE K, 1991, J BIOCHEM-TOKYO, V109, P828, DOI 10.1093/oxfordjournals.jbchem.a123466; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; ZINN SA, 1991, J BIOL CHEM, V266, P23850; [No title captured]	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32181	32186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798216				2022-12-27	WOS:A1994PX30400028
J	YAMAGUCHI, M; HAYASHI, Y; NISHIMOTO, Y; HIROSE, F; MATSUKAGE, A				YAMAGUCHI, M; HAYASHI, Y; NISHIMOTO, Y; HIROSE, F; MATSUKAGE, A			A NUCLEOTIDE-SEQUENCE ESSENTIAL FOR THE FUNCTION OF DRE, A COMMON PROMOTER ELEMENT FOR DROSOPHILA DNA REPLICATION-RELATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; GROWTH-REGULATION; BUDDING YEAST; EXPRESSION; MELANOGASTER; PROTEIN; TRANSCRIPTION; CYCLE; BINDING	Promoter regions of the Drosophila proliferating cell nuclear antigen (PCNA) gene and the DNA polymerase alpha 180-kDa catalytic subunit gene contain a common 8 base pair (bp) promoter element, 5'-TATCGATA (DRE, Drosophila DNA replication-related element), We have generated various base substitutions and internal deletions in and around DRE (nucleotide positions -93 to -100 with respect to the transcription initiation site) of the PCNA gene in vitro and subsequently examined their effects on the binding to DREF (DRE-binding factor) and PCNA gene promoter activity in cultured Drosophila Kc cells as well as in living flies, Gel mobility shift assays using nuclear extracts of Kc cells with and without competitor DNA fragments carrying the mutations indicated that the 10-bp sequence from positions -91 to -100 is essential for complex formation with DREF, Transient expression assays of chloramphenicol acetyltransferase (CAT) in Kc cells transfected with PCNA promoter-CAT fusion genes carrying the mutations revealed that the g-bp sequence from -93 to -100 is essential for activation of the promoter in Kc cells, Examination of lacZ expression hom PCNA promoter-lacZ fusion genes carrying the mutations, introduced into flies by germ-line transformation, revealed that the 8-bp sequence is also important for DRE function during development, However, we obtained two exceptional mutations in the 8-bp sequence that did not or only marginally affected the PCNA gene promoter activity in transgenic flies, Both of these mutations effectively reduced the promoter activity in CAT transient expression assay in He cells and the binding to DREF in vitro, Therefore, the 8-bp sequence requirement for DRE function appears to be less stringent in Living flies than in the cultured cell or in vitro cases.			YAMAGUCHI, M (corresponding author), AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							BASERGA R, 1991, J CELL SCI, V98, P433; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1994, JPN J CANCER RES, V85, P1; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEVINS JR, 1992, SCIENCE, V258, P424; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; [No title captured]	27	55	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15808	15814		10.1074/jbc.270.26.15808	http://dx.doi.org/10.1074/jbc.270.26.15808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797583	hybrid			2022-12-27	WOS:A1995RG53800056
J	FROELICHAMMON, SJ; PATCHAN, MW; OSHEROFF, N; THOMPSON, RB				FROELICHAMMON, SJ; PATCHAN, MW; OSHEROFF, N; THOMPSON, RB			TOPOISOMERASE-II BINDS TO ELLIPTICINE IN THE ABSENCE OR PRESENCE OF DNA - CHARACTERIZATION OF ENZYME DRUG-INTERACTIONS BY FLUORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; INTERCALATING AGENTS; ANTITUMOR DRUGS; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; BIOLOGICAL PROPERTIES; ANTINEOPLASTIC DRUGS; NUCLEOTIDE-SEQUENCE; FISSION YEAST; CELL-NUCLEI	Although a number of drugs currently in use for the treatment of human cancers act by stimulating topoisomerase II-mediated DNA breakage, little is known regarding interactions between these agents and the enzyme. To further define the mechanism of drug action, interactions between ellipticine (an intercalative drug with clinical relevance) and yeast topoisomerase II were characterized. By utilizing a yeast genetic system, topoisomerase II was identified as the primary cellular target of the drug. Furthermore, ellipticine did not inhibit enzyme-mediated DNA religation, suggesting that it stimulates DNA breakage by enhancing the forward rate of cleavage. Finally, ellipticine binding to DNA, topoisomerase II, and the enzyme . DNA complex was assessed by steady-state and frequency domain fluorescence spectroscopy. As determined by changes in fluorescence intensity and emission maximum wavelength, and by lifetime analysis, only the protonated species of ellipticine bound to a double stranded 40-mer oligonucleotide containing a topoisomerase II cleavage site (K-D approximate to 65 nM). In contrast, predominantly deprotonated ellipticine bound to the enzyme . DNA complex (K-D approximate to 1.5 mu M) or to the enzyme in the absence of nucleic acids (K-D approximate to 160 nM). These findings suggest that ellipticine interacts directly with topoisomerase II and that the enzyme dictates the ionic state of the drug in the ternary complex. A model is presented in which the topoisomerase II . ellipticine DNA complex is formed via initial drug binding to either the enzyme or DNA.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	Vanderbilt University; University System of Maryland; University of Maryland Baltimore				Patchan, Marcia/0000-0002-0485-0403	NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUCLAIR C, 1984, J MED CHEM, V27, P1161, DOI 10.1021/jm00375a013; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V58, P1; BUZDAR AU, 1990, ONCOLOGY, V47, P101; CHARCOSSET JY, 1985, CANCER RES, V45, P4229; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHOW KC, 1988, MOL PHARMACOL, V34, P467; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, ANTIMICROB AGENTS CH, V37, P2599, DOI 10.1128/AAC.37.12.2599; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DAVENPORT D, 1981, FLUORESCENCE SPECTRO, P203; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; GIACCONE G, 1994, ANTICANCER RES, V14, P269; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021/ja01517a031; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOOPER DC, 1989, REV INFECT DIS S5, V11, P902; HOOPER DC, 1993, DRUGS, V3, P8; JURAYJ J, 1994, J MED CHEM, V37, P2190, DOI 10.1021/jm00040a011; KATTAN J, 1994, AM J CLIN ONCOL-CANC, V17, P242, DOI 10.1097/00000421-199406000-00013; KOHN KW, 1975, CANCER RES, V35, P71; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LARUE L, 1988, J MED CHEM, V31, P1951, DOI 10.1021/jm00118a014; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MONNOT M, 1991, J BIOL CHEM, V266, P1820; NABIEV I, 1994, BIOCHEMISTRY-US, V33, P9013, DOI 10.1021/bi00196a020; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1993, CANCER RES, V53, P89; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PAOLETTI C, 1981, CANCER TREAT REP, V65, P107; PEREZ RP, 1992, INVEST NEW DRUG, V10, P99, DOI 10.1007/BF00873125; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; POMMIER Y, 1984, BIOCHEMISTRY-US, V23, P3194, DOI 10.1021/bi00309a013; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V26, P14585; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; ROUESSE J, 1993, EUR J CANCER, V29A, P856, DOI 10.1016/S0959-8049(05)80424-1; RUCKDESCHEL JC, 1992, J MED CHEM, V35, P4854, DOI 10.1021/jm00104a011; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHNEIDER E, 1989, BIOCHEM PHARMACOL, V38, P263, DOI 10.1016/0006-2952(89)90036-1; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SORACE RA, 1978, CHEM-BIOL INTERACT, V23, P379, DOI 10.1016/0009-2797(78)90098-4; SORENSEN BS, 1990, BIOCHEMISTRY-US, V29, P9507; STEINER RF, 1982, EXCITED STATES BOPOL, P203; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMPSON RB, 1988, ANAL CHEM, V60, P670, DOI 10.1021/ac00158a014; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; WAHL P, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P417, DOI 10.1073/pnas.65.2.417; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WATT PM, BIOCH J; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WOODWIN S, 1959, J AM CHEM SOC, V81, P4434; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; ZEGAR I, 1989, CHEM-BIOL INTERACT, V72, P277, DOI 10.1016/0009-2797(89)90004-5; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23; [No title captured]	74	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14998	15004		10.1074/jbc.270.25.14998	http://dx.doi.org/10.1074/jbc.270.25.14998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797481	hybrid			2022-12-27	WOS:A1995RE66600026
J	KETCHNER, SL; DRAPIER, D; OLIVE, J; GAUDRIAULT, S; GIRARDBASCOU, J; WOLLMAN, FA				KETCHNER, SL; DRAPIER, D; OLIVE, J; GAUDRIAULT, S; GIRARDBASCOU, J; WOLLMAN, FA			CHLOROPLASTS CAN ACCOMMODATE INCLUSION-BODIES - EVIDENCE FROM A MUTANT OF CHLAMYDOMONAS-REINHARDTII DEFECTIVE IN THE ASSEMBLY OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; II PROTEIN COMPLEX; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BODY FORMATION; NUCLEAR GENES; LARGE SUBUNIT; DNA-SEQUENCE; EXPRESSION; PHOTOPHOSPHORYLATION	We identified two neighboring missense mutations in the chloroplast atpA gene which are responsible for the defect of ATP synthase assembly in the FUD16 mutant from Chlamydomonas reinhardtii. The two corresponding amino acid substitutions, Ile(184) --> Asn and Asn(186) --> Tyr, occurred at strictly conserved sites among the alpha and beta subunits of (C)F-1 complexes from bacteria, mitochondria, and chloroplasts. The altered region in the alpha polypeptide chain is located 7 amino acids downstream of the P-loop, which forms most of the conserved nucleotide binding site. Although the resulting chloroplast mutant fails to accumulate most of the ATP synthase subunits, it displays an increased intracellular content in both the cy and beta subunits. We demonstrate that the two subunits do not bind to the thylakoid membranes but associate and overaccumulate in the chloroplast stroma as inclusion bodies. Increased rates of synthesis of the two subunits in the mutant point to an early interaction between the two subunits during their biogenesis.	INST BIOL PHYSICOCHIM, SERV PHOTOSYNTH, CNRS, URA 1187, F-75005 PARIS, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, MICROSCOPIE ELECTR LAB, CNRS, PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			, Gaudriault/AAK-9152-2021	, Gaudriault/0000-0003-2789-4959				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; ASCHENBRENNER M, 1993, FEBS LETT, V323, P27, DOI 10.1016/0014-5793(93)81441-2; ATTEIA A, 1994, CR ACAD SCI III-VIE, V317, P11; BEECHEY RB, 1975, BIOCHEM J, V148, P533, DOI 10.1042/bj1480533; BINDER M, 1991, EUR J CELL BIOL, V54, P305; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; DRON M, 1983, PLASMID, V9, P321, DOI 10.1016/0147-619X(83)90009-4; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; KIM JM, 1991, J BIOL CHEM, V266, P14931; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; LEMAIRE C, 1989, J BIOL CHEM, V264, P10228; LEU S, 1992, PLANT MOL BIOL, V18, P613, DOI 10.1007/BF00040681; LEVINE RP, 1960, ANNU REV MICROBIOL, V14, P197, DOI 10.1146/annurev.mi.14.100160.001213; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NICOLAS L, 1993, FEMS MICROBIOL LETT, V106, P275, DOI 10.1111/j.1574-6968.1993.tb05976.x; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1987, FEMS MICROBIOL LETT, V46, P13, DOI 10.1111/j.1574-6968.1987.tb02449.x; Sambrook J, 1989, MOL CLONING LABORATO; SMART EJ, 1993, J BIOENERG BIOMEMBR, V25, P275, DOI 10.1007/BF00762588; STOLLAR NE, 1994, PLANT PHYSIOL, V105, P1167, DOI 10.1104/pp.105.4.1167; TAYLOR G, 1986, BIO-TECHNOL, V4, P553, DOI 10.1038/nbt0686-553; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VALLON O, 1985, FEBS LETT, V183, P245, DOI 10.1016/0014-5793(85)80786-9; VANLOON APGM, 1983, GENE, V26, P261, DOI 10.1016/0378-1119(83)90196-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065	47	14	14	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15299	15306		10.1074/jbc.270.25.15299	http://dx.doi.org/10.1074/jbc.270.25.15299			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797517	hybrid			2022-12-27	WOS:A1995RE66600068
J	KOROTCHKINA, LG; PATEL, MS				KOROTCHKINA, LG; PATEL, MS			MUTAGENESIS STUDIES OF THE PHOSPHORYLATION SITES OF RECOMBINANT HUMAN PYRUVATE-DEHYDROGENASE - SITE-SPECIFIC REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; PHOSPHATE PHOSPHATASE; COMPLEX; HEART; KINASE; COMPONENT; BINDING; PYROPHOSPHATE; MUSCLE	Mammalian pyruvate dehydrogenase (alpha(2) beta(2)) (E(1)) is regulated by phosphorylation-dephosphorylation, catalyzed by the E(1)-kinase and the phospho-E(1)-phosphatase. Using site-directed mutagenesis of the three phosphorylation sites (sites 1, 2, and 3) on E(1) alpha, several human E(1) mutants were made with single, double, and triple mutations by changing Ser to Ala, Mutation at site 1 but not at sites 2 and/or 3 decreased E(1) specific activity and also increased K-m values for thiamin pyrophosphate and pyruvate. Sites 1, 2, and 3 in the E(1) mutants were phosphorylated either individually or in the presence of the other sites by the dihydrolipoamide acetyltransferase-protein X-E(1) kinase indicating a site-independent mechanism of phosphorylation. Phosphorylation of each site resulted in complete inactivation of the E(1). However, the rates of phosphorylation and inactivation were site-specific. Sites 1, 2, and 3 were dephosphorylated either individually or in the presence of the other sites by the phospho-E(1)-phosphatase resulting in complete reactivation of the E(1). The rates of dephosphorylation and reactivation were similar for sites 1, 2, and 3, indicating a random dephosphorylation mechanism.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI MS, 1993, J BIOL CHEM, V268, P22353; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JR, 1977, BIOCHEM BIOPH RES CO, V74, P1667, DOI 10.1016/0006-291X(77)90636-2; CATE RL, 1978, J BIOL CHEM, V253, P496; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; KERBEY AL, 1985, BIOCHEM J, V231, P523, DOI 10.1042/bj2310523; KERBEY AL, 1981, BIOCHEM J, V195, P51, DOI 10.1042/bj1950051; KERR DS, 1987, PEDIATR RES, V22, P312, DOI 10.1203/00006450-198709000-00015; Khailova L, 1990, BIOCH PHYSL TDP ENZY, P251; Khailova L S, 1977, Biokhimiia, V42, P113; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1985, BIOCHEM INT, V11, P509; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; Korochkina L G, 1993, Biokhimiia, V58, P1503; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; RAHMATULLAH M, 1986, J BIOL CHEM, V261, P6515; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; SALE GJ, 1982, BIOCHEM J, V203, P99, DOI 10.1042/bj2030099; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; SUGDEN PH, 1978, BIOCHEM J, V169, P433, DOI 10.1042/bj1690433; SUGDEN PH, 1979, BIOCHEM J, V181, P419, DOI 10.1042/bj1810419; TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	37	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14297	14304		10.1074/jbc.270.24.14297	http://dx.doi.org/10.1074/jbc.270.24.14297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782287	hybrid			2022-12-27	WOS:A1995RD45500013
J	SUDOL, M; BORK, P; EINBOND, A; KASTURY, K; DRUCK, T; NEGRINI, M; HUEBNER, K; LEHMAN, D				SUDOL, M; BORK, P; EINBOND, A; KASTURY, K; DRUCK, T; NEGRINI, M; HUEBNER, K; LEHMAN, D			CHARACTERIZATION OF THE MAMMALIAN YAP (YES-ASSOCIATED PROTEIN) GENE AND ITS ROLE IN DEFINING A NOVEL PROTEIN MODULE, THE WW DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; LIGAND-BINDING SITE; SH3 DOMAINS; C-SRC; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SMALL REGION; KINASE-C; SEARCH; CDNA	We report cDNA cloning and characterization of the human and mouse orthologs of the chicken YAP (Yes-associated protein) gene which encodes a novel protein that binds to the SH3 (Src homology 3) domain of the Yes proto-oncogene product. Sequence comparison between mouse, human, and chicken YAP proteins showed an inserted sequence in the mouse YAP that represented an imperfect repeat of an upstream sequence. Further analysis of this sequence revealed a putative protein module that is found in various structural, regulatory, and signaling molecules in yeast, nematode, and mammals including human dystrophin. Because one of the prominent features of this sequence motif is two tryptophans (W), we named it the WW domain (Bork, P., and Sudol, M. (1994) Trends Biochem. Sci. 19, 531-533). Since its delineation, more proteins have been shown to contain this domain, and we report here on the widespread distribution of the WW module and present a discussion of its possible function. We have also shown that the human YAP gene is well conserved among higher eukaryotes, but it may not be conserved in yeast. Its expression at the RNA level in adult human tissues is nearly ubiquitous, being relatively high in placenta, prostate, ovary, and testis, but is not detectable in peripheral blood leukocytes. Using fluorescence in situ hybridization on human metaphase chromosomes and by analyzing rodent-human hybrids by Southern blot hybridization and polymerase chain reaction amplification, we mapped the human YAP gene to chromosome band 11q13, a region to which the multiple endocrine neoplasia type I gene has been mapped.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	European Molecular Biology Laboratory (EMBL); Jefferson University	SUDOL, M (corresponding author), ROCKEFELLER UNIV,MOLEC ONCOL LAB,BOX 169,1230 YORK AVE,NEW YORK,NY 10021, USA.		Negrini, Massimo/J-2377-2016; Bork, Peer/F-1813-2013	Negrini, Massimo/0000-0002-0007-1920; Bork, Peer/0000-0002-2627-833X	NCI NIH HHS [CA01605, CA45757, CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BORK P, 1991, FEBS LETT, V286, P47, DOI 10.1016/0014-5793(91)80937-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; CICCHETTI P, 1992, SCIENCE, V267, P803; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FUJIMORI M, 1992, AM J HUM GENET, V50, P399; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUEBNER K, 1991, AM J HUM GENET, V48, P726; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUIBREGTSE JM, 1995, IN PRESS COLD SPRING, V59; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; LI N, 1993, NATURE, V63, P85; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOU ZW, 1993, GENE CHROMOSOME CANC, V7, P15, DOI 10.1002/gcc.2870070104; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAKAMURA Y, 1989, AM J HUM GENET, V44, P751; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OBRIEN SJ, 1993, GENOME PR R, P758; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; RHODE K, 1993, CABIOS, V9, P183; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; ROBERTS RG, 1994, HUM MUTAT, V4, P1, DOI 10.1002/humu.1380040102; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHIMKE RN, 1986, NEW ENGL J MED, V314, P1315, DOI 10.1056/NEJM198605153142010; SCHINZEL A, 1993, GENOME PRIORITY REPO, V1, P658; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TINSLEY MJ, 1994, P NATL ACAD SCI USA, V91, P8307; WENG Z, 1993, J BIOL CHEM, V2686, P14956; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	66	266	280	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14733	14741		10.1074/jbc.270.24.14733	http://dx.doi.org/10.1074/jbc.270.24.14733			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782338	hybrid			2022-12-27	WOS:A1995RD45500075
J	VANHORSSEN, AM; VANDENHURK, WH; BAILYES, EM; HUTTON, JC; MARTENS, GJM; LINDBERG, I				VANHORSSEN, AM; VANDENHURK, WH; BAILYES, EM; HUTTON, JC; MARTENS, GJM; LINDBERG, I			IDENTIFICATION OF THE REGION WITHIN THE NEUROENDOCRINE POLYPEPTIDE 7B2 RESPONSIBLE FOR THE INHIBITION OF PROHORMONE CONVERTASE PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY POLYPEPTIDE; PROCESSING ENDOPROTEASES; ENDOCRINE PROTEIN; SEQUENCE; CELLS; CLONING; RAT; PROOPIOMELANOCORTIN; PROINSULIN; VESICLES	The highly conserved polypeptide 7B2 and the subtilisin-related prohormone convertases PC1/PC3 and PC2 are broadly distributed in neurons and endocrine cells and are localized to secretory granules. We recently showed that recombinant 7B2 is in vitro a potent inhibitor of PC2 activity, but not of PC1/PC3, and that newly synthesized 7B2 is transiently associated with proPC2 in vivo. In the present study, in vitro mutagenesis was used to identify the region within the 7B2 sequence responsible for the inhibition of PC2. Mutant proteins were produced in a prokaryotic expression system and their effects on PC1/PC3 and PC2 activities were studied by two different in vitro enzyme assays. None of the 7B2 mutant proteins inhibited PC1/PC3 activity. Truncation studies revealed that a short segment within the COOH-terminal portion of 7B2 is critical for its inhibitory effect on PC2. This segment contains a pair of basic amino acid residues which may represent a recognition motif for PC2. Single amino acid substitutions within this Lys(171)-Lys(172) site strongly diminished and a double mutation abolished the inhibitory potency of 7B2. Our results indicate that, although amino acid residues directly surrounding this dibasic pair also contribute to PC2 inhibition, the Lys(171)-Lys(172) site is particularly important for the ability of 7B2 to inhibit PC2.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; CATHOLIC UNIV NIJMEGEN, DEPT ANIM PHYSIOL, 6525 ED NIJMEGEN, NETHERLANDS; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND	Louisiana State University System; Radboud University Nijmegen; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Martens, Gerard JM/D-1925-2010; Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, DA05084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; CROWTHER NJ, 1994, PROTEIN ENG, V7, P137, DOI 10.1093/protein/7.1.137; CULLINAN WE, 1991, ENZYME, V45, P285, DOI 10.1159/000468902; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1987, J NEUROCHEM, V49, P1810, DOI 10.1111/j.1471-4159.1987.tb02440.x; LAZURE C, 1991, INT J PEPT PROT RES, V38, P392; LINDBERG I, 1995, IN PRESS BIOCHEMISTR, V34; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PAQUET L, 1994, J BIOL CHEM, V269, P19279; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SIGAFOOS J, 1993, CELL MOL NEUROBIOL, V13, P271, DOI 10.1007/BF00733755; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; VIEAU D, 1991, J NEUROENDOCRINOL, V3, P229, DOI 10.1111/j.1365-2826.1991.tb00268.x; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; YI Z, 1993, J BIOL CHEM, V268, P5615	33	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14292	14296						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782286				2022-12-27	WOS:A1995RD45500012
J	AROCA, P; BOTTARO, DP; ISHIBASHI, T; AARONSON, SA; SANTOS, E				AROCA, P; BOTTARO, DP; ISHIBASHI, T; AARONSON, SA; SANTOS, E			HUMAN DUAL-SPECIFICITY PHOSPHATASE VHR ACTIVATES MATURATION PROMOTION FACTOR AND TRIGGERS MEIOTIC MATURATION IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE; ONCOGENE PRODUCT; M-PHASE; CELL-DIVISION; RAS PROTEINS; INDUCTION; EXTRACTS; CDC25; MPF	Bacterially expressed, dual specificity phosphatase VHR protein induced germinal vesicle breakdown (GVBD) when microinjected into Xenopus oocytes, albeit with slower kinetics than that observed in progesterone- or insulin-induced maturation, A mutant VHR protein missing an essential cysteine residue for its in vitro phosphatase activity completely lacked activity in injected oocytes, VHR injection done in conjunction with progesterone or insulin treatment resulted in highly synergized GVBD responses showing much faster kinetics than that produced by VHR or either hormone alone, The delayed kinetics of VHR-induced GVBD and the synergistic responses obtained in the presence of hormones suggested that this protein may be promoting G(2)/M transition by weakly mimicking the action of cdc25, the dual specificity phosphatase that physiologically activates the maturation promotion factor. Various experimental observations are consistent with such a role for the injected VHR in oocytes: 1) as opposed to hormone-treated oocytes, histone H1 kinase activation is not preceded by MAPK activation in the process of GVBD in VHR-injected oocytes; 2) incubation of purified VHR with highly concentrated cell-free extracts of untreated oocytes resulted in activation of histone H1 kinase activity in the lysates; 3) coinjection of VHR with activated Ras proteins resulted in synergized responses, faster than those produced by either protein alone; 4) coinjection of VHR with the purified aminoterminal SH2 domain of the p85 subunit of phosphatidylinositol 3-kinase (which blocks insulin-induced GVBD) does not affect VHR-induced maturation. The biological actions of VHR in oocytes clearly distinguish it from other dual specificity phosphatases, which have shown inhibitory effects when tested in oocytes, We speculate that VHR may represent a dual specificity phosphatase responsible for activation of cdk-cyclin complex(es) at a still undetermined stage of the cell cycle.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017; Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Aroca, Pilar/0000-0002-7557-6931; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALESSI DR, 1993, ONCOGENE, V8, P2015; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; ERIKSON E, 1990, J BIOL CHEM, V264, P13711; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRAZIANI G, 1992, ONCOGENE, V7, P229; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1993, P NATL ACAD SCI USA, V89, P12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARX J, 1994, SCIENCE, V263, P1093, DOI 10.1126/science.8108726; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1992, METHOD CELL BIOL, V36, P581; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	47	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14229	14234		10.1074/jbc.270.23.14229	http://dx.doi.org/10.1074/jbc.270.23.14229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775484	Green Submitted, hybrid			2022-12-27	WOS:A1995RC44800092
J	BAECKSTROM, D; ZHANG, K; ASKER, N; RUETSCHI, U; EK, M; HANSSON, GC				BAECKSTROM, D; ZHANG, K; ASKER, N; RUETSCHI, U; EK, M; HANSSON, GC			EXPRESSION OF THE LEUKOCYTE-ASSOCIATED SIALOGLYCOPROTEIN CD43 BY A COLON-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; WISKOTT-ALDRICH SYNDROME; MAJOR SIALOGLYCOPROTEIN; HUMAN-PLASMA; TUMOR-CELLS; LEUKOSIALIN; SIALOPHORIN; GLYCOPROTEINS; ADHESION; PROTEINS	The colon adenocarcinoma cell line COLO 205 secretes L-CanAg, a mucin-like glycoprotein carrying the carcinoma-associated sialyl-Lewis a carbohydrate epitope. In an attempt to identify its apoprotein, an NH2-terminal peptide sequence was obtained from purified L-CanAg. In all interpretable positions, this sequence showed 100% identity to the NH2-terminal of human CD43 (leukosialin, sialophorin), a plasma membrane bound sialoglycoprotein hitherto only identified in leukocytes and other hematopoietic cells. An antiserum against deglycosylated L-CanAg and an anti-CD43 antiserum both immunoprecipitated a 61-kDa band, interpreted as the CD43 precursor, from COLO 205 cells as well as hom the known CD43-expressing cell line HL-60. Results from immunoprecipitations following pulse-chase experiments and tunicamycin treatments were in agreement with earlier studies on the CD43 precursor. RNA blot analysis confirmed the expression of CD43 by the COLO 205 cell line, whereas three other colon carcinoma cell lines were negative. The glycosylation-dependent monoclonal antibody Leu-22, which recognizes leukocyte CD43, failed to bind L-CanAg, probably due to its much more extensive glycosylation, We conclude that L-CanAg is the secreted extracellular domain of a novel glycoform of CD43 and that CD43, if expressed in other carcinoma cells, may have escaped notice in studies relying on glycosylation-dependent monoclonal antibodies against leukocyte CD43.	GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	BAECKSTROM, D (corresponding author), GOTHENBURG UNIV, DEPT MED BIOCHEM, MEDICINAREGATAN 9A, S-41390 GOTHENBURG, SWEDEN.		Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				[Anonymous], 1994, PROGRAM MANUAL WISCO; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1993, CANCER RES, V53, P755; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARRAWAY KL, 1992, J CELL SCI, V103, P299; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GUM JR, 1987, J BIOL CHEM, V262, P1092; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; IOACHIM HL, 1994, INT J CANCER, P132; JOHANSSON C, 1991, TUMOR BIOL, V12, P159, DOI 10.1159/000217701; KRENOVA D, 1993, TRANSPL P, V25, P2797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; REMOLDODONNELL E, 1987, BIOCHEMISTRY-US, V26, P3908, DOI 10.1021/bi00387a025; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; SCHMID K, 1980, J BIOL CHEM, V255, P3221; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; WONG RCK, 1990, J IMMUNOL, V144, P1455; ZHANG K, 1994, INT J CANCER, V59, P823, DOI 10.1002/ijc.2910590619	39	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13688	13692		10.1074/jbc.270.23.13688	http://dx.doi.org/10.1074/jbc.270.23.13688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775421	hybrid			2022-12-27	WOS:A1995RC44800018
J	FAULKNER, KM; BONAVENTURA, C; CRUMBLISS, AL				FAULKNER, KM; BONAVENTURA, C; CRUMBLISS, AL			A SPECTROELECTROCHEMICAL METHOD FOR DIFFERENTIATION OF STERIC AND ELECTRONIC EFFECTS IN HEMOGLOBINS AND MYOGLOBINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE BINDING; METHYLENE-BLUE; OXYGEN; AUTOXIDATION; OXIDATION; REDUCTION; STEREOCHEMISTRY; AUTOOXIDATION; MECHANISM; SITE	Spectroelectrochemical techniques are described which enable us to compare anion effects on redox curves of structurally distinct hemoglobins with oxygenation curves obtained under equivalent conditions. Nernst plots for tetrameric vertebrate Hbs show evidence of cooperativity, with the T state conformation more resistant to oxidation than the R state. Anions shift the conformation toward the T state and decrease the ease of oxidation, with variations in anion sensitivity similar to those observed in oxygen equilibria. Oxygen binding, unlike electron exchange, is known to be subject to steric constraints that vary considerably in natural and engineered hemoglobins that have differences in the distal residues of the heme pocket. Since oxidation curves are not subject to steric hindrance, anion-induced differences between the oxidation and oxygenation curves can be indicative of anion-induced alterations in the stereochemistry of the heme pocket that alters the ease of ligand entry or exit. Addition of inositol hexaphosphate to solutions of Hb A in 0.2 M nitrate generates such differences: the ease of electron abstraction from deoxy (T state) Hb A is unaffected, while, as previously reported, the oxygenation of deoxy (T state) Hb A is greatly hindered. The difference between inositol hexaphosphate effects on initial stages of oxidation and oxygenation indicates that the explanation for ''multiple T states'' in oxygen binding lies in the ability of the polyanion to greatly increase steric hindrance to ligand entry, without appreciable changes in the electronic features of the heme environment.	DUKE UNIV,DEPT CHEM,DURHAM,NC 27708; DUKE UNIV,SCH ENVIRONM,MARINE LAB,BEAUFORT,NC 28516	Duke University; Duke University								ABRAHAM EC, 1975, J BIOL CHEM, V250, P3929; ALAYASH AI, 1992, ARCH BIOCHEM BIOPHYS, V298, P114, DOI 10.1016/0003-9861(92)90101-2; ANTONINI E, 1964, J BIOL CHEM, V239, P907; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1964, J BIOL CHEM, V239, P2340; BRUNORI M, 1968, J BIOL CHEM, V243, P2950; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CHANG CK, 1975, P NATL ACAD SCI USA, V72, P1166, DOI 10.1073/pnas.72.3.1166; DESBOIS A, 1975, J MOL BIOL, V92, P479, DOI 10.1016/0022-2836(75)90293-4; DICERA E, 1987, BIOCHEMISTRY-US, V26, P6494, DOI 10.1021/bi00394a031; DONG SJ, 1989, BIOELECTROCH BIOENER, V21, P233, DOI 10.1016/0302-4598(89)85003-2; EDELSTEIN SJ, 1975, J BIOL CHEM, V250, P961; ELLIS WR, 1986, THESIS CALTECH PASAD; FULTZ ML, 1982, ANAL CHIM ACTA, V140, P1, DOI 10.1016/S0003-2670(01)95447-9; GEIBEL J, 1978, J AM CHEM SOC, V100, P3575, DOI 10.1021/ja00479a047; GREENWALD RA, 1985, CRC HDB METHODS OXYG, P137; HEINEMAN WR, 1975, ANAL CHEM, V47, P79, DOI 10.1021/ac60351a001; Imai K., 1982, ALLOSTERIC EFFECTS H; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; Kiese M., 1974, METHEMOGLOBINEMIA CO; KRISTENSEN EW, 1991, J ELECTROANAL CHEM, V309, P61, DOI 10.1016/0022-0728(91)87004-N; LINSTROM T, 1973, BIOCHEMISTRY-US, V12, P134; MATTHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; OLSON JS, 1976, P NATL ACAD SCI USA, V73, P1140, DOI 10.1073/pnas.73.4.1140; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; Perrella M, 1981, Methods Enzymol, V76, P133; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1990, MECHANISMS COOPERATI; REISBERG PI, 1980, J BIOL CHEM, V255, P4144; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SONG SH, 1988, BIOELECTROCH BIOENER, V19, P337, DOI 10.1016/0302-4598(88)80014-X; SUSLICK KS, 1984, J AM CHEM SOC, V106, P4522, DOI 10.1021/ja00328a036; Taylor JF, 1942, J BIOL CHEM, V144, P15; TAYLOR JOHN FULLER, 1939, JOUR BIOL CHEM, V131, P649; TRAYLOR TG, 1980, J AM CHEM SOC, V102, P5939, DOI 10.1021/ja00538a055; TRAYLOR TG, 1982, ANNU REV BIOPHYS BIO, V11, P105, DOI 10.1146/annurev.bb.11.060182.000541; WINTERBOURN CC, 1985, ENVIRON HEALTH PERSP, V64, P321, DOI 10.2307/3430020; WOPSCHALL RH, 1967, ANAL CHEM, V39, P1527, DOI 10.1021/ac50156a019; YE JN, 1988, ANAL CHEM, V60, P2263, DOI 10.1021/ac00171a021	49	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13604	13612		10.1074/jbc.270.23.13604	http://dx.doi.org/10.1074/jbc.270.23.13604			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775411	hybrid			2022-12-27	WOS:A1995RC44800007
J	LI, QX; EVIN, G; SMALL, DH; MULTHAUP, G; BEYREUTHER, K; MASTERS, CL				LI, QX; EVIN, G; SMALL, DH; MULTHAUP, G; BEYREUTHER, K; MASTERS, CL			PROTEOLYTIC PROCESSING OF ALZHEIMERS-DISEASE BETA-A4 AMYLOID PRECURSOR PROTEIN IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN BRAIN; CALPAIN; IDENTIFICATION; PEPTIDE; CALCIUM; CELLS; INHIBITOR; PURIFICATION; EXPRESSION	The processing of amyloid precursor protein (APP) and production of beta A4 amyloid are events likely to influence the development and progression of Alzheimer's disease, since beta A4 is the major constituent of amyloid deposited in this disorder. Our previous studies showed that human platelets contain full-length APP (APP(FL)) and are a suitable substrate to study normal APP processing, In the present study, we show that a 22-kDa beta A4-containing carboxyl-terminal fragment (22-CTF) of APP is present in unstimulated platelets. Both APP(FL) and 22-CTF are proteolytically degraded when platelets are activated with thrombin, collagen, or calcium ionophore A23187. Complete cleavage of APP(FL) and 22-CTF require the presence of extracellular calcium, Following stimulation in the presence of calcium, a new CTF of 17 kDa is generated, and the NH2-terminal epitope of beta A4 amyloid is lost. Preincubation of platelets with the cell-permeable cysteine protease inhibitors calpeptin, (2S,3S)-trans-epoxysuccinyl-L-leucyl-amido-3-methylbutane ethyl ester (E64d), Na-alpha-p-tosyl-L-lysine chloromethyl ketone, or calcium chelator EGTA before platelet stimulation inhibits the degradation of both APP(FL) and 22-CTF. Divalent metal ions including zinc, copper, and cobalt inhibit the degradation of APP(FL) and 22-CTF. This study suggests that a calcium-dependent neutral cysteine protease is involved in the proteolytic processing of an amyloidogenic species of APP in human platelets.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL PK HOSP,MENTAL HLTH RES INST VICTORIA,PARKVILLE,VIC 3052,AUSTRALIA; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY	University of Melbourne; Ruprecht Karls University Heidelberg			Evin, Genevieve M/E-5891-2013					ARIYOSHI H, 1991, BIOCHEM INT, V23, P1019; ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FURUKAWA K, 1994, BRAIN RES, V662, P259, DOI 10.1016/0006-8993(94)90822-2; GARDELLA JE, 1992, LAB INVEST, V67, P303; GHISO J, 1994, NEUROSCI LETT, V171, P213, DOI 10.1016/0304-3940(94)90642-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNOPS J, 1992, J BIOL CHEM, V267, P16022; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; MATSUMOTO A, 1993, EUR J BIOCHEM, V217, P21, DOI 10.1111/j.1432-1033.1993.tb18213.x; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCGOWAN EB, 1983, ARCH BIOCHEM BIOPHYS, V227, P287, DOI 10.1016/0003-9861(83)90373-9; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; ODA A, 1993, J BIOL CHEM, V268, P12603; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1991, NEUROSCI LETT, V121, P239, DOI 10.1016/0304-3940(91)90694-O; PHILLIPS DR, 1977, J BIOL CHEM, V252, P5602; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHLOSSMACHER MG, 1992, NEUROBIOL AGING, V13, P421, DOI 10.1016/0197-4580(92)90117-G; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I; YOSHIDA N, 1983, J BIOL CHEM, V258, P7168; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	66	104	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14140	14147		10.1074/jbc.270.23.14140	http://dx.doi.org/10.1074/jbc.270.23.14140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775475	hybrid			2022-12-27	WOS:A1995RC44800080
J	RINDISBACHER, L; COTTET, S; WITTEK, R; KRAEHENBUHL, JP; CORTHESY, B				RINDISBACHER, L; COTTET, S; WITTEK, R; KRAEHENBUHL, JP; CORTHESY, B			PRODUCTION OF HUMAN SECRETORY COMPONENT WITH DIMERIC IGA BINDING-CAPACITY USING VIRAL EXPRESSION SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-EPITHELIAL TRANSPORT; INFECTIOUS VACCINIA VIRUS; HUMAN GASTRIC EPITHELIUM; 5' FLANKING SEQUENCE; IMMUNOGLOBULIN-A IGA; PROTEOLYTIC DEGRADATION; HELICOBACTER-PYLORI; CHOLERA-TOXIN; POLYMERIC IG; INSECT CELLS	The cDNA encoding the NH2-terminal 589 amino acids of the extracellular domain of the human polymeric immunoglobulin receptor was inserted into transfer vectors to generate recombinant baculo- and vaccinia viruses. Following infection of insect and mammalian cells, respectively, the resulting truncated protein corresponding to human secretory component (hSC) was secreted with high efficiency into serum-free culture medium. The Sf9 insect cell/baculovirus system yielded as much as 50 mg of hSC/liter of culture, while the mammalian cells/vaccinia virus system produced up to 10 mg of protein/liter. The M(r) of recombinant hSC varied depending on the cell line in which it was expressed (70,000 in Sf9 cells and 85-95,000 in CV-1, TK- 143B and HeLa). These variations in M(r) resulted from different glycosylation patterns, as evidenced by endoglycosidase digestion. Efficient single-step purification of the recombinant protein was achieved either by concanavalin A affinity chromatography or by Ni2+-chelate affinity chromatography, when a 6xHis tag was engineered to the carboxyl terminus of hSC. Recombinant hSC retained the capacity to specifically reassociate with dimeric IgA purified from hybridoma cells.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne								APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; APTER FM, 1993, INFECT IMMUN, V61, P5271, DOI 10.1128/IAI.61.12.5271-5278.1993; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; BERTHOLET C, 1985, P NATL ACAD SCI USA, V82, P2096, DOI 10.1073/pnas.82.7.2096; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BROWN WR, 1970, J CLIN INVEST, V49, P1374, DOI 10.1172/JCI106354; DRILLIEN R, 1983, VIROLOGY, V131, P385, DOI 10.1016/0042-6822(83)90506-8; EIFFERT H, 1984, H-S Z PHYSIOL CHEM, V365, P1489, DOI 10.1515/bchm2.1984.365.2.1489; ELBEIN AD, 1982, J BIOL CHEM, V257, P1573; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GARCIAPARDO A, 1979, MOL IMMUNOL, V16, P477; HANGGI M, 1986, EMBO J, V5, P1071, DOI 10.1002/j.1460-2075.1986.tb04324.x; HARLOW E, 1988, ANTIBODIES LABORATOR; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; KRAEHENBUHL JP, 1992, TRENDS CELL BIOL, V2, P134; KRAJCI P, 1989, BIOCHEM BIOPH RES CO, V158, P783, DOI 10.1016/0006-291X(89)92790-3; KUHN LC, 1982, TRENDS BIOCHEM SCI, V7, P299, DOI 10.1016/0968-0004(82)90017-2; LEE CK, 1994, INFECT IMMUN, V62, P887, DOI 10.1128/IAI.62.3.887-891.1994; LINDH E, 1977, ACTA PATH MICRO IM C, V85, P449; LINDH E, 1975, J IMMUNOL, V114, P284; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MCCUNE JM, 1981, J EXP MED, V154, P138, DOI 10.1084/jem.154.1.138; MESTECKY J, 1991, GASTROENTEROL CLIN N, V20, P441; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER LK, 1993, CURR OPIN GENET DEV, V3, P97, DOI 10.1016/S0959-437X(05)80348-X; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEUTRA MR, 1994, AM J TROP MED HYG, V50, P10; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; PARKHOUSE RM, 1973, BIOCHEM J, V136, P607, DOI 10.1042/bj1360607; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS S, V13; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1991, J MEMBRANE BIOL, V123, P93, DOI 10.1007/BF01998081; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	56	48	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14220	14228		10.1074/jbc.270.23.14220	http://dx.doi.org/10.1074/jbc.270.23.14220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775483	hybrid			2022-12-27	WOS:A1995RC44800091
J	SHARMA, S; ROSE, DR				SHARMA, S; ROSE, DR			CLONING, OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE CARBOXYL-TERMINAL NUCLEOTIDE-BINDING DOMAIN OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; MALTOSE-BINDING; PERIPLASMIC PERMEASES; STRUCTURAL MODEL; DRUG TRANSPORT; ATP HYDROLYSIS; GENE-PRODUCT; IDENTIFICATION	Multidrug-resistant tumor cells overexpress P-glycoprotein (170 kDa), a member of the ABC (ATP Binding Cassette)-transporter superfamily. P-glycoprotein has been implicated in transport of a broad range of amphiphilic, hydrophobic drugs from tumor cells. The sequence and structural organization of P-glycoprotein, which consists of 12 transmembrane helices and two cytoplasmic nucleotide binding domains, is similar to other ABC-transporters. It is believed that-the nucleotide binding domains of various ABC transporters, which have 30-50% sequence identity, play an important role in coupling ATP hydrolysis to the transport process. To allow structure-function studies of the nucleotide binding domains, the carboxyl-terminal nucleotide binding domain (NBD) of Chinese hamster P-gly-coprotein has been cloned, overexpressed, and purified both by itself and as a fusion with maltose-binding protein. It has been demonstrated that the carboxyl-terminal NBD, when overexpressed in Escherichia coli in the absence of transmembrane helices, has very low ATPase activity. This suggests that the amino-terminal nucleotide binding domain and possibly interaction with the transmembrane domains may be required for full ATPase activity. It is also consistent with the idea that the ATPase activity of P-glycoprotein is stimulated in the presence of drugs. Circular dichroism spectral analysis and the ability of carboxyl-terminal NBD, both by itself and as a fusion with maltose-binding protein, to bind ATP-agarose beads and P-glycoprotein specific monoclonal antibodies suggests that the polypeptide folds into a functional domain. Gel filtration chromatography and cross-linking studies indicate that the carboxyl-terminal NBD has a tendency to self-associate to form oligomers. It is speculated that the carboxyl-terminal NBD may play a role in self-association of P-glycoprotein molecules in the plasma membrane.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto	SHARMA, S (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1993, P NATL ACAD SCI USA, V89, P8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CLIFFLET S, 1988, ANAL BIOCHEM, V168, P1; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GALLAGHER MP, 1989, EUR J BIOCHEM, V180, P133, DOI 10.1111/j.1432-1033.1989.tb14623.x; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANN REV BIOCH, V92, P385; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUAN C, 1987, GENE, V67, P21; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KESSEL D, 1968, CANCER RES, V28, P938; KO YH, 1993, J BIOL CHEM, V268, P24330; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MAMAN JD, 1994, BIOCHEMISTRY-US, V33, P1300, DOI 10.1021/bi00172a003; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SHUMAN HA, 1980, J BIOL CHEM, V256, P560; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; 1992, PET SYSTEM MANUAL	40	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14085	14093		10.1074/jbc.270.23.14085	http://dx.doi.org/10.1074/jbc.270.23.14085			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775470	hybrid			2022-12-27	WOS:A1995RC44800073
J	ONRUST, R; FINKELSTEIN, J; TURNER, J; NAKTINIS, V; ODONNELL, M				ONRUST, R; FINKELSTEIN, J; TURNER, J; NAKTINIS, V; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .3. INTERFACE BETWEEN TWO POLYMERASES AND THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; SUBUNIT; GENE; IDENTIFICATION; CHI; PSI; OVEREXPRESSION; GAMMA; TAU	The nine-subunit DNA polymerase (Pol) III* coupled to its beta sliding clamp is a rapid and highly processive replicating machine. The multiple subunits are needed for the complicated task of duplicating the Escherichia coli chromosome. In this report, Pol III* was constituted from individual pure proteins, and its structure was studied. Constitution of the Pol III* particle requires an ordered addition of the subunits, and the final structure contains 14 polypeptides in the ratio alpha(2) epsilon(2) theta(2) tau(2) gamma(2) delta(1) delta(1)' chi(1) psi(1). The structure can be summarized as being composed of two core polymerases (alpha epsilon theta) held together by a dimer of tau and one gamma complex clamp loader (gamma(2) delta(1) delta(1)'chi(1) psi(1)) for loading beta onto DNA. At the center of the structure, the related tau and gamma subunits form a heterotetramer upon which the two core polymerases and clamp loader proteins assemble. The single copy nature of the delta, delta', chi, and psi subunits confers a structural asymmetry with respect to the two polymerases, presumably for the different functions of replicating the leading and lagging strands.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CARTER JR, 1993, MOL GEN GENET, V241, P399, DOI 10.1007/BF00284693; CARTER JR, 1993, J BACTERIOL, V174, P7013; DONG ZM, 1993, J BIOL CHEM, V268, P11758; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kornberg A., 1992, DNA REPLICATION, P165; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; ONRUST R, 1993, THESIS CORNELL U; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; XIAO H, 1995, J BIOL CHEM, P13378; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	25	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13366	13377		10.1074/jbc.270.22.13366	http://dx.doi.org/10.1074/jbc.270.22.13366			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768938	hybrid			2022-12-27	WOS:A1995RB43900063
J	STUKENBERG, PT; ODONNELL, M				STUKENBERG, PT; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .5. 4 DIFFERENT POLYMERASE CLAMP COMPLEXES ON DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SIZE CLASSES; SUBUNIT; PURIFICATION; FORK	Several different subassemblies of DNA polymerase III holoenzyme can be purified from Escherichia coli. Toward the goal of understanding the functional significance of these subassemblies, we have used the gamma complex clamp loader and the beta ring to assemble each different polymerase onto DNA. Through use of radioactive labeled proteins, the subunit structure of each resulting processive polymerase has been determined. Use of DNA polymerase III core, the gamma complex, and beta results in a core-beta complex on DNA; the gamma complex is not incorporated into the structure. The addition of tau to the assembly reaction to form either core(1)-tau(2) or core(2)-tau(2) results in a more efficient polymerase and more stabile association of core-tau beta on DNA, although the gamma complex still does not remain on DNA. The gamma complex clamp loader was retained on DNA with the other subunits only if it was first assembled into the polymerase (Pol) III* structure. The clamp loader within Pol III* appeared to be capable of loading two beta clamps onto DNA for both core polymerases within Pol III*, consistent with the hypothesis that one replicase can simultaneously replicate both strands of a duplex chromosome. These findings extend those of an earlier study showing that distinctive polymerases can be assembled depending on the presence or absence of tau (Maki, S., and Kornberg, A (1988) J. Biol. Chem. 263, 6561-6569). The significance of these distinct polymerases in separate paths of DNA metabolism is discussed.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University				Stukenberg, Todd/0000-0002-6788-2111	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5294; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FRADKIN LG, 1992, J BIOL CHEM, V267, P10318; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KELMAN Z, 1995, IN PRESS METHODS ENZ, V262; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MEYER TF, 1979, J BIOL CHEM, V254, P2636; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SINHA NK, 1980, J BIOL CHEM, V225, P4290; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1993, THESIS CORNELL U; XIAO H, 1993, J BIOL CHEM, V268, P11773; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	27	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13384	13391		10.1074/jbc.270.22.13384	http://dx.doi.org/10.1074/jbc.270.22.13384			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768940	hybrid			2022-12-27	WOS:A1995RB43900065
J	WAXMAN, DJ; RAM, PA; PARK, SH; CHOI, HK				WAXMAN, DJ; RAM, PA; PARK, SH; CHOI, HK			INTERMITTENT PLASMA GROWTH-HORMONE TRIGGERS TYROSINE PHOSPHORYLATION AND NUCLEAR TRANSLOCATION OF A LIVER-EXPRESSED, STAT 5-RELATED DNA-BINDING PROTEIN - PROPOSED ROLE AS AN INTRACELLULAR REGULATOR OF MALE-SPECIFIC LIVER GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEXUALLY DIMORPHIC EXPRESSION; C-FOS; RAT-LIVER; HYPOPHYSECTOMIZED RATS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PROLACTIN RECEPTOR; SECRETORY PATTERN; ULTRADIAN PATTERN; KINASE	Growth hormone (GH) exerts sexually dimorphic effects on liver gene transcription that are regulated by the temporal pattern of pituitary GH release, which is intermittent in male rats and nearly continuous in females. To investigate the influence of these GH secretory patterns on intracellular hepatocyte signaling, we compared the pattern of Liver nuclear protein tyrosine phosphorylation in male and female rats. An M(r) similar to 93,000 polypeptide, p93, was found to be tyrosine phosphorylated to a high level in male but not female rats. GH, but not prolactin, rapidly stimulated p93 tyrosine phosphorylation in hypophysectomized rats. Intermittent plasma GH pulses triggered repeated p93 phosphorylation, while continuous GH exposure led to desensitization and a dramatic decline in Liver nuclear p93. p93 was cross-reactive with two monoclonal antibodies raised to mammary Stat 5, whose tyrosine phosphorylation is stimulated by prolactin. Intermittent GH pulsation translocated Liver Stat 5/p93 protein from the cytosol to the nucleus and also activated its DNA binding activity, as demonstrated using a mammary Stat 5-binding DNA element derived from the beta-casein gene. p93 is thus a liver-expressed, Stat 5-related DNA binding protein that undergoes tyrosine phosphorylation and nuclear translocation in response to intermittent plasma GH stimulation and is proposed to be an intracellular mediator of the stimulatory effects of GH pulses on male-specific liver gene expression.			WAXMAN, DJ (corresponding author), BOSTON UNIV,DEPT BIOL,DIV CELL & MOLEC BIOL,5 CUMMINGTON ST,BOSTON,MA 02215, USA.			Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK033765, R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1992, J BIOL CHEM, V267, P22095; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASPLIN CM, 1989, J CLIN ENDOCR METAB, V69, P239, DOI 10.1210/jcem-69-2-239; BAXTER RC, 1984, ENDOCRINOLOGY, V115, P2009, DOI 10.1210/endo-115-5-2009; BICK T, 1992, ENDOCRINOLOGY, V131, P423, DOI 10.1210/en.131.1.423; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1988, J CLIN INVEST, V82, P1871, DOI 10.1172/JCI113804; JANSSON JO, 1987, ENDOCRINOLOGY, V120, P1551, DOI 10.1210/endo-120-4-1551; JANSSON JO, 1982, ACTA PHYSIOL SCAND, V114, P261, DOI 10.1111/j.1748-1716.1982.tb06980.x; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JEFFERY S, 1990, BIOCHEM J, V266, P69, DOI 10.1042/bj2660069; JOHNSON RJ, 1988, J ENDOCRINOL, V119, P101, DOI 10.1677/joe.0.1190101; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MACLEOD JN, 1991, J ENDOCRINOL, V131, P395, DOI 10.1677/joe.0.1310395; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MODE A, 1982, ENDOCRINOLOGY, V111, P1692, DOI 10.1210/endo-111-5-1692; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NAGANO M, 1994, J BIOL CHEM, V269, P13337; PAMPORI NA, 1991, BIOCHEM PHARMACOL, V41, P1299, DOI 10.1016/0006-2952(91)90101-A; PAMPORI NA, 1991, ACTA ENDOCRINOL-COP, V124, P283, DOI 10.1530/acta.0.1240283; POSTELVINAY MC, 1976, FEBS LETT, V69, P137, DOI 10.1016/0014-5793(76)80670-9; RAZ R, 1994, J BIOL CHEM, V269, P24391; ROBERTSON JA, 1990, MOL ENDOCRINOL, V4, P1235, DOI 10.1210/mend-4-8-1235; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUI H, 1994, J BIOL CHEM, V269, P5364; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TIONG TS, 1991, ENDOCRINOLOGY, V129, P1628, DOI 10.1210/endo-129-3-1628; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG X, 1994, P NATL ACAD SCI USA, V91, P1361; WANG XY, 1993, J BIOL CHEM, V268, P3573; WASMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WESTIN S, 1992, J STEROID BIOCHEM, V43, P1045, DOI 10.1016/0960-0760(92)90332-D; WINER LM, 1990, J CLIN ENDOCR METAB, V70, P1678, DOI 10.1210/jcem-70-6-1678; YAMADA K, 1984, BIOCHEM J, V220, P361, DOI 10.1042/bj2200361; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707; Zaphiropoulos P G, 1988, Acta Med Scand Suppl, V723, P161; ZHAO SP, 1994, FASEB J, V8, pA1250; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	69	208	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13262	13270		10.1074/jbc.270.22.13262	http://dx.doi.org/10.1074/jbc.270.22.13262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768925	hybrid			2022-12-27	WOS:A1995RB43900049
J	SMITH, JW; HU, D; SATTERTHWAIT, A; PINZSWEENEY, S; BARBAS, CF				SMITH, JW; HU, D; SATTERTHWAIT, A; PINZSWEENEY, S; BARBAS, CF			BUILDING SYNTHETIC ANTIBODIES AS ADHESIVE LIGANDS FOR INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SURFACE-PLASMON RESONANCE; PHASE PEPTIDE-SYNTHESIS; PLATELET-AGGREGATION; CELL-ADHESION; BINDING-SITE; MONOCLONAL-ANTIBODY; GPIIB-IIIA; RECEPTOR; FIBRINOGEN	An antibody engineering strategy was employed to build high affinity ligands and antagonists of integrins alpha(v) beta(3) and alpha(IIb)beta(3). Previously, we inserted the integrin recognition motif, RGD, into the antigen binding site of a human antibody and selected the optimal flanking sequences from a phage-display library (Barbas, C. F., Languino, L. R., and Smith, J. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10003-10007). The resulting antibody, Fab-9, blocked the function of integrin gp, but also bound to the ligand binding site of platelet integrin alpha(IIb)beta(3). In this report, the antibody engineering effort has been extended by 1) redesigning Fab-9 to achieve specificity for platelet integrin alpha(IIb)beta(3), 2) building non-RGD-containing antibodies that bind the ligand binding site of both beta(3)-integrins, and 3) testing the hypothesis that peptides derived from complementarity determining regions (CDR) can be used to emulate the activity of the parent synthetic antibody. These goals were accomplished by subjecting the original antibody, Fab-9, to a ''motif optimization'' (MTF). A phage library was constructed in which the residues flanking the RGD motif in Fab-9 were maintained, but the RGDX sequence was randomized. This library was panned on purified alpha(IIb)beta(3) to identify high affinity binders. Four function-blocking antibodies lacking RGD, but with specificity for alpha(IIb)beta(3), were characterized. The antibody with the highest preference for alpha(IIb)beta(3), MTF-10, had an adhesion sequence of KGDN. This sequence is similar in primary structure to the active sequence within the disintegrin barbourin, which also antagonizes alpha(IIb)beta(3) (Scarborough, R. M., Rose, J. W., Hsu, M. A., Phillips, D. R., Fried, V. A., Campbell, A. M., Nannizzi, L., and Charo, I. F. (1991) J. Biol. Chem. 266, 9359-9362). MTF-10 had a 70-fold higher affinity for alpha(IIb)beta(3) than alpha(v) beta(3). Through our selection strategy, we also identified several antibodies that lack RGD but still blocked ligand binding to both integrins with high affinity. Therefore, the RGD sequence is not necessary for a high affinity interaction with the ligand binding site of beta(3)-integrins. Further investigation showed that the activity of inhibitory antibodies could be emulated by synthetic peptides derived from the protein sequences of the antibody's HCDR3. CDR-derived peptides blocked ligand binding to integrins and maintained essentially the same specificity as the parent antibody.	SCRIPPS RES INST, DEPT MOLEC BIOL MB11, LA JOLLA, CA 92037 USA	Scripps Research Institute	SMITH, JW (corresponding author), Scripps Clinic, DEPT VASC VB1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA56483] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; Barbas Carlos F. Iii, 1993, Current Opinion in Biotechnology, V4, P526, DOI 10.1016/0958-1669(93)90072-5; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMURA Y, 1992, BLOOD, V80, P1247; ISOAI A, 1992, CANCER LETT, V65, P259, DOI 10.1016/0304-3835(92)90241-M; KARPATKIN S, 1981, ANN INTERN MED, V95, P636, DOI 10.7326/0003-4819-95-5-636; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MENTER DG, 1987, CANCER RES, V47, P6751; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; STEWART JM, 1984, SOLID PHASE PEPTIDE, P116; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, BLOOD, V79, P2302; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	44	48	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32788	32795						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806501				2022-12-27	WOS:A1994QA63800014
J	CHACKO, GW; DUCHEMIN, AM; COGGESHALL, KM; OSBORNE, JM; BRANDT, JT; ANDERSON, CL				CHACKO, GW; DUCHEMIN, AM; COGGESHALL, KM; OSBORNE, JM; BRANDT, JT; ANDERSON, CL			CLUSTERING OF THE PLATELET FC-GAMMA RECEPTOR INDUCES NONCOVALENT ASSOCIATION WITH THE TYROSINE KINASE P72(SYK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-G; MULTIPLE ISOFORMS; PROTEIN; IGG; EXPRESSION; RII; PHOSPHORYLATION	The Fc receptor for IgG in platelets was identified as the integral membrane isoform encoded by the Fc gamma RIIA gene. Functional analysis of this molecule determined that activated Fc gamma RIIA is tyrosine phosphorylated and that activation induced the physical association with the protein tyrosine kinase p72(syk). Other tyrosine-phosphorylated molecules also co-immunoadsorbed with the activated receptor. Tyrosine kinase activity co-immuno-adsorbing with the platelet Fc gamma R was enhanced upon activation and specifically induced the phosphorylation, on tyrosine residues, of a physically associated 72-kDa protein. These data support a model of Fc gamma receptor-mediated platelet activation where signal is transduced through inducible association of the tyrosine kinase p72(syk) with the low affinity Fc gamma receptor. Thrombin, a potent platelet agonist, has been shown to up-regulate the activity of the tyrosine kinase p72(syk) in platelets, Consequently, our findings identify a second pathway by which p72(syk) in activated in platelets.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chacko, George/I-4945-2014	Chacko, George/0000-0002-2127-1892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046652] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL46652] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1987, J IMMUNOL, V138, P2254; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANDERSON GP, 1990, BLOOD, V76, P1165; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BUDDE P, 1994, LEUKOCYTE TYPING, V5; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; GRIFFITH L, 1991, BLOOD, V78, P1753; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAO KJ, 1989, TRANSFUSION, V29, P774, DOI 10.1046/j.1537-2995.1989.29990070180.x; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLER MA, 1993, PCR METH APPL, V3, P32; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1990, CELL IMMUNOL, V128, P462, DOI 10.1016/0008-8749(90)90041-O; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; RAPPAPORT EF, 1993, EXP HEMATOL, V21, P689; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; ROSENFELD SI, 1989, PLATELET IMMUNOBIOLO, P337; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SEKI T, 1989, IMMUNOGENETICS, V30, P5, DOI 10.1007/BF02421463; SHEN ZH, 1994, J IMMUNOL, V152, P3017; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPF TF, 1983, J IMMUNOL, V131, P3064	50	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32435	32440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798242				2022-12-27	WOS:A1994PX30400063
J	LI, SW; FERBER, A; MIURA, M; BASERGA, R				LI, SW; FERBER, A; MIURA, M; BASERGA, R			MITOGENICITY AND TRANSFORMING ACTIVITY OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR WITH MUTATIONS IN THE TYROSINE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; RAT GLIOBLASTOMA; PHOSPHORYLATION; PROTEINS; CELLS; AUTOPHOSPHORYLATION; PROLIFERATION; EXPRESSION; ANTIGEN; IGF-1	We have investigated the effect of mutations in tyrosines 1131, 1135, and 1136 of the human insulin-like growth factor-I receptor (IGF-IR) on the growth and transformation of mammalian cells. We have used for this purpose R(-) cells, which are 3T3-like fibroblasts derived from mouse embryos with a targeted disruption of the IGF-IR genes. These cells have no IGF-IR, do not grow in serum-free medium supplemented with the growth factors that sustain the growth of 3T3 cells, and cannot be transformed by simian virus 40 large tumor antigen or other oncogenes. The R(-) cells were transfected with plasmids expressing: 1) a wild type human IGF-IR cDNA; 2) a receptor with a triple mutation in the above mentioned tyrosines; and 3) receptors with single tyrosine mutations. Cells expressing the wild type or the single tyrosine mutants Y1 (Y1131F) and Y2 (Y1135F) grew in serum-free medium supplemented solely with IGF-I. Cells expressing the triple tyrosine mutant YF or the single mutant Y3 (Y1136F) failed to grow in response to IGF-I only. Ah mutants, though, failed to form colonies in soft agar, indicating that a fully functional IGF-IR is more critical for anchorage-independent growth than for monolayer growth. The triple mutant expression plasmid also functioned as a dominant negative, inhibiting the growth of wild type cells transformed by the simian virus tumor antigen.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, INSULIN LIKE GROWTH; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BASERGA R, 1985, BIOL CELL REPRODUCTI; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; GOLDRING MB, 1991, EUKARYOTIC GENE EXPR, V1, P301; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MIURA M, 1994, CANCER RES, V54, P2472; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; REISS K, 1992, ONCOGENE, V7, P2243; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; SAOSAOKA T, 1994, J BIOL CHEM, V269, P13689; SASOAKA T, 1994, J BIOL CHEM, V269, P10734; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SMITH HS, 1971, VIROLOGY, V44, P359, DOI 10.1016/0042-6822(71)90267-4; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	43	97	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32558	32564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798258				2022-12-27	WOS:A1994PX30400080
J	CHAUSSIVERT, N; CONESA, C; SHAABAN, S; SENTENAC, A				CHAUSSIVERT, N; CONESA, C; SHAABAN, S; SENTENAC, A			COMPLEX INTERACTIONS BETWEEN YEAST TFIIIB AND TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TRANSCRIPTION FACTOR-TFIIB; FUNCTIONAL DOMAINS; INITIATION; PROTEIN; GENE; ACTIVATOR; ENCODES; SUBUNIT; HOMOLOGY	Transcription of yeast class III genes requires the sequential assembly of the general transcription factors TFIIIC and TFIIIB, and of RNA polymerase III, into an initiation complex composed of at least 25 polypeptides. The 70-kDa subunit of TFIIIB (TFIIIB70) is central in this network of interactions as it contacts both TATA-binding protein and a subunit of polymerase III. We show here that the TATA-binding protein interacts with the carboxyl-terminal part of TFIIIB70. TFIIIB70 also contacts TFIIIC (factor tau) via its tau 131 subunit. The protein domains of tau 131 and TFIIB70 involved in this interaction, either positively or negatively, were mapped using the two-hybrid system. We provide evidence that intramolecular interactions mask functional domains in both polypeptides.	CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay			Troffer-Charlier, Nathalie/B-1857-2017	Troffer-Charlier, Nathalie/0000-0001-6812-8375				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HARPER JW, 1993, CELL, V75, P805; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; RAMEAU R, 1994, MOL CELL BIOL, V14, P822; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	34	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15353	15358		10.1074/jbc.270.25.15353	http://dx.doi.org/10.1074/jbc.270.25.15353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797524	hybrid			2022-12-27	WOS:A1995RE66600076
J	MARX, UC; AUSTERMANN, S; BAYER, P; ADERMANN, K; EJCHART, A; STICHT, H; WALTER, S; SCHMID, FX; JAENICKE, R; FORSSMANN, WG; ROSCH, P				MARX, UC; AUSTERMANN, S; BAYER, P; ADERMANN, K; EJCHART, A; STICHT, H; WALTER, S; SCHMID, FX; JAENICKE, R; FORSSMANN, WG; ROSCH, P			STRUCTURE OF HUMAN PARATHYROID-HORMONE-1-37 IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING DOMAIN; LEUCINE-ZIPPER MOTIF; MOLECULAR-DYNAMICS; DISTANCE GEOMETRY; PEPTIDE-FRAGMENTS; ZINC FINGER; NMR; TRIFLUOROETHANOL	Human parathyroid hormone (hPTH), amino acids Ser(1) to Leu(37), is biologically active with respect to both receptor binding and activation of adenylate cyclase to influence the serum calcium concentration. It induces DNA synthesis via an unknown signal pathway. We investigated the structure of hPTH(1-37) in H2O/buffer solution under near physiological conditions, that is pH 6.0 and 270 mM salt, by circular dichroism, ultracentrifugation, nuclear magnetic resonance spectroscopy, and molecular dynamics calculations. Complete sequence specific assignments of all H-1 resonances were performed by using H-1 two-dimensional NMR measurements (double quantum-filtered correlated spectroscopy, nuclear Overhauser effect spectroscopy (NOESY), and total correlation spectroscopy with suppression of NOESY-type cross-peaks spectra). hPTH(1-37) obtained helical structure and showed hydrophobic interactions defining a tertiary structure. The NH2-terminal four amine acids of hPTH(1-37) did not show a stable conformation. Evidence for an alpha-helical region between IIe(5) and Asn(10) was found. This region was followed by a flexible link (Gly(12), Lys(13)) and a well defined turn region, His(14) to Ser(17). The latter was stabilized by hydrophobic interactions between Trp(23) and Leu(15). Ser(17) through at least Leu(28) formed an alpha-helix. Arg(20) and Lys(27) were involved in the core built by His(14) to Ser(17). Unrestrained molecular dynamics simulations indicated that the structure was stable on the 200 ps time scale.	UNIV BAYREUTH, LEHRSTUHL BIOCHEM, D-95440 BAYREUTH, GERMANY; NIEDERSACHS INST PEPTID FORSCH GMBH, D-30625 HANNOVER, GERMANY; UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93053 REGENSBURG, GERMANY	University of Bayreuth; University of Regensburg			Bayer, Peter/B-8803-2009; Rösch, Paul/I-5445-2014	Bayer, Peter/0000-0003-0435-7202; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X; Marx, Ute C./0000-0002-7077-9940				ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; Atherton E., 1990, SOLID PHASE PEPTIDE; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER A, 1993, X PLOR 3 1 MANUAL; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOREV M, 1994, STRUCTURE FUNCTION A, P139; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FORSSMANN WG, 1993, PEPTIDE CHEMISTRY 1992, P553; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JUNIUS FK, 1993, EUR J BIOCHEM, V214, P415, DOI 10.1111/j.1432-1033.1993.tb17937.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LANCELIN JM, 1994, FEBS LETT, V343, P261, DOI 10.1016/0014-5793(94)80568-7; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; LOPEZHILKER S, 1992, J LAB CLIN MED, V119, P738; MERUTKA G, 1993, BIOCHEMISTRY-US, V32, P13089, DOI 10.1021/bi00211a019; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORTON CJ, 1994, EUR J BIOCHEM, V219, P97, DOI 10.1111/j.1432-1033.1994.tb19919.x; MUJEEB A, 1994, P NATL ACAD SCI USA, V91, P8248, DOI 10.1073/pnas.91.17.8248; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; POTTS JT, 1982, ADV PROTEIN CHEM, V35, P323, DOI 10.1016/S0065-3233(08)60471-4; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SAUDEK V, 1991, PROTEIN ENG, V4, P519, DOI 10.1093/protein/4.5.519; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SOMJEN D, 1990, BIOCHEM J, V272, P781; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; VANBUUREN AR, 1993, BIOPOLYMERS, V33, P1159, DOI 10.1002/bip.360330802; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLBOLD D, 1994, SCIENCE, V264, P1584, DOI 10.1126/science.7515512; WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, CALCULATION PROTEIN, P208; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	64	68	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15194	15202		10.1074/jbc.270.25.15194	http://dx.doi.org/10.1074/jbc.270.25.15194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797503	hybrid			2022-12-27	WOS:A1995RE66600054
J	NEESE, RA; SCHWARZ, JM; FAIX, D; TURNER, S; LETSCHER, A; VU, D; HELLERSTEIN, MK				NEESE, RA; SCHWARZ, JM; FAIX, D; TURNER, S; LETSCHER, A; VU, D; HELLERSTEIN, MK			GLUCONEOGENESIS AND INTRAHEPATIC TRIOSE PHOSPHATE FLUX IN RESPONSE TO FASTING OR SUBSTRATE LOADS - APPLICATION OF THE MASS ISOTOPOMER DISTRIBUTION ANALYSIS TECHNIQUE WITH TESTING OF ASSUMPTIONS AND POTENTIAL PROBLEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-INDUCED HYPERTRIGLYCERIDEMIA; COA POOL INVIVO; HEPATIC GLYCOGEN; PYRUVATE-DEHYDROGENASE; STABLE ISOTOPES; C-13 NMR; GLUCOSE; HUMANS; RAT; PATHWAYS	We measured gluconeogenesis (GNG) in rats by mass isotopomer distribution analysis, which allows enrichment of the true biosynthetic precursor pool (hepatic cytosolic triose phosphates) to be determined. Fractional GNG from infused [3-C-13]lactate, [1-C-13]lactate, and [2-C-13]glycerol was 88 +/- 2, 89 +/- 3, and 87 +/- 2%, respectively, after 48 h of fasting, [2-C-13]Glycerol was the most efficient label and allowed measurement of rate of ap appearance of intrahepatic triose phosphate (Ra triose-P), by dilution. IV fructose (10-15 mg/kg/min) increased absolute GNG by 81-147%, Ra triose-P increased proportionately, but endogenous Ra triose-P was almost completely suppressed, suggesting feedback control, Interestingly, 15-17% of fructose was directly converted to glucose without entering hepatic triose-P, IV glucose reduced GNG and Ra triose-P, 24-h fasting reduced hepatic glucose production by half, but absolute GNG was unchanged due to increased fractional GNG (51-87%). Reduced hepatic glucose production was entirely due to decreased glycogen input, from 7.3 +/- 1.8 to 1.1 +/- 0.2 mg/kg/min, Ra triose-P fell during fasting, but efficiency of triose-P disposal into GNG increased, maintaining GNG constant, Secreted glucuronyl conjugates and plasma glucose results correlated closely, In summary, GNG and intrahepatic triose-P flux can be measured by mass isotopomer distribution analysis with [2-C-13]glycerol.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MED, DIV ENDOCRINOL & METAB, SAN FRANCISCO, CA 94101 USA	University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P396; BIERMANN CJ, 1989, ANAL CARBOHYDRATES G, P98; CHANDRAMOULI V, 1993, METABOLISM, V42, P1420, DOI 10.1016/0026-0495(93)90192-Q; CONSOLI A, 1993, DIABETES, V42, P732, DOI 10.2337/diabetes.42.5.732; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; DAVIDSON MB, 1981, METABOLISM, V30, P279, DOI 10.1016/0026-0495(81)90152-9; Exton J H, 1970, Recent Prog Horm Res, V26, P411; FAIX D, 1993, J LIPID RES, V34, P2063; FAIX D, 1992, FASEB J, V6, pA4933; Good CA, 1933, J BIOL CHEM, V100, P485; GOPHER A, 1990, P NATL ACAD SCI USA, V87, P5449, DOI 10.1073/pnas.87.14.5449; GUO ZK, 1992, ANAL BIOCHEM, V204, P273, DOI 10.1016/0003-2697(92)90238-3; HELLERSTEIN MK, 1994, J CLIN INVEST, V93, P265, DOI 10.1172/JCI116955; HELLERSTEIN MK, 1986, P NATL ACAD SCI USA, V83, P7044, DOI 10.1073/pnas.83.18.7044; HELLERSTEIN MK, 1995, METABOLISM, V44, P172, DOI 10.1016/0026-0495(95)90261-9; HELLERSTEIN MK, 1989, J CLIN INVEST, V84, P228, DOI 10.1172/JCI114145; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HELLERSTEIN MK, 1994, FASEB J, V8, pA957; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10912; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; HETENYI G, 1982, FED PROC, V41, P104; HIRANO T, 1988, AM J PHYSIOL, V255, pE236, DOI 10.1152/ajpendo.1988.255.3.E236; HOLNESS MJ, 1986, BIOCHEM J, V235, P441, DOI 10.1042/bj2350441; JAHOOR F, 1990, AM J PHYSIOL, V258, pE288, DOI 10.1152/ajpendo.1990.258.2.E288; JENSSEN T, 1990, J CLIN INVEST, V86, P489, DOI 10.1172/JCI114735; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; Katz J., 1991, AM J PHYSIOL, V259, pE757; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LETSCHER AE, 1994, FASEB J, V8, pA954; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; MCGARRY JD, 1987, ANNU REV NUTR, V7, P51, DOI 10.1146/annurev.nu.07.070187.000411; NEESE RA, 1994, FASEB J, V8, pA919; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; PARK OJ, 1992, BIOCHEM J, V282, P753, DOI 10.1042/bj2820753; ROGNSTAD R, 1988, Medical Science Research, V16, P293; ROTHER KI, 1994, DIABETES, V43, pA133; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SEGLEN PO, 1974, BIOCHIM BIOPHYS ACTA, V338, P317, DOI 10.1016/0304-4165(74)90292-X; SENIOR B, 1968, NEW ENGL J MED, V279, P965, DOI 10.1056/NEJM196810312791803; SHIKAMA H, 1978, AM J PHYSIOL, V235, pE354, DOI 10.1152/ajpendo.1978.235.4.E354; SHULMAN GI, 1990, AM J PHYSIOL, V259, pE335, DOI 10.1152/ajpendo.1990.259.3.E335; SHULMAN GI, 1992, PHYSIOL REV, V72, P1019, DOI 10.1152/physrev.1992.72.4.1019; SISTARE FD, 1985, J BIOL CHEM, V260, P2761; Soskin S, 1937, AM J PHYSIOL, V120, P761, DOI 10.1152/ajplegacy.1937.120.4.761; STEELE R, 1971, AM J PHYSIOL, V221, P883, DOI 10.1152/ajplegacy.1971.221.3.883; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TSIENG KY, 1984, ANAL CHEM, V56, P517; WALSH K, 1985, J BIOL CHEM, V260, P8430; WEINMAN EO, 1957, PHYSIOL REV, V37, P252, DOI 10.1152/physrev.1957.37.2.252; YOUN JH, 1990, AM J PHYSIOL, V258, pE899, DOI 10.1152/ajpendo.1990.258.6.E899; ZAVARONI I, 1982, METABOLISM, V31, P1077, DOI 10.1016/0026-0495(82)90155-X	59	123	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14452	14463		10.1074/jbc.270.24.14452	http://dx.doi.org/10.1074/jbc.270.24.14452			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782307	hybrid			2022-12-27	WOS:A1995RD45500035
J	POWELL, LD; VARKI, A				POWELL, LD; VARKI, A			I-TYPE LECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							B-CELL ANTIGEN; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MYELIN-ASSOCIATED GLYCOPROTEIN; IMMUNOGLOBULIN GENE SUPERFAMILY; HUMAN LYMPHOCYTES-B; ADHESION MOLECULE; HOMOPHILIC ADHESION; SIALIC ACIDS; T-CELLS; CD22		UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	POWELL, LD (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA.							AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; AFAR DEH, 1990, J NEUROCHEM, V55, P1418, DOI 10.1111/j.1471-4159.1990.tb03155.x; AGRAWAL HC, 1990, BIOCHEM BIOPH RES CO, V169, P953, DOI 10.1016/0006-291X(90)91986-3; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DORKEN B, 1986, J IMMUNOL, V136, P4470; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; ENGEL P, 1993, J IMMUNOL, V150, P4719; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FAHRIG T, 1987, EMBO J, V6, P2875, DOI 10.1002/j.1460-2075.1987.tb02590.x; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOLLER U, 1989, LEUCOCYTE TYPING 4, P812; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LANGMAN RE, 1987, MOL IMMUNOL, V24, P675, DOI 10.1016/0161-5890(87)90050-2; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MORRIS L, 1991, J CELL SCI, V99, P141; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, IN PRESS P NATL ACAD; SIMMONS D, 1988, J IMMUNOL, V141, P2797; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TCHILIAN EZ, 1994, BLOOD, V83, P3188; TORRES RM, 1992, J IMMUNOL, V149, P2641; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG XC, 1993, J BIOL CHEM, V268, P4355; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	69	203	207	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14243	14246		10.1074/jbc.270.24.14243	http://dx.doi.org/10.1074/jbc.270.24.14243			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782275	hybrid			2022-12-27	WOS:A1995RD45500001
J	MAMALAKI, A; BOUTOU, E; HUREL, C; PATSAVOUDI, E; TZARTOS, S; MATSAS, R				MAMALAKI, A; BOUTOU, E; HUREL, C; PATSAVOUDI, E; TZARTOS, S; MATSAS, R			THE BM88 ANTIGEN, A NOVEL NEURON-SPECIFIC MOLECULE, ENHANCES THE DIFFERENTIATION OF MOUSE NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; MONOCLONAL-ANTIBODIES; POSTNATAL-DEVELOPMENT; ADHESION MOLECULES; CEREBELLAR CORTEX; PROTEIN; EXPRESSION; RAT; FILOPODIA; CADHERIN	The BM88 antigen is a neuron-specific molecule widely distributed in the mammalian nervous system. It is a 22-kDa, apparently not glycosylated, integral membrane protein, which appears early during brain development and remains at high levels in the mature animal. Here, we describe the cDNA cloning of the porcine BM88 antigen and present evidence that this protein is involved in neuroblastoma cell differentiation. The deduced protein is a novel molecule consisting of 140 amino acids and bears a putative transmembrane domain at the COOH-terminal region. The mRNA of this protein is expressed only in neural tissues, where it is restricted to neurons. Stably transfected Neuro-2a cells overexpressing the BM88 antigen exhibited a significant change in morphology, reflected by enhanced process outgrowth, and a slower rate of division. Moreover, in the presence of differentiation agents, such as sucrose and retinoic acid, an accelerated differentiation of the transfected Neuro-2a cells was observed. Especially in the presence of sucrose, the consequent overexpression of the BM88 antigen in the transfected cells resulted in their enhanced morphological differentiation accompanied by the induction of neurofilament protein expression. Our results suggest that the BM88 antigen plays a role in the differentiation of neuroblastoma cells.	HELLEN INST PASTEUR,DEPT BIOCHEM,GR-11521 ATHENS,GREECE					Boutou, Effrossyni/0000-0003-0343-2434				ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FEANY MB, 1993, NATURE, V364, P537, DOI 10.1038/364537a0; GRAHAM F, 1973, VIROLOGY, V52, P452; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KIOUSSI C, 1992, NEUROSCIENCE, V50, P69, DOI 10.1016/0306-4522(92)90382-C; KUMAGAITOHDA C, 1993, J NEUROCHEM, V61, P526; KUMAR S, 1994, J BIOL CHEM, V269, P11318; LECLERC N, 1993, P NATL ACAD SCI USA, V90, P6223, DOI 10.1073/pnas.90.13.6223; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MERKOURI E, 1992, NEUROSCIENCE, V50, P53, DOI 10.1016/0306-4522(92)90381-B; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; PATSAVOUDI E, 1989, NEUROSCIENCE, V30, P463, DOI 10.1016/0306-4522(89)90266-2; PATSAVOUDI E, 1991, J NEUROCHEM, V56, P782, DOI 10.1111/j.1471-4159.1991.tb01992.x; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; ROSS J, 1975, TISSUE CELL, V7, P107, DOI 10.1016/S0040-8166(75)80010-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V82, P5463; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALSH FS, 1992, COLD SPRING HARB SYM, V57, P431, DOI 10.1101/SQB.1992.057.01.048; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14201	14208		10.1074/jbc.270.23.14201	http://dx.doi.org/10.1074/jbc.270.23.14201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775480	hybrid			2022-12-27	WOS:A1995RC44800088
J	XU, XX; YANG, WN; JACKOWSKI, S; ROCK, CO				XU, XX; YANG, WN; JACKOWSKI, S; ROCK, CO			CLONING OF A NOVEL PHOSPHOPROTEIN REGULATED BY COLONY-STIMULATING FACTOR-1 SHARES A DOMAIN WITH THE DROSOPHILA DISABLED GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; FMS PROTO-ONCOGENE; C-MYC EXPRESSION; PHOSPHATIDYLCHOLINE HYDROLYSIS; MITOGENIC RESPONSE; GROWTH-FACTOR; CSF-1; PURIFICATION; MACROPHAGES	A unique protein with an apparent molecular mass of 96 kilodaltons (p96) was detected in the murine macrophage cell line, BAC1.2F5. The murine cDNA encoding p96 was cloned and sequenced, along with cDNAs representing two alternatively spliced forms of the protein. All three proteins possessed identical amino-terminal domains with significant similarity to the amino-terminal domain of the Drosophila disabled gene product and carboxyl-terminal domains containing proline-rich sequences characteristic of src homology region (domain 3) binding regions. BAC1.2F5 cells predominately expressed the p96 protein, although mRNA and protein corresponding to the p67 splice variant were also detected. Electrophoretic gel retardation of p96 in response to stimulation of the cells with colony-stimulating factor 1 was noticeable within 5 min after growth factor addition and reached a maximum at 60 min. Metabolic labeling experiments showed that the gel retardation of p96 was associated with increased phosphorylation of the protein exclusively on serine residues. These data identify a novel protein that is phosphorylated in response to mitogenic growth factor stimulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [T32 CA09346, CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT RL, 1992, DEVELOPMENT, V116, P953; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GUILBERT LJ, 1986, J CELL BIOCHEM, V31, P203, DOI 10.1002/jcb.240310303; HARLOW E, 1988, ANTIBODIES LABORATOR; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VEIS N, 1991, J CELL PHYSIOL, V147, P298, DOI 10.1002/jcp.1041470215; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	129	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14184	14191		10.1074/jbc.270.23.14184	http://dx.doi.org/10.1074/jbc.270.23.14184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775479	hybrid			2022-12-27	WOS:A1995RC44800086
J	XIAO, H; NAKTINIS, V; ODONNELL, M				XIAO, H; NAKTINIS, V; ODONNELL, M			ASSEMBLY OF A CHROMOSOMAL REPLICATION MACHINE - 2 DNA-POLYMERASES, A CLAMP LOADER, AND SLIDING CLAMPS IN ONE HOLOENZYME PARTICLE .4. ATP-BINDING SITE MUTANTS IDENTIFY THE CLAMP LOADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; III HOLOENZYME; GAMMA-SUBUNIT; EXCISION REPAIR; BETA-SUBUNIT; TAU-SUBUNIT; PROTEIN; GENE; PURIFICATION; MECHANISM	The gamma complex (gamma delta delta'chi psi and tau complex (tau delta delta'chi psi) clamp loaders require ATP hydrolysis to load beta sliding clamps onto DNA. The beta sliding clamp tethers the polymerase (Pol) III* replicase to DNA for processive synthesis. Pol III* contains both gamma and tau, but only one each of the delta, delta', chi, and psi subunits. Hence, there is ambiguity with respect to which clamp loader, the gamma or tau complex, exists in the Pol III* replicase structure. In this study, ATP-binding site mutants of gamma and tau have been prepared, and these mutants, when assembled into either the gamma or tau complex, are inactive in clamp loading. These mutants have been used as a tool to determine the identity of the clamp loader in Pol III*. The nine-subunit Pol III* has been assembled using either mutant gamma or tau in place of wild-type gamma or tau. The results show that mutation of gamma inactivates Pol III* activity, but mutation of tau does not, indicating that the gamma complex (and not the tau complex) is the clamp loader of Pol III*. The tau subunit carries the task of dimerizing the core polymerase, and it is this association of tau with core that appears to direct the single copy subunits away from tau and onto gamma.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HEARST RES FDN,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; DONG A, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1992, BIOESSAYS, V14, P105, DOI 10.1002/bies.950140206; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	29	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13378	13383		10.1074/jbc.270.22.13378	http://dx.doi.org/10.1074/jbc.270.22.13378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768939	hybrid			2022-12-27	WOS:A1995RB43900064
J	TAMAOKA, A; ODAKA, A; ISHIBASHI, Y; USAMI, M; SAHARA, N; SUZUKI, N; NUKINA, N; MIZUSAWA, H; SHOJI, S; KANAZAWA, I; MORI, H				TAMAOKA, A; ODAKA, A; ISHIBASHI, Y; USAMI, M; SAHARA, N; SUZUKI, N; NUKINA, N; MIZUSAWA, H; SHOJI, S; KANAZAWA, I; MORI, H			APP717 MISSENSE MUTATION AFFECTS THE RATIO OF AMYLOID-BETA PROTEIN SPECIES (A-BETA-1-42/43 AND A-BETA-1-40) IN FAMILIAL ALZHEIMERS-DISEASE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRECURSOR PROTEIN; PEPTIDE; GENE; CODON-717; DEPOSITS; VAL->ILE; PLAQUE	We have biochemically purified A beta from brains of two unrelated familial Alzheimer's disease (FAD) pedigrees with the APP717 mutation (Val --> Ile) and from two sporadic Alzheimer's disease (AD) brains and characterized them by means of mass spectrometry and enzyme-linked immunosorbent assay, We observed two types of amyloid beta protein (A beta), the short-tail form (A beta 1-40) and the long tail form (A beta 1-42/43), in sporadic AD and FAD brains, and found that the ratio of the long-tail form of A beta (A beta 1-42/43) to total A beta was increased in FAD brains. These in vivo results were confirmed in vitro using cultured cells transfected with three kinds of APP cDNAs bearing the APP717 mutations (Val --> Ile, Gly, or Phe). Taken together with the hypothesis that A beta 1-42/43 functions as a ''seed'' that increases the kinetics of amyloid fibril formation (Jarrett, J. T., and Lansbury, P. T., Jr. (1993) Cell 73, 1055-1058), we conclude that the APP717 missense mutation does not create new A beta species but promotes the increased accumulation of A beta 1-42/43 in the brain, which results in the enhancement of amyloid fibril formation from soluble A beta. These findings provide a causal relationship between this FAD genotype and the pathological phenotype of A beta deposition and senile plaque formation.	TOKYO INST PSYCHIAT,DEPT MOLEC BIOL,SETAGAYA KU,TOKYO 156,JAPAN; UNIV TSUKUBA,INST CLIN MED,DEPT NEUROL,TSUKUBA,IBARAKI 305,JAPAN; TAKEDA CHEM IND LTD,DIV DISCOVERY RES,TSUKUBA,IBARAKI 30042,JAPAN; UNIV TOKYO,SCH MED,INST BRAIN RES,DEPT NEUROL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Institute of Psychiatry; University of Tsukuba; Takeda Chemical Industries; University of Tokyo			Nukina, Nobuyuki/GPP-6265-2022					CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; FRUCHT SJ, 1992, J NEUROPATH EXP NEUR, V51, P369; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; LADROR US, 1994, J BIOL CHEM, V269, P18422; LIEPNIEKS JJ, 1993, BIOCHEM BIOPH RES CO, V197, P386, DOI 10.1006/bbrc.1993.2491; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIZUSAWA H, 1992, 33RD P ANN M JAP SOC, P140; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SHOJI M, 1992, SCIENCE, V58, P126; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; YOSHIZAWA T, 1993, J NEUROL SCI, V117, P12, DOI 10.1016/0022-510X(93)90147-Q	23	154	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32721	32724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806491				2022-12-27	WOS:A1994QA63800004
J	BERG, JP; REE, AH; SANDVIK, JA; TASKEN, K; LANDMARK, BF; TORJESEN, PA; HAUG, E				BERG, JP; REE, AH; SANDVIK, JA; TASKEN, K; LANDMARK, BF; TORJESEN, PA; HAUG, E			1,25-DIHYDROXYVITAMIN D-3 ALTERS THE EFFECT OF CAMP IN THYROID-CELLS BY INCREASING THE REGULATORY SUBUNIT TYPE II-BETA OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; MOLECULAR-CLONING; CYCLIC-AMP; CDNA STRUCTURE; HORMONAL-REGULATION; RIBONUCLEIC-ACID; IODIDE UPTAKE; HUMAN TESTIS; RI-BETA; RAT	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) attenuates the stimulatory effects of cAMP on proliferation and iodide uptake in rat thyroid FRTL-5 cells. This study examines the effects of 1,25-(OH)(2)D-3 on the cAMP-dependent protein kinase (PKA). Cytosol proteins separated by anion exchange chromatography showed increased [H-3]cAMP binding activity as well as increased kinase activity in the fractions containing PKA type II in 1,25(OH)(2)D-3 (10 nM)-treated cells compared to the control cells, Western blot analysis of 1,25-(OH)(2)D-3-treated cells revealed a 4-fold increase in the cytosolic amount of the PKA regulatory subunit RII beta, whereas no changes were detected in the regulatory subunits RI alpha and RII alpha or the catalytic (C) subunit. Northern blot analyses showed a similar increase in RII beta mRNA in cells treated for 12 h with 1,25-(OH)(2)D-3 (10 nM), and RII beta mRNA increased further to 10-fold above control cell level after 96 h of incubation. Iodide uptake was synergistically stimulated with both PKAI- and PKAII-directed pairs of cAMP analogs, The PKAI synergism was, however, inhibited by 1,25-(OH)(2)D-3 treatment of the cells, whereas the PKAII synergism was unaffected. In conclusion, 1,25-(OH)(2)D-3 attenuates both PKAI formation and PKAI-stimulated iodide uptake in rat thyroid FRTL-5 cells by increasing the level of RII beta without altering the other PKA subunit levels.	NORWEGIAN RADIUM HOSP, INST CANC RES, DEPT TISSUE CULTURE, N-0310 OSLO, NORWAY; UNIV OSLO, INST MED BIOCHEM, N-0317 OSLO, NORWAY	University of Oslo; University of Oslo	BERG, JP (corresponding author), AKER HOSP, HORMONE LAB, TRONDHEIMSVEIEN 235, N-0514 OSLO, NORWAY.		Landmark, Brynjar/AAK-2165-2020; Berg, Jens P/G-1455-2012	Berg, Jens P/0000-0003-0157-5888; Ree, Anne H./0000-0002-8264-3223				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BERG JP, 1994, J STEROID BIOCHEM, V50, P145, DOI 10.1016/0960-0760(94)90021-3; BERG JP, 1991, ACTA ENDOCRINOL-COP, V125, P574, DOI 10.1530/acta.0.1250574; BERG JP, 1994, ENDOCRINOLOGY, V135, P595, DOI 10.1210/en.135.2.595; BERG JP, 1993, THYROID, V3, P245, DOI 10.1089/thy.1993.3.245; BERG JP, 1991, MOL CELL ENDOCRINOL, V76, P201, DOI 10.1016/0303-7207(91)90274-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COBB CE, 1988, METHOD ENZYMOL, V159, P202; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; EGAN JJ, 1988, ANAL BIOCHEM, V175, P552, DOI 10.1016/0003-2697(88)90583-0; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG-ALLARDT C, 1991, MOL CELL ENDOCRINOL, V81, P25, DOI 10.1016/0303-7207(91)90201-3; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OGREID D, 1989, EUR J BIOCHEM, V167, P27; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P1293; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5186; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TASKEN K, 1994, MOL CELL ENDOCRINOL, P185; TORTORA G, 1993, CELL GROWTH DIFFER, V4, P359; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANSANDE J, 1989, EUR J BIOCHEM, V183, P699, DOI 10.1111/j.1432-1033.1989.tb21101.x; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WALTER U, 1983, METHOD ENZYMOL, V99, P154; WALTERS MR, 1992, ENDOCR REV, V13, P4719; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P2123	48	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32233	32238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798223				2022-12-27	WOS:A1994PX30400036
J	KIMURA, M; HAMA, Y; SUMI, T; ASAKAWA, M; RAO, BNN; HORNE, AP; LI, SC; LI, YT; NAKAGAWA, H				KIMURA, M; HAMA, Y; SUMI, T; ASAKAWA, M; RAO, BNN; HORNE, AP; LI, SC; LI, YT; NAKAGAWA, H			CHARACTERIZATION OF A DEAMINATED NEURAMINIC ACID-CONTAINING GLYCOPROTEIN FROM THE SKIN MUCUS OF THE LOACH MISGURNUS-ANGUILLICAUDATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCAN CHAINS; RAINBOW-TROUT EGGS; RICH GLYCOPROTEIN; JELLY COAT; VITELLINE ENVELOPE; KDN; POLYSIALOGLYCOPROTEIN; CHROMATOGRAPHY; DETERMINANTS	Using NMR spectroscopy and mass spectrometry, the major sialic acid of the skin mucus of the leach, Misgurnus anguillicaudatus was found to be 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN). We have subsequently devised a method to isolate a KDN-containing glycoprotein preparation from leach skin mucus. The method involves the sonication of the skin mucus with 0.05 M Tris-HCl, pH 8.0, to solubilize the glycoprotein, followed by DE52-cellulose chromatography of the extract, Nuclease P-1 treatment, and Sepharose CL-4B gel filtration. The purified glycoprotein preparation was found to contain 38.5% KDN, 0.4% NeuAc, 24.6% GalNAc, 3.3% Gal, and 28.2% amino acids (w/w). The amino acid composition of this glycoprotein preparation revealed that it is unusually rich in Thr, and 6 amino acids, Thr, Ser, Glu (or Gin), Pro, Gly and Ala, account for 83% of the total amino acids. This glycoprotein is extremely poor in Cys, Met, Tyr, Phe, Arg, and Trp. Treatment of this glycoprotein with alkali resulted in the destruction of 83% of Thr suggesting that most of the sugar chains in this glycoprotein are linked through Thr. Alkaline borohydride treatment of 100 mg of the glycoprotein preparation, followed by Sephadex G-25 (superfine) gel filtration, yielded two major oligosaccharide alditols, I (15.4 mg) and II (15.6 mg). Using Liquid secondary ion mass spectrometry and methylation analysis, I was identified to be KDN alpha 2-->6GalNAc-ol and II, KDN alpha 2-->6(KDN alpha 2-->3)-GalNAc-ol. KDN alpha 2-->GalNAc is structurally similar to NeuAc alpha 2-->6GalNAc found in ovine submaxillary glycoprotein while II represents a novel structure which contains two sialic acids linked to a GalNAc through both alpha 2-->3 and alpha 2-->6 linkages. This structure has never been found in mucin type glycoproteins including mammalian epithelial mucin glycoproteins. This is the first report of the presence of a mucin type glycoprotein which contains ISDN instead of NeuAc or NeuGc in fish skin mucus.	TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA; SAGA UNIV, FAC AGR, DEPT APPL BIOL SCI, SAGA 840, JAPAN; KUMAMOTO UNIV, FAC EDUC, FOOD SCI LAB, KUMAMOTO 860, JAPAN; GLYCOMED INC, ALAMEDA, CA 94501 USA	Tulane University; Saga University; Kumamoto University					NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUDDECKE E, 1972, GLYCOPROTEINS      A, P535; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FAILLARD H, 1972, GLYCOPROTEINS THEIR, P1246; GOTTSCHALK A, 1972, GLYCOPROTEINS THEIR, P810; HARRIS G, 1954, CHEM IND-LONDON, P249; Haverkamp J., 1982, SIALIC ACIDS CHEM ME, P127; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; LI YT, 1990, J BIOL CHEM, V265, P21629; NADANO D, 1986, J BIOL CHEM, V261, P1550; PICKERING AD, 1974, J FISH BIOL, V6, P111, DOI 10.1111/j.1095-8649.1974.tb04531.x; RAUVALA H, 1977, CARBOHYD RES, V56, P1, DOI 10.1016/S0008-6215(00)84231-7; ROSE MC, 1989, METHOD ENZYMOL, V179, P3; SARTIN JL, 1980, J BIOL CHEM, V255, P8633; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; WHITEAR M, 1984, BIOL INTEGUMENT, V2, P8; WOLD JK, 1977, COMP BIOCHEM PHYS B, V56, P215, DOI 10.1016/0305-0491(77)90002-5; YU RK, 1970, J LIPID RES, V11, P506	28	56	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32138	32143						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798209				2022-12-27	WOS:A1994PX30400021
J	SANADA, K; KOKAME, K; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y; FUKADA, Y				SANADA, K; KOKAME, K; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y; FUKADA, Y			ROLE OF HETEROGENEOUS N-TERMINAL ACYLATION OF RECOVERIN IN RHODOPSIN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; ROD OUTER SEGMENTS; CGMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; LIGHT ADAPTATION; AMINO TERMINUS; ALPHA-SUBUNIT; RETINAL RODS; S-MODULIN; KINASE	Recoverin, a new member of the EF-hand superfamily, plays a critical role in the light/dark adaptation of retinal rods by regulating rhodopsin phosphorylation in a Ca2+-dependent manner. Recoverin is composed of four isoforms, each of which is modified at its N terminus by myristate (C14:0) or its structurally related fatty acid (C12:0, C14:2, or C14:1). Although the N-fatty acylation is implicated in protein-membrane and protein-protein interactions, the functional difference among the recoverin isoforms and the significance of the heterogeneous acylation have not been defined. Here we separated the heterogeneous recoverin into three fractions, C14:0-recoverin, C14:1-recoverin, and a mixture of C14:2- and C12:0- (C14:2/C12:0-) recoverin to evaluate the individual properties. Recoverin in every fraction bound Ca2+ as assessed by fluorescence spectroscopy and inhibited the light-dependent rhodopsin phosphorylation in the same range of free Ca2+ concentration (0.3-0.8 mu M). However, the magnitude of the inhibition at higher Ca2+ concentration was different among the isoforms and ranked in the same order of the hydrophobicity of the N fatty acyl groups: C14:0 > C14:1 > C14:2/C12:0. These results indicate that the diverged hydrophobicity of the recoverin N terminus plays an important role in the interaction with the membranes and/or its target protein but not with Ca2+.	UNIV TOKYO, GRAD SCH ARTS & SCI, DEPT LIFE SCI, MEGURO KU, TOKYO 153, JAPAN; OSAKA SANGYO UNIV, FAC ENGN, DEPT INFORMAT SYST ENGN, OSAKA 574, JAPAN; OSAKA UNIV, INST PROT RES, OSAKA 565, JAPAN	University of Tokyo; Osaka University			吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299; Sanada, Kamon/0000-0002-0280-8957				AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V86, P5262; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	35	31	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15459	15462		10.1074/jbc.270.26.15459	http://dx.doi.org/10.1074/jbc.270.26.15459			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797536	hybrid			2022-12-27	WOS:A1995RG53800005
J	YUN, HY; EIPPER, BA				YUN, HY; EIPPER, BA			ADDITION OF AN ENDOPLASMIC-RETICULUM RETENTION RETRIEVAL SIGNAL DOES NOT BLOCK MATURATION OF ENZYMATICALLY ACTIVE PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE PROCESSING ENZYME; SECRETORY GRANULES; PROTEIN RETENTION; ATT-20 CELLS; EXPRESSION; INTERMEDIATE; ACTIVATION; CLEAVAGE; CONTAIN; DOMAIN	Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the COOH-terminal alpha-amidation of neural and endocrine peptides via a two-step reaction carried out in sequence by the monooxygenase and lyase domains contained in this bifunctional protein. Peptide alpha-amidation is thought to take place primarily in the secretory granules in which mature bioactive peptides are stored, and it is not known where in the secretory compartment newly synthesized PAM protein becomes enzymatically active. To address this question, PAM-3, a soluble bifunctional protein, was modified by addition of the KDEL endoplasmic reticulum (ER) retention/retrieval signal to its COOH terminus. PAM 3 KDEL protein stably expressed in hEK-293 cells or in AtT-20 cells was efficiently retained in the ER based on immunocytochemistry, pulse-chase experiments, and maintained endoglycosidase H sensitivity. The effect of the KDEL sequence was specific since PAM-3 with an inactive ER retention/retrieval signal (PAM-3-KDEV) moved through the secretory pathway Like wild type PAM-3. In AtT-20 cells, PAM-3-KDEL was not subjected to the COOH-terminal endoproteolytic cleavage that generates a 75 kDa PAM protein from PAM-3 and PAM-3 KDEV. PAM-3-KDEL protein exhibited both monooxygenase and lyase activities with specific activities similar to those of the wild type PAM-3 and PAM-3-KDEV proteins. Thus, although PAM catalyzes a reaction that occurs primarily in the secretory granules, newly synthesized PAM protein becomes enzymatically competent in the ER.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R01DK032949, R37DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VINDROLA O, 1993, MOL ENDOCRINOL, V6, P1441; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; YUN HY, 1994, J BIOL CHEM, V269, P10946; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P777; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633; ZHOU A, 1994, J BIOL CHEM, V269, P17440	39	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15412	15416		10.1074/jbc.270.25.15412	http://dx.doi.org/10.1074/jbc.270.25.15412			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797530	hybrid			2022-12-27	WOS:A1995RE66600084
J	BRIGGS, SD; BRYANT, SS; JOVE, R; SANDERSON, SD; SMITHGALL, TE				BRIGGS, SD; BRYANT, SS; JOVE, R; SANDERSON, SD; SMITHGALL, TE			THE RAS GTPASE-ACTIVATING PROTEIN (GAP) IS AN SH3 DOMAIN-BINDING PROTEIN AND SUBSTRATE FOR THE SRC-RELATED TYROSINE KINASE, HCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE HCK; C-SRC; PHOSPHATIDYLINOSITOL 3'-KINASE; GROWTH-FACTOR; 3T3 CELLS; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; REGION; IDENTIFICATION	The Ras GTPase-activating protein (GAP) is a target for protein tyrosine kinases of both the receptor and cytoplasmic classes and may serve to integrate tyrosine kinase and Pas signaling pathways. In this report, we provide evidence that GAP is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase lick which has been implicated in the regulation of myeloid cell growth, differentiation, and function. Wild-type (WT) or kinase-inactive (K269E) mutant lick proteins were co expressed with bovine GAP using the baculovirus/Sf-9 cell system. GAP was readily phosphorylated on tyrosine by WT but not K269E lick. GAP was present in WT Hck immunoprecipitates from the coinfected cells, indicative of Hck . GAP complex formation. Unexpectedly, GAP also associated with the kinase-inactive mutant of Hck, suggesting that tyrosine autophosphorylation of Hck is not required for complex formation. The WT and K269E forms of Hck also associated with GAP mutants lacking either the C-terminaI catalytic domain (Delta CAT) or the Src homology region (Delta SH), indicating that these GAP domains are dispensable for complex formation. Recombinant GST fusion proteins containing the Hck, Src, Fyn, or Lck SH3 domains associated with full-length GAP, Delta CAT, and Delta SH, all of which share an N-terminal proline-rich region resembling an SH3-binding motif (PPLPPPPPQLP). Deletion of the highly conserved YXY sequence from the Hck SH3 domain abolished binding, GAP-SH3 interaction was also inhibited by the proline-rich peptide GFPPLP-PPPPQLPTLG, which corresponds to N-terminal amino acids 129-144 of bovine GAP. An N-terminal deletion mutant of GAP lacking this proline-rich region did not bind to the lick SH3 domain. These data implicate the Hck SH3 domain in GAP interaction, and suggest a general function for the SH3 domains of Src family kinases in recognition of GAP via its proline-rich N-terminal domain.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV MICHIGAN, SCH MED, MOLEC & CELLULAR BIOL PROGRAM, ANN ARBOR, MI 48109 USA	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan				Briggs, Scott D/0000-0003-2852-3594	NATIONAL CANCER INSTITUTE [R01CA055652, P30CA036727, R01CA058667] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727, CA58667, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOULET I, 1992, ONCOGENE, V7, P703; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKADA M, 1993, J BIOL CHEM, V268, P18070; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; PARK S, 1993, J BIOL CHEM, V268, P25728; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRONK GJ, 1992, ONCOGENE, V7, P389; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SANDERSON SD, 1994, J MED CHEM, V37, P3171, DOI 10.1021/jm00045a023; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	56	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14718	14724		10.1074/jbc.270.24.14718	http://dx.doi.org/10.1074/jbc.270.24.14718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782336	hybrid			2022-12-27	WOS:A1995RD45500073
J	HOLTMANN, MH; HADAC, EM; MILLER, LJ				HOLTMANN, MH; HADAC, EM; MILLER, LJ			CRITICAL CONTRIBUTIONS OF AMINO-TERMINAL EXTRACELLULAR DOMAINS IN AGONIST BINDING AND ACTIVATION OF SECRETIN AND VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS - STUDIES OF CHIMERIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; PEPTIDE; GENE	Secretin and vasoactive intestinal polypeptide (VIP) receptors are closely related G protein-coupled receptors in a recently described family possessing a large amino-terminal ectodomain, We postulated that this domain might be critical for agonist recognition and therefore constructed a series of six chimeric receptors, exchanging the amino terminus, the first extracellular loop, or both in secretin and VIP receptors, Constructs were expressed in COS cells and characterized by cAMP generation and binding of both secretin and MP radioligands, Wild type receptors demonstrated high affinity binding of respective ligands (IC50 values (in nM): at the secretin receptor: 2.2 for secretin, > 1000 for VIP; at the MP receptor: 2.2 for VIP, >1000 for secretin) and appropriately sensitive and selective biological responses (EC(50) values (in nM): at the secretin receptor: 1.5 for secretin, 127 for VIP; at the VIP receptor: 1.0 for VIP, 273 for secretin). Replacement of the secretin receptor amino terminus with that of the VIP receptor resulted in biological responsiveness typical of the VIP receptor (EC(50) = 120 nM for secretin, 1.7 nM for VIP), The converse was not true, with this domain of the secretin receptor not able to provide the same response when incorporated into the VIP receptor (EC(50) = 50 nM for VIP, 30 nM for secretin). The addition of both the first loop and the amino terminus of the secretin receptor was effective in yielding a secretin receptor-like response (EC(50) = 2.0 nM for secretin, 47 Im for VIP). All chimeric constructs expressing selectivity for secretin-stimulated activity bound this hormone with high affinity (IC50 = 0.2-2.2 nM); however, there was divergence between VIP binding and biological activity, Thus, the amino terminus of secretin and VIP receptors plays a key role in agonist recognition and responsiveness, with the first loop playing a critical complementary role for the secretin receptor.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MUTT V, 1980, GASTROINTESTINAL HOR, P85; ROSSELIN G, 1986, PEPTIDES, V7, P89, DOI 10.1016/0196-9781(86)90170-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6	19	166	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14394	14398		10.1074/jbc.270.24.14394	http://dx.doi.org/10.1074/jbc.270.24.14394			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782300	hybrid			2022-12-27	WOS:A1995RD45500027
J	OHGURO, H; VANHOOSER, JP; MILAM, AH; PALCZEWSKI, K				OHGURO, H; VANHOOSER, JP; MILAM, AH; PALCZEWSKI, K			RHODOPSIN PHOSPHORYLATION AND DEPHOSPHORYLATION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; LIGHT-DEPENDENT PHOSPHORYLATION; COUPLED RECEPTOR KINASES; PHOTOEXCITED RHODOPSIN; VISUAL TRANSDUCTION; BOVINE RHODOPSIN; 48-KDA PROTEIN; ACTIVATION; SITES; IDENTIFICATION	Rhodopsin is an important member of the superfamily of G protein-coupled receptors. In vitro studies have suggested that multiphosphorylation of rhodopsin is a pivotal step in phototransduction. Because the in vitro biochemical experiments were conducted under non-physiological conditions, we investigated the phosphorylation of mouse rhodopsin in vivo and determined the sites of phosphorylation and the time course of dephosphorylation. We found that a single phosphate group is incorporated into the rhodopsin molecule in a light-dependent manner, primarily at Ser(338) after flashes and at Ser(334) after continuous illumination. Dephosphorylation of these sites had different kinetics and spatial distribution in rod outer segments. Dephosphorylation of Ser(338) was complete within 30 min, while Ser(334) was dephosphorylated much slower (requiring up to 60 min), correlating with the regeneration of rhodopsin. These results suggest that phosphorylation of Ser(338) and Ser(334) plays different roles in phototransduction.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	OHGURO, H (corresponding author), UNIV WASHINGTON,SCH MED,DEPT OPHTHALMOL,RJ-10,SEATTLE,WA 98195, USA.				NATIONAL EYE INSTITUTE [R29EY008061, R01EY001311, R01EY008061, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY01311, EY08061, EY09339] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, HYBRIDOMA, V7, P237, DOI 10.1089/hyb.1988.7.237; ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BALKEMA GW, 1985, NATURE, V316, P630, DOI 10.1038/316630a0; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DOWLING JE, 1963, NATURE, V199, P972, DOI 10.1038/199972a0; DOWLING JE, 1963, J GEN PHYSIOL, V46, P1287, DOI 10.1085/jgp.46.6.1287; FARNSWORTH CC, 1982, METHOD ENZYMOL, V81, P124; FRANK RN, 1973, J BIOL CHEM, V248, P596; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HODGKIN AL, 1987, J PHYSIOL-LONDON, V391, P347, DOI 10.1113/jphysiol.1987.sp016742; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIEBMAN PA, 1983, J BIOL CHEM, V258, P1205; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MOLDAY RS, 1988, PROGR RETINAL RES, V8, P173; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1995, IN PRESS J BIOL CHEM; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; 1993, J AM VET MED ASSOC, V202, P2	38	166	170	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14259	14262		10.1074/jbc.270.24.14259	http://dx.doi.org/10.1074/jbc.270.24.14259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782279	hybrid			2022-12-27	WOS:A1995RD45500005
J	BENESCH, RE; KWONG, S				BENESCH, RE; KWONG, S			COUPLED REACTIONS IN HEMOGLOBIN - HEME-GLOBIN AND DIMER-DIMER ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMERS; CHAINS	Five different human hemoglobins were used to test the postulate that dissociation of hemoglobin (Hb) tetramers into alpha beta dimers and dissociation of heme from globin are linked reactions, Spectrophotometric measurements of the initial rate of heme transfer from Hb to serum albumin were made over a 3000-fold range of Hb concentration and yielded the heme-globin dissociation rate constant for tetramers and that for dimers. The tetramer-dimer dissociation constant (K-4,K-2) could then be calculated from the rate constant at intermediate concentrations. The values obtained for the five hemoglobins, spanning a 250-fold range in K-4,K-2, were in good agreement with those found by direct methods. The relation between this new linkage reaction of hemoglobin and the classical ones, such as the reciprocal relation between the binding of oxygen and protons, is discussed briefly.			BENESCH, RE (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-05791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005791, R01HL005791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENESCH RE, 1991, J PROTEIN CHEM, V10, P503, DOI 10.1007/BF01025478; BENESCH RE, 1994, METHOD ENZYMOL, V231, P496; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BUNN HF, 1968, J BIOL CHEM, V243, P465; Cassoly R, 1981, Methods Enzymol, V76, P121; CHARACHE S, 1975, JOHNS HOPKINS MED J, V136, P132; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x; JONES RT, 1967, J CLIN INVEST, V46, P1840, DOI 10.1172/JCI105674; Kilmartin J V, 1981, Methods Enzymol, V76, P167; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WINTERHALTER KH, 1971, BIOCHEMISTRY-US, V10, P3790, DOI 10.1021/bi00796a023; WYMAN J, 1948, ADV PROTEIN CHEM, V4, P407, DOI 10.1016/S0065-3233(08)60011-X; ZWART A, 1984, CLIN CHEM, V30, P373; ZWART A, 1981, J CLIN CHEM CLIN BIO, V19, P457	16	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13785	13786		10.1074/jbc.270.23.13785	http://dx.doi.org/10.1074/jbc.270.23.13785			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775434	hybrid			2022-12-27	WOS:A1995RC44800032
J	BORKOWSKI, JA; RANSOM, RW; SEABROOK, GR; TRUMBAUER, M; CHEN, H; HILL, RG; STRADER, CD; HESS, JF				BORKOWSKI, JA; RANSOM, RW; SEABROOK, GR; TRUMBAUER, M; CHEN, H; HILL, RG; STRADER, CD; HESS, JF			TARGETED DISRUPTION OF A B-2 BRADYKININ RECEPTOR GENE IN MICE ELIMINATES BRADYKININ ACTION IN SMOOTH-MUSCLE AND NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PHARMACOLOGICAL CHARACTERIZATION; VAS-DEFERENS; ANTAGONIST; RAT; POTENT; PHOSPHOLIPASE-A2; STIMULATION; KALLIKREIN; ACTIVATION	Mice that are homozygous for the targeted disruption of the gene encoding the B-2, bradykinin receptor have been generated. The gene disruption results in a deletion of the entire coding sequence for the B-2 receptor. The disruption of the B-2 receptor gene has been confirmed by genetic, biochemical, and pharmacological analyses. Mice that are homozygous for the disruption of the B-2 receptor gene are fertile and indistinguishable from their littermates by visual inspection. Bradykinin fails to produce responses in pharmacological preparations from ileum, uterus, and the superior cervical ganglia from these mice. Therefore, expression of a single gene appears to be responsible for conferring responsiveness to bradykinin in these tissues.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT ANIM BIOCHEM & MOLEC BIOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME RES LABS, DEPT NEW LEAD PHARMACOL, West Point, PA 19586 USA; MERCK SHARP & DOHME RES LABS, DEPT PHARMACOL, HARLOW CM20 2QR, ESSEX, ENGLAND	Merck & Company; Merck & Company; Merck & Company; Merck & Company								BORKOWSKI JA, 1995, IN PRESS CAN J PHYSL; BRAAS KM, 1988, BRIT J PHARMACOL, V94, P3, DOI 10.1111/j.1476-5381.1988.tb11492.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BURCH RM, 1989, AGENTS ACTIONS, V27, P258, DOI 10.1007/BF01972790; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; FARMER SG, 1989, MOL PHARMACOL, V36, P1; FARMER SG, 1994, BRIT J PHARMACOL, V112, P461, DOI 10.1111/j.1476-5381.1994.tb13095.x; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; HEDER G, 1994, ANDROLOGIA, V26, P295; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KAYA H, 1989, J BIOL CHEM, V264, P4972; LIEBMANN C, 1991, EUR J PHARMACOL, V199, P363, DOI 10.1016/0014-2999(91)90501-G; LIEBMANN C, 1994, MOL PHARMACOL, V46, P949; LINZ W, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199306229-00002; LLONA I, 1987, J PHARMACOL EXP THER, V241, P608; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PERKINS MN, 1993, BRIT J PHARMACOL, V110, P1441, DOI 10.1111/j.1476-5381.1993.tb13982.x; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; RANSOM RW, 1992, BRIT J PHARMACOL, V105, P919, DOI 10.1111/j.1476-5381.1992.tb09078.x; REGOLI D, 1986, EUR J PHARMACOL, V127, P219, DOI 10.1016/0014-2999(86)90367-5; REGOLI D, 1978, CAN J PHYSIOL PHARM, V56, P674, DOI 10.1139/y78-109; REGOLI D, 1977, CAN J PHYSIOL PHARM, V55, P855, DOI 10.1139/y77-115; REGOLI D, 1980, PHARMACOL REV, V32, P1; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; RIFO J, 1987, EUR J PHARMACOL, V142, P305, DOI 10.1016/0014-2999(87)90120-8; SAHA JK, 1990, J PHARMACOL EXP THER, V252, P1012; SAWUTZ DG, 1994, P NATL ACAD SCI USA, V91, P4693, DOI 10.1073/pnas.91.11.4693; SCHNECK KA, 1994, EUR J PHARM-MOLEC PH, V266, P277, DOI 10.1016/0922-4106(94)90137-6; SEABROOK GR, 1995, IN PRESS BR J PHARM; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; VALDES G, 1993, BIOL REPROD, V49, P802, DOI 10.1095/biolreprod49.4.802; Vavrek RJ, 1985, PEPTIDES, P655; WIRTH K, 1991, EUR J PHARMACOL, V205, P217, DOI 10.1016/0014-2999(91)90824-A; YAMAWAKI I, 1994, AM J PHYSIOL, V266, pL156, DOI 10.1152/ajplung.1994.266.2.L156; YOKOYAMA S, 1994, BIOCHEM BIOPH RES CO, V200, P634, DOI 10.1006/bbrc.1994.1495	47	203	203	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13706	13710		10.1074/jbc.270.23.13706	http://dx.doi.org/10.1074/jbc.270.23.13706			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775424	hybrid			2022-12-27	WOS:A1995RC44800021
J	CHEN, HF; KENDALL, DA				CHEN, HF; KENDALL, DA			ARTIFICIAL TRANSMEMBRANE SEGMENTS - REQUIREMENTS FOR STOP TRANSFER AND POLYPEPTIDE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; POSITIVELY CHARGED RESIDUES; AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; SIGNAL PEPTIDE; ANCHOR DOMAIN; STRUCTURAL REQUIREMENTS; HYDROPHOBIC DOMAIN; DELETION ANALYSIS	Transmembrane segments of proteins generally consist of a long stretch of hydrophobic amino acids, which can function to initiate membrane insertion (start-stop sequences), initiate translocation (signal-anchor sequences), or stop further translocation of the following polypeptide chain (stop-transfer sequences). In this study, we have taken Escherichia coli alkaline phosphatase, a transported and water-soluble protein, and examined the requirements for converting it into a transmembrane protein with particular orientation. Since the wild type enzyme is transported, there is no predisposition against membrane translocation, yet it is not a membrane protein, so it does not possess any intrinsic membrane topogenic preferences. A series of potential transmembrane segments was introduced into an internal position of the enzyme to test the ability of each to initiate translocation, stop translocation, and adopt a particular orientation. For this purpose, cassette mutagenesis was used to incorporate new structural segments composed of polymers of alanines and leucines. The threshold value of hydrophobicity required to function as a stop-transfer sequence was determined. For a transmembrane segment of typical length (21 residues), this value is equivalent to the hydrophobicity of 16 alanines and 5 leucines. Interestingly, much shorter segments mill also suffice to stop translocation, but these must be composed of more highly hydrophobic residues (e.g. 11 leucines). When the wild type amino-terminal signal peptide is deleted or made dysfunctional, sufficiently hydrophobic internal segments can initiate translocation of the following polypeptide and function as a signal anchor. Furthermore, in so doing, the orientation of the protein is changed from N-out-C-in to N-in-C-out.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269	University of Connecticut					NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ARFMANN HA, 1977, BIOPOLYMERS, V16, P1815, DOI 10.1002/bip.1977.360160815; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIS NG, 1986, P NATL ACAD SCI USA, V83, P5091, DOI 10.1073/pnas.83.14.5091; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FERRETTI JA, 1969, BIOPOLYMERS, V7, P155, DOI 10.1002/bip.1969.360070203; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HSU MC, 1983, VIROLOGY, V126, P361, DOI 10.1016/0042-6822(83)90485-3; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; TAHARA Y, 1992, BIOCHEMISTRY-US, V31, P8747, DOI 10.1021/bi00152a010; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x	51	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14115	14122		10.1074/jbc.270.23.14115	http://dx.doi.org/10.1074/jbc.270.23.14115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775472	hybrid			2022-12-27	WOS:A1995RC44800077
J	PLAWNER, LL; PHILBRICK, WM; BURTIS, WJ; BROADUS, AE; STEWART, AF				PLAWNER, LL; PHILBRICK, WM; BURTIS, WJ; BROADUS, AE; STEWART, AF			CELL-TYPE-SPECIFIC SECRETION OF PARATHYROID HORMONE-RELATED PROTEIN VIA THE REGULATED VERSUS THE CONSTITUTIVE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE; PRECURSOR; GLUCOSE; CANCER; GENE	Parathyroid hormone-related protein (PTHrP) is endoproteolytically processed to yield a family of mature secretory forms. These include an amino-terminal, a mid-region, and a carboxyl-terminal form. Prior studies suggested that the mid-region form is secreted via the regulated secretory pathway, whereas the amino- and carboxyl-terminal forms are secreted via the constitutive pathway. Further, PTHrP is unusual in that it is produced under normal circumstances by neuroendocrine cell types as well as by prototypical constitutively secreting cell types. The potential for cell-specific secretory pathway use by PTHrP has not been explored. Using immunohistochemical and perifusion techniques, we demonstrate that all three PTHrP daughter peptides are secreted via the regulated pathway in neuroendocrine cells. In contrast, all three daughter peptides are secreted in a constitutive fashion by non-neuroendocrine cells. Thus, the secretion of PTRrP is unique in that it appears to be cell-specific. When it is expressed in neuroendocrine cells that contain the regulated pathway, it is secreted in a regulated fashion; when it is expressed in non-neuroendocrine cells, it defaults to the constitutive pathway. This phenomenon has not previously been described for a polypeptide hormone in naturally occurring cells.	W HAVEN VET AFFAIRS MED CTR,DIV ENDOCRINOL & METAB,W HAVEN,CT 06516; YALE UNIV,SCH MED,DIV ENDOCRINOL & METAB,NEW HAVEN,CT 06520	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030102, R37AR030102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047168] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30102] Funding Source: Medline; NIDDK NIH HHS [DK47168] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDT DW, 1991, ENDOCRINOLOGY, V128, P2999, DOI 10.1210/endo-128-6-2999; BRANDT DW, 1991, ENDOCRINOLOGY, V129, P2466, DOI 10.1210/endo-129-5-2466; BURTIS WJ, 1994, J CLIN ENDOCR METAB, V78, P317, DOI 10.1210/jc.78.2.317; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; BUZZETTI R, 1989, J CLIN INVEST, V83, P733, DOI 10.1172/JCI113940; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; DEFTOS LJ, 1993, J CLIN INVEST, V92, P727, DOI 10.1172/JCI116643; DRUCKER DJ, 1989, MOL ENDOCRINOL, V3, P1589, DOI 10.1210/mend-3-10-1589; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; KELLY RB, 1985, SCIENCE, V240, P25; LI KW, 1994, ENDOCRINOLOGY, V134, P1812, DOI 10.1210/en.134.4.1812; LOH YP, 1993, MECHANISMS INTRACELL; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; RABBANI SA, 1993, BIOCHEMISTRY-US, V32, P4931, DOI 10.1021/bi00069a030; RIZZOLI R, 1994, INT J CANCER, V56, P422, DOI 10.1002/ijc.2910560323; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SOIFER NE, 1992, J BIOL CHEM, V267, P18236; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; VOLLMAR AM, 1994, J CLIN INVEST, V94, P539, DOI 10.1172/JCI117367; WU TL, 1991, J CLIN ENDOCR METAB, V73, P1002, DOI 10.1210/jcem-73-5-1002; YANG KH, 1994, BIOCHEMISTRY-US, V33, P7460, DOI 10.1021/bi00189a054; ZAWALICH WS, 1988, DIABETES, V37, P1294, DOI 10.2337/diabetes.37.9.1294	25	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14078	14084		10.1074/jbc.270.23.14078	http://dx.doi.org/10.1074/jbc.270.23.14078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775469	hybrid			2022-12-27	WOS:A1995RC44800072
J	WU, J; MATUNIS, MJ; KRAEMER, D; BLOBEL, G; COUTAVAS, E				WU, J; MATUNIS, MJ; KRAEMER, D; BLOBEL, G; COUTAVAS, E			NUP358, A CYTOPLASMICALLY EXPOSED NUCLEOPORIN WITH PEPTIDE REPEATS, RAN-GTP BINDING-SITES, ZINC FINGERS, A CYCLOPHILIN-A HOMOLOGOUS DOMAIN, AND A LEUCINE-RICH REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX PROTEIN; NUCLEAR-PORE; IMPORT; RECEPTOR; RAN/TC4	The Ras-related nuclear protein, Ran, has been implicated in nuclear transport, By screening a HeLa cell lambda expression library with Ran-GTP and sequencing overlapping cDNA clones, we have obtained the derived primary structure of a protein with a calculated molecular mass of 358 kDa, Using antibodies raised against an expressed segment of this protein, we obtained punctate nuclear surface staining by immunofluorescence microscopy that is characteristic for nucleoporins, Electron microscopy of immunogold-decorated rat liver nuclear envelopes sublocalized the 358-kDa protein at (or near) the tip of the cytoplasmic fibers of the nuclear pore complex (NPC), In agreement with current convention, this protein was therefore termed Nup358 (for nucleoporin of 358 kDa), Nup358 contains a leucine-rich region, four potential Ran binding sites (i.e. Ran binding protein 1 homologous domains) flanked by nucleoporin-characteristic FXFG or FG repeats, eight zinc finger motifs, and a C-terminal cyclophilin A homologous domain, Consistent with the location of Nup358 at the cytoplasmic fibers of the NPC, we found decoration with Ran-gold at only the cytoplasmic side of the NPC, Thus, Nup358 is the first nucleoporin shown to contain binding sites for two of three soluble nuclear transport factors so far isolated, namely karyopherin and Ran-GTP.			WU, J (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.			Coutavas, Elias/0000-0003-4904-0081; Matunis, Michael/0000-0002-9350-6611	NIGMS NIH HHS [1F32GM16758-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CULLEN BR, 1994, NATURE, V372, P319, DOI 10.1038/372319a0; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HARLOW E, 1988, ANTIBODIES LABORATOR; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1993, J CELL BIOL, V121, P1, DOI 10.1083/jcb.121.1.1; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sambrook J, 1989, MOL CLONING LABORATO; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	405	411	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14209	14213		10.1074/jbc.270.23.14209	http://dx.doi.org/10.1074/jbc.270.23.14209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775481	hybrid			2022-12-27	WOS:A1995RC44800089
J	GOFFIN, V; STRUMAN, I; MAINFROID, V; KINET, S; MARTIAL, JA				GOFFIN, V; STRUMAN, I; MAINFROID, V; KINET, S; MARTIAL, JA			EVIDENCE FOR A 2ND RECEPTOR-BINDING SITE ON HUMAN PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ALANINE-SCANNING MUTAGENESIS; EXTRACELLULAR DOMAIN; BIOLOGICAL PROPERTIES; LACTOGENIC HORMONES; BOVINE PROLACTIN; RATIONAL DESIGN; PROTEIN; FAMILY; ERYTHROPOIETIN	The existence of a second receptor binding site on human prolactin (hPRL) was investigated by site-directed mutagenesis. First, 12 residues of helices 1 and 3 were mutated to alanine. Since none of the resulting mutants exhibit reduced bioactivity in the Nb2 cell proliferation bioassay, the mutated residues do not appear to be functionally necessary. Next, small residues surrounding the helix 1-helix 3 interface were replaced with Arg and/or Trp, the aim being to sterically hinder the second binding site. Several of these mutants exhibit only weak agonistic properties, supporting our hypothesis that the channel between helices 1 and 3 is involved in a second receptor binding site. We then analyzed the antagonistic and self-antagonistic properties of native hPRL and of several hPRLs analogs altered at binding site 1 or 2. Even at high concentrations (similar to 10 mu M), no self-inhibition was observed with native hPRL; site 2 hPRL mutants self-antagonized while site 1 mutants did not. From these data, we propose a model of hPRL-PRL receptor interaction which slightly differs from that proposed earlier for the homologous human growth hormone (hGH) (Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., and Goeddel, D. V., and Well, J. A. (1992) Science 256, 1677-1680). Like hGH, hPRL would bind sequentially to two receptor molecules, first through site 1, then through site 2, but we would expect the two sites of hPRL to display, unlike the two binding sites of hGH, about the same binding affinity, thus preventing self-antagonism at high concentrations.	UNIV LIEGE,MOLEC BIOL & GENET ENGN LAB,B-4000 SART,BELGIUM	University of Liege			GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086; kinet, sandrina/0000-0003-0699-108X; struman, ingrid/0000-0003-2550-3707				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clarke W.C., 1980, Hormonal Proteins and Peptides, V8, P105; COOKE NE, 1981, J BIOL CHEM, V256, P4007; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FONTANA A, 1991, CURR OPIN BIOTECH, V2, P551, DOI 10.1016/0958-1669(91)90080-O; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; GOUT PW, 1980, CANCER RES, V40, P2433; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOUNG P R, 1992, Current Opinion in Biotechnology, V3, P408, DOI 10.1016/0958-1669(92)90170-N	43	65	71	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32598	32606						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798264				2022-12-27	WOS:A1994PX30400086
J	NISHIDA, M; KONG, KH; INOUE, H; TAKAHASHI, K				NISHIDA, M; KONG, KH; INOUE, H; TAKAHASHI, K			MOLECULAR-CLONING AND SITE-DIRECTED MUTAGENESIS OF GLUTATHIONE-S-TRANSFERASE FROM ESCHERICHIA-COLI - THE CONSERVED TYROSYL RESIDUE NEAR THE N-TERMINUS IS NOT ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; 3-DIMENSIONAL STRUCTURE; CDNA CLONE; COMPLEX; PURIFICATION; EXPRESSION; RESOLUTION; GENE; P1-1; TYROSINE-7	Glutathione S-transferase (GST) was purified from Escherichia coli K-12, and its N-terminal sequence was determined to be MKLFYKPGAXSLAS. The gene encoding this sequence was cloned and mapped at 1731-1732 kilobases on the E. coli gene map. It encoded a polypeptide of 201 amino acid residues with a calculated molecular weight of 22,860. The overexpressed product of the gene was confirmed to have GST activity toward 1-chloro-2,4-dinitrobenzene and ethacrynic acid and GSH-dependent peroxidase activity toward cumene hydroperoxide. The relative molecular mass of the gene product was determined to be 40,000 by gel chromatography and 25,000 by SDS-polyacrylamide gel electrophoresis, indicating a homodimeric structure. The deduced amino acid sequence was 54% identical with that of Proteus mirabilis GST. Although the homologies between the GSTs hom E. coli and mammals were low, many of the residues assigned to be important for the enzymatic function or structure in mammalian cytosolic GSTs were found to be conserved in E. coli GST. Therefore, E. coli GST is considered to have diverged from the same ancestor with other cytosolic GSTs. A specific tyrosyl residue in the vicinity of the N terminus is conserved in all of the known cytosolic GSTs and has been shown to function as a catalytic residue in alpha, mu, and pi class GSTs from mammals. Although Tyr(5) in E. coli GST appeared to be the counterpart of the catalytic residue, its replacement with phenylalanine did not significantly affect the enzymatic activity. Therefore, this apparently conserved tyrosyl residue is not essential for catalytic activity in E. coli GST.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AOYAGI T, 1992, J ANTIBIOT, V45, P1385, DOI 10.7164/antibiotics.45.1385; ARCA P, 1990, FEBS LETT, V263, P77, DOI 10.1016/0014-5793(90)80709-R; BOARD PG, 1987, P NATL ACAD SCI USA, V84, P2377, DOI 10.1073/pnas.84.8.2377; DIILIO C, 1991, BIOCHIM BIOPHYS ACTA, V1077, P141; DING GJF, 1985, J BIOL CHEM, V260, P3268; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; Habig W H, 1981, Methods Enzymol, V77, P398; IIZUKA M, 1989, J BACTERIOL, V171, P6039, DOI 10.1128/jb.171.11.6039-6042.1989; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KANO T, 1987, CANCER RES, V47, P5626; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1992, J BIOCHEM-TOKYO, V112, P725, DOI 10.1093/oxfordjournals.jbchem.a123965; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; KONG KH, 1993, PROTEIN ENG, V6, P1015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE SD, 1990, J BACTERIOL, V172, P164, DOI 10.1128/JB.172.1.164-171.1990; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MASAI E, 1993, FEBS LETT, V323, P135, DOI 10.1016/0014-5793(93)81465-C; MEYER DJ, 1991, BIOCHEM J, V274, P8430; MIGNOGNA G, 1993, EUR J BIOCHEM, V211, P421, DOI 10.1111/j.1432-1033.1993.tb17566.x; OGURA K, 1991, BIOCHEM BIOPH RES CO, V181, P1294, DOI 10.1016/0006-291X(91)92079-Y; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PICCOLOMINI R, 1989, J GEN MICROBIOL, V135, P3119; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN D, 1993, COMP BIOCHEM PHYS B, V104, P1, DOI 10.1016/0305-0491(93)90330-8; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STAYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; WANG RW, 1993, J BIOL CHEM, V268, P23981; WANG RW, 1992, J BIOL CHEM, V267, P19866; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	46	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32536	32541						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798255				2022-12-27	WOS:A1994PX30400077
J	SASAOKA, T; LANGLOIS, WJ; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM				SASAOKA, T; LANGLOIS, WJ; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM			THE SIGNALING PATHWAY COUPLING EPIDERMAL GROWTH-FACTOR RECEPTORS TO ACTIVATION OF P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE-ACTIVITY; GUANINE-NUCLEOTIDES; PROTO-ONCOGENE; RAS; GRB2; TRANSDUCTION; INSULIN; P21RAS; SH2	Epidermal growth factor (EGF) treatment causes autophosphorylation of the epidermal growth factor receptor (EGFR) leading to increased guanine nucleotide exchange factor (GEF; Sos) activity and enhanced formation of p21(ras)-GTP. The connection of the EGFR to p21(ras) activation can occur through binding of Grb2 Sos complexes to the EGFR or through the adaptor protein Shc via EGFR.Shc.Grb2.Sos multimeric complexes. Therefore, we investigated the importance of She in coupling the EGFR to activation of ras GEF (Sos). EGF treatment led to rapid tyrosine phosphorylation of She. Although phosphorylated EGFR can bind to both She and Grb2, the predominant linkage was observed between EGFR and She. Similarly, more Grb2 was associated with She than with EGFR after EGF stimulation. Immunoprecipitation of She from EGF-stimulated cells removed almost all EGFR-associated Grb2. Furthermore, immunodepletion of She proteins from membrane fractions of EGF-stimulated cells removed 93% of the ras GEF activity, whereas, precipitation of EGFR had only a small effect on ras GEF activity. These data indicate that coupling to She provides the major pathway linking activated EGFRs to Grb2.Sos and stimulation of the p21(ras) pathway,	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	28	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32621	32625						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798267				2022-12-27	WOS:A1994PX30400089
J	LISCUM, L; UNDERWOOD, KW				LISCUM, L; UNDERWOOD, KW			INTRACELLULAR CHOLESTEROL TRANSPORT AND COMPARTMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LIPOPROTEIN-DERIVED CHOLESTEROL; HAMSTER OVARY CELLS; NIEMANN-PICK DISEASE; PLASMA-MEMBRANE; CULTURED FIBROBLASTS; C FIBROBLASTS; ENDOPLASMIC-RETICULUM; LYSOSOMAL CHOLESTEROL; KINETIC POOLS; EFFLUX				LISCUM, L (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.							ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; COXEY RA, 1993, J LIPID RES, V34, P1165; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; DAHL NK, 1993, J BIOL CHEM, V268, P16979; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; Evans Robert M., 1994, Trends in Cell Biology, V4, P149, DOI 10.1016/0962-8924(94)90189-9; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; GLASER M, 1993, CURR OPIN STRUC BIOL, V3, P475, DOI 10.1016/0959-440X(93)90070-2; HANADA K, 1993, J BIOL CHEM, V268, P13820; HARMALA AS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P97, DOI 10.1016/0005-2760(93)90054-D; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1991, J BIOL CHEM, V266, P16599; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; OKWU AK, 1994, J LIPID RES, V35, P644; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; PORN MI, 1993, J LIPID RES, V34, P1385; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; RODRIGUEZLAFRAS.C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SARIA AJ, 1991, J BIOL CHEM, V267, P19455; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAZ WLC, 1993, CURR OPIN STRUC BIOL, V3, P482, DOI 10.1016/0959-440X(93)90071-R; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; XU XX, 1991, J BIOL CHEM, V266, P17040	60	201	204	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15443	15446		10.1074/jbc.270.26.15443	http://dx.doi.org/10.1074/jbc.270.26.15443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797533	hybrid			2022-12-27	WOS:A1995RG53800001
J	PEMBERTON, PA; WONG, DT; GIBSON, HL; KIEFER, MC; FITZPATRICK, PA; SAGER, R; BARR, PJ				PEMBERTON, PA; WONG, DT; GIBSON, HL; KIEFER, MC; FITZPATRICK, PA; SAGER, R; BARR, PJ			THE TUMOR-SUPPRESSOR MASPIN DOES NOT UNDERGO THE STRESSED TO RELAXED TRANSITION OR INHIBIT TRYPSIN-LIKE SERINE PROTEASES - EVIDENCE THAT MASPIN IS NOT A PROTEASE INHIBITORY SERPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CONFORMATIONAL CHANGE; ALPHA-1-ANTITRYPSIN; YEAST	The role of tumor suppressor proteins in the development of malignancy has made the understanding of their molecular mechanisms of action of great importance. Maspin is a tumor suppressor produced by a number of cell types of epithelial origin, Exogenous recombinant maspin has been shown to block the growth, motility, and invasiveness of breast tumor cell lines in vitro and in vivo. Although belonging to the the serine proteinase inhibitor (serpin) superfamily of proteins, the molecular mechanism of maspin is currently unknown, Here we show that the reactive site loop of maspin exists in an exposed conformation that does not require activation by cofactors. The reactive site loop of maspin, however, does not act as an inhibitor of proteinases such as chymotrypsin, elastase, plasmin, thrombin, and trypsin but rather as a substrate. Maspin is also unable to inhibit tissue and urokinase type plasminogen activators. Stability studies show that maspin cannot undergo the stressed-relaxed transition typical of proteinase-inhibitory serpins, and the protein is capable of spontaneous polymerization induced by changes in pH. It is likely, therefore, that maspin is structurally more closely related to ovalbumin and angiotensinogen, and its tumor suppressor activity is independent of a latent or intrinsic trypsin-like serine proteinase-inhibitory activity.	DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute	PEMBERTON, PA (corresponding author), LXR BIOTECHNOL,1401 MARINA WAY S,RICHMOND,CA 94804, USA.							BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; EVANS DLI, 1991, THESIS U CAMBRIDGE; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; GANESH S, 1994, CANCER RES, V54, P4065; GEORGE PM, 1989, BLOOD, V73, P490; GOLDENBERG DP, 1990, PROTEIN STRUCTURE PR, P225; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HOPKINS PCR, 1994, SCIENCE, V265, P1893; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P2720; MIKUS P, 1993, EUR J BIOCHEM, V278, P1071; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SAGER R, 1995, IN PRESS COLD SPRING; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; WEI A, 1994, STRUCT BIOL, V1, P251; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	124	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15832	15837		10.1074/jbc.270.26.15832	http://dx.doi.org/10.1074/jbc.270.26.15832			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797587	hybrid			2022-12-27	WOS:A1995RG53800060
J	COBB, MH; GOLDSMITH, EJ				COBB, MH; GOLDSMITH, EJ			HOW MAP KINASES ARE REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE; GROWTH-FACTOR; XENOPUS-OOCYTES; SIGNAL-TRANSDUCTION; ACTIVATION; PHOSPHORYLATION; TYROSINE; INVITRO; INSULIN; FAMILY		UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	COBB, MH (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK46993, DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993, R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAMPBELL JS, 1994, RECENT PROG HORM RES, V50, P131; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEVERS SJ, 1992, EMBO J, V11, P569; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WINITZ S, 1993, J BIOL CHEM, V268, P19196; XU S, 1995, IN PRESS P NATL ACAD; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG J, 1995, NATURE STRUCTURE, V3, P29; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	60	1614	1650	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14843	14846		10.1074/jbc.270.25.14843	http://dx.doi.org/10.1074/jbc.270.25.14843			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797459	hybrid			2022-12-27	WOS:A1995RE66600001
J	COLLINS, BS; PIPAS, JM				COLLINS, BS; PIPAS, JM			T ANTIGENS ENCODED BY REPLICATION-DEFECTIVE SIMIAN-VIRUS-40 MUTANT-DL1135 AND MUTANT-5080	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; SV40 LARGE-T; POLYMERASE-ALPHA-PRIMASE; DNA-REPLICATION; INSECT CELLS; PROTEIN PHOSPHATASE-2A; HYDROPHOBIC REGION; CELLULAR PROTEIN; VIRAL ORIGIN; BINDING	We present a preliminary biochemical characterization of two simian virus 40 mutants that affect different T antigen replication functions, SV40 T antigen mutants dl1135 (Delta 17-27 amino acids) and 5080 (P-L) have been studied extensively with regard to their ability to transform cells in culture and induce tumors in transgenic mice. Both mutants are defective for viral DNA replication in vivo. In order to assess in more detail the molecular basis for the in vivo replication defects of 5080 and dl1135, we expressed the mutant proteins using the baculovirus system and purified them by immunoaffinity chromatography. With each of the purified proteins, we examined some of the biochemical activities of T antigen required for replication, viz, ATPase, binding to the origin of replication (ori) and assembly on ori, DNA helicase and unwinding, and replication in in vitro assays, Consistent with previous studies, we found that the 5080 protein is defective for multiple biochemical activities including ATPase, helicase, ori-specific unwinding, and ATP-induced hexamerization. However, this mutant retains some sequence-specific DNA binding activity. In contrast, the dl1135 protein exhibited significant levels of activity in all assays, including the ability to drive SV40 DNA replication in vitro. Thus, dl1135 is one of several mutants with an altered aminoterminal domain which can replicate DNA in vitro, but not in vivo. Thus, while the 5080 mutation affects a T antigen enzymatic function directly required far viral DNA synthesis, dl1135 may alter an activity required to prepare the cell for viral replication.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA 09077] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COSMAN DJ, 1981, VIROLOGY, V112, P605, DOI 10.1016/0042-6822(81)90306-8; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DIXON RAF, 1985, J VIROL, V53, P1001, DOI 10.1128/JVI.53.3.1001-1004.1985; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; GANNON J V, 1990, New Biologist, V2, P84; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOSS A, 1990, J VIROL, V64, P4799; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MAULBECKER C, 1992, J VIROL, V66, P2195, DOI 10.1128/JVI.66.4.2195-2207.1992; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; SPENCE SL, 1994, VIROLOGY, V204, P200, DOI 10.1006/viro.1994.1524; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; VANDYKE TA, 1994, CANCER BIOL, V5, P47; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; YANIUK P, 1991, MOL CELL BIOL, V11, P2116	62	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15377	15384		10.1074/jbc.270.25.15377	http://dx.doi.org/10.1074/jbc.270.25.15377			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797527	hybrid			2022-12-27	WOS:A1995RE66600079
J	FERNANDEZMARTIN, R; REYES, F; DOMENECH, CE; CABRERA, E; BRAMLEY, PM; BARRERO, AF; AVALOS, J; CERDAOLMEDO, E				FERNANDEZMARTIN, R; REYES, F; DOMENECH, CE; CABRERA, E; BRAMLEY, PM; BARRERO, AF; AVALOS, J; CERDAOLMEDO, E			GIBBERELLIN BIOSYNTHESIS IN GIB MUTANTS OF GIBBERELLA-FUJIKUROI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-EXTRACTS; WILD-TYPE; PLANTS	The Ascomycete Gibberella fujikuroi synthesizes gibberellins, fujenal, carotenoids, and other terpenoids. Twelve gib mutants, isolated through the modified gibberellin fluorescence of their culture media, were subjected to chemical and biochemical analyses. Two mutants were specifically defective in the hydroxylation of carbon 13; their total gibberellin production was normal, but their main gibberellin was GA(7) instead of GA(3). Four mutants were blocked in the early reactions between geranylgeranyl pyrophosphate and 7-hydroxy-kaurenoic acid; two of them could not synthesize kaurene and another one was blocked in several oxidative steps. Six mutants had partial defects in early reactions, leading to the production of one-fifth to one-third of the wild type amounts of gibberellins and fujenal. Two of these produced considerable amounts of kaurenolides due to a defect in the conversion of kaurenoic acid to 7-hydroxykaurenoic acid. Another one produced no carotenoids, but attempts to isolate mutants of reactions shared by the carotenoid and gibberellin pathways failed. The gib mutations did not modify the ability of the fungus to live as a saprophyte.	UNIV SEVILLA, DEPT GENET, E-41080 SEVILLE, SPAIN; UNIV GRANADA, FAC CIENCIAS, DEPT QUIM ORGAN, E-18071 GRANADA, SPAIN; UNIV LONDON ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT BIOCHEM, EGHAM, SURREY, ENGLAND	University of Sevilla; University of Granada; University of London; Royal Holloway University London			Cabrera, Elisa/GPX-3455-2022; Avalos, Javier/B-4218-2011; Cerdá-Olmedo, Enrique/L-6165-2013; Alejandro, Barrero F/G-8243-2015; Reyes, Fernando/G-4027-2013	Avalos, Javier/0000-0001-5484-2893; Alejandro, Barrero F/0000-0002-3058-8760; Reyes, Fernando/0000-0003-1607-5106; Cerda-Olmedo, Enrique/0000-0001-8709-932X; Fernandez-Martin, Rafael/0000-0002-4838-407X				ASHMAN PJ, 1990, BIOCHIM BIOPHYS ACTA, V1036, P151, DOI 10.1016/0304-4165(90)90027-T; AVALOS J, 1988, BIOCHIM BIOPHYS ACTA, V966, P257, DOI 10.1016/0304-4165(88)90119-5; AVALOS J, 1985, APPL ENVIRON MICROB, V49, P187, DOI 10.1128/AEM.49.1.187-191.1985; AVALOS J, 1986, PHYTOCHEMISTRY, V25, P1837, DOI 10.1016/S0031-9422(00)81158-9; AVALOS J, 1987, CURR GENET, V11, P505, DOI 10.1007/BF00384613; BEALE MH, 1982, PHYTOCHEMISTRY, V21, P1279, DOI 10.1016/0031-9422(82)80126-X; BEARDER JR, 1974, PHYTOCHEMISTRY, V13, P911, DOI 10.1016/S0031-9422(00)91422-5; BEARDER JR, 1973, PHYTOCHEMISTRY, V12, P2655, DOI 10.1016/0031-9422(73)85074-5; Bearder JR, 1983, BIOCH PHYSL GIBBEREL, V1, P251; BRAMLEY PM, 1975, PHYTOCHEMISTRY, V14, P463, DOI 10.1016/0031-9422(75)85110-7; BRUCKNER B, 1989, BIOTECHNOLOGY VITAMI, P383; CANDAU R, 1991, APPL ENVIRON MICROB, V57, P3378, DOI 10.1128/AEM.57.11.3378-3382.1991; CASTELLARO SJ, 1990, PHYTOCHEMISTRY, V29, P1833, DOI 10.1016/0031-9422(90)85024-A; CERDAOLMEDO E, 1994, ANTON LEEUW INT J G, V65, P217, DOI 10.1007/BF00871950; CERDAOLMEDO E, 1994, CRIT REV MICROBIOL, V20, P151, DOI 10.3109/10408419409113554; CONRFORTH JW, 1971, J CHEM SOC C, P2786; CROZIER A, 1983, BIOCH PHYSL GIBBEREL, V1; CROZIER A, 1983, BIOCH PHYSL GIBBEREL, V2; CROZIER A, 1983, BIOCH PHYSL GIBBEREL, V1, P485; EROKHINA L I, 1970, Genetika, V6, P170; FALL RR, 1971, J BIOL CHEM, V246, P6913; GEISSMAN TA, 1966, PHYTOCHEMISTRY, V5, P933, DOI 10.1016/S0031-9422(00)82790-9; Hedden P., 1987, Principles and practice of plant hormone analysis. Volume 1, P9; JEFFREYS EG, 1970, ADVANCES APPLIED MIC, V13, P283, DOI DOI 10.1016/S0065-2164(08)70407-6; JENNINGS JC, 1993, PLANT PHYSIOL, V101, P925, DOI 10.1104/pp.101.3.925; JONES RL, 1973, ANNU REV PLANT PHYS, V24, P571, DOI 10.1146/annurev.pp.24.060173.003035; KJAER D, 1971, J CHEM SOC C, P2792, DOI 10.1039/j39710002792; KOLBLIN R, 1990, J BASIC MICROB, V30, P675, DOI 10.1002/jobm.3620300910; MANDER LN, 1992, CHEM REV, V92, P573, DOI 10.1021/cr00012a005; MARTIN CG, 1983, BIOCH PHYSL GIBBEREL, V2, P395; Oltra J.E., 1992, NAT PROD LETT, V1, P155; PHARIS RP, 1985, ANNU REV PLANT PHYS, V36, P517, DOI 10.1146/annurev.pp.36.060185.002505; REID JB, 1986, PLANT GENE RES GENET, P1; SANDMANN G, 1993, J PHOTOCH PHOTOBIO B, V18, P245, DOI 10.1016/1011-1344(93)80071-G; SOKOLOVA E V, 1969, Genetica (Dordrecht), V5, P100; SPECTOR C, 1968, PHYSIOL PLANTARUM, V21, P127, DOI 10.1111/j.1399-3054.1968.tb07237.x; Takahashi N, 1991, GIBBERELLINS, V1st; TAKENAKA M, 1992, J PESTIC SCI, V17, P213	38	19	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14970	14974		10.1074/jbc.270.25.14970	http://dx.doi.org/10.1074/jbc.270.25.14970			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797477	hybrid			2022-12-27	WOS:A1995RE66600022
J	SAGAMI, H; KIKUCHI, A; OGURA, K				SAGAMI, H; KIKUCHI, A; OGURA, K			A NOVEL TYPE OF PROTEIN MODIFICATION BY ISOPRENOID-DERIVED MATERIALS - DIPHYTANYLGLYCERYLATED PROTEINS IN HALOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CLEAVAGE REACTION; MEMBRANE; FARNESYLCYSTEINE; BIOSYNTHESIS; BINDING	Previous work from this laboratory has shown that a derivative of [H-3]mevalonic acid is incorporated into a number of specific proteins in Halobacterium halobium and Halobacterium cutirubrum and that the major radioactive material released by treatment with methyl iodide was neither farnesyl nor geranylgeranyl compound, which have been generally accepted to be prenyl groups of a number of prenylated proteins found in eukaryotic cells, but an unknown compound (Sagami, H., Kikuchi, A., and Ogura, K. (1994) Biochem. Biophys. Res. Commun, 203, 972-978). In the current study, the unknown compound was prepared in a large amount from H. halobium cells and analyzed by reverse and normal phase high performance liquid chromatographies followed by mass spectrometry. The mass spectrum of this compound exhibited a parent ion peak (M(+)) at m/z 682, suggesting that it is a 1-methylthio-2,3-di-O-(3',7',11',15'-tetramethylhexadecyl)glycerol (diphytanylglyceryl methylthioether). Diphytanylglyceryl methyl thioether was chemically synthesized, and its mass fragmentation pattern was completely coincident with that of the mevalonic acid-derived material from H. halobium. These results indicate that Halobacteria contains specific proteins with a novel type of modification of a cysteine residue of the proteins with a diphytanylglyceryl group in thioether linkage.			SAGAMI, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,AOBA KU,2-1-1 KATAHIRA,SENDAI,MIYAGI 980,JAPAN.							Blaurock A. E., 1971, NATURE-NEW BIOL, V233, P149; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KATES M, 1965, BIOCHEMISTRY-US, V4, P1595, DOI 10.1021/bi00884a020; KUSHWAHA SC, 1975, BIOCHIM BIOPHYS ACTA, V398, P33; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATTAR S, 1994, J BIOL CHEM, V269, P14939; MINNIKIN DE, 1975, J GEN MICROBIOL, V88, P200, DOI 10.1099/00221287-88-1-200; MOLDOVEANU N, 1988, BIOCHIM BIOPHYS ACTA, V960, P164, DOI 10.1016/0005-2760(88)90062-8; PUGH EL, 1971, CAN J BIOCHEM CELL B, V49, P953, DOI 10.1139/o71-138; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1994, BIOCHEM BIOPH RES CO, V203, P972, DOI 10.1006/bbrc.1994.2277; SLARKE S, 1992, ANN REV BIOHC, V61, P355; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	21	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14851	14854		10.1074/jbc.270.25.14851	http://dx.doi.org/10.1074/jbc.270.25.14851			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797461	hybrid			2022-12-27	WOS:A1995RE66600003
J	OGRAM, SA; REEVES, R				OGRAM, SA; REEVES, R			DIFFERENTIAL REGULATION OF A MULTIPROMOTER GENE - SELECTIVE 12-O-TETRADECANOYLPHORBOL-13-ACETATE INDUCTION OF A SINGLE TRANSCRIPTION START SITE IN THE HMG-I/Y GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN HMG-I(Y); DNA-BINDING DOMAIN; GROUP-I PROTEIN; CHROMOSOMAL-PROTEINS; MESSENGER-RNAS; SATELLITE DNA; CDC2 KINASE; BETA GENE; EXPRESSION; CELLS	The human HMG-I/Y gene, encoding the non-histone ''high mobility group'' proteins HMG-I and HMG-Y, is transcriptionally activated in human K562 erythroleukemia cells by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA), TPA treatment induces differentiation of K562 cells within 2-4 days after treatment. In this report, we show that transcriptional activation of the HMG-I/Y gene is dependent on protein synthesis and is an early event (2 h after induction) in the TPA-mediated differentiation process. Of the four functional transcription start sites present in the gene, only one (start site 2) is preferentially induced upon TPA treatment. This is the first report, to our knowledge, of the preferential utilization of a specific transcription start site in response to a particular stimulus in a gene that contains multiple promoters. This indicates that each start site in the gene has the potential to be independently regulated instead of being coordinately controlled as shown in a number of other genes. In addition, sequences upstream of the inducible start site, which contains a TPA-responsive element, mediates TPA inducibility through AP1 (or an AP1-like) transcription factor. The HMG-I/Y proteins function as key regulators of gene expression and play a significant role in chromatin structural changes as well. The cloning and sequence analyses previously reported indicated the structure of the HMG-I/Y gene to be highly complex and predicted its expression to be tightly regulated. The results presented here confirm and extend these earlier findings.	WASHINGTON STATE UNIV,DEPT BIOCHEM BIOPHYS,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164	Washington State University; Washington State University					NIAID NIH HHS [5-R01-AI26356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASMAN DC, 1994, J BIOL CHEM, V268, P12530; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BONHAM K, 1993, ONCOGENE, V8, P1973; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; JORCYK CL, 1990, ONCOGENE, V6, P323; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAZAR J, 1994, J BIOL CHEM, V269, P20352; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MAVROTHALASSITI.GJ, 1990, ONCOGENE, V5, P1337; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PATEL M, 1990, ONCOGENE, V5, P201; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; RAM T, 1992, GENETICS MOL BIOL BR, P65; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1993, J BIOL CHEM, V268, P21137; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAMIMI Y, 1993, CANCER RES, V53, P5512; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WINGETT D, 1991, J IMMUNOL, V147, P3653	51	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14235	14242		10.1074/jbc.270.23.14235	http://dx.doi.org/10.1074/jbc.270.23.14235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775485	hybrid			2022-12-27	WOS:A1995RC44800093
J	SPIRO, DJ; TAYLOR, TC; MELANCON, P; WESSLINGRESNICK, M				SPIRO, DJ; TAYLOR, TC; MELANCON, P; WESSLINGRESNICK, M			CYTOSOLIC ADP-RIBOSYLATION FACTORS ARE NOT REQUIRED FOR ENDOSOME-ENDOSOME FUSION BUT ARE NECESSARY FOR GTP-GAMMA-S INHIBITION OF FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; BREFELDIN-A; GOLGI MEMBRANES; PROTEIN ACTIVATORS; ENDOCYTIC VESICLES; GUANINE-NUCLEOTIDE; BINDING PROTEINS; CHOLERA-TOXIN; ARF PROTEIN; MDCK CELLS	A specific role for ADP-ribosylation factors (ARFs) in in vitro endosome-endosome fusion has been proposed (Lenhard, J. M., Kahn, R. A., and Stahl, P. D. (1992) J. Biol. Chem. 267, 13047-13052). However, in vivo studies have failed to support a function for ARFs in the endocytic pathway, since an antagonist of ARF activities, brefeldin A, does not interfere with receptor internalization (Schonhorn, J. E., and Wessling-Resnick, M. (1994) Mol. Cell. Biochem. 135, 159-164). This controversy surrounding the exact function of ARF in endocytic vesicle traffic prompted us to critically re-examine the involvement of ARFs in cell-free endosome fusion. Cytosol depleted of ARF activity was capable of supporting in. vitro endocytic vesicle fusion but failed to support inhibition of this reaction in the presence of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). Addition of purified ARF1 restored the ability of the ARF-depleted cytosol to inhibit endosome fusion when incubated with GTP gamma S. Both endocytic vesicle fusion and the GTP gamma S-mediated inhibition of vesicle fusion were unaffected by brefeldin A. Moreover, the ATP requirement and kinetics of cell-free fusion are not altered by brefeldin A or depletion of cytosolic ARFs. These results suggest that cytosolic ARFs are not necessary for endosomal vesicle fusion in vitro but are responsible for inhibition of fusion in the presence of GTP gamma S and cytosolic factors in a brefeldin A-resistant manner.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LENHARD JM, 1994, ARCH BIOCHEM BIOPHYS, V312, P474, DOI 10.1006/abbi.1994.1334; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORGAN A, 1993, FEBS LETT, V329, P121, DOI 10.1016/0014-5793(93)80206-A; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13693	13697		10.1074/jbc.270.23.13693	http://dx.doi.org/10.1074/jbc.270.23.13693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775422	hybrid			2022-12-27	WOS:A1995RC44800019
J	SVINARCHUK, F; PAOLETTI, J; MALVY, C				SVINARCHUK, F; PAOLETTI, J; MALVY, C			AN UNUSUALLY STABLE PURINE(PURINE-PYRIMIDINE) SHORT TRIPLEX - THE 3RD STRAND STABILIZES DOUBLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; GENE; INHIBITION; SEQUENCE; BINDING; TRANSCRIPTION; EXPRESSION; SITES; RNA	Classical models for DNA triple helix formation assume the stabilization of these structures through the formation of Hoogsteen hydrogen bonds. This assumes that G-rich duplex DNA is more stable than tripler DNA. We report the results of co-migration assay, dimethyl sulfate footprint, and UV spectroscopic melting studies that reveal that at least in some cases of short (13-mer) purine(purine-pyrimidine) tripler the stability of double-stranded DNA is increased by the binding of the third strand. Under conditions which are usually considered as physiological (10 mM MgCl2, 150 mM Na+ or K+) and with a rate of heating/cooling of 1 degrees C/min, there is a good reversibility of the melting profiles which is consistent with a high rate of tripler formation. Other factors than Hoogsteen hydrogen bonds should therefore be involved in tripler stabilization. We suggest that oligonucleotides with similar properties could be efficient agents for artificial gene regulation.	NOVOSIBIRSK BIOORGAN CHEM INST,DEPT BIOCHEM,NOVOSIBIRSK 630090,RUSSIA	Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS	SVINARCHUK, F (corresponding author), INST GUSTAVE ROUSSY,BIOCHIM ENZYMOL LAB,CNRS,URA 147,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							BADER BL, 1986, EMBO J, V8, P1868; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEASTY AM, 1988, NUCLEIC ACIDS RES, V16, P1517, DOI 10.1093/nar/16.4.1517; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; PORUMB H, 1994, GENE, V149, P101, DOI 10.1016/0378-1119(94)90417-0; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; SVINARCHUK F, 1994, NUCLEIC ACIDS RES, V22, P3742, DOI 10.1093/nar/22.18.3742; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	22	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					14068	14071		10.1074/jbc.270.23.14068	http://dx.doi.org/10.1074/jbc.270.23.14068			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775467	hybrid			2022-12-27	WOS:A1995RC44800070
J	CLEVENGER, CV; NGO, W; SOKOL, DL; LUGER, SM; GEWIRTZ, AM				CLEVENGER, CV; NGO, W; SOKOL, DL; LUGER, SM; GEWIRTZ, AM			VAV IS NECESSARY FOR PROLACTIN-STIMULATED PROLIFERATION AND IS TRANSLOCATED INTO THE NUCLEUS OF A T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NB2 LYMPHOMA-CELLS; NUCLEOTIDE EXCHANGE FACTOR; GROWTH-HORMONE RECEPTOR; HUMAN-BREAST CANCER; PROTEIN-KINASE-C; TYROSINE KINASE; PROTOONCOGENE PRODUCT; MAP KINASE; GENE-EXPRESSION; LYMPHOCYTES-T	Stimulation of the prolactin receptor (PRLr) with ligand activates multiple kinase cascades. The proximal mediators involved in the activation of the PRL-activated Raf-1 cascade in T-cells, however, remain poorly characterized. The role of one proximal signaling protein, namely p95(vav), during PRLr signal transduction was examined in the Nb2 T-cell line. The novel results obtained here indicate that Vav is transiently associated with the PRLr and is necessary for PRL-stimulated proliferation. During PRL stimulation, a rapid and dramatic increase in guanine nucleotide exchange factor (GEF) activity was found to be associated with Vav immunoprecipitates. Concomitantly, an increase in Vav phosphorylation on serine-threonine residues was observed. The Vav-associated GEF activation could be inhibited by staurosporine and calphostin, but not herbimycin, suggesting a modulatory role for phosphorylation at serine-threonine residues. Treatment of Nb-2 cells with antisense Vav oligonucleotide ablated Vav expression and blocked PRL-driven proliferation, but failed to inhibit PRL-induced GEF activation within Nb2 lysates. These data indicate that GEF activity may not be intrinsic to Vav as has been previously suggested, but either resides in or is complemented by an associated GEF. Subsequent to the transient activation of associated GEF activity, Vav was found to translocate into the Nb2 cell nucleus. Thus, Vav may utilize two independent mechanisms in T-cells, namely the activation of an associated GEF and direct nuclear internalization, to mediate PRLr signaling.	UNIV PENN,MED CTR,DEPT INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania	CLEVENGER, CV (corresponding author), UNIV PENN,MED CTR,DEPT LAB MED & PATHOL,509 BRB1,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA-36896, CA-54384] Funding Source: Medline; NIAID NIH HHS [AI-33510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054384, R23CA036896, R01CA036896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033510] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAMYR SM, 1994, CURRENT PROTOCOLS MO, P1; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CLEVENGER CV, 1985, CYTOMETRY, V6, P208, DOI 10.1002/cyto.990060306; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CROWE PD, 1991, MOL CELL ENDOCRINOL, V79, P29, DOI 10.1016/0303-7207(91)90092-7; CROZE F, 1988, MOL CELL ENDOCRINOL, V55, P253, DOI 10.1016/0303-7207(88)90140-2; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GOUT PW, 1980, CANCER RES, V40, P2433; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HU P, 1993, BIOESSAYS, V15, P179, DOI 10.1002/bies.950150306; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUGER SM, 1993, BLOOD, V82, P107; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUKHERJEE P, 1990, ENDOCRINOLOGY, V126, P88, DOI 10.1210/endo-126-1-88; NOBLE RL, 1980, CANCER RES, V40, P2437; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETH A, 1992, J BIOL CHEM, V267, P24769; SHIU RPC, 1985, J BIOL CHEM, V260, P1307; SHIU RPC, 1987, RECENT PROG HORM RES, V43, P277; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1990, BIOCHEM BIOPH RES CO, V173, P48, DOI 10.1016/S0006-291X(05)81019-8; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; XU YH, 1992, MOL ENDOCRINOL, V6, P375, DOI 10.1210/me.6.3.375; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZHANG R, 1995, P NATL ACAD SCI USA, V91, P12755; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZMUIDZINAS A, 1985, EMBO J, V14, P1	81	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13246	13253		10.1074/jbc.270.22.13246	http://dx.doi.org/10.1074/jbc.270.22.13246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768923	hybrid			2022-12-27	WOS:A1995RB43900047
J	BAENZIGER, NL; DALEMAR, LR; MACK, P; HADDOCK, RC				BAENZIGER, NL; DALEMAR, LR; MACK, P; HADDOCK, RC			HISTAMINE DEGRADATIVE UPTAKE BY CULTURED HUMAN PULMONARY VASCULAR ENDOTHELIAL-CELLS UTILIZES AN INFLAMMATORY CELL DIAMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; INDUCED LUNG INJURY; FIBROBLAST GROWTH-FACTOR; PROSTAGLANDIN BLOCKADE; PROSTACYCLIN SYNTHESIS; VASOACTIVE SUBSTANCES; COMPLEMENT ACTIVATION; SKIN FIBROBLASTS; LOCALIZATION; NEUTROPHIL	Neutrophil-endothelial interactions, altered clearance properties of the lung toward vasoactive mediators, and damaging effects of histamine that target the lung represent prominent elements of the inflammatory response at the systemic level, The pulmonary vasculature is unusual in that, unlike other tissues and vascular beds, it normally does not metabolize circulating histamine in vivo, although histamine-metabolizing enzyme activities have been detected in disrupted lung tissue, We have therefore explored the capability of human pulmonary artery endothelial cells in culture to express the receptor mediated histamine degradative uptake system we previously defined in systemic endothelial cells (Haddock, R. C., Mack, P., Leal, S., and Baenziger, N. L, (1990) J. Biol. Chem. 265, 14395-14401), Pulmonary endothelial cells display all components of this system: histamine methyltransferase generating the proximal cell-associated metabolite tele-methylhistamine and receptors binding diamine oxidase which generates the distal product methylimidazoleacetic acid that is accumulated by the cells, A diamine oxidase released from human neutrophil granules by activation with Ca2+ ionophore binds pulmonary and systemic endothelial cell and fibroblast diamine oxidase receptors and, thereby, participates in histamine degradative uptake, This enzyme utilizes cell-associated tele-methylhistamine as a substrate, preferentially generating methylimidazoleacetic acid in addition to reactive oxygen species, Thus the enzymatic and interactive cellular machinery for histamine clearance is inherently present as a functional unit in two major human pulmonary cell types, It interacts with products of inflammatory host defense cells, and pulmonary endothelial-neutrophil interactions via this pathway may influence the progression of inflammation.			BAENZIGER, NL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,BOX 8108,4566 SCOTT AVE,ST LOUIS,MO 63110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007296] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033699] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33699] Funding Source: Medline; NIADDK NIH HHS [2T32 AMO7296] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER N L, 1990, Journal of Cell Biology, V111, p184A; BAENZIGER NL, 1981, CELL, V24, P915, DOI 10.1016/0092-8674(81)90117-3; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BAENZIGER NL, 1994, J BIOL CHEM, V269, P14892; BENNETT A, 1965, BRIT J PHARM CHEMOTH, V24, P147, DOI 10.1111/j.1476-5381.1965.tb02089.x; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263; BOILEAU JC, 1970, CAN J PHYSIOL PHARM, V48, P681, DOI 10.1139/y70-100; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; BYRNE K, 1990, CRIT CARE MED, V18, P303, DOI 10.1097/00003246-199003000-00012; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; DANIELE B, 1990, GASTROENTEROLOGY, V99, P1675, DOI 10.1016/0016-5085(90)90474-F; DEMLING RH, 1990, CIRC SHOCK, V30, P297; EISEMAN B, 1964, J THORAC CARDIOV SUR, V48, P798, DOI 10.1016/S0022-5223(19)33363-X; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P543, DOI 10.1111/j.1476-5381.1973.tb17265.x; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GILLIS CN, 1976, BIOCHEM PHARMACOL, V25, P2547, DOI 10.1016/0006-2952(76)90508-6; GILLIS CN, 1982, ANN NY ACAD SCI, V384, P458, DOI 10.1111/j.1749-6632.1982.tb21392.x; GILLIS CN, 1982, ANNU REV PHYSIOL, V44, P269, DOI 10.1146/annurev.ph.44.030182.001413; GILLIS CN, 1986, AM REV RESPIR DIS, V134, P739; GLORIANO VV, 1969, P SOC EXP BIOL MED, V130, P387; HADDOCK RC, 1987, J BIOL CHEM, V262, P10220; HADDOCK RC, 1990, J BIOL CHEM, V265, P14395; HADDOCK RC, 1985, FED PROC, V44, P1843; HENSON PM, 1984, FED PROC, V43, P2799; HENSON PM, 1982, ANN NY ACAD SCI, V384, P287, DOI 10.1111/j.1749-6632.1982.tb21379.x; HERNANDEZ A, 1991, PHARMACOL RES, V24, P385, DOI 10.1016/1043-6618(91)90043-W; HOUGH LB, 1979, J PHARMACOL EXP THER, V208, P422; HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268; JOHNSON AR, 1985, FED PROC, V44, P19; JOHNSON AR, 1980, J CLIN INVEST, V65, P841, DOI 10.1172/JCI109736; JUNOD AF, 1982, ANN NY ACAD SCI, V384, P66, DOI 10.1111/j.1749-6632.1982.tb21363.x; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LEEPERWOODFORD SK, 1993, AM J RESP CELL MOL, V8, P169, DOI 10.1165/ajrcmb/8.2.169; LILJA B, 1961, J ALLERGY, V31, P492; LINDENSCHMIDT RC, 1986, AM REV RESPIR DIS, V133, P274; LONGENECKER JP, 1983, J CELL PHYSIOL, V114, P7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MCKENNA PJ, 1992, AM J PHYSIOL, V263, pH1492, DOI 10.1152/ajpheart.1992.263.5.H1492; OKUYAMA T, 1961, ARCH BIOCHEM BIOPHYS, V95, P242, DOI 10.1016/0003-9861(61)90141-2; RIGGS D, 1988, J APPL PHYSIOL, V64, P2508, DOI 10.1152/jappl.1988.64.6.2508; RINGEL EW, 1984, IMMUNOLOGY, V52, P649; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; RYAN US, 1976, TISSUE CELL, V8, P125, DOI 10.1016/0040-8166(76)90025-2; SELIG WM, 1986, J APPL PHYSIOL, V61, P233, DOI 10.1152/jappl.1986.61.1.233; SIELAFF TD, 1987, SURGERY, V102, P350; SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76, DOI 10.1139/y93-012; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STALCUP SA, 1982, ANN NY ACAD SCI, V384, P435, DOI 10.1111/j.1749-6632.1982.tb21391.x; TAKEDA T, 1992, J CELL SCI, V101, P745; THOMAS DP, 1967, NATURE, V216, P335, DOI 10.1038/216335a0; TILL GO, 1991, FREE RADICAL BIO MED, V10, P379, DOI 10.1016/0891-5849(91)90046-6; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALDMEIER PC, 1977, J NEUROCHEM, V29, P785, DOI 10.1111/j.1471-4159.1977.tb10719.x; WARD PA, 1990, J TRAUMA, V30, pS75; WIENERKRONISH JP, 1990, BRIT J ANAESTH, V65, P107, DOI 10.1093/bja/65.1.107; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZEIGER RS, 1976, J EXP MED, V144, P1049, DOI 10.1084/jem.144.4.1049; ZEIGER RS, 1976, J ALLERGY CLIN IMMUN, V58, P172, DOI 10.1016/0091-6749(76)90152-4; Zeller EA, 1938, HELV CHIM ACTA, V21, P880, DOI 10.1002/hlca.193802101115; ZIMMERMAN GA, 1984, AM REV RESPIR DIS, V129, P798, DOI 10.1164/arrd.1984.129.5.798	61	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32858	32864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806511				2022-12-27	WOS:A1994QA63800024
J	KATZAV, S; SUTHERLAND, M; PACKHAM, G; YI, TL; WEISS, A				KATZAV, S; SUTHERLAND, M; PACKHAM, G; YI, TL; WEISS, A			THE PROTEIN-TYROSINE KINASE ZAP-70 CAN ASSOCIATE WITH THE SH2 DOMAIN OF PROTO-VAV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CELL ANTIGEN RECEPTOR; AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; ZETA-CHAIN; TRANSCRIPTION FACTOR; PROTOONCOGENE PRODUCT	Stimulation of the T cell antigen receptor (TCR) leads to tyrosine phosphorylation of a number of cellular proteins, including the vav proto-oncogene product. We now report the detection of several phosphotyrosine proteins (80, 74, and 70 kDa) from TCR-stimulated T cells that bind to the Src homology 2 (SH2) domain of proto-Vav (Vav-SH2) and co-immunoprecipitate with the proto-Vav product. Their binding to Vav-SH2 differs from that observed with SH2 domains from other proteins. None of the Vav-SH2-associated phosphoproteins bind to either of the Src homology 3 (SH3) domains of proto-Vav or to mutant Vav-SH2 proteins. The association of the phosphoproteins with Vav-SH2 requires induction of tyrosine phosphorylation of cellular proteins since proteins from lysates of herbimycin A-treated TCR-activated T cells fail to associate with Vav-SH2. Among the proteins from T cells that co-immunoprecipitate with the proto-Vav product and bind to its SH2 domain, specific antibodies identified the 70-kDa tyrosine phosphoprotein as ZAP-70, a protein tyrosine kinase (PTK) involved in TCR signal transduction. Binding of this PTK to Vav-SH2 is inhibited by a ZAP-70-specific synthetic tyrosine phosphopeptide. We suggest that ZAP-70 may function as a PTK for proto-Vav.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, PQ, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, PQ, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; CLEVELAND CLIN FDN, DEPT CANC BIOL, CLEVELAND, OH 44195 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT IMMUNOL & MICROBIOL, SAN FRANCISCO, CA 94143 USA	McGill University; McGill University; St Jude Children's Research Hospital; Cleveland Clinic Foundation; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KATZAV, S (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL H3T 1E2, PQ, CANADA.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1992, BRIT J HAEMATOL, V81, P141, DOI 10.1111/j.1365-2141.1992.tb08198.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YI TL, 1991, BLOOD, V78, P2222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32579	32585						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798261				2022-12-27	WOS:A1994PX30400083
J	LOW, BC; ROSS, IK; GRIGOR, MR				LOW, BC; ROSS, IK; GRIGOR, MR			GLUCOSE DEPRIVATION AND ACUTE CYCLOHEXIMIDE TREATMENT STIMULATE SYSTEM-L AMINO-ACID TRANSPORT IN CULTURED VASCULAR SMOOTH MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC MURINE RETROVIRUSES; ELEVATED GLUCOSE; EXPRESSION CLONING; INSULIN-SECRETION; ENDOTHELIAL-CELLS; SURFACE RECEPTOR; GENE-EXPRESSION; RAT-KIDNEY; GROWTH; METABOLISM	The effect of glucose deprivation on the uptake of leucine has been examined in cultured vascular smooth muscle cells isolated from rat aortae. Equimolar substitution of sucrose or fructose for glucose in the culture medium enhanced the uptake of leucine in a time- and concentration-dependent manner. The effect was first detectable after 12 h and reached the maximum, 2-fold, after 48 h with an apparent half-maximal effect at 1 mM glucose and could be reversed after 48 h of glucose refeeding. The enhanced leucine uptake was completely inhibited by 2-amino-2-norbornane-carboxylic acid, a specific substrate for System L, but not by alpha-(methylamino)isobutyric acid or lysine. Kinetic analyses indicated that this stimulation was mediated via a homogenous system with a 1.7-fold increase in the V-max without any change in the K-m (0.15 mM). Prolonged treatments with cycloheximide (10 mu g/ml) or actinomycin D (10 mu g/ml) blocked this glucose deprivation effect and its reversal. However, cycloheximide also very rapidly stimulated leucine uptake, reaching the maximum, 2.5-fold over the basal at Ih. This effect occurred at concentrations that matched its inhibition on protein synthesis (half-maximal at 0.1 mu g/ml) and could be reproduced with puromycin as well as actinomycin D. The stimulatory effect of cycloheximide was also accompanied by an increase in the V-max but not in the K-m, being sensitive to 2-amino-2-norbornane-carboxylic acid inhibition only, and appeared to occur in an additive manner to that of glucose deprivation. Although the uptake of leucine was stimulated by glucose deprivation and brief exposure to cycloheximide, these treatments had no effect on the efflux of the substrate. These results are all consistent with the System L amino acids transport activity in cultured rat vascular smooth muscle cells being under the control of at least two non-hormonal regulatory mechanisms, one that is likely to involve a labile repressor molecule and the other involving de nova protein synthesis as a result of chronic glucose deprivation.	UNIV OTAGO,DEPT BIOCHEM,DUNEDIN,NEW ZEALAND	University of Otago			Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				ALIPUI C, 1993, CARDIOVASC RES, V27, P1229, DOI 10.1093/cvr/27.7.1229; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BERDANIER CD, 1994, FASEB J, V8, P4; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BROER S, 1994, BBA-BIOMEMBRANES, V1192, P95, DOI 10.1016/0005-2736(94)90147-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CONNELL JMC, 1986, TRENDS PHARMACOL SCI, V7, P412, DOI 10.1016/0165-6147(86)90404-9; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; GUMA A, 1992, BIOCHEM J, V281, P407, DOI 10.1042/bj2810407; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; Kakuda DK, 1993, TRANSGENE, V1, P91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOIBUCHI Y, 1992, CLIN RES, V40, P150; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LIU QR, 1993, J BIOL CHEM, V268, P22802; LOW BC, 1992, J BIOL CHEM, V267, P20740; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LOW SY, 1994, FASEB J, V8, P127, DOI 10.1096/fasebj.8.1.7905447; MAHADEVAN IC, 1991, NATURE, V249, P747; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MIYAMOTO K, 1993, BIOCHEM J, V295, P211, DOI 10.1042/bj2950211; MIZUTANI M, 1992, BIOCHEM BIOPH RES CO, V187, P664, DOI 10.1016/0006-291X(92)91246-M; MUNIZ R, 1993, PFLUG ARCH EUR J PHY, V423, P59, DOI 10.1007/BF00374961; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; NISHINO H, 1978, P NATL ACAD SCI USA, V75, P5048, DOI 10.1073/pnas.75.10.5048; OLIVETTI G, 1982, CIRC RES, V51, P19, DOI 10.1161/01.RES.51.1.19; ORTIZ PA, 1993, BIOCHEM J, V295, P67, DOI 10.1042/bj2950067; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; ULLREY D, 1975, ARCH BIOCHEM BIOPHYS, V167, P410, DOI 10.1016/0003-9861(75)90481-6; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEIR G C, 1986, Diabetes Metabolism Reviews, V2, P125; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1983, J BIOL CHEM, V258, P8028; WOODLOCK TJ, 1993, J BIOL CHEM, V268, P16020; YOREK MA, 1989, METABOLISM, V38, P16, DOI 10.1016/0026-0495(89)90174-1	54	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32098	32103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798204				2022-12-27	WOS:A1994PX30400016
J	WAKABAYASHI, Y; YAMADA, E; YOSHIDA, T; TAKAHASHI, H				WAKABAYASHI, Y; YAMADA, E; YOSHIDA, T; TAKAHASHI, H			ARGININE BECOMES AN ESSENTIAL AMINO-ACID AFTER MASSIVE RESECTION OF RAT SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMOLOGICAL EVIDENCE; CITRULLINE SYNTHESIS; RADIOCHEMICAL ASSAY; ENDOTHELIAL-CELLS; NITRIC-OXIDE; METABOLISM; GLUTAMATE; PYRROLINE-5-CARBOXYLATE; REQUIREMENTS; LIVER	We compared effects of feeding arginine- and/or proline- deficient diets (-Arg, -Pro, and -Arg,Pro) with those of a complete diet (Complete) in rats whose small intestine had been massively resected. After 4 weeks, the rats fed -Arg and -Arg,Pro lost weight (a mean of 28 and 32 g, respectively), whereas those fed Complete and -Pro gained 80 and 58 g,respectively, The average nitrogen balance was about 117, 100, -20 and -14 mg/day for Complete, -Pro, -Arg, and -Arg,Pro diets, respectively. The concentration of arginine in skeletal muscle was about 310, 330, 91, and 65 nmol/g for Complete, -Pro, -Arg, and -Arg,Pro, respectively; while plasma arginine concentration averaged 95, 107, 56, and 46 mu M, respectively. The weight loss, the negative nitrogen balance, and the markedly reduced arginine concentration in the muscle observed in rats fed -Arg and -Arg,Pro clearly indicate that arginine becomes a strictly essential amino acid in the rats with massive resection of the small intestine. However, sufficient proline can be synthesized from arginine in tissues such as the liver and kidney in the absence of the small intestine. Plasma glutamine, citrulline in the muscle and plasma, urinary excretion of erotic acid and nitrate (to assess nitric oxide formation from arginine) were also measured, and the changes in these metabolites are discussed.	KYOTO PREFECTURAL UNIV MED,DEPT ANESTHESIOL,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT CLIN LAB & MED,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT INTERNAL MED 1,KYOTO 602,JAPAN	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	WAKABAYASHI, Y (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT BIOCHEM,465 KAJIICHO HIROKOJI KAWARAMACHI KAMIKYOKU,KYOTO 602,JAPAN.							BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BONSNES RW, 1945, J BIOL CHEM, V158, P581; DEPOCAS F, 1951, REV CAN BIOL, V10, P289; DHANAKOTI SN, 1990, AM J PHYSIOL, V259, pE437, DOI 10.1152/ajpendo.1990.259.3.E437; DROTMAN RB, 1972, AM J PHYSIOL, V222, P973, DOI 10.1152/ajplegacy.1972.222.4.973; EAGLE H, 1965, J BIOL CHEM, V240, P3944; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; FEATHERSTON WR, 1973, AM J PHYSIOL, V224, P127, DOI 10.1152/ajplegacy.1973.224.1.127; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOSTER LB, 1971, CLIN CHEM, V17, P921; GIETZEN DW, 1993, J NUTR, V123, P610, DOI 10.1093/jn/123.4.610; GRAZER RE, 1984, ARCH INTERN MED, V144, P2278, DOI 10.1001/archinte.144.11.2278; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; HASSAN AS, 1981, METABOLISM, V30, P739, DOI 10.1016/0026-0495(81)90018-4; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HOOGENRAAD N, 1985, AM J PHYSIOL, V249, pG792, DOI 10.1152/ajpgi.1985.249.6.G792; IRWIN MI, 1971, J NUTR, V101, P539; JONES ME, 1961, ARCH BIOCHEM BIOPHYS, V95, P499, DOI 10.1016/0003-9861(61)90182-5; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; LEUNG PMB, 1968, J NUTR, V96, P303, DOI 10.1093/jn/96.3.303; MEZL VA, 1977, BIOCHEM J, V166, P105, DOI 10.1042/bj1660105; MILNER JA, 1979, J NUTR, V109, P663, DOI 10.1093/jn/109.4.663; MILNER JA, 1978, J NUTR, V108, P382, DOI 10.1093/jn/108.3.382; MILNER JA, 1975, METABOLISM, V24, P643, DOI 10.1016/0026-0495(75)90144-4; MILNER JA, 1974, J NUTR, V104, P1681, DOI 10.1093/jn/104.12.1681; MILNER JA, 1973, NATURE, V245, P212; MORGAN JF, 1958, J BIOL CHEM, V233, P664; Munro HN, 1970, MAMMALIAN PROTEIN ME, V4, P299; RAIJMAN L, 1974, BIOCHEM J, V138, P225, DOI 10.1042/bj1380225; RATNER S, 1980, ANAL BIOCHEM, V106, P134, DOI 10.1016/0003-2697(80)90129-3; RATNER S, 1983, ANAL BIOCHEM, V135, P479, DOI 10.1016/0003-2697(83)90716-9; Rose WC, 1938, PHYSIOL REV, V18, P109, DOI 10.1152/physrev.1938.18.1.109; SALLACH HJ, 1951, J AM CHEM SOC, V73, P4500, DOI 10.1021/ja01153a551; SCUDAMORE CH, 1983, GASTROENTEROLOGY, V84, P725; Scull CW, 1930, J BIOL CHEM, V89, P109; SMITH AD, 1967, BIOCHEM J, V104, P557, DOI 10.1042/bj1040557; STAJNER A, 1968, EXPERIENTIA, V24, P116, DOI 10.1007/BF02146929; Stetten MR, 1944, J BIOL CHEM, V153, P113; STETTEN MR, 1951, J BIOL CHEM, V189, P499; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P1, DOI 10.1016/0003-9861(91)90097-3; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P9, DOI 10.1016/0003-9861(91)90098-4; WAKABAYASHI Y, 1983, J BIOL CHEM, V258, P3865; WENNMALM A, 1993, CIRC RES, V73, P1121, DOI 10.1161/01.RES.73.6.1121; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; WINDMUELLER HG, 1981, AM J PHYSIOL, V241, pE473, DOI 10.1152/ajpendo.1981.241.6.E473; WINDMUELLER HG, 1974, J BIOL CHEM, V249, P5070; WOMACK M, 1947, J BIOL CHEM, V171, P37; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; YAMADA E, 1993, LANCET, V341, P1542, DOI 10.1016/0140-6736(93)90687-C	49	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32667	32671						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798273				2022-12-27	WOS:A1994PX30400096
J	WESTWOOD, ME; MCLELLAN, AC; THORNALLEY, PJ				WESTWOOD, ME; MCLELLAN, AC; THORNALLEY, PJ			RECEPTOR-MEDIATED ENDOCYTIC UPTAKE OF METHYLGLYOXAL-MODIFIED SERUM-ALBUMIN - COMPETITION WITH ADVANCED GLYCATION END PRODUCT-MODIFIED SERUM-ALBUMIN AT THE ADVANCED GLYCATION END-PRODUCT RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-MODIFIED PROTEINS; NONENZYMATICALLY GLYCOSYLATED PROTEINS; ALDEHYDE-MODIFIED PROTEINS; LOW-DENSITY LIPOPROTEINS; SCAVENGER RECEPTOR; MAILLARD REACTION; CELL-SURFACE; REACTION INTERMEDIATE; MACROPHAGE RECEPTOR; GLYOXALASE SYSTEM	Methylglyoxal binds and irreversibly modifies arginine and lysine residues in bovine serum albumin (BSA) under physiological conditions, producing a protein with an increased net negative charge at physiological pH. At 4 degrees C, methylglyoxal-modified BSA (MG-BSA) was bound by cell surface receptors on murine P388D(1) macrophages. The apparent dissociation constant K-D value was 435 +/- 2 nM, and there were 8.89 +/- 0.02 x 10(5) receptors/cell (n = 6), compare with an apparent K-D value of 263 +/- 52 nM and 10.17 +/- 0.93 x 10(5) receptors/cell (n = 11) for advanced glycation end product-modified BSA (AGE-BSA). AGE-ESA competed with MG-BSA for binding to a common receptor; however, a component of AGE-BSA receptor binding could not be displaced by MG-BSA, and a component of MG-BSA receptor binding could not be displaced by AGE-BSA, suggesting that there are binding sites for both AGE-BSA and MG-BSA, competitive and noncompetitive, to MG-BSA and AGE-BSA on P388D cells at 4 degrees C. At 37 degrees C, receptor binding of AGE-BSA and MG-BSA was followed by endocytosis and lysosomal degradation of the modified protein. Methylglyoxal-modified proteins are ligands for the AGE receptor, and their formation and metabolism may be linked to the development of diabetic complications.	UNIV ESSEX,DEPT CHEM & BIOL CHEM,COLCHESTER CO4 3SQ,ESSEX,ENGLAND	University of Essex				Thornalley, Paul/0000-0001-7659-443X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED MU, 1986, J BIOL CHEM, V261, P4889; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COSARNO ME, 1983, J CHROMATOGR, V266, P105, DOI 10.1016/S0021-9673(01)90883-0; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1988, J BIOL CHEM, V263, P18821; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; IMANI F, 1993, J EXP MED, V178, P2165, DOI 10.1084/jem.178.6.2165; JOHANSSON BG, 1972, SCAND J CLIN LAB INV, V29, P7, DOI 10.3109/00365517209102747; KARONEN SL, 1975, ANAL BIOCHEM, V67, P1, DOI 10.1016/0003-2697(75)90266-3; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; KAWAKISHI S, 1991, CARBOHYD RES, V211, P167, DOI 10.1016/0008-6215(91)84156-9; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO TWC, 1994, J BIOL CHEM, V269, P32299; Lo TWC, 1993, AMINO ACIDS, V5, P172; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; NJOROGE FG, 1989, MAILLARD REACTION AG, P85; Phillips S. A., 1993, BIOCHEM SOC T, V21, P163, DOI DOI 10.1042/BST021163S; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHIN DB, 1988, AGR BIOL CHEM TOKYO, V52, P1451; SHINODA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1826, DOI 10.1271/bbb.57.1826; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SMITH PR, 1993, CLIN SCI, V84, P87, DOI 10.1042/cs0840087; SMITH RE, 1978, ANAL BIOCHEM, V90, P246, DOI 10.1016/0003-2697(78)90029-5; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V986, P18, DOI 10.1016/0005-2736(89)90267-8; TEZUKA M, 1993, BIOCHEM BIOPH RES CO, V193, P674, DOI 10.1006/bbrc.1993.1677; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	54	94	98	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32293	32298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798229				2022-12-27	WOS:A1994PX30400044
J	TAKEDA, S; NORTH, DL; DIAGANA, T; MIYAGOE, Y; LAKICH, MM; WHALEN, RG				TAKEDA, S; NORTH, DL; DIAGANA, T; MIYAGOE, Y; LAKICH, MM; WHALEN, RG			MYOGENIC REGULATORY FACTORS CAN ACTIVATE TATA-CONTAINING PROMOTER ELEMENTS VIA AN E-BOX INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; CREATINE-KINASE ENHANCER; MUSCLE-SPECIFIC ENHANCER; ALPHA-SUBUNIT GENE; DNA-BINDING; SKELETAL-MUSCLE; TRANSCRIPTION INITIATION; IMMUNOGLOBULIN ENHANCER; MYOD FAMILY; EXPRESSION	We have studied the effect of several myogenic regulatory factors on the activity of the promoter for a mouse gene encoding a skeletal myosin heavy chain (MyHC) expressed in adult (type IIB) muscle fibers. Co-transfection of myogenic factors is necessary for activity of the IIB promoter in mouse C2 myotubes in culture but not in quail myotubes in culture. Although this promoter contains one E-box within the first 199 base pairs upstream of the transcriptional start site, mutations in this motif demonstrate that it is not required for the transactivation effect of the myogenic factors. Analysis of other mutants suggests that the MEF2 and MHox DNA-binding factor binds to an evolutionarily conserved AT-rich motif. In addition, the RR promoter appears to require the conserved TATA motif (CTATAAAAG) in order to be activated by the AT-rich sequences. The IIB promoter constructs produce RNA transcripts which begin at the natural site of transcriptional initiation in quail myotubes and in mouse Ca myotubes after co-transfection with myogenic factors; a second, minor, start site is also used in the co-transfected C2 myotubes. Results obtained after transfection of the mouse IIB promoter constructs in quail myotube cultures suggest that the overexpression of myogenic factors in C2 cultures does not result in an environment in which the control of IIB MyHC promoter activity is aberrant. Therefore, either the myogenic factors themselves, or other proteins induced by them, seem to interact directly with the basal transcription machinery to allow muscle-specific gene expression.	INST PASTEUR,DEPT MOLEC BIOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								AURADE F, 1994, DIFFERENTIATION, V55, P185, DOI 10.1046/j.1432-0436.1994.5530185.x; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V8, P5022; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1983, J BIOL CHEM, V258, P3883; MONTARRAS D, 1991, NEW BIOL, V3, P592; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUSSELL SD, 1993, DEV BIOL, V157, P359, DOI 10.1006/dbio.1993.1141; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TAKEDA S, 1992, CR ACAD SCI III-VIE, V315, P467; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TIMMERS HTM, 1992, GENE DEV, V5, P1946; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	53	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15664	15670		10.1074/jbc.270.26.15664	http://dx.doi.org/10.1074/jbc.270.26.15664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797566	hybrid			2022-12-27	WOS:A1995RG53800037
J	LIU, JH; GAGNON, Y; GAUTHIER, J; FURENLID, L; LHEUREUX, P; AUGER, M; NUREKI, O; YOKOYAMA, S; LAPOINTE, J				LIU, JH; GAGNON, Y; GAUTHIER, J; FURENLID, L; LHEUREUX, P; AUGER, M; NUREKI, O; YOKOYAMA, S; LAPOINTE, J			THE ZINC-BINDING SITE OF ESCHERICHIA-COLI GLUTAMYL-TRANSFER-RNA SYNTHETASE IS LOCATED IN THE ACCEPTOR-BINDING DOMAIN - STUDIES BY EXTENDED X-RAY-ABSORPTION FINE-STRUCTURE, MOLECULAR MODELING, AND SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS HB8; ISOLEUCYL-TRANSFER-RNA; GLTX-GENE; EXTREME THERMOPHILE; CLONING; PROTEIN; SEQUENCE; OVERPRODUCTION; METALLOPROTEIN	The zinc contents of fragments of Escherichia coli glutamyl-tRNA synthetase, as well as the conservation of the CYC sequence only in zinc-containing glutamyl-tRNA synthetases, suggested that the (98)CYCX(24),,CRHSHEHHADDEPC(138) includes some or all residues involved in binding its zinc atom (Liu, J., Lin, S.-X., Blochet, J.-E., Pezolet, M., and Lapointe, J. (1993) Biochemistry 32, 11390-11396). Extended x-ray absorption fine structure (EXAFS) shows that this zinc atom has a four-coordinate non-planar coordination environment with 3 sulfur and 1 nitrogen atoms with bond lengths, respectively, 2.37 +/- 0.02 Angstrom and 2.01 +/- 0.02 Angstrom, presumably belonging to and cysteine residues and 1 histidine residue. Conservative replacement of each histidine and cysteine residue of the C-98-C-138 segment, respectively, with glutamine (Q) and serine (S), yields variants H129Q, H131Q, H132Q, and C138S (which sustain the growth at 42 degrees C of E. coli JP1449, whose glutamyl-tRNA synthetase is thermosensitive) and C98S, C100S, C125S, and H127Q (which do not). The amount of this enzyme in these mutants is at least 1 order of magnitude larger than that in a wild type strain; however, no glutamyl-tRNA synthetase activity is detectable in extracts of the variants C100S and C125S, whereas its specific activity in those of C98S and H127Q is about 10-fold lower than in cells overproducing the wild type enzyme or the variants H129Q, H131Q, H132Q, and C138S. These results indicate that the zinc atom present in E. coli glutamyl-tRNA synthetase is bound by the 2 evolutionarily conserved cysteines at positions 98 and 100, and by Cys(125) and His(127). Molecular modeling of the N-terminal half of this enzyme, using the known structure of E. coli glutaminyl-tRNA synthetase, supports this conclusion and suggests that the C-98-H-127 segment does not have the characteristics of the classical zinc fingers.	UNIV LAVAL, FAC SCI & GENIE, DEPT BIOCHIM, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV LAVAL, FAC SCI & GENIE, DEPT CHIM, QUEBEC CITY, PQ G1K 7P4, CANADA; BROOKHAVEN NATL LAB, UPTON, NY 11973 USA; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Laval University; Laval University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Ausubel FM, 1988, MOL REPROD DEV; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOULDIN C, 1995, PHYSICA B, V208, P190, DOI 10.1016/0921-4526(94)01012-P; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1986, J BIOL CHEM, V261, P610; BRISSON A, 1989, BIOCHEM CELL BIOL, V67, P404, DOI 10.1139/o89-065; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P8275; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DYBVIG K, 1994, MOL MICROBIOL, V12, P547, DOI 10.1111/j.1365-2958.1994.tb01041.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FOURMY D, 1993, J MOL BIOL, V231, P1078, DOI 10.1006/jmbi.1993.1353; FOURMY D, 1993, J MOL BIOL, V231, P1068, DOI 10.1006/jmbi.1993.1352; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HUGHES MN, 1989, SPEC PUBL SOC GEN MI, V26, P1; HUNT JB, 1984, J BIOL CHEM, V259, P4793; KISSELEV LL, 1981, EUR J BIOCHEM, V120, P511, DOI 10.1111/j.1432-1033.1981.tb05729.x; KOHDA D, 1984, FEBS LETT, V174, P20, DOI 10.1016/0014-5793(84)81069-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABERGE S, 1989, J BACTERIOL, V171, P3926, DOI 10.1128/jb.171.7.3926-3932.1989; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; LANDRO JA, 1994, J BIOL CHEM, V269, P20217; LAPOINTE J, 1975, J BACTERIOL, V122, P352, DOI 10.1128/JB.122.2.352-358.1975; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; LIU J, 1995, THESIS U LAVAL QUEBE; LIU JH, 1993, BIOCHEMISTRY-US, V32, P11390, DOI 10.1021/bi00093a016; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MAYAUX JF, 1982, EUR J BIOCHEM, V128, P41; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, 1993, J BIOL CHEM, V268, P15368; NUREKI O, 1995, SCIENCE, V267, P1958, DOI 10.1126/science.7701318; NUREKI O, 1991, J BIOL CHEM, V266, P3268; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUSSELL RRB, 1971, J BACTERIOL, V108, P790, DOI 10.1128/JB.108.2.790-798.1971; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SCHWOB E, 1993, EMBO J, V12, P5201, DOI 10.1002/j.1460-2075.1993.tb06215.x; SHIELDS JM, 1993, THESIS CLEVELAND STA; STERN EA, 1983, HDB SYNCHROTRON RAD; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WICHLAN DG, 1993, J BACTERIOL, V175, P2936, DOI 10.1128/JB.175.10.2936-2942.1993; XU B, 1993, J BIOL CHEM, V268, P16259; YAMAO F, 1982, J BIOL CHEM, V257, P1639; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x	55	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15162	15169		10.1074/jbc.270.25.15162	http://dx.doi.org/10.1074/jbc.270.25.15162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797500	hybrid			2022-12-27	WOS:A1995RE66600049
J	LEHMANN, M; TSHISUAKA, B; FETZNER, S; LINGENS, F				LEHMANN, M; TSHISUAKA, B; FETZNER, S; LINGENS, F			MOLECULAR-CLONING OF THE ISOQUINOLINE 1-OXIDOREDUCTASE GENES FROM PSEUDOMONAS-DIMINUTA-7, STRUCTURAL-ANALYSIS OF IORA AND IORB, AND SEQUENCE COMPARISONS WITH OTHER MOLYBDENUM-CONTAINING HYDROXYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ALDEHYDE DEHYDROGENASE; QUINALDIC ACID 4-OXIDOREDUCTASE; LIVER XANTHINE DEHYDROGENASE; IRON-SULFUR PROTEIN; MICROBIAL-METABOLISM; NUCLEOTIDE-SEQUENCE; DROSOPHILA-MELANOGASTER; ESCHERICHIA-COLI; QUINOLINE OXIDOREDUCTASE; ACETOBACTER-POLYOXOGENES	The iorA and iorB genes from the isoquinoline-degrading bacterium Pseudomonas diminuta 7, encoding the heterodimeric molybdo-iron-sulfur-protein isoquinoline 1-oxidoreductase, were cloned and sequenced. The deduced amino acid sequences IorA and IorE showed homologies (i) to the small (gamma) and large (alpha) subunits of complex molybdenum-containing hydroxylases (alpha beta gamma/alpha(2) beta(2) gamma(2)) possessing a pterin molybdenum cofactor with a monooxo-monosulfido-type molybdenum center, (ii) to the N- and C-terminal regions of aldehyde oxidoreductase from Desulfovibrio gigas, and (iii) to the N- and C-terminal domains of eucaryotic xanthine dehydrogenases, respectively. The closest similarity to IorE was shown by aldehyde dehydrogenase (Adh) hom the acetic acid bacterium Acetobacter polyoxogenes. Five conserved domains of IorB were identified by multiple sequence alignments. Whereas IorB and Adh showed an identical sequential arrangement of these conserved domains, in all other molybdenum-containing hydroxylases the relative position of ''domain A'' differed. IorA contained eight conserved cysteine residues. The amino acid pattern harboring the four cysteine residues proposed to ligate the Fe/S I cluster was homologous to the consensus binding site of bacterial and chloroplast-type [2Fe-2S] ferredoxins, whereas the pattern including the four cysteines assumed to ligate the Fe/S II center showed no similarities to any described [2Fe-2S] binding motif. The N-terminal region of IorB comprised a putative signal peptide similar to typical leader peptides, indicating that isoquinoline 1-oxidoreductase is associated with the cell membrane.	UNIV HOHENHEIM,INST MIKROBIOL 250,D-70593 STUTTGART,GERMANY	University Hohenheim				Fetzner, Susanne/0000-0002-7228-1871				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BAUDER R, 1990, BIOL CHEM H-S, V371, P1137, DOI 10.1515/bchm3.1990.371.2.1137; BAUER G, 1992, BIOL CHEM H-S, V373, P699, DOI 10.1515/bchm3.1992.373.2.699; BENEN JAE, 1989, J GEN MICROBIOL, V135, P1787; Bray R. C., 1975, ENZYMES, P300; BRAY RC, 1991, BIOCHEM J, V280, P817, DOI 10.1042/bj2800817; CLARKE P, 1982, GENE, V18, P157, DOI 10.1016/0378-1119(82)90113-5; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; DAVIS RW, 1980, ADV BACTERIAL GENET, P120; DEBEYER A, 1993, BIOL CHEM H-S, V374, P101, DOI 10.1515/bchm3.1993.374.1-6.101; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FETZNER S, 1993, BIOL CHEM H-S, V374, P363, DOI 10.1515/bchm3.1993.374.1-6.363; FREUDENBERG W, 1988, FEMS MICROBIOL LETT, V52, P13; FUKAYA M, 1989, APPL ENVIRON MICROB, V55, P171, DOI 10.1128/AEM.55.1.171-176.1989; FUKAYA M, 1989, APPL MICROBIOL BIOT, V32, P176, DOI 10.1007/BF00165884; GRABAU C, 1991, J BIOL CHEM, V266, P3294; GRETHERBECK S, 1994, MOL MICROBIOL, V13, P929, DOI 10.1111/j.1365-2958.1994.tb00484.x; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HIGGINS D G, 1989, Gene (Amsterdam), V73, P237; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUGHES RK, 1992, BIOCHEM J, V285, P507, DOI 10.1042/bj2850507; KEITH TP, 1987, GENETICS, V116, P67; KRETZER A, 1993, J GEN MICROBIOL, V139, P2763, DOI 10.1099/00221287-139-11-2763; LEE CS, 1987, GENETICS, V116, P55; LEHMANN M, 1994, J BIOL CHEM, V269, P11254; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MEYER O, 1982, J BIOL CHEM, V257, P1333; Miller J. H., 1972, EXPT MOL GENETICS, P431; MOURA JJG, 1976, BIOCHEM BIOPH RES CO, V72, P782, DOI 10.1016/S0006-291X(76)80201-X; NAGEL M, 1990, ARCH MICROBIOL, V154, P605; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Palleroni N., 1984, BERGEYS MANUAL SYSTE, VVolume 1, P141; PEARSON DM, 1994, BBA-BIOENERGETICS, V1188, P432, DOI 10.1016/0005-2728(94)90066-3; PESCHKE B, 1991, BIOL CHEM H-S, V372, P1081, DOI 10.1515/bchm3.1991.372.2.1081; PUGSLEY AP, 1985, FEMS MICROBIOL LETT, V32, P3, DOI 10.1111/j.1574-6968.1985.tb01180.x; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; ROGER P, 1990, BIOL CHEM H-S, V371, P511, DOI 10.1515/bchm3.1990.371.1.511; ROHDE M, 1984, J BIOL CHEM, V259, P4788; ROMAO MJ, 1993, EUR J BIOCHEM, V215, P729, DOI 10.1111/j.1432-1033.1993.tb18085.x; SAEKI K, 1990, NUCLEIC ACIDS RES, V18, P1060, DOI 10.1093/nar/18.4.1060; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUTER M, 1993, BIOL CHEM H-S, V374, P1037, DOI 10.1515/bchm3.1993.374.7-12.1037; SCHAGGER H, 1987, ANAL BIOCHEM, V66, P368; SHJIMADA Y, 1993, BIOCHIM BIOPHYS ACTA, V1174, P79; TAMAKI T, 1989, J BIOCHEM-TOKYO, V106, P541, DOI 10.1093/oxfordjournals.jbchem.a122889; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WALLACE RG, 1980, GENE, V12, P179, DOI 10.1016/0378-1119(80)90100-6; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	63	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14420	14429		10.1074/jbc.270.24.14420	http://dx.doi.org/10.1074/jbc.270.24.14420			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782304	hybrid			2022-12-27	WOS:A1995RD45500031
J	ZHAO, YM; WAGNER, F; FRANK, SJ; KRAFT, AS				ZHAO, YM; WAGNER, F; FRANK, SJ; KRAFT, AS			THE AMINO-TERMINAL PORTION OF THE JAK2 PROTEIN-KINASE IS NECESSARY FOR BINDING AND PHOSPHORYLATION OF THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR BETA(C) CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; HIGH-AFFINITY; GM-CSF; CYTOPLASMIC DOMAINS; EXPRESSION CLONING; SUBUNIT; INTERLEUKIN-3; FAMILY	The binding of granulocyte-macrophage colony-stimulating factor (GM-CSF) to its receptor stimulates JAK2 protein kinase activation, protein phosphorylation, and JAK2 association with the beta(c) chain of the GM-CSF receptor. To better understand how different domains of the JAK2 function to regulate association and phosphorylation of the beta(c) receptor, the minimal portion of the beta(c) receptor necessary for JAK2 binding has been determined. Using glutathione S-transferase (GST) fusion proteins expressing different portions of the membrane-proximal domain of the beta(c) chain, we demonstrate that JAK2 binds to amino acids 458-495, but showed little binding to fusion proteins containing amino acids 483-559, 483-530, or 458-484. The GST-beta(c) 458-495 bound equally well to the wild type (WT) JAK2, a carboxyl-terminal deletion of JAK2 removing the protein kinase domain (amino acids 1000-1129), and a deletion of the kinase-like domain (amino acids 523-746). However, an amino-terminal JAK2 deletion (amino acids 2-239) markedly reduced binding to this GST-beta(c). Far Western blotting demonstrated that a GST fusion protein containing amino acids 1-294 of JAK2, but not fusion proteins containing amino acids 295-522, 523-746, or 747-1127, bound GST-beta(c) 458-559. When the JAK2 WT and deletions were transiently expressed along with the alpha and beta(c) subunits of the GM-CSF receptor and the cells were treated with GM-CSF, the following results were obtained: 1) WT JAK2 phosphorylated the beta(c) subunit in a GM-CSF-dependent manner, 2) the kinase-like domain deletion phosphorylated the beta(c) subunit, and 3) both the kinase domain deletion and the amino-terminal deletion failed to stimulate phosphorylation of the beta(c) subunit. Therefore, phosphorylation of the beta(c) subunit requires the binding of JAK2 through its amino terminus.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; DIV ENDOCRINOL,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741, R29DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK-46395, DK44741] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DURONIO V, 1992, J BIOL CHEM, V267, P21856; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; POLATSKAYA A, 1994, J BIOL CHEM, V269, P4607; POLATSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	32	133	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13814	13818		10.1074/jbc.270.23.13814	http://dx.doi.org/10.1074/jbc.270.23.13814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775438	hybrid			2022-12-27	WOS:A1995RC44800037
J	PACKMAN, LC; MEWIES, M; SCRUTTON, NS				PACKMAN, LC; MEWIES, M; SCRUTTON, NS			THE FLAVINYLATION REACTION OF TRIMETHYLAMINE DEHYDROGENASE - ANALYSIS BY DIRECTED MUTAGENESIS AND ELECTROSPRAY MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; BACTERIUM; COENZYME; CLONING; FLAVIN; ASSAY; AID	The flavinylation reaction products of wild-type and mutant forms of trimethylamine dehydrogenases purified from Methylophilus methylotrophus (bacterium W(3)A(1)) and Escherichia coli were studied by electrospray mass spectrometry (ESMS). The ESMS analyses demonstrated for the first time that wild-type enzyme expressed in M. methylotrophus is predominantly in the holoenzyme form, although a small proportion is present as the deflavo enzyme. ESMS demonstrated that the deflavo forms of the recombinant wild-type and mutant enzymes are not post-translationally modified and therefore prevented from assembling with flavin mononucleotide (FMN) because of previously unrecognized modifications. The data suggest that the higher proportion of deflavo enzyme observed for the recombinant wild-type enzyme is a consequence of the higher expression levels in E. coli. Mutagenesis of the putative flavinylation base (His-29 to Gln-29) did not prevent flavinylation, but the relative proportion of flavinylated product was substantially less than that seen for the recombinant mild-type enzyme. No flavinylation products were observed for a double mutant (His-29 to Cys-29; Cys-30 to His-30), in which the positions of the putative flavinylation base and cysteine nucleophile were exchanged. Taken together, the data indicate that the assembly of trimethylamine dehydrogenase with FMN occurs during the folding of the enzyme, and in the fully folded form, deflavo enzyme is unable to recognize FMN. Results of site-directed mutagenesis experiments in the FMN-binding site suggest that following mutation the affinity for FMN during the folding process is reduced. Consequently, in the folded mutant enzymes, less flavin is trapped in the active site, and reduced levels of flavinylated product are obtained.	UNIV CAMBRIDGE,DEPT BIOCHEM,CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge								BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MOORE SA, 1993, EMBO J, V12, P1767, DOI 10.1002/j.1460-2075.1993.tb05824.x; PACKMAN LC, 1995, EUR J BIOCHEM, V277, P510; RAINE ARC, 1994, PROTEIN SCI, V3, P1889, DOI 10.1002/pro.5560031028; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; ROHLFS RJ, 1995, J BIOL CHEM, V269, P30869; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, BIOCHEM J, V169, P263; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024	23	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13186	13191		10.1074/jbc.270.22.13186	http://dx.doi.org/10.1074/jbc.270.22.13186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768915	hybrid			2022-12-27	WOS:A1995RB43900038
J	YANG, L; YANG, YC				YANG, L; YANG, YC			REGULATION OF INTERLEUKIN (IL)-11 GENE-EXPRESSION IN IL-1 INDUCED PRIMATE BONE-MARROW STROMAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; MOLECULAR-CLONING; MAMMALIAN-CELLS; GRO-ALPHA; JUN-D; PROTEIN; TRANSCRIPTION; SEQUENCE	Interleukin (IL)-1 alpha treatment of a primate bone marrow stromal cell line, PU-34, transiently increased the steady state level of IL-11 mRNA, Nuclear run-on experiments showed that the transcription rate of the IL-11 gene was not affected appreciably by IL-1 alpha induction, but changes in the half-life of the IL-11 mRNA corresponded well with the changes in the steady state level of the IL-11 mRNA during the induction, Although transient transfection of PU-34 cells with IL-11 promoter constructs failed to respond to IL-1 alpha, a 10-base pair promoter region and JunD.AP-1 complex were found to be responsible for the basal level transcription of the IL-11 gene, The tyrosine kinase inhibitor genistein accelerated the degradation of the IL-11 mRNA without affecting the transcription rate of the IL-11 gene in IL-1 alpha stimulated cells, The insertion of DNA sequences corresponding spending to the 3'-untranslated region of the IL-11 gene into a rabbit beta-globin gene resulted in destabilization of the chimeric mRNA which failed to be induced by IL-1 alpha. Exogenous IL-11 expression generated from transient transfection with plasmid PCMV-IL-11, however, can be stabilized by IL-1 alpha. In contrast to the hypothesis that AUUUA motifs in the 3'-untranslated region are sufficient to regulate cytokine mRNA stability, our results suggest that IL-1 alpha induced stabilization of the IL-11 mRNA requires participation of RNA sequences from different regions of the IL-11 message.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER I, 1991, ONCOGENE, V6, P561; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1409, DOI 10.1073/pnas.75.3.1409; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELIAS JA, 1990, J IMMUNOL, V145, P161; ELIAS JA, 1994, J IMMUNOL, V152, P2421; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; MAIER R, 1993, J BIOL CHEM, V268, P21527; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MALTER JS, 1990, ENZYME, V44, P203, DOI 10.1159/000468758; MCKINLEY D, 1992, GENOMICS, V13, P814, DOI 10.1016/0888-7543(92)90158-O; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL SR, 1991, BLOOD, V77, P1723; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32732	32739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806493				2022-12-27	WOS:A1994QA63800006
J	PASHMFOROUSH, M; YOSHIMASA, Y; STEINER, DF				PASHMFOROUSH, M; YOSHIMASA, Y; STEINER, DF			EXON-11 ENHANCES INSULIN FINDING AFFINITY AND TYROSINE KINASE-ACTIVITY OF THE HUMAN INSULIN PRORECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; RECEPTOR PRECURSOR; PROTEIN-KINASE; CLEAVAGE SITE; EXPRESSION; RESISTANCE; CELLS; PHOSPHORYLATION; GLYCOSYLATION; LYMPHOCYTES	Data presented here show that there are significant differences in the insulin binding affinity and the tyrosine kinase activity of the insulin proreceptor isoforms which contain or lack exon 11. The exon 11(+) proreceptor does not show significant variations from the mature processed insulin receptor and has only a 3- to 4-fold reduced affinity for insulin. In contrast, the exon 11(-) proreceptor showed a markedly reduced insulin binding (25- to 50-fold less) when assayed on intact cells. Upon solubilization of the cells, exon 11(-) proreceptor bound insulin with somewhat higher affinity. Mild trypsin sin treatment of the cells expressing either isoform of the insulin proreceptor restored insulin binding to near-normal levels. Analysis of tyrosine kinase activity revealed that the exon 11(+) proreceptor required somewhat higher concentrations of insulin than the mature processed receptor to achieve maximal autophosphorylation. The exon 11(-) proreceptor failed to fully phosphorylate even at 10(-6) M insulin. Thus, the presence or absence of this short sequence of 12 amino acids affects the folding and/or conformation of the proreceptor so as to confer altered binding of insulin. We suggest that in the absence of exon 11 the proreceptor assumes a strained conformation that disrupts the insulin binding site. Cleavage of the proreceptor at the alpha-beta-subunit junction then allows the alpha-subunit to achieve its normal binding conformation.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; Howard Hughes Medical Institute; University of Chicago					NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKAKI RF, 1989, BIOCHEM BIOPH RES CO, V160, P296, DOI 10.1016/0006-291X(89)91655-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P1277, DOI 10.1073/pnas.69.5.1277; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; CZECH MP, 1977, ANNU REV BIOCHEM, V46, P359, DOI 10.1146/annurev.bi.46.070177.002043; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HEDO JA, 1983, J BIOL CHEM, V258, P20; KAHN CR, 1985, MOL BASIS INSULIN AC, P67; KAKEHI T, 1988, J CLIN INVEST, V81, P2020, DOI 10.1172/JCI113553; KASUGA M, 1982, J BIOL CHEM, V257, P392; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KUROSE T, 1994, J BIOL CHEM, V269, P29190; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOSTHAF L, 1991, P NATL ACAD SCI USA, V88, P4728, DOI 10.1073/pnas.88.11.4728; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PANG DT, 1984, J BIOL CHEM, V259, P8589; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PILCH PF, 1980, J BIOL CHEM, V255, P1722; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SASAOKA T, 1989, DIABETOLOGIA, V32, P371, DOI 10.1007/BF00277261; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VORM ERV, 1994, J BIOL CHEM, V269, P14297; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; YOSHIMASA Y, 1989, SCIENCE, V240, P783	42	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32639	32648						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798270				2022-12-27	WOS:A1994PX30400092
J	AOKI, Y; KIM, YT; STILLWELL, R; KIM, TJ; PILLAI, S				AOKI, Y; KIM, YT; STILLWELL, R; KIM, TJ; PILLAI, S			THE SH2 DOMAINS OF SRC FAMILY KINASES ASSOCIATE WITH SYK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES-B; ZETA-CHAIN; STIMULATION; EXPRESSION; GENE; PHOSPHORYLATION; ACTIVATION	Src family kinases (Lyn, Fyn, Lck, and Blk) and Syk, a tandem SH2 domain containing tyrosine kinase, have been demonstrated to be associated with the antigen receptor in B cells. Both of these categories of tyrosine kinases are presumed to be critical players in the process of antigen-mediated signal transduction. Cross linking of membrane immunoglobulin on the surface of B cells leads to the activation of Lyn, Fyn, and Blk, which presumably associate with the cytoplasmic tails of the membrane immunoglobulin-associated Ig alpha/beta heterodimer. Receptor ligation also leads to the tyrosine phosphorylation and catalytic activation of Syk, but the mechanism of association of this kinase with the antigen receptor remains to be established, A number of phosphoproteins that can associate with the SH2 domains of Blk, Lyn, and Fyn have been described in activated B cells. We demonstrate here that Syk is one of the proteins in the lysates of activated B cells which bind to the SH2 domains of Src family kinases. Syk binds directly to the SH2 domain of Blk and complexes in vivo with Lyn and Blk in activated B cells.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kim, Tae Jin/D-6544-2011	Kim, Tae Jin/0000-0001-9802-0568	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507, R29AI027835] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33507, AI-27835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1993, IMMUNOL REV, V132, P85, DOI 10.1111/j.1600-065X.1993.tb00838.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15658	15663		10.1074/jbc.270.26.15658	http://dx.doi.org/10.1074/jbc.270.26.15658			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797565	hybrid			2022-12-27	WOS:A1995RG53800036
J	GUO, WW; MORAN, JV; HOFFMAN, PW; HENKE, RM; BUTOW, RA; PERLMAN, PS				GUO, WW; MORAN, JV; HOFFMAN, PW; HENKE, RM; BUTOW, RA; PERLMAN, PS			THE MOBILE GROUP-I INTRON 3-ALPHA OF THE YEAST MITOCHONDRIAL COXI GENE ENCODES A 35-KDA PROCESSED PROTEIN THAT IS AN ENDONUCLEASE BUT NOT A MATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; SPLICE-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; DNA ENDONUCLEASE; POSTTRANSCRIPTIONAL PROCESSES; INTERVENING SEQUENCES; CYTOCHROME-OXIDASE; MEMBRANE SYSTEM; RIBOSOMAL-RNA; SCE-III	Three mitochondrial mutants were characterized that block the splicing of aI3 alpha, a mobile group I intron of the COXI gene of yeast mtDNA Mutant C1085 alters helical structures known to be important for splicing of group I introns. M44 and C1072 are point mutants in exon 3 that block correct splicing but allow some splicing at cryptic 5'-splice sites. M44 alters the P1 helix needed for 5'-splice site definition, while the mutation in C1072 is a new kind of mutation because it is located upstream of the exon sequence involved in the P1 helix. Ah three mutants accumulate novel proteins of 35 and 44 kDa (p35 and p44, respectively) detected both by labeling of mitochondrial translation products and by Western blotting, Partial protease digestions indicate that p44 and p35 are closely related, probably as precursor and processed protein. The level of the intron-encoded endonuclease activity, I-SceIII, is elevated similar to 10-fold in the mutants. Partial purification of I-SceIII from the mutants showed that most, if not all, of the activity is associated with p35. Finally, because aI3 alpha splices accurately in a petite mutant, we conclude that aI3 alpha splicing does not depend on a mtDNA-encoded maturase.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035510] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ANZIANO PQ, 1982, CELL, V30, P925, DOI 10.1016/0092-8674(82)90297-5; ANZIANO PQ, 1990, NUCLEIC ACIDS RES, V18, P3233, DOI 10.1093/nar/18.11.3233; ANZIANO PQ, 1984, THESIS OHIO STATE U; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; COOPER AA, 1993, BIOESSAYS, V15, P667, DOI 10.1002/bies.950151006; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DELASALLE H, 1982, CELL, V28, P721, DOI 10.1016/0092-8674(82)90051-4; Douglas M, 1979, Methods Enzymol, V56, P58; DUJARDIN G, 1982, NATURE, V298, P628, DOI 10.1038/298628a0; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; HALBREICH A, 1980, CELL, V19, P321, DOI 10.1016/0092-8674(80)90506-1; HALL DH, 1987, CELL, V48, P63, DOI 10.1016/0092-8674(87)90356-4; HANSON DK, 1982, J BIOL CHEM, V257, P3128; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HOFFMAN PW, 1989, THESIS OHIO STATE U; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3426; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1992, CR ACAD SCI III-VIE, V315, P37; MACREADIE IG, 1985, CELL, V41, P395, DOI 10.1016/S0092-8674(85)80012-X; MAHLER HR, 1976, GENETICS BIOGENESIS, P857; MECKLENBURG KL, 1987, THESIS OHIO STATE U; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1992, NUCLEIC ACIDS RES, V20, P4069, DOI 10.1093/nar/20.15.4069; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; PEREA J, 1993, NUCLEIC ACIDS RES, V21, P358, DOI 10.1093/nar/21.2.358; PEREA J, 1985, EMBO J, V4, P3281, DOI 10.1002/j.1460-2075.1985.tb04078.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERLMAN PS, 1990, METHOD ENZYMOL, V181, P539; PERLMAN PS, 1983, METHOD ENZYMOL, V9, P374; PRICE JV, 1987, J MOL BIOL, V196, P49, DOI 10.1016/0022-2836(87)90510-9; RALPH D, 1986, THESIS OHIO STATE U; SARGUEIL B, 1991, MOL GEN GENET, V225, P340, DOI 10.1007/BF00269867; SCHAPIRA M, 1993, NUCLEIC ACIDS RES, V21, P3683, DOI 10.1093/nar/21.16.3683; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1992, GENE, V113, P1, DOI 10.1016/0378-1119(92)90663-A; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SZCZEPANEK T, 1994, GENE, V139, P1, DOI 10.1016/0378-1119(94)90516-9; TABAK H, 1987, CELL, V39, P623; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VANDERHORST G, 1985, CELL, V40, P759, DOI 10.1016/0092-8674(85)90335-6; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEISSBRUMMER B, 1982, CELL, V29, P527, DOI 10.1016/0092-8674(82)90169-6; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WINTER AJ, 1988, NUCLEIC ACIDS RES, V16, P3845, DOI 10.1093/nar/16.9.3845; WINTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3897, DOI 10.1093/nar/20.15.3897; WOODSON SA, 1992, NUCLEIC ACIDS RES, V20, P4027, DOI 10.1093/nar/20.15.4027; WOODSON SA, 1993, MOL CELL BIOL, V13, P1137, DOI 10.1128/MCB.13.2.1137; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	68	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15563	15570		10.1074/jbc.270.26.15563	http://dx.doi.org/10.1074/jbc.270.26.15563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797552	hybrid			2022-12-27	WOS:A1995RG53800022
J	EMOTO, N; YANAGISAWA, M				EMOTO, N; YANAGISAWA, M			ENDOTHELIN-CONVERTING ENZYME-2 IS A MEMBRANE-BOUND, PHOSPHORAMIDON-SENSITIVE METALLOPROTEASE WITH ACIDIC PH OPTIMUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BIG ENDOTHELIN-1; CELLS; EXPRESSION; RECEPTOR; ANTAGONIST; SEQUENCE	Endothelins (ET) are a family of potent vasoactive peptides that are produced from biologically inactive intermediates, termed big endothelins, via a proteolytic processing at Trp(21)-Val/Ile(22). We recently cloned and characterized a membrane-bound metalloprotease that catalyzes this proteolytic activation, endothelin converting enzyme-1 (ECE-1) (Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D., and Yanagisawa, M. (1994) Cell 78, 473-485). This enzyme was shown to function in the secretory pathway as well as on the cell surface. Here we report molecular cloning of another novel enzyme, ECE-2, that produces mature ET-1 from big ET-1 both in vitro and in transfected cells. The cDNA sequence predicts that bovine ECE-2 is a metalloprotease structurally related to ECE-1, neutral endopeptidase 24.11, and human Kell blood group protein. The deduced amino acid sequence of ECE-2 is most similar to ECE-1, with an overall identity of 59%. ECE-2 resembles ECE-1 in that it is inhibited in vitro by phosphoramidon and FR901533 but not by thiorphan or captopril, and it converts big ET-1 more efficiently than big ET-2 or big ET-3. However, ECE-2 also exhibits the following striking differences hom ECE-1. (i) The sensitivity of ECE-2 to phosphoramidon is 250-fold higher as compared with ECE-1, while FR901533 inhibits both enzymes at similar concentrations. (ii) ECE-2 has an acidic pH optimum at pH 5.5, which is in sharp contrast to the neutral pH optimum of ECE-1. ECE-2 has a narrow pH profile and is virtually inactive at neutral pH, Chinese hamster ovary (CHO) cells, which lack detectable levels of endogenous ECE activity, secrete mature ET-1 into the medium when doubly transfected with ECE-2 and prepro-ET-1 cDNAs. However, ECE-2-transfected CHO cells do not efficiently produce mature ET-1 when present with an exogenous source of big ET-1 through coculture with prepro-ET-1-transfected CHO cells. These findings suggest that ECE-2 acts as an intracellular enzyme responsible for the conversion of endogenously synthesized big ET-1 at the trans-Golgi network, where the vesicular fluid is acidified.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Emoto, Noriaki/0000-0001-6673-2616				AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAX WA, 1994, TRENDS PHARMACOL SCI, V15, P379, DOI 10.1016/0165-6147(94)90159-7; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; OPGENORTH TJ, 1992, FASEB J, V6, P2653, DOI 10.1096/fasebj.6.9.1612289; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROQUES BP, 1993, PHARMACOL REV, V45, P87; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SEIDAH NG, 1993, ANN NY ACAD SCI, V680, P135, DOI 10.1111/j.1749-6632.1993.tb19680.x; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	32	406	419	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15262	15268		10.1074/jbc.270.25.15262	http://dx.doi.org/10.1074/jbc.270.25.15262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797512	hybrid			2022-12-27	WOS:A1995RE66600063
J	GENGRINOVITCH, S; GREENBERG, SM; COHEN, T; GITAYGOREN, H; ROCKWELL, P; MAIONE, TE; LEVI, BZ; NEUFELD, G				GENGRINOVITCH, S; GREENBERG, SM; COHEN, T; GITAYGOREN, H; ROCKWELL, P; MAIONE, TE; LEVI, BZ; NEUFELD, G			PLATELET FACTOR-IV INHIBITS THE MITOGENIC ACTIVITY OF VEGF(121) AND VEGF(165) USING SEVERAL CONCURRENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEPARIN-LIKE MOLECULES; FIBROBLAST GROWTH; FACTOR-IV; CELL-SURFACE; TUMOR-GROWTH; FACTOR RECEPTOR; FACTOR GENE; ANGIOGENESIS	The 121-amino acid form of vascular endothelial growth factor (VEGF(121)) and the 165-amino acid form (VEGF(165)) are mitogenic for vascular endothelial cells and induce angiogenesis in vivo. VEGF(165) possesses a heparin binding ability and in the absence of heparin-like molecules does not bind efficiently to the VEGF receptors of vascular endothelial cells, The binding of I-125-VEGF(165) to the VEGF receptors of endothelial cells, and the heparin dependent binding of I-125-VEGF(165) to a soluble extracellular domain of the VEGF receptor KDR/flk-1, were inhibited by the angiogenesis inhibitor platelet factor-4 (PF4). In contrast, PF4 was not able to inhibit the binding of VEGF(121), a VEGF isoform which lacks a heparin binding capacity, to the VEGF receptors of the cells or to KDR/flk-1. These results indicate that PF4 may inhibit VEGF(165) binding to VEGF receptors by disrupting the interaction of VEGF(165) with cell surface heparan sulfates, Since PF4 mutants lacking a heparin binding ability retain their anti-angiogenic activity, alternative inhibitory mechanisms were also examined. I-125-PF4 bound with high affinity (K-d 5 x 10(-9) M) to VEGF(165)-coated wells, The binding of I-125-PF4 to the VEGF(165)-coated wells was inhibited by several types of heparin binding proteins, including unlabeled PF4 and unlabeled VEGF(165). The binding was not inhibited by proteins which lack a heparin binding capacity, nor was it inhibited by VEGF(121). Heparinase did not inhibit the binding of I-125-PF4 to VEGF(165), indicating that heparin-like molecules are not required. These experiments suggest that PF4 can bind to heparin binding proteins such as VEGF(165) leading to an inhibition of their receptor binding ability, In agreement with these results, we have observed that PF4 inhibits efficiently the VEGF(165) induced proliferation of vascular endothelial cells. Unexpectedly, PF4 also inhibited efficiently the VEGF(121)-induced proliferation of the cells, indicating that PF4 can disrupt VEGF receptor mediated signal transduction using an unknown mechanism which does not interfere with VEGF(121) binding.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; REPLIGEN CORP,CAMBRIDGE,MA 02139; TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; IMCLONE SYST INC,NEW YORK,NY 10014	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Eli Lilly			Neufeld, Gera/F-1524-2019					BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; CAVARI S, 1993, FEBS LETT, V323, P155, DOI 10.1016/0014-5793(93)81469-G; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DANESI R, 1993, BRIT J CANCER, V68, P932, DOI 10.1038/bjc.1993.457; DIPIETRO LA, 1993, AM J PATHOL, V143, P678; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; GAGLIARDI A, 1993, CANCER RES, V53, P533; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVINE SP, 1990, BLOOD, V75, P902; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; NGUYEN NM, 1993, ANTICANCER RES, V13, P2143; NORRBY K, 1993, HAEMOSTASIS, V23, P141; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SATO Y, 1993, JPN J CANCER RES, V84, P485, DOI 10.1111/j.1349-7006.1993.tb00163.x; SATO Y, 1990, BIOCHEM BIOPH RES CO, V172, P595, DOI 10.1016/0006-291X(90)90715-Y; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SENGER DR, 1986, CANCER RES, V46, P5629; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILKS JW, 1991, INT J RADIAT BIOL, V60, P73, DOI 10.1080/09553009114551581; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	56	170	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15059	15065		10.1074/jbc.270.25.15059	http://dx.doi.org/10.1074/jbc.270.25.15059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797488	hybrid			2022-12-27	WOS:A1995RE66600034
J	KAMENS, J; PASKIND, M; HUGUNIN, M; TALANIAN, RV; ALLEN, H; BANACH, D; BUMP, N; HACKETT, M; JOHNSTON, CG; LI, P; MANKOVICH, JA; TERRANOVA, M; GHAYUR, T				KAMENS, J; PASKIND, M; HUGUNIN, M; TALANIAN, RV; ALLEN, H; BANACH, D; BUMP, N; HACKETT, M; JOHNSTON, CG; LI, P; MANKOVICH, JA; TERRANOVA, M; GHAYUR, T			IDENTIFICATION AND CHARACTERIZATION OF ICH-2, A NOVEL MEMBER OF THE INTERLEUKIN-1-BETA-CONVERTING ENZYME FAMILY OF CYSTEINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; PROTEOLYTIC CLEAVAGE; PRECURSOR; APOPTOSIS; CLONING; E-64	Interleukin-1 beta converting enzyme (ICE) is a cytoplasmic cysteine protease required for generating the bioactive form of the interleukin-1 beta cytokine from its inactive precursor, We report the identification of ICH-2, a novel human gene encoding a member of the ICE cysteine protease family, and characterization of its protein product. ICH-2 mRNA is widely expressed in human tissues in a pattern similar to, but distinct from, that of ICE. Overexpression of ICH-2 in insect cells induces apoptosis. Purified ICH-2 is functional as a protease in vitro. A comparison of the inhibitor profiles and substrate cleavage by ICH-2 and ICE shows that the enzymes share catalytic properties but may differ in substrate specificities, suggesting that the two enzymes have different functions in vivo.			KAMENS, J (corresponding author), BASF BIORES CORP, DEPT IMMUNOL, 100 RES DR, WORCESTER, MA 01605 USA.			Kamens, Joanne/0000-0002-7000-1477				Bachmann B.J., 1987, CELLULAR MOL BIOL, P1190; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KEANE KM, 1995, CYTOKINE, V7, P105, DOI 10.1006/cyto.1995.1014; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; PORATH J, 1992, PROTEIN EXPRES PURIF, V3, P263, DOI 10.1016/1046-5928(92)90001-D; REITER LA, 1994, INT J PEPT PROT RES, V43, P87; SHIVERS BD, 1995, ADV BEHAV BIOL, V44, P231; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	259	291	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15250	15256		10.1074/jbc.270.25.15250	http://dx.doi.org/10.1074/jbc.270.25.15250			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797510	hybrid			2022-12-27	WOS:A1995RE66600061
J	CAI, TQ; WRIGHT, SD				CAI, TQ; WRIGHT, SD			ENERGETICS OF LEUKOCYTE INTEGRIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; MONOCLONAL-ANTIBODIES; POLYMORPHONUCLEAR LEUKOCYTES; TRANSIENT ADHESION; HUMAN-MONOCYTES; BINDING-SITE; CD11B CD18; RECEPTOR; MACROPHAGES; PROTEIN	Cell adhesion mediated by leukocyte integrin CR3 (CD11b/CD18, alpha(m) beta(2)) may be rapidly modulated without changes in receptor number, and transient changes in adhesivity are thought to be driven by reversible alteration of the affinity of CR3 for ligand. Here we measure the binding affinity of CR3 using purified active and inactive receptor and the ligand, C3bi, coupled to alkaline phosphatase. Immobilized, active CR3 bound saturably and with high affinity (12.5 +/- 4.7 nM). In contrast, inactive CR3 exhibited no measurable binding. High affinity binding could be restored by the addition of the activating anti-CR3 monoclonal antibody KIM-127 to inactive CR3. Since the affinity of KIM-127 for active and inactive receptor was identical, it cannot contribute the energy to convert a low affinity receptor into a high affinity receptor. Rather, KIM-127 appears to facilitate binding of C3bi by lowering the activation energy for the shift from an inactive to an active state. These results suggest that CR3-mediated binding and detachment of cells is not driven by a reversible change in affinity but by two mechanistically distinct processes, an energetically neutral activation step for binding and an energy-dependent step that reverses binding of ligand.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University								ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P265; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CRAMER EB, 1986, J CELL BIOL, V102, P1868, DOI 10.1083/jcb.102.5.1868; DANA N, 1986, J IMMUNOL, V137, P3259; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUSTIN ML, 1989, NATURE, V34, P619; ELEMER GS, 1994, J IMMUNOL, V152, P5836; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HERMANOWSKIVOSA.A, 1992, CELL, V68, P341; HORWITZ A, 1986, J CELL BIOL, V101, P2134; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KHAN SA, 1982, J BIOL CHEM, V257, P1864; KILMARTIN IV, 1976, BR MED B, V32, P209; LAUFFENBURGER DA, 1993, RECEPTOR MODELS BIND, P32; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1979, J IMMUNOL, V123, P1388; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NAHAS GG, 1971, P SOC EXP BIOL MED, V138, P350; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Pangburn MK, 1986, IMMUNOBIOLOGY COMPLE, P45; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SMYTH SS, 1993, BLOOD, V81, P2827; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876	38	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14358	14365		10.1074/jbc.270.24.14358	http://dx.doi.org/10.1074/jbc.270.24.14358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782296	hybrid			2022-12-27	WOS:A1995RD45500022
J	DELAFONTAINE, P; MENG, XP; KU, L; DU, J				DELAFONTAINE, P; MENG, XP; KU, L; DU, J			REGULATION OF VASCULAR SMOOTH-MUSCLE CELL INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES - EFFECTS ON CELL-GROWTH AND EVIDENCE THAT SENSE TARGETING AT THE ATG SITE INCREASES RECEPTOR EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANTISENSE; FIBROBLASTS; RNA	We have recently shown that insulin-like growth factor I (IGF I) is a mediator of angiotensin II-induced mitogenesis in vascular smooth muscle cells (Delafontaine, P., and Lou H. (1993) J. Biol. Chem. 268, 16866-16870). To study the role of the IGF I receptor: in vascular smooth muscle cell growth, phosphorothioate oligonucleotides were used to modulate IGF I receptors. An antisense oligonucleotide targeting the ATG site inhibited basal and serum-induced DNA synthesis in vascular smooth muscle cells. Mismatch oligonucleotide had no effect, while surprisingly sense oligonucleotide increased IGF I receptor number and basal and serum-induced DNA synthesis. A 51% reduction in IGF I receptor number following exposure to 5 mu M antisense oligonucleotide markedly inhibited angiotensin II-induced mitogenesis. A 70% increase in IGF I receptor number following exposure to 5 mu M sense oligonucleotide resulted in a 4-fold increase in basal [H-3]thymidine incorporation, and angiotensin II (1-1000 nM) had no additive stimulatory effect. An antisense oligonucleotide targeting a sequence starting at +109 base pairs (relative to ATG) also reduced IGF I receptor number, however, the corresponding sense oligonucleotide was without effect. These findings demonstrate that alterations in vascular smooth muscle cell IGF I receptor density play a critical role in the proliferative response of vascular smooth muscle cells to serum and to angiotensin II. In addition, the surprising observation that an ATG-directed sense oligonucleotide up-regulates IGF I receptors identifies a novel effect of oligonucleotides on gene expression.	BETHUNE UNIV MED SCI,CLIN HOSP 2,CHANGCHUN 130021,PEOPLES R CHINA	Jilin University	DELAFONTAINE, P (corresponding author), EMORY UNIV,DEPT MED,DIV CARDIOL,PO DRAWER LL,ATLANTA,GA 30322, USA.			Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R29HL045317, R01HL045317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45317, HL47035] Funding Source: Medline; NIDDK NIH HHS [DK 45215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, INSULIN LIKE GROWTH; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; COLMAN A, 1990, J CELL SCI, V97, P399; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; DU J, 1995, IN PRESS CIRC RES; FRENSTER JH, 1994, CLIN RES, V42, P124; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNEE RS, 1994, ENDOCR SOC, V1140, P485; PFEIFLE B, 1987, ENDOCRINOLOGY, V120, P2251, DOI 10.1210/endo-120-6-2251; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; REISS K, 1991, CANCER RES, V51, P5997; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SHI Y, 1993, CIRCULATION, V88, P190; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; ULLRICH A, 1986, EMBO J, V10, P2503; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451	29	46	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14383	14388		10.1074/jbc.270.24.14383	http://dx.doi.org/10.1074/jbc.270.24.14383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782298	hybrid			2022-12-27	WOS:A1995RD45500025
J	LIN, YZ; YAO, SY; VEACH, RA; TORGERSON, TR; HAWIGER, J				LIN, YZ; YAO, SY; VEACH, RA; TORGERSON, TR; HAWIGER, J			INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-KAPPA-B BY A SYNTHETIC PEPTIDE-CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR-LOCALIZATION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; SIGNAL PEPTIDE; GROWTH-FACTOR; PROTEINS; ACTIVATION; PRECURSOR	To control agonist-induced nuclear translocation of transcription factor kappa B (NF-kappa B) in intact cells, cell-permeable synthetic peptides were devised. Their import into intact cells was dependent on a hydrophobic region selected from the signal peptide sequences and was verified by their inaccessibility to extracellular proteases and by confocal laser scanning microscopy. When a cell-permeable peptide carried a functional cargo representing the nuclear localization sequence of NF-kappa B p50, it inhibited in a concentration-dependent manner nuclear translocation of NF-kappa B in cultured endothelial and monocytic cells stimulated with lipopolysaccharide or tumor necrosis factor-alpha. Synthetic peptide analogues with deleted hydrophobic cell membrane-permeable motif or with a mutated nuclear localization sequence were inactive. Cell membrane-permeable peptides were not cytotoxic within the concentration range used in these experiments. These results suggest that cell permeable synthetic peptides carrying a functional cargo can be applied to control signal transduction-dependent subcellular traffic of transcription factors mediating the cellular responses to different agonists. Moreover, this approach can be used to study other intracellular processes involving proteins with functionally distinct domains.			LIN, YZ (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, 221 KIRKLAND HALL, NASHVILLE, TN 37232 USA.			Veach, Ruth Ann/0000-0003-0038-8802				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KAJSTURA J, 1989, FOLIA HISTOCHEM CYTO, V27, P39; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN YZ, 1988, BIOCHEMISTRY-US, V27, P5640, DOI 10.1021/bi00415a037; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WANG K, 1982, METHOD ENZYMOL, V85, P514; YAMANE K, 1988, J BIOL CHEM, V263, P5368	23	827	935	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14255	14258		10.1074/jbc.270.24.14255	http://dx.doi.org/10.1074/jbc.270.24.14255			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782278	hybrid			2022-12-27	WOS:A1995RD45500004
J	NAKADA, N; GMUNDER, H; HIRATA, T; ARISAWA, M				NAKADA, N; GMUNDER, H; HIRATA, T; ARISAWA, M			CHARACTERIZATION OF THE BINDING-SITE FOR CYCLOTHIALIDINE ON THE B-SUBUNIT OF DNA GYRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLONE ANTIBACTERIALS; CATALYTIC PROPERTIES; NALIDIXIC-ACID; A-PROTEIN; MECHANISM; INHIBITION; TOPOISOMERASES; PURIFICATION; NOVOBIOCIN; ATP	The mechanism of inhibition of DNA gyrase by cyclothialidine, a novel gyrase inhibitor isolated from Streptomyces filipinensis NR0484, has been studied further by using [C-14]benzoylcyclothialidine and a reconstituted Escherichia coli gyrase system consisting of the A subunit, the B subunit and relaxed ColE1 DNA The mechanism of inhibition was also studied with the 43-kDa N-terminal fragment of the B subunit. The [C-14]benzoylcyclothialidine could bind to the B subunit alone but not to the A subunit nor to the plasmid DNA alone. Furthermore, the compound also bound to the 43-kDa N-terminal fragment of the B subunit. Scatchard analysis of [C-14]benzoylcyclothialidine binding to DNA gyrase shelved that the binding affinity of the compound increased, depending on the assembly of the gyrase (A(2)B(2)). DNA complex. This suggests that the binding site of cyclothialidine on the B subunit or its vicinity causes a conformational change during the assembly of the gyrase . DNA complex (increase in affinity: B --> A(2)B(2) --> A(2)B(2) . DNA). Furthermore, displacement curves of [C-14]benzoylcyclothialidine binding by nonlabeled cyclothialidine, ATP analogues, and coumarin antibiotics indicated that cyclothialidine, coumarins, and ATP share a common (or overlapping) site of action on the E subunit of DNA gyrase; however, the microenvironment of the binding sites may differ.	F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND	Roche Holding	NAKADA, N (corresponding author), NIPPON ROCHE RES CTR, 200 KAJIWARA, KAMAKURA, KANAGAWA 247, JAPAN.							ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; DELCASTILLO I, 1991, P NATL ACAD SCI USA, V88, P8860, DOI 10.1073/pnas.88.19.8860; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KAMIYAMA T, 1994, J ANTIBIOT, V47, P37, DOI 10.7164/antibiotics.47.37; LEWIS RJ, 1994, J MOL BIOL, V241, P128, DOI 10.1006/jmbi.1994.1480; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKADA N, 1994, ANTIMICROB AGENTS CH, V38, P1966, DOI 10.1128/AAC.38.9.1966; NAKADA N, 1993, ANTIMICROB AGENTS CH, V37, P2656, DOI 10.1128/AAC.37.12.2656; OTTER R, 1983, METHOD ENZYMOL, V100, P171; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; WATANABE J, 1994, J ANTIBIOT, V47, P32, DOI 10.7164/antibiotics.47.32; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	31	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14286	14291		10.1074/jbc.270.24.14286	http://dx.doi.org/10.1074/jbc.270.24.14286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782285	hybrid			2022-12-27	WOS:A1995RD45500011
J	VILLACRES, EC; WU, ZL; HUA, TH; NIELSEN, MD; WATTERS, JJ; YAN, C; BEAVO, J; STORM, DR				VILLACRES, EC; WU, ZL; HUA, TH; NIELSEN, MD; WATTERS, JJ; YAN, C; BEAVO, J; STORM, DR			DEVELOPMENTALLY EXPRESSED CA2+-SENSITIVE ADENYLYL-CYCLASE ACTIVITY IS DISRUPTED IN THE BRAINS OF TYPE-I ADENYLYL-CYCLASE MUTANT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; CA1; STIMULATION; CALMODULIN; ONTOGENESIS; RECEPTORS; CALCIUM; NEURONS; AREA	The type I Ca2+-sensitive adenylyl cyclase has been implicated in several forms of synaptic plasticity in vertebrates. Mutant mice in which this enzyme was inactivated by targeted mutagenesis show deficient spatial memory and altered long term potentiation (Wu, Z. L., Thomas, S. A., Villacres, E., C., Xia, Z., Simmons, M. L., Chavkin, C., Palmiter, R. D., and Storm, D. R. (1995) Proc. Natl Acad Sci. U.S.A. 92, 220-224). Long term potentiation in the CA1 region of the rat hippocampus develops during the first 2 weeks after birth and reaches maximal expression at postnatal day 15 with a gradual decline at later stages of development. Here we report that Ca2+-stimulated adenylyl cyclase activity in rat hip pocampus, cerebellum, and cortex increases significantly between postnatal days 1-16. This increase appears to be due to enhanced expression of type I adenylyl cyclase rather than type VIII adenylyl cyclase, the other adenylyl cyclase that is directly stimulated by Ca2+ and calmodulin. Type I adenylyl cyclase mRNA in the hippocampus increased 7-fold during this developmental period. The developmental expression of Ca2+-stimulated adenylyl cyclase activity in mouse brain was attenuated in mutant mice lacking type I adenylyl cyclase. Changes in expression of the type I adenylyl cyclase during the period of long term potentiation development are consistent with the hypothesis that this enzyme is important for neuroplasticity and spatial memory in vertebrates.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Yan, Chen/0000-0002-1397-6358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498, K08NS001653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21723] Funding Source: Medline; NINDS NIH HHS [NS 20498, NS 01653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1988, MOL REPROD DEV; BROADDUS WC, 1990, DEV BRAIN RES, V52, P265, DOI 10.1016/0165-3806(90)90244-S; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRANK DA, 1994, CELL, V79, P45; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; KESHLES O, 1984, BIOCHEM PHARMACOL, V33, P3231, DOI 10.1016/0006-2952(84)90082-0; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; RIUS RA, 1994, BRAIN RES, V643, P50, DOI 10.1016/0006-8993(94)90007-8; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHWARTZKROIN PA, 1982, DEV BRAIN RES, V2, P453; STANTON PK, 1985, BRAIN RES, V358, P343, DOI 10.1016/0006-8993(85)90981-3; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; WAYMAN GA, 1994, J BIOL CHEM, V2695, P25400; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAN C, 1994, J NEUROSCI, V14, P973	31	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14352	14357		10.1074/jbc.270.24.14352	http://dx.doi.org/10.1074/jbc.270.24.14352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782295	hybrid			2022-12-27	WOS:A1995RD45500021
J	ANTONSSON, C; ARULAMPALAM, V; WHITELAW, ML; PETTERSSON, S; POELLINGER, L				ANTONSSON, C; ARULAMPALAM, V; WHITELAW, ML; PETTERSSON, S; POELLINGER, L			CONSTITUTIVE FUNCTION OF THE BASIC HELIX-LOOP-HELIX PAS FACTOR ARNT - REGULATION OF TARGET PROMOTERS VIA THE E-BOX MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC-RESPONSIVE ELEMENT; PROTEIN-DNA INTERACTIONS; AH-RECEPTOR; DIOXIN RECEPTOR; TRANSCRIPTION FACTOR; BINDING; ENHANCER; GENE; RECOGNITION; CLONING	Arnt is a nuclear basic helix-loop-helix (bHLH) transcription factor that, contiguous with the bHLH motif, contains a region of homology (PAS) with the Drosophila factors Per and Sim. Arnt dimerizes in a ligand-dependent manner with the bHLH dioxin receptor, a process that enables the dioxin-(2,3,7,8-tetrachlorodibenzo-p-dioxin)-activated Arnt-dioxin receptor complex to recognize dioxin response elements of target promoters. In the absence of dioxin, Arnt does not bind to this target sequence motif. The constitutive function of Arnt is presently not understood. Here we demonstrate that Arnt constitutively bound the E box motif CACGTG that is also recognized by a number of distinct bHLH factors, including USF and Max. Importantly, amino acids that have been identified to be critical for E box recognition by Max and USF are conserved in Arnt. Consistent with these observations, full-length Arnt, but not an Arnt deletion mutant lacking its potent C-terminal transactivation domain, constitutively activated CACGTG E box-driven reporter genes in vivo. These results indicate a role of Arnt in regulation of a network of target genes that is distinct from that regulated by the Arnt-dioxin receptor complex in dioxin-stimulated cells.	NOVUM,KAROLINSKA INST,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; NOVUM,KAROLINSKA INST,DEPT BIOSCI,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet			Pettersson, Sven/F-9511-2015					ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EMA M, 1994, J BIOCHEM-TOKYO, V116, P845, DOI 10.1093/oxfordjournals.jbchem.a124605; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GREGOR PD, 1992, GENE DEV, V4, P1730; HANKINSON O, 1994, TRENDS ENDOCRIN MET, V5, P240, DOI 10.1016/1043-2760(94)P3082-I; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORRD ND, 1994, MOL PHARMACOL, V46, P618; JAIN S, 1994, J BIOL CHEM, V269, P31518; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LI H, 1994, J BIOL CHEM, V269, P28098; LI H, 1994, J BIOL CHEM, V1, P639; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; LUSSKA A, 1994, J BIOL CHEM, V77, P451; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAMBROOKJ, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WESTON K, 1988, VIROLOGY, V162, P406, DOI 10.1016/0042-6822(88)90481-3; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; WOLBERGER C, 1994, STRUCT BIOL, V1, P413	48	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13968	13972		10.1074/jbc.270.23.13968	http://dx.doi.org/10.1074/jbc.270.23.13968			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775458	hybrid			2022-12-27	WOS:A1995RC44800057
J	GARDNER, PR; RAINERI, I; EPSTEIN, LB; WHITE, CW				GARDNER, PR; RAINERI, I; EPSTEIN, LB; WHITE, CW			SUPEROXIDE RADICAL AND IRON MODULATE ACONITASE ACTIVITY IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; DIHYDROXY-ACID DEHYDRATASE; TUMOR-NECROSIS-FACTOR; FE-S CLUSTER; ESCHERICHIA-COLI; RNA-BINDING; HYPERBARIC-OXYGEN; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; ELECTRON-TRANSFER	Aconitase is a member of a family of iron-sulfur-containing (de)hydratases whose activities are modulated in bacteria by superoxide radical (O-2(radical anion))-mediated inactivation and iron-dependent reactivation. The inactivation-reactivation of aconitase(s) in cultured mammalian cells was explored since these reactions may impact important and diverse aconitase functions in the cytoplasm and mitochondria. Conditions which increase O-2(radical anion) production including exposure to the redox-cycling agent phenazine methosulfate (PMS), inhibitors of mitochondrial ubiquinol-cytochrome c oxidoreductase, or hyperoxia inactivated aconitase in mammalian cells. Overproduction of mitochondrial Mn-superoxide dismutase protected aconitase from inactivation by PMS or inhibitors of ubiquinol-cytochrome c oxidoreductase, but not from normobaric hyperoxia. Aconitase activity was reactivated t(1/2), of 12 +/- 3 min) upon removal of PMS. The iron chelator deferoxamine impaired reactivation and increased net inactivation of aconitase by O-2(radical anion). The ability of ubiquinol-cytochrome c oxidoreductase-generated O-2(radical anion) to inactivate aconitase in several cell types correlated with the fraction of the aconitase activity localized in mitochondria. Extracellular O-2(radical anion) generated with xanthine oxidase did not affect aconitase activity nor did exogenous superoxide dismutase decrease aconitase inactivation by PMS. The results demonstrate a dynamic and cyclical O-2(radical anion)-mediated inactivation and iron-dependent reactivation of the mammalian [4Fe-4S] aconitases under normal and stress conditions and provide further evidence for the membrane compartmentalization of O-2(radical anion).	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV PULM MED, DENVER, CO 80206 USA; UNIV CALIF SAN FRANCISCO, SCH MED, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	National Jewish Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Gardner, Paul/0000-0001-8189-0903	NCI NIH HHS [CA27903, CA44446] Funding Source: Medline; NHLBI NIH HHS [HL46481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027903, R01CA044446, R37CA027903] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Boveris A., 1982, SUPEROXIDE DISMUTASE, VII, P15, DOI DOI 10.1007/978-1-4615-9035-4_5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BROWN OR, 1980, BIOCH INT, V1, P304; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; Crapo J D, 1978, Methods Enzymol, V53, P382; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GARDNER PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P106, DOI 10.1016/0003-9861(91)90270-S; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; IQBAL J, 1991, FREE RADICAL BIO MED, V10, P69, DOI 10.1016/0891-5849(91)90023-V; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KUO CF, 1987, J BIOL CHEM, V262, P4724; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINAKAMI S, 1958, J BIOCHEM-TOKYO, V45, P341, DOI 10.1093/oxfordjournals.jbchem.a126874; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SATO H, 1994, BIOCHEM BIOPH RES CO, V201, P38, DOI 10.1006/bbrc.1994.1666; SIWECKI G, 1990, BIOCHEM INT, V20, P191; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; SUZUKI YJ, 1994, FREE RADICAL BIO MED, V16, P63, DOI 10.1016/0891-5849(94)90244-5; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TANG CK, 1992, J BIOL CHEM, V267, P24466; TONG JJ, 1994, J BIOL CHEM, V269, P24920; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	58	413	424	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13399	13405		10.1074/jbc.270.22.13399	http://dx.doi.org/10.1074/jbc.270.22.13399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768942	hybrid			2022-12-27	WOS:A1995RB43900067
J	SWIERCZYNSKI, SL; BLACKSHEAR, PJ				SWIERCZYNSKI, SL; BLACKSHEAR, PJ			MEMBRANE ASSOCIATION OF THE MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) PROTEIN - MUTATIONAL ANALYSIS PROVIDES EVIDENCE FOR COMPLEX INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; MOLECULAR-CLONING; SUBCELLULAR-LOCALIZATION; DEPENDENT BINDING; GENE-PRODUCT; RAT-BRAIN; PHOSPHORYLATION; CELLS	The myristoylated alanine-rich C kinase substrate (MARCKS) protein, a prominent cellular substrate for protein kinase C, is associated with membranes in various cell types. MARCKS is myristoylated at its amino terminus; this modification is thought to play the major role in anchoring MARCKS to cellular membranes. Recent studies have suggested that the protein's basic phosphorylation site/calmodulin binding domain may also be involved in the membrane association of MARCKS through electrostatic interactions, The present studies used mutations in the primary structure of the protein to investigate the nature of the association between MARCKS and cell membranes. In chick embryo fibroblasts, activation of protein kinase C led to a decrease in MARCKS membrane association as determined by cell fractionation techniques. Cell-free assays revealed that nonmyristoylated MARCKS exhibited almost no affinity for fibroblast membranes, despite readily demonstrable binding of the mild-type protein. Similar experiments in which the four serines in the phosphorylation site domain were mutated to aspartic acids, mimicking phosphorylation, decreased, but did not eliminate, membrane binding when compared to either the wild-type protein or a comparable tetra-asparagine mutant. Addition of calmodulin in the presence of Ca2+ also inhibited binding of the wild-type protein to membranes, presumably by neutralizing the phosphorylation site domain, or by physically interfering with its membrane association. Surprisingly, expression of a nonmyristoylatable mutant form of MARCKS in intact cells led to only a 46% decrease in its plasma membrane association, as determined by cell fractionation and immunoelectron microscopy. These results are consistent with a complex model of the interaction of MARCKS with cellular membranes, in which the myristoyl moiety, the positively charged phosphorylation site domain, and possibly other domains make independent contributions to membrane binding in intact cells.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AMESS B, 1992, FEBS LETT, V297, P285; BIEMANS R, 1992, AIDS, V6, P541, DOI 10.1097/00002030-199206000-00003; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; BLACKSHEAR PJ, 1986, MECHANISMS INSULIN A, V7, P211; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FEDER D, 1991, J BIOL CHEM, V266, P19040; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; INUI K, 1980, BIOCHIM BIOPHYS ACTA, V598, P616, DOI 10.1016/0005-2736(80)90041-3; JAMES G, 1989, J BIOL CHEM, V264, P20998; KAMINCHIK J, 1991, J VIROL, V65, P583, DOI 10.1128/JVI.65.2.583-588.1991; KIM J, 1994, J BIOL CHEM, V268, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; STUMPO DJ, 1994, P NATL ACAD SCI USA, V92, P944; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	62	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13436	13445		10.1074/jbc.270.22.13436	http://dx.doi.org/10.1074/jbc.270.22.13436			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768946	hybrid			2022-12-27	WOS:A1995RB43900072
J	CREUTZ, CE; LIOU, A; SNYDER, SL; BROWNAWELL, A; WILLISON, K				CREUTZ, CE; LIOU, A; SNYDER, SL; BROWNAWELL, A; WILLISON, K			IDENTIFICATION OF THE MAJOR CHROMAFFIN GRANULE-BINDING PROTEIN, CHROMOBINDIN-A, AS THE CYTOSOLIC CHAPERONIN CCT (CHAPERONIN CONTAINING TCP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-COMPLEX POLYPEPTIDE-1; SECRETORY VESICLE; MEMBRANE; CA-2+; PARTICLE; SUBUNITS	Chromobindin A is a multisubunit complex ATPase that binds to chromaffin granule membranes in a calcium-dependent manner and requires ATP for release from the membrane (Martin, W. H., and Creutz, C. E. (1987) J. Biol. Chem. 262, 2803-2810). Here we report that the seven previously characterized subunits of chromobindin A cross react with antisera specific to subunits of CCT, the chaperonin containing TCP-1 (Kubota, H., Hynes, G., Came, A., Ashworth, A., and Willison, K. (1994) Curr. Biol. 4, 89-99). The chromobindin A subunits previously called chromobindins 12, 13, 14, 15, 16, 18, and 19 cross-react specifically with subunits beta, delta, theta, zeta, xi, and gamma, respectively, of CCT. Additional similarities in subunit molecular weights, isoelectric points, and the morphologies of the two protein complexes as determined by electron microscopy support identification of chromobindin A as an adrenal medullary form of CCT. The chromobindin A/CCT complex was found to bind at least 7-fold more efficiently to affinity columns of chromaffin granule membranes than of adrenal medullary cytosol proteins, suggesting a specific interaction occurs between the complex and membrane components. The results indicate that the previously described characteristics of chromobindin A are likely to be relevant to the functions of CCT and suggest that the adrenal medullary form of CCT may play a role in the activities of secretory vesicle membranes.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	CREUTZ, CE (corresponding author), UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.				NCI NIH HHS [CA40042] Funding Source: Medline; NIDDK NIH HHS [DK33151] Funding Source: Medline; NINDS NIH HHS [NS31618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CREUTZ CE, 1981, BIOCHEM BIOPH RES CO, V103, P1395, DOI 10.1016/0006-291X(81)90278-3; CREUTZ CE, 1985, J BIOL CHEM, V260, P7171; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CREUTZ CE, 1993, METHOD ENZYMOL, V221, P190, DOI 10.1016/0076-6879(93)21017-3; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEISOW MJ, 1982, J NEUROCHEM, V38, P1735, DOI 10.1111/j.1471-4159.1982.tb06656.x; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1994, IN PRESS GENE AMST; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MARTIN WH, 1987, J BIOL CHEM, V262, P2803; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; MARTIN WH, 1989, BIOCHEM BIOPH RES CO, V165, P37, DOI 10.1016/0006-291X(89)91030-9; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; ROOBOL A, 1993, J NEUROCHEM, V60, P2327, DOI 10.1111/j.1471-4159.1993.tb03524.x; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	24	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32035	32038						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798195				2022-12-27	WOS:A1994PX30400004
J	GAO, QS; SUN, M; TYUTYULKOVA, S; WEBSTER, D; REES, A; TRAMONTANO, A; MASSEY, RJ; PAUL, S				GAO, QS; SUN, M; TYUTYULKOVA, S; WEBSTER, D; REES, A; TRAMONTANO, A; MASSEY, RJ; PAUL, S			MOLECULAR-CLONING OF A PROTEOLYTIC ANTIBODY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CRYSTAL-STRUCTURE; AUTOANTIBODIES; COMPLEXES; SITES	The cDNA for an antibody light chain raised by immunization against vasoactive intestinal peptide (VIP) was cloned in a bacterial expression vector, and the recombinant light chain was purified to electrophoretic homogeneity, The light chain catalyzed the hydrolysis of VIP efficiently owing to its comparatively high affinity for the substrate, In control experiments, the catalytic activity was preserved at a constant level after further chromatography of the light chain on anion-exchange and gel-filtration fast protein liquid chromatography columns, and it was removed by immunoadsorption with immobilized anti-mouse light chain antibody. The amide bond linking methylcoumarinamide (MCA) and arginine in a tripeptide unrelated in sequence to VIP was cleaved by the light chain with lower affinity and kinetic efficiency (k(cat)/K-m). Hydrolysis of the peptidyl-MCA conjugate was inhibited competitively by the alternate substrate, VIP, The K-i and K-m values for MP were in the same range, indicating that peptide-MCA and VIP hydrolysis occurs at a common catalytic site in the light chain. Molecular modeling suggested the presence of a serine protease-like site in the light chain, This was supported by inhibition of the hydrolytic activity by serine protease inhibitors, but not by inhibitors of other classes of proteases, These observations suggest a poorly discriminatory catalytic site, with specificity for VIP arising chiefly by means of the antigen recognition function of the light chain combining site,	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT ANESTHESIOL, OMAHA, NE 68198 USA; UNIV BATH, DEPT BIOCHEM, BATH BA2 7AY, AVON, ENGLAND; IGEN INC, ROCKVILLE, MD 20852 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Bath					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44126] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KABAT EA, 1991, 913242 US DEP HLTH H; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAHANA W, 1994, SCAND J IMMUNOL, V39, P107, DOI 10.1111/j.1365-3083.1994.tb03347.x; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MODY R, 1994, INT J PEPT PROT RES, V44, P441; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; PAUL S, 1990, J IMMUNOL, V145, P1196; PEDERSEN JT, 1992, IMMUNOMETHODS, V1, P126; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STEIPE B, 1992, J MOL BIOL, V225, P739, DOI 10.1016/0022-2836(92)90398-4; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, IN PRESS ANN NY ACAD; SUN M, 1991, J BIOL CHEM, V266, P15571; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1556	30	73	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32389	32393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798238				2022-12-27	WOS:A1994PX30400057
J	WANG, XC; VERTINO, A; EDDY, RL; BYERS, MG; JANISAIT, SN; SHOWS, TB; LAU, JTY				WANG, XC; VERTINO, A; EDDY, RL; BYERS, MG; JANISAIT, SN; SHOWS, TB; LAU, JTY			CHROMOSOME MAPPING AND ORGANIZATION OF THE HUMAN BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE GENE - DIFFERENTIAL AND CELL-TYPE SPECIFIC USAGE OF UPSTREAM EXON SEQUENCES IN B-LYMPHOBLASTOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HUMAN LYMPHOCYTES-B; TRANSCRIPTIONAL REGULATION; INSITU HYBRIDIZATION; MARKER PROFILES; HUMAN-LEUKEMIA; HUMAN GENOME; T-CELLS; SIALYLTRANSFERASE; GLYCOSYLTRANSFERASES	The human beta-galactoside alpha2,6-sialyltransferase (EC 2.4.99.1) (SiaT-1) gene is localized to human chromosome 3 (q21-q28) by Southern analysis of somatic cell hybrids and by in situ hybridization of metaphase chromosomes. Comparative analysis between the human and the previously reported rat SiaT-1 genomic sequences demonstrates precise conservation of the intron/exon boundaries throughout the coding domains. Furthermore, there is extensive inter-species sequence similarity in some of the exons that contain information only for the 5'-leader regions. Human genomic sequences were also analyzed to reconcile reported differences in the 5'-untranslated region in SiaT-1 mRNAs. In cultured cell lines of the B-lineage, Reh, Nalm-6, Jok-1, Ball-1, Daudi, and Louckes, the study demonstrates that three upstream exons, Exons(Y+Z) and Exon(X), are mutually exclusively utilized, resulting in at least two distinct populations of SiaT-1 mRNA being synthesized. None of these exons is present in the SiaT-1 mRNA isotype expressed in HepG2 human hepatoma cells. In all B-lymphoblastoid cell lines examined, the basal level SiaT-1 mRNA is maintained by the expression of an isotype containing the Exons(Y+Z) sequence. The slightly smaller SiaT-1 mRNA, which contains the Exon(X) sequence but not Exons(Y+Z) sequence, is synthesized at a high level and found only in Jok-1, Daudi, and Louckes, the cell lines with mature B-cell phenotype. The study also provides further evidence that induced SiaT-1 expression accompanies the appearance of CDw75, a putatively sialylated cell surface epitope and a marker of human mature B-lymphocytes. The SiaT-1 induction is the result of the appearance of a novel form of SiaT-1 mRNA isotype.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Roswell Park Cancer Institute; Roswell Park Cancer Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038193] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00333] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM38193] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; CHERIF D, 1988, CANCER RES, V48, P1489; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P109; DUNCAN AMV, 1986, BIOCHEM BIOPH RES CO, V141, P1185, DOI 10.1016/S0006-291X(86)80169-3; EPSTEIN AL, 1984, J IMMUNOL, V133, P1028; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; GUY K, 1991, IMMUNOLOGY, V74, P206; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; KOYANAGI Y, 1984, MED MICROBIOL IMMUN, V173, P127, DOI 10.1007/BF02123761; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MITTLER RS, 1983, J IMMUNOL, V131, P1754; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MUNRO S, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90070-S; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OHANLON TP, 1992, GLYCOBIOLOGY, V2, P257, DOI 10.1093/glycob/2.3.257; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PETERSON RC, 1984, P NATL ACAD SCI-BIOL, V81, P4363, DOI 10.1073/pnas.81.14.4363; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; ROSSOWSKI W, 1983, BRIT J CANCER, V47, P158, DOI 10.1038/bjc.1983.19; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SASAKI R, 1982, LEUKEMIA RES, V6, P197, DOI 10.1016/0145-2126(82)90025-X; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SMELAND E, 1985, SCAND J IMMUNOL, V21, P205, DOI 10.1111/j.1365-3083.1985.tb01422.x; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1990, J BIOL CHEM, V265, P17849; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	45	111	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4355	4361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7786324				2022-12-27	WOS:A1993KN53300079
J	CUOZZO, JW; TAO, K; WU, QL; YOUNG, W; SAHAGIAN, GG				CUOZZO, JW; TAO, K; WU, QL; YOUNG, W; SAHAGIAN, GG			LYSINE-BASED STRUCTURE IN THE PROREGION OF PROCATHEPSIN-L IS THE RECOGNITION SITE FOR MANNOSE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME PHOSPHORYLATION; CATHEPSIN-L; PROTEIN; OLIGOSACCHARIDES; CELLS; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; IDENTIFICATION; DETERMINANTS; FIBROBLASTS; 6-PHOSPHATE	The recognition of lysosomal enzymes by UDP-GlcNAc: lysosomal-enzyme GlcNAc-1-phosphotransferase (phosphotransferase) is mediated by a protein structure on lysosomal enzymes, It has been previously demonstrated that lysine residues are required for phosphorylation of procathepsin L and are a common feature of the site on many lysosomal proteins. In this work, the procathepsin L recognition structure was further defined by identification of the region of the protein containing the structure and the critical lysine residues involved, Removal of the cathepsin L propeptide by low pH-induced autocatalytic processing abolished phosphorylation, The addition of either the purified propeptide or a glutathione S-transferase-propeptide fusion protein to the processed protein restored phosphorylation, Mutagenesis of individual lysine residues demonstrated that two propeptide lysine residues (Lys-54 and Lys-99) were required for efficient phosphorylation of procathepsin L, By comparison of the phosphorylation rates of procathepsin L, lysine-modified procathepsin L, and the procathepsin L oligosaccharide, lysine residues were shown to account for most, if not all, of the protein-dependent interaction, On this basis, it is concluded that the proregion lysine residues are the major elements of the procathepsin L recognition site, In addition, lysine residues in cathepsin D were shown to be as important for phosphorylation as those in procathepsin L, supporting a general model of the recognition site as a specific three dimensional arrangement of lysine residues exposed on the surface of lysosomal proteins.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University				Cuozzo, John/0000-0002-6229-0395	NIDDK NIH HHS [DK36632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; DISTLER J, 1979, P NATL ACAD SCI USA, V76, P4235, DOI 10.1073/pnas.76.9.4235; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; JOHN M, 1994, J BIOL CHEM, V269, P16247; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAH T, 1984, BIOCHEM J, V218, P601, DOI 10.1042/bj2180601; LANG L, 1984, J BIOL CHEM, V259, P4663; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; SAHAGIAN GG, 1994, LIVER BIOL PATHOBIOL, P375; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIERKS MR, 1992, BIOCHEMISTRY-US, V31, P8972, DOI 10.1021/bi00152a038; SMITH DB, 1993, CURRENT PROTOCOLS MO; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; WITHERS SG, 1990, BIOCHEMISTRY-US, V29, P6405, DOI 10.1021/bi00479a010; YAGEL S, 1989, CANCER RES, V49, P3553	36	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15611	15619		10.1074/jbc.270.26.15611	http://dx.doi.org/10.1074/jbc.270.26.15611			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797559	hybrid			2022-12-27	WOS:A1995RG53800029
J	DELPINO, MMS; HAWKINS, RA; PETERSON, DR				DELPINO, MMS; HAWKINS, RA; PETERSON, DR			BIOCHEMICAL DISCRIMINATION BETWEEN LUMINAL AND ABLUMINAL ENZYME AND TRANSPORT ACTIVITIES OF THE BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; AMINO-ACID-TRANSPORT; LOCALIZATION; CAPILLARIES; MEMBRANE; CELLS; MICROVESSELS; POLARITY; ISOFORMS; SYSTEMS	Luminal and abluminal membrane vesicles derived from bovine brain endothelial cells, the site of the blood-brain barrier, were fractionated in a discontinuous Ficoll gradient. A mathematical analysis was developed to determine the membrane distribution of membrane marker enzyme activities as well as the ratio of luminal to abluminal membrane in each fraction of the gradient. The results of this analysis indicate that gamma-glutamyl transpeptidase and amino acid transport system A are located on the luminal and abluminal membranes, respectively. Conversely, 5'-nucleotidase and alkaline phosphatase activities are evenly distributed between both membranes. Although Na+/K+-ATPase activity is primarily located on the abluminal membrane, approximately 25% of the activity is of luminal origin. Na+/K+-ATPase activities associated with each membrane showed different ouabain sensitivities, suggesting that different isoenzymes are located in luminal and abluminal membranes. The analytical procedure used in this study provides a quantitative means to determine the distribution of marker enzymes and transport proteins in partially purified membrane vesicle populations.	FINCH UNIV HLTH SCI, CHICAGO MED SCH, DEPT PHYS & BIOPHYS, N CHICAGO, IL 60064 USA	Chicago Medical School			del Pino, Manuel M. Sánchez/I-3977-2015	del Pino, Manuel M. Sánchez/0000-0001-9696-7600	NIDDK NIH HHS [DK42331] Funding Source: Medline; NINDS NIH HHS [NS 16389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BETZ AL, 1986, ANNU REV PHYSIOL, V48, P241; BETZ AL, 1994, J CEREBR BLOOD F MET, V14, P29, DOI 10.1038/jcbfm.1994.5; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; BORBRODT AW, 1988, PROG HISTOCHEM CYTOC, V18, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; DEWALD B, 1973, J BIOL CHEM, V248, P7223; FREY A, 1991, EUR J BIOCHEM, V202, P421, DOI 10.1111/j.1432-1033.1991.tb16391.x; FUJIWARA T, 1984, AM J ANAT, V170, P39, DOI 10.1002/aja.1001700104; GHANDOUR MS, 1980, NEUROSCI LETT, V20, P125, DOI 10.1016/0304-3940(80)90133-0; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; Hayat MA, 1973, PRINCIPLES TECHNIQUE, V3, P237; HJELLE JT, 1981, KIDNEY INT, V20, P71, DOI 10.1038/ki.1981.106; Lever J E, 1980, CRC Crit Rev Biochem, V7, P187, DOI 10.3109/10409238009105462; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P242, DOI 10.1016/S0022-5320(66)80109-0; MURER H, 1976, BIOCHIM BIOPHYS ACTA, V433, P509, DOI 10.1016/0005-2736(76)90277-7; NAG S, 1990, ACTA NEUROPATHOL, V80, P7, DOI 10.1007/BF00294215; PARDRIDGE WM, 1985, J NEUROCHEM, V44, P1178, DOI 10.1111/j.1471-4159.1985.tb08741.x; RABITO CA, 1984, J BIOL CHEM, V259, P574; SCHLOSSHAUER B, 1993, BIOESSAYS, V15, P341, DOI 10.1002/bies.950150508; SMITH QR, 1991, ADV EXP MED BIOL, V291, P55; TAYARANI I, 1987, J CEREBR BLOOD F MET, V7, P585, DOI 10.1038/jcbfm.1987.109; VORBRODT AW, 1982, BRAIN RES, V243, P225, DOI 10.1016/0006-8993(82)90245-1; ZLOKOVIC BV, 1993, J BIOL CHEM, V268, P8019	29	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					14907	14912		10.1074/jbc.270.25.14907	http://dx.doi.org/10.1074/jbc.270.25.14907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797469	hybrid			2022-12-27	WOS:A1995RE66600013
J	KOSSYKH, VG; SCHLAGMAN, SL; HATTMAN, S				KOSSYKH, VG; SCHLAGMAN, SL; HATTMAN, S			PHAGE-T4 DNA [N-6-ADENINE]METHLYLTRANSFERASE - OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADENINE METHYLASE; CATALYTIC PROPERTIES; HOMOGENEOUS ENZYME; METHYLTRANSFERASE; BACTERIOPHAGE-T4; RESTRICTION; GENE; DAM; RECOGNITION	The bacteriophage T4 dam gene, encoding the Dam DNA [N-6-adenine]methyltransferase (MTase), has been subcloned into the plasmid expression vector, pJW2, In this construct, designated pINT4dam, transcription is from the regulatable phage lambda p(R) and p(L) promoters, arranged in tandem, A two-step purification scheme using DEAE-cellulose and phosphocellulose columns in series, followed by hydroxyapatite chromatography, was developed to purify the enzyme to near homogeneity, The yield of purified protein was 2 mg/g of cell paste. The MTase has an s(20,w) of 3.0 S and a Stokes radius of 23 Angstrom and exists in solution as a monomer. The K-m for the methyl donor, S-adenosylmethionine, is 0.1 x 10(-6) M, and the K-m for substrate nonglucosylated, unmethylated T4 gt(-)dam(-) DNA is 1.1 x 10(-12) M. The products of DNA methylation, S-adenosyl-L-homocysteine and methylated DNA, are competitive inhibitors of the reaction; K-i values of 2.4 x 10(-6) M and 4.6 x 10(-12) M, respectively, were observed. T4 Dam methylates the palindromic tetranucleotide, GATC, designated the canonical sequence, However, at high MTase:DNA ratios, T4 Dam can methylate some noncanonical sequences belonging to GAY (where Y represents cytosine or thymine).			KOSSYKH, VG (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029227] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29227] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS JE, 1978, J MOL BIOL, V126, P381, DOI 10.1016/0022-2836(78)90047-5; CHANDRASEGARAN S, 1988, GENE, V74, P15, DOI 10.1016/0378-1119(88)90240-5; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; CHENG SC, 1984, J BIOL CHEM, V259, P1571; DELACAMPA AG, 1987, J MOL BIOL, V196, P457, DOI 10.1016/0022-2836(87)90024-6; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P1579, DOI 10.1093/nar/20.7.1579; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Hattman S, 1983, BACTERIOPHAGE T4, P152; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; KASZUBSKA W, 1992, GENE, V118, P5, DOI 10.1016/0378-1119(92)90242-H; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Miller J. H., 1972, EXPT MOL GENETICS, P433; Modrich P., 1982, NUCLEASES, P109; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; NWOSU VU, 1992, BIOCHEM J, V283, P745, DOI 10.1042/bj2830745; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sambrook J, 1989, MOL CLONING LABORATO; SCHLAGMAN SL, 1983, GENE, V22, P139, DOI 10.1016/0378-1119(83)90098-7; SCHLAGMAN SL, 1989, NUCLEIC ACIDS RES, V17, P9101, DOI 10.1093/nar/17.22.9101; SCHLAGMAN SL, 1988, GENE, V73, P517, DOI 10.1016/0378-1119(88)90516-1; SHAPIRO SK, 1966, ANAL BIOCHEM, V15, P323, DOI 10.1016/0003-2697(66)90038-8; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAYLOR JD, 1990, BIOCHEMISTRY-US, V29, P10727, DOI 10.1021/bi00500a003; WANG HY, 1990, NUCLEIC ACIDS RES, V18, P1070, DOI 10.1093/nar/18.4.1070; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WOODBURY CP, 1980, J BIOL CHEM, V255, P1526; WU JC, 1988, NUCLEIC ACIDS RES, V16, P703, DOI 10.1093/nar/16.2.703	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14389	14393		10.1074/jbc.270.24.14389	http://dx.doi.org/10.1074/jbc.270.24.14389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782299	hybrid			2022-12-27	WOS:A1995RD45500026
J	REDDY, R; SMITH, D; WAYMAN, G; WU, ZL; VILLACRES, EC; STORM, DR				REDDY, R; SMITH, D; WAYMAN, G; WU, ZL; VILLACRES, EC; STORM, DR			VOLTAGE-SENSITIVE ADENYLYL-CYCLASE ACTIVITY IN CULTURED NEURONS - A CALCIUM-INDEPENDENT PHENOMENON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; RAT-BRAIN; AREA CA1; CALMODULIN; PROTEIN; ACTIVATION; CLONING; STIMULATION; EXPRESSION; HIPPOCAMPUS	Catalytic subunits of mammalian adenylyl cyclases have been proposed to contain 12 transmembrane domains, a property shared with some voltage-sensitive ion channels. Here we report that adenylyl cyclase activity in cerebellar neurons is synergistically stimulated by depolarizing agents and beta-adrenergic receptor activation. This phenomenon is Ca2+-independent and not attributable to Ca2+-stimulated adenylyl cyclase activity. Cholera toxin and forskolin also synergistically stimulate adenylyl cyclase activity in combination with depolarizing agents. We hypothesize that conformational changes in the catalytic subunit of the enzymes caused by changes in the membrane potential may enhance stimulation of adenylyl cyclases by the guanylyl nucleotide stimulatory protein. This novel mechanism for regulation of adenylyl cyclases generates robust cAMP signals that may contribute to various neuromodulatory events including some forms of neuroplasticity.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NINDS NIH HHS [NS20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARRETT EF, 1988, J PHYSIOL-LONDON, V402, P65, DOI 10.1113/jphysiol.1988.sp017194; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CATTERALL WA, 1975, J BIOL CHEM, V250, P4053; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHEUNG WY, 1982, HDB EXP PHARM, V58, P301; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; MAY DC, 1985, J BIOL CHEM, V260, P5829; MOSS J, 1977, J BIOL CHEM, V252, P2455; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NARAHASHI T, 1964, J GEN PHYSIOL, V47, P965, DOI 10.1085/jgp.47.5.965; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SHIMIZU H, 1970, MOL PHARMACOL, V6, P184; STEVENS CF, 1994, NEURON, V13, P769, DOI 10.1016/0896-6273(94)90244-5; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	55	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14340	14346		10.1074/jbc.270.24.14340	http://dx.doi.org/10.1074/jbc.270.24.14340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782293	hybrid			2022-12-27	WOS:A1995RD45500019
J	RICCI, B; SHARP, D; OROURKE, E; KIENZLE, B; BLINDERMAN, L; GORDON, D; SMITHMONROY, C; ROBINSON, G; GREGG, RE; RADER, DJ; WETTERAU, JR				RICCI, B; SHARP, D; OROURKE, E; KIENZLE, B; BLINDERMAN, L; GORDON, D; SMITHMONROY, C; ROBINSON, G; GREGG, RE; RADER, DJ; WETTERAU, JR			A 30-AMINO ACID TRUNCATION OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN LARGE SUBUNIT DISRUPTS ITS INTERACTION WITH PROTEIN DISULFIDE-ISOMERASE AND CAUSES ABETALIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; ENDOPLASMIC-RETICULUM; GENE; MUTAGENESIS; COMPLEX; CLONING	The microsomal triglyceride transfer protein (MTP) is a heterodimer composed of the multifunctional enzgme, protein disulfide-isomerase, and a unique large, 97 kDa, subunit. It is found as a soluble protein within the lumen of the endoplasmic reticulum of liver and intestine and is required for the assembly of very low density lipoproteins and chylomicrons. Mutations in MTP which result in an absence of MTP function have been shown to cause abetalipoproteinemia. Here, the gene encoding the MTP 97-kDa subunit of an abetalipoproteinemic subject, which we have previously demonstrated lacks MTP activity and protein (Wetterau, J. R., Aggerbeck, L. P., Bouma, M.-E., Eisenberg, C., Munck, A., Hermier, M., Schmitz, J., Gay, G., Rader, D. J., and Gregg, R. E. (1992) Science 258, 999-1001), was isolated and sequenced. A nonsense mutation, which predicts the truncation of the protein by 30 amino acids, was identified. To investigate if this apparently subtle change in MTP could explain the observed absence of MTP, protein disulfide-isomerase was co-expressed with either the normal or mutant MTP 97-kDa subunit in Sf9 insect cells using a baculovirus expression system. Although there were high levels of expression of both the normal and mutant forms of the MTP 97-kDA subunit, only the normal subunit was able to form a stable, soluble complex with protein disulfide-isomerase. These results indicate that the carboxyl-terminal 30 amino acids of the MTP 97-kDa subunit plays an important role in its interaction with protein disulfide-isomerase.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV PENN,DEPT MED,DIV MED GENET,PHILADELPHIA,PA 19104	Bristol-Myers Squibb; Bristol-Myers Squibb; University of Pennsylvania								ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; PATEL SB, 1994, CIRCULATION, V90, P186; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, CIRCULATION, V90, P186; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	20	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	1995	270	24					14281	14285		10.1074/jbc.270.24.14281	http://dx.doi.org/10.1074/jbc.270.24.14281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RD455	7782284	hybrid			2022-12-27	WOS:A1995RD45500010
J	ZURAWSKI, SM; CHOMARAT, P; DJOSSOU, O; BIDAUD, C; MCKENZIE, ANJ; MIOSSEC, P; BANCHEREAU, J; ZURAWSKI, G				ZURAWSKI, SM; CHOMARAT, P; DJOSSOU, O; BIDAUD, C; MCKENZIE, ANJ; MIOSSEC, P; BANCHEREAU, J; ZURAWSKI, G			THE PRIMARY BINDING SUBUNIT OF THE HUMAN INTERLEUKIN-4 RECEPTOR IS ALSO A COMPONENT OF THE INTERLEUKIN-13 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-4; HIGH-AFFINITY; SIGNAL-TRANSDUCTION; MOUSE INTERLEUKIN-2; EXPRESSION CLONING; LIGAND-BINDING; GAMMA-CHAIN; IL-13; PROTEINS; CELLS	Interleukin (IL)-13 elicits a subset of the biological activities of the related IL-4. The basis of this functional similarity is that their specific cell-surface receptors (called IL-13R and IL-4R) are distinct, yet are complex and share a common subunit(s). The IL-4R primary binding subunit (called IL-4R alpha) does not by itself bind IL-13. We show that the ability of IL-13 to partially compete for IL-4 binding to some human cell types depended on co-expression of IL-4R and IL-13R. However, IL-13 binding was always associated with IL-4 binding. Hyperexpression of IL-4R alpha on cells expressing both IL-4R and IL-13R decreased their binding affinity for IL-4, abrogated the ability of IL-13 to compete for IL-4 binding, and yet had no effect on IL-13R properties. Anti-human IL-4R alpha monoclonal antibodies which blocked the biological function and binding of IL-4 also blocked the function and binding of IL-13. These data show that IL-4R alpha is a secondary component of IL-13R.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304; SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Schering Plough Corporation								ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FERNANDEZBOTRAN R, 1990, P NATL ACAD SCI USA, V87, P4202, DOI 10.1073/pnas.87.11.4202; FOXWELL BMJ, 1989, EUR J IMMUNOL, V19, P1637, DOI 10.1002/eji.1830190918; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GARONNE P, 1991, EUR J IMMUNOL, V21, P1365; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HARADA N, 1992, IL 4 STRUCTURE FUNCT, P33; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; HURWITZ R, 1979, INT J CANCER, V23, P174, DOI 10.1002/ijc.2910230206; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE HV, 1988, J BIOL CHEM, V263, P10817; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RENARD N, 1994, BLOOD, V84, P2253; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VANKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	38	216	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13869	13878		10.1074/jbc.270.23.13869	http://dx.doi.org/10.1074/jbc.270.23.13869			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775445	hybrid			2022-12-27	WOS:A1995RC44800044
J	CASASNOVAS, JM; SPRINGER, TA				CASASNOVAS, JM; SPRINGER, TA			KINETICS AND THERMODYNAMICS OF VIRUS BINDING TO RECEPTOR - STUDIES WITH RHINOVIRUS, INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1), AND SURFACE-PLASMON RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE FORMS; NEUTRALIZATION; ANTIBODY; CELLS; IMMUNOGLOBULIN; EXPRESSION; VARIANTS; CANYON; LFA-1	We have studied the kinetics and thermodynamics of a virus interacting with its receptor using human rhinovirus serotype 3 (HRV3), soluble intercellular adhesion molecule-1 (ICAM-1, CD54) containing Ig superfamily domains 1-5 (sICAM-1), and surface plasmon resonance. There were two classes of binding sites for sICAM-1 on HRV3, each comprising about 50% of the total sites, with association rate constants of 2450 +/- 300 and 134 +/- 11 M(-1) s(-1). These rates are low, consistent with binding to a relatively inaccessible site in the rhinovirus canyon. By contrast, three monoclonal antibodies bound to sICAM-1 with a single rate constant of 17,000-48,000 M(-1) s(-1). The dissociation rate constant for RRV3 was 1.7 +/- 0.1 x 10(-3) s(-1), giving calculated dissociation constants of 0.7 +/- 0.1 and 12.5 +/- 1.2 mu M. Agreement was good with saturation binding in solution, which showed two sites of similar abundance with K-D of 0.55 +/- 0.2 and 5.7 +/- 2.0 mu M. A bivalent chimera of ICAM-1 with the IgA1 Fc region bound with K-D = 50 and 410 nar, showing 17-fold enhanced affinity. Lowering pH from 8.0 to 6.0 reduced affinity by approximately 50-fold, primarily by reducing the on rate. Thermodynamic measurements showed that binding of ICAM-1 to HRV3 is endothermic, by contrast to binding to monoclonal antibody. The heat that is absorbed of 3.5 and 6.3 kcal/mol for the two classes of ICAM-1 binding sites may contribute to receptor-mediated disruption of virions, which has an activation energy of about 42 kcal/mol.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School			Casasnovas, Jose M/L-6299-2014	Casasnovas, Jose M/0000-0002-2873-6410				Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CASASNOVAS JM, 1994, J VIROL, V68, P5882, DOI 10.1128/JVI.68.9.5882-5889.1994; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GREVE JM, 1991, J VIROL, V65, P6015, DOI 10.1128/JVI.65.11.6015-6023.1991; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KAPLAN G, 1990, J VIROL, V64, P4697, DOI 10.1128/JVI.64.10.4697-4702.1990; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KIM S, 1989, J MOL BIOL, V210, P91, DOI 10.1016/0022-2836(89)90293-3; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; MCCLELLAND A, 1991, P NATL ACAD SCI USA, V88, P7993, DOI 10.1073/pnas.88.18.7993; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; RUECKERT RR, 1990, VIROLOGY, P507; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; YAFAL AG, 1993, VIROLOGY, V197, P507	35	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13216	13224		10.1074/jbc.270.22.13216	http://dx.doi.org/10.1074/jbc.270.22.13216			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768920	hybrid			2022-12-27	WOS:A1995RB43900043
J	KUDO, S; FUKUDA, M				KUDO, S; FUKUDA, M			TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATION OF HUMAN LEUKOSIALIN (CD43) GENE IS ACHIEVED BY DNA METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; MONOCLONAL-ANTIBODY; CPG METHYLATION; SURFACE SIALOGLYCOPROTEIN; MAJOR SIALOGLYCOPROTEIN; CELL-DIFFERENTIATION; BINDING PROTEIN; IDENTIFICATION; ACTIVATION; SEQUENCE	The expression of human leukosialin (CD43), a major sialoglycoprotein on the surface of hematopoietic cells, is regulated in cell lineage-specific as well as differentiation stage-specific manners. me have shown previously that transcription from the TATA-less promoter is mediated by the transcription factor Spl, which binds to repeats of a GGGTGG motif in the 3'-flanking sequence. This regulatory region is ubiquitously functional in mammalian cells, providing a high transcriptional potential. No cis-acting element responsible for the specificity of this gene expression was revealed by extensive studies using transient as well as stable expression systems. Here, we demonstrate that DNA methylation plays a key role in leukosialin gene expression. Southern blot analysis of genomic DNAs from various human cell lines with methylation-sensitive and -insensitive restriction enzymes showed a tight correlation between gene activity and demethylation state of the 5'-region of the leukosialin gene. Consistent results were obtained from the same analysis of genomic DNAs from various human tissues. In addition, in vitro DNA methylation of the 3'-region drastically reduced transcriptional activity in a transient expression system. These results indicate that DNA methylation around the 5'-region of the leukosialin gene is required to shut off a high level of transcription. Thus, the tissue-specific expression of the leukosialin gene is constitutively achieved by alteration of DNA methylation.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON LC, 1978, BLOOD, V52, P57; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BETTAIEB A, 1988, BLOOD, V71, P1226; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; DYER MJS, 1981, J EXP MED, V154, P1164, DOI 10.1084/jem.154.4.1164; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELGNER P, 1987, P NATL ACAD SCI USA, V87, P7413; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; KUDO S, 1990, J BIOL CHEM, V265, P1102; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MEEHAN RR, 1989, GENE DEV, V2, P921; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Sambrook J, 1989, MOL CLONING LABORATO; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	38	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13298	13302		10.1074/jbc.270.22.13298	http://dx.doi.org/10.1074/jbc.270.22.13298			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768930	hybrid			2022-12-27	WOS:A1995RB43900054
J	SANKAR, S; MAHOOTIBROOKS, N; CENTRELLA, M; MCCARTHY, TL; MADRI, JA				SANKAR, S; MAHOOTIBROOKS, N; CENTRELLA, M; MCCARTHY, TL; MADRI, JA			EXPRESSION OF TRANSFORMING GROWTH-FACTOR TYPE-III RECEPTOR IN VASCULAR ENDOTHELIAL-CELLS INCREASES THEIR RESPONSIVENESS TO TRANSFORMING GROWTH-FACTOR-BETA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; SURFACE PROTEINS; BINDING; CLONING; RESISTANT; GROWTH-FACTOR-BETA-2; INHIBITION; BETAGLYCAN	Bovine aortic endothelial cells (BAECs) express both type I and type II receptors for transforming growth factor beta (TGF beta). These cells respond to TGF beta 1 but are relatively refractory to another isoform of TGF beta, termed TGF beta 2. TGF beta s are thought to signal through receptor complexes composed of type I and/or type II receptors, both of which appear to be functional serine-threonine kinases. The TGF beta type III receptor, on the other hand, does not seem to have any direct signaling capacity. We have now stably transfected BAECs with the type III receptor cDNA. These cells displayed surface expression of the type III receptor protein, as determined by crosslinking with iodinated TGF beta 1 and immunoprecipitation with antibodies to the type III receptor protein. Transfected BAECs exhibit increased responsiveness to TGF beta 2 by several different criteria including an increase in plasminogen activator inhibitor-1 protein and inhibition of migration and proliferation. Thus, the type III receptor protein may play a role in presenting TGF beta 2 to the type II receptor and increase responsiveness to TGF beta 2 to a level comparable to that of TGF beta 1.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PLAST SURG,NEW HAVEN,CT 06510	Yale University; Yale University					NHLBI NIH HHS [R01HL28373] Funding Source: Medline; NIAMS NIH HHS [R01AR39201] Funding Source: Medline; NIDDK NIH HHS [P01 DK38979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYD FT, 1989, J BIOL CHEM, V264, P1172; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1995, IN PRESS MOL CELL BI; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHINKERS M, 1987, J CELL PHYSIOL, V130, P1, DOI 10.1002/jcp.1041300102; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRANZEN P, 1993, EXP CELL RES, V207, P681; GEISER AG, 1992, J BIOL CHEM, V267, P2588; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MADRI JA, 1980, HUM PATHOL, V11, P353, DOI 10.1016/S0046-8177(80)80031-1; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1987, AM J PATHOL, V94, P179; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; PRATT BM, 1984, AM J PATHOL, V117, P349; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROLL FJ, 1980, J CELL BIOL, V859, P597; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TENDIJKE P, 1990, MOL CELL BIOL, V10, P4473, DOI 10.1128/MCB.10.9.4473; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; WANG XF, 1991, CELL, V51, P797; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	47	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13567	13572		10.1074/jbc.270.22.13567	http://dx.doi.org/10.1074/jbc.270.22.13567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768960	hybrid			2022-12-27	WOS:A1995RB43900090
J	SMID, A; RIVA, M; BOUET, F; SENTENAC, A; CARLES, C				SMID, A; RIVA, M; BOUET, F; SENTENAC, A; CARLES, C			THE ASSOCIATION OF 3 SUBUNITS WITH YEAST RNA-POLYMERASE IS STABILIZED BY A14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; GENE DISRUPTION; H ACTIVITY; DNA; PROTEIN; TRANSFORMATION; MUTAGENESIS; CYCLOPHILIN; PLASMIDS	RNA polymerase I of Saccharomyces cerevisiae is composed of 14 subunits. Ah of the corresponding genes have been cloned with the exception of the RPB14 gene encoding A14, a specific polypeptide of this enzyme. We report the cloning and the characterization of RPA14. The A14 polypeptide was separated from the other RNA polymerase I subunits by reverse-phase high pressure Liquid chromatography and digested with proteinase It. Based on the amino acid sequence of one of the resulting peptides, a degenerate oligonucleotide was synthesized and used to isolate the RPA14 gene from a yeast subgenomic DNA Library. RPA14 is a single copy gene that maps to chromosome IV and is flanked by CYP1 and HOM2. Disruption of RPA14 is not lethal, but growth of the rpal4=URA3 mutant strain is impaired at 37 and 38 degrees C. RNA polymerase I was purified from the rpa14=URA3 strain. After two purification steps, the enzyme did not contain the subunits A14, ABC23, and A43. This form of the enzyme was not active in a nonspecific in vitro transcription assay. These results demonstrate that A14 is a genuine subunit of RNA polymerase I and suggest that A14 plays a role in the stability of a subgroup of subunits.	CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE; CEA SACLAY,INGN PROT LAB,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUHLER JM, 1974, J BIOL CHEM, V249, P5963; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BUHLER JM, 1979, STRUCTURAL STUDIES Y; CARLES C, 1991, J BIOL CHEM, V266, P24092; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HAGER GL, 1977, BIOCHEMISTRY-US, V16, P1, DOI 10.1021/bi00620a001; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUET J, 1976, BIOCHIMIE, V58, P71, DOI 10.1016/S0300-9084(76)80357-4; HUET J, 1976, NATURE, V261, P431, DOI 10.1038/261431a0; HUET J, 1975, P NATL ACAD SCI USA, V72, P3034, DOI 10.1073/pnas.72.8.3034; HUET J, 1977, J BIOL CHEM, V252, P8848; IBORRA F, 1979, J BIOL CHEM, V254, P920; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; LINK AJ, 1991, GENETICS, V127, P681; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCLAUGHLIN MM, 1992, GENE, V111, P85, DOI 10.1016/0378-1119(92)90606-P; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SIKORSKI RS, 1989, GENETICS, V122, P19; STETTLER S, 1992, J BIOL CHEM, V267, P21390; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THOMAS D, 1989, MOL GEN GENET, V217, P149, DOI 10.1007/BF00330954; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; THURIAUX P, 1992, MOL CELLULAR BIOL YE, P1; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; VALENZUELA P, 1976, BIOCHEM BIOPH RES CO, V71, P26, DOI 10.1016/0006-291X(76)90244-8; WERNER M, 1993, J BIOL CHEM, V268, P20721; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	1995	270	22					13534	13540		10.1074/jbc.270.22.13534	http://dx.doi.org/10.1074/jbc.270.22.13534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RB439	7768955	hybrid			2022-12-27	WOS:A1995RB43900085
J	LARABADJEBARI, F; LEGROS, C; CREST, M; CEARD, B; ROMI, R; MANSUELLE, P; JACQUET, G; VANRIETSCHOTEN, J; GOLA, M; ROCHAT, H; BOUGIS, PE; MARTINEAUCLAIRE, MF				LARABADJEBARI, F; LEGROS, C; CREST, M; CEARD, B; ROMI, R; MANSUELLE, P; JACQUET, G; VANRIETSCHOTEN, J; GOLA, M; ROCHAT, H; BOUGIS, PE; MARTINEAUCLAIRE, MF			THE KALIOTOXIN FAMILY ENLARGED - PURIFICATION, CHARACTERIZATION, AND PRECURSOR NUCLEOTIDE-SEQUENCE OF KTX(2) FROM ANDROCTONUS-AUSTRALIS VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDES; DEPENDENT POTASSIUM CHANNELS; CENTRUROIDES-NOXIUS HOFFMANN; INSECT SELECTIVE NEUROTOXIN; K+-CHANNEL; BLOCKING PEPTIDE; SCORPION TOXINS; CHARYBDOTOXIN; EXPRESSION; CLONING	Kaliotoxin (KTX) has been originally described as an inhibitor of the intermediate conductance Ca2+-activated K+ channel (Crest, M., Jacquet, G., Cola, M., Zerrouk, H., Benslimane, A., Rochat, H., Mansuelle, P., and Martin-Eauclaire, M.-F. (1992) J. Biol. Chem. 267, 1640-1647). However, the radioiodinated I-125-KTX-(1-37) was also able to bind to the dendrotoxin sensitive voltage-dependent K+ channel (Romi, R., Crest, M., Cola, M., Sampieri, El, Jacquet, G., Zerrouk, H., Mansuelle, P., Sorokine, O., Van Dorsselaer, A., Rochat, H., Martin Eauclaire, M.-F., and Van Rietschoten, J. (1993) J. Biol. Chem. 268, 26302-26309). By following the ability to compete with I-125-KTX-(1-37) for binding to its receptor on rat brain synaptosomes, a new kaliotoxin-like peptide, KTX(2), was isolated from Androctonus australis scorpion venom. It is a 37-amino acid residue peptide, and its sequence shares 76% identity with KTX. The differences between the two peptides concern the NH2-terminal region and the residues 31 and 34 located in the region involved in the channel recognition. These differences may explain the 5-fold decrease of the molluscan Ca2+-activated K+ channel blocage by KTX(2) (k(d) = 135 nM) as well as of its binding affinity to rat brain synaptosomes (IC50 = 50 pM), compared with KTX. Specific antibodies raised against KTX-(1-37) were not able to recognize KTX(2). Using degenerate primers, a 370-base pair cDNA encoding the KTX(2) precursor was amplified by polymerase chain reaction from a cDNA library of A. australis venom glands. It encoded a presumed signal peptide of 22 residues followed by the sequence of the mature peptide.	FAC MED NORD,BIOCHIM INGN PROT LAB,CNRS,URA 1455,F-13916 MARSEILLE 20,FRANCE; CNRS,UPR 9024,NEUROBIOL LAB,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Legros, Christian/K-1346-2015; Fatima, Laraba-Djebari/N-8463-2016; BOUGIS, Pierre E/I-2111-2013	Fatima, Laraba-Djebari/0000-0003-4641-261X; LEGROS, Christian/0000-0002-3346-7059; mansuelle, pascal/0000-0002-4504-6809				BECERRIL B, 1993, GENE, V128, P165, DOI 10.1016/0378-1119(93)90559-L; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; CREST M, 1992, J BIOL CHEM, V267, P1640; DELORI P, 1981, TOXICON, V19, P393, DOI 10.1016/0041-0101(81)90044-1; DIMARCQ JL, 1990, EMBO J, V9, P2507, DOI 10.1002/j.1460-2075.1990.tb07430.x; ELAYEB M, 1983, TOXICON, V21, P709, DOI 10.1016/0041-0101(83)90276-3; FERNANDEZ I, 1994, IN PRESS BIOCHEMISTR; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLA M, 1990, J PHYSIOL-LONDON, V420, P73, DOI 10.1113/jphysiol.1990.sp017902; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; HARVEY AL, 1994, IN PRESS TOXICON; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; KNAPP DR, 1990, METHOD ENZYMOL, V193, P314, DOI 10.1016/0076-6879(90)93423-I; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MARTINEAUCLAIRE MF, 1992, FEBS LETT, V302, P220, DOI 10.1016/0014-5793(92)80445-M; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PHILIPSON LH, 1992, TRENDS PHARMACOL SCI, V13, P8, DOI 10.1016/0165-6147(92)90005-Q; PONGS O, 1993, TRENDS PHARMACOL SCI, V14, P435, DOI 10.1016/0165-6147(93)90182-J; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; POSSANI LD, 1982, CARLSBERG RES COMMUN, V47, P285, DOI 10.1007/BF02907789; ROGOWSKI RS, 1994, P NATL ACAD SCI USA, V91, P1475, DOI 10.1073/pnas.91.4.1475; ROMI R, 1993, J BIOL CHEM, V268, P26302; RUPPERSBERG JP, 1993, CELL PHYSIOL BIOCHEM, V3, P250; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LA, 1990, J TOXICOL-TOXIN REV, V9, P243, DOI 10.3109/15569549009033116; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; TAUC M, 1993, PFLUG ARCH EUR J PHY, V425, P126, DOI 10.1007/BF00374512; VASQUEZ J, 1990, J BIOL CHEM, V265, P15564; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; ZERROUK H, 1991, TOXICON, V29, P951, DOI 10.1016/0041-0101(91)90078-6; ZILBERBERG N, 1991, TOXICON, V29, P1155, DOI 10.1016/0041-0101(91)90213-B	46	69	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32835	32843						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806508				2022-12-27	WOS:A1994QA63800021
